🔗 Share

Patent application title:

Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer

Publication number:

US20060183131A1

Publication date:

2006-08-17

Application number:

11/043,842

Filed date:

2005-01-27

Abstract:

Novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.

Inventors:

Naomi Keren 10 🇮🇱 Givat Shmuel, Israel
Shira WALACH 33 🇮🇱 Hod Hasharon, Israel
Zurit Levine 36 🇮🇱 Herzlia, Israel
Dvir Dahary 42 🇮🇱 Tel Aviv, Israel

Osnat Sella-Tavor 38 🇮🇱 Kfar Kish, Israel
MICHAL AYALON-SOFFER 31 🇮🇱 RAMAT-HASHARON, Israel
Sarah Pollock 40 🇮🇱 Tel-Aviv, Israel
Shirley Sameah-Greenwald 44 🇮🇱 Kfar Saba, Israel

Pinchas Akiva 16 🇮🇱 Ramat-Gan, Israel
Rotem Sorek 15 🇮🇱 Rechovot, Israel
Ronen Shemesh 17 🇮🇱 Modiln, Israel
Amir Toporik 27 🇮🇱 Azur, Israel

Alexander Diber 6 🇮🇱 Richon-LeZion, Israel
Maxim Shklar 7 🇮🇱 Tel-Aviv, Israel
Amit Novik 2 🇮🇱 Beit-Ha-Sharon, Israel

Interested in similar patents?

Get notified when new applications in this technology area are published.

Create Free Alert

Classification:

G01N33/57415 » CPC main

Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer; Specifically defined cancers of breast

C07K14/47 » CPC further

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

C12Q1/6886 » CPC further

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids; Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

C12Q2600/112 » CPC further

Oligonucleotides characterized by their use Disease subtyping, staging or classification

C12Q2600/158 » CPC further

Oligonucleotides characterized by their use Expression markers

C12Q1/68 IPC

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids

G01N33/574 IPC

C07H21/04 IPC

Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

C12P21/06 IPC

Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

C07K14/82 IPC

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof Translation products from oncogenes

C07K16/30 IPC

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Description

CROSS-REFERENCE TO RELATED APPLICATION(S)

THIS APPLICATION IS RELATED TO NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF BREAST CANCER, AND CLAIMS PRIORITY TO THE BELOW U.S. PROVISIONAL APPLICATIONS WHICH ARE INCORPORATED BY REFERENCE HEREIN:

APPLICATION NO. 60/620,916 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN COLON CANCER

APPLICATION NO. 60/628,123 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN COLON CANCER II

APPLICATION NO. 60/621,131 FILED OCT. 25, 2004—DIAGNOSTIC MARKERS FOR COLON CANCER, AND ASSAYS AND METHODS OF USE THEREOF

APPLICATION NO. 60/620,917 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BREAST CANCER

APPLICATION NO. 60/628,101 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BREAST CANCER II

APPLICATION NO. 60/620,874 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN OVARIAN CANCER

APPLICATION NO. 60/628,134 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN OVARIAN CANCER II

APPLICATION NO. 60/620,924 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN STOMACH CANCER

APPLICATION NO. 60/628,111 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN STOMACH CANCER II

APPLICATION NO. 60/620,853 FILED OCT. 22, 2004-28814—DIFFERENTIAL EXPRESSION OF MARKERS IN LUNG CANCER

APPLICATION NO. 60/628,112 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN LUNG CANCER II

APPLICATION NO. 60/620,974 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN PANCREATIC CANCER

APPLICATION NO. 60/628,145 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN PANCREATIC CANCER II

APPLICATION NO. 60/620,656 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN PROSTATE CANCER

APPLICATION NO. 60/628,251 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN PROSTATE CANCER II

APPLICATION NO. 60/620,975 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BRAIN CANCER

APPLICATION NO. 60/628,178 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BRAIN CANCER II

APPLICATION NO. 60/628,231 FILED NOV. 17, 2004—NOVEL DIAGNOSTIC SERUM MARKERS, AND ASSAYS AND METHODS OF USE THEREOF

APPLICATION NO. 60/620,918 FILED OCT. 22, 2004—DIAGNOSTIC MARKERS FOR RENAL CANCER, AND ASSAYS AND METHODS OF USE THEREOF

APPLICATION NO. 60/628,156 FILED NOV. 17, 2004—DIAGNOSTIC MARKERS FOR RENAL CANCER, AND ASSAYS AND METHODS OF USE THEREOF II

APPLICATION NO. 60/628,167 FILED NOV. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BLADDER CANCER II

APPLICATION NO. 60/621,004 FILED OCT. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN SKIN AND EPITHELIAL CANCER II

APPLICATION NO. ----NA----- FILED NOV. 17, 2004—NOVEL DIAGNOSTIC MARKERS, AND ASSAYS AND METHODS OF USE THEREOF

APPLICATION NO. 60/539,129 FILED JAN. 27, 2004—METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES

APPLICATION NO. 60/539,128 FILED JAN. 27, 2004—EVOLUTIONARY CONSERVED SPLICED SEQUENCES AND METHODS AND SYSTEMS FOR IDENTIFYING THEREOF

FIELD OF THE INVENTION

The present invention is related to novel nucleotide and protein sequences that are diagnostic markers for breast cancer, and assays and methods of use thereof.

BACKGROUND OF THE INVENTION

Breast cancer is the most commonly occurring cancer in women, comprising almost a third of all malignancies in females. It is the leading cause of death for women between the ages 40-55 in the United States and one out of 8 females in the United States will develop breast cancer at some point in her life.

The death rate from breast cancer has been slowly declining over the past decade, partially due do the usage of molecular markers that facilitate the discovery, tumor typing (and therefore choice of treatment), response to treatment and recurrence.

The most widely used serum markers for breast cancers are Mucin1 (measured as CA 15-3) and CEA (CarcinoEmbryonic Antigen). Mucin 1 (MUC1) is present on the apical surface of normal epithelial cells. Its extracellular domain consists of a heavily O-linked glycosylated peptide core made up of variable number of multiple repeats of 20 amino acid sequence referred to as VNTR (Variable Number Tandem Repeat). This variability results in natural polymorphism of MUC1. Each VNTR has five potential O-linkage sites. The breast cancer disease state alters the enzymes which glycosylate Mucin 1 and therefore the polysaccharide side chains of tumor associated MUC1 are generally shorter than those on the normally expressed molecule. Both aberrant and up-regulated expression of MUC1 are features of malignancy and MUC1 related markers are based on it. Though CA 15-3 is a broadly used marker for breast cancer, a combination of CA 15-3 and CEA is more sensitive than using a single marker.

For the purpose of monitoring therapeutic response, CA 15-3, CEA and ESR (Erythrocyte Sedimentation Rate) are used as a panel, leading to over 90% of patients biochemically assessable. Serum markers used to monitor therapeutic response in patients with metastatic breast cancer are associated with the “spike phenomenon”. It is an initial transient rise of tumor marker levels which can be seen in up to 30% of responders in the first 3 months of commencing a therapy. It is important not to interpret this as a sign of disease progression leading to premature change of an effective therapy.

CA 27.29 is a new monoclonal antibody directed against a different part of MUC1 and it is a newer marker than CA 15-3. It detects a different glycosylation pattern of MUC1, as compared with CA 15-3. CA 27.29 is the first FDA-approved blood test for breast cancer recurrence. Because of superior sensitivity and specificity, CA 27.29 has supplanted CA 15-3 as the preferred tumor marker in breast cancer. The CA 27.29 level is elevated in approximately one third of women with early-stage breast cancer (stage I or II) and in two thirds of women with late-stage disease (stage III or IV). CA 27.29 lacks predictive value in the earliest stages of breast cancer and thus has no role in screening for or diagnosing the malignancy. CA 27.29 also can be found in patients with benign disorders of the breast, liver, and kidney, and in patients with ovarian cysts. However, CA 27.29 levels higher than 100 units per mL are rare in benign conditions.

Recently Estrogen 2 (beta) was shown to have a diagnostic role in breast cancer. It has been shown that the expression of the ‘cx’ variant of Estrogen 2 is correlated with response to Hormone adjuvant therapy. In addition it has been shown it may assist in better characterization of ER-1 positive breast cancers (together with progesterone receptor).

HER-2 (also known as c-erbB2) is a membrane proto-oncogene with intrinsic tyrosine kinase activity. Tumor expressing HER-2 are associated with shorter survival, shorter time-to-relapse and an overall worse prognosis. Tumors expressing HER-2 can be targeted with Trastuzumab—a biological adjuvant therapy which blocks the growth promoting action of HER-2. The ImmunoHistoChemistry (IHC) and Fluorescence In Situ Hybridization (FISH) tests are used to detect HER2: 1.IHC: The most common test used to check HER2 status is an ImmunoHistoChemistry (IHC) test. The IHC test measures the protein made by the HER2 gene. 2.FISH: This test measures the number of copies of the HER2 gene present in the tumor cell.

Measurement of the extracellular domain of HER-2 has been reported to show a better assessment of response to chemotherapy than a biochemical index score based on measurement of CA 15.3, CEA and ESR in a small series of patient. That finding is yet to be confirmed in a larger group of patient with HER-2 expressing tumors.

Other molecular markers, mainly used for the diagnosis for cancers other than breast cancer were shown to have a diagnostic potential in breast cancer. For example, CA125 which is a major marker for ovarian cancer is also associated with breast cancer. High levels of CA 19-9, a major marker for colorectal and pancreatic cancers, can be found in breast cancer. Overall, these markers are not frequently used for the detection of breast cancer to due their inferiority compared with other markers already described.

Panels of markers for the diagnosis and typing of breast cancer are being used by pathologists, including both markers described above and additional markers, such as immunohistochemistry markers that have been shown to have a beneficial value for the diagnosis of breast cancer, including PCNA and Ki-67 are maybe the most important and highly used immunohistochemistry markers for breast cancer. Other markers as E-Cadherin, Cathepsin D and TFF1 are also used for that purpose.

Despite relevant research efforts and the identification of many putative good prognosticators, few of them are proving clinically useful for identifying patients at minimal risk of relapse, patients with a worse prognosis, or patients likely to benefit from specific treatments. Most of them, such as epidermal growth factor receptor, cyclin E, p53 (this mutation is present in approximately 40% of human breast cancers as an acquired defect), bcl-2, vascular endothelial growth factor, urokinase-type plasminogen activator-1 and the anti-apoptosis protein survivin, are suggested for possible inclusion in the category of biomarkers with a high level of clinico-laboratory effectiveness. However, no single biomarker was able to identify those patients with the best (or worst) prognosis or those patients who would be responsive to a given therapy. High level cyclin E expression has been associated with the initiation or progression of different human cancers, in particular breast cancer but also leukemia, lymphoma and others. Cyclin-E expression level in the breast cancer was found to be a very strong indicator for prognosis, stronger than any other biological marker.

There are some non-cancerous pathological conditions which represent an increased risk factor for development breast cancer. Non-limiting examples of these conditions include:

- Ductal hyperplasia without atypia. It is the most frequently encountered breast biopsy result that is associated with increased risk of future development of breast cancer (2 fold increased risk). In particular, the loss of expression of transforming growth factor beta receptor II in the affected epithelial cells is associated with an increased risk of invasive breast cancer.
- Atypical hyperplasia. Women having atypical hyperplasia with over-expression of HER-2 have a greater than 7-fold increased risk of developing invasive breast carcinoma, as compared with women with non-proliferative benign breast lesions and no evidence of HER-2 amplification.

These pathological conditions should be effectively diagnosed and monitored in order to facilitate early detection of breast cancer.

SUMMARY OF THE INVENTION

The background art does not teach or suggest markers for breast cancer that are sufficiently sensitive and/or accurate, alone or in combination.

The present invention overcomes these deficiencies of the background art by providing novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient (biological) samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.

According to preferred embodiments of the present invention, examples of suitable biological samples which may optionally be used with preferred embodiments of the present invention include but are not limited to blood, serum, plasma, blood cells, urine, sputum, saliva, stool, spinal fluid or CSF, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, milk, neuronal tissue, breast tissue, any human organ or tissue, including any tumor or normal tissue, any sample obtained by lavage (for example of the bronchial system or of the breast ductal system), and also samples of in vivo cell culture constituents. In a preferred embodiment, the biological sample comprises breast tissue and/or a serum sample and/or a urine sample and/or a milk sample and/or any other tissue or liquid sample. The sample can optionally be diluted with a suitable eluant before contacting the sample to an antibody and/or performing any other diagnostic assay.

Information given in the text with regard to cellular localization was determined according to four different software programs: (i) tmhmm (from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/TMHMM/TMHMM2.0b.guide.php) or (ii) tmpred (from EMBnet, maintained by the ISREC Bionformatics group and the LICR Information Technology Office, Ludwig Institute for Cancer Research, Swiss Institute of Bioinformatics, http://www.ch.embnet.org/software/TMPRED_form.html) for transmembrane region prediction; (iii) signalp_hmm or (iv) signalp_nn (both from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/SignalP/background/prediction.php) for signal peptide prediction. The terms “signalp_hmm” and “signalp_nn” refer to two modes of operation for the program SignalP: hmm refers to Hidden Markov Model, while nn refers to neural networks. Localization was also determined through manual inspection of known protein localization and/or gene structure, and the use of heuristics by the individual inventor. In some cases for the manual inspection of cellular localization prediction inventors used the ProLoc computational platform [Einat Hazkani-Covo, Erez Levanon, Galit Rotman, Dan Graur and Amit Novik; (2004) “Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in Saccharomyces, Drosophila and Caenorhabditis.” Cell Biology International 2004;28(3):171-8.], which predicts protein localization based on various parameters including, protein domains (e.g., prediction of trans-membranous regions and localization thereof within the protein), pI, protein length, amino acid composition, homology to pre-annotated proteins, recognition of sequence patterns which direct the protein to a certain organelle (such as, nuclear localization signal, NLS, mitochondria localization signal), signal peptide and anchor modeling and using unique domains from Pfam that are specific to a single compartment.

Information is given in the text with regard to SNPs (single nucleotide polymorphisms). A description of the abbreviations is as follows. “T→C”, for example, means that the SNP results in a change at the position given in the table from T to C. Similarly, “M→Q”, for example, means that the SNP has caused a change in the corresponding amino acid sequence, from methionine (M) to glutamine (Q). If, in place of a letter at the right hand side for the nucleotide sequence SNP, there is a space, it indicates that a frameshift has occurred. A frameshift may also be indicated with a hyphen (-). A stop codon is indicated with an asterisk at the right hand side (*). As part of the description of an SNP, a comment may be found in parentheses after the above description of the SNP itself. This comment may include an FTId, which is an identifier to a SwissProt entry that was created with the indicated SNP. An FTId is a unique and stable feature identifier, which allows construction of links directly from position-specific annotation in the feature table to specialized protein-related databases. The FTId is always the last component of a feature in the description field, as follows: FTId=XXX_number, in which XXX is the 3-letter code for the specific feature key, separated by an underscore from a 6-digit number. In the table of the amino acid mutations of the wild type proteins of the selected splice variants of the invention, the header of the first column is “SNP position(s) on amino acid sequence”, representing a position of a known mutation on amino acid sequence. SNPs may optionally be used as diagnostic markers according to the present invention, alone or in combination with one or more other SNPs and/or any other diagnostic marker. Preferred embodiments of the present invention comprise such SNPs, including but not limited to novel SNPs on the known (WT or wild type) protein sequences given below, as well as novel nucleic acid and/or amino acid sequences formed through such SNPs, and/or any SNP on a variant amino acid and/or nucleic acid sequence described herein.

Information given in the text with regard to the Homology to the known proteins was determined by Smith-Waterman version 5.1.2 using special (non default) parameters as follows:



	model=sw.model
	GAPEXT=0
	GAPOP=100.0
	MATRIX=blosum100

Information is given with regard to overexpression of a cluster in cancer based on ESTs. A key to the p values with regard to the analysis of such overexpression is as follows:

- library-based statistics: P-value without including the level of expression in cell-lines (P1)
- library based statistics: P-value including the level of expression in cell-lines (P2)
- EST clone statistics: P-value without including the level of expression in cell-lines (SP1)
- EST clone statistics: predicted overexpression ratio without including the level of expression in cell-lines (R3)
- EST clone statistics: P-value including the level of expression in cell-lines (SP2)
- EST clone statistics: predicted overexpression ratio including the level of expression in cell-lines (R4)

Library-based statistics refer to statistics over an entire library, while EST clone statistics refer to expression only for ESTs from a particular tissue or cancer.

Information is given with regard to overexpression of a cluster in cancer based on microarrays. As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for which expression was measured. There are two types of microarray results: those from microarrays prepared according to a design by the present inventors, for which the microarray fabrication procedure is described in detail in Materials and Experimental Procedures section herein; and those results from microarrays using Affymetrix technology. As a microarray reference, in the specific segment paragraphs, the unabbreviated tissue name was used as the reference to the type of chip for which expression was measured. For microarrays prepared according to a design by the present inventors, the probe name begins with the name of the cluster (gene), followed by an identifying number. Oligonucleotide microarray results taken from Affymetrix data were from chips available from Affymetrix Inc, Santa Clara, Calif., USA (see for example data regarding the Human Genome U133 (HG-U133) Set at www.affymetrix.com/products/arrays/specific/hgu133..affx; GeneChip Human Genome U133A 2.0 Array at www.affymetrix.com/products/arrays/specific/hgu133av2.affx; and Human Genome U133 Plus 2.0 Array at www.affymetrix.com/products/arrays/specific/hgu133plus.affx). The probe names follow the Affymetrix naming convention. The data is available from NCBI Gene Expression Omnibus (see www.ncbi.nlm.nih.gov/projects/geo/ and Edgar et al, Nucleic Acids Research, 2002, Vol. 30, No. 1207-210). The dataset (including results) is available from www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1133 for the Series GSE1133 database (published on March 2004); a reference to these results is as follows: Su et al (Proc Natl Acad Sci USA. Apr. 20, 2004;101(16):6062-7. Epub Apr. 09, 2004). The probes designed according to the present inventors are listed below.


>Z21368_0_0_61857
AGTTCATCCTTCTTCAGTGTGACCAGTAAATTCTTCCCATACTCTTGAAG	(SEQ ID NO:895)

>HUMGRP5E_0_0_16630
GCTGATATGGAAGTTGGGGAATCTGAATTGCCAGAGAATCTTGGGAAGAG	(SEQ ID NO:896)

>HUMGRP5E_0_2_0
TCTCATAGAAGCAAAGGAGAACAGAAACCACCAGCCACCTCAACCCAAGG	(SEQ ID NO:897)

>HSENA78_0_1_0
TGAAGAGTGTGAGGAAAACCTATGTTTGCCGCTTAAGCTTTCAGCTCAGC	(SEQ ID NO:898)

>M85491_0_0_25999
GACATCTTTGCATATCATGTCAGAGCTATAACATCATTGTGGAGAAGCTC	(SEQ ID NO:899)

>M85491_0_14_0
GTCATGAAAATCAACACCGAGGTGCGGAGCTTCGGACCTGTGTCCCGCAG	(SEQ ID NO:900)

>HSSTROL3_0_0_12518
ATGAGAGTAACCTCACCCGTGCACTAGTTTACAGAGCATTCACTGCCCCA	(SEQ ID NO:901)

>HSSTROL3_0_0_12517
CAGAGATGAGAGCCTGGAGCATTGCAGATGCCAGGGACTTCACAAATGAA	(SEQ ID NO:902)

>HUMCA1XIA_0_0_14909
GCTGCAATCTAAGTTTCGGAATACTTATACCACTCCAGAAATAATCCTCG	(SEQ ID NO:903)

>HUMCA1XIA_0_18_0
TTCAGAACTGTTAACATCGCTGACGGGAAGTGGCATCGGGTAGCAATCAG	(SEQ ID NO:904)

>R20779_0_0_30670
CCGCGTTGCTTCTAGAGGCTGAATGCCTTTCAAATGGAGAAGGCTTCCAT	(SEQ ID NO:905)

>HSS100PCB_0_0_12280
CTCAAAATGAAACTCCCTCTCGCAGAGCACAATTCCAATTCGCTCTAAAA	(SEQ ID NO:906)

>HSCOC4_0_0_9892
AAGGACCAGAGTCCATGCCAAGACCACCCTTCAGCTTCCAAGGCCCTCCA	(SEQ ID NO:907)

>HSCOC4_0_39_0
ATCCTCCAGCCATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTC	(SEQ ID NO:908)

>HSCOC4_0_0_9883
CCTGTTTGCTCTGACACCAACTTCCTACCCTCTCAGCCTCAAAGTAACTC	(SEQ ID NO:909)

>HSCOC4_0_0_9885
GCTGAGGTGTGGCCGAGGACCTGACCATCTGGAAGTGTGAAAATCCCCTT	(SEQ ID NO:910)

>T11628_0_9_0
ACAAGATCCCCGTGAAGTACCTGGAGTTCATCTCGGAATGCATCATCCAG	(SEQ ID NO:911)

>T11628_0_0_45174
TAAACAATCAAAGAGCATGTTGGCCTGGTCCTTTGCTAGGTACTGTAGAG	(SEQ ID NO:912)

>T11628_0_0_45161
TGCCTCGCCACAATGGCACCTGCCCTAAAATAGCTTCCCATGTGAGGGCT	(SEQ ID NO:913)

>M78076_0_7_0
GAGAAGATGAACCCGCTGGAACAGTATGAGCGAAAGGTGAATGCGTCTGT	(SEQ ID NO:914)

>HSMUC1A_0_37_0
AAAAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCTACTGAG	(SEQ ID NO:915)

>HSMUC1A_0_0_11364
AAAGGCTGGCATAGGGGGAGGTTTCCCAGGTAGAAGAAGAAGTGTCAGCA	(SEQ ID NO:916)

>HSMUC1A_0_0_11365
AATTAACCCTTTGAGAGCTGGCCAGGACTCTGGACTGATTACCCCAGCCT	(SEQ ID NO:917)

The following list of abbreviations for tissues was used in the TAA histograms. The term “TAA” stands for “Tumor Associated Antigen”, and the TAA histograms, given in the text, represent the cancerous tissue expression pattern as predicted by the biomarkers selection engine, as described in detail in examples 1-5 below.



	“BONE” for “bone”;
	“COL” for “colon”;
	“EPI” for “epithelial”;
	“GEN” for “general”;
	“LIVER” for “liver”;
	“LUN” for “lung”;
	“LYMPH” for “lymph nodes”;
	“MARROW” for “bone marrow”;
	“OVA” for “ovary”;
	“PANCREAS” for “pancreas”;
	“PRO” for “prostate”;
	“STOMACH” for “stomach”;
	“TCELL” for “T cells”;
	“THYROID” for “Thyroid”;
	“MAM” for “breast”;
	“BRAIN” for “brain”;
	“UTERUS” for “uterus”;
	“SKIN” for “skin”;
	“KIDNEY” for “kidney”;
	“MUSCLE” for “muscle”;
	“ADREN” for “adrenal”;
	“HEAD” for “head and neck”;
	“BLADDER” for “bladder”;

It should be noted that the terms “segment”, “seg” and “node” are used interchangeably in reference to nucleic acid sequences of the present invention, they refer to portions of nucleic acid sequences that were shown to have one or more properties as described below. They are also the building blocks that were used to construct complete nucleic acid sequences as described in greater detail below. Optionally and preferably, they are examples of oligonucleotides which are embodiments of the present invention, for example as amplicons, hybridization units and/or from which primers and/or complementary oligonucleotides may optionally be derived, and/or for any other use.

As used herein the phrase “breast cancer” refers to cancers of the breast or surrounding tissue, including but not limited to ductal carcinoma (in-situ or invasive), lobular carcinoma (in-situ or invasive), inflammatory breast cancer, mucinous carcinoma, tubular carcinoma, or Paget's disease of the nipple, as well as conditions that are indicative of a higher risk factor for later development of breast cancer, including but not limited to ductal hyperplasia without atypia and atypical hyperplasia, referred to herein collectively as “indicative conditions”.

The term “marker” in the context of the present invention refers to a nucleic acid fragment, a peptide, or a polypeptide, which is differentially present in a sample taken from subjects (patients) having breast cancer (or one of the above indicative conditions) as compared to a comparable sample taken from subjects who do not have breast cancer (or one of the above indicative conditions).

The phrase “differentially present” refers to differences in the quantity of a marker present in a sample taken from patients having breast cancer (or one of the above indicative conditions) as compared to a comparable sample taken from patients who do not have breast cancer (or one of the above indicative conditions). For example, a nucleic acid fragment may optionally be differentially present between the two samples if the amount of the nucleic acid fragment in one sample is significantly different from the amount of the nucleic acid fragment in the other sample, for example as measured by hybridization and/or NAT-based assays. A polypeptide is differentially present between the two samples if the amount of the polypeptide in one sample is significantly different from the amount of the polypeptide in the other sample. It should be noted that if the marker is detectable in one sample and not detectable in the other, then such a marker can be considered to be differentially present.

As used herein the phrase “diagnostic” means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity. The “sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of “true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay are termed “true negatives.” The “specificity” of a diagnostic assay is 1 minus the false positive rate, where the “false positive” rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.

As used herein the phrase “diagnosing” refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery. The term “detecting” may also optionally encompass any of the above.

Diagnosis of a disease according to the present invention can be effected by determining a level of a polynucleotide or a polypeptide of the present invention in a biological sample obtained from the subject, wherein the level determined can be correlated with predisposition to, or presence or absence of the disease. It should be noted that a “biological sample obtained from the subject” may also optionally comprise a sample that has not been physically removed from the subject, as described in greater detail below.

As used herein, the term “level” refers to expression levels of RNA and/or protein or to DNA copy number of a marker of the present invention.

Typically the level of the marker in a biological sample obtained from the subject is different (i.e., increased or decreased) from the level of the same variant in a similar sample obtained from a healthy individual (examples of biological samples are described herein).

Numerous well known tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of DNA, RNA and/or polypeptide of the variant of interest in the subject.

Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy (e.g., brain biopsy), and lavage. Regardless of the procedure employed, once a biopsy/sample is obtained the level of the variant can be determined and a diagnosis can thus be made.

Determining the level of the same variant in normal tissues of the same origin is preferably effected along-side to detect an elevated expression and/or amplification and/or a decreased expression, of the variant as opposed to the normal tissues.

A “test amount” of a marker refers to an amount of a marker in a subject's sample that is consistent with a diagnosis of breast cancer (or one of the above indicative conditions). A test amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals).

A “control amount” of a marker can be any amount or a range of amounts to be compared against a test amount of a marker. For example, a control amount of a marker can be the amount of a marker in a patient with breast cancer (or one of the above indicative conditions) or a person without breast cancer (or one of the above indicative conditions). A control amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals). “Detect” refers to identifying the presence, absence or amount of the object to be detected.

A “label” includes any moiety or item detectable by spectroscopic, photo chemical, biochemical, immunochemical, or chemical means. For example, useful labels include ³²P, ³⁵S, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavadin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target. The label often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantify the amount of bound label in a sample. The label can be incorporated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated nucleotides that are recognized by streptavadin. The label may be directly or indirectly detectable. Indirect detection can involve the binding of a second label to the first label, directly or indirectly. For example, the label can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavadin, or a nucleotide sequence, which is the binding partner for a complementary sequence, to which it can specifically hybridize. The binding partner may itself be directly detectable, for example, an antibody may be itself labeled with a fluorescent molecule. The binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules (see, e.g., P. D. Fahrlander and A. Klausner, Bio/Technology 6:1165 (1988)). Quantitation of the signal is achieved by, e.g., scintillation counting, densitometry, or flow cytometry.

Exemplary detectable labels, optionally and preferably for use with immunoassays, include but are not limited to magnetic beads, fluorescent dyes, radiolabels, enzymes (e.g., horse radish peroxide, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic beads. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture.

“Immunoassay” is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide (or other epitope), refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times greater than the background (non-specific signal) and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to seminal basic protein from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with seminal basic protein and not with other proteins, except for polymorphic variants and alleles of seminal basic protein. This selection may be achieved by subtracting out antibodies that cross-react with seminal basic protein molecules from other species. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T10888_PEA_1_T1 (SEQ ID NO: 1)
	T10888_PEA_1_T4 (SEQ ID NO: 2)
	T10888_PEA_1_T5 (SEQ ID NO: 3)
	T10888_PEA_1_T6 (SEQ ID NO: 4)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T10888_PEA_1_node_11 (SEQ ID NO: 5)
	T10888_PEA_1_node_12 (SEQ ID NO: 6)
	T10888_PEA_1_node_17 (SEQ ID NO: 7)
	T10888_PEA_1_node_4 (SEQ ID NO: 8)
	T10888_PEA_1_node_6 (SEQ ID NO: 9)
	T10888_PEA_1_node_7 (SEQ ID NO: 10)
	T10888_PEA_1_node_9 (SEQ ID NO: 11)
	T10888_PEA_1_node_15 (SEQ ID NO: 12)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below amino acid sequence comprising a sequence in the table below:



Protein Name

	T10888_PEA_1_P2 (SEQ ID NO: 14)
	T10888_PEA_1_P4 (SEQ ID NO: 15)
	T10888_PEA_1_P5 (SEQ ID NO: 16)
	T10888_PEA_1_P6 (SEQ ID NO: 17)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T39971_T10 (SEQ ID NO: 18)
	T39971_T12 (SEQ ID NO: 19)
	T39971_T16 (SEQ ID NO: 20)
	T39971_T5 (SEQ ID NO: 21)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T39971_node_0 (SEQ ID NO: 22)
	T39971_node_18 (SEQ ID NO: 23)
	T39971_node_21 (SEQ ID NO: 24)
	T39971_node_22 (SEQ ID NO: 25)
	T39971_node_23 (SEQ ID NO: 26)
	T39971_node_31 (SEQ ID NO: 27)
	T39971_node_33 (SEQ ID NO: 28)
	T39971_node_7 (SEQ ID NO: 29)
	T39971_node_1 (SEQ ID NO: 30)
	T39971_node_10 (SEQ ID NO: 31)
	T39971_node_11 (SEQ ID NO: 32)
	T39971_node_12 (SEQ ID NO: 33)
	T39971_node_15 (SEQ ID NO: 34)
	T39971_node_16 (SEQ ID NO: 35)
	T39971_node_17 (SEQ ID NO: 36)
	T39971_node_26 (SEQ ID NO: 37)
	T39971_node_27 (SEQ ID NO: 38)
	T39971_node_28 (SEQ ID NO: 39)
	T39971_node_29 (SEQ ID NO: 40)
	T39971_node_3 (SEQ ID NO: 41)
	T39971_node_30 (SEQ ID NO: 42)
	T39971_node_34 (SEQ ID NO: 43)
	T39971_node_35 (SEQ ID NO: 44)
	T39971_node_36 (SEQ ID NO: 45)
	T39971_node_4 (SEQ ID NO: 46)
	T39971_node_5 (SEQ ID NO: 47)
	T39971_node_8 (SEQ ID NO: 48)
	T39971_node_9 (SEQ ID NO: 49)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below:



Protein Name

	T39971_P6 (SEQ ID NO: 51)
	T39971_P9 (SEQ ID NO: 52)
	T39971_P11 (SEQ ID NO: 53)
	T39971_P12 (SEQ ID NO: 54)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	Z21368_PEA_1_T10 (SEQ ID NO: 55)
	Z21368_PEA_1_T11 (SEQ ID NO: 56)
	Z21368_PEA_1_T23 (SEQ ID NO: 57)
	Z21368_PEA_1_T24 (SEQ ID NO: 58)
	Z21368_PEA_1_T5 (SEQ ID NO: 59)
	Z21368_PEA_1_T6 (SEQ ID NO: 60)
	Z21368_PEA_1_T9 (SEQ ID NO: 61)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	Z21368_PEA_1_node_0 (SEQ ID NO: 62)
	Z21368_PEA_1_node_15 (SEQ ID NO: 63)
	Z21368_PEA_1_node_19 (SEQ ID NO: 64)
	Z21368_PEA_1_node_2 (SEQ ID NO: 65)
	Z21368_PEA_1_node_21 (SEQ ID NO: 66)
	Z21368_PEA_1_node_33 (SEQ ID NO: 67)
	Z21368_PEA_1_node_36 (SEQ ID NO: 68)
	Z21368_PEA_1_node_37 (SEQ ID NO: 69)
	Z21368_PEA_1_node_39 (SEQ ID NO: 70)
	Z21368_PEA_1_node_4 (SEQ ID NO: 71)
	Z21368_PEA_1_node_41 (SEQ ID NO: 72)
	Z21368_PEA_1_node_43 (SEQ ID NO: 73)
	Z21368_PEA_1_node_45 (SEQ ID NO: 74)
	Z21368_PEA_1_node_53 (SEQ ID NO: 75)
	Z21368_PEA_1_node_56 (SEQ ID NO: 76)
	Z21368_PEA_1_node_58 (SEQ ID NO: 77)
	Z21368_PEA_1_node_66 (SEQ ID NO: 78)
	Z21368_PEA_1_node_67 (SEQ ID NO: 79)
	Z21368_PEA_1_node_69 (SEQ ID NO: 80)
	Z21368_PEA_1_node_11 (SEQ ID NO: 81)
	Z21368_PEA_1_node_12 (SEQ ID NO: 82)
	Z21368_PEA_1_node_16 (SEQ ID NO: 83)
	Z21368_PEA_1_node_17 (SEQ ID NO: 84)
	Z21368_PEA_1_node_23 (SEQ ID NO: 85)
	Z21368_PEA_1_node_24 (SEQ ID NO: 86)
	Z21368_PEA_1_node_30 (SEQ ID NO: 87)
	Z21368_PEA_1_node_31 (SEQ ID NO: 88)
	Z21368_PEA_1_node_38 (SEQ ID NO: 89)
	Z21368_PEA_1_node_47 (SEQ ID NO: 90)
	Z21368_PEA_1_node_49 (SEQ ID NO: 91)
	Z21368_PEA_1_node_51 (SEQ ID NO: 92)
	Z21368_PEA_1_node_61 (SEQ ID NO: 93)
	Z21368_PEA_1_node_68 (SEQ ID NO: 94)
	Z21368_PEA_1_node_7 (SEQ ID NO: 95)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	Z21368_PEA_1_P2 (SEQ ID NO: 97)
	Z21368_PEA_1_P5 (SEQ ID NO: 98)
	Z21368_PEA_1_P15 (SEQ ID NO: 99)
	Z21368_PEA_1_P16 (SEQ ID NO: 100)
	Z21368_PEA_1_P22 (SEQ ID NO: 101)
	Z21368_PEA_1_P23 (SEQ ID NO: 102)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T59832_T11 (SEQ ID NO: 103)
	T59832_T15 (SEQ ID NO: 104)
	T59832_T22 (SEQ ID NO: 105)
	T59832_T28 (SEQ ID NO: 106)
	T59832_T6 (SEQ ID NO: 107)
	T59832_T8 (SEQ ID NO: 108)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T59832_node_1 (SEQ ID NO: 109)
	T59832_node_22 (SEQ ID NO: 110)
	T59832_node_23 (SEQ ID NO: 111)
	T59832_node_24 (SEQ ID NO: 112)
	T59832_node_29 (SEQ ID NO: 113)
	T59832_node_39 (SEQ ID NO: 114)
	T59832_node_7 (SEQ ID NO: 115)
	T59832_node_10 (SEQ ID NO: 116)
	T59832_node_11 (SEQ ID NO: 117)
	T59832_node_12 (SEQ ID NO: 118)
	T59832_node_14 (SEQ ID NO: 119)
	T59832_node_16 (SEQ ID NO: 120)
	T59832_node_19 (SEQ ID NO: 121)
	T59832_node_2 (SEQ ID NO: 122)
	T59832_node_20 (SEQ ID NO: 123)
	T59832_node_25 (SEQ ID NO: 124)
	T59832_node_26 (SEQ ID NO: 125)
	T59832_node_27 (SEQ ID NO: 126)
	T59832_node_28 (SEQ ID NO: 127)
	T59832_node_3 (SEQ ID NO: 128)
	T59832_node_30 (SEQ ID NO: 129)
	T59832_node_31 (SEQ ID NO: 130)
	T59832_node_32 (SEQ ID NO: 131)
	T59832_node_34 (SEQ ID NO: 132)
	T59832_node_35 (SEQ ID NO: 133)
	T59832_node_36 (SEQ ID NO: 134)
	T59832_node_37 (SEQ ID NO: 135)
	T59832_node_38 (SEQ ID NO: 136)
	T59832_node_4 (SEQ ID NO: 137)
	T59832_node_5 (SEQ ID NO: 138)
	T59832_node_6 (SEQ ID NO: 139)
	T59832_node_8 (SEQ ID NO: 140)
	T59832_node_9 (SEQ ID NO: 141)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	T59832_P5 (SEQ ID NO: 143)
	T59832_P7 (SEQ ID NO: 144)
	T59832_P9 (SEQ ID NO: 145)
	T59832_P12 (SEQ ID NO: 146)
	T59832_P18 (SEQ ID NO: 147)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	Z41644_PEA_1_T5 (SEQ ID NO: 208)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	Z41644_PEA_1_node_0 (SEQ ID NO: 209)
	Z41644_PEA_1_node_11 (SEQ ID NO: 210)
	Z41644_PEA_1_node_12 (SEQ ID NO: 211)
	Z41644_PEA_1_node_15 (SEQ ID NO: 212)
	Z41644_PEA_1_node_20 (SEQ ID NO: 213)
	Z41644_PEA_1_node_24 (SEQ ID NO: 214)
	Z41644_PEA_1_node_1 (SEQ ID NO: 215)
	Z41644_PEA_1_node_10 (SEQ ID NO: 216)
	Z41644_PEA_1_node_13 (SEQ ID NO: 217)
	Z41644_PEA_1_node_16 (SEQ ID NO: 218)
	Z41644_PEA_1_node_17 (SEQ ID NO: 219)
	Z41644_PEA_1_node_19 (SEQ ID NO: 220)
	Z41644_PEA_1_node_2 (SEQ ID NO: 221)
	Z41644_PEA_1_node_21 (SEQ ID NO: 222)
	Z41644_PEA_1_node_22 (SEQ ID NO: 223)
	Z41644_PEA_1_node_23 (SEQ ID NO: 224)
	Z41644_PEA_1_node_25 (SEQ ID NO: 225)
	Z41644_PEA_1_node_3 (SEQ ID NO: 226)
	Z41644_PEA_1_node_4 (SEQ ID NO: 227)
	Z41644_PEA_1_node_6 (SEQ ID NO: 228)
	Z41644_PEA_1_node_9 (SEQ ID NO: 229)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	Z41644_PEA_1_P10 (SEQ ID NO: 231)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HUMGRP5E_T4	(SEQ ID NO:148)

	HUMGRP5E_T5	(SEQ ID NO:149)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HUMGRP5E_node_0	(SEQ ID NO:150)

	HUMGRP5E_node_2	(SEQ ID NO:151)

	HUMGRP5E_node_8	(SEQ ID NO:152)

	HUMGRP5E_node_3	(SEQ ID NO:153)

	HUMGRP5E_node_7	(SEQ ID NO:154)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HUMGRP5E_P4	(SEQ ID NO:156)

	HUMGRP5E_P5	(SEQ ID NO:157)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	AA155578_PEA_1_T10 (SEQ ID NO: 158)
	AA155578_PEA_1_T12 (SEQ ID NO: 159)
	AA155578_PEA_1_T13 (SEQ ID NO: 160)
	AA155578_PEA_1_T8 (SEQ ID NO: 161)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	AA155578_PEA_1_node_11 (SEQ ID
	NO: 162)
	AA155578_PEA_1_node_12 (SEQ ID
	NO: 163)
	AA155578_PEA_1_node_14 (SEQ ID
	NO: 164)
	AA155578_PEA_1_node_19 (SEQ ID
	NO: 165)
	AA155578_PEA_1_node_21 (SEQ ID
	NO: 166)
	AA155578_PEA_1_node_23 (SEQ ID
	NO: 167)
	AA155578_PEA_1_node_24 (SEQ ID
	NO: 168)
	AA155578_PEA_1_node_25 (SEQ ID
	NO: 169)
	AA155578_PEA_1_node_4 (SEQ ID NO: 170)
	AA155578_PEA_1_node_7 (SEQ ID NO: 171)
	AA155578_PEA_1_node_15 (SEQ ID
	NO: 172)
	AA155578_PEA_1_node_18 (SEQ ID
	NO: 173)
	AA155578_PEA_1_node_22 (SEQ ID
	NO: 174)
	AA155578_PEA_1_node_6 (SEQ ID NO: 175)
	AA155578_PEA_1_node_8 (SEQ ID NO: 176)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	AA155578_PEA_1_P4 (SEQ ID NO: 178)
	AA155578_PEA_1_P6 (SEQ ID NO: 179)
	AA155578_PEA_1_P8 (SEQ ID NO: 180)
	AA155578_PEA_1_P9 (SEQ ID NO: 181)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HSENA78_T5	(SEQ ID NO:182)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HSENA78_node_0	(SEQ ID NO:183)

	HSENA78_node_2	(SEQ ID NO:184)

	HSENA78_node_6	(SEQ ID NO:185)

	HSENA78_node_9	(SEQ ID NO:186)

	HSENA78_node_3	(SEQ ID NO:187)

	HSENA78_node_4	(SEQ ID NO:188)

	HSENA78_node_8	(SEQ ID NO:189)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below:



Protein Name

	HSENA78_P2	(SEQ ID NO:191)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T94936_PEA_1_T1 (SEQ ID NO: 192)
	T94936_PEA_1_T2 (SEQ ID NO: 193)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T94936_PEA_1_node_14 (SEQ ID NO: 194)
	T94936_PEA_1_node_16 (SEQ ID NO: 195)
	T94936_PEA_1_node_2 (SEQ ID NO: 196)
	T94936_PEA_1_node_20 (SEQ ID NO: 197)
	T94936_PEA_1_node_23 (SEQ ID NO: 198)
	T94936_PEA_1_node_0 (SEQ ID NO: 199)
	T94936_PEA_1_node_11 (SEQ ID NO: 200)
	T94936_PEA_1_node_13 (SEQ ID NO: 201)
	T94936_PEA_1_node_17 (SEQ ID NO: 202)
	T94936_PEA_1_node_6 (SEQ ID NO: 203)
	T94936_PEA_1_node_8 (SEQ ID NO: 204)
	T94936_PEA_1_node_9 (SEQ ID NO: 205)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	T94936_PEA_1_P2 (SEQ ID NO: 206)
	T94936_PEA_1_P3 (SEQ ID NO: 207)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	M85491_PEA_1_T16 (SEQ ID NO: 232)
	M85491_PEA_1_T20 (SEQ ID NO: 233)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	M85491_PEA_1_node_0 (SEQ ID NO: 234)
	M85491_PEA_1_node_13 (SEQ ID NO: 235)
	M85491_PEA_1_node_21 (SEQ ID NO: 236)
	M85491_PEA_1_node_23 (SEQ ID NO: 237)
	M85491_PEA_1_node_24 (SEQ ID NO: 238)
	M85491_PEA_1_node_8 (SEQ ID NO: 239)
	M85491_PEA_1_node_9 (SEQ ID NO: 240)
	M85491_PEA_1_node_10 (SEQ ID NO: 241)
	M85491_PEA_1_node_18 (SEQ ID NO: 242)
	M85491_PEA_1_node_19 (SEQ ID NO: 243)
	M85491_PEA_1_node_6 (SEQ ID NO: 244)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	M85491_PEA_1_P13 (SEQ ID NO: 246)
	M85491_PEA_1_P14 (SEQ ID NO: 247)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HSSTROL3_T5	(SEQ ID NO:248)

	HSSTROL3_T8	(SEQ ID NO:249)

	HSSTROL3_T9	(SEQ ID NO:250)

	HSSTROL3_T10	(SEQ ID NO:251)

	HSSTROL3_T11	(SEQ ID NO:252)

	HSSTROL3_T12	(SEQ ID NO:253)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HSSTROL3_node_6	(SEQ ID NO:254)

	HSSTROL3_node_10	(SEQ ID NO:255)

	HSSTROL3_node_13	(SEQ ID NO:256)

	HSSTROL3_node_15	(SEQ ID NO:257)

	HSSTROL3_node_19	(SEQ ID NO:258)

	HSSTROL3_node_21	(SEQ ID NO:259)

	HSSTROL3_node_24	(SEQ ID NO:260)

	HSSTROL3_node_25	(SEQ ID NO:261)

	HSSTROL3_node_26	(SEQ ID NO:262)

	HSSTROL3_node_28	(SEQ ID NO:263)

	HSSTROL3_node_29	(SEQ ID NO:264)

	HSSTROL3_node_11	(SEQ ID NO:265)

	HSSTROL3_node_17	(SEQ ID NO:266)

	HSSTROL3_node_18	(SEQ ID NO:267)

	HSSTROL3_node_20	(SEQ ID NO:268)

	HSSTROL3_node_27	(SEQ ID NO:269)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HSSTROL3_P4	(SEQ ID NO:271)

	HSSTROL3_P5	(SEQ ID NO:272)

	HSSTROL3_P7	(SEQ ID NO:273)

	HSSTROL3_P8	(SEQ ID NO:274)

	HSSTROL3_P9	(SEQ ID NO:275)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	AY180924_PEA_1_T1 (SEQ ID NO: 276)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	AY180924_PEA_1_node_3 (SEQ ID NO: 277)
	AY180924_PEA_1_node_0 (SEQ ID NO: 278)
	AY180924_PEA_1_node_2 (SEQ ID NO: 279)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	AY180924_PEA_1_P3 (SEQ ID NO: 281)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	R75793_PEA_1_T1 (SEQ ID NO: 282)
	R75793_PEA_1_T3 (SEQ ID NO: 283)
	R75793_PEA_1_T5 (SEQ ID NO: 284)

a nucleic acid sequence comprising a sequence in the table below:



	R75793_PEA_1_node_0 (SEQ ID NO: 285)
	R75793_PEA_1_node_9 (SEQ ID NO: 286)
	R75793_PEA_1_node_11 (SEQ ID NO: 287)
	R75793_PEA_1_node_14 (SEQ ID NO: 288)
	R75793_PEA_1_node_4 (SEQ ID NO: 289)
	R75793_PEA_1_node_5 (SEQ ID NO: 290)
	R75793_PEA_1_node_6 (SEQ ID NO: 291)
	R75793_PEA_1_node_8 (SEQ ID NO: 292)
	R75793_PEA_1_node_13 (SEQ ID NO: 293)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	R75793_PEA_1_P2 (SEQ ID NO: 295)
	R75793_PEA_1_P5 (SEQ ID NO: 296)
	R75793_PEA_1_P6 (SEQ ID NO: 297)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HUMCA1XIA_T16	(SEQ ID NO:298)

	HUMCA1XIA_T17	(SEQ ID NO:299)

	HUMCA1XIA_T19	(SEQ ID NO:300)

	HUMCA1XIA_T20	(SEQ ID NO:301)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HUMCA1XIA_node_0	(SEQ ID NO:302)

	HUMCA1XIA_node_2	(SEQ ID NO:303)

	HUMCA1XIA_node_4	(SEQ ID NO:304)

	HUMCA1XIA_node_6	(SEQ ID NO:305)

	HUMCA1XIA_node_8	(SEQ ID NO:306)

	HUMCA1XIA_node_9	(SEQ ID NO:307)

	HUMCA1XIA_node_18	(SEQ ID NO:308)

	HUMCA1XIA_node_54	(SEQ ID NO:309)

	HUMCA1XIA_node_55	(SEQ ID NO:310)

	HUMCA1XIA_node_92	(SEQ ID NO:311)

	HUMCA1XIA_node_11	(SEQ ID NO:312)

	HUMCA1XIA_node_15	(SEQ ID NO:313)

	HUMCA1XIA_node_19	(SEQ ID NO:314)

	HUMCA1XIA_node_21	(SEQ ID NO:315)

	HUMCA1XIA_node_23	(SEQ ID NO:316)

	HUMCA1XIA_node_25	(SEQ ID NO:317)

	HUMCA1XIA_node_27	(SEQ ID NO:318)

	HUMCA1XIA_node_29	(SEQ ID NO:319)

	HUMCA1XIA_node_31	(SEQ ID NO:320)

	HUMCA1XIA_node_33	(SEQ ID NO:321)

	HUMCA1XIA_node_35	(SEQ ID NO:322)

	HUMCA1XIA_node_37	(SEQ ID NO:323)

	HUMCA1XIA_node_39	(SEQ ID NO:324)

	HUMCA1XIA_node_41	(SEQ ID NO:325)

	HUMCA1XIA_node_43	(SEQ ID NO:326)

	HUMCA1XIA_node_45	(SEQ ID NO:327)

	HUMCA1XIA_node_47	(SEQ ID NO:328)

	HUMCA1XIA_node_49	(SEQ ID NO:329)

	HUMCA1XIA_node_51	(SEQ ID NO:330)

	HUMCA1XIA_node_57	(SEQ ID NO:331)

	HUMCA1XIA_node_59	(SEQ ID NO:332)

	HUMCA1XIA_node_62	(SEQ ID NO:333)

	HUMCA1XIA_node_64	(SEQ ID NO:334)

	HUMCA1XIA_node_66	(SEQ ID NO:335)

	HUMCA1XIA_node_68	(SEQ ID NO:336)

	HUMCA1XIA_node_70	(SEQ ID NO:337)

	HUMCA1XIA_node_72	(SEQ ID NO:338)

	HUMCA1XIA_node_74	(SEQ ID NO:339)

	HUMCA1XIA_node_76	(SEQ ID NO:340)

	HUMCA1XIA_node_78	(SEQ ID NO:341)

	HUMCA1XIA_node_81	(SEQ ID NO:342)

	HUMCA1XIA_node_83	(SEQ ID NO:343)

	HUMCA1XIA_node_85	(SEQ ID NO:344)

	HUMCA1XIA_node_87	(SEQ ID NO:345)

	HUMCA1XIA_node_89	(SEQ ID NO:346)

	HUMCA1XIA_node_91	(SEQ ID NO:347)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HUMCA1XIA_P14	(SEQ ID NO:350)

	HUMCA1XIA_P15	(SEQ ID NO:351)

	HUMCA1XIA_P16	(SEQ ID NO:352)

	HUMCA1XIA_P17	(SEQ ID NO:353)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	R20779_T7 (SEQ ID NO: 354)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	R20779_node_0 (SEQ ID NO: 355)
	R20779_node_2 (SEQ ID NO: 356)
	R20779_node_7 (SEQ ID NO: 357)
	R20779_node_9 (SEQ ID NO: 358)
	R20779_node_18 (SEQ ID NO: 359)
	R20779_node_21 (SEQ ID NO: 360)
	R20779_node_24 (SEQ ID NO: 361)
	R20779_node_27 (SEQ ID NO: 362)
	R20779_node_28 (SEQ ID NO: 363)
	R20779_node_30 (SEQ ID NO: 364)
	R20779_node_31 (SEQ ID NO: 365)
	R20779_node_32 (SEQ ID NO: 366)
	R20779_node_1 (SEQ ID NO: 367)
	R20779_node_3 (SEQ ID NO: 368)
	R20779_node_10 (SEQ ID NO: 369)
	R20779_node_11 (SEQ ID NO: 370)
	R20779_node_14 (SEQ ID NO: 371)
	R20779_node_17 (SEQ ID NO: 372)
	R20779_node_19 (SEQ ID NO: 373)
	R20779_node_20 (SEQ ID NO: 374)
	R20779_node_22 (SEQ ID NO: 375)
	R20779_node_23 (SEQ ID NO: 376)
	R20779_node_25 (SEQ ID NO: 377)
	R20779_node_29 (SEQ ID NO: 378)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence according to R20779_P2 (SEQ ID NO:380).

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HSS100PCB_T1	(SEQ ID NO:381)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HSS100PCB_node_3	(SEQ ID NO:382)

	HSS100PCB_node_4	(SEQ ID NO:383)

	HSS100PCB_node_5	(SEQ ID NO:384)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence according to HSS100PCB_P3 (SEQ ID NO:386).

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HSCOC4_PEA_1_T1	(SEQ ID NO:387)

	HSCOC4_PEA_1_T2	(SEQ ID NO:388)

	HSCOC4_PEA_1_T3	(SEQ ID NO:389)

	HSCOC4_PEA_1_T4	(SEQ ID NO:390)

	HSCOC4_PEA_1_T5	(SEQ ID NO:391)

	HSCOC4_PEA_1_T7	(SEQ ID NO:392)

	HSCOC4_PEA_1_T8	(SEQ ID NO:393)

	HSCOC4_PEA_1_T11	(SEQ ID NO:394)

	HSCOC4_PEA_1_T12	(SEQ ID NO:395)

	HSCOC4_PEA_1_T14	(SEQ ID NO:396)

	HSCOC4_PEA_1_T15	(SEQ ID NO:397)

	HSCOC4_PEA_1_T20	(SEQ ID NO:398)

	HSCOC4_PEA_1_T21	(SEQ ID NO:399)

	HSCOC4_PEA_1_T25	(SEQ ID NO:400)

	HSCOC4_PEA_1_T28	(SEQ ID NO:401)

	HSCOC4_PEA_1_T30	(SEQ ID NO:402)

	HSCOC4_PEA_1_T31	(SEQ ID NO:403)

	HSCOC4_PEA_1_T32	(SEQ ID NO:404)

	HSCOC4_PEA_1_T40	(SEQ ID NO:405)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HSCOC4_PEA_1_node_1	(SEQ ID NO:406)

	HSCOC4_PEA_1_node_5	(SEQ ID NO:407)

	HSCOC4_PEA_1_node_7	(SEQ ID NO:408)

	HSCOC4_PEA_1_node_30	(SEQ ID NO:409)

	HSCOC4_PEA_1_node_33	(SEQ ID NO:410)

	HSCOC4_PEA_1_node_35	(SEQ ID NO:411)

	HSCOC4_PEA_1_node_37	(SEQ ID NO:412)

	HSCOC4_PEA_1_node_39	(SEQ ID NO:413)

	HSCOC4_PEA_1_node_43	(SEQ ID NO:414)

	HSCOC4_PEA_1_node_48	(SEQ ID NO:415)

	HSCOC4_PEA_1_node_49	(SEQ ID NO:416)

	HSCOC4_PEA_1_node_51	(SEQ ID NO:417)

	HSCOC4_PEA_1_node_58	(SEQ ID NO:418)

	HSCOC4_PEA_1_node_59	(SEQ ID NO:419)

	HSCOC4_PEA_1_node_62	(SEQ ID NO:420)

	HSCOC4_PEA_1_node_66	(SEQ ID NO:421)

	HSCOC4_PEA_1_node_72	(SEQ ID NO:422)

	HSCOC4_PEA_1_node_77	(SEQ ID NO:423)

	HSCOC4_PEA_1_node_79	(SEQ ID NO:424)

	HSCOC4_PEA_1_node_93	(SEQ ID NO:425)

	HSCOC4_PEA_1_node_100	(SEQ ID NO:426)

	HSCOC4_PEA_1_node_105	(SEQ ID NO:427)

	HSCOC4_PEA_1_node_107	(SEQ ID NO:428)

	HSCOC4_PEA_1_node_108	(SEQ ID NO:429)

	HSCOC4_PEA_1_node_109	(SEQ ID NO:430)

	HSCOC4_PEA_1_node_110	(SEQ ID NO:431)

	HSCOC4_PEA_1_node_112	(SEQ ID NO:432)

	HSCOC4_PEA_1_node_113	(SEQ ID NO:433)

	HSCOC4_PEA_1_node_2	(SEQ ID NO:434)

	HSCOC4_PEA_1_node_8	(SEQ ID NO:435)

	HSCOC4_PEA_1_node_10	(SEQ ID NO:436)

	HSCOC4_PEA_1_node_12	(SEQ ID NO:437)

	HSCOC4_PEA_1_node_14	(SEQ ID NO:438)

	HSCOC4_PEA_1_node_17	(SEQ ID NO:439)

	HSCOC4_PEA_1_node_19	(SEQ ID NO:440)

	HSCOC4_PEA_1_node_21	(SEQ ID NO:441)

	HSCOC4_PEA_1_node_22	(SEQ ID NO:442)

	HSCOC4_PEA_1_node_28	(SEQ ID NO:443)

	HSCOC4_PEA_1_node_29	(SEQ ID NO:444)

	HSCOC4_PEA_1_node_41	(SEQ ID NO:445)

	HSCOC4_PEA_1_node_45	(SEQ ID NO:446)

	HSCOC4_PEA_1_node_47	(SEQ ID NO:447)

	HSCOC4_PEA_1_node_50	(SEQ ID NO:448)

	HSCOC4_PEA_1_node_53	(SEQ ID NO:449)

	HSCQC4_PEA_1_node_55	(SEQ ID NO:450)

	HSCOC4_PEA_1_node_57	(SEQ ID NO:451)

	HSCOC4_PEA_1_node_60	(SEQ ID NO:452)

	HSCOC4_PEA_1_node_64	(SEQ ID NO:453)

	HSCOC4_PEA_1_node_69	(SEQ ID NO:454)

	HSCOC4_PEA_1_node_70	(SEQ ID NO:455)

	HSCOC4_PEA_1_node_71	(SEQ ID NO:456)

	HSCOC4_PEA_1_node_73	(SEQ ID NO:457)

	HSCOC4_PEA_1_node_74	(SEQ ID NO:458)

	HSCOC4_PEA_1_node_75	(SEQ ID NO:459)

	HSCOC4_PEA_1_node_76	(SEQ ID NO:460)

	HSCOC4_PEA_1_node_78	(SEQ ID NO:461)

	HSCOC4_PEA_1_node_80	(SEQ ID NO:462)

	RSCOC4_PEA_1_node_82	(SEQ ID NO:463)

	HSCOC4_PEA_1_node_83	(SEQ ID NO:464)

	HSCOC4_PEA_1_node_84	(SEQ ID NO:465)

	HSCOC4_PEA_1_node_85	(SEQ ID NO:466)

	HSCOC4_PEA_1_node_86	(SEQ ID NO:467)

	HSCOC4_PEA_1_node_87	(SEQ ID NO:468)

	HSCOC4_PEA_1_node_88	(SEQ ID NO:469)

	HSCOC4_PEA_1_node_89	(SEQ ID NO:470)

	HSCOC4_PEA_1_node_90	(SEQ ID NO:471)

	HSCOC4_PEA_1_node_91	(SEQ ID NO:472)

	HSCOC4_PEA_1_node_92	(SEQ ID NO:473)

	HSCOC4_PEA_1_node_94	(SEQ ID NO:474)

	HSCOC4_PEA_1_node_96	(SEQ ID NO:475)

	HSCOC4_PEA_1_node_97	(SEQ ID NO:476)

	HSCOC4_PEA_1_node_98	(SEQ ID NO:477)

	HSCOC4_PEA_1_node_99	(SEQ ID NO:478)

	HSCOC4_PEA_1_node_101	(SEQ ID NO:479)

	HSCOC4_PEA_1_node_102	(SEQ ID NO:480)

	HSCOC4_PEA_1_node_103	(SEQ ID NO:481)

	HSCOC4_PEA_1_node_104	(SEQ ID NO:482)

	HSCOC4_PEA_1_node_106	(SEQ ID NO:483)

	HSCOC4_PEA_1_node_111	(SEQ ID NO:484)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HSCOC4_PEA_1_P3	(SEQ ID NO:488)

	HSCOC4_PEA_1_P5	(SEQ ID NO:489)

	HSCOC4_PEA_1_P6	(SEQ ID NO:490)

	HSCOC4_PEA_1_P12	(SEQ ID NO:491)

	HSCOC4_PEA_1_P15	(SEQ ID NO:492)

	HSCOC4_PEA_1_P16	(SEQ ID NO:493)

	HSCOC4_PEA_1_P20	(SEQ ID NO:494)

	HSCOC4_PEA_1_P9	(SEQ ID NO:495)

	HSCOC4_PEA_1_P22	(SEQ ID NO:496)

	HSCOC4_PEA_1_P23	(SEQ ID NO:497)

	HSCOC4_PEA_1_P24	(SEQ ID NO:498)

	HSCOC4_PEA_1_P25	(SEQ ID NO:499)

	HSCOC4_PEA_1_P26	(SEQ ID NO:500)

	HSCOC4_PEA_1_P30	(SEQ ID NO:501)

	HSCOC4_PEA_1_P38	(SEQ ID NO:502)

	HSCOC4_PEA_1_P39	(SEQ ID NO:503)

	HSCOC4_PEA_1_P40	(SEQ ID NO:504)

	HSCOC4_PEA_1_P41	(SEQ ID NO:505)

	HSCOC4_PEA_1_P42	(SEQ ID NO:506)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HUMTREFAC_PEA_2_T4	(SEQ ID NO:507)

	HUMTREFAC_PEA_2_T5	(SEQ ID NO:508)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HUMTREFAC_PEA_2_node_0	(SEQ ID NO:509)

	HUMTREFAC_PEA_2_node_9	(SEQ ID NO:510)

	HUMTREFAC_PEA_2_node_2	(SEQ ID NO:511)

	HUMTREFAC_PEA_2_node_3	(SEQ ID NO:512)

	HUMTREFAC_PEA_2_node_4	(SEQ ID NO:513)

	HUMTREFAC_PEA_2_node_5	(SEQ ID NO:514)

	HUMTREFAC_PEA_2_node_8	(SEQ ID NO:515)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HUMTREFAC_PEA_2_P7	(SEQ ID NO:517)

	HUMTREFAC_PEA_2_P8	(SEQ ID NO:518)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HUMOSTRO_PEA_1_PEA_1_T14	(SEQ ID NO:519)

	HUMOSTRO_PEA_1_PEA_1_T16	(SEQ ID NO:520)

	HUMOSTRO_PEA_1_PEA_1_T30	(SEQ ID NO:521)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HUMOSTRO_PEA_1_PEA_1_node_0	(SEQ ID NO:522)

	HUMOSTRO_PEA_1_PEA_1_node_10	(SEQ ID NO:523)

	HUMOSTRO_PEA_1_PEA_1_node_16	(SEQ ID NO:524)

	HUMOSTRO_PEA_1_PEA_1_node_23	(SEQ ID NO:525)

	HUMOSTRO_PEA_1_PEA_1_node_31	(SEQ ID NO:526)

	HUMOSTRO_PEA_1_PEA_1_node_43	(SEQ ID NO:527)

	HUMOSTRO_PEA_1_PEA_1_node_3	(SEQ ID NO:528)

	HUMOSTRO_PEA_1_PEA_1_node_5	(SEQ ID NO:529)

	HUMOSTRO_PEA_1_PEA_1_node_7	(SEQ ID NO:530)

	HUMOSTRO_PEA_1_PEA_1_node_8	(SEQ ID NO:531)

	HUMOSTRO_PEA_1_PEA_1_node_15	(SEQ ID NO:532)

	HUMOSTRO_PEA_1_PEA_1_node_17	(SEQ ID NO:533)

	HUMOSTRO_PEA_1_PEA_1_node_20	(SEQ ID NO:534)

	HUMOSTRO_PEA_1_PEA_1_node_21	(SEQ ID NO:535)

	HUMOSTRO_PEA_1_PEA_1_node_22	(SEQ ID NO:536)

	HUMOSTRO_PEA_1_PEA_1_node_24	(SEQ ID NO:537)

	HUMOSTRO_PEA_1_PEA_1_node_26	(SEQ ID NO:538)

	HUMOSTRO_PEA_1_PEA_1_node_27	(SEQ ID NO:539)

	HUMOSTRO_PEA_1_PEA_1_node_28	(SEQ ID NO:540)

	HUMOSTRO_PEA_1_PEA_1_node_29	(SEQ ID NO:541)

	HUMOSTRO_PEA_1_PEA_1_node_30	(SEQ ID NO:542)

	HUMOSTRO_PEA_1_PEA_1_node_32	(SEQ ID NO:543)

	HUMOSTRO_PEA_1_PEA_1_node_34	(SEQ ID NO:544)

	HUMOSTRO_PEA_1_PEA_1_node_36	(SEQ ID NO:545)

	HUMOSTRO_PEA_1_PEA_1_node_37	(SEQ ID NO:546)

	HUMOSTRO_PEA_1_PEA_1_node_38	(SEQ ID NO:547)

	HUMOSTRO_PEA_1_PEA_1_node_39	(SEQ ID NO:548)

	HUMOSTRO_PEA_1_PEA_1_node_40	(SEQ ID NO:549)

	HUMOSTRO_PEA_1_PEA_1_node_41	(SEQ ID NO:550)

	HUMOSTRO_PEA_1_PEA_1_node_42	(SEQ ID NO:551)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HUMOSTRO_PEA_1_PEA_1_P21	(SEQ ID NO:553)

	HUMOSTRO_PEA_1_PEA_1_P25	(SEQ ID NO:554)

	HUMOSTRO_PEA_1_PEA_1_P30	(SEQ ID NO:555)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a polynucleotide having a sequence selected from the group consisting of: R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560), or R11723_PEA_—1_T6 (SEQ ID NO:561).

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a node having a sequence selected from the group consisting of: R11723_PEA_—1_node_—13 (SEQ ID NO:562), R11723_PEA_—1_node_—16 (SEQ ID NO:563), R11723_PEA_—1_node_—19 (SEQ ID NO:564), R11723_PEA_—1_node_—2 (SEQ ID NO:565), R11723_PEA_—1_node_—22 (SEQ ID NO:566), R11723_PEA_—1_node_—31 (SEQ ID NO:567), R11723_PEA_—1_node_—10 (SEQ ID NO:568), R11723_PEA_—1_node_—11 (SEQ ID NO:569), R11723_PEA_—1_node_—15 (SEQ ID NO:570), R11723_PEA_—1_node_—18 (SEQ ID NO:571), R11723_PEA_—1_node_—20 (SEQ ID NO:572), R11723_PEA_—1_node_—21 (SEQ ID NO:573), R11723_PEA_—1_node_—23 (SEQ ID NO:574), R11723_PEA_—1_node_—24 (SEQ ID NO:575), R11723_PEA_—1_node_—25 (SEQ ID NO:576), R11723_PEA_—1_node_—26 (SEQ ID NO:577), R11723_PEA_—1_node_—27 (SEQ ID NO:578), R11723_PEA_—1_node_—28 (SEQ ID NO:579), R11723_PEA_—1_node_—29 (SEQ ID NO:580), R11723_PEA_—1_node_—3 (SEQ ID NO:581), R11723_PEA_—1_node_—30 (SEQ ID NO:582), R11723_PEA_—1_node_—4 (SEQ ID NO:583), R11723_PEA_—1_node_—5 (SEQ ID NO:584), R11723_PEA_—1_node_—6 (SEQ ID NO:585), R11723_PEA_—1_node_—7 (SEQ ID NO:586) or R11723_PEA_—1_node_—8 (SEQ ID NO:587).

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising a polypeptide having a sequence selected from the group consisting of: R11723_PEA_—1₁₃P2 (SEQ ID NO:588), R11723_PEA_—1_P6 (SEQ ID NO:589), R11723_PEA_—1_P7 (SEQ ID NO:590), R11723_PEA_—1_P13 (SEQ ID NO:591), or R11723_PEA_—1_P10 (SEQ ID NO:592).

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T46984_PEA_1_T2 (SEQ ID NO: 593)
	T46984_PEA_1_T3 (SEQ ID NO: 594)
	T46984_PEA_1_T12 (SEQ ID NO: 595)
	T46984_PEA_1_T13 (SEQ ID NO: 596)
	T46984_PEA_1_T14 (SEQ ID NO: 597)
	T46984_PEA_1_T15 (SEQ ID NO: 598)
	T46984_PEA_1_T19 (SEQ ID NO: 599)
	T46984_PEA_1_T23 (SEQ ID NO: 600)
	T46984_PEA_1_T27 (SEQ ID NO: 601)
	T46984_PEA_1_T32 (SEQ ID NO: 602)
	T46984_PEA_1_T34 (SEQ ID NO: 603)
	T46984_PEA_1_T35 (SEQ ID NO: 604)
	T46984_PEA_1_T40 (SEQ ID NO: 605)
	T46984_PEA_1_T42 (SEQ ID NO: 606)
	T46984_PEA_1_T43 (SEQ ID NO: 607)
	T46984_PEA_1_T46 (SEQ ID NO: 608)
	T46984_PEA_1_T47 (SEQ ID NO: 609)
	T46984_PEA_1_T48 (SEQ ID NO: 610)
	T46984_PEA_1_T51 (SEQ ID NO: 611)
	T46984_PEA_1_T52 (SEQ ID NO: 612)
	T46984_PEA_1_T54 (SEQ ID NO: 613)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T46984_PEA_1_node_2 (SEQ ID NO: 614)
	T46984_PEA_1_node_4 (SEQ ID NO: 615)
	T46984_PEA_1_node_6 (SEQ ID NO: 616)
	T46984_PEA_1_node_12 (SEQ ID NO: 617)
	T46984_PEA_1_node_14 (SEQ ID NO: 618)
	T46984_PEA_1_node_25 (SEQ ID NO: 619)
	T46984_PEA_1_node_29 (SEQ ID NO: 620)
	T46984_PEA_1_node_34 (SEQ ID NO: 621)
	T46984_PEA_1_node_46 (SEQ ID NO: 622)
	T46984_PEA_1_node_47 (SEQ ID NO: 623)
	T46984_PEA_1_node_52 (SEQ ID NO: 624)
	T46984_PEA_1_node_65 (SEQ ID NO: 625)
	T46984_PEA_1_node_69 (SEQ ID NO: 626)
	T46984_PEA_1_node_75 (SEQ ID NO: 627)
	T46984_PEA_1_node_86 (SEQ ID NO: 628)
	T46984_PEA_1_node_9 (SEQ ID NO: 629)
	T46984_PEA_1_node_13 (SEQ ID NO: 630)
	T46984_PEA_1_node_19 (SEQ ID NO: 631)
	T46984_PEA_1_node_21 (SEQ ID NO: 632)
	T46984_PEA_1_node_22 (SEQ ID NO: 633)
	T46984_PEA_1_node_26 (SEQ ID NO: 634)
	T46984_PEA_1_node_28 (SEQ ID NO: 635)
	T46984_PEA_1_node_31 (SEQ ID NO: 636)
	T46984_PEA_1_node_32 (SEQ ID NO: 637)
	T46984_PEA_1_node_38 (SEQ ID NO: 638)
	T46984_PEA_1_node_39 (SEQ ID NO: 639)
	T46984_PEA_1_node_40 (SEQ ID NO: 640)
	T46984_PEA_1_node_42 (SEQ ID NO: 641)
	T46984_PEA_1_node_43 (SEQ ID NO: 642)
	T46984_PEA_1_node_48 (SEQ ID NO: 643)
	T46984_PEA_1_node_49 (SEQ ID NO: 644)
	T46984_PEA_1_node_50 (SEQ ID NO: 645)
	T46984_PEA_1_node_51 (SEQ ID NO: 646)
	T46984_PEA_1_node_53 (SEQ ID NO: 647)
	T46984_PEA_1_node_54 (SEQ ID NO: 648)
	T46984_PEA_1_node_55 (SEQ ID NO: 649)
	T46984_PEA_1_node_57 (SEQ ID NO: 650)
	T46984_PEA_1_node_60 (SEQ ID NO: 651)
	T46984_PEA_1_node_62 (SEQ ID NO: 652)
	T46984_PEA_1_node_66 (SEQ ID NO: 653)
	T46984_PEA_1_node_67 (SEQ ID NO: 654)
	T46984_PEA_1_node_70 (SEQ ID NO: 655)
	T46984_PEA_1_node_71 (SEQ ID NO: 656)
	T46984_PEA_1_node_72 (SEQ ID NO: 657)
	T46984_PEA_1_node_73 (SEQ ID NO: 658)
	T46984_PEA_1_node_74 (SEQ ID NO: 659)
	T46984_PEA_1_node_83 (SEQ ID NO: 660)
	T46984_PEA_1_node_84 (SEQ ID NO: 661)
	T46984_PEA_1_node_85 (SEQ ID NO: 662)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	T46984_PEA_1_P2 (SEQ ID NO: 664)
	T46984_PEA_1_P3 (SEQ ID NO: 665)
	T46984_PEA_1_P10 (SEQ ID NO: 666)
	T46984_PEA_1_P11 (SEQ ID NO: 667)
	T46984_PEA_1_P12 (SEQ ID NO: 668)
	T46984_PEA_1_P21 (SEQ ID NO: 669)
	T46984_PEA_1_P27 (SEQ ID NO: 670)
	T46984_PEA_1_P32 (SEQ ID NO: 671)
	T46984_PEA_1_P34 (SEQ ID NO: 672)
	T46984_PEA_1_P35 (SEQ ID NO: 673)
	T46984_PEA_1_P38 (SEQ ID NO: 674)
	T46984_PEA_1_P39 (SEQ ID NO: 675)
	T46984_PEA_1_P45 (SEQ ID NO: 676)
	T46984_PEA_1_P46 (SEQ ID NO: 677)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	T11628_PEA_1_T3 (SEQ ID NO: 678)
	T11628_PEA_1_T4 (SEQ ID NO: 679)
	T11628_PEA_1_T5 (SEQ ID NO: 680)
	T11628_PEA_1_T7 (SEQ ID NO: 681)
	T11628_PEA_1_T9 (SEQ ID NO: 682)
	T11628_PEA_1_T11 (SEQ ID NO: 683)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	T11628_PEA_1_node_7 (SEQ ID NO: 684)
	T11628_PEA_1_node_11 (SEQ ID NO: 685)
	T11628_PEA_1_node_16 (SEQ ID NO: 686)
	T11628_PEA_1_node_22 (SEQ ID NO: 687)
	T11628_PEA_1_node_25 (SEQ ID NO: 688)
	T11628_PEA_1_node_31 (SEQ ID NO: 689)
	T11628_PEA_1_node_37 (SEQ ID NO: 690)
	T11628_PEA_1_node_0 (SEQ ID NO: 691)
	T11628_PEA_1_node_4 (SEQ ID NO: 692)
	T11628_PEA_1_node_9 (SEQ ID NO: 693)
	T11628_PEA_1_node_13 (SEQ ID NO: 694)
	T11628_PEA_1_node_14 (SEQ ID NO: 695)
	T11628_PEA_1_node_17 (SEQ ID NO: 696)
	T11628_PEA_1_node_18 (SEQ ID NO: 697)
	T11628_PEA_1_node_19 (SEQ ID NO: 698)
	T11628_PEA_1_node_24 (SEQ ID NO: 699)
	T11628_PEA_1_node_27 (SEQ ID NO: 700)
	T11628_PEA_1_node_28 (SEQ ID NO: 701)
	T11628_PEA_1_node_29 (SEQ ID NO: 702)
	T11628_PEA_1_node_30 (SEQ ID NO: 703)
	T11628_PEA_1_node_32 (SEQ ID NO: 704)
	T11628_PEA_1_node_33 (SEQ ID NO: 705)
	T11628_PEA_1_node_34 (SEQ ID NO: 706)
	T11628_PEA_1_node_35 (SEQ ID NO: 707)
	T11628_PEA_1_node_36 (SEQ ID NO: 708)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	T11628_PEA_1_P2 (SEQ ID NO: 712)
	T11628_PEA_1_P5 (SEQ ID NO: 713)
	T11628_PEA_1_P7 (SEQ ID NO: 714)
	T11628_PEA_1_P10 (SEQ ID NO: 715)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	M78076_PEA_1_T2 (SEQ ID NO: 716)
	M78076_PEA_1_T3 (SEQ ID NO: 717)
	M78076_PEA_1_T5 (SEQ ID NO: 718)
	M78076_PEA_1_T13 (SEQ ID NO: 719)
	M78076_PEA_1_T15 (SEQ ID NO: 720)
	M78076_PEA_1_T23 (SEQ ID NO: 721)
	M78076_PEA_1_T26 (SEQ ID NO: 722)
	M78076_PEA_1_T27 (SEQ ID NO: 723)
	M78076_PEA_1_T28 (SEQ ID NO: 724)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	M78076_PEA_1_node_0 (SEQ ID NO: 725)
	M78076_PEA_1_node_10 (SEQ ID NO: 726)
	M78076_PEA_1_node_15 (SEQ ID NO: 727)
	M78076_PEA_1_node_18 (SEQ ID NO: 728)
	M78076_PEA_1_node_20 (SEQ ID NO: 729)
	M78076_PEA_1_node_24 (SEQ ID NO: 730)
	M78076_PEA_1_node_26 (SEQ ID NO: 731)
	M78076_PEA_1_node_29 (SEQ ID NO: 732)
	M78076_PEA_1_node_32 (SEQ ID NO: 733)
	M78076_PEA_1_node_35 (SEQ ID NO: 734)
	M78076_PEA_1_node_37 (SEQ ID NO: 735)
	M78076_PEA_1_node_46 (SEQ ID NO: 736)
	M78076_PEA_1_node_47 (SEQ ID NO: 737)
	M78076_PEA_1_node_54 (SEQ ID NO: 738)
	M78076_PEA_1_node_1 (SEQ ID NO: 739)
	M78076_PEA_1_node_2 (SEQ ID NO: 740)
	M78076_PEA_1_node_3 (SEQ ID NO: 741)
	M78076_PEA_1_node_6 (SEQ ID NO: 742)
	M78076_PEA_1_node_7 (SEQ ID NO: 743)
	M78076_PEA_1_node_12 (SEQ ID NO: 744)
	M78076_PEA_1_node_22 (SEQ ID NO: 745)
	M78076_PEA_1_node_27 (SEQ ID NO: 746)
	M78076_PEA_1_node_30 (SEQ ID NO: 747)
	M78076_PEA_1_node_31 (SEQ ID NO: 748)
	M78076_PEA_1_node_34 (SEQ ID NO: 749)
	M78076_PEA_1_node_36 (SEQ ID NO: 750)
	M78076_PEA_1_node_41 (SEQ ID NO: 751)
	M78076_PEA_1_node_42 (SEQ ID NO: 752)
	M78076_PEA_1_node_43 (SEQ ID NO: 753)
	M78076_PEA_1_node_45 (SEQ ID NO: 754)
	M78076_PEA_1_node_49 (SEQ ID NO: 755)
	M78076_PEA_1_node_50 (SEQ ID NO: 756)
	M78076_PEA_1_node_51 (SEQ ID NO: 757)
	M78076_PEA_1_node_52 (SEQ ID NO: 758)
	M78076_PEA_1_node_53 (SEQ ID NO: 759)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	M78076_PEA_1_P3 (SEQ ID NO: 761)
	M78076_PEA_1_P4 (SEQ ID NO: 762)
	M78076_PEA_1_P12 (SEQ ID NO: 763)
	M78076_PEA_1_P14 (SEQ ID NO: 764)
	M78076_PEA_1_P21 (SEQ ID NO: 765)
	M78076_PEA_1_P24 (SEQ ID NO: 766)
	M78076_PEA_1_P2 (SEQ ID NO: 767)
	M78076_PEA_1_P25 (SEQ ID NO: 768)

According to preferred embodiments of the present invention, there is provided an isolated polynucleotide comprising a nucleic acid sequence in the table below and/or:



Transcript Name

	HSMUC1A_PEA_1_T12	(SEQ ID NO:769)

	HSMUC1A_PEA_1_T26	(SEQ ID NO:770)

	HSMUC1A_PEA_1_T28	(SEQ ID NO:771)

	HSMUC1A_PEA_1_T29	(SEQ ID NO:772)

	HSMUC1A_PEA_1_T30	(SEQ ID NO:773)

	HSMUC1A_PEA_1_T31	(SEQ ID NO:774)

	HSMUC1A_PEA_1_T33	(SEQ ID NO:775)

	HSMUC1A_PEA_1_T34	(SEQ ID NO:776)

	HSMUC1A_PEA_1_T35	(SEQ ID NO:777)

	HSMUC1A_PEA_1_T36	(SEQ ID NO:778)

	HSMUC1A_PEA_1_T40	(SEQ ID NO:779)

	HSMUC1A_PEA_1_T42	(SEQ ID NO:780)

	HSMUC1A_PEA_1_T43	(SEQ ID NO:781)

	HSMUC1A_PEA_1_T47	(SEQ ID NO:782)

a nucleic acid sequence comprising a sequence in the table below:



Segment Name

	HSMUC1A_PEA_1_node_0	(SEQ ID NO:783)

	HSMUC1A_PEA_1_node_14	(SEQ ID NO:784)

	HSMUC1A_PEA_1_node_24	(SEQ ID NO:785)

	HSMUC1A_PEA_1_node_29	(SEQ ID NO:786)

	HSMUC1A_PEA_1_node_35	(SEQ ID NO:787)

	HSMUC1A_PEA_1_node_38	(SEQ ID NO:788)

	HSMUC1A_PEA_1_node_3	(SEQ ID NO:789)

	HSMUC1A_PEA_1_node_4	(SEQ ID NO:790)

	HSMUC1A_PEA_1_node_5	(SEQ ID NO:791)

	HSMUC1A_PEA_1_node_6	(SEQ ID NO:792)

	HSMUC1A_PEA_1_node_7	(SEQ ID NO:793)

	HSMUC1A_PEA_1_node_17	(SEQ ID NO:794)

	HSMUC1A_PEA_1_node_18	(SEQ ID NO:795)

	HSMUC1A_PEA_1_node_20	(SEQ ID NO:796)

	HSMUC1A_PEA_1_node_21	(SEQ ID NO:797)

	HSMUC1A_PEA_1_node_23	(SEQ ID NO:798)

	HSMUC1A_PEA_1_node_26	(SEQ ID NO:799)

	HSMUC1A_PEA_1_node_27	(SEQ ID NO:800)

	HSMUC1A_PEA_1_node_31	(SEQ ID NO:801)

	HSMUC1A_PEA_1_node_34	(SEQ ID NO:802)

	HSMUC1A_PEA_1_node_36	(SEQ ID NO:803)

	HSMUC1A_PEA_1_node_37	(SEQ ID NO:804)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide comprising an amino acid sequence in the table below



Protein Name

	HSMUC1A_PEA_1_P25	(SEQ ID NO:806)

	HSMUC1A_PEA_1_P29	(SEQ ID NO:807)

	HSMUC1A_PEA_1_P30	(SEQ ID NO:808)

	HSMUC1A_PEA_1_P32	(SEQ ID NO:809)

	HSMUC1A_PEA_1_P36	(SEQ ID NO:810)

	HSMUC1A_PEA_1_P39	(SEQ ID NO:811)

	HSMUC1A_PEA_1_P45	(SEQ ID NO:812)

	HSMUC1A_PEA_1_P49	(SEQ ID NO:813)

	HSMUC1A_PEA_1_P52	(SEQ ID NO:814)

	HSMUC1A_PEA_1_P53	(SEQ ID NO:815)

	HSMUC1A_PEA_1_P56	(SEQ ID NO:816)

	HSMUC1A_PEA_1_P58	(SEQ ID NO:817)

	HSMUC1A_PEA_1_P59	(SEQ ID NO:818)

	HSMUC1A_PEA_1_P63	(SEQ ID NO:819)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), comprising a first amino acid sequence being at least 90% homologous to MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSV corresponding to amino acids 1-45 of MUC1_HUMAN (SEQ ID NO:805), which also corresponds to amino acids 1-45 of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK (SEQ ID NO:946) corresponding to amino acids 46-85 of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK (SEQ ID NO:946) in HSMUC1A_PEA_—1_P63 (SEQ ID NO:819).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P2 (SEQ ID NO:664), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNV corresponding to amino acids 1-498 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-498 of T46984_PEA_—1_P2 (SEQ ID NO:664), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VCA corresponding to amino acids 499-501 of T46984_PEA_—1_P2 (SEQ ID NO:664), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P3 (SEQ ID NO:665), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQ corresponding to amino acids 1-433 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-433 of T46984_PEA_—1_P3 (SEQ ID NO:665), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ICHIWKLIFLP (SEQ ID NO:947) corresponding to amino acids 434-444 of T46984_PEA_—1_P3 (SEQ ID NO:665), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P3 (SEQ ID NO:665), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ICHIWKLIFLP (SEQ ID NO:947) in T46984_PEA_—1_P3 (SEQ ID NO:665).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P10 (SEQ ID NO:666), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNV corresponding to amino acids 1-498 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-498 of T46984_PEA_—1_P10 (SEQ ID NO:666), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LMDQK (SEQ ID NO:948) corresponding to amino acids 499-503 of T46984_PEA_—1_P10 (SEQ ID NO:666), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P10 (SEQ ID NO:666), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LMDQK (SEQ ID NO:948) in T46984_PEA_—1_P10 (SEQ ID NO:666).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P11 (SEQ ID NO:667), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNVADVVIKFPEEEAPSTVLSQNLFTPKQEIQHLFREPEK RPPTVVSNTFTALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGLMYVYWT QLNMFQTLKYLAILGSVTFLAGNRMLAQQAVKR corresponding to amino acids 1-628 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-628 of T46984_PEA_—1_P11 (SEQ ID NO:667).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P12 (SEQ ID NO:668), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMN corresponding to amino acids 1-338 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-338 of T46984_PEA_—1_P12 (SEQ ID NO:668), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SQDLH (SEQ ID NO:949) corresponding to amino acids 339-343 of T46984_PEA_—1_P12 (SEQ ID NO:668), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P12 (SEQ ID NO:668), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SQDLH (SEQ ID NO:949) in T46984_PEA_—1_P12 (SEQ ID NO:668).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P21 (SEQ ID NO:669), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence M corresponding to amino acids 1-1 of T46984_PEA_—1_P21 (SEQ ID NO:669), and a second amino acid sequence being at least 90% homologous to KACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSSVTQIYHAV AALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVA RLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFES LSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKL EHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVEL RVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQLVDVNT GAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDSASGTYTLYLII GDATLKNPILWNVADVVIKFPEEEAPSTVLSQNLFTPKQEIQHLFREPEKRPPTVVSNTF TALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGLMYVYWTQLNMFQTLKY LAILGSVTFLAGNRMLAQQAVKRTAH corresponding to amino acids 70-631 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 2-563 of T46984_PEA_—1_P21 (SEQ ID NO:669), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P27 (SEQ ID NO:670), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFA corresponding to amino acids 1-415 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-415 of T46984_PEA_—1_P27 (SEQ ID NO:670), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence FGSGLVPMSPTSLLLLARLYFTWDMLLCWDSCMSTGLSSTCSRP (SEQ ID NO:950) corresponding to amino acids 416-459 of T46984_PEA_—1_P27 (SEQ ID NO:670), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P27 (SEQ ID NO:670), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence FGSGLVPMSPTSLLLLARLYFTWDMLLCWDSCMSTGLSSTCSRP (SEQ ID NO:950) in T46984_PEA_—1_P27 (SEQ ID NO:670).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P32 (SEQ ID NO:671), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVE corresponding to amino acids 1-364 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-364 of T46984_PEA_—1_P32 (SEQ ID NO:671), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GQVRWLTPVIPALWEAKAGGSPEVRSSILAWPT (SEQ ID NO:951) corresponding to amino acids 365-397 of T46984_PEA_—1_P32 (SEQ ID NO:671), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P32 (SEQ ID NO:671), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GQVRWLTPVIPALWEAKAGGSPEVRSSILAWPT (SEQ ID NO:951) in T46984_PEA_—1_P32 (SEQ ID NO:671).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P34 (SEQ ID NO:672), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVG corresponding to amino acids 1-329 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-329 of T46984_PEA_—1₁₃P34 (SEQ ID NO:672).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P35 (SEQ ID NO:673), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAI corresponding to amino acids 1-287 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-287 of T46984_PEA_—1_P35 (SEQ ID NO:673), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GCWPSRQSREQHISSRRKMEILKTECQEKESRTIHSMRRKMEKKNFI (SEQ ID NO:952) corresponding to amino acids 288-334 of T46984_PEA_—1_P35 (SEQ ID NO:673), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P35 (SEQ ID NO:673), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GCWPSRQSREQHISSRRKMEILKTECQEKESRTIHSMRRKMEKKNFI (SEQ ID NO:952) in T46984_PEA_—1_P35 (SEQ ID NO:673).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P38 (SEQ ID NO:674), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEAL corresponding to amino acids 1-145 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-145 of T46984_PEA_—1_P38 (SEQ ID NO:674), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MDPDWCQCLQLHFCS (SEQ ID NO:953) corresponding to amino acids 146-160 of T46984_PEA_—1_P38 (SEQ ID NO:674), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P38 (SEQ ID NO:674), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MDPDWCQCLQLHFCS (SEQ ID NO:953) in T46984_PEA_—1_P38 (SEQ ID NO:674)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P39 (SEQ ID NO:675), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLA corresponding to amino acids 1-160 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-160 of T46984_PEA_—1_P39 (SEQ ID NO:675).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P45 (SEQ ID NO:676), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCE corresponding to amino acids 1-101 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-101 of T46984_PEA_—1_P45 (SEQ ID NO:676), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) corresponding to amino acids 102-116 of T46984_PEA_—1_P45 (SEQ ID NO:676), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P45 (SEQ ID NO:676), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) in T46984_PEA_—1_P45 (SEQ ID NO:676).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T46984_PEA_—1_P46 (SEQ ID NO:677), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAK corresponding to amino acids 1-69 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-69 of T46984_PEA_—1_P46 (SEQ ID NO:677), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) corresponding to amino acids 70-84 of T46984_PEA_—1_P46 (SEQ ID NO:677), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T46984_PEA_—1_P46 (SEQ ID NO:677), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) in T46984_PEA_—1_P46 (SEQ ID NO:677).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T11628_PEA_—1_P2 (SEQ ID NO:712), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE (SEQ ID NO:956) corresponding to amino acids 1-55 of T11628_PEA_—1_P2 (SEQ ID NO:712), and a second amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 1-99 of Q8WVH6 (SEQ ID NO:711), which also corresponds to amino acids 56-154 of T11628_PEA_—1_P2 (SEQ ID NO:712), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of T11628_PEA_—1_P2 (SEQ ID NO:712), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE	(SEQ ID NO:956)

of T11628_PEA_1_P2.	(SEQ ID NO:712)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T11628_PEA_—1_P5 (SEQ ID NO:713), comprising a first amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 56-154 of MYG_HUMAN_V1 (SEQ ID NO:710), which also corresponds to amino acids 1-99 of T11628_PEA_—1_P5 (SEQ ID NO:713).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T11628_PEA_—1_P7 (SEQ ID NO:714), comprising a first amino acid sequence being at least 90% homologous to MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDEMK ASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQVLQ SKHPGDFGADAQGAMNK corresponding to amino acids 1-134 of MYG_HUMAN_V1 (SEQ ID NO:710), which also corresponds to amino acids 1-134 of T11628_PEA_—1_P7 (SEQ ID NO:714) and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence G corresponding to amino acids 135-135 of T11628_PEA_—1_P7 (SEQ ID NO:714), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T11628_PEA_—1_P10 (SEQ ID NO:715), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE (SEQ ID NO:956) corresponding to amino acids 1-55 of T111628_PEA_—1_P10 (SEQ ID NO:715), and a second amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 1-99 of Q8WVH6 (SEQ ID NO:711), which also corresponds to amino acids 56-154 of T11628_PEA_—1_P10 (SEQ ID NO:715), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of T11628_PEA_—1_P10 (SEQ ID NO:715), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE (SEQ ID NO:956) of T11628_PEA_—1_P10 (SEQ ID NO:715).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P3 (SEQ ID NO:761), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKD corresponding to amino acids 1-517 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-517 of M78076_PEA_—1_P3 (SEQ ID NO:761), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GE corresponding to amino acids 518-519 of M78076_PEA_—1_P3 (SEQ ID NO:761), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P4 (SEQ ID NO:762), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKG corresponding to amino acids 1-526 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-526 of M78076_PEA_—1_P4 (SEQ ID NO:762), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ECLTVNPSLQIPLNP (SEQ ID NO:958) corresponding to amino acids 527-541 of M78076_PEA_—1_P4 (SEQ ID NO:762), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P4 (SEQ ID NO:762), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECLTVNPSLQIPLNP (SEQ ID NO:958) in M78076_PEA_—1_P4 (SEQ ID NO:762).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P12 (SEQ ID NO:763), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKG corresponding to amino acids 1-526 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-526 of M78076_PEA_—1_P12 (SEQ ID NO:763), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ECVCSKGFPFPLIGDSEG (SEQ ID NO:959) corresponding to amino acids 527-544 of M78076_PEA_—1_P12 (SEQ ID NO:763), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P12 (SEQ ID NO:763), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECVCSKGFPFPLIGDSEG (SEQ ID NO:959) in M78076_PEA_—1_P12 (SEQ ID NO:763).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P14 (SEQ ID NO:764), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKGST EQDAASPEKEKMNPLEQYERKVNASVPRGFPFHSSEIQRDEL corresponding to amino acids 1-570 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-570 of M78076_PEA_—1_P14 (SEQ ID NO:764), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRGGTAGYLGEETRGQRPGCDSQSHTGPSKKPSAPSPLPAGTSWDRGVP (SEQ ID NO:960) corresponding to amino acids 571-619 of M78076_PEA_—1_P14 (SEQ ID NO:764), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P14 (SEQ ID NO:764), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRGGTAGYLGEETRGQRPGCDSQSHTGPSKKPSAPSPLPAGTSWDRGVP (SEQ ID NO:960) in M78076_PEA_—1_P14 (SEQ ID NO:764).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P21 (SEQ ID NO:765), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN E corresponding to amino acids 1-352 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-352 of M78076_PEA_—1_P21 (SEQ ID NO:765), and a second amino acid sequence being at least 90% homologous to AERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQ SLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMT LPKGSTEQDAASPEKEKMNPLEQYERKVNASVPRGFPFHSSEIQRDELAPAGTGVSREA VSGLLIMGAGGGSLIVLSMLLLRRKKPYGAISHGVVEVDPMLTLEEQQLRELQRHGYE NPTYRFLEERP corresponding to amino acids 406-650 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 353-597 of M78076_PEA_—1_P21 (SEQ ID NO:765), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of M78076_PEA_—1_P21 (SEQ ID NO:765), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EA, having a structure as follows: a sequence starting from any of amino acid numbers 352-x to 352; and ending at any of amino acid numbers 353+((n−2)−x), in which x varies from 0 to n-2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P24 (SEQ ID NO:766), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQI corresponding to amino acids 1-481 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-481 of M78076_PEA_—1_P24 (SEQ ID NO:766), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RECLLPWLPLQISEGRS (SEQ ID NO:961) corresponding to amino acids 482-498 of M78076_PEA_—1_P24 (SEQ ID NO:766), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P24 (SEQ ID NO:766), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RECLLPWLPLQISEGRS (SEQ ID NO:961) in M78076_PEA_—1_P24 (SEQ ID NO:766).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P2 (SEQ ID NO:767), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQV corresponding to amino acids 1-449 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-449 of M78076_PEA_—1_P2 (SEQ ID NO:767), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LTSFQLPNAPLFLRRPRLRLFSCPLDPLSVSWTPSYPLNTASLPLPSLSAQLPDPETWTLT CCVFDPCFLALGFLLPPPSILCSVPWIFTAFPRIVFFFFFFLRQVLALSPRQESSVRSWLIAT STSWVQAILLPQPLE (SEQ ID NO:962) corresponding to amino acids 450-588 of M78076_PEA_—1_P2 (SEQ ID NO:767), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P2 (SEQ ID NO:767), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


LTSFQLPNAPLFLRRPRLRLFSCPLDPLSVSWTPSYPLNTASLPLPSLSAQLPDPETWTLT	(SEQ ID NO:962)
CCVFDPCFLALGFLLPPPSILCSVPWIFTAFPRIVFFFFFFLRQVLALSPRQESSVRSWLIAT
STSWVQAILLPQPLE

in M78076_PEA_1_P2.	(SEQ ID NO:767)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M78076_PEA_—1_P25 (SEQ ID NO:768), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQ corresponding to amino acids 1-448 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-448 of M78076_PEA_—1_P25 (SEQ ID NO:768), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence PQNPNSQPRAAGSLEVIISHPFVRRLEILISPFQFQNSIPKNSQIVPAASPRGTSSP (SEQ ID NO:963) corresponding to amino acids 449-505 of M78076_PEA_—1_P25 (SEQ ID NO:768), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M78076_PEA_—1_P25 (SEQ ID NO:768), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PQNPNSQPRAAGSLEVIISHPFVRRLEILISPFQFQNSIPKNSQIVPAASPRGTSSP (SEQ ID NO:963) in M78076_PEA_—1_P25 (SEQ ID NO:768).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M85491_PEA_—1_P13 (SEQ ID NO:246), comprising a first amino acid sequence being at least 90% homologous to MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIR TYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYY EADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGF YLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVD VPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPIN SRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSG GREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAV NGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYEL QYYEK corresponding to amino acids 1-476 of EPB2_HUMAN (SEQ ID NO:245), which also corresponds to amino acids 1-476 of M85491_PEA_—1_P13 (SEQ ID NO:246), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPIGWVLSPSPTSLRAPLPG (SEQ ID NO:964) corresponding to amino acids 477-496 of M85491_PEA_—1_P13 (SEQ ID NO:246), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M85491_PEA_—1_P13 (SEQ ID NO:246), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPIGWVLSPSPTSLRAPLPG (SEQ ID NO:964) in M85491_PEA_—1_P13 (SEQ ID NO:246).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for M85491_PEA_—1_P14 (SEQ ID NO:247), comprising a first amino acid sequence being at least 90% homologous to MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIR TYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYY EADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGF YLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVD VPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCR corresponding to amino acids 1-270 of EPB2_HUMAN (SEQ ID NO:245), which also corresponds to amino acids 1-270 of M85491_PEA_—1_P14 (SEQ ID NO:247), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ERQDLTMLSRLVLNSWPQMILPPQPPKVLEL (SEQ ID NO:965) corresponding to amino acids 271-301 of M85491_PEA_—1_P14 (SEQ ID NO:247), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of M85491_PEA_—1_P14 (SEQ ID NO:247), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ERQDLTMLSRLVLNSWPQMILPPQPPKVLEL (SEQ ID NO:965) in M85491_PEA_—1_P14 (SEQ ID NO:247).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROL3_P4 (SEQ ID NO:271), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P4 (SEQ ID NO:271), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P4 (SEQ ID NO:271), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPE KNKIYFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADG corresponding to amino acids 165-445 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-445 of HSSTROL3_P4 (SEQ ID NO:271), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ALGVRQLVGGGHSSRFSHLVVAGLPHACHRKSGSSSQVLCPEPSALLSVAG (SEQ ID NO:966) corresponding to amino acids 446-496 of HSSTROL3_P4 (SEQ ID NO:271), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSSTROL3_P4 (SEQ ID NO:271), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ALGVRQLVGGGHSSRFSHLVVAGLPHACHRKSGSSSQVLCPEPSALLSVAG (SEQ ID NO:966) in HSSTROL3_P4 (SEQ ID NO:271).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROL³_P5 (SEQ ID NO:272), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P5 (SEQ ID NO:272), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P5 (SEQ ID NO:272), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQ corresponding to amino acids 165-358 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-358 of HSSTROL3_P5 (SEQ ID NO:272), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ELGFPSSTGRDESLEHCRCQGLHK (SEQ ID NO:967) corresponding to amino acids 359-382 of HSSTROL3_P5 (SEQ ID NO:272), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSSTROL3_P5 (SEQ ID NO:272), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ELGFPSSTGRDESLEHCRCQGLHK (SEQ ID NO:967) in HSSTROL3_P5 (SEQ ID NO:272).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROL3_P7 (SEQ ID NO:273), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P7 (SEQ ID NO:273), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P7 (SEQ ID NO:273), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQG corresponding to amino acids 165-359 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-359 of HSSTROL3_P7 (SEQ ID NO:273), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TTGVSTPAPGV (SEQ ID NO:968) corresponding to amino acids 360-370 of HSSTROL3_P7 (SEQ ID NO:273), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSSTROL3_P7 (SEQ ID NO:273), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV (SEQ ID NO:968) in HSSTROL3_P7 (SEQ ID NO:273).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROL3_P8 (SEQ ID NO:274), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P8 (SEQ ID NO:274), a bridging amino acid H corresponding to amino acid 164of HSSTROL3_P8 (SEQ ID NO:274), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLE corresponding to amino acids 165-286 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-286 of HSSTROL3_P8 (SEQ ID NO:274), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRPCLPVPLLLCWPL (SEQ ID NO:969) corresponding to amino acids 287-301 of HSSTROL3_P8 (SEQ ID NO:274), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSSTROL3_P8 (SEQ ID NO:274), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRPCLPVPLLLCWPL (SEQ ID NO:969) in HSSTROL3_P8 (SEQ ID NO:274).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROL3_P9 (SEQ ID NO:275), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQK corresponding to amino acids 1-96 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-96 of HSSTROL3_P9 (SEQ ID NO:275), a second amino acid sequence being at least 90% homologous to RILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 113-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 97-147 of HSSTROL3_P9 (SEQ ID NO:275), a bridging amino acid H corresponding to amino acid 148 of HSSTROL3_P9 (SEQ ID NO:275), a third amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQG corresponding to amino acids 165-359 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 149-343 of HSSTROL3_P9 (SEQ ID NO:275), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TTGVSTPAPGV (SEQ ID NO:968) corresponding to amino acids 344-354 of HSSTROL3_P9 (SEQ ID NO:275), wherein said first amino acid sequence, second amino acid sequence, bridging amino acid, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HSSTROL3_P9 (SEQ ID NO:275), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KR, having a structure as follows: a sequence starting from any of amino acid numbers 96-x to 96; and ending at any of amino acid numbers 97+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSSTROL3_P9 (SEQ ID NO:275), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV (SEQ ID NO:968) in HSSTROL3_P9 (SEQ ID NO:275).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for AY180924_PEA_—1_P3 (SEQ ID NO:281), comprising a first amino acid sequence being at least 90% homologous to MLNVSGLFVLLCGLLVSSSAQEVLAGVSSQLLN corresponding to amino acids 1-33 of LATH_HUMAN (SEQ ID NO:280), which also corresponds to amino acids 1-33 of AY180924_PEA_—1_P3 (SEQ ID NO:281), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GETVLLWVMQNPEPMPVKFSLAKYLGHNEHY (SEQ ID NO:971) corresponding to amino acids 34-64 of AY180924_PEA_—1_P3 (SEQ ID NO:281), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of AY180924_PEA_—1_P3 (SEQ ID NO:281), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GETVLLWVMQNPEPMPVKFSLAKYLGHNEHY (SEQ ID NO:971) in AY180924_PEA_—1_P3 (SEQ ID NO:281).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for R75793_PEA_—1_P2 (SEQ ID NO:295), comprising a first amino acid sequence being at least 90% homologous to MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAATTATTAAPT TATTAASTTARKDIP corresponding to amino acids 1-74 of Q96DR8 (SEQ ID NO:294), which also corresponds to amino acids 1-74 of R75793_PEA_—1_P2 (SEQ ID NO:295), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AP corresponding to amino acids 75-76 of R75793_PEA_—1_P2 (SEQ ID NO:295), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMCA1XIA_P14 (SEQ ID NO:350), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAG PRGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQG PIGPPGEKGPQGKPGLAGLPGADGPPGHPGKEGQSGEKGALGPPGPQGPIGYPGPRGVK GADGVRGLKGSKGEKGEDGFPGFKGDMGLKGDRGEVGQIGPRGEDGPEGPKGRAGPT GDPGPSGQAGEKGKLGVPGLPGYPGRQGPKGSTGFPGFPGANGEKGARGVAGKPGPR GQRGPTGPRGSRGARGPTGKPGPKGTSGGDGPPGPPGERGPQGPQGPVGFPGPKGPPGP PGKDGLPGHPGQRGETGFQGKTGPPGPGGVVGPQGPTGETGPIGERGHPGPPGPPGEQG LPGAAGKEGAKGDPGPQGISGKDGPAGLRGFPGERGLPGAQGAPGLKGGEGPQGPPGP V corresponding to amino acids 1-1056 of CA1B_HUMAN_V5 (SEQ ID NO:349), which also corresponds to amino acids 1-1056 of HUMCA1XIA_P14 (SEQ ID NO:350), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSMMIINSQTIMVVNYSSSFITLML (SEQ ID NO:972) corresponding to amino acids 1057-1081 of HUMCA1XIA_P14 (SEQ ID NO:350), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMCA1XIA_P14 (SEQ ID NO:350), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSMMIINSQTIMVVNYSSSFITLML (SEQ ID NO:972) in HUMCA1XIA_P14 (SEQ ID NO:350).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMCA1XIA_P15 (SEQ ID NO:351 ), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAG PRGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQG PIGPPGEK corresponding to amino acids 1-714 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-714 of HUMCA1XIA_P15 (SEQ ID NO:351), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MCCNLSFGILIPLQK (SEQ ID NO:973) corresponding to amino acids 715-729 of HUMCA1XIA_P15 (SEQ ID NO:351), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMCA1XIA_P15 (SEQ ID NO :351 ), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MCCNLSFGILIPLQK (SEQ ID NO:973) in HUMCA1XIA_P15 (SEQ ID NO:351).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMCA1XIA_P16 (SEQ ID NO:352), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEA corresponding to amino acids 1-648 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-648 of HUMCA1XIA_P16 (SEQ ID NO:352), a second amino acid sequence being at least 90% homologous to GMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQGPIGPPGEK corresponding to amino acids 667-714 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 649-696 of HUMCA1XIA_P16 (SEQ ID NO:352), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSFSFSLFYKKVIKFACDKRFVGRHDERKVVKLSLPLYLIYE (SEQ ID NO:974) corresponding to amino acids 697-738 of HUMCA1XIA_P16 (SEQ ID NO:352), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMCA1XIA_P16 (SEQ ID NO:352), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 648-x to 648; and ending at any of amino acid numbers 649+((n−2)−x), in which x varies from 0 to n-2.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMCA1XIA_P16 (SEQ ID NO:352), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSFSFSLFYKKVIKFACDKRFVGRHDERKVVKLSLPLYLIYE (SEQ ID NO:974) in HUMCA1XIA_P16 (SEQ ID NO:352).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMCA1XIA_P17 (SEQ ID NO:353), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDE corresponding to amino acids 1-260 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-260 of HUMCA1XIA_P17 (SEQ ID NO:353), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRSTRPEKVFVFQ (SEQ ID NO:975) corresponding to amino acids 261-273 of HUMCA1XIA_P17 (SEQ ID NO:353), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMCA1XIA_P17 (SEQ ID NO:353), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRSTRPEKVFVFQ (SEQ ID NO:975) in HUMCA1XIA_P17 (SEQ ID NO:353).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for R20779_P2 (SEQ ID NO:380), comprising a first amino acid sequence being at least 90% homologous to MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLV NAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGKSFIKDALKCKAHALRH RFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQENTRVIVEMIHFKDLLLHE corresponding to amino acids 1-169 of STC2_HUMAN (SEQ ID NO:379), which also corresponds to amino acids 1-169 of R20779_P2 (SEQ ID NO:380), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CYKIEITMPKRRKVKLRD (SEQ ID NO:976) corresponding to amino acids 170-187 of R20779_P2 (SEQ ID NO:380), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of R20779_P2 (SEQ ID NO:380), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CYKIEITMPKRRKVKLRD (SEQ ID NO:976) in R20779_P2 (SEQ ID NO:380).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P3 (SEQ ID NO:488), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTV corresponding to amino acids 1-865 of CO4_HUMAN, which also corresponds to amino acids 1-865 of HSCOC4_PEA_—1_P3 (SEQ ID NO:488), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RPHRSLSIQELGEPGPSEGWGG (SEQ ID NO:977) corresponding to amino acids 866-887 of HSCOC4_PEA_—1_P3 (SEQ ID NO:488), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P3 (SEQ ID NO:488), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RPHRSLSIQELGEPGPSEGWGG (SEQ ID NO:977) in HSCOC4_PEA_—1_P3 (SEQ ID NO:488).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P5 (SEQ ID NO:489), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKG corresponding to amino acids 1-818 of CO4_HUMAN, which also corresponds to amino acids 1-818 of HSCOC4_PEA_—1_P5 (SEQ ID NO:489), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) corresponding to amino acids 819-843 of HSCOC4_PEA_—1_P5 (SEQ ID NO:489), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P5 (SEQ ID NO:489), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) in HSCOC4_PEA_—1_P5 (SEQ ID NO:489).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P6 (SEQ ID NO:490), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKG corresponding to amino acids 1-1052 of CO4_HUMAN, which also corresponds to amino acids 1-1052 of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGCKGKQEGGQERTVTGRWTAQEATEGKKGGP (SEQ ID NO:979) corresponding to amino acids 1053-1084 of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGCKGKQEGGQERTVTGRWTAQEATEGKKGGP (SEQ ID NO:979) in HSCOC4_PEA_—1_P6 (SEQ ID NO:490).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P12 (SEQ ID NO:491), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKV corresponding to amino acids 1-1380 of CO4_HUMAN_V1(SEQ ID NO:486), which also corresponds to amino acids 1-1380 of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RAREGVGPGTGGGEGVE (SEQ ID NO:980) corresponding to amino acids 1381-1397 of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RAREGVGPGTGGGEGVE (SEQ ID NO:980) in HSCOC4_PEA_—1_P12 (SEQ ID NO:491).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P15 (SEQ ID NO:492), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQ corresponding to amino acids 1-1359 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1359 of HSCOC4_PEA_—1_P15 (SEQ ID NO:492), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VNHSLVNHSLAWVARTPGPRGQARSRPQPPTRGIPAALLPGVFGGRLTSWLRDLEL (SEQ ID NO:981) corresponding to amino acids 1360-1415 of HSCOC4_PEA_—1_P15 (SEQ ID NO:492), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P15 (SEQ ID NO:492), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VNHSLVNHSLAWVARTPGPRGQARSRPQPPTRGIPAALLPGVFGGRLTSWLRDLEL (SEQ ID NO:981) in HSCOC4_PEA_—1_P15 (SEQ ID NO:492).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P16 (SEQ ID NO:493), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPK corresponding to amino acids 1-1457 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1457 of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AERQGGAVWHGHRGRHPPEWIPRPAC (SEQ ID NO:982) corresponding to amino acids 1458-1483 of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AERQGGAVWHGHRGRHPPEWIPRPAC (SEQ ID NO:982) in HSCOC4_PEA_—1_P16 (SEQ ID NO:493).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P20 (SEQ ID NO:494), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQ corresponding to amino acids 1-1303 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1303 of HSCOC4_PEA_—1_P20 (SEQ ID NO:494), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGAVPGLWRGWVVLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH (SEQ ID NO:983) corresponding to amino acids 1304-1349 of HSCOC4_PEA_—1_P20 (SEQ ID NO:494), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P20 (SEQ ID NO:494), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO: 983)

VGAVPGLWRGWVVLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH

(SEQ ID NO: 494)

in HSCOC4_PEA_1_P20.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P9 (SEQ ID NO:495), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSV corresponding to amino acids 1-1529 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1529 of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGER (SEQ ID NO:984) corresponding to amino acids 1530-1533 of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGER (SEQ ID NO:984) in HSCOC4_PEA_—1_P9 (SEQ ID NO:495).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P22 (SEQ ID NO:496), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAF RLFETKITQVLHF corresponding to amino acids 1-1653 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1653 of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SMKQTGEAGRAGGRQGG (SEQ ID NO:985) corresponding to amino acids 1654-1670 of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SMKQTGEAGRAGGRQGG (SEQ ID NO:985) in HSCOC4_PEA_—1_P22 (SEQ ID NO:496).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P23 (SEQ ID NO:497), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYG corresponding to amino acids 1-1626 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1626 of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence QSSHRGPGLTLPRGPAVLVSLGVACSSYRSCTQPVCSDTNFLPSQPQSNSPFPLLLTPS (SEQ ID NO:986) corresponding to amino acids 1627-1685 of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence QSSHRGPGLTLPRGPAVLVSLGVACSSYRSCTQPVCSDTNFLPSQPQSNSPFPLLLTPS (SEQ ID NO:986) in HSCOC4_PEA_—1_P23 (SEQ ID NO:497).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P24 (SEQ ID NO:498), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDS corresponding to amino acids 1-1528 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1528 of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SADVLCFTGHQVRADSWPPCVLLKSASVLRGSALASVAPWSGVCRTRMATG (SEQ ID NO:987) corresponding to amino acids 1529-1579 of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


SADVLCFTGHQVRADSWPPCVLLKSASVLRGSALASVAPWSGVCRTRMATG	(SEQ ID NO: 987)

in HSCOC4_PEA_1_P24.	(SEQ ID NO: 498)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P25 (SEQ ID NO:499), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEG corresponding to amino acids 1-1593 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1593 of HSCOC4_PEA_—1_P25 (SEQ ID NO:499), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRLPG (SEQ ID NO:988) corresponding to amino acids 1594-1657 of HSCOC4_PEA_—1_P25 (SEQ ID NO:499), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P25 (SEQ ID NO:499), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC	(SEQ ID NO: 988)
GVRLPG

in HSCOC4_PEA_1_P25.	(SEQ ID NO: 499)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P26 (SEQ ID NO:500), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEG corresponding to amino acids 1-1593 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1593 of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC	(SEQ ID NO: 989)
GVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL

corresponding to amino acids 1594-1691 of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC	(SEQ ID NO: 989)
GVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL

in HSCOC4_PEA_1_P26.	(SEQ ID NO: 500)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P30 (SEQ ID NO:501), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGS corresponding to amino acids 1-1232 of CO4_HUMAN_V3 (SEQ ID NO:487), which also corresponds to amino acids 1-1232 of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RNPVRLLQPRAQMFCVLRGTK (SEQ ID NO:990) corresponding to amino acids 1233-1253 of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RNPVRLLQPRAQMFCVLRGTK (SEQ ID NO:990) in HSCOC4_PEA_—1_P30 (SEQ ID NO:501).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P38 (SEQ ID NO:502), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKG corresponding to amino acids 1-818 of CO4_HUMAN, which also corresponds to amino acids 1-818 of HSCOC4_PEA_—1_P38 (SEQ ID NO:502), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) corresponding to amino acids 819-843 of HSCOC4_PEA_—1_P38 (SEQ ID NO:502), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P38 (SEQ ID NO:502), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) in HSCOC4_PEA_—1_P38 (SEQ ID NO:502).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P39 (SEQ ID NO:503), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQ corresponding to amino acids 1-387 of CO4_HUMAN, which also corresponds to amino acids 1-387 of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSSRGEG (SEQ ID NO:992) corresponding to amino acids 388-394 of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSSRGEG (SEQ ID NO:992) in HSCOC4_PEA_—1_P39 (SEQ ID NO:503).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P40 (SEQ ID NO:504), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKY corresponding to amino acids 1-236 of CO4_HUMAN, which also corresponds to amino acids 1-236 of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AGEWTEPHFPLKGRVPGRPGEAEYGHY (SEQ ID NO:993) corresponding to amino acids 237-263 of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AGEWTEPHFPLKGRVPGRPGEAEYGHY (SEQ ID NO:993) in HSCOC4_PEA_—1_P40 (SEQ ID NO:504).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P41 (SEQ ID NO:505), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSV corresponding to amino acids 1-1529 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1529 of HSCOC4_PEA_—1_P41 (SEQ ID NO:505), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGER (SEQ ID NO:984) corresponding to amino acids 1530-1533 of HSCOC4_PEA_—1_P41 (SEQ ID NO:505), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_{—l P}41 (SEQ ID NO:505), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGER (SEQ ID NO:984) in HSCOC4_PEA_—1_P41 (SEQ ID NO:505).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIW corresponding to amino acids 1-1473 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1473 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence WAPGAALGQGREGRTQAGAGLLEPAQAEPGRQLTRLHR (SEQ ID NO:1021) corresponding to amino acids 1474-1511 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), a third amino acid sequence being at least 90% homologous to RNGKVGLSGMAIADVTLLSGFHALRADLEK corresponding to amino acids 1474-1503 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1512-1541 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VWSATQGNPLCPRY (SEQ ID NO:995) corresponding to amino acids 1542-1555 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), wherein said first amino acid sequence, second amino acid sequence, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for WAPGAALGQGREGRTQAGAGLLEPAQAEPGRQLTRLHR (SEQ ID NO: 1021), corresponding to HSCOC4_PEA_—1_P42 (SEQ ID NO:506).

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VWSATQGNPLCPRY (SEQ ID NO:995) in HSCOC4_PEA_—1_P42 (SEQ ID NO:506).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), comprising a first amino acid sequence being at least 90% homologous to MAARALCMLGLVLALLSSSSAEEYVGL corresponding to amino acids 1-27 of TFF3_HUMAN (SEQ ID NO:516), which also corresponds to amino acids 1-27 of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence WKVHLPKGEGFSSG (SEQ ID NO:996) corresponding to amino acids 28-41 of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence WKVHLPKGEGFSSG (SEQ ID NO:996) in HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), comprising a first amino acid sequence being at least 90% homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQ corresponding to amino acids 1-58 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-58 of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VFLNFS (SEQ ID NO:997) corresponding to amino acids 59-64 of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VFLNFS (SEQ ID NO:997) in HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), comprising a first amino acid sequence being at least 90 % homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQ corresponding to amino acids 1-31 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-31 of HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence H corresponding to amino acids 32-32 of HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), comprising a first amino acid sequence being at least 90 % homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQ corresponding to amino acids 1-31 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-31 of HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSIFYVFI (SEQ ID NO:998)corresponding to amino acids 32-39 of HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSIFYVFI (SEQ ID NO:998)in HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T10888_PEA_—1_P2 (SEQ ID NO:14), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLY GPDVPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGS YMCQAHNSATGLNRTTVTMITVS corresponding to amino acids 1-319 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-319 of T10888_PEA_—1_P2 (SEQ ID NO:14), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DWTRP (SEQ ID NO:999)corresponding to amino acids 320-324 of T10888_PEA_—1_P2 (SEQ ID NO:14), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T10888_PEA_—1_P2 (SEQ ID NO:14), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DWTRP (SEQ ID NO:999)in T10888_PEA_—1_P2 (SEQ ID NO:14).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T10888_PEA._—1_P4 (SEQ ID NO:15), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL corresponding to amino acids 1-234 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-234 of T10888_PEA_—1_P4 (SEQ ID NO:15), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000)corresponding to amino acids 235-256 of T10888_PEA_—1_P4 (SEQ ID NO:15), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T10888_PEA_—1_P4 (SEQ ID NO:15), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000)in T10888_PEA_—1_P4 (SEQ ID NO:15).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T10888_PEA_—1_P4 (SEQ ID NO:15), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL corresponding to amino acids 1-234 of Q13774, which also corresponds to amino acids 1-234 of T10888_PEA_—1_P4 (SEQ ID NO:15), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000)corresponding to amino acids 235-256 of T10888_PEA_—1_P4 (SEQ ID NO:15), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T10888_PEA_—1_P5 (SEQ ID NO:16), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLY GPDVPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGS YMCQAHNSATGLNRTTVTMITVSG corresponding to amino acids 1-320 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-320 of T10888_PEA_—1_P5 (SEQ ID NO:16), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KWIHEALASHFQVESGSQRRARKKFSFPTCVQGAHANPKFSPEPSQFTSADSFPLVFLFF VVFCFLISHV (SEQ ID NO:1001)corresponding to amino acids 321-390 of T10888_PEA_—1_P5 (SEQ ID NO:16), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T10888_PEA_—1_P5 (SEQ ID NO:16), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


KWIHEALASHFQVESGSQRRARKKFSFPTCVQGAHANPKFSPEPSQFTSADSFPLVFLFF	(SEQ ID NO: 1001)
VVFCFLISHV

in T10888_PEA_1_P5.	(SEQ ID NO: 16)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T10888_PEA_—1_P6 (SEQ ID NO:17), comprising a first amino acid sequence being at least 90% homologous to


MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLA

HNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQ

NDTGFYTLQVIKSDLVNEEATGQFHVY

corresponding to amino acids 1-141 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-141 of T10888_PEA₁₃1_P6 (SEQ ID NO:17), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


	(SEQ ID NO: 1002)

REYFHMTSGCWGSVLLPTYGIVRPGLCLWPSLHYILYQGLDI

corresponding to amino acids 142-183 of T10888_PEA_—1_P6 (SEQ ID NO:17), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T10888_PEA_—1_P6 (SEQ ID NO:17), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence REYFHMTSGCWGSVLLPTYGIVRPGLCLWPSLHYILYQGLDI (SEQ ID NO:1002) in T10888_PEA_—1_P6 (SEQ IDNO:17.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P6 (SEQ ID NO:51), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKG corresponding to amino acids 1-276 of VTNC_HUMAN, which also corresponds to amino acids 1-276 of T39971_P6 (SEQ ID NO:51), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TQGVVGD (SEQ ID NO:1003) corresponding to amino acids 277-283 of T39971_P6 (SEQ ID NO:51), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T39971_P6 (SEQ ID NO:51), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TQGVVGD (SEQ ID NO:1003) in T39971_P6 (SEQ ID NO:51).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P9 (SEQ ID NO:52), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRT corresponding to amino acids 1-325 of VTNC_HUMAN, which also corresponds to amino acids 1-325 of T39971_P9 (SEQ ID NO:52), and a second amino acid sequence being at least 90% homologous to SGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGA NNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYWLGC PAPGHL corresponding to amino acids 357-478 of VTNC_HUMAN, which also corresponds to amino acids 326-447 of T39971_P9 (SEQ ID NO:52), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of T39971_P9 (SEQ ID NO:52) comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise TS, having a structure as follows: a sequence starting from any of amino acid numbers 325-x to 325; and ending at any of amino acid numbers 326+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P11 (SEQ ID NO:53), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRTS corresponding to amino acids 1-326 of VTNC_HUMAN, which also corresponds to amino acids 1-326 of T39971_P11 (SEQ ID NO:53), and a second amino acid sequence being at least 90% homologous to DKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL corresponding to amino acids 442-478 of VTNC_HUMAN, which also corresponds to amino acids 327-363 of T39971_P11 (SEQ ID NO:53), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of T39971_P11 (SEQ ID NO:53), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise SD, having a structure as follows: a sequence starting from any of amino acid numbers 326-x to 326; and ending at any of amino acid numbers 327+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P11 (SEQ ID NO:53), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRTS corresponding to amino acids 1-326 of Q9BSH7, which also corresponds to amino acids 1-326 of T39971_P11 (SEQ ID NO:53), and a second amino acid sequence being at least 90% homologous to DKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL corresponding to amino acids 442-478 of Q9BSH7, which also corresponds to amino acids 327-363 of T39971_P11 (SEQ ID NO:53), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P12 (SEQ ID NO:54), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFK corresponding to amino acids 1-223 of VTNC_HUMAN, which also corresponds to amino acids 1-223 of T39971_P12 (SEQ ID NO:54), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPGAVGQGRKHLGRV (SEO ID NO:1004) corresponding to amino acids 224-238 of T39971_P12 (SEQ ID NO:54 , wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T39971_P12 (SEQ ID NO:54), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPGAVGQGRKHLGRV (SEQ ID NO:1004) in T39971_P12 (SEQ ID NO:54) According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T39971_P12 (SEQ ID NO:54), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFK corresponding to amino acids 1-223 of Q9BSH7, which also corresponds to amino acids 1-223 of T39971_P12 (SEQ ID NO:54), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPGAVGQGRKHLGRV (SEQ ID NO:1004) corresponding to amino acids 224-238 of T39971_P12 (SEQ ID NO:54), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P2 (SEO ID NO:97), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFL VERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARYQTACEQPGQKWQCIEDTSGK LRIHKCKGPSDLLTVRQSTRNLYARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQ GTPKYKPRFVHTRQTRSLSVEFEGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQ ASSGGNRGRMLADSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYI DKEIEALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKE AAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWN corresponding to amino acids 1-761 of SUL1_HUMAN, which also corresponds to amino acids 1-761 of Z21368_PEA_—1_P2 (SEQ ID NO:97), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence PHKYSAHGRTRHFESATRTTNGAQKLSRI (SEQ ID NO:1005) corresponding to amino acids 762-790 of Z21368_PEA_—1_P2 (SEQ ID NO:97), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of Z21368_PEA_—1_P2 (SEQ ID NO:97), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PHKYSAHGRTRHFESATRTTNGAQKLSRI (SEQ ID NO:1005) in Z21368_PEA_—1_P2 (SEQ ID NO:97).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVEL corresponding to amino acids 1-57 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 1-57 of Z21368_PEA_—1_P5 (SEQ ID NO:98), second bridging amino acid sequence comprising A, and a third amino acid sequence being at least 90% homologous to FFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITN ESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNM DKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYT ADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDT PPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHL PKYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLY ARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEFE GEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPT TVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKR RKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKER KEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNE THNFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCN PRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 139-871 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 59-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise LAF having a structure as follows (numbering according to Z21368_PEA_—1_P5 (SEQ ID NO:98) ): a sequence starting from any of amino acid numbers 57-x to 57; and ending at any of amino acid numbers 59+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELAFF GKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNES INYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNMDK HWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYTAD HGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDTPP DVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLP KYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYA RGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEFEGE IYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPTTV RVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKRRK PEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKERKE KRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETH NFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNQLHVQLME (SEQ ID NO:1006) corresponding to amino acids 1-751 of Z21368_PEA_—1_P5 (SEQ ID NO:98), and a second amino acid sequence being at least 90% homologous to LRSCQGYKQCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 1-40 of AAH12997 (SEQ ID NO:841), which also corresponds to amino acids 752-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELAFF	(SEQ ID NO: 1006)

GKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNES

INYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNMDK

HWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYTAD

HGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDTPP

DVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLP

KYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYA

RGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEFEGE

IYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPTTV

RVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKRRK

PEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKERKE

KRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETH

NFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNQLHVQLME

of Z21368_PEA_1_P5.	(SEQ ID NO: 98)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVEL corresponding to amino acids 1-57 of SUL1_HUMAN, which also corresponds to amino acids 1-57 of Z21368_PEA_—1_P5 (SEQ ID NO:98), and a second amino acid sequence being at least 90% homologous to AFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLIT NESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPN MDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYII YTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGL DTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSN HLPKYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRN LYARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVE FEGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGP PTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHL KRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRK KERKEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRT VNETHNFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYK QCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 138-871 of SUL1_HUMAN, which also corresponds to amino acids 58-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise LA, having a structure as follows: a sequence starting from any of amino acid numbers 57-x to 57; and ending at any of amino acid numbers 58+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P15 (SEQ ID NO:99), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFL VERG corresponding to amino acids 1-416 of SUL1_HUMAN, which also corresponds to amino acids 1-416 of Z21368_PEA_—1_P15 (SEQ ID NO:99).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P16 (SEQ ID NO:100), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNR corresponding to amino acids 1-397 of SUL1_HUMAN, which also corresponds to amino acids 1-397 of Z21368_PEA_—1_P16 (SEQ ID NO:100), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CVIVPPLSQPQIH (SEQ ID NO:1007) corresponding to amino acids 398-410 of Z21368_PEA_—1_P16 (SEQ ID NO:100), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of Z21368_PEA_—1_P16 (SEQ ID NO:100), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CVIVPPLSQPQIH (SEQ ID NO:1007) in Z21368_PEA_—1-P16 (SEQ ID NO:100).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P22 (SEQ ID NO:101), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAK corresponding to amino acids 1-188 of SUL1_HUMAN, which also corresponds to amino acids 1-188 of Z21368_PEA_—1_P22 (SEQ ID NO:101), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ARYDGDQPRCAPRPRGLSPTVF (SEQ ID NO:1008) corresponding to amino acids 189-210 of Z21368_PEA_—1_P22 (SEQ ID NO:101), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of Z21368_PEA_—1_P22 (SEQ ID NO:101), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably, at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ARYDGDQPRCAPRPRGLSPTVF (SEQ ID NO:1008) in Z21368_PEA_—1P22 (SEQ ID NO:101) .

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P23 (SEQ ID NO:102), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRT corresponding to amino acids 1-137 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 1-137 of Z21368_PEA_—1_P23 (SEQ ID NO:102), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GLLHRLNH (SEQ ID NO:1009) corresponding to amino acids 138-145 of Z21368_PEA_—1_P23 (SEQ ID NO:102), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of Z21368_PEA_—1_P23 (SEQ ID NO:102), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GLLHRLNH (SEQ ID NO:1009) in Z21368_PEA_—1_P23 (SEQ ID NO:102).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z21368_PEA_—1_P23 (SEB ID NO:102), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRT corresponding to amino acids 1-137 of SUL1_HUMAN, which also corresponds to amino acids 1-137 of Z21368_PEA_—1_P23 (SEQ ID NO:102), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GLLHRLNH (SEQ ID NO:1009) corresponding to amino acids 138-145 of Z21368 PEA_—1_P23 (SEQ ID NO:102), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P5 (SEO ID NO:143), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 12-55 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-44 of T59832_P5 (SEQ ID NO:143), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGTATGRAGWREQAPCRGTRLLLSPQTSQGKTRAPRGRCPCRVPGKTLFSSRRCGHTP SVPFRFRIPHLRGAAASTRLVPPKGSMSAYCVLLGQELGSPFVAQGTSSAAGQGPPACIL AATLDAFIPARAGLACLWDLLGRCPRG (SEQ ID NO:1010) corresponding to amino acids 45-189 of T59832_P5 (SEQ ID NO:143), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T59832_P5 (SEQ ID NO:143), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


VGTATGRAGWREQAPCRGTRLLLSPQTSQGKTRAPRGRCPCRVPGKTLFSSRRCGHTP	(SEQ ID NO: 1010)

SVPFRFRIPHLRGAAASTRLVPPKGSMSAYCVLLGQELGSPFVAQGTSSAAGQGPPACIL

AATLDAFIPARAGLACLWDLLGRCPRG

in T59832_P5.	(SEQ ID NO: 143)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 12-223 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011 ) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T59832_P7 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) in T59832_P7 (SEQ ID NO:144).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 1-212 of BAC98466 (SEQ ID NO:848), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVC MEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYV PWVTVNGVRIFLALSLTLIVPWSQGWTRQRDQR corresponding to amino acids 1-148 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of T59832_P7 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)

PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P7.	(SEQ ID NO: 144)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 1-212 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 12-214 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T59832_P9 (SEQ ID NO:145), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) in T59832_P9 (SEO ID NO:145).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-203 of BAC98466 (SEQ ID NO:848), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832 P9 (SEO ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P9 (SEQ ID NO:145), second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVC MEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-113 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-203 of T59832_P9 (SEQ ID NO:145), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of T59832_P9 (SEQ ID NO:145), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)

PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P9.	(SEQ ID NO: 145)

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-203 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


	(SEQ ID NO: 1013)

NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR

corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE corresponding to amino acids 12-141 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-130 of T59832_P12 (SEQ ID NO:146), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 173-261 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 131-219 of T59832_P12 (SEQ ID NO:146), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of T59832_P12 (SEQ ID NO:146), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P12 (SEQ ID NO:146), second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVE corresponding to amino acids 1-40 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-130 of T59832_P12 (SEQ ID NO:146), third amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 72-122 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 131-181 of T59832_P 12 (SEQ ID NO:146), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK (SEQ ID NO:1016) corresponding to amino acids 182-219 of T59832_P12 (SEQ ID NO:146), wherein said first, second, third and fourth amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of T59832_P12 (SEQ ID NO:146), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)

PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P12.	(SEQ ID NO: 146)

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T59832_P 12 (SEQ ID NO:146), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KPLEDQTQLLTLVCQLYQGKKPDVCPS STS SLRSVCFK (SEO ID NO:1016) in T59832_P12 (SEQ IDNO:146).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE corresponding to amino acids 1-130 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-130 of T59832_P12 (SEQ ID NO:146), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 131-219 of T59832_P12 (SEQ ID NO:146), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 12-55 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 173-261 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of T59832_PI18 (SEQ ID NO:147), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 1-44 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of T59832_P18 (SEQ ID NO:147), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 1-44 of Q8NE14 (SEQ ID NO:851), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8NE14 (SEQ ID NO:851), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMGRP5E-P4 (SEQ ID NO:1566), comprising a first amino acid sequence being at least 90% homologous to MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK corresponding to amino acids 1-127 of GRP_HUMAN, which also corresponds to amino acids 1-127 of HUMGRP5E_P4 (SEQ ID NO:156), and a second amino acid sequence being at least 90% homologous to GSQREGRNPQLNQQ corresponding to amino acids 135-148 of GRP_HUMAN, which also corresponds to amino acids 128-141 of HUMGRP5E_P4 (SEQ ID NO:156), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMGRP5E_P4 (SEQ ID NO:156), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KG, having a structure as follows: a sequence starting from any of amino acid numbers 127-x to 127; and ending at any of amino acid numbers 128 +((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMGRP5E_P5 (SEQ ID NO:157), comprising a first amino acid sequence being at least 90% homologous to MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK corresponding to amino acids 1-127 of GRP_HUMAN, which also corresponds to amino acids 1-127 of HUMGRP5E_P5 (SEQ ID NO:157), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DSLLQVLNVKEGTPS (SEQ ID NO:1017) corresponding to amino acids 128-142 of HUMGRP5E_P5 (SEQ ID NO:157), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMGRP5E_P5 (SEQ ID NO:157), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DSLLQVLNVKEGTPS (SEQ ID NO:1017) in HUMGRP5E_P5 (SEQ ID NO:157).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for AA155578_PEA_—1_P4 (SEQ ID NO:178), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAPCARGSQ PWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLLLLQGEQLRRTT RSVVHPKYHQGSGPILPRRTDEHDLMLLKLARP corresponding to amino acids 1-146 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-146 of AA155578_PEA_—1_P4 (SEQ ID NO:178), and a second amino acid sequence being at least 90% homologous to YNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGIL SWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN corresponding to amino acids 184-276 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 147-239 of AA155578_PEA_—1_P4 (SEQ ID NO:178), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of AA155578_PEA_—1_P4 (SEQ ID NO:178), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise PY, having a structure as follows: a sequence starting from any of amino acid numbers 146-x to 146; and ending at any of amino acid numbers 147+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for AA155578_PEA_—1_P6 (SEQ ID NO:179), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLW corresponding to amino acids 1-29 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-29 of AA155578_PEA_—1 P6 (SEQ ID NO:179), and a second amino acid sequence being at least 90 % homologous to VKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQ GILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN corresponding to amino acids 182-276 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 30-124 of AA155578_PEA_—1_P6 (SEQ ID NO:179), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of AA155578_PEA_—1_P6 (SEQ ID NO: 179), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise WV, having a structure as follows: a sequence starting from any of amino acid numbers 29-x to 29; and ending at any of amino acid numbers 30+((n−2)−x), in which x varies from 0 to n−2.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for AA155578_PEA_—1_P8 (SEQ ID NO:180), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLW corresponding to amino acids 1-29 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-29 of AA155578_PEA_—1_P8 (SEQ ID NO:180), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GHCGLE (SEQ ID NO:1018) corresponding to amino acids 30-35 of AA155578_PEA_—1_P8 (SEQ ID NO:180), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of AA155578-PEA_—1_P8 (SEQ ID NO:180), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GHCGLE (SEO ID NO:1018) in AA155578_PEA_—1_P8 (SEQ ID NO:180).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for AA155578_PEA_—1_P9 (SEQ ID NO:181), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAPCARGSQ PWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK corresponding to amino acids 1-90 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-90 of AA155578_PEA_—1_—P9 (SEQ ID NO:181).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSENA78_P2 (SEQ ID NO:919), comprising a first amino acid sequence being at least 90% homologous to MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVLRELRCVCLQTTQGVHP KMISNLQVFAIGPQCSKVEVV corresponding to amino acids 1-81 of SZ05_HUMAN (SEQ ID NO:190), which also corresponds to amino acids 1-81 of HSENA78_P2 (SEQ ID NO:191) According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T94936_PEA_—1_P2 (SEQ ID NO:206), comprising a first amino acid sequence being at least 90% homologous to MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEEGLFYAQKS KKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNLMHETTDKNLSPDGQY VPRIMFVDPSLTVRADIAGRYSNRLYTYEPRDLPL corresponding to amino acids 1-150 of Q8TD06 (SEQ ID NO:858), which also corresponds to amino acids 1-150 of T94936_PEA_—1_P2 (SEQ ID NO:206).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for T94936_PEA_—1_P3 (SEQ ID NO:207), comprising a first amino acid sequence being at least 90% homologous to MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEEGLFYAQKS KKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNLMHETTDKNLSPDGQY VPRIMFV corresponding to amino acids 1-122 of Q8TD06 (SEQ ID NO:858), which also corresponds to amino acids 1-122 of T94936_PEA_—1_P3 (SEQ ID NO:207), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GMYVISFHQIYKISRNQHSCFYF (SEO ID NO:1019) corresponding to amino acids 123-145 of T94936_PEA_—1_P3 (SEQ ID NO:207), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of T94936_PEA_—1_P3 (SEQ ID NO:207), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GMYVISFHQIYKISRNQHSCFYF (SEQ ID NO:1019) in T94936_PEA_—1_P3 (SEQ ID NO:207).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 1-95 of SZ14_HUMAN (SEQ ID NO:230), which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) in Z41644_PEA_—1-P10 (SEQ ID NO:231).

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 13-107 of Q9NS21 (SEQ ID NO:862), which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 13-107 of AAQ89265, which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

According to preferred embodiments of the present invention, there is provided an isolated oligonucleotide, comprising an amplicon selected from the group consisting of SEQ ID NOs: 891 or 894.

According to preferred embodiments of the present invention, there is provided a primer pair, comprising a pair of isolated oligonucleotides capable of amplifying the above. Optionally, the pair of isolated oligonucleotides is selected from the group consisting of: SEQ NOs 889 and 890; or 892 and 893.

According to preferred embodiments of the present invention, there is provided an antibody capable of specifically binding to an epitope of an amino acid sequence as described herein. Optionally, the epitope may comprise a tail, head, or edge portion as described herein.

According to preferred embodiments of the present invention, the antibody is capable of differentiating between a splice variant having said epitope and a corresponding known protein.

According to preferred embodiments of the present invention, there is provided an kit for detecting breast cancer, comprising a kit detecting overexpression of a splice variant as described herein. Optionally, the kit comprises a NAT-based technology. Preferably, the kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence as described herein. Optionally, the kit further comprises at least one oligonucleotide capable of selectively hybridizing to a nucleic acid sequence as described herein.

Optionally, the kit comprises an antibody as described herein. Preferably, the kit further comprises at least one reagent for performing an ELISA or a Western blot.

According to preferred embodiments of the present invention, there is provided a method for detecting breast cancer, comprising detecting overexpression of a splice variant as described herein.

Optionally detecting overexpression is performed with a NAT-based technology. Preferably, detecting overexpression is performed with an immunoassay. More preferably, the immunoassay comprises an antibody as described herein.

According to preferred embodiments of the present invention, there is provided a biomarker capable of detecting breast cancer, comprising any of the above nucleic acid sequences or a fragment thereof, or any of the above amino acid sequences or a fragment thereof.

According to preferred embodiments of the present invention, preferably any of the above nucleic acid and/or amino acid sequences further comprises any sequence having at least about 70%, preferably at least about 80%, more preferably at least about 90%, most preferably at least about 95% homology thereto.

Unless otherwise noted, all experimental data relates to variants of the present invention, named according to the segment being tested (as expression was tested through RT-PCR as described).

All nucleic acid sequences and/or amino acid sequences shown herein as embodiments of the present invention relate to their isolated form, as isolated polynucleotides (including for all transcripts), oligonucleotides (including for all segments, amplicons and primers), peptides (including for all tails, bridges, insertions or heads, optionally including other antibody epitopes as described herein) and/or polypeptides (including for all proteins). It should be noted that oligonucleotide and polynucleotide, or peptide and polypeptide, may optionally be used interchangeably.

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). All of these are hereby incorporated by reference as if fully set forth herein. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is schematic summary of cancer biomarkers selection engine and the wet validation stages.

FIG. 2. Schematic illustration, depicting grouping of transcripts of a given cluster based on presence or absence of unique sequence regions.

FIG. 3 is schematic summary of quantitative real-time PCR analysis.

FIG. 4 is schematic presentation of the oligonucleotide based microarray fabrication.

FIG. 5 is schematic summary of the oligonucleotide based microarray experimental flow.

FIG. 6 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster T10888, demonstrating overexpression in colorectal cancer, a mixture of malignant tumors from different tissues, pancreas carcinoma and gastric carcinoma.

FIG. 7 is a histogram showing expression of the CEA6_HUMAN (SEQ ID NO:13) Carcinoembryonic antigen-related cell adhesion molecule 6 (T10888) transcripts, which are detectable by amplicon as depicted in sequence name T10888 junc11-17, in normal and cancerous breast tissues.

FIG. 8 is a histogram showing the expression of CEA6_HUMAN (SEQ ID NO:13) Carcinoembryonic antigen-related cell adhesion molecule 6 T10888 transcripts which are detectable by amplicon as depicted in sequence name T10888junc11-17 (SEQ ID NO:832) in different normal tissues.

FIG. 9 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster T39971, demonstrating overexpression in liver cancer, lung malignant tumors and pancreas carcinoma.

FIG. 10 is a histogram showing the expression of of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein) T39971 transcripts, which are detectable by amplicon as depicted in sequence name T39971 junc23-33 (SEQ ID NO:836) in normal and cancerous breast tissues.

FIG. 11 is a histogram showing the expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein), antisense to SARM1 (T23434), T39971 transcripts, which are detectable by amplicon as depicted in sequence name T39971junc23-33, in different normal tissues.

FIG. 12 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster Z21368, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

FIG. 13 is a histogram showing the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1Z21368 transcripts, which are detectable by amplicon as depicted in sequence name Z21368seg39 (SEQ ID NO:844), in normal and cancerous breast tissues.

FIG. 14 is a histogram showing the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1Z21368 transcripts, which are detectable by amplicon as depicted in sequence name Z21368seg39 (SEQ ID NO:844), in different normal tissues.

FIG. 15 is a histogram showing the expression of SUL 1_HUMAN—Extracellular sulfatase Sulf-1 Z21368 transcripts which are detectable by amplicon as depicted in sequence name Z21368junc17-21 (SEQ ID NO:847) in normal and cancerous breast tissues.

FIG. 16 is a histogram showing the expression of SUL 1_HUMAN—Extracellular sulfatase Sulf-1 Z21368 transcripts, which are detectable by amplicon as depicted in sequence name Z21368junc17-21, in different normal tissues.

FIG. 17 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster T59832, demonstrating overexpression in brain malignant tumors, breast malignant tumors, ovarian carcinoma and pancreas carcinoma.

FIG. 18 is a histogram showing low over expression observed for cluster T59832, amplicon name: T59832 junc6-25-26 (SEQ ID NO:854), in one experiment carried out with breast cancer samples panel.

FIG. 19 is a histogram showing the expression of GRP_HUMAN—gastrin-releasing peptide (HUMGRP5E) transcripts, which are detectable by amplicon, as depicted insequence name HUMGRP5Ejunc3-7 (SEQ ID NO:857) in normal and cancerous breast tissues.

FIG. 20 is a histogram showing the expression of GRP_HUMAN—gastrin-releasing peptide (HUMGRP5E) transcripts, which are detectable by amplicon, as depicted in sequence name HUMGRP5Ejunc3-7 (SEQ ID NO:857), in different normal tissues.

FIG. 21 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster AA155578, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

FIG. 22 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSENA78, demonstrating overexpression in epithelial malignant tumors and lung malignant tumors.

FIG. 23 is a histogram showing the expression of Homo sapiens breast cancer membrane protein 11 (BCMP11) T94936 transcripts which are detectable by amplicon as depicted in sequence name T94936 seg14 (SEQ ID NO:861) in normal and cancerous Breast tissues.

FIG. 24 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster Z41644, demonstrating overexpression in lung malignant tumors, breast malignant tumors and pancreas carcinoma.

FIG. 25 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster M85491, demonstrating overexpression in epithelial malignant tumors and a mixture of malignant tumors from different tissues.

FIG. 26 is a histogram showing the expression of Ephrin type-B receptor 2 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor EPH-3) M85491 transcripts which are detectable by amplicon as depicted in sequence name M85491seg24 (SEQ ID NO:866) in normal and cancerous breast tissues.

FIG. 27 is a histogram showing the expression of Ephrin type-B receptor 2 precursor M85491 transcripts,-which are detectable by amplicon as depicted in sequence name M85491 seg24, in different normal tissues.

FIG. 28 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSSTROL3, demonstrating overexpression in transitional cell carcinoma, epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

FIG. 29A is a histogram showing the expression of Expression of Stromelysin-3 precursor (SEQ ID NO:270) (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) SL-3 HSSTROL3 transcripts which are detectable by amplicon as depicted in sequence name HSSTROL3 seg24 (SEQ ID NO:869) in normal and cancerous breast tissues.

FIG. 29B is a histogram showing the expression of Stromelysin-3 precursor (SEQ ID NO:270) (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) HSSTROL3 transcripts, which are detectable by amplicon as depicted in sequence name HSSTROL3 seg24 (SEQ ID NO:869), in different normal tissues.

FIGS. 30A-30C shows histograms showing over expression of various Stromelysin-3 precursor (SEQ ID NO:270) transcripts in cancerous breast samples relative to the normal samples.

FIG. 31 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster R75793, demonstrating overexpression in epithelial malignant tumors and a mixture of malignant tumors from different tissues.

FIG. 32 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HUMCA1XIA, demonstrating overexpression in bone malignant tumors, epithelial malignant tumors, a mixture of malignant tumors from different tissues and lung malignant tumors.

FIG. 33 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster R20779, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues and lung malignant tumors.

FIG. 34 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSS100PCB, demonstrating overexpression in a mixture of malignant tumors from different tissues.

FIG. 35 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSCOC4, demonstrating overexpression in brain malignant tumors, a mixture of malignant tumors from different-tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

FIG. 36 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HUMTREFAC, demonstrating overexpression in a mixture of malignant tumors from different tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

FIG. 37 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HUMOSTRO, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues, lung malignant tumors, breast malignant tumors, ovarian carcinoma and skin malignancies.

FIG. 38 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster R11723, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues and kidney malignant tumors.

FIG. 39 is a histogram showing the expression of of R11723 transcripts which are detectable by amplicon as depicted in sequence name R11723 seg13 (SEQ ID NO:891) in normal and cancerous breast tissues.

FIG. 40 is a histogram showing the expression of R11723 transcripts, which are detectable by amplicon as depicted in sequence name R11723seg13 (SEQ ID NO:891), in different normal tissues.

FIGS. 41A and B are histograms showing the expression of R11723 transcripts, which are detectable by amplicon as depicted in sequence name R11723 junc11-18 (SEQ ID NO:894) in normal and cancerous breast tissues (FIG. 41A) or on a panel of normal tissues (FIG. 41B).

FIG. 42 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster T46984, demonstrating overexpression in epithelial malignant tumors, a mixture of malignant tumors from different tissues, breast malignant tumors, ovarian carcinoma and pancreas carcinoma.

FIG. 43 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSMUC 1A, demonstrating overexpression in a mixture of malignant tumors from different tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

FIGS. 44-47 are histograms showing the combined expression of 8 sequences (T10888seg11-17, HUMGR5Ejunc3-7, HSSTROL3seg24, T94936 Seg 14, Z21368 seg39, Z21368junc17-21 T59832jun6-25-26 and M85491seg24 (SEQ ID NO:866)) in normal and cancerous breast tissues.

FIG. 48 is a histogram showing Cancer and cell-line vs. normal tissue expression for Cluster HSU33147, demonstrating overexpression in a mixture of malignant tumors from different tissues.

DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention is of novel markers for breast cancer that are both sensitive and accurate. Furthermore, at least certain of these markers are able to distinguish between different stages of breast cancer, such as 1. Ductal carcinoma (in-situ, invasive) 2. Lobular carcinoma (is-situ, invasive) 3. inflammatory breast cancer 4. Mucinous carcinoma 5. Tubular carcinoma 6. Paget's disease of nipple, alone or in combination; or one of the indicative conditions described above.

The markers of the present invention, alone or in combination, can be used for prognosis, prediction, screening, early diagnosis, staging, therapy selection and treatment monitoring of breast cancer. For example, optionally and preferably, these markers may be used for staging breast cancer and/or monitoring the progression of the disease. Furthermore, the markers of the present invention, alone or in combination, can be used for detection of the source of metastasis found in anatomical places other then breast. Also, one or more of the markers may optionally be used in combination with one or more other breast cancer markers (other than those described herein).

Biomolecular sequences (amino acid and/or nucleic acid sequences) uncovered using the methodology of the present invention and described herein can be efficiently utilized as tissue or pathological markers and/or as drugs or drug targets for treating or preventing a disease.

These markers are specifically released to the bloodstream under conditions of breast cancer (or one of the above indicative conditions), and/or are otherwise expressed at a much higher level and/or specifically expressed in breast cancer tissue or cells, and/or tissue or cells under one of the above indicative conditions. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer and/or a condition that it is indicative of a higher risk for breast cancer.

The present invention therefore also relates to diagnostic assays for breast cancer and/or an indicative condition, and methods of use of such markers for detection of breast cancer and/or an indicative condition, optionally and preferably in a sample taken from a subject (patient), which is more preferably some type of blood sample.

According to a preferred embodiment of the present invention, use of the marker optionally and preferably permits a non-cancerous breast disease state to be distinguished from breast cancer and/or an indicative condition. A non limiting example of a non-cancerous breast disease state includes breast fibrosis and/or cysts. According to another preferred embodiment of the present invention, use of the marker optionally and preferably permits an indicative condition to be distinguished from breast cancer.

In another embodiment, the present invention relates to bridges, tails, heads and/or insertions, and/or analogs, homologs and derivatives of such peptides. Such bridges, tails, heads and/or insertions are described in greater detail below with regard to the Examples.

As used herein a “tail” refers to a peptide sequence at the end of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a tail may optionally be considered as a chimera, in that at least a first portion of the splice variant is typically highly homologous (often 100% identical) to a portion of the corresponding known protein, while at least a second portion of the variant comprises the tail.

As used herein a “head” refers to a peptide sequence at the beginning of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a head may optionally be considered as a chimera, in that at least a first portion of the splice variant comprises the head, while at least a second portion is typically highly homologous (often 100% identical) to a portion of the corresponding known protein.

As used herein “an edge portion” refers to a connection between two portions of a splice variant according to the present invention that were not joined in the wild type or known protein. An edge may optionally arise due to a join between the above “known protein” portion of a variant and the tail, for example, and/or may occur if an internal portion of the wild type sequence is no longer present, such that two portions of the sequence are now contiguous in the splice variant that were not contiguous in the known protein. A “bridge” may optionally be an edge portion as described above, but may also include a join between a head and a “known protein” portion of a variant, or a join between a tail and a “known protein” portion of a variant, or a join between an insertion and a “known protein” portion of a variant.

Optionally and preferably, a bridge between a tail or a head or a unique insertion, and a “known protein” portion of a variant, comprises at least about 10 amino acids, more preferably at least about 20 amino acids, most preferably at least about 30 amino acids, and even more preferably at least about 40 amino acids, in which at least one amino acid is from the tail/head/insertion and at least one amino acid is from the “known protein” portion of a variant. Also optionally, the bridge may comprise any number of amino acids from about 10 to about 40 amino acids (for example, 10, 11, 12, 13 . . . 37, 38, 39, 40 amino acids in length, or any number in between).

It should be noted that a bridge cannot be extended beyond the length of the sequence in either direction, and it should be assumed that every bridge description is to be read in such manner that the bridge length does not extend beyond the sequence itself.

Furthermore, bridges are described with regard to a sliding window in certain contexts below. For example, certain descriptions of the bridges feature the following format: a bridge between two edges (in which a portion of the known protein is not present in the variant) may optionally be described as follows: a bridge portion of CONTIG-NAME_P1 (representing the name of the protein), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise XX (2 amino acids in the center of the bridge, one from each end of the edge), having a structure as follows (numbering according to the sequence of CONTIG-NAME_P1): a sequence starting from any of amino acid numbers 49-x to 49 (for example); and ending at any of amino acid numbers 50+((n−2)−x) (for example), in which x varies from 0 to n−2. In this example, it should also be read as including bridges in which n is any number of amino acids between 10-50 amino acids in length. Furthermore, the bridge polypeptide cannot extend beyond the sequence, so it should be read such that 49-x (for example) is not less than 1, nor 50+((n−2)−x) (for example) greater than the total sequence length.

In another embodiment, this invention provides antibodies specifically recognizing the splice variants and polypeptide fragments thereof of this invention. Preferably such antibodies differentially recognize splice variants of the present invention but do not recognize a corresponding known protein (such known proteins are discussed with regard to their splice variants in the Examples below).

In another embodiment, this invention provides an isolated nucleic acid molecule encoding for a splice variant according to the present invention, having a nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an isolated nucleic acid molecule, having a nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an oligonucleotide of at least about 12 nucleotides, specifically hybridizable with the nucleic acid molecules of this invention. In another embodiment, this invention provides vectors, cells, liposomes and compositions comprising the isolated nucleic acids of this invention.

In another embodiment, this invention provides a method for detecting a splice variant according to the present invention in a biological sample, comprising: contacting a biological sample with an antibody specifically recognizing a splice variant according to the present invention under conditions whereby the antibody specifically interacts with the splice variant in the biological sample but do not recognize known corresponding proteins (wherein the known protein is discussed with regard to its splice variant(s) in the Examples below), and detecting said interaction; wherein the presence of an interaction correlates with the presence of a splice variant in the biological sample.

In another embodiment, this invention provides a method for detecting a splice variant nucleic acid sequences in a biological sample, comprising: hybridizing the isolated nucleic acid molecules or oligonucleotide fragments of at least about a minimum length to a nucleic acid material of a biological sample and detecting a hybridization complex; wherein the presence of a hybridization complex correlates with the presence of a splice variant nucleic acid sequence in the biological sample.

According to the present invention, the splice variants described herein are non-limiting examples of markers for diagnosing breast cancer and/or an indicative condition. Each splice variant marker of the present invention can be used alone or in combination, for various uses, including but not limited to, prognosis, prediction, screening, early diagnosis, determination of progression, therapy selection and treatment monitoring of breast cancer and/or an indicative condition, including a transition from an indicative condition to breast cancer.

According to optional but preferred embodiments of the present invention, any marker according to the present invention may optionally be used alone or combination. Such a combination may optionally comprise a plurality of markers described herein, optionally including any subcombination of markers, and/or a combination featuring at least one other marker, for example a known marker. Furthermore, such a combination may optionally and preferably be used as described above with regard to determining a ratio between a quantitative or semi-quantitative measurement of any marker described herein to any other marker described herein, and/or any other known marker, and/or any other marker. With regard to such a ratio between any marker described herein (or a combination thereof) and a known marker, more preferably the known marker comprises the “known protein” as described in greater detail below with regard to each cluster or gene.

According to other preferred embodiments of the present invention, a splice variant protein or a fragment thereof, or a splice variant nucleic acid sequence or a fragment thereof, may be featured as a biomarker for detecting breast cancer and/or an indicative condition, such that a biomarker may optionally comprise any of the above.

According to still other preferred embodiments, the present invention optionally and preferably encompasses any amino acid sequence or fragment thereof encoded by a nucleic acid sequence corresponding to a splice variant protein as described herein. Any oligopeptide or peptide relating to such an amino acid sequence or fragment thereof may optionally also (additionally or alternatively) be used as a biomarker, including but not limited to the unique amino acid sequences of these proteins that are depicted as tails, heads, insertions, edges or bridges. The present invention also optionally encompasses antibodies capable of recognizing, and/or being elicited by, such oligopeptides or peptides.

The present invention also optionally and preferably encompasses any nucleic acid sequence or fragment thereof, or amino acid sequence or fragment thereof, corresponding to a splice variant of the present invention as described above, optionally for any application.

Non-limiting examples of methods or assays are described below.

The present invention also relates to kits based upon such diagnostic methods or assays.

Nucleic Acid Sequences and Oligonucleotides

Various embodiments of the present invention encompass nucleic acid sequences described hereinabove; fragments thereof, sequences hybridizable therewith, sequences homologous thereto, sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or artificially induced, either randomly or in a targeted fashion.

The present invention encompasses nucleic acid sequences described herein; fragments thereof, sequences hybridizable therewith, sequences homologous thereto [e.g., at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, least 95% or more say 100% identical to the nucleic acid sequences set forth below], sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or man induced, either randomly or in a targeted fashion. The present invention also encompasses homologous nucleic acid sequences (i.e., which form a part of a polynucleotide sequence of the present invention) which include sequence regions unique to the polynucleotides of the present invention.

In cases where the polynucleotide sequences of the present invention encode previously unidentified polypeptides, the present invention also encompasses novel polypeptides or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

A “nucleic acid fragment” or an “oligonucleotide” or a “polynucleotide” are used herein interchangeably to refer to a polymer of nucleic acids. A polynucleotide sequence of the present invention refers to a single or double stranded nucleic acid sequences which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).

As used herein the phrase “complementary polynucleotide sequence” refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified in vivo or in vitro using a DNA dependent DNA polymerase.

As used herein the phrase “genomic polynucleotide sequence” refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.

As used herein the phrase “composite polynucleotide sequence” refers to a sequence, which is composed of genomic and cDNA sequences. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.

Preferred embodiments of the present invention encompass oligonucleotide probes.

An example of an oligonucleotide probe which can be utilized by the present invention is a single stranded polynucleotide which includes a sequence complementary to the unique sequence region of any variant according to the present invention, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon described herein).

Alternatively, an oligonucleotide probe of the present invention can be designed to hybridize with a nucleic acid sequence encompassed by any of the above nucleic acid sequences, particularly the portions specified above, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon described herein).

Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes 1-111 Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988) and “Oligonucleotide Synthesis” Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by deprotection, desalting and purification by for example, an automated trityl-on method or HPLC.

Oligonucleotides used according to this aspect of the present invention are those having a length selected from a range of about 10 to about 200 bases preferably about 15 to about 150 bases, more preferably about 20 to about 100 bases, most preferably about 20 to about 50 bases. Preferably, the oligonucleotide of the present invention features at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 or at least 40, bases specifically hybridizable with the biomarkers of the present invention.

The oligonucleotides of the present invention may comprise heterocylic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3′ to 5′ phosphodiester linkage.

Preferably used oligonucleotides are those modified at one or more of the backbone, internucleoside linkages or bases, as is broadly described hereinunder.

Specific examples of preferred oligonucleotides useful according to this aspect of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. Nos: 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466, 677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid for also be used.

Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone modifications, which can be used in the present invention are disclosed in U.S. Pat. No: 6,303,374.

Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, “unmodified” or “natural” bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases particularly useful for increasing the binding affinity of the oligomeric compounds of the invention include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety, as disclosed in U.S. Pat. No: 6,303,374.

It is not necessary for all positions in a given oligonucleotide molecule to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

It will be appreciated that oligonucleotides of the present invention may include further modifications for more efficient use as diagnostic agents and/or to increase bioavailability, therapeutic efficacy and reduce cytotoxicity.

To enable cellular expression of the polynucleotides of the present invention, a nucleic acid construct according to the present invention may be used, which includes at least a coding region of one of the above nucleic acid sequences, and further includes at least one cis acting regulatory element. As used herein, the phrase “cis acting regulatory element” refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting regulator and regulates the transcription of a coding sequence located downstream thereto.

Any suitable promoter sequence can be used by the nucleic acid construct of the present invention.

Preferably, the promoter utilized by the nucleic acid construct of the present invention is active in the specific cell population transformed. Examples of cell type-specific and/or tissue-specific promoters include promoters such as albumin that is liver specific, lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) EMBO J. 8:729-733] and immunoglobulins; [Banerji et al. (1983) Cell 33729-740], neuron-specific promoters such as the neurofilament promoter [Byrne et al. (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477], pancreas-specific promoters [Edlunch et al. (1985) Science 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). The nucleic acid construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the transcription therefrom.

The nucleic acid construct of the present invention preferably further includes an appropriate selectable marker and/or an origin of replication. Preferably, the nucleic acid construct utilized is a shuttle vector, which can propagate both in E. coli (wherein the construct comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome.

Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (±), pGL3, PzeoSV2 (±), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. (www.invitrogen.com). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the trasgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5′LTR promoter.

Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems. Useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct. In addition, such a construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such constructs will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.

Hybridization Assays

Detection of a nucleic acid of interest in a biological sample may optionally be effected by hybridization-based assays using an oligonucleotide probe (non-limiting examples of probes according to the present invention were previously described).

Traditional hybridization assays include PCR, RT-PCR, Real-time PCR, RNase protection, in-situ hybridization, primer extension, Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection) (NAT type assays are described in greater detail below). More recently, PNAs have been described (Nielsen et al. 1999, Current Opin. Biotechnol. 10:71-75). Other detection methods include kits containing probes on a dipstick setup and the like.

Hybridization based assays which allow the detection of a variant of interest (i.e., DNA or RNA) in a biological sample rely on the use of oligonucleotides which can be 10, 15, 20, or 30 to 100 nucleotides long preferably from 10 to 50, more preferably from 40 to 50 nucleotides long.

Thus, the isolated polynucleotides (oligonucleotides) of the present invention are preferably hybridizable with any of the herein described nucleic acid sequences under moderate to stringent hybridization conditions.

Moderate to stringent hybridization conditions are characterized by a hybridization solution such as containing 10% dextrane sulfate, 1 M NaCl, 1% SDS and 5×10⁶cpm ³²P labeled probe, at 65° C., with a final wash solution of 0.2×SSC and 0.1% SDS and final wash at 65° C and whereas moderate hybridization is effected using a hybridization solution containing 10% dextrane sulfate, 1 M NaCl, 1% SDS and 5×10⁶cpm ³²p labeled probe, at 65° C, with a final wash solution of 1×SSC and 0.1% SDS and final wash at 50° C.

More generally, hybridization of short nucleic acids (below 200 bp in length, e.g. 17-40 bp in length) can be effected using the following exemplary hybridization protocols which can be modified according to the desired stringency; (i) hybridization solution of 6×SSC and 1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature of 1-1.5° C. below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS at 1-1.5° C. below the T_m; (ii) hybridization solution of 6×SSC and 0.1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature of 2-2.5° C. below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS at 1-1.5° C. below the T_m, final wash solution of 6×SSC, and final wash at 22° C.; (iii) hybridization solution of 6×SSC and 1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature.

The detection of hybrid duplexes can be carried out by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Such labels refer to radioactive, fluorescent, biological or enzymatic tags or labels of standard use in the art. A label can be conjugated to either the oligonucleotide probes or the nucleic acids derived from the biological sample.

Probes can be labeled according to numerous well known methods. Non-limiting examples of radioactive labels include 3H, 14C, 32P, and 35S. Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include biotin and radio-nucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe.

For example, oligonucleotides of the present invention can be labeled subsequent to synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif.] can be attached to the oligonucleotides.

Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes.

It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays. For instance, samples may be hybridized to an irrelevant probe and treated with RNAse A prior to hybridization, to assess false hybridization.

Although the present invention is not specifically dependent on the use of a label for the detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to numerous well known methods.

As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting examples of radioactive labels include ³H, ¹⁴C, ³²P, and ³⁵S.

It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays.

Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and a-nucleotides and the like. Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.

NAT Assays

Detection of a nucleic acid of interest in a biological sample may also optionally be effected by NAT-based assays, which involve nucleic acid amplification technology, such as PCR for example (or variations thereof such as real-time PCR for example).

As used herein, a “primer” defines an oligonucleotide which is capable of annealing to (hybridizing with) a target sequence, thereby creating a double stranded region which can serve as an initiation point for DNA synthesis under suitable conditions.

Amplification of a selected, or target, nucleic acid sequence may be carried out by a number of suitable methods. See generally Kwoh et al., 1990, Am. Biotechnol. Lab. 8:14 Numerous amplification techniques have been described and can be readily adapted to suit particular needs of a person of ordinary skill. Non-limiting examples of amplification techniques include polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-based amplification, the q3 replicase system and NASBA (Kwoh et al., 1989, Proc. NatI. Acad. Sci. USA 86, 1173-1177; Lizardi et al., 1988, BioTechnology 6:1197-1202; Malek et al., 1994, Methods Mol. Biol., 28:253-260; and Sambrook et al., 1989, supra).

The terminology “amplification pair” (or “primer pair”) refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification processes, preferably a polymerase chain reaction. Other types of amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based amplification, as explained in greater detail below. As commonly known in the art, the oligos are designed to bind to a complementary sequence under selected conditions.

In one particular embodiment, amplification of a nucleic acid sample from a patient is amplified under conditions which favor the amplification of the most abundant differentially expressed nucleic acid. In one preferred embodiment, RT-PCR is carried out on an mRNA sample from a patient under conditions which favor the amplification of the most abundant mRNA. In another preferred embodiment, the amplification of the differentially expressed nucleic acids is carried out simultaneously. It will be realized by a person skilled in the art that such methods could be adapted for the detection of differentially expressed proteins instead of differentially expressed nucleic acid sequences.

The nucleic acid (i.e. DNA or RNA) for practicing the present invention may be obtained according to well known methods.

Oligonucleotide primers of the present invention may be of any suitable length, depending on the particular assay format and the particular needs and targeted genomes employed. Optionally, the oligonucleotide primers are at least 12 nucleotides in length, preferably between 15 and 24 molecules, and they may be adapted to be especially suited to a chosen nucleic acid amplification system. As commonly known in the art, the oligonucleotide primers can be designed by taking into consideration the melting point of hybridization thereof with its targeted sequence (Sambrook et al., 1989, Molecular Cloning—A Laboratory Manual, 2nd Edition, CSH Laboratories; Ausubel et al., 1989, in Current Protocols in Molecular Biology, John Wiley & Sons Inc., N.Y.).

It will be appreciated that antisense oligonucleotides may be employed to quantify expression of a splice isoform of interest. Such detection is effected at the pre-mRNA level. Essentially the ability to quantitate transcription from a splice site of interest can be effected based on splice site accessibility. Oligonucleotides may compete with splicing factors for the splice site sequences. Thus, low activity of the antisense oligonucleotide is indicative of splicing activity.

The polymerase chain reaction and other nucleic acid amplification reactions are well known in the art (various non-limiting examples of these reactions are described in greater detail below). The pair of oligonucleotides according to this aspect of the present invention are preferably selected to have compatible melting temperatures (Tm), e.g., melting temperatures which differ by less than that 7° C., preferably less than 5° C., more preferably less than 4° C., most preferably less than 3° C., ideally between 3° C. and 0° C.

Polymerase Chain Reaction (PCR): The polymerase chain reaction (PCR), as described in U.S. Pat. Nos. 4,683,195 and 4,683,202 to Mullis and Mullis et al., is a method of increasing the concentration of a segment of target sequence in a mixture of genomic DNA without cloning or purification. This technology provides one approach to the problems of low target sequence concentration. PCR can be used to directly increase the concentration of the target to an easily detectable level. This process for amplifying the target sequence involves the introduction of a molar excess of two oligonucleotide primers which are complementary to their respective strands of the double-stranded target sequence to the DNA mixture containing the desired target sequence. The mixture is denatured and then allowed to hybridize. Following hybridization, the primers are extended with polymerase so as to form complementary strands. The steps of denaturation, hybridization (annealing), and polymerase extension (elongation) can be repeated as often as needed, in order to obtain relatively high concentrations of a segment of the desired target sequence.

The length of the segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and, therefore, this length is a controllable parameter. Because the desired segments of the target sequence become the dominant sequences (in terms of concentration) in the mixture, they are said to be “PCR-amplified.”

Ligase Chain Reaction (LCR or LAR): The ligase chain reaction [LCR; sometimes referred to as “Ligase Amplification Reaction” (LAR)] has developed into a well-recognized alternative method of amplifying nucleic acids. In LCR, four oligonucleotides, two adjacent oligonucleotides which uniquely hybridize to one strand of target DNA, and a complementary set of adjacent oligonucleotides, which hybridize to the opposite strand are mixed and DNA ligase is added to the mixture. Provided that there is complete complementarity at the junction, ligase will covalently link each set of hybridized molecules. Importantly, in LCR, two probes are ligated together only when they base-pair with sequences in the target sample, without gaps or mismatches. Repeated cycles of denaturation, and ligation amplify a short segment of DNA. LCR has also been used in combination with PCR to achieve enhanced detection of single-base changes: see for example Segev, PCT Publication No. W09001069 A1 (1990). However, because the four oligonucleotides used in this assay can pair to form two short ligatable fragments, there is the potential for the generation of target-independent background signal. The use of LCR for mutant screening is limited to the examination of specific nucleic acid positions.

Self-Sustained Synthetic Reaction (3SR/NASBA): The self-sustained sequence replication reaction (3SR) is a transcription-based in vitro amplification system that can exponentially amplify RNA sequences at a uniform temperature. The amplified RNA can then be utilized for mutation detection. In this method, an oligonucleotide primer is used to add a phage RNA polymerase promoter to the 5′ end of the sequence of interest. In a cocktail of enzymes and substrates that includes a second primer, reverse transcriptase, RNase H, RNA polymerase and ribo-and deoxyribonucleoside triphosphates, the target sequence undergoes repeated rounds of transcription, cDNA synthesis and second-strand synthesis to amplify the area of interest. The use of 3SR to detect mutations is kinetically limited to screening small segments of DNA (e.g., 200-300 base pairs).

Q-Beta (Qβ) Replicase: In this method, a probe which recognizes the sequence of interest is attached to the replicatable RNA template for Qβ replicase. A previously identified major problem with false positives resulting from the replication of unhybridized probes has been addressed through use of a sequence-specific ligation step. However, available thermostable DNA ligases are not effective on this RNA substrate, so the ligation must be performed by T4 DNA ligase at low temperatures (37 degrees C.). This prevents the use of high temperature as a means of achieving specificity as in the LCR, the ligation event can be used to detect a mutation at the junction site, but not elsewhere.

A successful diagnostic method must be very specific. A straight-forward method of controlling the specificity of nucleic acid hybridization is by controlling the temperature of the reaction. While the 3SR/NASBA, and Qβ systems are all able to generate a large quantity of signal, one or more of the enzymes involved in each cannot be used at high temperature (i.e., >55 degrees C). Therefore the reaction temperatures cannot be raised to prevent non-specific hybridization of the probes. If probes are shortened in order to make them melt more easily at low temperatures, the likelihood of having more than one perfect match in a complex genome increases. For these reasons, PCR and LCR currently dominate the research field in detection technologies.

The basis of the amplification procedure in the PCR and LCR is the fact that the products of one cycle become usable templates in all subsequent cycles, consequently doubling the population with each cycle. The final yield of any such doubling system can be expressed as: (1+X)ⁿ=y, where “X” is the mean efficiency (percent copied in each cycle), “n” is the number of cycles, and “y” is the overall efficiency, or yield of the reaction. If every copy of a target DNA is utilized as a template in every cycle of a polymerase chain reaction, then the mean efficiency is 100%. If 20 cycles of PCR are performed, then the yield will be 2²⁰, or 1,048,576 copies of the starting material. If the reaction conditions reduce the mean efficiency to 85%, then the yield in those 20 cycles will be only 1.85²⁰, or 220,513 copies of the starting material. In other words, a PCR running at 85% efficiency will yield only 21% as much final product, compared to a reaction running at 100% efficiency. A reaction that is reduced to 50% mean efficiency will yield less than 1% of the possible product.

In practice, routine polymerase chain reactions rarely achieve the theoretical maximum yield, and PCRs are usually run for more than 20 cycles to compensate for the lower yield. At 50% mean efficiency, it would take 34 cycles to achieve the million-fold amplification theoretically possible in 20, and at lower efficiencies, the number of cycles required becomes prohibitive. In addition, any background products that amplify with a better mean efficiency than the intended target will become the dominant products.

Also, many variables can influence the mean efficiency of PCR, including target DNA length and secondary structure, primer length and design, primer and dNTP concentrations, and buffer composition, to name but a few. Contamination of the reaction with exogenous DNA (e.g., DNA spilled onto lab surfaces) or cross-contamination is also a major consideration. Reaction conditions must be carefully optimized for each different primer pair and target sequence, and the process can take days, even for an experienced investigator. The laboriousness of this process, including numerous technical considerations and other factors, presents a significant drawback to using PCR in the clinical setting. Indeed, PCR has yet to penetrate the clinical market in a significant way. The same concerns arise with LCR, as LCR must also be optimized to use different oligonucleotide sequences for each target sequence. In addition, both methods require expensive equipment, capable of precise temperature cycling.

Many applications of nucleic acid detection technologies, such as in studies of allelic variation, involve not only detection of a specific sequence in a complex background, but also the discrimination between sequences with few, or single, nucleotide differences. One method of the detection of allele-specific variants by PCR is based upon the fact that it is difficult for Taq polymerase to synthesize a DNA strand when there is a mismatch between the template strand and the 3′ end of the primer. An allele-specific variant may be detected by the use of a primer that is perfectly matched with only one of the possible alleles; the mismatch to the other allele acts to prevent the extension of the primer, thereby preventing the amplification of that sequence. This method has a substantial limitation in that the base composition of the mismatch influences the ability to prevent extension across the mismatch, and certain mismatches do not prevent extension or have only a minimal effect.

A similar 3′-mismatch strategy is used with greater effect to prevent ligation in the LCR. Any mismatch effectively blocks the action of the thermostable ligase, but LCR still has the drawback of target-independent background ligation products initiating the amplification. Moreover, the combination of PCR with subsequent LCR to identify the nucleotides at individual positions is also a clearly cumbersome proposition for the clinical laboratory.

The direct detection method according to various preferred embodiments of the present invention may be, for example a cycling probe reaction (CPR) or a branched DNA analysis.

When a sufficient amount of a nucleic acid to be detected is available, there are advantages to detecting that sequence directly, instead of making more copies of that target, (e.g., as in PCR and LCR). Most notably, a method that does not amplify the signal exponentially is more amenable to quantitative analysis. Even if the signal is enhanced by attaching multiple dyes to a single oligonucleotide, the correlation between the final signal intensity and amount of target is direct. Such a system has an additional advantage that the products of the reaction will not themselves promote further reaction, so contamination of lab surfaces by the products is not as much of a concern. Recently devised techniques have sought to eliminate the use of radioactivity and/or improve the sensitivity in automatable formats. Two examples are the “Cycling Probe Reaction” (CPR), and “Branched DNA” (bDNA).

Cycling probe reaction (CPR): The cycling probe reaction (CPR), uses a long chimeric oligonucleotide in which a central portion is made of RNA while the two termini are made of DNA. Hybridization of the probe to a target DNA and exposure to a thermostable RNase H causes the RNA portion to be digested. This destabilizes the remaining DNA portions of the duplex, releasing the remainder of the probe from the target DNA and allowing another probe molecule to repeat the process. The signal, in the form of cleaved probe molecules, accumulates at a linear rate. While the repeating process increases the signal, the RNA portion of the oligonucleotide is vulnerable to RNases that may carried through sample preparation.

Branched DNA: Branched DNA (bDNA), involves oligonucleotides with branched structures that allow each individual oligonucleotide to carry 35 to 40 labels (e.g., alkaline phosphatase enzymes). While this enhances the signal from a hybridization event, signal from non-specific binding is similarly increased.

The detection of at least one sequence change according to various preferred embodiments of the present invention may be accomplished by, for example restriction fragment length polymorphism (RFLP analysis), allele specific oligonucleotide (ASO) analysis, Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE), Single-Strand Conformation Polymorphism (SSCP) analysis or Dideoxy fingerprinting (ddF).

The demand for tests which allow the detection of specific nucleic acid sequences and sequence changes is growing rapidly in clinical diagnostics. As nucleic acid sequence data for genes from humans and pathogenic organisms accumulates, the demand for fast, cost-effective, and easy-to-use tests for as yet mutations within specific sequences is rapidly increasing.

A handful of methods have been devised to scan nucleic acid segments for mutations. One option is to determine the entire gene sequence of each test sample (e.g., a bacterial isolate). For sequences under approximately 600 nucleotides, this may be accomplished using amplified material (e.g., PCR reaction products). This avoids the time and expense associated with cloning the segment of interest. However, specialized equipment and highly trained personnel are required, and the method is too labor-intense and expensive to be practical and effective in the clinical setting.

In view of the difficulties associated with sequencing, a given segment of nucleic acid may be characterized on several other levels. At the lowest resolution, the size of the molecule can be determined by electrophoresis by comparison to a known standard run on the same gel. A more detailed picture of the molecule may be achieved by cleavage with combinations of restriction enzymes prior to electrophoresis, to allow construction of an ordered map. The presence of specific sequences within the fragment can be detected by hybridization of a labeled probe, or the precise nucleotide sequence can be determined by partial chemical degradation or by primer extension in the presence of chain-terminating nucleotide analogs.

Restriction fragment length polymorphism (RFLP): For detection of single-base differences between like sequences, the requirements of the analysis are often at the highest level of resolution. For cases in which the position of the nucleotide in question is known in advance, several methods have been developed for examining single base changes without direct sequencing. For example, if a mutation of interest happens to fall within a restriction recognition sequence, a change in the pattern of digestion can be used as a diagnostic tool (e.g., restriction fragment length polymorphism [RFLP] analysis).

Single point mutations have been also detected by the creation or destruction of RFLPs. Mutations are detected and localized by the presence and size of the RNA fragments generated by cleavage at the mismatches. Single nucleotide mismatches in DNA heteroduplexes are also recognized and cleaved by some chemicals, providing an alternative strategy to detect single base substitutions, generically named the “Mismatch Chemical Cleavage” (MCC). However, this method requires the use of osmium tetroxide and piperidine, two highly noxious chemicals which are not suited for use in a clinical laboratory.

RFLP analysis suffers from low sensitivity and requires a large amount of sample. When RFLP analysis is used for the detection of point mutations, it is, by its nature, limited to the detection of only those single base changes which fall within a restriction sequence of a known restriction endonuclease. Moreover, the majority of the available enzymes have 4 to 6 base-pair recognition sequences, and cleave too frequently for many large-scale DNA manipulations. Thus, it is applicable only in a small fraction of cases, as most mutations do not fall within such sites.

A handful of rare-cutting restriction enzymes with 8 base-pair specificities have been isolated and these are widely used in genetic mapping, but these enzymes are few in number, are limited to the recognition of G+C-rich sequences, and cleave at sites that tend to be highly clustered. Recently, endonucleases encoded by group I introns have been discovered that might have greater than 12 base-pair specificity, but again, these are few in number.

Allele specific oligonucleotide (ASO): If the change is not in a recognition sequence, then allele-specific oligonucleotides (ASOs), can be designed to hybridize in proximity to the mutated nucleotide, such that a primer extension or ligation event can bused as the indicator of a match or a mis-match. Hybridization with radioactively labeled allelic specific oligonucleotides (ASO) also has been applied to the detection of specific point mutations. The method is based on the differences in the melting temperature of short DNA fragments differing by a single nucleotide. Stringent hybridization and washing conditions can differentiate between mutant and wild-type alleles. The ASO approach applied to PCR products also has been extensively utilized by various researchers to detect and characterize point mutations in ras genes and gsp/gip oncogenes. Because of the presence of various nucleotide changes in multiple positions, the ASO method requires the use of many oligonucleotides to cover all possible oncogenic mutations.

With either of the techniques described above (i.e., RFLP and ASO), the precise location of the suspected mutation must be known in advance of the test. That is to say, they are inapplicable when one needs to detect the presence of a mutation within a gene or sequence of interest.

Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE): Two other methods rely on detecting changes in electrophoretic mobility in response to minor sequence changes. One of these methods, termed “Denaturing Gradient Gel Electrophoresis” (DGGE) is based on the observation that slightly different sequences will display different patterns of local melting when electrophoretically resolved on a gradient gel. In this manner, variants can be distinguished, as differences in melting properties of homoduplexes versus heteroduplexes differing in a single nucleotide can detect the presence of mutations in the target sequences because of the corresponding changes in their electrophoretic mobilities. The fragments to be analyzed, usually PCR products, are “clamped” at one end by a long stretch of G-C base pairs (30-80) to allow complete denaturation of the sequence of interest without complete dissociation of the strands. The attachment of a GC “clamp” to the DNA fragments increases the fraction of mutations that can be recognized by DGGE. Attaching a GC clamp to one primer is critical to ensure that the amplified sequence has a low dissociation temperature. Modifications of the technique have been developed, using temperature gradients, and the method can be also applied to RNA:RNA duplexes.

Limitations on the utility of DGGE include the requirement that the denaturing conditions must be optimized for each type of DNA to be tested. Furthermore, the method requires specialized equipment to prepare the gels and maintain the needed high temperatures during electrophoresis. The expense associated with the synthesis of the clamping tail on one oligonucleotide for each sequence to be tested is also a major consideration. In addition, long running times are required for DGGE. The long running time of DGGE was shortened in a modification of DGGE called constant denaturant gel electrophoresis (CDGE). CDGE requires that gels be performed under different denaturant conditions in order to reach high efficiency for the detection of mutations.

A technique analogous to DGGE, termed temperature gradient gel electrophoresis (TGGE), uses a thermal gradient rather than a chemical denaturant gradient. TGGE requires the use of specialized equipment which can generate a temperature gradient perpendicularly oriented relative to the electrical field. TGGE can detect mutations in relatively small fragments of DNA therefore scanning of large gene segments requires the use of multiple PCR products prior to running the gel.

Single-Strand Conformation Polymorphism (SSCP): Another common method, called “Single-Strand Conformation Polymorphism” (SSCP) was developed by Hayashi, Sekya and colleagues and is based on the observation that single strands of nucleic acid can take on characteristic conformations in non-denaturing conditions, and these conformations influence electrophoretic mobility. The complementary strands assume sufficiently different structures that one strand may be resolved from the other. Changes in sequences within the fragment will also change the conformation, consequently altering the mobility and allowing this to be used as an assay for sequence variations.

The SSCP process involves denaturing a DNA segment (e.g., a PCR product) that is labeled on both strands, followed by slow electrophoretic separation on a non-denaturing polyacrylamide gel, so that intra-molecular interactions can form and not be disturbed during the run. This technique is extremely sensitive to variations in gel composition and temperature. A serious limitation of this method is the relative difficulty encountered in comparing data generated in different laboratories, under apparently similar conditions.

Dideoxy fingerprinting (ddF): The dideoxy fingerprinting (ddF) is another technique developed to scan genes for the presence of mutations. The ddF technique combines components of Sanger dideoxy sequencing with SSCP. A dideoxy sequencing reaction is performed using one dideoxy terminator and then the reaction products are electrophoresed on nondenaturing polyacrylamide gels to detect alterations in mobility of the termination segments as in SSCP analysis. While ddF is an improvement over SSCP in terms of increased sensitivity, ddF requires the use of expensive dideoxynucleotides and this technique is still limited to the analysis of fragments of the size suitable for SSCP (i.e., fragments of 200-300 bases for optimal detection of mutations).

In addition to the above limitations, all of these methods are limited as to the size of the nucleic acid fragment that can be analyzed. For the direct sequencing approach, sequences of greater than 600 base pairs require cloning, with the consequent delays and expense of either deletion sub-cloning or primer walking, in order to cover the entire fragment. SSCP and DGGE have even more severe size limitations. Because of reduced sensitivity to sequence changes, these methods are not considered suitable for larger fragments. Although SSCP is reportedly able to detect 90% of single-base substitutions within a 200 base-pair fragment, the detection drops to less than 50% for 400 base pair fragments. Similarly, the sensitivity of DGGE decreases as the length of the fragment reaches 500 base-pairs. The ddF technique, as a combination of direct sequencing and SSCP, is also limited by the relatively small size of the DNA that can be screened.

According to a presently preferred embodiment of the present invention the step of searching for any of the nucleic acid sequences described here, in tumor cells or in cells derived from a cancer patient is effected by any suitable technique, including, but not limited to, nucleic acid sequencing, polymerase chain reaction, ligase chain reaction, self-sustained synthetic reaction, Qβ-Replicase, cycling probe reaction, branched DNA, restriction fragment length polymorphism analysis, mismatch chemical cleavage, heteroduplex analysis, allele-specific oligonucleotides, denaturing gradient gel electrophoresis, constant denaturant gel electrophoresis, temperature gradient gel electrophoresis and dideoxy fingerprinting.

Detection may also optionally be performed with a chip or other such device. The nucleic acid sample which includes the candidate region to be analyzed is preferably isolated, amplified and labeled with a reporter group. This reporter group can be a fluorescent group such as phycoerythrin. The labeled nucleic acid is then incubated with the probes immobilized on the chip using a fluidics station. describe the fabrication of fluidics devices and particularly microcapillary devices, in silicon and glass substrates.

Once the reaction is completed, the chip is inserted into a scanner and patterns of hybridization are detected. The hybridization data is collected, as a signal emitted from the reporter groups already incorporated into the nucleic acid, which is now bound to the probes attached to the chip. Since the sequence and position of each probe immobilized on the chip is known, the identity of the nucleic acid hybridized to a given probe can be determined.

It will be appreciated that when utilized along with automated equipment, the above described detection methods can be used to screen multiple samples for a disease and/or pathological condition both rapidly and easily.

Amino Acid Sequences and Peptides

The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms “polypeptide,” “peptide” and “protein” include glycoproteins, as well as non-glycoproteins.

Polypeptide products can be biochemically synthesized such as by employing standard solid phase techniques. Such methods include but are not limited to exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.

Solid phase polypeptide synthesis procedures are well known in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Peptide Syntheses (2nd Ed., Pierce Chemical Company, 1984).

Synthetic polypeptides can optionally be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.], after which their composition can be confirmed via amino acid sequencing.

In cases where large amounts of a polypeptide are desired, it can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.

The present invention also encompasses polypeptides encoded by the polynucleotide sequences of the present invention, as well as polypeptides according to the amino acid sequences described herein. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95% or more say 100% homologous to the amino acid sequences set forth below, as can be determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters, optionally and preferably including the following: filtering on (this option filters repetitive or low-complexity sequences from the query using the Seg (protein) program), scoring matrix is BLOSUM62 for proteins, word size is 3, E value is 10, gap costs are 11, 1 (initialization and extension), and number of alignments shown is 50. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or artificially induced, either randomly or in a targeted fashion. Homology/identity of nucleic acid sequences is preferably determined by using BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters, which preferably include using the DUST filter program, and also preferably include having an E value of 10, filtering low complexity sequences and a word size of 11.

It will be appreciated that peptides identified according the present invention may be degradation products, synthetic peptides or recombinant peptides as well as peptidomimetics, typically, synthetic peptides and peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S═O, O═C—NH, CH2-O, CH2-CH2, S═C—NH, CH═CH or CF═CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified. Further details in this respect are provided hereinunder.

Peptide bonds (—CO—NH—) within the peptide may be substituted, for example, by N-methylated bonds (—N(CH3)-CO—), ester bonds (—C(R)H—C—O—O—C(R)—N—), ketomethylen bonds (—CO—CH2-), α-aza bonds (—NH—N(R)—CO—), wherein R is any alkyl, e.g., methyl, carba bonds (—CH2-NH—), hydroxyethylene bonds (—CH(OH)—CH2-), thioamide bonds (—CS—NH—), olefinic double bonds (—CH═CH—), retro amide bonds (—NH—CO—), peptide derivatives (—N(R)—CH2-CO—), wherein R is the “normal” side chain, naturally presented on the carbon atom.

These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.

Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.

In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc).

As used herein in the specification and in the claims section below the term “amino acid” or “amino acids” is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term “amino acid” includes both D- and L-amino acids.

Table 1 non-conventional or modified amino acids which can be used with the present invention.

TABLE 1


Non-conventional amino
acid	Code	Non-conventional amino acid	Code

α-aminobutyric acid	Abu	L-N-methylalanine	Nmala
α-amino-α-methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
Carboxylate		L-N-methylaspartic acid	Nmasp
aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbornyl-	Norb	L-N-methylglutamine	Nmgin
Carboxylate		L-N-methylglutamic acid	Nmglu
Cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
Cyclopentylalanine	Cpen	L-N-methylisolleucine	Nmile
D-alanine	Dal	L-N-methylleucine	Nmleu
D-arginine	Darg	L-N-methyllysine	Nmlys
D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
D-isoleucine	Dile	L-N-methylproline	Nmpro
D-leucine	Dleu	L-N-methylserine	Nmser
D-lysine	Dlys	L-N-methylthreonine	Nmthr
D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
D-phenylalanine	Dphe	L-N-methylvaline	Nmval
D-proline	Dpro	L-N-methylethylglycine	Nmetg
D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
D-threonine	Dthr	L-norleucine	Nle
D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	α-methyl-aminoisobutyrate	Maib
D-valine	Dval	α-methyl-γ-aminobutyrate	Mgabu
D-α-methylalanine	Dmala	α-methylcyclohexylalanine	Mchexa
D-α-methylarginine	Dmarg	α-methylcyclopentylalanine	Mcpen
D-α-methylasparagine	Dmasn	α-methyl-α-napthylalanine	Manap
D-α-methylaspartate	Dmasp	α-methylpenicillamine	Mpen
D-α-methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D-α-methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
D-α-methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
D-α-methylisoleucine	Dmile	N-amino-α-methylbutyrate	Nmaabu
D-α-methylleucine	Dmleu	α-napthylalanine	Anap
D-α-methyllysine	Dmlys	N-benzylglycine	Nphe
D-α-methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
D-α-methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D-α-methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D-α-methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D-α-methylserine	Dmser	N-cyclobutylglycine	Ncbut
D-α-methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
D-α-methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D-α-methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
D-α-methylvaline	Dmval	N-cyclododeclglycine	Ncdod
D-α-methylalnine	Dnmala	N-cyclooctylglycine	Ncoct
D-α-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
D-α-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D-α-methylasparatate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D-α-methylcysteine	Dnmcys	N-(3,3-	Nbhe
		diphenylpropyl)glycine
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl) glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl-γ-aminobutyrate	Nmgabu
N-	Nmchexa	D-N-methylmethionine	Dnmmet
methylcyclohexylalanine
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nva
D-N-methyltyrosine	Dnmtyr	N-methyla-napthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ-aminobutyric acid	Gabu	N-(p-hydroxyphenyl)glycine	Nhtyr
L-t-butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L-α-methylalanine	Mala
L-α-methylarginine	Marg	L-α-methylasparagine	Masn
L-α-methylaspartate	Masp	L-α-methyl-t-butylglycine	Mtbug
L-α-methylcysteine	Mcys	L-methylethylglycine	Metg
L-α-methylglutamine	Mgln	L-α-methylglutamate	Mglu
L-α-methylhistidine	Mhis	L-α-methylhomo	Mhphe
		phenylalanine
L-α-methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
D-N-methylglutamine	Dnmgln	N-(3-	Narg
		guanidinopropyl)glycine
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl-γ-aminobutyrate	Nmgabu
N-	Nmchexa	D-N-methylmethionine	Dnmmet
methylcyclohexylalanine
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyla-napthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ-aminobutyric acid	Gabu	N-(p-hydroxyphenyl)glycine	Nhtyr
L-t-butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L-α-methylalanine	Mala
L-α-methylarginine	Marg	L-α-methylasparagine	Masn
L-α-methylaspartate	Masp	L-α-methyl-t-butylglycine	Mtbug
L-α-methylcysteine	Mcys	L-methylethylglycine	Metg
L-α-methylglutamine	Mgln	L-α-methylglutamate	Mglu
L-α-methylhistidine	Mhis	L-α-	Mhphe
		methylhomophenylalanine
L-α-methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L-α-methylleucine	Mleu	L-α-methyllysine	Mlys
L-α-methylmethionine	Mmet	L-α-methylnorleucine	Mnle
L-α-methylnorvaline	Mnva	L-α-methylornithine	Morn
L-α-methylphenylalanine	Mphe	L-α-methylproline	Mpro
L-α-methylserine	mser	L-α-methylthreonine	Mthr
L-α-methylvaline	Mtrp	L-α-methyltyrosine	Mtyr
L-α-methylleucine	Mval	L-N-	Nmhphe
	Nnbhm	methylhomophenylalanine
N-(N-(2,2-diphenylethyl)		N-(N-(3,3-diphenylpropyl)
carbamylmethyl-glycine	Nnbhm	carbamylmethyl(1)glycine	Nnbhe
1-carboxy-1-(2,2-diphenylethylamino)	Nmbc
cyclopropane

Since the peptides of the present invention are preferably utilized in diagnostics which require the peptides to be in soluble form, the peptides of the present invention preferably include one or more non-natural or natural polar amino acids, including but not limited to serine and threonine which are capable of increasing peptide solubility due to their hydroxyl-containing side chain.

The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclicization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized.

The peptides of present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis well known in the art, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.

Synthetic peptides can be purified by preparative high performance liquid chromatography and the composition of which can be confirmed via amino acid sequencing.

In cases where large amounts of the peptides of the present invention are desired, the peptides of the present invention can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463 and also as described above.

Antibodies

“Antibody” refers to a polypeptide ligand that is preferably substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically binds and recognizes an epitope (e.g., an antigen). The recognized immunoglobulin genes include the kappa and lambda light chain constant region genes, the alpha, gamma, delta, epsilon and mu heavy chain constant region genes, and the myriad-immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. This includes, e.g., Fab′ and F(ab)′₂fragments. The term “antibody,” as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies. It also includes polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, or single chain antibodies. “Fc” portion of an antibody refers to that portion of an immunoglobulin heavy chain that comprises one or more heavy chain constant region domains, CH1, CH2 and CH3, but does not include the heavy chain variable region.

The functional fragments of antibodies, such as Fab, F(ab′)2, and Fv that are capable of binding to macrophages, are described as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab′, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule; (3) (Fab′)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].

Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10,: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and-Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

Preferably, the antibody of this aspect of the present invention specifically binds at least one epitope of the polypeptide variants of the present invention. As used herein, the term “epitope” refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.

Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

Optionally, a unique epitope may be created in a variant due to a change in one or more post-translational modifications, including but not limited to glycosylation and/or phosphorylation, as described below. Such a change may also cause a new epitope to be created, for example through removal of glycosylation at a particular site.

An epitope according to the present invention may also optionally comprise part or all of a unique sequence portion of a variant according to the present invention in combination with at least one other portion of the variant which is not contiguous to the unique sequence portion in the linear polypeptide itself, yet which are able to form an epitope in combination. One or more unique sequence portions may optionally combine with one or more other non-contiguous portions of the variant (including a portion which may have high homology to a portion of the known protein) to form an epitope.

Immunoassays

In another embodiment of the present invention, an immunoassay can be used to qualitatively or quantitatively detect and analyze markers in a sample. This method comprises: providing an antibody that specifically binds to a marker; contacting a sample with the antibody; and detecting the presence of a complex of the antibody bound to the marker in the sample.

To prepare an antibody that specifically binds to a marker, purified protein markers can be used. Antibodies that specifically bind to a protein marker can be prepared using any suitable methods known in the art.

After the antibody is provided, a marker can be detected and/or quantified using any of a number of well recognized immunological binding assays. Useful assays include, for example, an enzyme immune assay (EIA) such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or a slot blot assay see, e.g., U.S. Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). Generally, a sample obtained from a subject can be contacted with the antibody that specifically binds the marker.

Optionally, the antibody can be fixed to a solid support to facilitate washing and subsequent isolation of the complex, prior to contacting the antibody with a sample. Examples of solid supports include but are not limited to glass or plastic in the form of, e.g., a microtiter plate, a stick, a bead, or a microbead. Antibodies can also be attached to a solid support.

After incubating the sample with antibodies, the mixture is washed and the antibody-marker complex formed can be detected. This can be accomplished by incubating the washed mixture with a detection reagent. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, marker, volume of solution, concentrations and the like. Usually the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C. to 40° C.

The immunoassay can be used to determine a test amount of a marker in a sample from a subject. First, a test amount of a marker in a sample can be detected using the immunoassay methods described above. If a marker is present in the sample, it will form an antibody-marker complex with an antibody that specifically binds the marker under suitable incubation conditions described above. The amount of an antibody-marker complex can optionally be determined by comparing to a standard. As noted above, the test amount of marker need not be measured in absolute units, as long as the unit of measurement can be compared to a control amount and/or signal.

Preferably used are antibodies which specifically interact with the polypeptides of the present invention and not with wild type proteins or other isoforms thereof, for example. Such antibodies are directed, for example, to the unique sequence portions of the polypeptide variants of the present invention, including but not limited to bridges, heads, tails and insertions described in greater detail below. Preferred embodiments of antibodies according to the present invention are described in greater detail with regard to the section entitled “Antibodies”.

Radio-immunoassay (RIA): In one version, this method involves precipitation of the desired substrate and in the methods detailed hereinbelow, with a specific antibody and radiolabelled antibody binding protein (e.g., protein A labeled with I¹²⁵) immobilized on a precipitable carrier such as agarose beads. The number of counts in the precipitated pellet is proportional to the amount of substrate.

In an alternate version of the RIA, a labeled substrate and an unlabelled antibody binding protein are employed. A sample containing an unknown amount of substrate is added in varying amounts. The decrease in precipitated counts from the labeled substrate is proportional to the amount of substrate in the added sample.

Enzyme linked immunosorbent assay (ELISA): This method involves fixation of a sample (e.g., fixed cells or a proteinaceous solution) containing a protein substrate to a surface such as a well of a microtiter plate. A substrate specific antibody coupled to an enzyme is applied and allowed to bind to the substrate. Presence of the antibody is then detected and quantitated by a colorimetric reaction employing the enzyme coupled to the antibody. Enzymes commonly employed in this method include horseradish peroxidase and alkaline phosphatase. If well calibrated and within the linear range of response, the amount of substrate present in the sample is proportional to the amount of color produced. A substrate standard is generally employed to improve quantitative accuracy.

Western blot: This method involves separation of a substrate from other protein by means of an acrylamide gel followed by transfer of the substrate to a membrane (e.g., nylon or PVDF). Presence of the substrate is then detected by antibodies specific to the substrate, which are in turn detected by antibody binding reagents. Antibody binding reagents may be, for example, protein A, or other antibodies. Antibody binding reagents may be radiolabelled or enzyme linked as described hereinabove. Detection may be by autoradiography, colorimetric reaction or chemiluminescence. This method allows both quantitation of an amount of substrate and determination of its identity by a relative position on the membrane which is indicative of a migration distance in the acrylamide gel during electrophoresis.

Immunohistochemical analysis: This method involves detection of a substrate in situ in fixed cells by substrate specific antibodies. The substrate specific antibodies may be enzyme linked or linked to fluorophores. Detection is by microscopy and subjective evaluation. If enzyme linked antibodies are employed, a colorimetric reaction may be required.

Fluorescence activated cell sorting (FACS): This method involves detection of a substrate in situ in cells by substrate specific antibodies. The substrate specific antibodies are linked to fluorophores. Detection is by means of a cell sorting machine which reads the wavelength of light emitted from each cell as it passes through a light beam. This method may employ two or more antibodies simultaneously.

Radio-Imaging Methods

These methods include but are not limited to, positron emission tomography (PET) single photon emission computed tomography (SPECT). Both of these techniques are non-invasive, and can be used to detect and/or measure a wide variety of tissue events and/or functions, such as detecting cancerous cells for example. Unlike PET, SPECT can optionally be used with two labels simultaneously. SPECT has some other advantages as well, for example with regard to cost and the types of labels that can be used. For example, US Patent No. 6,696,686 describes the use of SPECT for detection of breast cancer, and is hereby incorporated by reference as if fully set forth herein.

Display Libraries

According to still another aspect of the present invention there is provided a display library comprising a plurality of display vehicles (such as phages, viruses or bacteria) each displaying at least 6, at least 7, at least 8, at least 9, at least 10, 10-15, 12-17, 15-20, 15-30 or 20-50 consecutive amino acids derived from the polypeptide sequences of the present invention.

Methods of constructing such display libraries are well known in the art. Such methods are described in, for example, Young A C, et al., “The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes” J Mol Biol Dec. 12, 1997;274(4):622-34; Giebel L B et al. “Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities” Biochemistry Nov. 28, 1995;34(47):15430-5; Davies E L et al., “Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes” J Immunol Methods Oct. 12, 1995;186(l):125-35; Jones C R T al. “Current trends in molecular recognition and bioseparation” J Chromatogr A Jul. 14, 1995;707(1):3-22; Deng S J et al. “Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries” Proc Natl Acad Sci USA May 23, 1995;92(11):4992-6; and Deng S J et al. “Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display” J Biol Chem Apr. 1, 1994;269(13):9533-8, which are incorporated herein by reference.

The following sections relate to Candidate Marker Examples (first section) and to Experimental Data for these Marker Examples (second section).

CANDIDATE MARKER EXAMPLES SECTION

This Section relates to Examples of sequences according to the present invention, including illustrative methods of selection thereof.

DESCRIPTION OF THE METHODOLOGY UNDERTAKEN TO UNCOVER THE BIOMOLECULAR SEQUENCES OF THE PRESENT INVENTION

Human ESTs and cDNAs were obtained from GenBank versions 136 (Jun. 15, 2003 ftp.ncbi.nih.gov/genbank/release.notes/gb136.release.notes); NCBI genome assembly of April 2003; RefSeq sequences from June 2003; Genbank version 139 (December 2003); Human Genome from NCBI (Build 34) (from October 2003); RefSeq sequences from December 2003; and from LifeSeq library of Incyte Corp (Wilmington, Del., USA; ESTs only). With regard to GenBank sequences, the human EST sequences from the EST (GBEST) section and the human mRNA sequences from the primate (GBPRI) section were used; also the human nucleotide RefSeq mRNA sequences were used (see for example www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html and for a reference to the EST section, see www.ncbi.nlm.nih.gov/dbEST/; a general reference to dbEST, the EST database in GenBank, may be found in Boguski et al, Nat Genet. 1993 Aug.;4(4):332-3; all of which are hereby incorporated by reference as if fully set forth herein).

Novel splice variants were predicted using the LEADS clustering and assembly system as described in Sorek, R., Ast, G. & Graur, D. Alu-containing exons are alternatively spliced. Genome Res 12, 1060-7 (2002); U.S. Pat. No: 6,625,545; and U.S. patent application Ser. No. 10/426,002, published as US20040101876 on May 27 2004; all of which are hereby incorporated by reference as if fully set forth herein. Briefly, the software cleans the expressed sequences from repeats, vectors and immunoglobulins. It then aligns the expressed sequences to the genome taking alternatively splicing into account and clusters overlapping expressed sequences into “clusters” that represent genes or partial genes.

These were annotated using the GeneCarta (Compugen, Tel-Aviv, Israel) platform. The GeneCarta platform includes a rich pool of annotations, sequence information (particularly of spliced sequences), chromosomal information, alignments, and additional information such as SNPs, gene ontology terms, expression profiles, functional analyses, detailed domain structures, known and predicted proteins and detailed homology reports.

A brief explanation is provided with regard to the method of selecting the candidates. However, it should noted that this explanation is provided for descriptive purposes only, and is not intended to be limiting in any way. The potential markers were identified by a computational process that was designed to find genes and/or their splice variants that are over-expressed in tumor tissues, by using databases of expressed sequences. Various parameters related to the information in the EST libraries, determined according to a manual classification process, were used to assist in locating genes and/or splice variants thereof that are over-expressed in cancerous tissues. The detailed description of the selection method is presented in Example 1 below. The cancer biomarkers selection engine and the following wet validation stages are schematically summarized in FIG. 1.

EXAMPLE 1 Identification of Differentially Expressed Gene Products—Algorithm

In order to distinguish between differentially expressed gene products and constitutively expressed genes (i.e., house keeping genes ) an algorithm based on an analysis of frequencies was configured. A specific algorithm for identification of transcripts over expressed in cancer is described hereinbelow.

Dry Analysis

Library annotation—EST libraries are manually classified according to:

- (i) Tissue origin
- (ii) Biological source—Examples of frequently used biological sources for construction of EST libraries include cancer cell-lines; normal tissues; cancer tissues; fetal tissues; and others such as normal cell lines and pools of normal cell-lines, cancer cell-lines and combinations thereof. A specific description of abbreviations used below with regard to these tissues/cell lines etc is given above.
- (iii) Protocol of library construction—various methods are known in the art for library construction including normalized library construction; non-normalized library construction; subtracted libraries; ORESTES and others. It will be appreciated that at times the protocol of library construction is not indicated.

The following rules were followed:

EST libraries originating from identical biological samples are considered as a single library.

EST libraries which included above-average levels of contamination, such as DNA contamination for example, were eliminated. The presence of such contamination was determined as follows. For each library, the number of unspliced ESTs that are not fully contained within other spliced sequences was counted. If the percentage of such sequences (as compared to all other sequences) was at least 4 standard deviations above the average for all libraries being analyzed, this library was tagged as being contaminated and was eliminated from further consideration in the below analysis (see also Sorek, R. & Safer, H. M. A novel algorithm for computational identification of contaminated EST libraries. Nucleic Acids Res 31, 1067-74 (2003)for further details).

Clusters (genes) having at least five sequences including at least two sequences from the tissue of interest were analyzed. Splice variants were identified by using the LEADS software package as described above.

EXAMPLE 2 Identification of Genes Over Expressed in Cancer

Two different scoring algorithms were developed.

Libraries score—candidate sequences which are supported by a number of cancer libraries, are more likely to serve as specific and effective diagnostic markers.

The basic algorithm—for each cluster the number of cancer and normal libraries contributing sequences to the cluster was counted. Fisher exact test was used to check if cancer libraries are significantly over-represented in the cluster as compared to the total number of cancer and normal libraries.

Library counting: Small libraries (e.g., less than 1000 sequences) were excluded from consideration unless they participate in the cluster. For this reason, the total number of libraries is actually adjusted for each cluster.

Clones no. score—Generally, when the number of ESTs is much higher in the cancer libraries relative to the normal libraries it might indicate actual over-expression.

The algorithm—

Clone counting: For counting EST clones each library protocol class was given a weight based on our belief of how much the protocol reflects actual expression levels:

(i) non-normalized: 1

(ii) normalized: 0.2

(iii) all other classes: 0.1

Clones number score—The total weighted number of EST clones from cancer libraries was compared to the EST clones from normal libraries. To avoid cases where one library contributes to the majority of the score, the contribution of the library that gives most clones for a given cluster was limited to 2 clones.

The score was computed as c + 1 C / n + 1 N
where:

c—weighted number of “cancer” clones in the cluster.

C—weighted number of clones in all “cancer” libraries.

n—weighted number of “normal” clones in the cluster.

N—weighted number of clones in all “normal” libraries.

Clones number score significance—Fisher exact test was used to check if EST clones from cancer libraries are significantly over-represented in the cluster as compared to the total number of EST clones from cancer and normal libraries.

Two search approaches were used to find either general cancer-specific candidates or tumor specific candidates.

- Libraries/sequences originating from tumor tissues are counted as well as libraries originating from cancer cell-lines (“normal” cell-lines were ignored).
- Only libraries/sequences originating from tumor tissues are counted

EXAMPLE 3 Identification of tissue Specific Genes

For detection of tissue specific clusters, tissue libraries/sequences were compared to the total number of libraries/sequences in cluster. Similar statistical tools to those described in above were employed to identify tissue specific genes. Tissue abbreviations are the same as for cancerous tissues, but are indicated with the header “normal tissue”.

The algorithm—for each tested tissue T and for each tested cluster the following were examined:

1. Each cluster includes at least 2 libraries from the tissue T. At least 3 clones (weighed—as described above) from tissue T in the cluster; and

2. Clones from the tissue T are at least 40% from all the clones participating in the tested cluster

Fisher exact test P-values were computed both for library and weighted clone counts to check that the counts are statistically significant.

EXAMPLE 4 Identification of Splice Variants Expressed in Cancer of Clusters Which are Not Over Expressed in Cancer

Cancer-Specific Splice Variants Containing a Unique Region were Identified.

Identification of unique sequence regions in splice variants A Region is defined as a group of adjacent exons that always appear or do not appear together in each splice variant.

A “segment” (sometimes referred also as “seg” or “node”) is defined as the shortest contiguous transcribed region without known splicing inside.

Only reliable ESTs were considered for region and segment analysis. An EST was defined as unreliable if:

(i) Unspliced;

(ii) Not covered by RNA;

(iii) Not covered by spliced ESTs; and

(iv) Alignment to the genome ends in proximity of long poly-A stretch or starts in proximity of long poly-T stretch.

Only reliable regions were selected for further scoring. Unique sequence regions were considered reliable if:

(i) Aligned to the genome; and

(ii) Regions supported by more than 2 ESTs.

The algorithm

Each unique sequence region divides the set of transcripts into 2 groups:

(i) Transcripts containing this region (group TA).

(ii) Transcripts not containing this region (group TB).

The set of EST clones of every cluster is divided into 3 groups:

(i) Supporting (originating from) transcripts of group TA (S1).

(ii) Supporting transcripts of group TB (S2).

(iii) Supporting transcripts from both groups (S3).

Library and clones number scores described above were given to S1 group.

Fisher Exact Test P-values were used to check if:

S1 is significantly enriched by cancer EST clones compared to S2; and

S1 is significantly enriched by cancer EST clones compared to cluster background (S1+S2+S3).

Identification of unique sequence regions and division of the group of transcripts accordingly is illustrated in FIG. 2. Each of these unique sequence regions corresponds to a segment, also termed herein a “node”.

Region 1: common to all transcripts, thus it is preferably not considered for determining differential expression between variants; Region 2: specific to Transcript 1; Region 3: specific to Transcripts 2+3; Region 4: specific to Transcript 3; Region 5: specific to Transcripts 1 and 2; Region 6: specific to Transcript 1.

EXAMPLE 5 Identification of Cancer Specific Splice Variants of Genes Over Expressed in Cancer

A search for EST supported (no mRNA) regions for genes of:

(i) known cancer markers

(ii) Genes shown to be over-expressed in cancer in published micro-array experiments.

Reliable EST supported-regions were defined as supported by minimum of one of the following:

(i) 3 spliced ESTs; or

(ii) 2 spliced ESTs from 2 libraries;

(iii) 10 unspliced ESTs from 2 libraries, or

(iv) 3 libraries.

ACTUAL MARKER EXAMPLES

The following examples relate to specific actual marker examples.

EXPERIMENTAL EXAMPLES SECTION

This Section relates to Examples describing experiments involving these sequences, and illustrative, non-limiting examples of methods, assays and uses thereof. The materials and experimental procedures are explained first, as all experiments used them as a basis for the work that was performed.

The markers of the present invention were tested with regard to their expression in various cancerous and non-cancerous tissue samples. A description of the samples used in the panel is provided in Table 1 below. A description of the samples used in the normal tissue panel is provided in Table 2 below. Tests were then performed as described in the “Materials and Experimental Procedures” section below.

TABLE 1


Tissue samples in testing panel

sample					sex/
rename	Lot no	source	pathology	grade	age	TNM	stage

52-B-ILC G1	A605360	Biochain	Invasive	1	F/60
			Lobular
			Carcinoma
51-B-IDC G1	A605361	Biochain	IDC	1	F/79
6-A-IDC G1	7238T	ABS	IDC	1	F/60	T2N0M0	stage
							2A
7-A-IDC G2	7263T	ABS	IDC	2	F/43	T1N0M0	stage 1
12-A-IDC G2	1432T	ABS	IDC	2	F/46	T2N0M0	stage
							2A
13-A-IDC G2	A0133T	ABS	IDC	2	F/63	T2N1a
						Mx
14-A-IDC G2	A0135T	ABS	IDC	2	F/37	T2N2Mx
15-A-IDC G2	7259T	ABS	IDC	2	F/59	T3N1M0	stage
							3A
16-A-IDC G2	4904020032T	ABS	IDC	2	NA	T3N1Mx
17-A-IDC G2	4904020036T	ABS	IDC	2-3	NA	T3N1Mx
43-B-IDC G2	A609183	Biochain	IDC	2	F/40
44-B-IDC G2	A609198	Biochain	IDC	2	F/77
45-B-IDC G2	A609181	Biochain	IDC	2	F/58
48-B-IDC G2	A609222	Biochain	IDC	2	F/44
49-B-IDC G2	A609223	Biochain	IDC	2	F/54
50-B-IDC G2	A609224	Biochain	IDC	2	F/69
53-B-IDC G2	A605151	Biochain	IDC	2	F/44
54-B-IDC G2	A605353	Biochain	IDC	2	F/41
55-B-IDC G2	A609179	Biochain	IDC	2	F/42
61-B-IDC G2	A610029	Biochain	IDC	2	F/46
62-B-IDC G2	A609194	Biochain	IDC	2	F/51
47-B-IDC G2	A609221	Biochain	IDC	2
46-B-Carci G2	A609177	Biochain	Carcinoma	2	F/48
26-A-IDC G3	7249T	ABS	IDC	3	F/60	T2N0M0	stage
							2A
27-A-IDC G3	4907020072T	ABS	IDC	3	NA	T2N0Mx
42-A-IDC G3	6005020031T	ABS	IDC	3	NA	T1cN0
						Mx
31-CG-IDC	CG-154	Ichilov	IDC		NA
32-A-Muc	7116T	ABS	Mucinous		F/54	T2N0M0	stage
Carci			carcinoma				2A
35-A-N M6	7238N	ABS	Normal		F/60
			matched
			to 6T
36-A-N M7	7263N	ABS	Normal		F/43
			matched
			to 7T
39-A-N M15	7259N	ABS	Normal		F/59
			matched
			to 15T
40-A-N M12	1432N	ABS	Normal		F/46
			matched
			to 12T
41-A-N M26	7249N	ABS	Normal		F/60
			matched
			to 26T
56-B-N	A609235	Biochain	Normal		F/59
			PM
57-B-N	A609233	Biochain	Normal		F/34
			PM
58-B-N	A609232	Biochain	Normal		F/65
			PM
59-B-N	A607155	Biochain	Normal		F/35
			PM
60-B-N	A609234	Biochain	Normal		F/36
			PM
63-Am-N	26486	Ambion	Normal PS		F/43
64-Am-N	23036	Ambion	Normal		F/57
			PM
65-Am-N	31410	Ambion	Normal		F/63
			PM
66-Am-N	36678	Ambion	Normal		F/45
			PM
67-Am-N	073P010602086A	Ambion	Normal		F/64
			PM

TABLE 2


Tissue samples in normal panel:

	Lot no.	Source	Tissue	Pathology	Sex/Age

1-Am-Colon (C71)	071P10B	Ambion	Colon	PM	F/43
2-B-Colon (C69)	A411078	Biochain	Colon	PM-Pool of 10	M&F
3-Cl-Colon (C70)	1110101	Clontech	Colon	PM-Pool of 3	M&F
4-Am-Small Intestine	091P0201A	Ambion	Small Intestine	PM	M/75
5-B-Small Intestine	A501158	Biochain	Small Intestine	PM	M/63
6-B-Rectum	A605138	Biochain	Rectum	PM	M/25
7-B-Rectum	A610297	Biochain	Rectum	PM	M/24
8-B-Rectum	A610298	Biochain	Rectum	PM	M/27
9-Am-Stomach	110P04A	Ambion	Stomach	PM	M/16
10-B-Stomach	A501159	Biochain	Stomach	PM	M/24
11-B-Esophagus	A603814	Biochain	Esophagus	PM	M/26
12-B-Esophagus	A603813	Biochain	Esophagus	PM	M/41
13-Am-Pancreas	071P25C	Ambion	Pancreas	PM	M/25
14-CG-Pancreas	CG-255-2	Ichilov	Pancreas	PM	M/75
15-B-Lung	A409363	Biochain	Lung	PM	F/26
16-Am-Lung (L93)	111P0103A	Ambion	Lung	PM	F/61
17-B-Lung (L92)	A503204	Biochain	Lung	PM	M/28
18-Am-Ovary (O47)	061P43A	Ambion	Ovary	PM	F/16
19-B-Ovary (O48)	A504087	Biochain	Ovary	PM	F/51
20-B-Ovary (O46)	A504086	Biochain	Ovary	PM	F/41
21-Am-Cervix	101P0101A	Ambion	Cervix	PM	F/40
22-B-Cervix	A408211	Biochain	Cervix	PM	F/36
23-B-Cervix	A504089	Biochain	Cervix	PM-Pool of 5	M&F
24-B-Uterus	A411074	Biochain	Uterus	PM-Pool of 10	M&F
25-B-Uterus	A409248	Biochain	Uterus	PM	F/43
26-B-Uterus	A504090	Biochain	Uterus	PM-Pool of 5	M&F
27-B-Bladder	A501157	Biochain	Bladder	PM	M/29
28-Am-Bladder	071P02C	Ambion	Bladder	PM	M/20
29-B-Bladder	A504088	Biochain	Bladder	PM-Pool of 5	M&F
30-Am-Placenta	021P33A	Ambion	Placenta	PB	F/33
31-B-Placenta	A410165	Biochain	Placenta	PB	F/26
32-B-Placenta	A411073	Biochain	Placenta	PB-Pool of 5	M&F
33-B-Breast (B59)	A607155	Biochain	Breast	PM	F/36
34-Am-Breast (B63)	26486	Ambion	Breast	PM	F/43
35-Am-Breast (B64)	23036	Ambion	Breast	PM	F/57
36-Cl-Prostate (P53)	1070317	Clontech	Prostate	PB-Pool of 47	M&F
37-Am-Prostate (P42)	061P04A	Ambion	Prostate	PM	M/47
38-Am-Prostate (P59)	25955	Ambion	Prostate	PM	M/62
39-Am-Testis	111P0104A	Ambion	Testis	PM	M/25
40-B-Testis	A411147	Biochain	Testis	PM	M/74
41-Cl-Testis	1110320	Clontech	Testis	PB-Pool of 45	M&F
42-CG-Adrenal	CG-184-10	Ichilov	Adrenal	PM	F/81
43-B-Adrenal	A610374	Biochain	Adrenal	PM	F/83
44-B-Heart	A411077	Biochain	Heart	PB-Pool of 5	M&F
45-CG-Heart	CG-255-9	Ichilov	Heart	PM	M/75
46-CG-Heart	CG-227-1	Ichilov	Heart	PM	F/36
47-Am-Liver	081P0101A	Ambion	Liver	PM	M/64
48-CG-Liver	CG-93-3	Ichilov	Liver	PM	F/19
49-CG-Liver	CG-124-4	Ichilov	Liver	PM	F/34
50-Cl-BM	1110932	Clontech	Bone Marrow	PM-Pool of 8	M&F
51-CGEN-Blood	WBC#5	CGEN	Blood		M
52-CGEN-Blood	WBC#4	CGEN	Blood		M
53-CGEN-Blood	WBC#3	CGEN	Blood		M
54-CG-Spleen	CG-267	Ichilov	Spleen	PM	F/25
55-CG-Spleen	111P0106B	Ambion	Spleen	PM	M/25
56-CG-Spleen	A409246	Biochain	Spleen	PM	F/12
56-CG-Thymus	CG-98-7	Ichilov	Thymus	PM	F/28
58-Am-Thymus	101P0101A	Ambion	Thymus	PM	M/14
59-B-Thymus	A409278	Biochain	Thymus	PM	M/28
60-B-Thyroid	A610287	Biochain	Thyroid	PM	M/27
61-B-Thyroid	A610286	Biochain	Thyroid	PM	M/24
62-CG-Thyroid	CG-119-2	Ichilov	Thyroid	PM	F/66
63-Cl-Salivary Gland	1070319	Clontech	Salivary Gland	PM-Pool of 24	M&F
64-Am-Kidney	111P0101B	Ambion	Kidney	PM-Pool of 14	M&F
65-Cl-Kidney	1110970	Clontech	Kidney	PM-Pool of 14	M&F
66-B-Kidney	A411080	Biochain	Kidney	PM-Pool of 5	M&F
67-CG-Cerebellum	CG-183-5	Ichilov	Cerebellum	PM	M/74
68-CG-Cerebellum	CG-212-5	Ichilov	Cerebellum	PM	M/54
69-B-Brain	A411322	Biochain	Brain	PM	M/28
70-Cl-Brain	1120022	Clontech	Brain	PM-Pool of 2	M&F
71-B-Brain	A411079	Biochain	Brain	PM-Pool of 2	M&F
72-CG-Brain	CG-151-1	Ichilov	Brain	PM	F/86
73-Am-Skeletal Muscle	101P013A	Ambion	Skeletal Muscle	PM	F/28
74-Cl-Skeletal Muscle	1061038	Clontech	Skeletal Muscle	PM-Pool of 2	M&F

Materials and Experimental Procedures

RNA preparation—RNA was obtained from Clontech (Franklin Lakes, N.J. USA 07417, www.clontech.com), BioChain Inst. Inc. (Hayward, Calif. 94545 USA www.biochain.com), ABS (Wilmington, Del. 19801, USA, http://www.absbioreagents.com) or Ambion (Austin, Tex. 78744 USA, http://www.ambion.com). Alternatively, RNA was generated from tissue samples using TRI-Reagent (Molecular Research Center), according to Manufacturer's instructions. Tissue and RNA samples were obtained from patients or from postmortem. Total RNA samples were treated with DNaseI (Ambion) and purified using RNeasy columns (Qiagen).

RT PCR—Purified RNA (1 μg) was mixed with 150 ng Random Hexamer primers (Invitrogen) and 500 μM dNTP in a total volume of 15.6 μl. The mixture was incubated for 5 min at 65° C. and then quickly chilled on ice. Thereafter, 5 μl of 5× SuperscriptII first strand buffer (Invitrogen), 2.4 μl 0.1M DTT and 40 units RNasin (Promega) were added, and the mixture was incubated for 10 min at 25° C., followed by further incubation at 42° C. for 2 min. Then, 1 μl (200units) of SuperscriptII (Invitrogen) was added and the reaction (final volume of 25μl) was incubated for 50 min at 42° C. and then inactivated at 70° C. for 15 min. The resulting cDNA was diluted 1:20 in TE buffer (10 mM Tris pH=8, 1 mM EDTA pH=8).

Real-Time RT-PCR analysis—cDNA (5 μl), prepared as described above, was used as a template in Real-Time PCR reactions using the SYBR Green I assay (PE Applied Biosystem) with specific primers and UNG Enzyme (Eurogentech or ABI or Roche). The amplification was effected as follows: 50° C. for 2 min, 95° C. for 10 min, and then 40 cycles of 95° C. for 15 sec, followed by 60° C. for 1 min. Detection was performed by using the PE Applied Biosystem SDS 7000. The cycle in which the reactions achieved a threshold level (Ct) of fluorescence was registered and was used to calculate the relative transcript quantity in the RT reactions. The relative quantity was calculated using the equation Q=efficiencylˆ^−Ct. The efficiency of the PCR reaction was calculated from a standard curve, created by using serial dilutions of several reverse transcription (RT) reactions. To minimize inherent differences in the RT reaction, the resulting relative quantities were normalized to the geometric mean of the relative quantities of several housekeeping (HSKP) genes. Schematic summary of quantitative real-time PCR analysis is presented in FIG. 3. As shown, the x-axis shows the cycle number. The C_T=Threshold Cycle point, which is the cycle that the amplification curve crosses the fluorescence threshold that was set in the experiment. This point is a calculated cycle number in which PCR product signal is above the background level (passive dye ROX) and still in the Geometric/Exponential phase (as shown, once the level of fluorescence crosses the measurement threshold, it has a geometrically increasing phase, during which measurements are most accurate, followed by a linear phase and a plateau phase; for quantitative measurements, the latter two phases do not provide accurate measurements). The y-axis shows the normalized reporter fluorescence. It should be noted that this type of analysis provides relative quantification.

The sequences of the housekeeping genes measured in all the examples on breast cancer panel were as follows:


G6PD (GenBank Accession No. NM_000402	(SEQ ID NO: 918))

G6PD Forward primer:	(SEQ ID NO: 919)
gaggccgtcaccaagaacat

G6PD Reverse primer:	(SEQ ID NO: 920)
ggacagccggtcagagctc

G6PD-amplicon:	(SEQ ID NO: 921)

gaggccgtcaccaagaacattcacgagtcctgcatgagccagataggctggaaccgcatcatcgtggagaagcccttcgggagggacct

gcagagctctgaccggctgtcc

SDHA (GenBank Accession No. NM_004168	(SEQ ID NO: 922))

SDHA Forward primer:	(SEQ ID NO: 923)
TGGGAACAAGAGGGCATCTG

SDHA reverse primer:	(SEQ ID NO: 924)
CCACCACTGCATCAAATTCATG

SDHA-amplicon:	(SEQ ID NO: 925)

TGGGAACAAGAGGGCATCTGCTAAAGTTTCAGATTCCATTTCTGCTCAGTATCCAGT
AGTGGATCATGAATTTGATGCAGTGGTGG

PBGD (GenBank Accession No. BC019323,	(SEQ ID NO: 926))

PBGD Forward primer:	(SEQ ID NO: 927)
TGAGAGTGATTCGCGTGGG

PBGD Reverse primer:	(SEQ ID NO: 928)
CCAGGGTACGAGGCTTTCAAT

PBGD-amplicon:	(SEQ ID NO: 929)

TGAGAGTGATTCGCGTGGGTACCCGCAAGAGCCAGCTTGCTCGCATACAGACGGAC
AGTGTGGTGGCAACATTGAAAGCCTCGTACCCTGG

HPRT1 (GenBank Accession No. NM_000194,	(SEQ ID NO: 930))

HPRT1 Forward primer:	(SEQ ID NO: 931)
TGACACTGGCAAAACAATGCA

HPRT1 reverse primer:	(SEQ ID NO: 932)
GGTCCTTTTCACCAGCAAGCT

HPRT1-amplicon:	(SEQ ID NO: 933)

TGACACTGGCAAAACAATGCAGACTTTGCTTTCCTTGGTCAGGCAGTATAATCCAA
AGATGGTCAAGGTCGCAAGCTTGCTGGTGAAAAGGACC

The sequences of the housekeeping genes measured in all the examples on normal tissue samples panel were as follows:


RPL19 (GenBank Accession No. NM_000981,	(SEQ ID NO: 934))

RPL19 Forward primer:	(SEQ ID NO: 935)
TGGCAAGAAGAAGGTCTGGTTAG

RPL19 reverse primer:	(SEQ ID NO: 936)
TGATCAGCCCATCTTTGATGAG

RPL19-amplicon:	(SEQ ID NO: 937)

TGGCAAGAAGAAGGTCTGGTTAGACCCCAATGAGACCAATGAAATCGCCAATGCCA
ACTCCCGTCAGCAGATCCGGAAGCTCATCAAAGATGGGCTGATCA

TATA box (GenBank Accession No. NM_003194,	(SEQ ID NO: 938))

TATA box Forward primer:	(SEQ ID NO: 939)
CGGTTTGCTGCGGTAATCAT

TATA box Reverse primer:	(SEQ ID NO: 940)
TTTCTTGCTGCCAGTCTGGAC

TATA box-amplicon:	(SEQ ID NO: 941)

CGGTTTGCTGCGGTAATCATGAGGATAAGAGAGCCACGAACCACGGCACTGATTTT
CAGTTCTGGGAAAATGGTGTGCACAGGAGCCAAGAGTGAAGAACAGTCCAGACTG
GCAGCAAGAAA

UBC (GenBank Accession No. BC000449	(SEQ ID NO: 942))

UBC Forward primer:	(SEQ ID NO: 943)
ATTTGGGTCGCGGTTCTTG

UBC reverse primer:	(SEQ ID NO: 944)
TGCCTTGACATTCTCGATGGT

UBC-amplicon:	(SEQ ID NO: 945)

ATTTGGGTCGCGGTTCTTGTTTGTGGATCGCTGTGATCGTCACTTGACAATGCAGAT
CTTCGTGAAGACTCTGACTGGTAAGACCATCACCCTCGAGG
TTGAGCCCAGTGACACCATCGAGAATGTCAAGGCA

SDHA (GenBank Accession No. NM_004168	(SEQ ID NO: 922))

SDHA Forward primer:	(SEQ ID NO: 923)
TGGGAACAAGAGGGCATCTG

SDHA reverse primer:	(SEQ ID NO: 924)
CCACCACTGCATCAAATTCATG

SDHA-amplicon:	(SEQ ID NO: 925)

TGGGAACAAGAGGGCATCTGCTAAAGTTTCAGATTCCATTTCTGCTCAGTATCCAGT
AGTGGATCATGAATTTGATGCAGTGGTGG

Oligonucleotide-Based Micro-Array Experiment Protocol—

Microarray Fabrication

Microarrays (chips) were printed by pin deposition using the MicroGrid II MGII 600 robot from BioRobotics Limited (Cambridge, UK). 50-mer oligonucleotides target sequences were designed by Compugen Ltd (Tel-Aviv, IL) as described by A. Shoshan et al, “Optical technologies and informatics”, Proceedings of SPIE. Vol 4266, pp. 86-95 (2001). The designed oligonucleotides were synthesized and purified by desalting with the Sigma-Genosys system (The Woodlands, Tex., US) and all of the oligonucleotides were joined to a C6 amino-modified linker at the 5′ end, or being attached directly to CodeLink slides (Cat #25-6700-01. Amersham Bioscience, Piscataway, N.J., US). The 50-mer oligonucleotides, forming the target sequences, were first suspended in Ultra-pure DDW (Cat # 01-866-1A Kibbutz Beit-Haemek, Israel) to a concentration of 50 μM. Before printing the slides, the oligonucleotides were resuspended in 300 mM sodium phosphate (pH 8.5) to final concentration of 150 mM and printed at 35-40% relative humidity at 21° C.

Each slide contained a total of 9792 features in 32 subarrays. Of these features, 4224 features were sequences of interest according to the present invention and negative controls that were printed in duplicate. An additional 288 features (96 target sequences printed in triplicate) contained housekeeping genes from Human Evaluation Library2, Compugen Ltd, Israel. Another 384 features are E.coli spikes 1-6, which are oligos to E-Coli genes which are commercially available in the Array Control product (Array control-sense oligo spots, Ambion Inc. Austin, Tex. Cat # 1781, Lot # 112K06).

Post-Coupling Processing of Printed Slides

After the spotting of the oligonucleotides to the glass (CodeLink) slides, the slides were incubated for 24 hours in a sealed saturated NaCl humidification chamber (relative humidity 70-75%).

Slides were treated for blocking of the residual reactive groups by incubating them in blocking solution at 50° C for 15 minutes (10 ml/slide of buffer containing 0.1M Tris, 50 mM ethanolamine, 0.1% SDS). The slides were then rinsed twice with Ultra-pure DDW (double distilled water). The slides were then washed with wash solution (10 ml/slide. 4×SSC, 0.1% SDS)) at 50° C. for 30 minutes on the shaker. The slides were then rinsed twice with Ultra-pure DDW, followed by drying by centrifugation for 3 minutes at 800 rpm.

Next, in order to assist in automatic operation of the hybridization protocol, the slides were treated with Ventana Discovery hybridization station barcode adhesives. The printed slides were loaded on a Bio-Optica (Milan, Italy) hematology staining device and were incubated for 10 minutes in 50 ml of 3-Aminopropyl Triethoxysilane (Sigma A3648 lot #122K589). Excess fluid was dried and slides were then incubated for three hours in 20 mm/Hg in a dark vacuum desiccator (Pelco 2251, Ted Pella, Inc. Redding Calif.).

The following protocol was then followed with the Genisphere 900-RP (random primer), with mini elute columns on the Ventana Discovery HybStation™, to perform the microarray experiments. Briefly, the protocol was performed as described with regard to the instructions and information provided with the device itself. The protocol included cDNA synthesis and labeling. cDNA concentration was measured with the TBS-380 (Turner Biosystems. Sunnyvale, Calif.) PicoFlour, which is used with the OliGreen ssDNA Quantitation reagent and kit. Hybridization was performed with the Ventana Hybridization device, according to the provided protocols (Discovery Hybridization Station Tuscon Ariz.).

The slides were then scanned with GenePix 4000B dual laser scanner from Axon Instruments Inc, and analyzed by GenePix Pro 5.0 software.

Schematic summary of the oligonucleotide based microarray fabrication and the experimental flow is presented in FIGS. 4 and 5.

Briefly, as shown in FIG. 4, DNA oligonucleotides at 25 uM were deposited (printed) onto Amersham ‘CodeLink’ glass slides generating a well defined ‘spot’. These slides are covered with a long-chain, hydrophilic polymer chemistry that creates an active 3-D surface that covalently binds the DNA oligonucleotides 5′-end via the C6-amine modification. This binding ensures that the full length of the DNA oligonucleotides is available for hybridization to the cDNA and also allows lower background, high sensitivity and reproducibility.

FIG. 5 shows a schematic method for performing the microarray experiments. It should be noted that stages on the left-hand or right-hand side may optionally be performed in any order, including in parallel, until stage 4 (hybridization). Briefly, on the left-hand side, the target oligonucleotides are being spotted on a glass microscope slide (although optionally other materials could be used) to form a spotted slide (stage 1). On the right hand side, control sample RNA and cancer sample RNA are Cy3 and Cy5 labeled, respectively (stage 2), to form labeled probes. It should be noted that the control and cancer samples come from corresponding tissues (for example, normal prostate tissue and cancerous prostate tissue). Furthermore, the tissue from which the RNA was taken is indicated below in the specific examples of data for particular clusters, with regard to overexpression of an oligonucleotide from a “chip” (microarray), as for example “prostate” for chips in which prostate cancerous tissue and normal tissue were tested as described above. In stage 3, the probes are mixed. In stage 4, hybridization is performed to form a processed slide. In stage 5, the slide is washed and scanned to form an image file, followed by data analysis in stage 6.

Description for Cluster T10888

Cluster T10888 features 4 transcript(s) and 8 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	T10888_PEA_1_T1	1
	T10888_PEA_1_T4	2
	T10888_PEA_1_T5	3
	T10888_PEA_1_T6	4

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	T10888_PEA_1_node_11	5
	T10888_PEA_1_node_12	6
	T10888_PEA_1_node_17	7
	T10888_PEA_1_node_4	8
	T10888_PEA_1_node_6	9
	T10888_PEA_1_node_7	10
	T10888_PEA_1_node_9	11
	T10888_PEA_1_node_15	12

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	T10888_PEA_1_P2	14
	T10888_PEA_1_P4	15
	T10888_PEA_1_P5	16
	T10888_PEA_1_P6	17

These sequences are variants of the known protein Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13) (SwissProt accession identifier CEA6_HUMAN; known also according to the synonyms Normal cross-reacting antigen; Nonspecific crossreacting antigen; CD66c antigen), SEQ ID NO:13, referred to herein as the previously known protein.

The sequence for protein Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13) is given at the end of the application, as “Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

138	F -> L
239	V -> G

Protein Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13) localization is believed to be Attached to the membrane by a GPI-anchor.

The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Cancer. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Immunostimulant. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Imaging agent; Anticancer; Immunostimulant; Immunoconjugate; Monoclonal antibody, murine; Antisense therapy; antibody.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: signal transduction; cell-cell signaling, which are annotation(s) related to Biological Process; and integral plasma membrane protein, which are annotation(s) related to Cellular Component.

The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>.

Cluster T10888 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the right hand column of the table and the numbers on the y-axis of FIG. 6 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 6 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: colorectal cancer, a mixture of malignant tumors from different tissues, pancreas carcinoma and gastric carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Bladder	0
	Colon	107
	Epithelial	52
	General	22
	head and neck	40
	Lung	237
	Breast	0
	pancreas	32
	Prostate	12
	Stomach	0

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

Bladder	5.4e−01	3.4e−01	5.6e−01	1.8	4.6e−01	1.9
Colon	1.2e−01	1.7e−01	2.8e−05	3.7	7.9e−04	2.8
epithelial	3.3e−02	2.1e−01	2.8e−20	2.8	4.8e−10	1.9
General	3.3e−05	2.2e−03	1.9e−44	4.9	4.6e−27	3.3
head and neck	4.6e−01	4.3e−01	1	0.8	7.5e−01	1.0
Lung	7.6e−01	8.2e−01	8.9e−01	0.6	1	0.3
Breast	3.7e−02	4.1e−02	1.5e−01	3.3	3.1e−01	2.4
pancreas	2.6e−01	2.4e−01	8.6e−23	2.8	1.5e−19	4.5
Prostate	9.1e−01	9.3e−01	4.1e−02	1.2	1.0e−01	1.0
Stomach	4.5e−02	5.6e−02	5.1e−04	4.1	4.7e−04	6.3

As noted above, cluster T10888 features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13). A description of each variant protein according to the present invention is now provided.

Variant protein T10888_PEA_—1_P2 (SEQ ID NO:14) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10888_PEA_—1_T1 (SEQ ID NO:1). An alignment is given to the known protein (Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T10888_PEA_—1_P2 (SEQ ID NO:14) and CEA6_HUMAN (SEQ ID NO:13):

1. An isolated chimeric polypeptide encoding for T10888_PEA_—1_P2 (SEQ ID NO:14), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLY GPDVPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGS YMCQAHNSATGLNRTTVTMITVS corresponding to amino acids 1-319 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-319 of T10888_PEA_—1_P2 (SEQ ID NO:14), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DWTRP (SEQ ID NO:999) corresponding to amino acids 320-324 of T10888_PEA_—1_P2 (SEQ ID NO:14), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T10888_PEA_—1_P2 (SEQ ID NO:14), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DWTRP (SEQ ID NO:999) in T10888_PEA_—1_P2 (SEQ ID NO:14).

Variant protein T10888_PEA_—1_P2 (SEQ ID NO:14) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P2 (SEQ ID NO:14) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

13	V ->	No
232	N -> D	No
324	P ->	No
63	I ->	No
92	G ->	No

Variant protein T10888_PEA_—1_P2 (SEQ ID NO:14) is encoded by the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10888_PEA_—1_T1 (SEQ ID NO:1) is shown in bold; this coding portion starts at position 151 and ends at position 1122. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_—P2 (SEQ ID NO:14) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

119	C -> T	No
120	A -> T	No
1062	A -> G	Yes
1120	C ->	No
1297	G -> T	Yes
1501	A -> G	Yes
1824	G -> A	No
2036	A -> C	No
2036	A -> G	No
2095	A -> C	No
2242	A -> C	No
2245	A -> C	No
189	C ->	No
2250	A -> T	Yes
2339	C -> A	Yes
276	G -> A	Yes
338	T ->	No
424	G ->	No
546	A -> G	No
702	C -> T	No
844	A -> G	No
930	C -> T	Yes

Variant protein T10888_PEA_—1_P4 (SEQ ID NO:15 according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10888_PEA_—1_T4 (SEQ ID NO:2). An alignment is given to the known protein (Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T10888_PEA_—1_P4 (SEQ ID NO:15) and CEA6_HUMAN SEQ ID NO:13):

1. An isolated chimeric polypeptide encoding for T10888_PEA_—1_P4 (SEQ ID NO:15), comprising a first amino acid sequence being at least 90% homologous to


MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP

QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG

FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL

WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL

corresponding to amino acids 1-234 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-234 of T10888_PEA_—1_P4 (SEQ ID NO:15), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000) corresponding to amino acids 235-256 of T10888_PEA_—1_P4 (SEQ ID NO:15), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T10888_PEA_—1_P4 (SEQ ID NO:15), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000) in T10888_PEA_—1_P4 (SEQ ID NO:15).

Comparison report between T10888_PEA_—1_P4 (SEQ ID NO:15) and Q13774 (SEQ ID NO:829):

1. An isolated chimeric polypeptide encoding for T10888_PEA_—1_P4 (SEQ ID NO:15), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL corresponding to amino acids 1-234 of Q13774, which also corresponds to amino acids 1-234 of T10888_PEA_—1_P4 (SEQ ID NO:15), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LLLSSQLWPPSASRLECWPGWL (SEQ ID NO:1000) corresponding to amino acids 235-256 of T10888_PEA_—1_P4 (SEQ ID NO:15), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T10888_PEA_—1_P4 (SEQ ID NO:15 also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P4 (SEQ ID NO:15) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

13	V ->	No
232	N -> D	No
63	I ->	No
92	G ->	No

Variant protein T10888_PEA_—1_P4 (SEQ ID NO:15) is encoded by the following transcript(s): T10888_PEA_—1_T4 (SEQ ID NO:2), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10888_PEA_—1_T4 (SEQ ID NO:2) is shown in bold; this coding portion starts at position 151 and ends at position 918. The transcript also the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P4 SEQ ID NO:15) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

119	C -> T	No
120	A -> T	No
978	C ->	No
1155	G -> T	Yes
1359	A -> G	Yes
1682	G -> A	No
1894	A -> C	No
1894	A -> G	No
1953	A -> C	No
2100	A -> C	No
2103	A -> C	No
2108	A -> T	Yes
189	C ->	No
2197	C -> A	Yes
276	G -> A	Yes
338	T ->	No
424	G ->	No
546	A -> G	No
702	C -> T	No
844	A -> G	No
958	G ->	No

Variant protein T10888_PEA_—1_P5 (SEQ ID NO:16) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10888_PEA_—1_T5 (SEQ ID NO:3). An alignment is given to the known protein (Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T10888_PEA_—1_P5 (SEQ ID NO:16) and CEA6_HUMAN (SEQ ID NO:13):

1. An isolated chimeric polypeptide encoding for T10888_PEA_—1_P5 (SEQ ID NO:16), comprising a first amino acid sequence being at least 90% homologous to MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLAHNLP QNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTG FYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYL WWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLY GPDVPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGS YMCQAHNSATGLNRTTVTMITVSG corresponding to amino acids 1-320 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-320 of T10888_PEA_—1_P5 (SEQ ID NO:16), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KWIHEALASHFQVESGSQRRARKKFSFPTCVQGAHANPKFSPEPSQFTSADSFPLVFLFF VVFCFLISHV (SEQ ID NO:1001) corresponding to amino acids 321-390 of T10888_PEA_—1_P5 (SEQ ID NO:16), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T10888_PEA_—1_P5 (SEQ ID NO:16), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


KWIHEALASHFQVESGSQRRARKKFSFPTCVQGAHANPKFSPEPSQFTSADSFPLVFLFF	(SEQ ID NO: 1001)
VVFCFLISHV

in T10888_PEA_1_P5.	(SEQ ID NO: 16)

Variant protein T10888_PEA_—1_P5 (SEQ ID NO:16) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P5 (SEQ ID NO:16) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

13	V ->	No
232	N -> D	No
63	I ->	No
92	G ->	No

Variant protein T10888_PEA_—1_P5 (SEQ ID NO 16) is encoded by the following transcript(s): T10888_PEA_—1_T5 (SEQ ID NO:3), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10888_PEA_—1_T5 (SEQ ID NO:3) is shown in bold; this coding portion starts at position 151 and ends at position 1320. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P5 (SEQ ID NO:16) sequence provides support for the deduced sequence of variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

119	C -> T	No
120	A -> T	No
1062	A -> G	Yes
1943	C -> A	Yes
2609	C -> T	Yes
2647	C -> G	No
2701	C -> T	Yes
2841	T -> C	Yes
189	C ->	No
276	G -> A	Yes
338	T ->	No
424	G ->	No
546	A -> G	No
702	C -> T	No
844	A -> G	No
930	C -> T	Yes

Variant protein T10888_PEA_—1_P6 (SEQ ID NO:17) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T10888_PEA_—1_T6 (SEQ ID NO:4). An alignment is given to the known protein (Carcinoembryonic antigen-related cell adhesion molecule 6 precursor (SEQ ID NO:13)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application.

Comparison report between T10888_PEA_—1_P6 (SEQ ID NO:17) and CEA6_HUMAN (SEQ ID NO:13):

1. An isolated chimeric polypeptide encoding for T10888_PEA_—1_P6 (SEQ ID NO:17), comprising a first amino acid sequence being at least 90% homologous to


MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLA

HNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQ

NDTGFYTLQVIKSDLVNEEATGQFHVY

corresponding to amino acids 1-141 of CEA6_HUMAN (SEQ ID NO:13), which also corresponds to amino acids 1-141 of T10888_PEA_—1_P6 (SEQ ID NO:17), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


	(SEQ ID NO: 1002)

REYFHMTSGCWGSVLLPTYGIVRPGLCLWPSLHYILYQGLDI

corresponding to amino acids 142-183 of T10888_PEA_—1_P6 (SEQ ID NO:17), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T10888_PEA_—1_P6 (SEQ ID NO:17), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


	(SEQ ID NO: 1002)

	REYFHMTSGCWGSVLLPTYGIVRPGLCLWPSLHYILYQGLDI

(SEQ ID NO: 17)

in T10888_PEA_1_P6.

Variant protein T10888_PEA_—1_P6 (SEQ ID NO:17) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P6 (SEQ ID NO:17) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

13	V ->	No
63	I ->	No
92	G ->	No

Variant protein T10888_PEA_—1_P6 (SEQ ID NO:17) is encoded by the following transcript(s): T10888_PEA_—1_T6 (SEQ ID NO:4), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T10888_PEA_—1_T6 (SEQ ID NO:4) is shown in bold; this coding portion starts at position 151 and ends at position 699. The transcript also as the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T10888_PEA_—1_P6 (SEQ ID NO:17) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

119	C -> T	No
120	A -> T	No
189	C ->	No
276	G -> A	Yes
338	T ->	No
424	G ->	No
546	A -> G	No

As noted above, cluster T10888 features 8 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T10888_PEA_—1_node_—11 (SEQ ID NO:5) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1) and T10888_PEA_—1_T5 (SEQ ID NO:3). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T1 (SEQ ID	854	1108
NO: 1)
T10888_PEA_1_T5 (SEQ ID	854	1108
NO: 3)

Segment cluster T10888_PEA_—1_node_—12 (SEQ ID NO:6) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T5 (SEQ ID NO:3). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T5 (SEQ ID	1109	3004
NO: 3)

Segment cluster T10888_PEA_—1_node_—17 (SEQ ID NO:7) according to the present invention is supported by 160 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1) and T10888_PEA_—1_T4 (SEQ ID NO:2). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T1 (SEQ ID	1109	2518
NO: 1)
T10888_PEA_1_T4 (SEQ ID	967	2376
NO: 2)

Segment cluster T10888_PEA_—1_node_—4 (SEQ ID NO:8) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1), T10888_PEA_—1_T4 (SEQ ID NO:2), T10888_PEA_—1_T5 (SEQ ID NO:3) and T10888_PEA_—1_T6 (SEQ ID NO:4). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T1 (SEQ ID	1	214
NO: 1)
T10888_PEA_1_T4 (SEQ ID	1	214
NO: 2)
T10888_PEA_1_T5 (SEQ ID	1	214
NO: 3)
T10888_PEA_1_T6 (SEQ ID	1	214
NO: 4)

Segment cluster T10888_PEA_—1_node_—6 (SEQ ID NO:9) according to the present invention is supported by 81 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1), T10888_PEA_—1_T4 (SEQ ID NO:2), T10888_PEA_—1_T5 (SEQ ID NO:3) and T10888_PEA_—1_T6 (SEQ ID NO:4). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T1 (SEQ ID	215	574
NO: 1)
T10888_PEA_1_T4 (SEQ ID	215	574
NO: 2)
T10888_PEA_1_T5 (SEQ ID	215	574
NO: 3)
T10888_PEA_1_T6 (SEQ ID	215	574
NO: 4)

Segment cluster T10888_PEA_—1_node_—7 (SEQ ID NO:10) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T6 (SEQ ID NO:4). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T6 (SEQ ID	575	1410
NO: 4)

Segment cluster T10888_PEA_—1_node_—9 (SEQ ID NO:11) according to the present invention is supported by 72 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T1 (SEQ ID NO:1), T10888_PEA_—1_T4 (SEQ ID NO:2) and T10888_PEA_—1_T5 (SEQ ID NO:3). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T1 (SEQ ID	575	853
NO: 1)
T10888_PEA_1_T4 (SEQ ID	575	853
NO: 2)
T10888_PEA_1_T5 (SEQ ID	575	853
NO: 3)

According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.

Segment cluster T10888_PEA_—1_node_—15 (SEQ ID NO:12) according to the present invention is supported by 39 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T10888_PEA_—1_T4 (SEQ ID NO:2). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T10888_PEA_1_T4 (SEQ ID	854	966
NO: 2)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/tM4EgaoKvm/vuztUrlRc7:CEA6_HUMAN (SEQ ID NO:13).

Sequence documentation:

Alignment of: T10888_PEA_—1_P2 (SEQ ID NO:14)×CEA6_HUMAN (SEQ ID NO:13)

Alignment segment 1/1:



Quality:	3163.00
Escore:	0
Matching length:	319	Total length:	319
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150

	. . . . .
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200

	. . . . .
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDVPTISPSKANYR	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDVPTISPSKANYR	250

	. . . . .
251	PGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQ	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	PGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQ	300

	.
301	AHNSATGLNRTTVTMITVS	319
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	AHNSATGLNRTTVTMITVS	319

Sequence name: /tmp/Yjl1gj7TCe/PgdufzLOlW:CEA6_HUMAN (SEQ ID NO:13)

Sequence documentation:

Alignment of: T10888_PEA_—1_P4 (SEQ ID NO:15)×CEA6_HUMAN (SEQ ID NO:13).

Alignment segment 1/1:



Quality:	2310.00
Escore:	0
Matching length:	234	Total length:	234
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATCQFHVYPELPKPSIS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150

	. . . . .
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200

	. . .
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL	234
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL	234

Sequence name: /tmp/Yjl1gj7TCe/PgdufzLOlW:Q13774

Sequence documentation:

Alignment of: T10888_PEA_—1_P4 (SEQ ID NO:15)×Q13774.

Alignment segment 1/1:



Quality:	2310.00
Escore:	0
Matching length:	234	Total length:	234
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150

	. . . . .
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200

	. . .
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL	234
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVL	234

Sequence name: /tmp/x5xDBacdpj/rTXRGepv3y:CEA6_HUMAN (SEQ ID NO:13)

Sequence documentation:

Alignment of: T10888_PEA_—1_P5 (SEQ ID NO:16)×CEA6_HUMAN (SEQ ID NO:13).

Alignment segment 1/1:



Quality:	3172.00
Escore:	0
Matching length:	320	Total length:	320
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSIS	150

	. . . . .
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	SNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTL	200

	. . . . .
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDVPTISPSKANYR	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	TLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDVPTISPSKANYR	250

	. . . . .
251	PGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQ	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	PGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQ	300

	. .
301	AHNSATGLNRTTVTMITVSG	320
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	AHNSATGLNRTTVTMITVSG	320

Sequence name: /tmp/VAhvYFeatq/QNEM573uCo:CEA6_HUMAN (SEQ ID NO:13)

Sequence documentation:

Alignment of: T10888_PEA_—1_P6 (SEQ ID NO:17)×CEA6_HUMAN (SEQ ID NO:13).

Alignment segment 1/1:



Quality:	1393.00
Escore:	0
Matching length:	143	Total length:	143
Matching Percent	99.30	Matching Percent Identity:	99.30
Similarity:
Total Percent Similarity:	99.30	Total Percent Identity:	99.30
Gaps:	0

Alignment:


	. . . . .
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYRE	143
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPE	143

Alignment of: T10888_PEA_—1_P6 (SEQ ID NO:17)×CEA6_HUMAN (SEQ ID NO:13).

Alignment segment 1/1:



Quality:	101.00
Escore:	0
Matching length:	141	Total length:	183
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	77.05	Total Percent Identity:	77.05
Gaps:	1

Alignment:


	. . . . .
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPPSAPPCRLHVPWKEVLLTASLLTFWNPPTTAKLTIESTPFNVAEGKE	50

	. . . . .
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRET	100

	. . . . .
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYREYFHMTSG	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	IYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVY.........	141

	. . .
151	CWGSVLLPTYGIVRPGLCLWPSLHYILYQGLDI	183

141	.................................	141

Expression of CEA6_HUMAN Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (T10888) Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T10888 junc11-17 in Normal and Cancerous Breast Tissues

Expression of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 transcripts detectable by or according to junc11-17, T10888junc11-17 (SEQ ID NO:832) amplicon(s) and T10888junc11-17F (SEQ ID NO:830) and T10888junc11-17R primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922Q; amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67 Table 1, “Tissue samples in testing panel”, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 7 is a histogram showing over expression of the above-indicated CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 transcripts in cancerous breast samples relative to the normal samples. Values represent the average of duplicate experiments. Error bars indicate the minimal and maximal values obtained. The number and percentage of samples that exhibit at least 5 fold over-expression, out of the total number of samples tested, is indicated in the bottom.

As is evident from FIG. 7, the expression of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67 Table 1, “Tissue samples in testing panel”). Notably an over-expression of at least 5 fold was found in 19 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 transcripts detectable by the above amplicon(s) in breast cancer samples versus the normal tissue samples was determined by T test as 2.00E-03.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 8.44E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: T10888junc11-17F (SEQ ID NO:830) forward primer; and T10888junc11-17R reverse primer.

The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: T10888junc11-17.


T10888junc11-17F	(SEQ ID NO: 830)

CCAGCAATCCACACAAGAGCT

T10888junc11-17R

(SEQ ID NO: 831)

CAGGGTCTGGTCCAATCAGAG

T10888junc11-17

(SEQ ID NO: 832)

CCAGCAATCCACACAAGAGCTCTTTATCCCCAACATCACTGTGAATAATAGC
GGATCCTATATGTGCCAAGCCCATAACTCAGCCACTGGCCTCAATAGGACCACAGT
CACGATGATCACAGTCTCTGATTGGACCAGACCCTG

Expression of CEA6_HUMAN Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6T10888 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T10888junc11-17 (SEQ ID NO:832) in Different Normal Tissues

Expression of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 transcripts detectable by or according to T10888 junc11-17 amplicon(s) (SEQ ID NO:832) and T10888 junc11-17F (SEQ ID NO:830) and T10888 junc11-17R (SEQ ID NO:831) was measured by real time PCR. In parallel the expression of four housekeeping genes—RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945 ) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the ovary samples (Sample Nos. 18-20, Table 2 “Tissue samples in normal panel” above), to obtain a value of relative expression of each sample relative to median of the ovary samples. Primers and amplicon are as above.

The results are presented in FIG. 8, demonstrating the expression of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 T10888 transcripts, which are detectable by amplicon as depicted in sequence name T10888junc11-17 (SEQ ID NO:832), in different normal tissues.

Description for Cluster T39971

Cluster T39971 features 4 transcript(s) and 28 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	T39971_T10	18
	T39971_T12	19
	T39971_T16	20
	T39971_T5	21

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	T39971_node_0	22
	T39971_node_18	23
	T39971_node_21	24
	T39971_node_22	25
	T39971_node_23	26
	T39971_node_31	27
	T39971_node_33	28
	T39971_node_7	29
	T39971_node_1	30
	T39971_node_10	31
	T39971_node_11	32
	T39971_node_12	33
	T39971_node_15	34
	T39971_node_16	35
	T39971_node_17	36
	T39971_node_26	37
	T39971_node_27	38
	T39971_node_28	39
	T39971_node_29	40
	T39971_node_3	41
	T39971_node_30	42
	T39971_node_34	43
	T39971_node_35	44
	T39971_node_36	45
	T39971_node_4	46
	T39971_node_5	47
	T39971_node_8	48
	T39971_node_9	49

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	T39971_P6	51
	T39971_P9	52
	T39971_P11	53
	T39971_P12	54

These sequences are variants of the known protein Vitronectin precursor (SwissProt accession identifier VTNC_HUMAN; known also according to the synonyms Serum spreading factor; S-protein; V75), SEQ ID NO:50, referred to herein as the previously known protein.

Protein Vitronectin precursor (SEQ ID NO:50) is known or believed to have the following function(s): Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interacts with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway. The sequence for protein Vitronectin precursor is given at the end of the application, as “Vitronectin precursor amino acid sequence” (SEQ ID NO:50). Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

122	A -> S. /FTId = VAR_012983.
268	R -> Q. /FTId = VAR_012984.
400	T -> M. /FTId = VAR_012985.
50	C -> N
225	S -> N
366	A -> T

Protein Vitronectin precursor (SEQ ID NO:50) localization is believed to be Extracellular.

The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Cancer, melanoma. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Alphavbeta3 integrin antagonist; Apoptosis agonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anticancer.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: immune response; cell adhesion, which are annotation(s) related to Biological Process; protein binding; heparin binding, which are annotation(s) related to Molecular Function; and extracellular space, which are annotation(s) related to Cellular Component.

Cluster T39971 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the right hand column of the table and the numbers on the y-axis of FIG. 9 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 9 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: liver cancer, lung malignant tumors and pancreas carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	adrenal	60
	bladder	0
	Bone	0
	Brain	9
	Colon	0
	epithelial	79
	general	29
	Liver	2164
	Lung	0
	lymph nodes	0
	breast	0
	pancreas	0
	prostate	0
	Skin	0
	uterus	0

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	6.9e−01	7.4e−01	2.0e−02	2.3	5.3e−02	1.8
bladder	5.4e−01	6.0e−01	5.6e−01	1.8	6.8e−01	1.5
Bone	1	6.7e−01	1	1.0	7.0e−01	1.4
Brain	8.0e−01	8.6e−01	3.0e−01	1.9	5.3e−01	1.2
Colon	4.2e−01	4.8e−01	7.0e−01	1.6	7.7e−01	1.4
epithelial	6.6e−01	5.7e−01	1.0e−01	0.8	8.7e−01	0.6
general	5.1e−01	3.8e−01	9.2e−08	1.6	8.3e−04	1.3
Liver	1	6.7e−01	2.3e−03	0.3	1	0.2
Lung	2.4e−01	9.1e−02	1.7e−01	4.3	8.1e−03	5.0
lymph nodes	1	5.7e−01	1	1.0	5.8e−01	2.3
breast	1	6.7e−01	1	1.0	8.2e−01	1.2
pancreas	9.5e−02	1.8e−01	1.5e−11	6.5	8.2e−09	4.6
prostate	7.3e−01	6.0e−01	6.7e−01	1.5	5.6e−01	1.7
Skin	1	4.4e−01	1	1.0	6.4e−01	1.6
uterus	5.0e−01	2.6e−01	1	1.1	8.0e−01	1.4

As noted above, cluster T39971 features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Vitronectin precursor (SEQ ID NO:50). A description of each variant protein according to the present invention is now provided.

Variant protein T39971_P6 (SEQ ID NO:51) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T39971_T5 (SEQ ID NO:21). An alignment is given to the known protein (Vitronectin precursor (SEQ ID NO:50)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T39971_P6 (SEQ ID NO:51) and VTNC_HUMAN (SEQ ID NO:50):

1. An isolated chimeric polypeptide encoding for T39971_P6 (SEQ ID NO:51), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKG corresponding to amino acids 1-276 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 1-276 of T39971_P6 (SEQ ID NO:51),and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TQGVVGD (SEQ ID NO:1003) corresponding to amino acids 277-283 of T39971_P6 (SEQ ID NO:51), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T39971_P6 (SEQ ID NO:51), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TQGVVGD (SEQ ID NO:1003) in T39971_P6 (SEQ ID NO:51).

Variant protein T39971_P6 (SEQ ID NO:51) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P6 (SEQ ID NO:51) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

122	A -> S	Yes
145	G ->	No
268	R -> Q	Yes
280	V -> A	Yes
180	C ->	No
180	C -> W	No
192	Y ->	No
209	A ->	No
211	T ->	No
267	G ->	No
267	G -> A	No
268	R ->	No

Variant protein T39971_P6 (SEQ ID NO:51) is encoded by the following transcript(s): T39971_T5 (SEQ ID NO:21), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T39971_T5 (SEQ ID NO:21) is shown in bold; this coding portion starts at position 756 and ends at position 1604. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P6 (SEQ ID NO:51) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

417	G -> C	Yes
459	T -> C	Yes
1387	C ->	No
1406	-> A	No
1406	-> G	No
1555	G ->	No
1555	G -> C	No
1558	G ->	No
1558	G -> A	Yes
1594	T -> C	Yes
1642	T -> C	Yes
1770	C -> T	Yes
529	G -> T	Yes
1982	A -> G	No
2007	G ->	No
2029	T -> C	No
2094	T -> C	No
2117	C -> G	No
2123	C -> T	Yes
2152	C -> T	Yes
2182	G -> T	No
2185	A -> C	No
2297	T -> C	Yes
1119	G -> T	Yes
2411	G ->	No
2411	G -> T	No
2487	T -> C	Yes
1188	G ->	No
1295	C ->	No
1295	C -> G	No
1324	-> T	No
1331	C ->	No
1381	C ->	No

Variant protein T39971_P9 (SEQ ID NO:52) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T39971_T10 (SEQ ID NO:18). An alignment is given to the known protein (Vitronectin precursor (SEQ ID NO:50)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T39971_P9 (SEQ ID NO:52) and VTNC_HUMAN (SEQ ID NO:50):

1. An isolated chimeric polypeptide encoding for T39971_P9 (SEQ ID NO:52), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRT corresponding to amino acids 1-325 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 1-325 of T39971_P9 (SEQ ID NO:52), and a second amino acid sequence being at least 90% homologous to SGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNONSRRPSRATWLSLFSSEESNLGA NNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYWLGC PAPGHL corresponding to amino acids 357-478 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 326-447 of T39971_P9 (SEQ ID NO:52), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of T39971_P9 (SEQ ID NO:52), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise TS, having a structure as follows: a sequence starting from any of amino acid numbers 325-x to 325; and ending at any of amino acid numbers 326+((n−2)−x), in which x varies from 0 to n−2.

Variant protein T39971_P9 (SEQ ID NO:52) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P9 (SEQ ID NO:52) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

122	A -> S	Yes
145	G ->	No
268	R -> Q	Yes
328	M -> T	No
350	S -> P	No
369	T -> M	Yes
379	S -> I	No
380	N -> T	No
180	C ->	No
180	C -> W	No
192	Y ->	No
209	A ->	No
211	T ->	No
267	G ->	No
267	G -> A	No
268	R ->	No

Variant protein T39971_P9 (SEQ ID NO:52) is encoded by the following transcript(s): T39971_T10 (SEQ ID NO:18), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T39971_T10 (SEQ ID NO:18) is shown in bold; this coding portion starts at position 756 and ends at position 2096. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P9 (SEQ ID NO:52) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

417	G -> C	Yes
459	T -> C	Yes
1387	C ->	No
1406	-> A	No
1406	-> G	No
1555	G ->	No
1555	G -> C	No
1558	G ->	No
1558	G -> A	Yes
1738	T -> C	No
1803	T -> C	No
1826	C -> G	No
529	G -> T	Yes
1832	C -> T	Yes
1861	C -> T	Yes
1891	G -> T	No
1894	A -> C	No
2006	T -> C	Yes
2120	G ->	No
2120	G -> T	No
2196	T -> C	Yes
1119	G -> T	Yes
1188	G ->	No
1295	C ->	No
1295	C -> G	No
1324	-> T	No
1331	C ->	No
1381	C ->	No

Variant protein T39971_P11 (SEQ ID NO:53) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T39971_T12 (SEQ ID NO:19). An alignment is given to the known protein (Vitronectin precursor (SEQ ID NO:50)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T39971_P11 (SEQ ID NO:53) and VTNC_HUMAN (SEQ ID NO:50):

1. An isolated chimeric polypeptide encoding for T39971_P11 (SEQ ID NO:53), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRTS corresponding to amino acids 1-326 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 1-326 of T39971_P11 (SEQ ID NO:53), and a second amino acid sequence being at least 90% homologous to DKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL corresponding to amino acids 442-478 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 327-363 of T39971_P11 (SEQ ID NO:53), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of T39971_P11 (SEQ ID NO:53), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise SD, having a structure as follows: a sequence starting from any of amino acid numbers 326-x to 326; and ending at any of amino acid numbers 327+((n−2)−x), in which x varies from 0 to n−2.

Comparison report between T39971_P11 (SEQ ID NO:53) and Q9BSH7 (SEQ ID NO:833):

1. An isolated chimeric polypeptide encoding for T39971_P11 (SEQ ID NO:53), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGV LDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEE CEGSSLSAVFEHFAMMQRDSWEDIFELLFWGRTS corresponding to amino acids 1-326 of Q9BSH7, which also corresponds to amino acids 1-326 of T39971_P11 (SEQ ID NO:53), and a second amino acid sequence being at least 90% homologous to DKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL corresponding to amino acids 442-478 of Q9BSH7, which also corresponds to amino acids 327-363 of T39971_P11 (SEQ ID NO:53), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T39971_P11 (SEQ ID NO:53) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P11 (SEQ ID NO:53) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

122	A -> S	Yes
145	G ->	No
268	R -> Q	Yes
180	C ->	No
180	C -> W	No
192	Y ->	No
209	A ->	No
211	T ->	No
267	G ->	No
267	G -> A	No
268	R ->	No

Variant protein T39971_P11 (SEQ ID NO:53) is encoded by the following transcript(s): T39971_T12 (SEQ ID NO:19), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T39971_T12 (SEQ ID NO:19) is shown in bold; this coding portion starts at position 756 and ends at position 1844. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P11 (SEQ ID NO:53) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

417	G -> C	Yes
459	T -> C	Yes
1387	C ->	No
1406	-> A	No
1406	-> G	No
1555	G ->	No
1555	G -> C	No
1558	G ->	No
1558	G -> A	Yes
1754	T -> C	Yes
1868	G ->	No
1868	G -> T	No
529	G -> T	Yes
1944	T -> C	Yes
1119	G -> T	Yes
1188	G ->	No
1295	C ->	No
1295	C -> G	No
1324	-> T	No
1331	C ->	No
1381	C ->	No

Variant protein T39971_P12 (SEQ ID NO:54) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T39971_T16 (SEQ ID NO:20). An alignment is given to the known protein (Vitronectin precursor (SEQ ID NO:50)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T39971_P12 (SEQ ID NO:54) and VTNC_HUMAN (SEQ ID NO:50):

1. An isolated chimeric polypeptide encoding for T39971_P12 (SEQ ID NO:54), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFK corresponding to amino acids 1-223 of VTNC_HUMAN (SEQ ID NO:50), which also corresponds to amino acids 1-223 of T39971_P12 (SEQ ID NO:54), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPGAVGQGRKHLGRV (SEQ ID NO:1004) corresponding to amino acids 224-238 of T39971_P12 (SEQ ID NO:54), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T39971_P12 (SEQ ID NO:54), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPGAVGQGRKHLGRV (SEQ ID NO:1004) in T39971_P12 (SEQ ID NO:54).

Comparison report between T39971_P12 (SEQ ID NO:54) and Q9BSH7:

1. An isolated chimeric polypeptide encoding for T39971_P12 (SEQ ID NO:54), comprising a first amino acid sequence being at least 90% homologous to MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAEC KPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPV LKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFR GQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFK corresponding to amino acids 1-223 of Q9BSH7, which also corresponds to amino acids 1-223 of T39971_P12 (SEQ ID NO:54), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPGAVGQGRKHLGRV (SEQ ID NO:1004) corresponding to amino acids 224-238 of T39971_P12 (SEQ ID NO:54), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T39971_P12 (SEQ ID NO:54) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P 12 (SEQ ID NO:54) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

122	A -> S	Yes
145	G ->	No
180	C ->	No
180	C -> W	No
192	Y ->	No
209	A ->	No
211	T ->	No

Variant protein T39971_P12 (SEQ ID NO:54) is encoded by the following transcript(s): T39971_T16 (SEQ ID NO:20), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T39971_T16 (SEQ ID NO:20) is shown in bold; this coding portion starts at position 756 and ends at position 1469. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T39971_P12 (SEQ ID NO:54) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

417	G -> C	Yes
459	T -> C	Yes
1387	C ->	No
1406	-> A	No
1406	-> G	No
529	G -> T	Yes
1119	G -> T	Yes
1188	G ->	No
1295	C ->	No
1295	C -> G	No
1324	-> T	No
1331	C ->	No
1381	C ->	No

As noted above, cluster T39971 features 28 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T39971_node_—0 (SEQ ID NO:22) according to the present invention is supported by 76 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T1 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1	810
T39971_T12 (SEQ ID NO: 19)	1	810
T39971_T16 (SEQ ID NO: 20)	1	810
T39971_T5 (SEQ ID NO: 21)	1	810

Segment cluster T39971_node_—18 (SEQ ID NO:23) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T16 (SEQ ID NO:20). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T16 (SEQ ID NO: 20)	1425	1592

Segment cluster T39971_node_—21 (SEQ ID NO:24) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1425	1581
T39971_T12 (SEQ ID NO: 19)	1425	1581
T39971_T5 (SEQ ID NO: 21)	1425	1581

Segment cluster T39971_node_—22 (SEQ ID NO:25) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T5 (SEQ ID NO:21). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T5 (SEQ ID NO: 21)	1582	1779

Segment cluster T39971_node_—23 (SEQ ID NO:26) according to the present invention is supported by 101 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1582	1734
T39971_T12 (SEQ ID NO: 19)	1582	1734
T39971_T5 (SEQ ID NO: 21)	1780	1932

Segment cluster T39971_node_—31 (SEQ ID NO:27) according to the present invention is supported by 94 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18) and T39971_T5 (SEQ ID NO:21). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1847	1986
T39971_T5 (SEQ ID NO: 21)	2138	2277

Segment cluster T39971_node_—33 (SEQ ID NO:28) according to the present invention is supported by 77 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1987	2113
T39971_T12 (SEQ ID NO: 19)	1735	1861
T39971_T5 (SEQ ID NO: 21)	2278	2404

Segment cluster T39971_node_—7 (SEQ ID NO:29) according to the present invention is supported by 87 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T11 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	940	1162
T39971_T12 (SEQ ID NO: 19)	940	1162
T39971_T16 (SEQ ID NO: 20)	940	1162
T39971_T5 (SEQ ID NO: 21)	940	1162

Segment cluster T39971_node_—1 (SEQ ID NO:30) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	811	819
T39971_T12 (SEQ ID NO: 19)	811	819
T39971_T16 (SEQ ID NO: 20)	811	819
T39971_T5 (SEQ ID NO: 21)	811	819

Segment cluster T39971_node_—10 (SEQ ID NO:31) according to the present invention is supported by 77 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1189	1232
T39971_T12 (SEQ ID NO: 19)	1189	1232
T39971_T16 (SEQ ID NO: 20)	1189	1232
T39971_T5 (SEQ ID NO: 21)	1189	1232

Segment cluster T39971_node_—11 (SEQ ID NO:32) according to the present invention is supported by 79 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1233	1270
T39971_T12 (SEQ ID NO: 19)	1233	1270
T39971_T16 (SEQ ID NO: 20)	1233	1270
T39971_T5 (SEQ ID NO: 21)	1233	1270

Segment cluster T39971_node_—12 (SEQ ID NO:33) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1271	1284
T39971_T12 (SEQ ID NO: 19)	1271	1284
T39971_T16 (SEQ ID NO: 20)	1271	1284
T39971_T5 (SEQ ID NO: 21)	1271	1284

Segment cluster T39971_node_—15 (SEQ ID NO:34) according to the present invention is supported by 79 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1285	1316
T39971_T12 (SEQ ID NO: 19)	1285	1316
T39971_T16 (SEQ ID NO: 20)	1285	1316
T39971_T5 (SEQ ID NO: 21)	1285	1316

Segment cluster T39971_node_—16 (SEQ ID NO:35) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1317	1340
T39971_T12 (SEQ ID NO: 19)	1317	1340
T39971_T16 (SEQ ID NO: 20)	1317	1340
T39971_T5 (SEQ ID NO: 21)	1317	1340

Segment cluster T39971_node_—17 (SEQ ID NO:36) according to the present invention is supported by 86 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1341	1424
T39971_T12 (SEQ ID NO: 19)	1341	1424
T39971_T16 (SEQ ID NO: 20)	1341	1424
T39971_T5 (SEQ ID NO: 21)	1341	1424

Segment cluster T39971_node_—26 (SEQ ID NO:37) according to the present invention is supported by 85 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T5 (SEQ ID NO:21). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T5 (SEQ ID NO: 21)	1933	1974

Segment cluster T39971_node_—27 (SEQ ID NO:38) according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T5 (SEQ ID NO:21). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T5 (SEQ ID NO: 21)	1975	2025

Segment cluster T39971_node_—28 (SEQ ID NO:39) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18) and T39971_T5 (SEQ ID NO:21). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1735	1743
T39971_T5 (SEQ ID NO: 21)	2026	2034

Segment cluster T39971_node_—29 (SEQ ID NO:40) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO 18) and T39971_T5 (SEQ ID NO:21). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1744	1838
T39971_T5 (SEQ ID NO: 21)	2035	2129

Segment cluster T39971_node_—3 (SEQ ID NO:41) according to the present invention is supported by 78 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	820	861
T39971_T12 (SEQ ID NO: 19)	820	861
T39971_T16 (SEQ ID NO: 20)	820	861
T39971_T5 (SEQ ID NO: 21)	820	861

Segment cluster T39971_node_—30 (SEQ ID NO:42) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18) and T39971_T5 (SEQ ID NO:21). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	1839	1846
T39971_T5 (SEQ ID NO: 21)	2130	2137

Segment cluster T39971_node_—34 (SEQ ID NO:43) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	2114	2120
T39971_T12 (SEQ ID NO: 19)	1862	1868
T39971_T5 (SEQ ID NO: 21)	2405	2411

Segment cluster T39971_node_—35 (SEQ ID NO:44) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	2121	2137
T39971_T12 (SEQ ID NO: 19)	1869	1885
T39971_T5 (SEQ ID NO: 21)	2412	2428

Segment cluster T39971_node_—36 (SEQ ID NO:45) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19) and T39971_T5 (SEQ ID NO:21). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	2138	2199
T39971_T12 (SEQ ID NO: 19)	1886	1947
T39971_T5 (SEQ ID NO: 21)	2429	2490

Segment cluster T39971_node_—4 (SEQ ID NO:46) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T39971_T10 (SEQ ID NO: 18)	862	881
T39971_T12 (SEQ ID NO: 19)	862	881
T39971_T16 (SEQ ID NO: 20)	862	881
T39971_T5 (SEQ ID NO: 21)	862	881

Segment cluster T39971_node_—5 (SEQ ID NO:47) according to the present invention is supported by 80 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:2 1). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

T39971_T10 (SEQ ID NO: 18)	882	939
T39971_T12 (SEQ ID NO: 19)	882	939
T39971_T16 (SEQ ID NO: 20)	882	939
T39971_T5 (SEQ ID NO: 21)	882	939

Segment cluster T39971_node_—8 (SEQ ID NO:48) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

T39971_T10 (SEQ ID NO: 18)	1163	1168
T39971_T12 (SEQ ID NO: 19)	1163	1168
T39971_T16 (SEQ ID NO: 20)	1163	1168
T39971_T5 (SEQ ID NO: 21)	1163	1168

Segment cluster T39971_node_—9 (SEQ ID NO:49) according to the present invention can be found in the following transcript(s): T39971_T10 (SEQ ID NO:18), T39971_T12 (SEQ ID NO:19), T39971_T16 (SEQ ID NO:20) and T39971_T5 (SEQ ID NO:21). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

T39971_T10 (SEQ ID NO: 18)	1169	1188
T39971_T12 (SEQ ID NO: 19)	1169	1188
T39971_T16 (SEQ ID NO: 20)	1169	1188
T39971_T5 (SEQ ID NO: 21)	1169	1188

Variant protein alignment to the previously known protein:

Sequence name: /tmp/xkraCL2OcZ/43L7YcPH7x:VTNC_HUMAN (SEQ ID NO:50)

Sequence documentation:

Alignment of: T39971_P6 (SEQ ID NO:51)×VTNC_HUMAN (SEQ ID NO:50).

Alignment segment 1/1:



Quality:	2774.00
Escore:	0
Matching length:	278	Total length:	278
Matching Percent	99.64	Matching Percent Identity:	99.64
Similarity:
Total Percent Similarity:	99.64	Total Percent Identity:	99.64
Gaps:	0

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. . . . .
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250

	. .
251	PDNVDAALALPAHSYSGRERVYFFKGTQ	278
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|
251	PDNVDAALALPAHSYSGRERVYFFKGKQ	278

Sequence name: /tmp/X4DeeuSlB4/yMubSR5FPs:VTNC_HUMAN (SEQ ID NO:50)

Sequence documentation:

Alignment of: T39971_P9 (SEQ ID NO:52)×VTNC_HUMAN (SEQ ID NO:50).

Alignment segment 1/1:



Quality:	4430.00
Escore:	0
Matching length:	447	Total length:	478
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	93.51	Total Percent Identity:	93.51
Gaps:	1

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. . . . .
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250

	. . . . .
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300

	. . . . .
301	VFEHFAMMQRDSWEDIFELLFWGRT.........................	325
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAM	350

	. . . . .
326	......SGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRAT	369
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	AGRIYISGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRAT	400

	. . . . .
370	WLSLFSSEESNLGANNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLR	419
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	WLSLFSSEESNLGANNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLR	450

	. .
420	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	447
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	478

Sequence name: /tmp/jvp1VtnxNy/wxNSeFVZZw:VTNC_HUMAN (SEQ ID NO:50)

Sequence documentation:

Alignment of: T39971_P11 (SEQ ID NO:53)×VTNC_HUMAN (SEQ ID NO:50).

Alignment segment 1/1:



Quality:	3576.00
Escore:	0
Matching length:	363	Total length:	478
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	75.94	Total Percent Identity:	75.94
Gaps:	1

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. . . . .
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRTNCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250

	. . . . .
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300

	. . . . .
301	VFEHFAMMQRDSWEDIFELLFWGRTS........................	326
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAM	350

	. . . . .
326	..................................................	326

351	AGRIYISGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRAT	400

	. . . . .
327	.........................................DKYYRVNLR	335
	\|\|\|\|\|\|\|\|\|
401	WLSLFSSEESNLGANNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLR	450

	. .
336	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	363
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	478

Sequence name: /tmp/jvp1VtnxNy/wxNSeFVZZw:Q9BSH7

Sequence documentation:

Alignment of: T39971_P11 (SEQ ID NO:53)×Q9BSH7

Alignment segment 1/1:



Quality:	3576.00
Escore:	0
Matching length:	363	Total length:	478
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	75.94	Total Percent Identity:	75.94
Gaps:	1

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. . . . .
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYPRNISDGFDGI	250

	. . . . .
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	PDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA	300

	. . . . .
301	VFEHFAMMQRDSWEDIFELLFWGRTS........................	326
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAM	350

	. . . . .
326	..................................................	326

351	AGRIYISGMAPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRAM	400

	. . . . .
327	.........................................DKYYRVNLR	335
	\|\|\|\|\|\|\|\|\|
401	WLSLFSSEESNLGANNYDDYRMDWLVPATCEPIQSVFFFSGDKYYRVNLR	450

	. .
336	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	363
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	TRRVDTVDPPYPRSIAQYWLGCPAPGHL	478

Sequence name: /tmp/fgebv7ir4i/48bTBMziJ0:VTNC_HUMAN (SEQ ID NO:50)

Sequence documentation:

Alignment of: T39971_P12 (SEQ ID NO:54)×VTNC_HUMAN (SEQ ID NO:50).

Alignment segment 1/1:



Quality:	2237.00
Escore:	0
Matching length:	223	Total length:	223
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. .
201	GIEGPIDAAFTRINCQGKTYLFK	223
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRINCQGKTYLFK	223

Sequence name: /tmp/fgebv7ir4i/48bTBMziJ0:Q9BSH7

Sequence documentation:

Alignment of: T39971_P12 (SEQ ID NO:54)×Q9BSH7

Alignment segment 1/1:



Quality:	2237.00
Escore:	0
Matching length:	223	Total length:	223
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSC	50

	. . . . .
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CTDYTAECKPQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTS	100

	. . . . .
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	DLQAQSKGNPEQTPVLKPEEEAPAPEVGASKPEGIDSRPETLHPGRPQPP	150

	. . . . .
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	AEEELCSGKPFDAFTDLKNGSLFAFRGQYCYELDEKAVRPGYPKLIRDVW	200

	. .
201	GIEGPIDAAFTRINCQGKTYLFK	223
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	GIEGPIDAAFTRINCQGKTYLFK	223

Expression of VTNC_HUMAN Vitronectin (Serum Spreading Factor, Somatomedin B, Complement S-Protein) T39971 Transcripts, Which are Detectable by Amplicon as Depicted in Sequence Name T39971 junc23-33 (SEQ ID NO:836) in Normal and Cancerous Breast Tissues

Expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein) transcripts detectable by or according to junc23-33, T39971 junc23-33 amplicon (SEQ ID NO:836) and T39971 junc23-33F (SEQ ID NO:834) and T39971 junc23-33R (SEQ ID NO:835) primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)), was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”), to obtain a value of fold differetial expression for each sample relative to median of the normal PM samples.

FIG. 10 is a histogram showing down regulation of the above-indicated VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein) transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 10, the expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein) transcripts detectable by the above amplicon in cancer samples was significantly lower than in the non-cancerous samples (Sample Nos. 56-60, 63-67 Table 1, “Tissue samples in testing panel”).

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: T39971 junc23-33F (SEQ ID NO:834) forward primer; and T39971 junc23-33R (SEQ ID NO:835) reverse primer.


T39971junc22-33F (SEQ ID NO: 834):
GGGGCAGAACCTCTGACAAG

T39971junc22-33R (SEQ ID NO: 835):
GGGCAGCCCAGCCAGTA

T39971junc22-33 amplicon (SEQ ID NO: 836):
GGGGCAGAACCTCTGACAAGTACTACCGAGTCAATCTTCGCACACGGCGAGTGGAC
ACTGTGGACCCTCCCTACCCACGCTCCATCGCTCAGTACTGGCTGGGCTGCCC

Expression of VTNC_HUMAN Vitronectin (Serum Spreading Factor, Somatomedin B, Complement S-Protein), Antisense to SARM1 (T23434), T39971 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T39971junc23-33 (SEQ ID NO:836) in Different Normal Tissues

Expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein), transcripts detectable by or according to T39971junc23-33 amplicon (SEQ ID NO:836) and T39971junc23-33F (SEQ ID NO:834) and T39971junc23-33R (SEQ ID NO:835) was measured by real time PCR. In parallel the expression of four housekeeping genes-RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the breast samples (Sample Nos. 33-35, Table 2, “Tissue samples in normal panel” above), to obtain a value of relative expression of each sample relative to median of the breast samples. Primers and amplicon are as above.

The results are presented in FIG. 11, demonstrating the expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein), antisense to SARM1 (T23434), T39971 transcripts, which are detectable by amplicon as depicted in sequence name T39971junc23-33 (SEQ ID NO:836), in different normal tissues.

Expression of VTNC_HUMAN Vitronectin (Serum Spreading Factor, Somatomedin B, Complement S-Protein) T39971 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T39971 Seg22 (SEQ ID NO:839) in Normal and Cancerous Breast Tissues

Expression of VTNC_HUMAN vitronectin (serum spreading factor, somatomedin B, complement S-protein) transcripts detectable by or according to seg22, T39971 seg22 (SEQ ID NO:839) amplicon(s) and primers T39971 seg22F (SEQ ID NO:837) and T39971 seg22R (SEQ ID NO:838) was measured by real time PCR. In parallel the expression of four housekeeping genes-PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)); G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)), was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold differential expression for each sample relative to median of the normal PM samples.

In one experiment that was carried out no differential expression in the cancerous samples relative to the normal PM samples was observed. However, this may be due to a problem that is specific to this particular experiment.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: T39971 seg22F (SEQ ID NO:837) forward primer; and T39971 seg22R (SEQ ID NO:838) reverse primer.


Forward primer T39971 seg22F:	(SEQ ID NO: 837)
GCAGTCTTGGATTCCTTTCACATT

Reverse primer T39971 seg22R:	(SEQ ID NO: 838)
GAGGCTGTTGAAGTTAGGATCTCC

Amplicon T39971 seg22:	(SEQ ID NO: 839)

GCAGTCTTGGATTCCTTTCACATTTCACTGGGGACAGGCCTCAGCATGTGCCCACCC
CTGACCCCCACCTCATGCTGGGAGATCCTAACTTCAACAGCCTC

Description for Cluster Z21368

Cluster Z21368 features 7 transcript(s) and 34 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	Z21368_PEA_1_T10	55
	Z21368_PEA_1_T11	56
	Z21368_PEA_1_T23	57
	Z21368_PEA_1_T24	58
	Z21368_PEA_1_T5	59
	Z21368_PEA_1_T6	60
	Z21368_PEA_1_T9	61

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	Z21368_PEA_1_node_0	62
	Z21368_PEA_1_node_15	63
	Z21368_PEA_1_node_19	64
	Z21368_PEA_1_node_2	65
	Z21368_PEA_1_node_21	66
	Z21368_PEA_1_node_33	67
	Z21368_PEA_1_node_36	68
	Z21368_PEA_1_node_37	69
	Z21368_PEA_1_node_39	70
	Z21368_PEA_1_node_4	71
	Z21368_PEA_1_node_41	72
	Z21368_PEA_1_node_43	73
	Z21368_PEA_1_node_45	74
	Z21368_PEA_1_node_53	75
	Z21368_PEA_1_node_56	76
	Z21368_PEA_1_node_58	77
	Z21368_PEA_1_node_66	78
	Z21368_PEA_1_node_67	79
	Z21368_PEA_1_node_69	80
	Z21368_PEA_1_node_11	81
	Z21368_PEA_1_node_12	82
	Z21368_PEA_1_node_16	83
	Z21368_PEA_1_node_17	84
	Z21368_PEA_1_node_23	85
	Z21368_PEA_1_node_24	86
	Z21368_PEA_1_node_30	87
	Z21368_PEA_1_node_31	88
	Z21368_PEA_1_node_38	89
	Z21368_PEA_1_node_47	90
	Z21368_PEA_1_node_49	91
	Z21368_PEA_1_node_51	92
	Z21368_PEA_1_node_61	93
	Z21368_PEA_1_node_68	94
	Z21368_PEA_1_node_7	95

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	Z21368_PEA_1_P2	97
	Z21368_PEA_1_P5	98
	Z21368_PEA_1_P15	99
	Z21368_PEA_1_P16	100
	Z21368_PEA_1_P22	101
	Z21368_PEA_1_P23	102

These sequences are variants of the known protein Extracellular sulfatase Sulf-1 precursor (SwissProt accession identifier SUL1_HUMAN; known also according to the synonyms EC 3.1.6.-; HSulf-1), SEQ ID NO:96, referred to herein as the previously known protein.

Protein Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96) is known or believed to have the following function(s): Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin. Diminishes HSPG (heparan sulfate proteoglycans) sulfation, inhibits signaling by heparin-dependent growth factors, diminishes proliferation, and facilitates apoptosis in response to exogenous stimulation. The sequence for protein Extracellular sulfatase Sulf-1 precursor is given at the end of the application, as “Extracellular sulfatase Sulf-1 precursor amino acid sequence” (SEQ ID NO:96). Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

87-88	CC->AA: LOSS OF ARYLSULFATASE
	ACTIVITY AND LOSS OF ABILITY TO
	MODULATE APOPTOSIS.
49	L -> P
728	K -> R

Protein Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96) localization is believed to be Endoplasmic reticulum and Golgi stack; also localized on the cell surface (By similarity).

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: apoptosis; metabolism; heparan sulfate proteoglycan metabolism, which are annotation(s) related to Biological Process; arylsulfatase; hydrolase, which are annotation(s) related to Molecular Function; and extracellular space; endoplasmic reticulum; Golgi apparatus, which are annotation(s) related to Cellular Component.

Cluster Z21368 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the right hand column of the table and the numbers on the y-axis of FIG. 12 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 12 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	bladder	123
	Bone	557
	Brain	34
	Colon	94
	epithelial	56
	general	68
	head and neck	0
	kidney	35
	Lung	22
	lymph nodes	0
	breast	52
	muscle	31
	ovary	0
	pancreas	0
	prostate	44
	skin	67
	stomach	109
	T cells	0
	Thyroid	0
	uterus	140

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

bladder	5.4e−01	6.6e−01	6.4e−01	1.0	8.5e−01	0.7
bone	4.5e−01	8.2e−01	9.1e−01	0.4	1	0.3
brain	5.5e−01	7.3e−01	1.5e−01	1.5	5.0e−01	0.9
colon	1.4e−01	2.8e−01	1.0e−01	2.0	3.0e−01	1.4
epithelial	1.1e−03	1.5e−01	1.2e−07	2.1	1.0e−01	1.1
general	1.4e−05	5.3e−02	1.9e−06	1.6	6.7e−01	0.8
head and neck	2.4e−02	7.1e−02	4.6e−01	2.5	7.5e−01	1.4
kidney	8.9e−01	9.0e−01	1	0.4	1	0.4
lung	3.5e−01	4.1e−01	7.2e−03	2.6	1.0e−01	1.6
lymph nodes	7.7e−02	3.1e−01	2.3e−02	8.5	1.9e−01	3.2
breast	4.0e−01	6.1e−01	5.4e−02	2.3	3.0e−01	1.3
muscle	7.5e−02	3.5e−02	1	1.0	1.7e−01	1.7
ovary	3.8e−01	4.2e−01	2.2e−01	2.9	3.4e−01	2.2
pancreas	2.2e−02	6.9e−02	1.4e−08	6.5	1.4e−06	4.6
prostate	8.3e−01	8.9e−01	3.1e−01	1.4	5.2e−01	1.1
skin	6.1e−01	8.1e−01	6.0e−01	1.2	1	0.3
stomach	4.4e−02	5.0e−01	5.0e−01	0.8	9.7e−01	0.4
T cells	5.0e−01	6.7e−01	3.3e−01	3.1	7.2e−01	1.4
Thyroid	3.6e−01	3.6e−01	1	1.1	1	1.1
uterus	3.5e−01	7.8e−01	4.6e−01	0.9	9.1e−01	0.5

As noted above, cluster Z21368 features 7 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96). A description of each variant protein according to the present invention is now provided.

Variant protein Z21368_PEA_—1_P2 (SEQ ID NO:97) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T5 (SEQ ID NO:59). An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P2 (SEQ ID NO:97) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P2 (SEQ ID NO:97), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFL VERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARYQTACEQPGQKWQCIEDTSGK LRIHKCKGPSDLLTVRQSTRNLYARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNO GTPKYKPRFVHTRQTRSLSVEFEGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQ ASSGGNRGRMLADSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYI DKEIEALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKE AAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWN corresponding to amino acids 1-761 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-761 of Z21368_PEA_—1_P2 (SEQ ID NO:97), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence PHKYSAHGRTRHFESATRTTNGAQKLSRI (SEQ ID NO:1005) corresponding to amino acids 762-790 of Z21368_PEA_—1_P2 (SEQ ID NO:97), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of Z21368_PEA_—1_P2 (SEQ ID NO:97), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence PHKYSAHGRTRHFESATRTTNGAQKLSRI (SEQ ID NO:1005) in Z21368_PEA_—1_P2 (SEQ ID NO:97).

Variant protein Z21368_PEA_—1_P2 (SEQ ID NO:97) is encoded by the following transcript(s): Z21368_PEA_—1_T5 (SEQ ID NO:59), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T5 (SEQ ID NO:59) is shown in bold; this coding portion starts at position 529 and ends at position 2898.

Variant protein Z21368_PEA_—1_P5 (SEQ ID NO:98) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T9 (SEQ ID NO:61). An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P5 (SEQ ID NO:98) and Q7Z2W2 (SEQ ID NO:840) (SEQ ID NO:840):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVEL corresponding to amino acids 1-57 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 1-57 of Z21368_PEA_—1_P5 (SEQ ID NO:98), second bridging amino acid sequence comprising A, and a third amino acid sequence being at least 90% homologous to FFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITN ESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNM DKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYT ADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDT PPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHL PKYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLY ARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNOGTPKYKPRFVHTRQTRSLSVEFE GEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPT TVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKR RKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKER KEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNE THNFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNOLHVQLMELRSCQGYKQCN PRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 139-871 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 59-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for an edge portion of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise LAF having a structure as follows (numbering according to Z21368_PEA_—1_P5 (SEQ ID NO:98)): a sequence starting from any of amino acid numbers 57-x to 57; and ending at any of amino acid numbers 59+((n−2)−x), in which x varies from 0 to n−2.

Comparison report between Z21368_PEA_—1_P5 (SEQ ID NO:98) and AAH12997 (SEQ ID NO:841) (SEQ ID NO:841):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELAFF GKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNES INYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNMDK HWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYTAD HGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDTPP DVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLP KYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYA RGFHDKDKECSCRESGYRASRSQRKSQRQFLRNOGTPKYKPRFVHTRQTRSLSVEFEGE IYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPTTV RVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKRRK PEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKERKE KRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETH NFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNOLHVQLME (SEQ ID NO:1006) corresponding to amino acids 1-751 of Z21368_PEA_—1_P5 (SEQ ID NO:98), and a second amino acid sequence being at least 90% homologous to LRSCQGYKQCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 1-40 of AAH12997 (SEQ ID NO:841), which also corresponds to amino acids 752-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELAFF	(SEQ ID NO: 1006)

GKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNES

INYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPNMDK

HWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYIIYTAD

HGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGLDTPP

DVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLP

KYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYA

RGFHDKDKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEFEGE

IYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGPPTTV

RVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHLKRRK

PEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRKKERKE

KRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETH

NFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNQLHVQLME

of Z21368_PEA_1_P5.	(SEQ ID NO: 98)

Comparison report between Z21368_PEA_—1_P5 (SEQ ID NO:98) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVEL corresponding to amino acids 1-57 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-57 of Z21368_PEA_—1_P5 (SEQ ID NO:98), and a second amino acid sequence being at least 90% homologous to AFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLIT NESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYNYAPN MDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNMLVETGELENTYII YTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEPGSIVPQIVLNIDLAPTILDIAGL DTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFLVERGKFLRKKEES SKNIQQSN HLPKYERVKELCQQARYQTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRN LYARGFHDKDKECSCRESGYRASRSQRKSQRQFLRNOGTPKYKPRFVHTRQTRSLSVE FEGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLADSSNAVGP PTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEIEALQDKIKNLREVRGHL KRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLHPFKEAAQEVDSKLQLFKENNRRRK KERKEKRRQRKGEECSLPGLTCFTHDNNHWQTAPFWNLGSFCACTSSNNNTYWCLRT VNETHNFLFCEFATGFLEYFDMNTDPYQLTNTVHTVERGILNOLHVQLMELRSCQGYK QCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG corresponding to amino acids 138-871 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 58-791 of Z21368_PEA_—1_P5 (SEQ ID NO:98), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of Z21368_PEA_—1_P5 (SEQ ID NO:98), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise LA, having a structure as follows: a sequence starting from any of amino acid numbers 57-x to 57; and ending at any of amino acid numbers 58+((n−2)−x), in which x varies from 0 to n−2.

Variant protein Z21368_PEA_—1_P5 (SEQ ID NO:98) is encoded by the following transcript(s): Z21368_PEA_—1_T9 (SEQ ID NO:61), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T9 (SEQ ID NO:61) is shown in bold; this coding portion starts at position 556 and ends at position 2928.

Variant protein Z21368_PEA_—1_P15 (SEQ ID NO:99) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T23 (SEQ ID NO:57). An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P15 (SEQ ID NO:99) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P15 (SEQ ID NO.99), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRTNKKAKIWRDTFL VERG corresponding to amino acids 1-416 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-416 of Z21368_PEA_—1_P15 (SEQ ID NO:99).

Variant protein Z21368_PEA_—1_P15 (SEQ ID NO:99) is encoded by the following transcript(s): Z21368_PEA_—1_T23 (SEQ ID NO:57), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T23 (SEQ ID NO:57) is shown in bold; this coding portion starts at position 691 and ends at position 1938.

Variant protein Z21368_PEA_—1_P16 (SEQ ID NO:100) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T24 (SEQ ID NO:58). An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P16 (SEQ ID NO:100) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P16 (SEQ ID NO:100), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAKDYFTDLITNESINYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQ FSKLYPNASQHITPSYNYAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDD SVERLYNMLVETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVEP GSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNR corresponding to amino acids 1-397 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-397 of Z21368_PEA_—1_P 16 (SEQ ID NO:100), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CVIVPPLSQPQIH (SEQ ID NO:1007) corresponding to amino acids 398-410 of Z21368_PEA_—1_P16 (SEQ ID NO:100), wherein said first and second amino acid sequnes are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of Z21368_PEA_—1_P 16 (SEQ ID NO:100), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CVIVPPLSQPQIH (SEQ ID NO:1007) in Z21368_PEA_—1_P16 (SEQ ID NO:100).

Variant protein Z21368_PEA_—1_P16 (SEQ ID NO:100) is encoded by the following transcript(s): Z21368_PEA_—1_T24 (SEQ ID NO:58), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T24 (SEQ ID NO:58) is shown in bold; this coding portion starts at position 691 and ends at position 1920.

Variant protein Z21368_PEA_—1_P22 (SEQ ID NO:101) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T10 (SEQ ID NO:55) An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P22 (SEQ ID NO:101) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P22 (SEQ ID NO:101), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGSYIPPGWREWLGLIKNSRFYNYTVCR NGIKEKHGFDYAK corresponding to amino acids 1-188 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-188 of Z21368_PEA_—1_P22 (SEQ ID NO:101), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ARYDGDQPRCAPRPRGLSPTVF (SEQ ID NO:1008) corresponding to amino acids 189-210 of Z21368_PEA_—1_P22 (SEQ ID NO:101), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of Z21368_PEA_—1_P22 (SEQ ID NO:101), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ARYDGDQPRCAPRPRGLSPTVF (SEQ ID NO:1008) in Z21368_PEA_—1_P22 (SEQ ID NO:101).

Variant protein Z21368_PEA_—1_P22 (SEQ ID NO:101) is encoded by the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T10 (SEQ ID NO:55) is shown in bold; this coding portion starts at position 691 and ends at position 1320.

Variant protein Z21368_PEA_—1_P23 (SEQ ID NO:102) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z21368_PEA_—1_T10 (SEQ ID NO:56). An alignment is given to the known protein (Extracellular sulfatase Sulf-1 precursor (SEQ ID NO:96)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z21368_PEA_—1_P23 (SEQ ID NO:102) and Q7Z2W2 (SEQ ID NO:840):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P23 (SEQ ID NO:102), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRT corresponding to amino acids 1-137 of Q7Z2W2 (SEQ ID NO:840), which also corresponds to amino acids 1-137 of Z21368_PEA_—1_P23 (SEQ ID NO:102), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GLLHRLNH (SEQ ID NO:1009) corresponding to amino acids 138-145 of Z21368_PEA_—1_P23 (SEQ ID NO:102), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of Z21368_PEA_—1_P23 (SEQ ID NO:102), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GLLHRLNH (SEQ ID NO:1009) in Z21368_PEA_—1_P23 (SEQ ID NO:102).

Comparison report between Z21368_PEA_—1_P23 (SEQ ID NO:102) and SUL1_HUMAN (SEQ ID NO:96):

1. An isolated chimeric polypeptide encoding for Z21368_PEA_—1_P23 (SEQ ID NO:102), comprising a first amino acid sequence being at least 90% homologous to MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLTDDQDVELGSL QVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYVHNHNVYTNNENCSSPSW QAMHEPRTFAVYLNNTGYRT corresponding to amino acids 1-137 of SUL1_HUMAN (SEQ ID NO:96), which also corresponds to amino acids 1-137 of Z21368_PEA_—1_P23 (SEQ ID NO:102), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GLLHRLNH (SEQ ID NO:1009) corresponding to amino acids 138-145 of Z21368_PEA_—1_P23 (SEQ ID NO:102), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein Z21368_PEA_—1_P23 (SEQ ID NO:102) is encoded by the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:56), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z21368_PEA_—1_T11 (SEQ ID NO:56) is shown in bold; this coding portion starts at position 691 and ends at position 1125.

As noted above, cluster Z21368 features 34 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster Z21368_PEA_—1_node_—0 (SEQ ID NO:62) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 7 below describes the starting and ending position of this segment on each transcript.

TABLE 7


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T9 (SEQ ID	1	327
NO: 61)

Segment cluster Z21368_PEA_—1_node_—15 (SEQ ID NO:63) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 8 below describes the starting and ending position of this segment on each transcript.

TABLE 8


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	631	807
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	631	807
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	631	807
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	631	807
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	469	645
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	469	645
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	496	672
NO: 61)

Segment cluster Z21368_PEA_—1_node_—19 (SEQ ID NO:64) according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59) and Z21368_PEA_—1_T6 (SEQ ID NO:60). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	863	1102
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	863	1102
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	863	1102
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	863	1102
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	701	940
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	701	940
NO: 60)

Segment cluster Z21368_PEA_—1_node_—2 (SEQ ID NO:65) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59) and Z21368_PEA_—1_T6 (SEQ ID NO:60). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	1	300
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1	300
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1	300
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1	300
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1	300
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1	300
NO: 60)

Segment cluster Z21368_PEA_—1_node_—21 (SEQ ID NO:66) according to the present invention is supported by 37 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA 1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	1103	1254
ID NO: 55)
Z21368_PEA_1_T23 (SEQ	1103	1254
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1103	1254
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	941	1092
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	941	1092
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	728	879
NO: 61)

Segment cluster Z21368_PEA_—1_node_—33 (SEQ ID NO:67) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	1502	1677
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1424	1599
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1576	1751
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1576	1751
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1414	1589
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1414	1589
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1201	1376
NO: 61)

Segment cluster Z21368_PEA_—1_node_—36 (SEQ ID NO:68) according to the present invention is supported by 44 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment ending
Transcript name	starting position	position

Z21368_PEA_1_T10 (SEQ	1678	1806
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1600	1728
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1752	1880
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1752	1880
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1590	1718
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1590	1718
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1377	1505
NO: 61)

Segment cluster Z21368_PEA_—1_node_—37 (SEQ ID NO:69) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T24 (SEQ ID NO:58). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

Z21368_PEA_1_T24	1881	2159
(SEQ ID NO: 58)

Segment cluster Z21368_PEA_—1_node_—39 (SEQ ID NO:70) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T23 (SEQ ID NO:57) and Z21368_PEA_—1_T24 (SEQ ID NO:58). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

		Segment
Transcript name	Segment starting position	ending position

Z21368_PEA_1_T23 (SEQ	1938	2790
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	2217	3069
ID NO: 58)

Segment cluster Z21368_PEA_—1_node_—4 (SEQ ID NO:71) according to the present invention is supported by 13 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57) and Z21368_PEA_—1_T24 (SEQ ID NO:58). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

		Segment
Transcript name	Segment starting position	ending position

Z21368_PEA_1_T10 (SEQ	301	462
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	301	462
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	301	462
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	301	462
ID NO: 58)

Segment cluster Z21368_PEA_—1_node_—41 (SEQ ID NO:72) according to the present invention is supported by 49 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1864	1993
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1786	1915
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	1776	1905
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1776	1905
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1563	1692
NO: 61)

Segment cluster Z21368_PEA_—1_node_—43 (SEQ ID NO:73) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1994	2210
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1916	2132
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	1906	2122
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1906	2122
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1693	1909
NO: 61)

Segment cluster Z21368_PEA_—1_node_—45 (SEQ ID NO:74) according to the present invention is supported by 64 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2211	2466
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2133	2388
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2123	2378
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2123	2378
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1910	2165
NO: 61)

Segment cluster Z21368_PEA_—1_node_—53 (SEQ ID NO:75) according to the present invention is supported by 60 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2725	2900
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2647	2822
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2637	2812
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2637	2812
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2424	2599
NO: 61)

Segment cluster Z21368_PEA_—1_node_—56 (SEQ ID NO:76) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2901	3043
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2823	2965
ID NO: 56)
Z21368_PEA_1_T9 (SEQ	2600	2742
ID NO: 61)

Segment cluster Z21368_PEA_—1_node_—58 (SEQ ID NO:77) according to the present invention is supported by 71 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	3044	3167
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2966	3089
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2813	2936
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2813	2936
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2743	2866
NO: 61)

Segment cluster Z21368_PEA_—1_node_—66 (SEQ ID NO:78) according to the present invention is supported by 142 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56, Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	3202	3789
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	3124	3711
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2971	3558
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2971	3558
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2901	3488
NO: 61)

Segment cluster Z21368_PEA_—1_node_—67 (SEQ ID NO:79) according to the present invention is supported by 181 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	3790	4374
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	3712	4296
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	3559	4143
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	3559	4143
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	3489	4073
NO: 61)

Segment cluster Z21368_PEA_—1_node_—69 (SEQ ID NO:80) according to the present invention is supported by 150 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	4428	4755
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	4350	4677
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	4197	5384
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	4197	4524
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	4127	4454
NO: 61)

Segment cluster Z21368_PEA_—1_node_—11 (SEQ ID NO:81) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	558	602
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	558	602
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	558	602
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	558	602
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	396	440
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	396	440
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	423	467
NO: 61)

Segment cluster Z21368_PEA_—1_node_—12 (SEQ ID NO:82) according to the present invention is supported by 23 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56, Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1T9 (SEQ ID NO:61). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	603	630
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	603	630
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	603	630
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	603	630
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	441	468
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	441	468
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	468	495
NO: 61)

Segment cluster Z21368_PEA_—1_node_—16 (SEQ ID NO:83) according to the present invention can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	808	822
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	808	822
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	808	822
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	808	822
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	646	660
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	646	660
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	673	687
NO: 61)

Segment cluster Z21368_PEA_—1_node_—17 (SEQ ID NO:84) according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	823	862
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	823	862
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	823	862
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	823	862
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	661	700
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	661	700
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	688	727
NO: 61)

Segment cluster Z21368_PEA_—1_node_—23 (SEQ ID NO:85) according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T11 (SEQ	1103	1176
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1255	1328
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1255	1328
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1093	1166
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1093	1166
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	880	953
NO: 61)

Segment cluster Z21368_PEA_—1_node_—24 (SEQ ID NO:86) according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1255	1350
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1177	1272
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1329	1424
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1329	1424
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1167	1262
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1167	1262
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	954	1049
NO: 61)

Segment cluster Z21368_PEA_—1_node_—30 (SEQ ID NO:87) according to the present invention is supported by 39 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1351	1409
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1273	1331
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1425	1483
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1425	1483
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1263	1321
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1263	1321
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1050	1108
NO: 61)

Segment cluster Z21368_PEA_—1_node_—31 (SEQ ID NO:88) according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1410	1501
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1332	1423
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1484	1575
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	1484	1575
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1322	1413
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1322	1413
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1109	1200
NO: 61)

Segment cluster Z21368_PEA_—1_node_—38 (SEQ ID NO:89) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	1807	1863
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	1729	1785
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	1881	1937
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	2160	2216
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	1719	1775
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	1719	1775
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	1506	1562
NO: 61)

Segment cluster Z21368_PEA_—1_node_—47 (SEQ ID NO:90) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2467	2563
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2389	2485
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2379	2475
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2379	2475
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2166	2262
NO: 61)

Segment cluster Z21368_PEA_—1_node_—49 (SEQ ID NO 91) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2564	2658
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2486	2580
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2476	2570
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2476	2570
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2263	2357
NO: 61)

Segment cluster Z21368_PEA_—1_node_—51 (SEQ ID NO:92) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	2659	2724
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	2581	2646
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2571	2636
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2571	2636
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2358	2423
NO: 61)

Segment cluster Z21368_PEA_—1_node_—61 (SEQ ID NO:93) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	3168	3201
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	3090	3123
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	2937	2970
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	2937	2970
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	2867	2900
NO: 61)

Segment cluster Z21368_PEA_—1_node_—68 (SEQ ID NO 94) according to the present invention is supported by 87 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	4375	4427
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	4297	4349
ID NO: 56)
Z21368_PEA_1_T5 (SEQ ID	4144	4196
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	4144	4196
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	4074	4126
NO: 61)

Segment cluster Z21368_PEA_—1_node_—7 (SEQ ID NO:95) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z21368_PEA_—1_T10 (SEQ ID NO:55), Z21368_PEA_—1_T11 (SEQ ID NO:56), Z21368_PEA_—1_T23 (SEQ ID NO:57), Z21368_PEA_—1_T24 (SEQ ID NO:58), Z21368_PEA_—1_T5 (SEQ ID NO:59), Z21368_PEA_—1_T6 (SEQ ID NO:60) and Z21368_PEA_—1_T9 (SEQ ID NO:61). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

Z21368_PEA_1_T10 (SEQ	463	557
ID NO: 55)
Z21368_PEA_1_T11 (SEQ	463	557
ID NO: 56)
Z21368_PEA_1_T23 (SEQ	463	557
ID NO: 57)
Z21368_PEA_1_T24 (SEQ	463	557
ID NO: 58)
Z21368_PEA_1_T5 (SEQ ID	301	395
NO: 59)
Z21368_PEA_1_T6 (SEQ ID	301	395
NO: 60)
Z21368_PEA_1_T9 (SEQ ID	328	422
NO: 61)

Overexpression of at least a portion of this cluster was determined according to oligonucleotides and one or more chips. The results were as follows: Oligonucleotide Z21368_—0_—0_—61857 was on the TAA chip and was found to be overexpressed in breast cancer.

Variant protein alignment to the previously known protein:

Sequence name: /tmp/5ER3vIMKE2/9L0Y7lDlTQ:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P2 (SEQ ID NO:97)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	7664.00
Score:	0
Matching length:	761	Total length:	761
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150

	. . . . .
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200

	. . . . .
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250

	. . . . .
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300

	. . . . .
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350

	. . . . .
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400

	. . . . .
401	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	450

	. . . . .
451	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	500

	. . . . .
501	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEF	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEF	550

	. . . . .
551	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	600

	. . . . .
601	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	650

	. . . . .
651	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	700

	. . . . .
701	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	750

	.
751	NNHWQTAPFWN	761
	\|\|\|\|\|\|\|\|\|\|\|
751	NNHWQTAPFWN	761

Sequence name: /tmp/tt3yfXIUKV/YxSTFWr66h:Q7Z2W2 (SEQ ID NO:840)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P5 (SEQ ID NO:98)×Q7Z2W2 (SEQ ID NO:840).

Alignment segment 1/1:



Quality:	7869.00
Score:	0
Matching length:	791	Total length:	871
Matching Percent	99.87	Matching Percent Identity:	99.87
Similarity:
Total Percent Similarity:	90.70	Total Percent Identity:	90.70
Gaps:	1

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELA..........................................	58
	\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFTNAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
59	......................................FFGKYLNEYNGS	70
	\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTVFFGKYLNEYNGS	150

	. . . . .
71	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	120
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200

	. . . . .
121	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	170
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NYFKMSKRMYPHRPVMMVISHAAPRGPEDSAPQFSKLYPNASQHITPSYN	250

	. . . . .
171	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	220
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300

	. . . . .
221	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	270
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350

	. . . . .
271	PGSIVPQIVLNIDLAPTILDTAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	320
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400

	. . . . .
321	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	370
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	450

	. . . . .
371	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	420
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	500

	. . . . .
421	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEF	470
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQRRSLSVEF	550

	. . . . .
471	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	520
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	600

	. . . . .
521	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	570
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	650

	. . . . .
571	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	620
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	700

	. . . . .
621	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	670
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	750

	. . . . .
671	NNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETHNFLFCEFATGFLEY	720
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	NNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETHNFLFCEFATGFLEY	800

	. . . . .
721	FDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCNPRPKNLDV	770
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	FDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCNPRPKNLDV	850

	. .
771	GNKDGGSYDLHRGQLWDGWEG	791
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	GNKDGGSYDLHRGQLWDGWEG	871

Sequence name: /tmp/tt3yfXIUKV/YxSTFWr66h:AAH12997 (SEQ ID NO:841)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P5 (SEQ ID NO:98)×AAH12997 (SEQ ID NO:841).

Alignment segment 1/1:



Quality:	420.00
Score:	0
Matching length:	40	Total length:	40
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . .
752	LRSCQGYKQCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG	791
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	LRSCQGYKQCNPRPKNLDVGNKDGGSYDLHRGQLWDGWEG	40

Sequence name: /tmp/tt3yfXIUKV/YxSTFWr66h:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P5 (SEQ ID NO:98)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	7878.00
Score:	0
Matching length:	791	Total length:	871
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	90.82	Total Percent Identity:	90.82
Gaps:	1

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVEL...........................................	57
	\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
58	.....................................AFFGKYLNEYNGS	70
	\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150

	. . . . .
71	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	120
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200

	. . . . .
121	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	170
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250

	. . . . .
171	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	220
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300

	. . . . .
221	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	270
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350

	. . . . .
271	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	320
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400

	. . . . .
321	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	370
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	NKKAKIWRDTFLVERGKFLRKKEESSKNIQQSNHLPKYERVKELCQQARY	450

	. . . . .
371	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	420
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	QTACEQPGQKWQCIEDTSGKLRIHKCKGPSDLLTVRQSTRNLYARGFHDK	500

	. . . . .
421	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEF	470
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	DKECSCRESGYRASRSQRKSQRQFLRNQGTPKYKPRFVHTRQTRSLSVEF	550

	. . . . .
471	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	520
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	EGEIYDINLEEEEELQVLQPRNIAKRHDEGHKGPRDLQASSGGNRGRMLA	600

	. . . . .
521	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	570
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	DSSNAVGPPTTVRVTHKCFILPNDSIHCERELYQSARAWKDHKAYIDKEI	650

	. . . . .
571	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	620
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	EALQDKIKNLREVRGHLKRRKPEECSCSKQSYYNKEKGVKKQEKLKSHLH	700

	. . . . .
621	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	670
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	PFKEAAQEVDSKLQLFKENNRRRKKERKEKRRQRKGEECSLPGLTCFTHD	750

	. . . . .
671	NNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETHNFLFCEFATGFLEY	720
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	NNHWQTAPFWNLGSFCACTSSNNNTYWCLRTVNETHNFLFCEFATGFLEY	800

	. . . . .
721	FDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCNPRPKNLDV	770
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	FDMNTDPYQLTNTVHTVERGILNQLHVQLMELRSCQGYKQCNPRPKNLDV	850

	. .
771	GNKDGGSYDLHRGQLWDGWEG	791
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	GNKDGGSYDLHRGQLWDGWEG	871

Sequence name: /tmp/AVAZGWHuF0/RzHFOnHIsT:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P15 (SEQ ID NO:99)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	4174.00
Escore:	0
Matching length:	416	Total length:	416
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150

	. . . . .
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200

	. . . . .
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250

	. . . . .
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300

	. . . . .
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350

	. . . . .
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNRFRT	400

	.
401	NKKAKIWRDTFLVERG	416
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	NKKAKIWRDTFLVERG	416

Sequence name: /tmp/JhwgRdKqmt/kqSmjxkWWk:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P16 (SEQ ID NO:100)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	3985.00
Escore:	0
Matching length:	397	Total length:	397
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150

	. . . . .
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAKDYFTDLITNESI	200

	. . . . .
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NYFKMSKRMYPHRPVMMVISHAAPHGPEDSAPQFSKLYPNASQHITPSYN	250

	. . . . .
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YAPNMDKHWIMQYTGPMLPIHMEFTNILQRKRLQTLMSVDDSVERLYNML	300

	. . . . .
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VETGELENTYIIYTADHGYHIGQFGLVKGKSMPYDFDIRVPFFIRGPSVE	350

	. . . .
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNR	397
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	PGSIVPQIVLNIDLAPTILDIAGLDTPPDVDGKSVLKLLDPEKPGNR	397

Sequence name: /tmp/GPlnIw3BOg/zXFdxqG4ow:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P22 (SEQ ID NO:101)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	1897.00
Escore:	0
Matching length:	188	Total length:	188
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . . . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRTAFFGKYLNEYNGS	150

	. . .
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAK	188
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YIPPGWREWLGLIKNSRFYNYTVCRNGIKEKHGFDYAK	188

Sequence name: /tmp/oji5Fs74fB/8xeB9KrGjp:Q7Z2W2 (SEQ ID NO:840)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P23 (SEQ ID NO:102)×Q7Z2W2 (SEQ ID NO:840).

Alignment segment 1/1:



Quality:	1368.00
Escore:	0.000511
Matching length:	137	Total length:	137
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRT	137
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRT	137

Sequence name: /tmp/oji5Fs74fB/8xeB9KrGjp:SUL1_HUMAN (SEQ ID NO:96)

Sequence documentation:

Alignment of: Z21368_PEA_—1_P23 (SEQ ID NO:102)×SUL1_HUMAN (SEQ ID NO:96).

Alignment segment 1/1:



Quality:	1368.00
Escore:	0.000511
Matching length:	137	Total length:	137
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKYSCCALVLAVLGTELLGSLCSTVRSPRFRGRIQQERKNIRPNIILVLT	50

	. . . . .
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	DDQDVELGSLQVMNKTRKIMEHGGATFINAFVTTPMCCPSRSSMLTGKYV	100

	. . .
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRT	137
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	HNHNVYTNNENCSSPSWQAMHEPRTFAVYLNNTGYRT	137

Expression of SUL1_HUMAN—Extracellular Sulfatase Sulf-1Z21368 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name Z21368seg39 (SEQ ID NO:844) in Normal and Cancerous Breast Tissues

Expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by or according to seg39, Z21368seg39 (SEQ ID NO:844) amplicon and Z21368seg39F (SEQ ID NO:842) and Z21368seg39R (SEQ ID NO:843) primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926), amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60,63-67, Table 1 above, Tissue samples in testing panel), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 13 is a histogram showing over expression of the above-indicated SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts in cancerous breast samples relative to the normal samples. Values represent the average of duplicate experiments. Error bars indicate the minimal and maximal values obtained. The number and percentage of samples that exhibit at least 5-fold over-expression, out of the total number of samples tested is indicated in the bottom.

As is evident from FIG. 13, the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos 56-60,63-67, Table 1 above, Tissue samples in testing panel). Notably an over-expression of at least 5 fold was found in 13 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by the above amplicon(s) in breast cancer samples versus the normal tissue samples was determined by T test as 2.14E-03.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 6.91E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: Z21368seg39F forward primer (SEQ ID NO:842); Z21368seg39R reverse primer (SEQ ID NO:843).


Z21368seg39F	(SEQ ID NO: 842)-

GTTGCATTTCTCAGTGCTGGTTT

Z21368seg39R

(SEQ ID NO: 843)-

AGGGTGCCGGGTGAGG

Z21368seg39

(SEQ ID NO: 844)-

GTTGCATTTCTCAGTGCTGGTTTCTAATCAGACCAGTGGATTGAGTTTCTCTACCATC
CTCCCCACGTTCTTCTCTAAGCTGCCTCCAAGCCTCACCCGGCACCCT

Expression of SUL1_HUMAN—Extracellular Sulfatase Sulf-1Z21368 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name Z21368seg39 (SEQ ID NO:844) in Different Normal Tissues

Expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by or according to Z21368seg39 (SEQ ID NO:844) amplicon and Z21368seg39F (SEQ ID NO:842) Z21368seg39R (SEQ ID NO:843) was measured by real time PCR. In parallel the expression of four housekeeping genes—[RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the breast samples (sample nos. 33-35 in table 2 “Tissue samples in normal panel”) to obtain a value of relative expression of each sample relative to median of the Normal samples. Primers and amplicon are as above.

The results are presented in FIG. 14, demonstrating the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1Z21368 transcripts, which are detectable by amplicon as depicted in sequence name Z21368seg39 (SEQ ID NO:844), in different normal tissues.

Expression of SUL1_HUMAN—Extracellular Sulfatase Sulf-1Z21368 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name Z21368junc17-21 (SEQ ID NO:847) in Normal and Cancerous Breast Tissues

Expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by or according to Z21368junc17-21 (SEQ ID NO:847) amplicon and Z21368junc17-21F (SEQ ID NO:845) and Z21368junc17-21R (SEQ ID NO:846) primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos 56-60,63-67 Table 1 above, “Tissue samples in testing panel”), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 15 is a histogram showing over expression of the above-indicated SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts in cancerous breast samples relative to the normal samples. Values represent the average of duplicate experiments. Error bars indicate the minimal and maximal values obtained. The number and percentage of samples that exhibit at least 5 fold over-expression, out of the total number of samples tested is indicated in the bottom.

As is evident from FIG. 15, the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos 56-60,63-67, Table 1 above, Tissue samples in testing panel). Notably an over-expression of at least 5 fold was found in 11 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 1.78E-02 as checked by exact fisher test. The above values demonstrate statistical significance of the results. Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: Z21368junc17-21F forward primer (SEQ ID NO:845); Z21368junc17-21R reverse primer (SEQ ID NO:846).


Z21368junc17-21F	(SEQ ID NO: 845)-

GGACGGATACAGCAGGAACG

Z21368junc17-21R

(SEQ ID NO: 846)-

TATTTTCCAAAAAAGGCCAGCTC

Z21368junc17-21

(SEQ ID NO: 847)-

GGACGGATACAGCAGGAACGAAAAAACATCCGACCCAACATTATTCTTGTGCTTAC
CGATGATCAAGATGTGGAGCTGGCCTTTTTTGGAAAATA

Expression of SUL1_HUMAN—Extracellular Sulfatase Sulf-1 Z21368 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name Z21368junc17-21 (SEQ ID NO:847) in Different Normal Tissues

Expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 Z21368 transcripts detectable by or according to amplicon Z21368junc17-21 (SEQ ID NO:847) was measured by real time PCR. In parallel the expression of four housekeeping genes—RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes, as above. The normalized quantity of each RT sample was then divided by the median of the quantities of the breast samples (Sample Nos.—33-35 Table 2 above, “Tissue samples on normal panel”), to obtain a value of relative expression of each sample relative to median of the breast samples. Primers and amplicon are as above.

The results are presented in FIG. 16, demonstrating the expression of SUL1_HUMAN—Extracellular sulfatase Sulf-1 Z21368 transcripts, which are detectable by amplicon as depicted in sequence name Z21368junc17-21 (SEQ ID NO:847), in different normal tissues.

Description for Cluster T59832

Cluster T59832 features 6 transcript(s) and 33 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the 5 application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No

	T59832_T11	103
	T59832_T15	104
	T59832_T22	105
	T59832_T28	106
	T59832_T6	107
	T59832_T8	108

TABLE 2


Segments of interest

	Segment Name	Sequence ID No

	T59832_node_1	109
	T59832_node_22	110
	T59832_node_23	111
	T59832_node_24	112
	T59832_node_29	113
	T59832_node_39	114
	T59832_node_7	115
	T59832_node_10	116
	T59832_node_11	117
	T59832_node_12	118
	T59832_node_14	119
	T59832_node_16	120
	T59832_node_19	121
	T59832_node_2	122
	T59832_node_20	123
	T59832_node_25	124
	T59832_node_26	125
	T59832_node_27	126
	T59832_node_28	127
	T59832_node_3	128
	T59832_node_30	129
	T59832_node_31	130
	T59832_node_32	131
	T59832_node_34	132
	T59832_node_35	133
	T59832_node_36	134
	T59832_node_37	135
	T59832_node_38	136
	T59832_node_4	137
	T59832_node_5	138
	T59832_node_6	139
	T59832_node_8	140
	T59832_node_9	141

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No

	T59832_P5	143
	T59832_P7	144
	T59832_P9	145
	T59832_P12	146
	T59832_P18	147

These sequences are variants of the known protein Gamma-interferon inducible lysosomal thiol reductase precursor (SwissProt accession identifier GILT_HUMAN; known also according to the synonyms Gamma-interferon-inducible protein IP-30), SEQ ID NO: 142, referred to herein as the previously known protein.

Protein Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142) is known or believed to have the following function(s): Cleaves disulfide bonds in proteins by reduction. May facilitate the complet unfolding of proteins destined for lysosomal degradation. May be involved in MHC class II-restricted antigen processing. The sequence for protein Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142) is given at the end of the application, as “Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

109	L -> S
130	H -> L

Protein Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142) localization is believed to be Lysosomal.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: extracellular; lysosome, which are annotation(s) related to Cellular Component.

Cluster T59832 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 17 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 17 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: brain malignant tumors, breast malignant tumors, ovarian carcinoma and pancreas carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Adrenal	208
	Bladder	205
	Bone	200
	Brain	18
	Colon	236
	Epithelial	143
	General	280
	head and neck	192
	Kidney	71
	Liver	53
	Lung	459
	lymph nodes	248
	Breast	0
	bone marrow	94
	Ovary	0
	Pancreas	20
	Prostate	86
	Skin	29
	Stomach	109
	T cells	557
	Thyroid	0
	Uterus	63

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	4.9e−01	5.9e−01	4.7e−03	1.1	2.9e−02	0.8
bladder	3.7e−01	5.6e−01	3.7e−02	1.3	2.5e−01	0.9
Bone	6.6e−01	6.7e−01	3.4e−01	0.6	9.1e−01	0.4
Brain	1.8e−01	2.9e−01	4.3e−03	3.8	2.8e−02	2.5
colon	4.4e−01	5.2e−01	6.1e−01	0.9	8.1e−01	0.7
epithelial	2.5e−02	1.6e−01	1.2e−05	1.6	9.8e−02	1.1
general	1.3e−02	1.6e−01	1	0.8	1	0.6
Head and neck	3.4e−01	3.3e−01	1	0.4	9.4e−01	0.5
kidney	7.7e−01	8.5e−01	1.4e−01	1.3	4.2e−01	0.9
Liver	8.3e−01	7.6e−01	1	0.5	1	0.6
Lung	5.7e−01	8.3e−01	3.5e−01	0.8	9.8e−01	0.5
lymph nodes	5.7e−01	6.6e−01	7.6e−01	0.8	3.6e−02	1.1
breast	5.0e−02	1.3e−01	2.5e−03	6.5	4.4e−02	3.6
Bone marrow	6.2e−01	7.8e−01	1	0.3	9.5e−01	0.5
ovary	2.2e−01	9.4e−02	3.2e−03	6.1	8.3e−03	5.3
pancreas	9.0e−02	1.6e−02	1.1e−03	4.0	7.9e−04	4.2
prostate	8.1e−01	8.0e−01	5.7e−01	0.9	4.1e−01	0.9
skin	1.6e−01	1.2e−01	2.3e−02	6.0	1.0e−02	2.2
stomach	5.5e−01	7.4e−01	9.4e−01	0.6	4.9e−01	1.0
T cells	1	6.7e−01	6.9e−01	1.0	9.8e−01	0.5
Thyroid	2.3e−01	2.3e−01	5.9e−02	2.5	5.9e−02	2.5
uterus	7.4e−02	4.7e−02	2.2e−02	2.0	6.2e−02	1.7

As noted above, cluster T59832 features 6 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142). A description of each variant protein according to the present invention is now provided.

Variant protein T59832_P5 (SEQ ID NO:143) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T59832_T6 (SEQ ID NO:107). An alignment is given to the known protein (Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application.

Comparison report between T59832_P5 (SEQ ID NO:143) and GILT_HUMAN (SEQ ID NO:142):

1. An isolated chimeric polypeptide encoding for T59832_P5 (SEQ ID NO:143), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 12-55 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-44 of T59832_P5 (SEQ ID NO:143), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGTATGRAGWREQAPCRGTRLLLSPQTSQGKTRAPRGRCPCRVPGKTLFSSRRCGHTP SVPFRFRIPHLRGAAASTRLVPPKGSMSAYCVLLGQELGSPFVAQGTSSAAGQGPPACIL AATLDAFIPARAGLACLWDLLGRCPRG (SEQ ID NO:1010) corresponding to amino acids 45-189 of T59832_P5 (SEQ ID NO:143), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T59832_P5 (SEQ ID NO:143), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


VGTATGRAGWREQAPCRGTRLLLSPQTSQGKTRAPRGRCPCRVPGKTLFSSRRCGHTP	(SEQ ID NO: 1010)
SVPFRFRIPHLRGAAASTRLVPPKGSMSAYCVLLGQELGSPFVAQGTSSAAGQGPPACIL
AATLDAFIPARAGLACLWDLLGRCPRG

in T59832_P5.	(SEQ ID NO: 143)

Variant protein T59832_P5 (SEQ ID NO:143) is encoded by the following transcript(s): T59832_T6 (SEQ ID NO:107), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T59832_T6 (SEQ ID NO:107) is shown in bold; this coding portion starts at position 149 and ends at position 715. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P5 (SEQ ID NO:143) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

61	C -> T	Yes
148	G -> T	Yes
1505	G -> C	Yes
1651	T ->	No
1652	T -> G	Yes
1717	C -> A	No
1722	C ->	No
1722	C -> G	No
1752	A -> G	Yes
1817	A -> G	Yes
1854	C ->	No
1854	C -> A	No
212	-> A	No
1871	C -> T	Yes
1886	T -> G	No
1906	G -> A	No
1906	G -> C	No
1942	C ->	No
1942	C -> T	No
1971	C ->	No
1986	G -> A	No
2001	G -> T	Yes
2008	A ->	No
241	G -> T	No
2030	-> T	No
2031	C -> T	No
2050	C ->	No
2056	A -> G	Yes
2068	G -> A	Yes
2111	A -> C	Yes
2136	A -> C	Yes
2144	T -> C	Yes
244	A -> G	Yes
962	C -> T	Yes
1074	G -> A	Yes
1248	G -> C	Yes
1441	G -> A	Yes
1443	G -> A	No

Variant protein T59832_P7 (SEQ ID NO:144) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T59832_T8 (SEQ ID NO:108). An alignment is given to the known protein (Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T59832_P7 (SEQ ID NO:144) and GILT_HUMAN (SEQ ID NO:142):

1. An isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 12-223 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T59832_P7 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) in T59832_P7 (SEQ ID NO:144).

Comparison report between T59832_P7 (SEQ ID NO:144) and BAC98466 (SEQ ID NO:848):

1. An isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 1-212 of BAC98466 (SEQ ID NO:848), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between T59832_P7 (SEQ ID NO:144) and BAC85622 (SEQ ID NO:849):

1. An isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVC MEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYV PWVTVNGVRIFLALSLTLIVPWSQGWTRQRDQR corresponding to amino acids 1-148 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of T59832_P7 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)
PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P7.	(SEQ ID NO: 144)

Comparison report between T59832_P7 (SEQ ID NO:144) and Q8WU77 (SEQ ID NO:850):

1. An isolated chimeric polypeptide encoding for T59832_P7 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 1-212 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-212 of T59832_P7 (SEQ ID NO:144), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRIFLALSLTLIVPWSQGWTRQRDQR (SEQ ID NO:1011) corresponding to amino acids 213-238 of T59832_P7 (SEQ ID NO:144), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T59832_P7 (SEQ ID NO:144) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P7 (SEQ ID NO:144) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

146	I ->	No
146	I -> M	Yes
168	P -> Q	No
170	L ->	No
170	L -> V	No
180	M -> V	Yes
76	R -> Q	Yes
77	A -> T	No

Variant protein T59832_P7 (SEQ ID NO:144) is encoded by the following transcript(s): T59832_T8 (SEQ ID NO:108), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T59832_T8 (SEQ ID NO:108) is shown in bold; this coding portion starts at position 149 and ends at position 862. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P7 (SEQ ID NO:144) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

61	C -> T	Yes
148	G -> T	Yes
651	C -> A	No
656	C ->	No
656	C -> G	No
686	A -> G	Yes
751	A -> G	Yes
1004	T -> G	Yes
1206	C ->	No
1206	C -> A	No
1223	C -> T	Yes
1238	T -> G	No
212	-> A	No
1258	G -> A	No
1258	G -> C	No
1294	C ->	No
1294	C -> T	No
1323	C ->	No
1338	G -> A	No
1353	G -> T	Yes
1360	A ->	No
1382	-> T	No
1383	C -> T	No
241	G -> T	No
1402	C ->	No
1408	A -> G	Yes
1420	G -> A	Yes
1463	A -> C	Yes
1488	A -> C	Yes
1496	T -> C	Yes
244	A -> G	Yes
375	G -> A	Yes
377	G -> A	No
439	G -> C	Yes
585	T ->	No
586	T -> G	Yes

Variant protein T59832_P9 (SEQ ID NO:145) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T59832_T11 (SEQ ID NO:103). An alignment is given to the known protein (Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T59832_P9 (SEQ ID NO:145) and GILT_HUMAN (SEQ ID NO:2):

1. An isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 12-214 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T59832_P9 (SEQ ID NO:145), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) in T59832_P9 (SEQ ID NO:145).

Comparison report between-T59832_P9 (SEQ ID NO:145) and BAC98466 (SEQ ID NO:848):

1. An isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-203 of BAC98466 (SEQ ID NO:848), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between T59832_P9 (SEQ ID NO:145) and BAC85622 (SEQ ID NO:849):

1. An isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P9 (SEQ ID NO:145), second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVC MEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-113 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-203 of T59832_P9 (SEQ ID NO:145), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of T59832_P9 (SEQ ID NO:145), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)
PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P9.	(SEQ ID NO: 145)

3. An isolated polypeptide encoding for a tail of T59832_P9 (SEQ ID NO:145), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR (SEQ ID NO:1013) in T59832_P9 (SEQ ID NO:145).

Comparison report between T59832_P9 (SEQ ID NO:145) and Q8WU77 (SEQ ID NO:850):

1. An isolated chimeric polypeptide encoding for T59832_P9 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVEACVLDELDMELAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIM ECAMGDRGMQLMHANAQRTDALQPPHE corresponding to amino acids 1-203 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-203 of T59832_P9 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


	(SEQ ID NO: 1013)

NPWKIRPSSLPLSASCTRARSRMSALPQPAPSGVFASSDGR

corresponding to amino acids 204-244 of T59832_P9 (SEQ ID NO:145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T59832_P9 (SEQ ID NO:145) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P9 SEQ ID NO:145) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

146	I ->	No
146	I -> M	Yes
222	A -> P	No
222	A -> T	No
234	P ->	No
234	P -> S	No
243	G ->	No
76	R -> Q	Yes
77	A -> T	No
168	P -> Q	No
170	L ->	No
170	L -> V	No
180	M -> V	Yes
204	N ->	No
204	N -> K	No
210	P -> L	Yes
215	L -> W	No

Variant protein T59832_P9 (SEQ ID NO:145) is encoded by the following transcript(s): T59832_T11 (SEQ ID NO:103), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T59832_T11 (SEQ ID NO:103) is shown in bold; this coding portion starts at position 149 and ends at position 880. The transcript also has the following SNPs as listed in Table 11 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P9 (SEQ ID NO:145) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

61	C -> T	Yes
148	G -> T	Yes
651	C -> A	No
656	C ->	No
656	C -> G	No
686	A -> G	Yes
751	A -> G	Yes
760	C ->	No
760	C -> A	No
777	C -> T	Yes
792	T -> G	No
812	G -> A	No
212	-> A	No
812	G -> C	No
848	C ->	No
848	C -> T	No
877	C ->	No
892	G -> A	No
907	G -> T	Yes
914	A ->	No
936	-> T	No
937	C -> T	No
956	C ->	No
241	G -> T	No
962	A -> G	Yes
974	G -> A	Yes
1017	A -> C	Yes
1042	A -> C	Yes
1050	T -> C	Yes
244	A -> G	Yes
375	G -> A	Yes
377	G -> A	No
439	G -> C	Yes
585	T ->	No
586	T -> G	Yes

Variant protein T59832_P12 (SEQ ID NO:146) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T59832_T15 (SEQ ID NO:104). An alignment is given to the known protein (Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T59832_P12 (SEQ ID NO:146) and GILT_HUMAN (SEQ ID NO:142):

1. An isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE corresponding to amino acids 12-141 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-130 of T59832_P12 (SEQ ID NO:146), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 173-261 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 131-219 of T59832_P12 (SEQ ID NO:146), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of T59832_P12 (SEQ ID NO:146), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+((n−2)−x), in which x varies from 0 to n−2.

Comparison report between T59832_P12 (SEQ ID NO:146) and BAC85622 (SEQ ID NO:849):

1. An isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLV (SEQ ID NO:1012) corresponding to amino acids 1-90 of T59832_P12 (SEQ ID NO:146), second amino acid sequence being at least 90% homologous to MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVE corresponding to amino acids 1-40 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 91-130 of T59832_P12 (SEQ ID NO:146), third amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNG corresponding to amino acids 72-122 of BAC85622 (SEQ ID NO:849), which also corresponds to amino acids 131-181 of T59832_P12 (SEQ ID NO:146), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK (SEQ ID NO:1016) corresponding to amino acids 182-219 of T59832_P12 (SEQ ID NO:146), wherein said first, second, third and fourth amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of T59832_P12 (SEQ ID NO:146), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA	(SEQ ID NO: 1012)
PLVNVTLYYEALCGGCRAFLIRELFPTWLLV

of T59832_P12.	(SEQ ID NO: 146)

3. An isolated chimeric polypeptide encoding for an edge portion of T59832_P12 (SEQ ID NO:146), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EC, having a structure as follows: a sequence starting from any of amino acid numbers 130-x to 130; and ending at any of amino acid numbers 131+((n−2)−x), in which x varies from 0 to n−2.

4. An isolated polypeptide encoding for a tail of T59832_P12 (SEQ ID NO:146), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK (SEQ ID NO:1016) in T59832_P12 (SEQ ID NO:146).

Comparison report between T59832_P12 (SEQ ID NO:146) and Q8WU77 (SEQ ID NO:850):

1. An isolated chimeric polypeptide encoding for T59832_P12 (SEQ ID NO:146), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYLRGPLKKSNA PLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVPYGNAQEQNVSGRWEFKC QHGEEECKFNKVE corresponding to amino acids 1-130 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-130 of T59832_P12 (SEQ ID NO:146), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 131-219 of T59832_P12 (SEQ ID NO:146), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T59832_P12 (SEQ ID NO:146) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 12, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P12 (SEQ ID NO:146) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

137	P -> Q	No
139	L ->	No
76	R -> Q	Yes
77	A -> T	No
139	L -> V	No
149	M -> V	Yes
183	P ->	No
183	P -> T	No
200	G -> A	No
200	G -> D	No
212	S ->	No
212	S -> F	No

Variant protein T59832_P12 (SEQ ID NO:146) is encoded by the following transcript(s): T59832_T15 (SEQ ID NO:104), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T59832_T15 (SEQ ID NO:104) is shown in bold; this coding portion starts at position 149 and ends at position 805. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P12 (SEQ ID NO:146) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

61	C -> T	Yes
148	G -> T	Yes
563	C -> G	No
593	A -> G	Yes
658	A -> G	Yes
695	C ->	No
695	C -> A	No
712	C -> T	Yes
727	T -> G	No
747	G -> A	No
747	G -> C	No
783	C ->	No
212	-> A	No
783	C -> T	No
812	C ->	No
827	G -> A	No
842	G -> T	Yes
849	A ->	No
871	-> T	No
872	C -> T	No
891	C ->	No
897	A -> G	Yes
909	G -> A	Yes
241	G -> T	No
952	A -> C	Yes
977	A -> C	Yes
985	T -> C	Yes
244	A -> G	Yes
375	G -> A	Yes
377	G -> A	No
439	G -> C	Yes
558	C -> A	No
563	C ->	No

Variant protein T59832_P18 (SEQ ID NO:147) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T59832_T22 (SEQ ID NO:105). An alignment is given to the known protein (Gamma-interferon inducible lysosomal thiol reductase precursor (SEQ ID NO:142)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T59832_P18 (SEQ ID NO:147) and GILT_HUMAN (SEQ ID NO:142):

1. An isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 12-55 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 173-261 of GILT_HUMAN (SEQ ID NO:142), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of T59832_P18 (SEQ ID NO:147), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KC, having a structure as follows: a sequence starting from any of amino acid numbers 44-x to 44; and ending at any of amino acid numbers 45+((n−2)−x), in which x varies from 0 to n−2.

Comparison report between T59832_P18 (SEQ ID NO:147) and Q8WU77 (SEQ ID NO:850):

1. An isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 1-44 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8WU77 (SEQ ID NO:850), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between T59832_P18 (SEQ ID NO:147) and Q8NE14 (SEQ ID NO:851):

1. An isolated chimeric polypeptide encoding for T59832_P18 (SEQ ID NO:147), comprising a first amino acid sequence being at least 90% homologous to MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK corresponding to amino acids 1-44 of Q8NE14 (SEQ ID NO:851), which also corresponds to amino acids 1-44 of T59832_P18 (SEQ ID NO:147), and a second amino acid sequence being at least 90% homologous to CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQPPHEYVPWVTVNGKPLED QTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK corresponding to amino acids 162-250 of Q8NE14 (SEQ ID NO:851), which also corresponds to amino acids 45-133 of T59832_P18 (SEQ ID NO:147), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein T59832_P18 (SEQ ID NO:147) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P18 (SEQ ID NO:147) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

114	G -> A	No
114	G -> D	No
126	S ->	No
126	S -> F	No
51	P -> Q	No
53	L ->	No
53	L -> V	No
63	M -> V	Yes
97	P ->	No
97	P -> T	No

Variant protein T59832_P18 (SEQ ID NO:147) is encoded by the following transcript(s): T59832_T22 (SEQ ID NO:105), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T59832_T22 (SEQ ID NO:105) is shown in bold; this coding portion starts at position 149 and ends at position 547. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T59832_P18 (SEQ ID NO:147) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

61	C -> T	Yes
148	G -> T	Yes
437	C ->	No
437	C -> A	No
454	C -> T	Yes
469	T -> G	No
489	G -> A	No
489	G -> C	No
525	C ->	No
525	C -> T	No
554	C ->	No
569	G -> A	No
212	-> A	No
584	G -> T	Yes
591	A ->	No
613	-> T	No
614	C -> T	No
633	C ->	No
639	A -> G	Yes
651	G -> A	Yes
694	A -> C	Yes
719	A -> C	Yes
727	T -> C	Yes
241	G -> T	No
244	A -> G	Yes
300	C -> A	No
305	C ->	No
305	C -> G	No
335	A -> G	Yes
400	A -> G	Yes

As noted above, cluster T59832 features 33 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T59832_node_—1 (SEQ ID NO:109) according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	1	123
NO: 103)
T59832_T15 (SEQ ID	1	123
NO: 104)
T59832_T22 (SEQ ID	1	123
NO: 105)
T59832_T6 (SEQ ID NO: 107)	1	123
T59832_T8 (SEQ ID NO: 108)	1	123

Segment cluster T59832_node_—22 (SEQ ID NO:110) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T28 (SEQ ID NO:106). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T28 (SEQ ID	1	523
NO: 106)

Segment cluster T59832_node_—23 (SEQ ID NO:111) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T28 (SEQ ID NO:106). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T28 (SEQ ID	524	652
NO: 106)

Segment cluster T59832_node_—24 (SEQ ID NO:112) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T28 (SEQ ID NO:106). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T28 (SEQ ID	653	901
NO: 106)

Segment cluster T59832_node_—29 (SEQ ID NO:113) according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T28 (SEQ ID NO:106) and T59832_T8 (SEQ ID NO:108). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T28 (SEQ ID	1055	1472
NO: 106)
T59832_T8 (SEQ ID NO: 108)	785	1202

Segment cluster T59832_node_—39 (SEQ ID NO:114) according to the present invention is supported by 195 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	1031	1084
NO: 103)
T59832_T15 (SEQ ID	966	1019
NO: 104)
T59832_T22 (SEQ ID	708	761
NO: 105)
T59832_T28 (SEQ ID	1747	1800
NO: 106)
T59832_T6 (SEQ ID NO: 107)	2125	2178
T59832_T8 (SEQ ID NO: 108)	1477	1530

Segment cluster T59832_node_—7 (SEQ ID NO:115) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T6 (SEQ ID NO:107). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T6 (SEQ ID NO: 107)	281	1346

Segment cluster T59832_node_—10 (SEQ ID NO:116) according to the present invention is supported by 332 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	338	382
NO: 103)
T59832_T15 (SEQ ID	338	382
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1404	1448
T59832_T8 (SEQ ID NO: 108)	338	382

Segment cluster T59832_node_—11 (SEQ ID NO:117) according to the present invention is supported by 306 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	383	417
NO: 103)
T59832_T15 (SEQ ID	383	417
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1449	1483
T59832_T8 (SEQ ID NO: 108)	383	417

Segment cluster T59832_node_—12 (SEQ ID NO:118) according to the present invention is supported by 280 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	418	463
NO: 103)
T59832_T15 (SEQ ID	418	463
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1484	1529
T59832_T8 (SEQ ID NO: 108)	418	463

Segment cluster T59832_node_—14 (SEQ ID NO:119) according to the present invention is supported by 280 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	464	502
NO: 103)
T59832_T15 (SEQ ID	464	502
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1530	1568
T59832_T8 (SEQ ID NO: 108)	464	502

Segment cluster T59832_node_—16 (SEQ ID NO:120) according to the present invention is supported by 287 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	503	538
NO: 103)
T59832_T15 (SEQ ID	503	538
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1569	1604
T59832_T8 (SEQ ID NO: 108)	503	538

Segment cluster T59832_node_—19 (SEQ ID NO:121) according to the present invention is supported by 300 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	539	577
NO: 103)
T59832_T6 (SEQ ID NO: 107)	1605	1643
T59832_T8 (SEQ ID NO: 108)	539	577

Segment cluster T59832_node_—2 (SEQ ID NO:122) according to the present invention is supported by 258 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	124	154
NO: 103)
T59832_T15 (SEQ ID	124	154
NO: 104)
T59832_T22 (SEQ ID	124	154
NO: 105)
T59832_T6 (SEQ ID NO: 107)	124	154
T59832_T8 (SEQ ID NO: 108)	124	154

Segment cluster T59832_node_—20 (SEQ ID NO:123) according to the present invention is supported by 318 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	578	631
NO: 103)
T59832_T6 (SEQ ID NO: 107)	1644	1697
T59832_T8 (SEQ ID NO: 108)	578	631

Segment cluster T59832_node_—25 (SEQ ID NO:124) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	632	653
NO: 103)
T59832_T15 (SEQ ID	539	560
NO: 104)
T59832_T22 (SEQ ID	281	302
NO: 105)
T59832_T28 (SEQ ID	902	923
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1698	1719
T59832_T8 (SEQ ID NO: 108)	632	653

Segment cluster T59832_node_—26 (SEQ ID NO:125) according to the present invention is supported by 342 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	654	717
NO: 103)
T59832_T15 (SEQ ID	561	624
NO: 104)
T59832_T22 (SEQ ID	303	366
NO: 105)
T59832_T28 (SEQ ID	924	987
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1720	1783
T59832_T8 (SEQ ID NO: 108)	654	717

Segment cluster T59832_node_—27 (SEQ ID NO:126) according to the present invention is supported by 314 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	718	756
NO: 103)
T59832_T15 (SEQ ID	625	663
NO: 104)
T59832_T22 (SEQ ID	367	405
NO: 105)
T59832_T28 (SEQ ID	988	1026
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1784	1822
T59832_T8 (SEQ ID NO: 108)	718	756

Segment cluster T59832_node_—28 (SEQ ID NO:127) according to the present invention is supported by 284 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T15 (SEQ ID	664	691
NO: 104)
T59832_T22 (SEQ ID	406	433
NO: 105)
T59832_T28 (SEQ ID	1027	1054
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1823	1850
T59832_T8 (SEQ ID NO: 108)	757	784

Segment cluster T59832_node_—3 (SEQ ID NO:128) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	155	172
NO: 103)
T59832_T15 (SEQ ID	155	172
NO: 104)
T59832_T22 (SEQ ID	155	172
NO: 105)
T59832_T6 (SEQ ID NO: 107)	155	172
T59832_T8 (SEQ ID NO: 108)	155	172

Segment cluster T59832_node_—30 (SEQ ID NO:129) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	757	760
NO: 103)
T59832_T15 (SEQ ID	692	695
NO: 104)
T59832_T22 (SEQ ID	434	437
NO: 105)
T59832_T28 (SEQ ID	1473	1476
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1851	1854
T59832_T8 (SEQ ID NO: 108)	1203	1206

Segment cluster T59832_node_—31 (SEQ ID NO:130) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	761	780
NO: 103)
T59832_T15 (SEQ ID	696	715
NO: 104)
T59832_T22 (SEQ ID	438	457
NO: 105)
T59832_T28 (SEQ ID	1477	1496
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1855	1874
T59832_T8 (SEQ ID NO: 108)	1207	1226

Segment cluster T59832_node_—32 (SEQ ID NO:131) according to the present invention is supported by 287 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	781	810
NO: 103)
T59832_T15 (SEQ ID	716	745
NO: 104)
T59832_T22 (SEQ ID	458	487
NO: 105)
T59832_T28 (SEQ ID	1497	1526
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1875	1904
T59832_T8 (SEQ ID NO: 108)	1227	1256

Segment cluster T59832_node_—34 (SEQ ID NO:132) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	811	832
NO: 103)
T59832_T15 (SEQ ID	746	767
NO: 104)
T59832_T22 (SEQ ID	488	509
NO: 105)
T59832_T28 (SEQ ID	1527	1548
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1905	1926
T59832_T8 (SEQ ID NO: 108)	1257	1278

Segment cluster T59832_node_—35 (SEQ ID NO:133) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	833	836
NO: 103)
T59832_T15 (SEQ ID	768	771
NO: 104)
T59832_T22 (SEQ ID	510	513
NO: 105)
T59832_T28 (SEQ ID	1549	1552
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1927	1930
T59832_T8 (SEQ ID NO: 108)	1279	1282

Segment cluster T59832_node_—36 (SEQ ID NO:134) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	837	845
NO: 103)
T59832_T15 (SEQ ID	772	780
NO: 104)
T59832_T22 (SEQ ID	514	522
NO: 105)
T59832_T28 (SEQ ID	1553	1561
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1931	1939
T59832_T8 (SEQ ID NO: 108)	1283	1291

Segment cluster T59832_node_—37 (SEQ ID NO:135) according to the present invention is supported by 300 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	846	945
NO: 103)
T59832_T15 (SEQ ID	781	880
NO: 104)
T59832_T22 (SEQ ID	523	622
NO: 105)
T59832_T28 (SEQ ID	1562	1661
NO: 106)
T59832_T6 (SEQ ID NO: 107)	1940	2039
T59832_T8 (SEQ ID NO: 108)	1292	1391

Segment cluster T59832_node_—38 (SEQ ID NO:136) according to the present invention is supported by 247 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T28 (SEQ ID NO:106), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 43 below describes the starting and ending position of this segment on each transcript.

TABLE 43


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	946	1030
NO: 103)
T59832_T15 (SEQ ID	881	965
NO: 104)
T59832_T22 (SEQ ID	623	707
NO: 105)
T59832_T28 (SEQ ID	1662	1746
NO: 106)
T59832_T6 (SEQ ID NO: 107)	2040	2124
T59832_T8 (SEQ ID NO: 108)	1392	1476

Segment cluster T59832_node_—4 (SEQ ID NO:137) according to the present invention is supported by 296 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 44 below describes the starting and ending position of this segment on each transcript.

TABLE 44


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	173	223
NO: 103)
T59832_T15 (SEQ ID	173	223
NO: 104)
T59832_T22 (SEQ ID	173	223
NO: 105)
T59832_T6 (SEQ ID NO: 107)	173	223
T59832_T8 (SEQ ID NO: 108)	173	223

Segment cluster T59832_node_—5 (SEQ ID NO:138) according to the present invention is supported by 305 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 45 below describes the starting and ending position of this segment on each transcript.

TABLE 45


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	224	259
NO: 103)
T59832_T15 (SEQ ID	224	259
NO: 104)
T59832_T22 (SEQ ID	224	259
NO: 105)
T59832_T6 (SEQ ID NO: 107)	224	259
T59832_T8 (SEQ ID NO: 108)	224	259

Segment cluster T59832_node_—6 (SEQ ID NO:139) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T22 (SEQ ID NO:105), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 46 below describes the starting and ending position of this segment on each transcript.

TABLE 46


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	260	280
NO: 103)
T59832_T15 (SEQ ID	260	280
NO: 104)
T59832_T22 (SEQ ID	260	280
NO: 105)
T59832_T6 (SEQ ID NO: 107)	260	280
T59832_T8 (SEQ ID NO: 108)	260	280

Segment cluster T59832_node_—8 (SEQ ID NO:140) according to the present invention can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 47 below describes the starting and ending position of this segment on each transcript.

TABLE 47


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	281	301
NO: 103)
T59832_T15 (SEQ ID	281	301
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1347	1367
T59832_T8 (SEQ ID NO: 108)	281	301

Segment cluster T59832_node_—9 (SEQ ID NO:141) according to the present invention is supported by 330 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T59832_T11 (SEQ ID NO:103), T59832_T15 (SEQ ID NO:104), T59832_T6 (SEQ ID NO:107) and T59832_T8 (SEQ ID NO:108). Table 48 below describes the starting and ending position of this segment on each transcript.

TABLE 48


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T59832_T11 (SEQ ID	302	337
NO: 103)
T59832_T15 (SEQ ID	302	337
NO: 104)
T59832_T6 (SEQ ID NO: 107)	1368	1403
T59832_T8 (SEQ ID NO: 108)	302	337

Variant protein alignment to the previously known protein:

Sequence name: /tmp/YQPBtaxsLQ/JxSZR3ZR2p:GILT_HUMAN (SEQ ID NO:142)

Sequence documentation:

Alignment of: T59832_P5 (SEQ ID NO:143)×GILT_HUMAN (SEQ ID NO:142).

Alignment segment 1/1:



Quality:	429.00
Escore:	0
Matching length:	46	Total length:	46
Matching Percent	97.83	Matching Percent Identity:	97.83
Similarity:
Total Percent Similarity:	97.83	Total Percent Identity:	97.83
Gaps:	0

Alignment:


	. . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKVG	46
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|
12	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTG	57

Sequence name: /tmp/9HrQ57oZG0/ugNVzp0l7X:GILT_HUMAN (SEQ ID NO:142)

Sequence documentation:

Alignment of: T59832_P7 (SEQ ID NO:144)×GILT_HUMAN (SEQ ID NO:142).

Alignment segment 1/1:



Quality:	2110.00
Escore:	0
Matching length:	212	Total length:	212
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
12	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	61

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
62	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	111

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
112	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	161

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
162	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	211

	.
201	PHEYVPWVTVNG	212
	\|\|\|\|\|\|\|\|\|\|\|\|
212	PHEYVPWVTVNG	223

Sequence name: /tmp/9HrQ57oZG0/ugNVzp0l7X:BAC98466 (SEQ ID NO:848)

Sequence documentation:

Alignment of: T59832_P7 (SEQ ID NO:144)×BAC98466 (SEQ ID NO:848).

Alignment segment 1/1:



Quality:	2110.00
Escore:	0
Matching length:	212	Total length:	212
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

	.
201	PHEYVPWVTVNG	212
	\|\|\|\|\|\|\|\|\|\|\|\|
201	PHEYVPWVTVNG	212

Sequence name: /tmp/9HrQ57oZG0/ugNVzp0l7X:BAC85622 (SEQ ID NO:849)

Sequence documentation:

Alignment of: T59832_P7 (SEQ ID NO:144)×BAC85622 (SEQ ID NO:849).

Alignment segment 1/1:



Quality:	1496.00
Escore:	0
Matching length:	148	Total length:	148
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
91	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDME	140
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDME	50

	. . . . .
141	LAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHA	190
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	LAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHA	100

	. . . .
191	NAQRTDALQPPHEYVPWVTVNGVRIFLALSLTLIVPWSQGWTRQRDQR	238
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	NAQRTDALQPPHEYVPWVTVNGVRIFLALSLTLIVPWSQGWTRQRDQR	148

Sequence name: /tmp/9HrQ57oZG0/ugNVzp0l7X:Q8WU77 (SEQ ID NO:850)

Sequence documentation:

Alignment of: T59832_P7 (SEQ ID NO:144)×Q8WU77 (SEQ ID NO:850).

Alignment segment 1/1:



Quality:	2110.00
Escore:	0
Matching length:	212	Total length:	212
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps: 0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

	.
201	PHEYVPWVTVNG	212
	\|\|\|\|\|\|\|\|\|\|\|\|
201	PHEYVPWVTVNG	212

Sequence name: /tmp/lttCiW30od/feIXLDs4rU:GILT_HUMAN (SEQ ID NO:142)

Sequence documentation:

Alignment of: T59832_P9 (SEQ ID NO:145)×GILT_HUMAN (SEQ ID NO:142).

Alignment segment 1/1:



Quality:	2016.00
Escore:	0
Matching length:	203	Total length:	203
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDEFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
12	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	61

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
62	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	111

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
112	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	161

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
162	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	211

201	PHE	203
	\|\|\|
212	PHE	214

Sequence name: /tmp/lttCiW30od/feIXLDs4rU:BAC98466 (SEQ ID NO:848)

Sequence documentation:

Alignment of: T59832_P9 (SEQ ID NO:145)×BAC98466 (SEQ ID NO:848).

Alignment segment 1/1:



Quality:	2016.00
Escore:	0
Matching length:	203	Total length:	203
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

201	PHE	203
	\|\|\|
201	PHE	203

Sequence name: /tmp/lttCiW30od/feIXLDs4rU:BAC85622 (SEQ ID NO:849)

Sequence documentation:

Alignment of: T59832_P9 (SEQ ID NO:145)×BAC85622 (SEQ ID NO:849).

Alignment segment 1/1:



Quality:	1145.00
Escore:	0
Matching length:	113	Total length:	113
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
91	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKENKVEACVLDELDME	140
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDME	50

	. . . . .
141	LAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHA	190
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	LAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHA	100

	.
191	NAQRTDALQPPHE	203
	\|\|\|\|\|\|\|\|\|\|\|\|\|
101	NAQRTDALQPPHE	113

Sequence name: /tmp/lttCiW30od/feIXLDs4rU:Q8WU77 (SEQ ID NO:850)

Sequence documentation:

Alignment of: T59832_P9 (SEQ ID NO:145)×Q8WU77 (SEQ ID NO:850).

Alignment segment 1/1:



Quality:	2016.00
Escore:	0
Matching length:	203	Total length:	203
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

201	PHE	203
	\|\|\|
201	PHE	203

Sequence name: /tmp/sIHTwdduiK/ToMKmEJiZc:GILT_HUMAN (SEQ ID NO:142)

Sequence documentation:

Alignment of: T59832_P12 (SEQ ID NO:146)×GILT_HUMAN (SEQ ID NO:142).

Alignment segment 1/1:



Quality:	2084.00
Escore:	0
Matching length:	219	Total length:	250
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	87.60	Total Percent Identity:	87.60
Gaps:	1

Alignment:


1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
12	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	61

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
62	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	111

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVE....................	130
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
112	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	161

	. . . . .
131	...........CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	169
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
162	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	211

	. . . . .
170	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	219
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
212	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	261

Sequence name: /tmp/sIHTwdduiK/ToMKmEJiZc:BAC85622 (SEQ ID NO:849)

Sequence documentation:

Alignment of: T59832_P12 (SEQ ID NO:146)×BAC85622 (SEQ ID NO:849).

Alignment segment 1/1:



Quality:	835.00
Escore:	0
Matching length:	91	Total length:	122
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	74.59	Total Percent Identity:	74.59
Gaps:	1

Alignment:


	. . . . .
91	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVE..........	130
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEILNVTLVPYGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDME	50

	. . . . .
131	.....................CLQLYAPGLSPDTIMECAMGDRGMQLMHA	159
\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	LAFLTIVCMEEFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHA	100

	. .
160	NAQRTDALQPPHEYVPWVTVNG	181
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	NAQRTDALQPPHEYVPWVTVNG	122

Sequence name: /tmp/sIHTwdduiK/ToMKmEJiZc:Q8WU77 (SEQ ID NO:850)

Sequence documentation:

Alignment of: T59832_P12 (SEQ ID NO:146)×Q8WU77 (SEQ ID NO:850).

Alignment segment 1/1:



Quality:	2084.00
Escore:	0
Matching length:	219	Total length:	250
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	87.60	Total Percent Identity:	87.60
Gaps:	1

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVE....................	130
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
131	...........CLQLYAPGLSPDTIMECAMGDRCMQLMHANAQRTDALQP	169
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

	. . . . .
170	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	219
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	250

Sequence name: /tmp/LH4xf8J65f/a95JQoTfNB:GILT_HUMAN (SEQ ID NO:142)

Sequence documentation:

Alignment of: T59832_P18 (SEQ ID NO:147)×GILT_HUMAN (SEQ ID NO:142).

Alignment segment 1/1:



Quality:	1222.00
Escore:	0
Matching length:	133	Total length:	250
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	53.20	Total Percent Identity:	53.20
Gaps:	1

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK......	44
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
12	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	61

	. . . . .
44	..................................................	44

62	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	111

	. . . . .
44	..................................................	44

112	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	161

	. . . . .
45	...........CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
162	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	211

	. . . . .
84	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	133
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
212	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	261

Sequence name: /tmp/LH4xf8J65f/a95JQoTfNB:Q8WU77 (SEQ ID NO:850)

Sequence documentation:

Alignment of: T59832_P18 (SEQ ID NO:147)×Q8WU77 (SEQ ID NO:850).

Alignment segment 1/1:



Quality:	1222.00
Escore:	0
Matching length:	133	Total length:	250
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	53.20	Total Percent Identity:	53.20
Gaps:	1

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK......	44
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
44	..................................................	44

51	RGPLKKSNAPLVNVTLYYEALCGGCRAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
44	..................................................	44

101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
45	...........CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

	. . . . .
84	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	133
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	250

Sequence name: /tmp/LH4xf8J65f/a95JQoTfNB:Q8NEI4 (SEQ ID NO:851)

Sequence documentation:

Alignment of: T59832_P18 (SEQ ID NO:147)×Q8NEI4 (SEQ ID NO:851).

Alignment segment 1/1:



Quality:	1222.00
Escore:	0
Matching length:	133	Total length:	250
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	53.20	Total Percent Identity:	53.20
Gaps:	1

Alignment:


	. . . . .
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYK......	44
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTLSPLLLFLPPLLLLLDVPTAAVQASPLQALDFFGNGPPVNYKTGNLYL	50

	. . . . .
44	..................................................	44

51	RGPLKKSNAPLVNVTLYYEALCGGCQAFLIRELFPTWLLVMEILNVTLVP	100

	. . . . .
44	..................................................	44

101	YGNAQEQNVSGRWEFKCQHGEEECKFNKVEACVLDELDMELAFLTIVCME	150

	. . . . .
45	...........CLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	EFEDMERSLPLCLQLYAPGLSPDTIMECAMGDRGMQLMHANAQRTDALQP	200

	. . . . .
84	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	133
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	PHEYVPWVTVNGKPLEDQTQLLTLVCQLYQGKKPDVCPSSTSSLRSVCFK	250

Expression of Gamma-Interferon Inducible Lysosomal Thiol Reductase (GILT) T59832 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T59832junc6-25-26 (SEQ ID NO:854) in Normal and Cancerous Breast Tissues

Expression of gamma-interferon inducible lysosomal thiol reductase (GILT) transcripts detectable by or according to junc6-25-26, T59832junc6-25-26 (SEQ ID NO:854) amplicon and primers T59832junc6-25-26F (SEQ ID NO:852) T59832junc6-25-26R (SEQ ID NO:853) was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO :925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)), was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1 above, “Tissue samples in testing panel”, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 18 is a histogram showing over expression of the above-indicated gamma-interferon inducible lysosomal thiol reductase (GILT) transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 18, the expression of gamma-interferon inducible lysosomal thiol reductase (GILT) transcripts detectable by the above amplicon(s) in cancer samples was higher in a few samples than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 1 above, “Tissue samples in testing panel”). Notably an over-expression of at least 7 fold was found in 3 out of 28 adenocarcinoma samples.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: T59832junc6-25-26F forward primer (SEQ ID NO:852); and T59832junc6-25-26R reverse primer (SEQ ID NO:853).


Forward primer T59832junc6-25-26F:	(SEQ ID NO: 852)
CCACCAGTTAACTACAAGTGCCTG

Reverse primer T59832junc6-25-26R:	(SEQ ID NO: 853)
GCGTGCATGAGCTGCATG

Amplicon T59832junc6-25-26:	(SEQ ID NO: 854)

CCACCAGTTAACTACAAGTGCCTGCAGCTCTACGCCCCAGGGCTGTCGCCAGACAC
TATCATGGAGTGTGCAATGGGGGACCGCGGCATGCAGCTCATGCACGC

Description for Cluster HUMGRP5E

Cluster HUMGRP5E features 2 transcript(s) and 5 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HUMGRP5E_T4	148
	HUMGRP5E_T5	149

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HUMGRP5E_node_0	150
	HUMGRP5E_node_2	151
	HUMGRP5E_node_8	152
	HUMGRP5E_node_3	153
	HUMGRP5E_node_7	154

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	HUMGRP5E_P4	156
	HUMGRP5E_P5	157

These sequences are variants of the known protein Gastrin-releasing peptide precursor (SEQ ID NO: 155) (SwissProt accession identifier GRP_HUMAN; known also according to the synonyms GRP; GRP-10), SEQ ID NO: 155, referred to herein as the previously known protein.

Gastrin-releasing peptide is known or believed to have the following function(s): stimulates gastrin release as well as other gastrointestinal hormones. The sequence for protein Gastrin-releasing peptide precursor (SEQ ID NO:155) is given at the end of the application, as “Gastrin-releasing peptide precursor (SEQ ID NO:155) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

4	S -> R

Protein Gastrin-releasing peptide localization is believed to be Secreted.

The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Diabetes, Type II. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Bombesin antagonist; Insulinotropin agonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anorectic/Antiobesity; Releasing hormone; Anticancer; Respiratory; Antidiabetic.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: signal transduction; neuropeptide signaling pathway, which are annotation(s) related to Biological Process; growth factor, which are annotation(s) related to Molecular Function; and secreted, which are annotation(s) related to Cellular Component.

As noted above, cluster HUMGRP5E features 2 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Gastrin-releasing peptide precursor (SEQ ID NO:155). A description of each variant protein according to the present invention is now provided.

Variant protein HUMGRP5E_P4 (SEQ ID NO:156) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMGRP5E_T4 (SEQ ID NO:148). An alignment is given to the known protein (Gastrin-releasing peptide precursor (SEQ ID NO:155) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMGRP5E_P4 (SEQ ID NO:156) and GRP_HUMAN (SEQ ID NO:155):

1.An isolated chimeric polypeptide encoding for HUMGRP5E_P4 (SEQ ID NO:156), comprising a first amino acid sequence being at least 90% homologous to MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK corresponding to amino acids 1-127 of GRP_HUMAN (SEQ ID NO:155), which also corresponds to amino acids 1-127 of HUMGRP5E_P4 (SEQ ID NO:156), and a second amino acid sequence being at least 90% homologous to GSQREGRNPQLNQQ corresponding to amino acids 135-148 of GRP_HUMAN (SEQ ID NO:155), which also corresponds to amino acids 128-141 of HUMGRP5E_P4 (SEQ ID NO:156), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2.An isolated chimeric polypeptide encoding for an edge portion of HUMGRP5E_P4 (SEQ ID NO:156), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KG, having a structure as follows: a sequence starting from any of amino acid numbers 127-x to 127; and ending at any of amino acid numbers 128+((n−2)−x), in which x varies from 0 to n−2.

Variant protein HUMGRP5E_P4 (SEQ ID NO:156) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMGRP5E_P4 (SEQ ID NO:156) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 5


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	S -> R	Yes

Variant protein HUMGRP5E_P4 (SEQ ID NO:156) is encoded by the following transcript(s): HUMGRP5E_T4 (SEQ ID NO:148), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMGRP5E_T4 (SEQ ID NO:148) is shown in bold; this coding portion starts at position 622 and ends at position 1044. The transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMGRP5E_P4 (SEQ ID NO:156) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

541	-> T	No
542	G -> T	No
631	A -> C	Yes
672	G -> A	Yes
1340	C ->	No
1340	C -> A	No
1341	A ->	No
1341	A -> G	No

Variant protein HUMGRP5E_P5 (SEQ ID NO:157) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMGRP5E_T5 (SEQ ID NO:149). An alignment is given to the known protein (Gastrin-releasing peptide precursor (SEQ ID NO:155) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMGRP5E_P5 (SEQ ID NO:157) and GRP_HUMAN (SEQ ID NO:155):

1. An isolated chimeric polypeptide encoding for HUMGRP5E_P5 (SEQ ID NO:157), comprising a first amino acid sequence being at least 90% homologous to MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLMGKKSTG ESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSED SSNFKDVGSKGK corresponding to amino acids 1-127 of GRP_HUMAN (SEQ ID NO:155), which also corresponds to amino acids 1-127 of HUMGRP5E_P5 (SEQ ID NO:157), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DSLLQVLNVKEGTPS (SEQ ID NO:1017) corresponding to amino acids 128-142 of HUMGRP5E_P5 (SEQ ID NO:157), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HUMGRP5E_P5 (SEQ ID NO:157), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DSLLQVLNVKEGTPS (SEQ ID NO:1017) in HUMGRP5E_P5 (SEQ ID NO:157).

Variant protein HUMGRP5E_P5 (SEQ ID NO:157) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMGRP5E_P5 (SEQ ID NO:157) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	S -> R	Yes

Variant protein HUMGRP5E_P5 (SEQ ID NO:157) is encoded by the following transcript(s): HUMGRP5E_T5 (SEQ ID NO:149), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMGRP5E_T5 (SEQ ID NO:149) is shown in bold; this coding portion starts at position 622 and ends at position 1047. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMGRP5E_P5 (SEQ ID NO:157) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

541	-> T	No
542	G -> T	No
631	A -> C	Yes
672	G -> A	Yes
1354	C ->	No
1354	C -> A	No
1355	A ->	No
1355	A -> G	No

As noted above, cluster HUMGRP5E features 5 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HUMGRP5E_node_—0 (SEQ ID NO:150) according to the present invention is supported by 21 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMGRP5E_T4 (SEQ ID NO:148) and HUMGRP5E_T5 (SEQ ID NO:149). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

HUMGRP5E_T4	1	760
(SEQ ID NO: 148)

HUMGRP5E_T5	1	760
(SEQ ID NO: 149)

Segment cluster HUMGRP5E_node_—2 (SEQ ID NO:151) according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMGRP5E_T4 (SEQ ID NO:148) and HUMGRP5E_T5 (SEQ ID NO:149). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

HUMGRP5E_T4	761	984
(SEQ ID NO: 148)

HUMGRP5E_T5	761	984
(SEQ ID NO: 149)

Segment cluster HUMGRP5E_node_—8 (SEQ ID NO:152) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMGRP5E_T4 (SEQ ID NO:148) and HUMGRP5E_T5 (SEQ ID NO:149). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

HUMGRP5E_T4	1004	1362
(SEQ ID NO: 148)

HUMGRP5E_T5	1018	1376
(SEQ ID NO: 149)

Segment cluster HUMGRP5E_node_—3 (SEQ ID NO:153) according to the present invention can be found in the following transcript(s): HUMGRP5E_T4 (SEQ ID NO:148) and HUMGRP5E_T5 (SEQ ID NO:149). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

HUMGRP5E_T4	985	1003
(SEQ ID NO: 148)

HUMGRP5E_T5	985	1003
(SEQ ID NO: 149)

Segment cluster HUMGRP5E_node_—7 (SEQ ID NO:154) according to the present invention can be found in the following transcript(s): HUMGRP5E_T5 (SEQ ID NO:149). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segement	Segment
Transcript name	starting position	ending position

HUMGRP5E_T5	1004	1017

(SEQ ID NO:149)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/412zs2mwyT/B0wjOUAX0d:GRP_HUMAN (SEQ ID NO:155)

Sequence documentation:

Alignment of: HUMGRP5E_P4 (SEQ ID NO:156)×GRP_HUMAN (SEQ ID NO:155).

Alignment segment 1/1:



Quality:	1291.00
Escore:	0
Matching length:	141	Total length:	148
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	95.27	Total Percent Identity:	95.27
Gaps:	1

Alignment:


	. . . . .
1	MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLM	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLM	50
	. . . . .
51	GKKSTGESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQ	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	GKKSTGESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQ	100
	. . . .
101	PKALGNQQPSWDSEDSSNFKDVGSKGK.......GSQREGRNPQLNQQ	141
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	PKALGNQQPSWDSEDSSNFKDVGSKGKVGRLSAPGSQREGRNPQLNQQ	148

Sequence name: /tmp/1me9ldnvfv/KbP5io8PtU:GRP_HUMAN (SEQ ID NO:155)

Sequence documentation:

Alignment of: HUMGRP5E_P5 (SEQ ID NO:157)×GRP HUMAN (SEQ ID NO:155).

Alignment segment 1/1:



Quality:	1248.00
Escore:	0
Matching length:	127	Total length:	127
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLM	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRGSELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLM	50
	. . . . .
51	GKKSTGESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQ	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	GKKSTGESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQ	100
	. .
101	PKALGNQQPSWDSEDSSNFKDVGSKGK	127
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	PKALGNQQPSWDSEDSSNFKDVGSKGK	127

Expression of GRP_HUMAN-Gastrin-Releasing Peptide(HUMGRP5E) Transcripts, Which are Detectable by Amplicon, as Depicted in Sequence Name HUMGRP5Ejunc3-7 (SEQ ID NO:857) in Normal and Cancerous Breast Tissues

Expression of GRP_HUMAN-gastrin-releasing peptide transcripts detectable by or according to junc3-7, HUMGRP5Ejunc3-7 (SEQ ID NO:857) amplicon(s) and HUMGRP5Ejunc3-7F (SEQ ID NO:855) and HUMGRP5Ejunc3-7R (SEQ ID NO:856) primers was measured by real time PCR. In parallel the expression of four housekeeping genes PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), and SDHA (GenBank Accession No. NM_—004168. (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925 ), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67 Table 1, “Tissue samples in testing panel”), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 19 is a histogram showing over expression of the above-indicated GRP_HUMAN-gastrin-releasing peptide transcripts in cancerous breast samples relative to the normal samples. Values represent the average of duplicate experiments. Error bars indicate the minimal and maximal values obtained.

As is evident from FIG. 19, the expression of GRP_HUMAN-gastrin-releasing peptide transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 1 “Tissue samples in testing panel”). Notably an over-expression of at least 5 fold was found in 12 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of GRP_HUMAN-gastrin-releasing peptide transcripts detectable by the above amplicon(s) in breast cancer samples versus the normal tissue samples was determined by T test as 7.22E-04.

Threshold of 5 fold over expression was found to differentiate between cancer and normal samples with P value of 1.12E-02 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: HUMGRP5Ejunc3-7F forward primer (SEQ ID NO:855); and HUMGRP5Ejunc3-7R reverse primer (SEQ ID NO:856).


HUMGRP5Ejunc3-7.	(SEQ ID NO:857)

HUMGRP5Ejunc3-7F	(SEQ ID NO:855)
ACCAGCCACCTCAACCCA

HUMGRP5Ejunc3-7R	(SEQ ID NO:856)
CTGGAGCAGAGAGTCTTTGCCT

HUMGRP5Ejunc3-7	(SEQ ID NO:857)

ACCAGCCACCTCAACCCAAGGCCCTGGGCAATCAGCAGCCTTCGTGGGAT
TCAGAGGATAGCAGCAACTTCAAAGATGTAGGTTCAAAAGGCAAAGACTC
TCTGCTCCAG

Expression of GRP_HUMAN-Gastrin-Releasing Peptide (HUMGRP5E) Transcripts, Which are Detectable by Amplicon, as Depicted in Sequence Name HUMGRP5Ejunc3-7 (SEQ ID NO:857) in Different Normal Tissues

Expression of GRP_HUMAN-gastrin-releasing peptide transcripts detectable by or according to HUMGRP5E junc3-7 amplicon(s) and HUMGRP5E junc3-7F and HUMGRP5E junc3-7R was measured by real time PCR. In parallel the expression of four housekeeping genes—RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937 ), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the breast samples (Sample Nos. 33-35 above, Table 2, “Tissue samples in normal panel”), to obtain a value of relative expression of each sample relative to median of the breast samples. Primers and amplicon are as above.

The results are presented in FIG. 20, demonstrating the expression of GRP_HUMAN—gastrin-releasing peptide (HUMGRP5E) transcripts, which are detectable by amplicon, as depicted in sequence name HUMGRP5Ejunc3-7 (SEQ ID NO:857), in different normal tissues.

Description for Cluster AA155578

Cluster AA155578 features 4 transcript(s) and 15 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	AA155578_PEA_1_T10	158
	AA155578_PEA_1_T12	159
	AA155578_PEA_1_T13	160
	AA155578_PEA_1_T8	161

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	AA155578_PEA_1_node_11	162
	AA155578_PEA_1_node_12	163
	AA155578_PEA_1_node_14	164
	AA155578_PEA_1_node_19	165
	AA155578_PEA_1_node_21	166
	AA155578_PEA_1_node_23	167
	AA155578_PEA_1_node_24	168
	AA155578_PEA_1_node_25	169
	AA155578_PEA_1_node_4	170
	AA155578_PEA_1_node_7	171
	AA155578_PEA_1_node_15	172
	AA155578_PEA_1_node_18	173
	AA155578_PEA_1_node_22	174
	AA155578_PEA_1_node_6	175
	AA155578_PEA_1_node_8	176

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	AA155578_PEA_1_P4	178
	AA155578_PEA_1_P6	179
	AA155578_PEA_1_P8	180
	AA155578_PEA_1_P9	181

These sequences are variants of the known protein Kallikrein 10 precursor (SEQ ID NO:177) (SwissProt accession identifier KLKA_HUMAN; known also according to the synonyms EC 3.4.21.-; Protease serine-like 1; Normal epithelial cell-specific 1), SEQ ID NO: 177, referred to herein as the previously known protein.

Protein Kallikrein 10 precursor (SEQ ID NO:177) is known or believed to have the following function(s): Has a tumor-suppressor role for NES1 in breast and prostate cancer. The sequence for protein Kallikrein 10 precursor (SEQ ID NO:177) is given at the end of the application, as “Kallikrein 10 precursor (SEQ ID NO:177) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

50	A -> S
149	P -> L

Protein Kallikrein 10 precursor (SEQ ID NO:177) localization is believed to be Secreted (Probable).

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: proteolysis and peptidolysis, which are annotation(s) related to Biological Process; chymotrypsin; trypsin; serine-type peptidase; hydrolase, which are annotation(s) related to Molecular Function; and extracellular, which are annotation(s) related to Cellular Component.

Cluster AA155578 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 21 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 21 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Brain	0
	Colon	0
	epithelial	17
	general	5
	head and neck	0
	Lung	14
	Ovary	0
	pancreas	0
	prostate	4
	Skin	80
	stomach	0
	Uterus	45

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

Brain	1	3.7e−01	1	1.0	3.5e−02	5.1
Colon	6.3e−02	2.9e−02	2.4e−01	2.9	1.6e−01	3.2
epithelial	4.9e−03	2.0e−02	7.5e−04	2.1	2.3e−03	1.9
general	7.8e−07	7.2e−06	3.8e−10	4.8	2.6e−10	4.4
head and neck	1.0e−02	3.5e−02	4.6e−01	2.5	7.5e−01	1.4
Lung	8.5e−01	9.2e−01	1	0.5	1	0.5
Ovary	2.2e−01	1.6e−01	1.0e−02	3.3	1.8e−02	3.4
pancreas	3.3e−01	6.9e−02	3.2e−02	3.7	2.4e−04	10.0
prostate	8.3e−01	8.7e−01	6.7e−01	1.2	7.5e−01	1.1
Skin	6.0e−01	8.1e−01	3.2e−01	1.9	1	0.3
stomach	3.0e−01	2.7e−01	2.5e−01	3.0	1.6e−01	2.3
Uterus	1.8e−01	3.2e−01	5.6e−01	0.8	6.8e−01	0.8

As noted above, cluster AA155578 features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Kallikrein 10 precursor (SEQ ID NO:177). A description of each variant protein according to the present invention is now provided.

Variant protein AA155578_PEA_—1_P4 (SEQ ID NO:178) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) AA155578_PEA_—1_T10 (SEQ ID NO:158). An alignment is given to the known protein (Kallikrein 10 precursor (SEQ ID NO:177) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between AA155578_PEA_—1_P4 (SEQ ID NO:178) and KLKA_HUMAN (SEQ ID NO:177):

1. An isolated chimeric polypeptide encoding for AA155578_PEA_—1_P4 (SEQ ID NO:178), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAPCARGSQ PWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLLLLQGEQLRRTT RSVVHPKYHQGSGPILPRRTDEHDLMLLKLARP corresponding to amino acids 1-146 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-146 of AA155578_PEA_—1_P4 (SEQ ID NO:178), and a second amino acid sequence being at least 90% homologous to YNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGIL SWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN corresponding to amino acids 184-276 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 147-239 of AA155578_PEA_—1_P4 (SEQ ID NO:178), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of AA155578_PEA_—1_P4 (SEQ ID NO:178), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise PY, having a structure as follows: a sequence starting from any of amino acid numbers 146-x to 146; and ending at any of amino acid numbers 147+((n−2)−x), in which x varies from 0 to n−2.

Variant protein AA155578_PEA_—1_P4 (SEQ ID NO:178) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P4 (SEQ ID NO:178) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

123	Q -> R	No
145	R -> G	No
145	R -> M	Yes
168	Y ->	No
19	K ->	No
194	G ->	No
43	L -> S	No
50	A -> S	Yes
60	Q -> R	No

Variant protein AA155578_PEA_—1_P4 (SEQ ID NO:178) is encoded by the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript AA155578_PEA_—1_T10 SEQ ID NO:158) is shown in bold; this coding portion starts at position 148 and ends at position 864. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P4 (SEQ ID NO:178) sequence provides support for the deduced sequence variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

19	C -> G	Yes
88	G ->	No
570	A -> G	Yes
580	A -> G	No
581	G -> T	Yes
651	C ->	No
729	C ->	No
733	C -> T	No
875	G -> A	No
906	C -> A	No
907	C -> A	No
952	C -> A	No
204	G ->	No
953	C -> A	No
994	C -> A	Yes
1125	C -> T	Yes
1192	C -> T	Yes
1330	G ->	No
1330	G -> T	Yes
275	T -> C	No
295	G -> T	Yes
326	A -> G	No
444	C -> T	Yes
465	C -> A	Yes
483	G -> C	Yes
515	A -> G	No

Variant protein AA155578_PEA_—1_P6 (SEQ ID NO:179) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) AA155578_PEA_—1_T12 (SEQ ID NO:159). An alignment is given to the known protein (Kallikrein 10 precursor (SEQ ID NO:177) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between AA155578_PEA_—1_P6 (SEQ ID NO:179) and KLKA_HUMAN (SEQ ID NO:177):

1. An isolated chimeric polypeptide encoding for AA155578_PEA_—1_P6 (SEQ ID NO:179), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLW corresponding to amino acids 1-29 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-29 of AA155578_PEA_—1_P6 (SEQ ID NO:179), and a second amino acid sequence being at least 90% homologous to VKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQ GILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN corresponding to amino acids 182-276 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 30-124 of AA155578_PEA_—1_P6 (SEQ ID NO:179), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of AA155578_PEA_—1_P6 (SEQ ID NO:179), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise WV, having a structure as follows: a sequence starting from any of amino acid numbers 29-x to 29; and ending at any of amino acid numbers 30+((n−2)−x), in which x varies from 0 to n−2.

Variant protein AA155578_PEA_—1_P6 (SEQ ID NO:179) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P6 (SEQ ID NO:179) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

19	K ->	No
53	Y ->	No
79	G ->	No

Variant protein AA155578_PEA_—1_P6 (SEQ ID NO:179) is encoded by the following transcript(s): AA155578_PEA_—1_T12 (SEQ ID NO:159), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript AA155578_PEA_—1_T12 (SEQ ID NO:159) is shown in bold; this coding portion starts at position 148 and ends at position 519. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P6 (SEQ ID NO:179) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

19	C -> G	Yes
88	G ->	No
608	C -> A	No
649	C -> A	Yes
780	C -> T	Yes
847	C -> T	Yes
985	G ->	No
985	G -> T	Yes
204	G ->	No
306	C ->	No
384	C ->	No
388	C -> T	No
530	G -> A	No
561	C -> A	No
562	C -> A	No
607	C -> A	No

Variant protein AA155578_PEA_—1_P8 (SEQ ID NO:180) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) AA155578_PEA_—1_T8 (SEQ ID NO:161). An alignment is given to the known protein (Kallikrein 10 precursor (SEQ ID NO:177) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between AA155578_PEA_—1_P8 (SEQ ID NO:180) and KLKA_HUMAN (SEQ ID NO:177):

1. An isolated chimeric polypeptide encoding for AA155578_PEA_—1_P8 (SEQ ID NO:180), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLW corresponding to amino acids 1-29 of KLKA_HUMAN (SEQ ID NO:177 , which also corresponds to amino acids 1-29 of AA155578_PEA_—1_P8 (SEQ ID NO:180), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GHCGLE (SEQ ID NO:1018) corresponding to amino acids 30-35 of AA155578_PEA_—1_P8 (SEQ ID NO:180), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of AA155578_PEA_—1_P8 (SEQ ID NO:180), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GHCGLE (SEQ ID NO:1018) in AA155578_PEA_—1_P8 (SEQ ID NO:180).

Variant protein AA155578_PEA_—1_P8 (SEQ ID NO:180) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P8 (SEQ ID NO:180) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

19	K ->	No

Variant protein AA155578_PEA_—1_P8 (SEQ ID NO:180) is encoded by the following transcript(s): AA155578_PEA_—1_T8 (SEQ ID NO:161), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript AA155578_PEA_—1_T8 (SEQ ID NO:161) is shown in bold; this coding portion starts at position 285 and ends at position 389. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P8 (SEQ ID NO:180) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

341	G ->	No
400	C -> T	Yes
718	C ->	No
796	C ->	No
800	C -> T	No
942	G -> A	No
973	C -> A	No
974	C -> A	No
1019	C -> A	No
1020	C -> A	No
1061	C -> A	Yes
1192	C -> T	Yes
421	C -> A	Yes
1259	C -> T	Yes
1397	G ->	No
1397	G -> T	Yes
439	G -> C	Yes
471	A -> G	No
526	A -> G	Yes
536	A -> G	No
537	G -> T	Yes
549	C -> T	Yes
587	T -> C	No

Variant protein AA155578_PEA_—1_P9 (SEQ ID NO:181) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) AA155578_PEA_—1_T13 (SEQ ID NO:160). An alignment is given to the known protein (Kallikrein 10 precursor (SEQ ID NO:177)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between AA155578_PEA_—1_P9 (SEQ ID NO:181) and KLKA_HUMAN (SEQ ID NO:177):

1. An isolated chimeric polypeptide encoding for AA155578_PEA_—1_P9 (SEQ ID NO:181), comprising a first amino acid sequence being at least 90% homologous to MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAPCARGSQ PWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK corresponding to amino acids 1-90 of KLKA_HUMAN (SEQ ID NO:177), which also corresponds to amino acids 1-90 of AA155578_PEA_—1_P9 (SEQ ID NO:181).

Variant protein AA155578_PEA_—1_P9 (SEQ ID NO:181) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P9 (SEQ ID NO:181) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

19	K ->	No
43	L -> S	No
50	A -> S	Yes
60	Q -> R	No

Variant protein AA155578_PEA_—1_P9 (SEQ ID NO:181) is encoded by the following transcript(s): AA155578_PEA_—1_T13 (SEQ ID NO:160), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript AA155578_PEA_—1_T13 (SEQ ID NO:160) is shown in bold; this coding portion starts at position 148 and ends at position 417. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AA155578_PEA_—1_P9 (SEQ ID NO:181) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

19	C -> G	Yes
88	G ->	No
204	G ->	No
275	T -> C	No
295	G -> T	Yes
326	A -> G	No
559	G -> C	Yes
560	C -> G	Yes
582	A -> G	Yes
919	T -> A	Yes

As noted above, cluster AA155578 features 15 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster AA155578_PEA_—1_node_—11 (SEQ ID NO:162) according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158) and AA155578_PEA_—1_T13 (SEQ ID NO:160). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

AA155578_PEA_1_T10	236	416
(SEQ ID NO: 158)
AA155578_PEA_1_T13	236	416
(SEQ ID NO: 160)

Segment cluster AA155578_PEA_—1_node_—12 (SEQ ID NO:163) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T13 (SEQ ID NO:160). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

AA155578_PEA_1_T13	417	935
(SEQ ID NO: 160)

Segment cluster AA155578_PEA_—1_node_—14 (SEQ ID NO:164) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	417	585
(SEQ ID NO: 158)
AA155578_PEA_1_T8	373	541
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—19 (SEQ ID NO:165) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	586	714
(SEQ ID NO: 158)
AA155578_PEA_1_T12	241	369
(SEQ ID NO: 159)
AA155578_PEA_1_T8	653	781
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—21 (SEQ ID NO:166) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	715	863
(SEQ ID NO: 158)
AA155578_PEA_1_T12	370	518
(SEQ ID NO: 159)
AA155578_PEA_1_T8	782	930
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—23 (SEQ ID NO:167) according to the present invention is supported by 71 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	887	1063
(SEQ ID NO: 158)
AA155578_PEA_1_T12	542	718
(SEQ ID NO: 159)
AA155578_PEA_1_T8	954	1130
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—24 (SEQ ID NO:168) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	1064	1184
(SEQ ID NO: 158)
AA155578_PEA_1_T12	719	839
(SEQ ID NO: 159)
AA155578_PEA_1_T8	1131	1251
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—25 (SEQ ID NO:169) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	1185	1397
(SEQ ID NO: 158)
AA155578_PEA_1_T12	840	1052
(SEQ ID NO: 159)
AA155578_PEA_1_T8	1252	1464
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—4 (SEQ ID NO:170) according to the present invention is supported by 21 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T13 (SEQ ID NO:160). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	1	138
(SEQ ID NO: 158)
AA155578_PEA_1_T12	1	138
(SEQ ID NO: 159)
AA155578_PEA_1_T13	1	138
(SEQ ID NO: 160)

Segment cluster AA155578_PEA_—1_node_—7 (SEQ ID NO:171) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T8	92	275
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—15 (SEQ ID NO:172) according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T8	542	647
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—18 (SEQ ID NO:173) according to the present invention can be found in the following transcript(s): AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T12	236	240
(SEQ ID NO: 159)
AA155578_PEA_1_T8	648	652
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—22 (SEQ ID NO:174) according to the present invention can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	864	886
(SEQ ID NO: 158)
AA155578_PEA_1_T12	519	541
(SEQ ID NO: 159)
AA155578_PEA_1_T8	931	953
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—6 (SEQ ID NO:175) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T8	1	91
(SEQ ID NO: 161)

Segment cluster AA155578_PEA_—1_node_—8 (SEQ ID NO:176) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AA155578_PEA_—1_T10 (SEQ ID NO:158), AA155578_PEA_—1_T12 (SEQ ID NO:159), AA155578_PEA_—1_T13 (SEQ ID NO:160) and AA155578_PEA_—1_T8 (SEQ ID NO:161). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AA155578_PEA_1_T10	139	235
(SEQ ID NO: 158)
AA155578_PEA_1_T12	139	235
(SEQ ID NO: 159)
AA155578_PEA_1_T13	139	235
(SEQ ID NO: 160)
AA155578_PEA_1_T8	276	372
(SEQ ID NO: 161)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/4gXdRV0C1z/cQ4LqHmh5A:KLKA_HUMAN (SEQ ID NO:177)

Sequence documentation:

Alignment of: AA155578_PEA_—1_P4 (SEQ ID NO:178)×KLKA_HUMAN (SEQ ID NO:177).

Alignment segment 1/1:



Quality:	2283.00
Escore:	0
Matching length:	239	Total length:	276
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	86.59	Total Percent Identity:	86.59
Gaps:	1

Alignment:


	. . . . .
1	MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGA	50
	. . . . .
51	PCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDH	100
	. . . . .
101	LLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARP....	146
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	LLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVPG	150
	. . . . .
147	.................................YNKGLTCSSITILSPKE	163
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKE	200
	. . . . .
164	CEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPC	213
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	CEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPC	250
	. .
214	GSAQHPAVYTQICKYMSWINKVIRSN	239
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	GSAQHPAVYTQICKYMSWINKVIRSN	276

Sequence name: /tmp/3VxcRS97HN/X9ncdxjYQx:KLKA_HUMAN (SEQ ID NO:177)

Sequence documentation:

Alignment of: AA155578_PEA_—1_P6 (SEQ ID NO:179)×KLKA_HUMAN (SEQ ID NO:177).

Alignment segment 1/1:



Quality:	1140.00
Escore:	0
Matching length:	124	Total length:	276
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	44.93	Total Percent Identity:	44.93
Gaps:	1

Alignment:


	. . . . .
1	MRAPHLHLSAASGARALAKLLPLLMAQLW.....................	29
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGA	50
	. . . . .
29	..................................................	29

51	PCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDH	100
	. . . . .
29	..................................................	29

101	LLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVPG	150
	. . . . .
30	...............................VKYNKGLTCSSITILSPKE	48
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKE	200
	. . . . .
49	CEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPC	98
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	CEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPC	250
	. .
99	GSAQHPAVYTQICKYMSWINKVIRSN	124
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	GSAQHPAVYTQICKYMSWINKVIRSN	276

Sequence name: /tmp/LsSdTeu0qX/6luiCMKTi9:KLKA_HUMAN (SEQ ID NO:177)

Sequence documentation:

Alignment of: AA155578_PEA_—1_P8 (SEQ ID NO:180)×KLKA_HUMAN (SEQ ID NO:177).

Alignment segment 1/1:



Quality:	279.00
Escore:	0
Matching length:	29	Total length:	29
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. .
1	MRAPHLHLSAASGARALAKLLPLLMAQLW	29
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRAPHLHLSAASGARALAKLLPLLMAQLW	29

Sequence name: /tmp/kcfKGMcF7s/YnKnMy8D1q:KLKA_HUMAN (SEQ ID NO:177)

Sequence documentation:

Alignment of: AA155578_PEA_—1_P9 (SEQ ID NO:181)×KLKA_HUMAN (SEQ ID NO:177)

Alignment segment 1/1:



Quality:	887.00
Escore:	0
Matching length:	90	Total length:	90
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGA	50
	. . . .
51	PCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK	90
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNK	90

Description for Cluster HSENA78

Cluster HSENA78 features 1 transcript(s) and 7 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSENA78_T5	182

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSENA78_node_0	183
	HSENA78_node_2	184
	HSENA78_node_6	185
	HSENA78_node_9	186
	HSENA78_node_3	187
	HSENA78_node_4	188
	HSENA78_node_8	189

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	HSENA78_P2	191

These sequences are variants of the known protein Small inducible cytokine B5 precursor (SEQ ID NO:190) (SwissProt accession identifier SZ05_HUMAN; known also according to the synonyms CXCL5; Epithelial-derived neutrophil activating protein 78; Neutrophil-activating peptide ENA-78), SEQ ID NO: 190, referred to herein as the previously known protein.

Protein Small inducible cytokine B5 precursor (SEQ ID NO:190) is known or believed to have the following function(s): Involved in neutrophil activation. The sequence for protein Small inducible cytokine B5 precursor (SEQ ID NO:190) is given at the end of the application, as “Small inducible cytokine B5 precursor (SEQ ID NO:190) amino acid sequence”. Protein Small inducible cytokine B5 precursor (SEQ ID NO:190) localization is believed to be Secreted.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: chemotaxis; signal transduction; cell-cell signaling; positive control of cell proliferation, which are annotation(s) related to Biological Process; and chemokine, which are annotation(s) related to Molecular Function.

Cluster HSENA78 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 22 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 22 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors and lung malignant tumors.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	Colon	0
	epithelial	2
	general	38
	kidney	0
	Lung	3
	Breast	8
	Skin	0
	stomach	36
	Uterus	4

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

colon	2.6e−01	3.3e−01	1.7e−01	2.7	2.7e−01	2.2
epithelial	2.5e−01	9.0e−02	3.2e−03	4.1	8.5e−07	5.5
general	8.4e−01	7.2e−01	1	0.3	1	0.4
kidney	1	7.2e−01	1	1.0	1.7e−01	1.9
lung	8.5e−01	4.8e−01	4.1e−01	1.9	4.0e−05	3.8
breast	9.5e−01	8.7e−01	1	0.8	6.8e−01	1.2
skin	2.9e−01	4.7e−01	1.4e−01	7.0	6.4e−01	1.6
stomach	5.0e−01	4.3e−01	7.5e−01	1.0	4.3e−01	1.3
uterus	7.1e−01	8.5e−01	6.6e−01	1.3	8.0e−01	1.0

As noted above, cluster HSENA78 features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Small inducible cytokine B5 precursor (SEQ ID NO:190). A description of each variant protein according to the present invention is now provided.

Variant protein HSENA78_P2 (SEQ ID NO:191) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSENA78_T5 (SEQ ID NO:182). An alignment is given to the known protein (Small inducible cytokine B5 precursor (SEQ ID NO:190)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSENA78_P2 (SEQ ID NO:191) and SZ05_HUMAN (SEQ ID NO:190):

1. An isolated chimeric polypeptide encoding for HSENA78_P2 (SEQ ID NO:191), comprising a first amino acid sequence being at least 90% homologous to MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVLRELRCVCLQTTQGVHP KMISNLQVFAIGPQCSKVEVV corresponding to amino acids 1-81 of SZ05_HUMAN (SEQ ID NO:190), which also corresponds to amino acids 1-81 of HSENA78_P2 (SEQ ID NO:191).

Variant protein HSENA78_P2 (SEQ ID NO:191) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSENA78_P2 (SEQ ID NO:191) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Amino acid mutations

SNP position(s) on	Alternative	Previously known
amino acid sequence	amino acid(s)	SNP?

80	V ->	No
81	V ->	No

Variant protein HSENA78_P2 (SEQ ID NO:191) is encoded by the following transcript(s): HSENA78_T5 (SEQ ID NO:182), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSENA78_T5 (SEQ ID NO:182) is shown in bold; this coding portion starts at position 149 and ends at position 391. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSENA78_P2 (SEQ ID NO:191) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

92	C -> T	Yes
144	C -> T	No
1151	A -> T	Yes
1389	T -> C	No
1867	C -> G	Yes
145	C -> T	No
181	C -> T	Yes
316	G -> A	Yes
388	G ->	No
390	T ->	No
605	T ->	No
972	C -> T	Yes
1105	A -> G	Yes

As noted above, cluster HSENA78 features 7 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSENA78_node_—0 (SEQ ID NO:183) according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 8 below describes the starting and ending position of this segment on each transcript.

TABLE 8


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	1	257

(SEQ ID NO:182)

Segment cluster HSENA78_node_—2 (SEQ ID NO:184) according to the present invention is supported by 22 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	258	390

(SEQ ID NO:182)

Segment cluster HSENA78_node_—6 (SEQ ID NO:185) according to the present invention is supported by 68 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	585	2370

(SEQ ID NO:182)

Segment cluster HSENA78_node_—9 (SEQ ID NO:186) according to the present invention is supported by 28 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	2394	2546

(SEQ ID NO:182)

Segment cluster HSENA78_node_—3 (SEQ ID NO:187) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	391	500

(SEQ ID NO:182)

Segment cluster HSENA78_node_—4 (SEQ ID NO:188) according to the present invention is supported by 17 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	501	584

(SEQ ID NO:182)

Segment cluster HSENA78_node_—8 (SEQ ID NO:189) according to the present invention can be found in the following transcript(s): HSENA78_T5 (SEQ ID NO:182). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSENA78_T5	2371	2393

(SEQ ID NO:182)

Microarray (chip) data is also available for this gene as follows. As described above with regard to the cluster itself, various oligonucleotides were tested for being differentially expressed in various disease conditions, particularly cancer. The following oligonucleotides were found to hit this segment (in relation to breast cancer), shown in Table 15.

TABLE 15


Oligonucleotides related to this gene

	Overexpressed
Oligonucleotide name	in cancers	Chip reference

HSENA78_0_1_0	breast cancer	Breast

(SEQ ID NO:898)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/5kiQY6MxWx/pLnTrxsCqk:SZ05_HUMAN (SEQ ID NO:190)

Sequence documentation:

Alignment of: HSENA78_P2 (SEQ ID NO:191)×SZ05_HUMAN (SEQ ID NO:190).

Alignment segment 1/1:



Quality:	767.00
Escore:	0
Matching length:	81	Total length:	81
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVLRELRCV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVLRELRCV	50
	. . .
51	CLQTTQGVHPKMISNLQVFAIGPQCSKVEVV	81
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CLQTTQGVHPKMISNLQVFAIGPQCSKVEVV	81

Description for Cluster T94936

Cluster T94936 features 2 transcript(s) and 12 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	T94936_PEA_1_T1	192
	T94936_PEA_1_T2	193

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	T94936_PEA_1_node_14	194
	T94936_PEA_1_node_16	195
	T94936_PEA_1_node_2	196
	T94936_PEA_1_node_20	197
	T94936_PEA_1_node_23	198
	T94936_PEA_1_node_0	199
	T94936_PEA_1_node_11	200
	T94936_PEA_1_node_13	201
	T94936_PEA_1_node_17	202
	T94936_PEA_1_node_6	203
	T94936_PEA_1_node_8	204
	T94936_PEA_1_node_9	205

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	T94936_PEA_1_P2	206
	T94936_PEA_1_P3	207

As noted above, cluster T94936 features 2 transcript(s), which were listed in Table 1 above. A description of each variant protein according to the present invention is now provided.

Variant protein T94936_PEA_—1_P2 (SEQ ID NO:206) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T94936_PEA_—1_T1 (SEQ ID NO:192). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T94936_PEA_—1_P2 (SEQ ID NO:206) and Q8TD06 (SEQ ID NO:858) (SEQ ID NO:858):

1. An isolated chimeric polypeptide encoding for T94936_PEA_—1_P2 (SEQ ID NO:206), comprising a first amino acid sequence being at least 90% homologous to MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEEGLFYAQKS KKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNLMHETTDKNLSPDGQY VPRIMFVDPSLTVRADIAGRYSNRLYTYEPRDLPL corresponding to amino acids 1-150 of Q8TD06 (SEQ ID NO:858), which also corresponds to amino acids 1-150 of T94936_PEA_—1_P2 (SEQ ID NO:206).

Variant protein T94936_PEA_—1_P2 (SEQ ID NO:206) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 4, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T94936_PEA_—1_P2 (SEQ ID NO:206) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 4


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

104	T -> A	No
28	K -> R	No

Variant protein T94936_PEA_—1_P2 (SEQ ID NO:206) is encoded by the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T94936_PEA_—1_T1 (SEQ ID NO:192) is shown in bold; this coding portion starts at position 76 and ends at position 525. The transcript also has the following SNPs as listed in Table 5 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T94936_PEA_—1_P2 (SEQ ID NO:206) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 5


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

158	A -> G	No
186	A -> G	No
385	A -> G	No

Variant protein T94936_PEA_—1_P3 (SEQ ID NO:207) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T94936_PEA_—1_T2 (SEQ ID NO:193). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T94936_PEA_—1_P3 (SEQ ID NO:207) and Q8TD06 (SEQ ID NO:858):

1. An isolated chimeric polypeptide encoding for T94936_PEA_—1_P3 (SEQ ID NO:207), comprising a first amino acid sequence being at least 90% homologous to MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEEGLFYAQKS KKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNLMHETTDKNLSPDGQY VPRIMFV corresponding to amino acids 1-122 of Q8TD06 (SEQ ID NO:858), which also corresponds to amino acids 1-122 of T94936_PEA_—1_P3 (SEQ ID NO:207), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GMYVISFHQIYKISRNQHSCFYF (SEQ ID NO: 1019) corresponding to amino acids 123-145 of T94936_PEA_—1_P3 (SEQ ID NO:207), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T94936_PEA_—1_P3 (SEQ ID NO:207), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GMYVISFHQIYKISRNQHSCFYF (SEQ ID NO:1019) in T94936_PEA_—1_P3 (SEQ ID NO:207).

Variant protein T94936_PEA_—1_P3 (SEQ ID NO:207) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T94936_PEA_—1_P3 (SEQ ID NO:207) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

104	T -> A	No
28	K -> R	No

Variant protein T94936_PEA_—1_P3 (SEQ ID NO:207) is encoded by the following transcript(s): T94936_PEA_—1_T2 (SEQ ID NO:193), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T94936_PEA_—1_T2 (SEQ ID NO:193) is shown in bold; this coding portion starts at position 76 and ends at position 510. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T94936_PEA_—1_P3 (SEQ ID NO:207) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

158	A -> G	No
186	A -> G	No
385	A -> G	No
746	T -> C	No
889	A -> C	No
889	A -> G	No
980	A ->	No
1006	A ->	No
1105	A ->	No
1356	A -> G	No

As noted above, cluster T94936 features 12 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T94936_PEA_—1_node_—14 (SEQ ID NO:194) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T2 (SEQ ID NO:193). Table 8 below describes the starting and ending position of this segment on each transcript.

TABLE 8


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T2 (SEQ ID	443	803
NO: 193)

Segment cluster T94936_PEA_—1_node_—16 (SEQ ID NO:195) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T2 (SEQ ID NO:193). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T2 (SEQ ID	804	1213
NO: 193)

Segment cluster T94936_PEA_—1_node_—2 (SEQ ID NO:196) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	49	184
NO: 192)
T94936_PEA_1_T2 (SEQ ID	49	184
NO: 193)

Segment cluster T94936_PEA_—1_node_—20 (SEQ ID NO:197) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T2 (SEQ ID NO:193). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T2 (SEQ ID	1298	1526
NO: 193)

Segment cluster T94936_PEA_—1_node_—23 (SEQ ID NO:198) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	527	751
NO: 192)

Segment cluster T94936_PEA_—1_node_—0 (SEQ ID NO:199) according to the present invention is supported by 32 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	1	48
NO: 192)
T94936_PEA_1_T2 (SEQ ID	1	48
NO: 193)

Segment cluster T94936_PEA_—1_node_—11 (SEQ ID NO:200) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	302	378
NO: 192)
T94936_PEA_1_T2 (SEQ ID	302	378
NO: 193)

Segment cluster T94936_PEA_—1_node_—13 (SEQ ID NO:201) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	379	442
NO: 192)
T94936_PEA_1_T2 (SEQ ID	379	442
NO: 193)

Segment cluster T94936_PEA_—1_node_—17 (SEQ ID NO:202) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	443	526
NO: 192)
T94936_PEA_1_T2 (SEQ ID	1214	1297
NO: 193)

Segment cluster T94936_PEA _—1node_—6 (SEQ ID NO:203) according to the present invention is supported by 74 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	185	248
NO: 192)
T94936_PEA_1_T2 (SEQ ID	185	248
NO: 193)

Segment cluster T94936_PEA_—1_node_—8 (SEQ ID NO:204) according to the present invention can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO:192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	249	252
NO: 192)
T94936_PEA_1_T2 (SEQ ID	249	252
NO: 193)

Segment cluster T94936_PEA_—1_node_—9 (SEQ ID NO:205) according to the present invention is supported by 68 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T94936_PEA_—1_T1 (SEQ ID NO: 192) and T94936_PEA_—1_T2 (SEQ ID NO:193). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T94936_PEA_1_T1 (SEQ ID	253	301
NO: 192)
T94936_PEA_1_T2 (SEQ ID	253	301
NO: 193)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/1R8BEXWutz/cdFRKHIcZR:Q8TD06 (SEQ ID NO:858).

Sequence documentation:

Alignment of: T94936_PEA_—1_P2 (SEQ ID NO:206)×Q8TD06 (SEQ ID NO:858).

Alignment segment 1/1:



Quality:	1486.00
Escore:	0
Matching length:	150	Total length:	150
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEE	50
	. . . . .
51	GLFYAQKSKKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	GLFYAQKSKKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNL	100
	. . . . .
101	MHETTDKNLSPDGQYVPRIMFVDPSLTVRADIAGRYSNRLYTYEPRDLPL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	MHETTDKNLSPDGQYVPRIMFVDPSLTVRADIAGRYSNRLYTYEPRDLPL	150

Sequence name: /tmp/AG3unO0N3y/kjgGehygST:Q8TD06 (SEQ ID NO:858)

Sequence documentation:

Alignment of: T94936_PEA_—1_P3 (SEQ ID NO:207)×Q8TD06 (SEQ ID NO:858).

Alignment segment 1/1:



Quality:	1214.00
Escore:	0
Matching length:	122	Total length:	122
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEE	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MMLHSALGLCLLLVTVSSNLAIAIKKEKRPPQTLSRGWGDDITWVQTYEE	50
	. . . . .
51	GLFYAQKSKKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	GLFYAQKSKKPLMVIHHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNL	100
	. .
101	MHETTDKNLSPDGQYVPRIMFV	122
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	MHETTDKNLSPDGQYVPRIMFV	122

Expression of Homo sapiens Breast Cancer Membrane Protein 11 (BCMP11) T94936 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name T94936 seg14 (SEQ ID NO:861) in Normal and Cancerous Breast Tissues

Expression of Homo sapiens breast cancer membrane protein 11 (BCMP11) transcripts detectable by or according to seg14, T94936 seg14 (SEQ ID NO:861) amplicon(s) and T94936 seg14F (SEQ ID NO:859) and T94936 seg14R (SEQ ID NO:860) primers was measured by real time PCR. In this specific example, the real-time PCR reaction efficiency was assumed to be 2 and was not calculated by a standard curve reaction (as detailed above in the section of “Real-Time RT-PCR analysis”). In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 23 is a histogram showing over expression of the above-indicated Homo sapiens breast cancer membrane protein 11 (BCMP11) transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 23, the expression of Homo sapiens breast cancer membrane protein 11 (BCMP11) transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”). Notably an over-expression of at least 5 fold was found in 17 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of Homo sapiens breast cancer membrane protein 11 (BCMP11) transcripts detectable by the above amplicon(s) in breast cancer samples versus the normal tissue samples was determined by T test as 7.94E-02.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 6.74E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: T94936 seg14F forward primer (SEQ ID NO:859); and T94936 seg14R reverse primer (SEQ ID NO:860).


T94936 seg14 Forward primer:	(SEQ ID NO:859)
TACAAAATTAGTAGAAATCAGCATTCTTGC

T94936 seg14 Reverse primer:	(SEQ ID NO:860)
TGTAGAACTAACAAGAGCTGATATTATTGGAT

T94936 seg14 Amplicon:	(SEQ ID NO:861)

TACAAAATTAGTAGAAATCAGCATTCTTGCTTTTATTTTTAAATGCTAGT
TCAAGTACTATTCTTTTTAAAGAGAAGTCATTTCTAATCCAATAATATCA
GCTCTTGTTAGTTCTACA

Description for Cluster Z41644

Cluster Z41644 features 1 transcript(s) and 21 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	Z41644_PEA_1_T5	208

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	Z41644_PEA_1_node_0	209
	Z41644_PEA_1_node_11	210
	Z41644_PEA_1_node_12	211
	Z41644_PEA_1_node_15	212
	Z41644_PEA_1_node_20	213
	Z41644_PEA_1_node_24	214
	Z41644_PEA_1_node_1	215
	Z41644_PEA_1_node_10	216
	Z41644_PEA_1_node_13	217
	Z41644_PEA_1_node_16	218
	Z41644_PEA_1_node_17	219
	Z41644_PEA_1_node_19	220
	Z41644_PEA_1_node_2	221
	Z41644_PEA_1_node_21	222
	Z41644_PEA_1_node_22	223
	Z41644_PEA_1_node_23	224
	Z41644_PEA_1_node_25	225
	Z41644_PEA_1_node_3	226
	Z41644_PEA_1_node_4	227
	Z41644_PEA_1_node_6	228
	Z41644_PEA_1_node_9	229

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	Z41644_PEA_1_P10	231

These sequences are variants of the known protein Small inducible cytokine B14 precursor (SEQ ID NO:230) (SwissProt accession identifier SZ14_HUMAN; known also according to the synonyms CXCL14; Chemokine BRAK), SEQ ID NO: 230, referred to herein as the previously known protein.

Protein Small inducible cytokine B14 precursor (SEQ ID NO:230) is known or believed to have the following function(s): Not chemotactive for T-cells, B-cells, monocytes, natural killer cells or ghranulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays. The sequence for protein Small inducible cytokine B14 precursor (SEQ ID NO:230) is given at the end of the application, as “Small inducible cytokine B14 precursor (SEQ ID NO:230) amino acid sequence”. Protein Small inducible cytokine B14 precursor (SEQ ID NO:230) localization is believed to be Secreted.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: chemotaxis; signal transduction; cell-cell signaling, which are annotation(s) related to Biological Process; and chemokine, which are annotation(s) related to Molecular Function.

Cluster Z41644 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 24 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 24 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: lung malignant tumors, breast malignant tumors and pancreas carcinoma.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	bone	45
	brain	62
	colon	327
	epithelial	179
	general	104
	head and neck	10
	kidney	219
	lung	6
	lymph nodes	37
	breast	87
	bone marrow	0
	muscle	20
	ovary	36
	Pancreas	0
	prostate	78
	skin	591
	stomach	109
	Thyroid	386
	uterus	218

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

bone	4.9e−01	8.5e−01	1.8e−01	1.9	5.3e−01	1.0
brain	6.7e−01	8.0e−01	9.1e−01	0.6	9.9e−01	0.4
colon	6.4e−01	7.7e−01	9.7e−01	0.4	1	0.3
epithelial	4.1e−01	9.4e−01	9.6e−01	0.7	1	0.4
general	1.5e−01	9.4e−01	1.8e−01	1.0	1	0.5
head and neck	1.9e−01	3.3e−01	4.6e−01	2.8	7.5e−01	1.5
kidney	7.7e−01	8.2e−01	7.0e−01	0.7	9.5e−01	0.5
lung	2.2e−01	5.0e−01	1.3e−04	8.7	8.1e−03	4.1
lymph nodes	6.3e−01	8.7e−01	6.3e−01	1.2	9.2e−01	0.6
breast	4.0e−01	6.5e−01	3.9e−04	3.5	2.9e−02	1.9
bone marrow	1	6.7e−01	1	1.0	5.3e−01	1.9
muscle	5.2e−01	6.1e−01	2.7e−01	3.2	6.3e−01	1.2
ovary	6.7e−01	7.1e−01	7.6e−01	1.0	8.6e−01	0.8
pancreas	2.2e−02	2.3e−02	5.7e−03	7.8	1.6e−03	8.2
prostate	8.8e−01	9.0e−01	8.3e−01	0.6	9.3e−01	0.5
skin	5.9e−01	6.9e−01	2.3e−01	0.3	1	0.0
stomach	6.1e−01	8.9e−01	8.1e−01	0.7	9.9e−01	0.4
Thyroid	7.0e−01	7.0e−01	9.9e−01	0.4	9.9e−01	0.4
uterus	5.3e−01	8.2e−01	9.5e−01	0.5	1	0.3

As noted above, cluster Z41644 features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Small inducible cytokine B14 precursor (SEQ ID NO:230). A description of each variant protein according to the present invention is now provided.

Variant protein Z41644_PEA_—1_P10 (SEQ ID NO:231) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) Z41644_PEA_—1_T5 (SEQ ID NO:208). An alignment is given to the known protein (Small inducible cytokine B14 precursor (SEQ ID NO:230)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between Z41644_PEA_—1_P10 (SEQ ID NO:231) and SZ14_HUMAN (SEQ ID NO:230):

1. An isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 1-95 of SZ14_HUMAN (SEQ ID NO:230), which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) in Z41644_PEA_—1_P10 (SEQ ID NO:231).

Comparison report between Z41644_PEA_—1_P10 (SEQ ID NO:231) and Q9NS21 (SEQ ID NO:862):

1. An isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 13-107 of Q9NS21 (SEQ ID NO:862), which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between Z41644_PEA_—1_P10 (SEQ ID NO:231) and AAQ89265 (SEQ ID NO:863):

1. An isolated chimeric polypeptide encoding for Z41644_PEA_—1_P10 (SEQ ID NO:231), comprising a first amino acid sequence being at least 90% homologous to MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVII TTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR corresponding to amino acids 13-107 of AAQ89265, which also corresponds to amino acids 1-95 of Z41644_PEA_—1_P10 (SEQ ID NO:231), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YAPPLLTFLPTRPSCGSQDGKGPPHQVI (SEQ ID NO:1020) corresponding to amino acids 96-123 of Z41644_PEA_—1_P10 (SEQ ID NO:231), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein Z41644_PEA_—1_P10 (SEQ ID NO:231) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z41644_PEA_—1_P10 (SEQ ID NO:231) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

32	P -> H	Yes
64	S ->	No
80	T -> A	No
80	T -> P	No

Variant protein Z41644_PEA_—1_P10 (SEQ ID NO:231) is encoded by the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript Z41644_PEA_—1_T5 (SEQ ID NO:208) is shown in bold; this coding portion starts at position 744 and ends at position 1112. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein Z41644_PEA_—1_P10 (SEQ ID NO:231) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

102	A -> G	Yes
572	C ->	No
3707	C -> T	Yes
3735	C -> T	Yes
4079	G -> A	No
4123	G -> A	Yes
4233	A -> G	Yes
4328	C ->	No
4350	A -> G	Yes
4376	G -> A	Yes
4390	A -> G	Yes
4619	G -> T	Yes
838	C -> A	Yes
4754	C -> T	No
4757	C -> A	No
4794	T -> G	No
4827	G ->	No
934	C ->	No
981	A -> C	No
981	A -> G	No
1817	A -> C	Yes
2546	T ->	No
2684	T -> A	No
2885	T -> C	Yes

As noted above, cluster Z41644 features 21 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster Z41644_PEA_—1_node_—0 (SEQ ID NO:209) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 8 below describes the starting and ending position of this segment on each transcript.

TABLE 8


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	1	616
NO: 208)

Segment cluster Z41644_PEA_—1_node_—11 (SEQ ID NO:210) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	1028	2089
NO: 208)

Segment cluster Z41644_PEA_—1_node_—12 (SEQ ID NO:211) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	2090	2350
NO: 208)

Segment cluster Z41644_PEA_—1_node_—15 (SEQ ID NO:212) according to the present invention is supported by 23 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	2368	3728
NO: 208)

Segment cluster Z41644_PEA_—1_node_—20 (SEQ ID NO:213) according to the present invention is supported by 260 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	3938	4506
NO: 208)

Segment cluster Z41644_PEA_—1_node_—24 (SEQ ID NO:214) according to the present invention is supported by 185 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	4637	4799
NO: 208)

Segment cluster Z41644_PEA_—1_node_—1 (SEQ ID NO:215) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	617	697
NO: 208)

Segment cluster Z41644_PEA_—1_node_—10 (SEQ ID NO:216) according to the present invention is supported by 138 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	972	1027
NO: 208)

Segment cluster Z41644_PEA_—1_node_—13 (SEQ ID NO:217) according to the present invention can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	2351	2367
NO: 208)

Segment cluster Z41644_PEA_—1_node_—16 (SEQ ID NO:218) according to the present invention is supported by 152 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	ending
	starting	position
Transcript name	position	Segment

Z41644_PEA_1_T5 (SEQ ID	3729	3809
NO: 208)

Segment cluster Z41644_PEA_—1_node_—17 (SEQ ID NO:219) according to the present invention can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	3810	3829
NO: 208)

Segment cluster Z41644_PEA_—1_node_—19 (SEQ ID NO:220) according to the present invention is supported by 112 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	3830	3937
NO: 208)

Segment cluster Z41644_PEA_—1_node_—2 (SEQ ID NO:221) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	698	737
NO: 208)

Segment cluster Z41644_PEA_—1_node_—21 (SEQ ID NO:222) according to the present invention can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	4507	4529
NO: 208)

Segment cluster Z41644_PEA_—1_node_—22 (SEQ ID NO:223) according to the present invention is supported by 164 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	4530	4582
NO: 208)

Segment cluster Z41644_PEA_—1_node_—23 (SEQ ID NO:224) according to the present invention is supported by 169 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	4583	4636
NO: 208)

Segment cluster Z41644_PEA_—1_node_—25 (SEQ ID NO:225) according to the present invention is supported by 138 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	4800	4902
NO: 208)

Segment cluster Z41644_PEA_—1_node_—3 (SEQ ID NO:226) according to the present invention is supported by 75 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	738	773
NO: 208)

Segment cluster Z41644_PEA_—1_node_—4 (SEQ ID NO:227) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	774	807
NO: 208)

Segment cluster Z41644_PEA_—1_node_—6 (SEQ ID NO:228) according to the present invention is supported by 101 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	808	913
NO: 208)

Segment cluster Z41644_PEA_—1_node_—9 (SEQ ID NO:229) according to the present invention is supported by 134 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): Z41644_PEA_—1_T5 (SEQ ID NO:208). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

Z41644_PEA_1_T5 (SEQ ID	914	971
NO: 208)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/p5SSvhT9Xp/HQeIMsUrfm:SZ14_HUMAN (SEQ ID NO:230)

Sequence documentation:

Alignment of: Z41644_PEA_—1_P10 (SEQ ID NO:231)×SZ14_HUMAN (SEQ ID NO:230).

Alignment segment 1/1:



Quality:	953.00
Escore:	0
Matching length:	95	Total length:	95
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	50
	. . . .
51	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR	95
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR	95

Sequence name: /tmp/p5SSvhT9Xp/HQeIMsUrfm:Q9NS21 (SEQ ID NO:862)

Sequence documentation:

Alignment of: Z41644_PEA_—1_P10 (SEQ ID NO:231)×Q9NS21 (SEQ ID NO:862).

Alignment segment 1/1:



Quality:	957.00
Escore:	0
Matching length:	96	Total length:	96
Matching Percent	100.00	Matching Percent Identity:	98.96
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	98.96
Gaps:	0

Alignment:


	. . . . .
1	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
13	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	62
	. . . .
51	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRRY	96
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|:
63	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRRF	108

Sequence name: /tmp/p5SSvhT9Xp/HQeIMsUrfm:AAQ89265

Sequence documentation:

Alignment of: Z41644_PEA_—1_P10 (SEQ ID NO:231)×AAQ89265.

Alignment segment 1/1:



Quality:	953.00
Escore:	0
Matching length:	95	Total length:	95
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
13	MRLLAAALLLLLLALYTARVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPH	62
	. . . .
51	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR	95
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
63	CEEKMVIITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRR	107

Description for Cluster M85491

Cluster M85491 features 2 transcript(s) and 11 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	M85491_PEA_1_T16	232
	M85491_PEA_1_T20	233

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	M85491_PEA_1_node_0	234
	M85491_PEA_1_node_13	235
	M85491_PEA_1_node_21	236
	M85491_PEA_1_node_23	237
	M85491_PEA_1_node_24	238
	M85491_PEA_1_node_8	239
	M85491_PEA_1_node_9	240
	M85491_PEA_1_node_10	241
	M85491_PEA_1_node_18	242
	M85491_PEA_1_node_19	243
	M85491_PEA_1_node_6	244

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	M85491_PEA_1_P13	246
	M85491_PEA_1_P14	247

These sequences are variants of the known protein Ephrin type-B receptor 2 [precursor] (SEQ ID NO:245) (SwissProt accession identifier EPB2_HUMAN; known also according to the synonyms EC 2.7.1.112; Tyrosine-protein kinase receptor EPH-3; DRT; Receptor protein-tyrosine kinase HEK5; ERK), SEQ ID NO: 245, referred to herein as the previously known protein.

Protein Ephrin type-B receptor 2 [precursor] (SEQ ID NO:245) is known to have the following function(s): Receptor for members of the ephrin-B family. The sequence for protein Ephrin type-B receptor 2 [precursor] (SEQ ID NO:245) is given at the end of the application, as “Ephrin type-B receptor 2 [precursor] (SEQ ID NO:245) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNPposition(s) on
amino acid sequence	Comment

671	A -> R./FTId = VAR_004162.

120	MALRRLGAALLLLPLLAAVE −>
	MWVPVLALPVCTYA

923	E -> K

956	L -> V

958	V -> L

154	G -> D

476	K -> KQ

495-496	Missing

532	E -> D

568	R -> RR

589	M -> I

788	I -> F

853	S -> A

Protein Ephrin type-B receptor 2 [precursor] (SEQ ID NO:245) localization is believed to be Type I membrane protein.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: protein amino acid phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; neurogenesis, which are annotation(s) related to Biological Process; protein tyrosine kinase; receptor; transmembrane-ephrin receptor; ATP binding; transferase, which are annotation(s) related to Molecular Function; and integral membrane protein, which are annotation(s) related to Cellular Component.

Cluster M85491 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 25 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 25 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors and a mixture of malignant tumors from different tissues.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Bladder	0
	Bone	0
	Brain	10
	Colon	31
	epithelial	10
	general	12
	Kidney	0
	Liver	0
	Lung	5
	Breast	8
	Muscle	5
	Ovary	36
	pancreas	10
	Skin	0
	stomach	0

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

bladder	5.4e−01	6.0e−01	3.2e−01	2.5	4.6e−01	1.9
Bone	1	2.8e−01	1	1.0	7.0e−01	1.8
Brain	3.4e−01	3.6e−01	1.2e−01	2.9	1.8e−02	2.7
Colon	3.4e−02	5.7e−02	8.2e−02	2.8	2.0e−01	2.1
epithelial	1.7e−03	3.5e−03	2.0e−03	2.8	1.1e−02	2.2
general	4.8e−04	5.2e−04	6.7e−04	2.3	1.3e−03	1.9
Kidney	4.3e−01	3.7e−01	1	1.1	7.0e−01	1.5
Liver	1	4.5e−01	1	1.0	6.9e−01	1.5
Lung	2.2e−01	2.7e−01	6.9e−02	3.6	3.4e−02	3.6
Breast	8.2e−01	7.3e−01	6.9e−01	1.2	6.8e−01	1.2
Muscle	9.2e−01	4.8e−01	1	0.8	1.5e−01	3.2
Ovary	8.5e−01	7.3e−01	9.0e−01	0.7	6.7e−01	1.0
pancreas	5.5e−01	2.0e−01	6.7e−01	1.2	3.5e−01	1.8
Skin	2.9e−01	4.7e−01	1.4e−01	7.0	6.4e−01	1.6
stomach	1.5e−01	3.2e−01	1	1.0	8.0e−01	1.3

As noted above, cluster M85491 features 2 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Ephrin type-B receptor 2 [precursor]. A description of each variant protein according to the present invention is now provided.

Variant protein M85491_PEA_—1_P13 (SEQ ID NO:246) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M85491_PEA_—1_T16 (SEQ ID NO:232). An alignment is given to the known protein (Ephrin type-B receptor 2 [precursor]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M85491_PEA_—1_P13 (SEQ ID NO:246) and EPB2_HUMAN (SEQ ID NO:245):

1. An isolated chimeric polypeptide encoding for M8549 1_PEA_—1_P13 (SEQ ID NO:246), comprising a first amino acid sequence being at least 90% homologous to MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIR TYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYY EADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGF YLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVD VPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPIN SRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSG GREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAV NGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYEL QYYEK corresponding to amino acids 1-476 of EPB2_HUMAN (SEQ ID NO:245), which also corresponds to amino acids 1-476 of M85491_PEA_—1_P13 (SEQ ID NO:246), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPIGWVLSPSPTSLRAPLPG (SEQ ID NO:964) corresponding to amino acids 477-496 of M85491_PEA_—1_P13 (SEQ ID NO:246), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of M85491_PEA_—1_P 13 (SEQ ID NO:246), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPIGWVLSPSPTSLRAPLPG (SEQ ID NO:964) in M85491_PEA_—1_P13 (SEQ ID NO:246).

The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region. Variant protein M85491_PEA_—1_P13 (SEQ ID NO:246) is encoded by the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M85491_PEA_—1_T16 (SEQ ID NO:232) is shown in bold; this coding portion starts at position 143 and ends at position 1630. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M85491_PEA_—1_P13 (SEQ ID NO:246) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

799	G -> A	Yes
1066	C -> T	Yes
1519	A -> G	Yes
1872	C -> T	Yes
2044	T -> C	Yes
2156	G -> A	Yes
2606	C -> A	Yes
2637	G -> C	Yes

Variant protein M85491_PEA_—1_P14 (SEQ ID NO:247) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M85491_PEA_—1_T20 (SEQ ID NO:233). An alignment is given to the known protein (Ephrin type-B receptor 2 [precursor]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M85491_PEA_—1_P14 (SEQ ID NO:247) and EPB2_HUMAN (SEQ ID NO:245):

1. An isolated chimeric polypeptide encoding for M85491_PEA_—1_P14 (SEQ ID NO:247), comprising a first amino acid sequence being at least 90% homologous to MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIR TYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYY EADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGF YLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVD VPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCR corresponding to amino acids 1-270 of EPB2_HUMAN (SEQ ID NO:245), which also corresponds to amino acids 1-270 of M85491_PEA_—1_P14 (SEQ ID NO:247), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ERQDLTMLSRLVLNSWPQMILPPQPPKVLEL (SEQ ID NO:965) corresponding to amino acids 271-301 of M85491_PEA_—1_P14 (SEQ ID NO:247), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of M85491_PEA_—1_P14 (SEQ ID NO:247), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ERQDLTMLSRLVLNSWPQMILPPQPPKVLEL (SEQ ID NO:965) in M85491_PEA_—1_P14 (SEQ ID NO:247).

Variant protein M85491_PEA_—1_P14 (SEQ ID NO:247) is encoded by the following transcript(s): M85491_PEA_—1_T20 (SEQ ID NO:233), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M85491_PEA_—1_T20 (SEQ ID NO:233) is shown in bold; this coding portion starts at position 143 and ends at position 1045. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M85491_PEA_—1_P14 (SEQ ID NO:247) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

799	G -> A	Yes
1135	T -> C	Yes
1160	T -> C	Yes
1172	A -> C	Yes
1176	T -> A	Yes

As noted above, cluster M85491 features 11 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster M85491_PEA_—1_node_—0 (SEQ ID NO:234) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232) and M85491_PEA_—1_T20 (SEQ ID NO:233). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	1	203
ID NO: 232)
M85491_PEA_1_T20 (SEQ	1	203
ID NO: 233)

Segment cluster M85491_PEA_—1_node_—13 (SEQ ID NO:235) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T20 (SEQ ID NO:233). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T20 (SEQ	954	1182
ID NO: 233)

Segment cluster M85491_PEA_—1_node_—21 (SEQ ID NO:236) according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	1110	1445
ID NO: 232)

Segment cluster M85491_PEA_—1_node_—23 (SEQ ID NO:237) according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	1446	1570
ID NO: 232)

Segment cluster M85491_PEA_—1_node_—24 (SEQ ID NO:238) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	1571	2875
ID NO: 232)

Segment cluster M85491_PEA_—1_node_—8 (SEQ ID NO:239) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232) and M85491_PEA_—1_T20 (SEQ ID NO:233). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	269	672
ID NO: 232)
M85491_PEA_1_T20 (SEQ	269	672
ID NO: 233)

Segment cluster M85491_PEA_—1_node_—9 (SEQ ID NO:240) according to the present invention is supported by 20 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232) and M85491_PEA_—1_T20 (SEQ ID NO:233). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	673	856
ID NO: 232)
M85491_PEA_1_T20 (SEQ	673	856
ID NO: 233)

Segment cluster M85491_PEA_—1_node_—10 (SEQ ID NO:241) according to the present invention is supported by 17 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232) and M85491_PEA_—1_T20 (SEQ ID NO:233). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	857	953
ID NO: 232)
M85491_PEA_1_T20 (SEQ	857	953
ID NO: 233)

Segment cluster M85491_PEA_—1_node_—18 (SEQ ID NO:242) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	954	1044
ID NO: 232)

Segment cluster M85491_PEA_—1_node_—19 (SEQ ID NO:243) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	1045	1109
ID NO: 232)

Segment cluster M85491_PEA_—1_node_—6 (SEQ ID NO:244) according to the present invention is supported by 11 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M85491_PEA_—1_T16 (SEQ ID NO:232) and M85491_PEA_—1_T20 (SEQ ID NO:233). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M85491_PEA_1_T16 (SEQ	204	268
ID NO: 232)
M85491_PEA_1_T20 (SEQ	204	268
ID NO: 233)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/qfmsU9VtxS/DylcLC9j8v:EPB2_HUMAN (SEQ ID NO:245)

Sequence documentation:

Alignment of: M85491_PEA_—1_P13 (SEQ ID NO:246)×EPB2_HUMAN (SEQ ID NO:245).

Alignment segment 1/1:



Quality:	4726.00
Escore:	0
Matching length:	476	Total length:	476
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYD	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYD	50
	. . . . .
51	ENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSI	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	ENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSI	100
	. . . . .
101	PSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQV	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	PSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQV	150
	. . . . .
151	DLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRI	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	DLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRI	200
	. . . . .
201	IQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVP	250
	. . . . .
251	IGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	IGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGA	300
	. . . . .
301	TNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDS	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDS	350
	. . . . .
351	GGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLA	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	GGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLA	400
	. . . . .
401	HTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVD	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	HTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVD	450
	. .
451	SITLSWSQPDQPNGVILDYELQYYEK	476
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	SITLSWSQPDQPNGVILDYELQYYEK	476

Sequence name: /tmp/rmnzuDbot6/GiHbjeU8iR:EPB2_HUMAN (SEQ ID NO:245)

Sequence documentation:

Alignment of: M85491_PEA_—1_P14 (SEQ ID NO:247)×EPB2_HUMAN (SEQ ID NO:245).

Alignment segment 1/1:



Quality:	2673.00
Escore:	0
Matching length:	270	Total length:	270
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYD	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYD	50
	. . . . .
51	ENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSI	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	ENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSI	100
	. . . . .
101	PSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQV	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	PSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQV	150
	. . . . .
151	DLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRI	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	DLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRI	200
	. . . . .
201	IQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVP	250
	. .
251	IGRCMCKAGFEAVENGTVCR	270
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	IGRCMCKAGFEAVENGTVCR	270

Expression of Ephrin Type-B Receptor 2 Precursor (EC 2.7.1.112) (Tyrosine-Protein Kinase Receptor EPH-3) M85491 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name M85491seg24 (SEQ ID NO:866) in Normal and Cancerous Breast Tissues

Expression of Ephrin type-B receptor 2 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor EPH-3) transcripts detectable by or according to seg24, M85491seg24 (SEQ ID NO:866) amplicon and M85491seg24F (SEQ ID NO:864) M85491seg24R (SEQ ID NO:8656) primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 26 is a histogram showing over expression of the above-indicated Ephrin type-B receptor 2 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor EPH-3) transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 26, the expression of Ephrin type-B receptor 2 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor EPH-3) transcripts detectable by the above amplicon in a few cancer samples was higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”).

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: M85491seg24F (SEQ ID NO:864) forward primer; and M85491seg24R (SEQ ID NO:865) reverse primer.


M85491seg24 Forward primer (SEQ ID NO:864):
GGCGTCTTTCTCCCTCTGAAC

M85491seg24 Reverse primer (SEQ ID NO:865):
GTCCCATTCTGGGTGCTGTG

M85491seg24 Amplicon (SEQ ID NO:866):
GGCGTCTTTCTCCCTCTGAACCTCAGTTTCCACCTGTGTCGAGTGTGGGT
GAGACCCCTCGCGGGGAGCTATGCAGGTTACGGAGAAAAGGCAGCACAGC
ACCCAGAATGGGAC

Expression of Ephrin Type-B Receptor 2 Precursor M85491 Transcripts, Which are Detectable by Amplicon as Depicted in Sequence Name M85491 seg24 (SEQ ID NO:866) in Different Normal Tissues

Expression of Ephrin type-B receptor 2 precursor transcripts detectable by or according to M85491 seg24 amplicon(s) (SEQ ID NO:866) and M85491 seg24F (SEQ ID NO:864) and M85491 seg24R (SEQ ID NO:865) priemrs was measured by real time PCR. In parallel the expression of four housekeeping genes—RPL 19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934) RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the colon samples (Sample Nos. 1-3 Table 2,“Tissue samples on normal panel”, above), to obtain a value of relative expression of each sample relative to median of the colon samples. Primers and amplicon are as above.

The results are presented in FIG. 27, demonstrating the expression of Ephrin type-B receptor 2 precursor M85491 transcripts, which are detectable by amplicon as depicted in sequence name M85491 seg24 (SEQ ID NO:866), in different normal tissues.

Description for Cluster HSSTROL3

Cluster HSSTROL3 features 6 transcript(s) and 16 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSSTROL3_T5	248
	HSSTROL3_T8	249
	HSSTROL3_T9	250
	HSSTROL3_T10	251
	HSSTROL3_T11	252
	HSSTROL3_T12	253

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSSTROL3_node_6	254
	HSSTROL3_node_10	255
	HSSTROL3_node_13	256
	HSSTROL3_node_15	257
	HSSTROL3_node_19	258
	HSSTROL3_node_21	259
	HSSTROL3_node_24	260
	HSSTROL3_node_25	261
	HSSTROL3_node_26	262
	HSSTROL3_node_28	263
	HSSTROL3_node_29	264
	HSSTROL3_node_11	265
	HSSTROL3_node_17	266
	HSSTROL3_node_18	267
	HSSTROL3_node_20	268
	HSSTROL3_node_27	269

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

HSSTROL3_P4	271	HSSTROL3_T5
		(SEQ ID NO:248)

HSSTROL3_P5	272	HSSTROL3_T8
		(SEQ ID NO:249);
		HSSTROL3_T9
		(SEQ ID NO:250)

HSSTROL3_P7	273	HSSTROL3_T10
		(SEQ ID NO:251)

HSSTROL3_P8	274	HSSTROL3_T11
		(SEQ ID NO:252)

HSSTROL3_P9	275	HSSTROL3_T12
		(SEQ ID NO:253)

These sequences are variants of the known protein Stromelysin-3 precursor (SEQ ID NO:270) (SwissProt accession identifier MM11_HUMAN; known also according to the synonyms EC 3.4.24.-; Matrix metalloproteinase-11; MMP-11; ST3; SL-3), SEQ ID NO: 270, referred to herein as the previously known protein.

Protein Stromelysin-3 precursor (SEQ ID NO:270) is known or believed to have the following function(s): May play an important role in the progression of epithelial malignancies. The sequence for protein Stromelysin-3 precursor (SEQ ID NO:270) is given at the end of the application, as “Stromelysin-3 precursor (SEQ ID NO:270) amino acid sequence”.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: proteolysis and peptidolysis; developmental processes; morphogenesis, which are annotation(s) related to Biological Process; stromelysin 3; calcium binding; zinc binding; hydrolase, which are annotation(s) related to Molecular Function; and extracellular matrix, which are annotation(s) related to Cellular Component.

Cluster HSSTROL3 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 28 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 28 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: transitional cell carcinoma, epithelial malignant tumors, a mixture of malignant tumors from different tissues and pancreas carcinoma.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	Adrenal	0
	Bladder	0
	Brain	1
	Colon	63
	Epithelial	33
	General	13
	head and neck	101
	Kidney	0
	lung	11
	breast	8
	ovary	14
	pancreas	0
	prostate	2
	skin	99
	Thyroid	0
	uterus	181

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	1	4.6e−01	1	1.0	5.3e−01	1.9
bladder	2.7e−01	3.4e−01	3.3e−03	4.9	2.1e−02	3.3
brain	3.5e−01	2.6e−01	1	1.7	3.3e−01	2.8
colon	7.7e−02	1.5e−01	3.1e−01	1.4	5.2e−01	1.0
epithelial	1.2e−04	1.2e−02	1.3e−06	2.7	4.6e−02	1.4
general	5.4e−09	3.1e−05	1.8e−16	5.0	3.1e−07	2.6
head and neck	4.6e−01	4.3e−01	1	0.6	9.4e−01	0.7
kidney	2.5e−01	3.5e−01	1.1e−01	4.0	2.4e−01	2.8
lung	1.8e−01	4.5e−01	1.9e−01	2.7	5.1e−01	1.4
breast	2.0e−01	3.4e−01	7.3e−02	3.3	2.5e−01	2.0
ovary	2.6e−01	3.2e−01	2.2e−02	2.0	7.0e−02	1.6
pancreas	9.5e−02	1.8e−01	1.8e−04	7.8	1.6e−03	5.5
prostate	8.2e−01	7.8e−01	4.5e−01	1.8	5.6e−01	1.5
skin	5.2e−01	5.8e−01	7.1e−01	0.8	1	0.3
Thyroid	2.9e−01	2.9e−01	1	1.1	1	1.1
uterus	4.2e−01	8.0e−01	7.5e−01	0.6	9.9e−01	0.4

As noted above, cluster HSSTROL3 features 6 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Stromelysin-3 precursor (SEQ ID NO:270). A description of each variant protein according to the present invention is now provided.

Variant protein HSSTROL3_P4 (SEQ ID NO:271) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROL3_T5 (SEQ ID NO:248). An alignment is given to the known protein (Stromelysin-3 precursor (SEQ ID NO:270)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSSTROL3_P4 (SEQ ID NO:271) and MM11_HUMAN (SEQ ID NO:270):

1. An isolated chimeric polypeptide encoding for HSSTROL3_P4 (SEQ ID NO:271), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P4 (SEQ ID NO:271), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P4 (SEQ ID NO:271), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPE KNKIYFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADG corresponding to amino acids 165-445 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-445 of HSSTROL3_P4 (SEQ ID NO:271), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ALGVRQLVGGGHSSRFSHLVVAGLPHACHRKSGSSSQVLCPEPSALLSVAG (SEQ ID NO:966) corresponding to amino acids 446-496 of HSSTROL3_P4 (SEQ ID NO:271), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSSTROL3_P4 (SEQ ID NO:271), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:966)

ALGVRQLVGGGHSSRFSHLVVAGLPHACHRKSGSSSQVLCPEPSALLSVA
G
in

(SEQ ID NO:271)

HSSTROL3_P4.

Variant protein HSSTROL3_P4 (SEQ ID NO:271) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P4 (SEQ ID NO:271) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Amino acid mutations

SNP position(s) on amino		Previously known
acid sequence	Alternative amino acid(s)	SNP?

38	V -> A	Yes
104	R -> P	Yes
214	A ->	No
323	Q -> H	Yes

Variant protein HSSTROL3_P4 (SEQ ID NO:271) is encoded by the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSSTROL3_T5 (SEQ ID NO:248) is shown in bold; this coding portion starts at position 24 and ends at position 1511. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P4 (SEQ ID NO:271) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on nucleotide		Previously known
sequence	Alternative nucleic acid	SNP?

136	T -> C	Yes
334	G -> C	Yes
663	G ->	No
699	-> T	No
992	G -> C	Yes
1528	A -> G	Yes
1710	A -> G	Yes
2251	A -> G	Yes
2392	C ->	No
2444	C -> A	Yes
2470	A -> T	Yes
2687	-> G	No
2696	-> G	No
2710	C ->	No
2729	-> A	No
2755	T -> C	No
2813	A ->	No
2813	A -> C	No
2963	A ->	No
2963	A -> C	No
2993	T -> C	Yes
3140	-> T	No

Variant protein HSSTROL3_P5 (SEQ ID NO:272) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROL3_T8 (SEQ ID NO:249) and HSSTROL3_T9 (SEQ ID NO:250). An alignment is given to the known protein (Stromelysin-3 precursor (SEQ ID NO:270)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSSTROL3_P5 (SEQ ID NO:272) and MM11_HUMAN (SEQ ID NO:270):

1. An isolated chimeric polypeptide encoding for HSSTROL3_P5 (SEQ ID NO:272), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P5 (SEQ ID NO:272), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P5 (SEQ ID NO:272), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQ corresponding to amino acids 165-358 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-358 of HSSTROL3_P5 (SEQ ID NO:272), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ELGFPSSTGRDESLEHCRCQGLHK (SEQ ID NO:967) corresponding to amino acids 359-382 of HSSTROL3_P5 (SEQ ID NO:272), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSSTROL3_P5 (SEQ ID NO:272), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ELGFPSSTGRDESLEHCRCQGLHK (SEQ ID NO:967) in HSSTROL3_P5 (SEQ ID NO:272).

Variant protein HSSTROL3_P5 (SEQ ID NO:272) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P5 (SEQ ID NO:272) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on amino		Previously known
acid sequence	Alternative amino acid(s)	SNP?

38	V -> A	Yes
104	R -> P	Yes
214	A ->	No
323	Q -> H	Yes

Variant protein HSSTROL3_P5 (SEQ ID NO:272) is encoded by the following transcript(s): HSSTROL3_T8 (SEQ ID NO:249) and HSSTROL3_T9 (SEQ ID NO:250), for which the sequence(s) is/are given at the end of the application.

The coding portion of transcript HSSTROL3_T8 (SEQ ID NO:249) is shown in bold; this coding portion starts at position 24 and ends at position 1169. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P5 (SEQ ID NO:272) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

136	T -> C	Yes
334	G -> C	Yes
663	G ->	No
699	-> T	No
992	G -> C	Yes
1903	C ->	No
1955	C -> A	Yes
1981	A -> T	Yes
2198	-> G	No
2207	-> G	No
2221	C ->	No
2240	-> A	No
2266	T -> C	No
2324	A ->	No
2324	A -> C	No
2474	A ->	No
2474	A -> C	No
2504	T -> C	Yes
2651	-> T	No

The coding portion of transcript HSSTROL3_T9 (SEQ ID NO:250) is shown in bold; this coding portion starts at position 24 and ends at position 1169. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P5 (SEQ ID NO:272) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

136	T -> C	Yes
334	G -> C	Yes
663	G ->	No
699	-> T	No
992	G -> C	Yes
1666	A -> G	Yes
1848	A -> G	Yes
2389	A -> G	Yes
2530	C ->	No
2582	C -> A	Yes
2608	A -> T	Yes
2825	-> G	No
2834	-> G	No
2848	C ->	No
2867	-> A	No
2893	T -> C	No
2951	A ->	No
2951	A -> C	No
3101	A ->	No
3101	A -> C	No
3131	T -> C	Yes
3278	-> T	No

Variant protein HSSTROL3_P7 (SEQ ID NO:273) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROL3_T10 (SEQ ID NO:251). An alignment is given to the known protein (Stromelysin-3 precursor (SEQ ID NO:270)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSSTROL3_P7 (SEQ ID NO:273) and MM11_HUMAN (SEQ ID NO:270):

1. An isolated chimeric polypeptide encoding for HSSTROL3_P7 (SEQ ID NO:273), comprising a first amino acid sequence being at least 90 % homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P7 (SEQ ID NO:273), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P7 (SEQ ID NO:273), a second amino acid sequence being at least 90 % homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQG corresponding to amino acids 165-359 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-359 of HSSTROL3_P7 (SEQ ID NO:273), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TTGVSTPAPGV (SEQ ID NO:968) corresponding to amino acids 360-370 of HSSTROL3_P7 (SEQ ID NO:273), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSSTROL3_P7 (SEQ ID NO:273), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV (SEQ ID NO:968) in HSSTROL3_P7 (SEQ ID NO:273).

Variant protein HSSTROL3_P7 (SEQ ID NO:273) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P7 (SEQ ID NO:273) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on	Alternative	Previously known
amino acid sequence	amino acid(s)	SNP?

38	V -> A	Yes
104	R -> P	Yes
214	A ->	No
323	Q -> H	Yes

Variant protein HSSTROL3_P7 (SEQ ID NO:273) is encoded by the following transcript(s): HSSTROL3_T10 (SEQ ID NO:251), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSSTROL3_T10 (SEQ ID NO:251) is shown in bold; this coding portion starts at position 24 and ends at position 1133. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P7 (SEQ ID NO:273) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

136	T -> C	Yes
334	G -> C	Yes
663	G ->	No
699	-> T	No
992	G -> C	Yes
1386	A -> G	Yes
1568	A -> G	Yes
2109	A -> G	Yes
2250	C ->	No
2302	C -> A	Yes
2328	A -> T	Yes
2545	-> G	No
2554	-> G	No
2568	C ->	No
2587	-> A	No
2613	T -> C	No
2671	A ->	No
2671	A -> C	No
2821	A ->	No
2821	A -> C	No
2851	T -> C	Yes
2998	-> T	No

Variant protein HSSTROL3_P8 (SEQ ID NO:274) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROL3_T11 (SEQ ID NO:252). An alignment is given to the known protein (Stromelysin-3 precursor (SEQ ID NO:270)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSSTROL3_P8 (SEQ ID NO:274) and MM11_HUMAN (SEQ ID NO:270):

1. An isolated chimeric polypeptide encoding for HSSTROL3_P8 (SEQ ID NO:274), comprising a first amino acid sequence being at least 90 % homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFP WQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 1-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-163 of HSSTROL3_P8 (SEQ ID NO:274), a bridging amino acid H corresponding to amino acid 164 of HSSTROL3_P8 (SEQ ID NO:274), a second amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLE corresponding to amino acids 165-286 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 165-286 of HSSTROL3_P8 (SEQ ID NO:274), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRPCLPVPLLLCWPL (SEQ ID NO:969) corresponding to amino acids 287-301 of HSSTROL3_P8 (SEQ ID NO:274), wherein said first amino acid sequence, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSSTROL3_P8 (SEQ ID NO:274), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRPCLPVPLLLCWPL (SEQ ID NO:969) in HSSTROL3_P8 (SEQ ID NO:274).

Variant protein HSSTROL3_P8 (SEQ ID NO:274) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P8 (SEQ ID NO:274) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on	Alternative	Previously known
amino acid sequence	amino acid(s)	SNP?

38	V -> A	Yes
104	R -> P	Yes
214	A ->	No

Variant protein HSSTROL3_P8 (SEQ ID NO:274) is encoded by the following transcript(s): HSSTROL3_T11 (SEQ ID NO:252), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSSTROL3_T11 (SEQ ID NO:252) is shown in bold; this coding portion starts at position 24 and ends at position 926. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P8 (SEQ ID NO:274) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

136	T -> C	Yes
334	G -> C	Yes
663	G ->	No
699	-> T	No
935	G -> A	Yes
948	G -> A	Yes
1084	G -> C	Yes
1557	C ->	No
1609	C -> A	Yes
1635	A -> T	Yes
1852	-> G	No
1861	-> G	No
1875	C ->	No
1894	-> A	No
1920	T -> C	No
1978	A ->	No
1978	A -> C	No
2128	A ->	No
2128	A -> C	No
2158	T -> C	Yes
2305	-> T	No

Variant protein HSSTROL3_P9 (SEQ ID NO:275) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROL3_T12 (SEQ ID NO:253). An alignment is given to the known protein (Stromelysin-3 precursor (SEQ ID NO:270)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSSTROL3_P9 (SEQ ID NO:275) and MM11_HUMAN (SEQ ID NO:270):

1. An isolated chimeric polypeptide encoding for HSSTROL3_P9 (SEQ ID NO:275), comprising a first amino acid sequence being at least 90% homologous to MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSS PAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQK corresponding to amino acids 1-96 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 1-96 of HSSTROL3_P9 (SEQ ID NO:275), a second amino acid sequence being at least 90% homologous to RILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYW corresponding to amino acids 113-163 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 97-147 of HSSTROL3_P9 (SEQ ID NO:275), a bridging amino acid H corresponding to amino acid 148 of HSSTROL3_P9 (SEQ ID NO:275), a third amino acid sequence being at least 90% homologous to GDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLG LQHTTAAKALMSAFYTFRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTN EIAPLEPDAPPDACEASFDAVSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGL PSPVDAAFEDAQGHIWFFQG corresponding to amino acids 165-359 of MM11_HUMAN (SEQ ID NO:270), which also corresponds to amino acids 149-343 of HSSTROL3_P9 (SEQ ID NO:275), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TTGVSTPAPGV (SEQ ID NO:968) corresponding to amino acids 344-354 of HSSTROL3_P9 (SEQ ID NO:275), wherein said first amino acid sequence, second amino acid sequence, bridging amino acid, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of HSSTROL3_P9 (SEQ ID NO:275), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KR, having a structure as follows: a sequence starting from any of amino acid numbers 96-x to 96; and ending at any of amino acid numbers 97+((n-2)−x), in which x varies from 0 to n-2.

3. An isolated polypeptide encoding for a tail of HSSTROL3_P9 (SEQ ID NO:275), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TTGVSTPAPGV (SEQ ID NO:968) in HSSTROL3_P9 (SEQ ID NO:275).

Variant protein HSSTROL3_P9 (SEQ ID NO:275) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P9 (SEQ ID NO:275) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Amino acid mutations

SNP position(s) on	Alternative	Previously known
amino acid sequence	amino acid(s)	SNP?

38	V -> A	Yes
198	A ->	No
307	Q -> H	Yes

Variant protein HSSTROL3_P9 (SEQ ID NO:275) is encoded by the following transcript(s): HSSTROL3_T12 (SEQ ID NO:253), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSSTROL3_T12 (SEQ ID NO:253) is shown in bold; this coding portion starts at position 24 and ends at position 1085. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROL3_P9 (SEQ ID NO:275) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 16


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

136	T -> C	Yes
615	G ->	No
651	-> T	No
944	G -> C	Yes
1275	C ->	No
1327	C -> A	Yes
1353	A -> T	Yes
1570	-> G	No
1579	-> G	No
1593	C ->	No
1612	-> A	No
1638	T -> C	No
1696	A ->	No
1696	A -> C	No
1846	A ->	No
1846	A -> C	No
1876	T -> C	Yes
2023	-> T	No

As noted above, cluster HSSTROL3 features 16 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSSTROL3_node_—6 (SEQ ID NO:254) according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	1	131

HSSTROL3_T8 (SEQ ID NO:249)	1	131

HSSTROL3_T9 (SEQ ID NO:250)	1	131

HSSTROL3_T10 (SEQID NO:251)	1	131

HSSTROL3_T11 (SEQ ID NO:252)	1	131

HSSTROL3_T12 (SEQ ID NO:253)	1	131

Segment cluster HSSTROL3_node_—10 (SEQ ID NO:255) according to the present invention is supported by 21 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEO ID NO:248)	132	313

HSSTROL3_T8 (SEQ ID NO:249)	132	313

HSSTROL3_T9 (SEQ ID NO:250)	132	313

HSSTROL3_T10 (SEQ ID NO:251)	132	313

HSSTROL3_T11 (SEQ ID NO:252)	132	313

HSSTROL3_T12 (SEQ ID NO:253)	132	313

Segment cluster HSSTROL3_node_—13 (SEQ ID NO:256) according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Seguent
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	362	505

HSSTROL3_T8 (SEQ ID NO:249)	362	505

HSSTROL3_T9 (SEQ ID NO:250)	362	505

HSSTROL3_T10 (SEQ ID NO:251)	362	505

HSSTROL3_T11 (SEQ ID NO:252)	362	505

HSSTROL3_T12 (SEQ ID NO:253)	314	457

Segment cluster HSSTROL3_node_—15 (SEQ ID NO:257) according to the present invention is supported by 47 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	506	639

HSSTROL3_T8 (SEQ ID NO:249)	506	639

HSSTROL3_T9 (SEQ ID NO:250)	506	639

HSSTROL3_T10 (SEQ ID NO:251)	506	639

HSSTROL3_T11 (SEQ ID NO:252)	506	639

HSSTROL3_T12 (SEQ ID NO:253)	458	591

Segment cluster HSSTROL3_node_—19 (SEQ ID NO:258) according to the present invention is supported by 63 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	699	881

HSSTROL3_T8 (SEQ ID NO:249)	699	881

HSSTROL3_T9 (SEQ ID NO:250)	699	881

HSSTROL3_T10 (SEQ ID NO:251)	699	881

HSSTROL3_T11 (SEQ ID NO:252)	699	881

HSSTROL3_T12 (SEQ ID NO:253)	651	833

Segment cluster HSSTROL3_node_—21 (SEQ ID NO:259) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	882	1098

HSSTROL3_T8 (SEQ ID NO:249)	882	1098

HSSTROL3_T9 (SEQ ID NO:250)	882	1098

HSSTROL3_T10 (SEQ ID NO:251)	882	1098

HSSTROL3_T11 (SEQ ID NO:252)	974	1190

HSSTROL3_T12 (SEQ ID NO:253)	834	1050

Segment cluster HSSTROL3_node_—24 (SEQ ID NO:260) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T8 (SEQ ID NO:249) and HSSTROL3_T9 (SEQ ID NO:250). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T8 (SEQ ID NO:249)	1099	1236

HSSTROL3_T9 (SEQ ID NO:250)	1099	1236

Segment cluster HSSTROL3_node_—25 (SEQ ID NO:261) according to the present invention is supported by 13 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T8 (SEQ ID NO:249). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T8 (SEQ ID NO:249)	1237	1536

Segment cluster HSSTROL3_node_—26 (SEQ ID NO:262) according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250) and HSSTROL3_T11 (SEQ ID NO:252). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	1099	1240

HSSTROL3_T8 (SEQ ID NO:249)	1537	1678

HSSTROL3_T9 (SEQ ID NO:250)	1237	1378

HSSTROL3_T11(SEQ ID NO:252)	1191	1332

Segment cluster HSSTROL3_node_—28 (SEQ ID NO:263) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T9 (SEQ ID NO:250) and HSSTROL3_T1O (SEQ ID NO:251). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	1357	2283

HSSTROL3_T9 (SEQ ID NO:250)	1495	2421

HSSTROL3_T10 (SEQ ID NO:251)	1215	2141

Segment cluster HSSTROL3_node_—29 (SEQ ID NO:264) according to the present invention is supported by 109 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T11 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	2284	3194

HSSTROL3_T8 (SEQ ID NO:249)	1795	2705

HSSTROL3_T9 (SEQ ID NO:250)	2422	3332

HSSTROL3_T10 (SEQ IDNO:251)	2142	3052

HSSTROL3_T11 (SEQ ID NO:252)	1449	2359

HSSTROL3_T12 (SEQ ID NO:253)	1167	2077

Segment cluster HSSTROL3_node_—11 (SEQ ID NO:265) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251) and HSSTROL3_T11 (SEQ ID NO:252). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	314	361

HSSTROL3_T8 (SEQ ID NO:249)	314	361

HSSTROL3_T9 (SEQ ID NO:250)	314	361

HSSTROL3_T10 (SEQ ID NO:251)	314	361

HSSTROL3_T11 (SEQ ID NO:252)	314	361

Segment cluster HSSTROL3_node_—17 (SEQ ID NO:266) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	640	680

HSSTROL3_T8 (SEQ ID NO:249)	640	680

HSSTROL3_T9 (SEQ ID NO:250)	640	680

HSSTROL3_T10 (SEQ ID NO:251)	640	680

HSSTROL3_T11 (SEQ ID NO:252)	640	680

HSSTROL3_T12 (SEQ ID NO:253)	592	632

Segment cluster HSSTROL3_node_—18 (SEQ ID NO:267) according to the present invention can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	681	698

HSSTROL3_T8 (SEQ ID NO:249)	681	698

HSSTROL3_T9 (SEQ ID NO:250)	681	698

HSSTROL3_T10 (SEQ ID NO:251)	681	698

HSSTROL3_T11 (SEQ ID NO:252)	681	698

HSSTROL3_T12 (SEQ ID NO:253)	633	650

Segment cluster HSSTROL3_node_—20 (SEQ ID NO:268) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T11 (SEQ ID NO:252). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T11 (SEQ ID NO:252)	882	973

Segment cluster HSSTROL3_node_—27 (SEQ ID NO:269) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROL3_T5 (SEQ ID NO:248), HSSTROL3_T8 (SEQ ID NO:249), HSSTROL3_T9 (SEQ ID NO:250), HSSTROL3_T10 (SEQ ID NO:251), HSSTROL3_T11 (SEQ ID NO:252) and HSSTROL3_T12 (SEQ ID NO:253). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSSTROL3_T5 (SEQ ID NO:248)	1241	1356

HSSTROL3_T8 (SEQ ID NO:249)	1679	1794

HSSTROL3_T9 (SEQ ID NO:250)	1379	1494

HSSTROL3_T10 (SEQ ID NO:251)	1099	1214

HSSTROL3_T11 (SEQ ID NO:252)	1333	1448

HSSTROL3_T12 (SEQ ID NO:253)	1051	1166

Variant protein alignment to the previously known protein:

Sequence name: MM11_HUMAN (SEQ ID NO:270)

Sequence documentation:

Alignment of: HSSTROL3_P4 (SEQ ID NO:271)×MM11_HUMAN (SEQ ID NO:270).

Alignment segment 1/1:



Quality:	4444.00
Escore:	0
Matching length:	445	Total length:	445
Matching Percent	99.78	Matching Percent Identity:	99.78
Similarity:
Total Percent Similarity:	99.78	Total Percent Identity:	99.78
Gaps:	0

Alignment:


	. . . . .
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	. . . . .
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	. . . . .
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	. . . . .
151	GRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	GRADIMIDFARYWDGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	. . . . .
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	. . . . .
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	. . . . .
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350
	. . . . .
351	QGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPEKNKI	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	QGHIWFFQGAQYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPEKNKI	400
	. . . .
401	YFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADG	445
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	YFFRGRDYWRFHPSTRRVDSPVPRRATDWRGVPSEIDAAFQDADG	445

Sequence name: MM11_HUMAN (SEQ ID NO:270)

Sequence documentation:

Alignment of: HSSTROL3_P5 (SEQ ID NO:272)×MM11_HUMAN (SEQ ID NO:270).

Alignment segment 1/1:



Quality:	3566.00
Escore:	0
Matching length:	358	Total length:	358
Matching Percent	99.72	Matching Percent Identity:	99.72
Similarity:
Total Percent Similarity:	99.72	Total Percent Identity:	99.72
Gaps:	0

Alignment:


	. . . . .
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	. . . . .
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	. . . . .
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	. . . . .
151	GRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	GRADIMIDFARYWDGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	. . . . .
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	. . . . .
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	. . . . .
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350

351	QGHIWFFQ	358
	\|\|\|\|\|\|\|\|
351	QGHIWFFQ	358

Sequence name: MM11_HUMAN (SEQ ID NO:270)

Sequence documentation:

Alignment of: HSSTROL3_P7 (SEQ ID NO:273)×MM11_HUMAN (SEQ ID NO:270).

Alignment segment 1/1:



Quality:	3575.00
Escore:	0
Matching length:	359	Total length:	359
Matching Percent	99.72	Matching Percent Identity:	99.72
Similarity:
Total Percent Similarity:	99.72	Total Percent Identity:	99.72
Gaps:	0

Alignment:


	. . . . .
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	. . . . .
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	. . . . .
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	. . . . .
151	GRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	GRADIMIDFARYWDGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	. . . . .
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	. . . . .
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	. . . . .
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350

351	QGHIWFFQG	359
	\|\|\|\|\|\|\|\|\|
351	QGHIWFFQG	359

Sequence name: MM11_HUMAN (SEQ ID NO:270)

Sequence documentation:

Alignment of: HSSTROL3_P8 (SEQ ID NO:274)×MM11_HUMAN (SEQ ID NO:270).

Alignment segment 1/1:



Quality:	2838.00
Escore:	0
Matching length:	286	Total length:	286
Matching Percent	99.65	Matching Percent Identity:	99.65
Similarity:
Total Percent Similarity:	99.65	Total Percent Identity:	99.65
Gaps:	0

Alignment:


	. . . . .
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	. . . . .
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	. . . . .
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	. . . . .
151	GRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	GRADIMIDFARYWDGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	. . . . .
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	. . .
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLE	286
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLE	286

Sequence name: MM11_HUMAN (SEQ ID NO:270)

Sequence documentation:

Alignment of: HSSTROL3_P9 (SEQ ID NO:275)×MM11_HUMAN (SEQ ID NO:270).

Alignment segment 1/1:



Quality:	3316.00
Escore:	0
Matching length:	343	Total length:	359
Matching Percent	99.71	Matching Percent Identity:	99.71
Similarity:
Total Percent Similarity:	95.26	Total Percent Identity:	95.26
Gaps:	1

Alignment:


	. . . . .
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQP	50
	. . . . .
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQK....	96
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	WHAALPSSPAPAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVL	100
	. . . . .
97	............RILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	134
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SGGRWEKTDLTYRILRFPWQLVQEQVRQTMAEALKVWSDVTPLTFTEVHE	150
	. . . . .
135	GRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	184
	\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	GRADIMIDFARYWDGDDLPFDGPGGILAHAFFPKTHREGDVHFDYDETWT	200
	. . . . .
185	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	234
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	IGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFRYPLSLSPDDC	250
	. . . . .
235	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	284
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	RGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA	300
	. . . . .
285	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	334
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDA	350

335	QGHIWFFQG	343
	\|\|\|\|\|\|\|\|\|
351	QGHIWFFQG	359

Expression of Stromelysin-3 Precursor (EC 3.4.24.-) (Matrix Metalloproteinase-11) (MMP-11) (ST3) SL-3 HSSTROL3 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name HSSTROL3 seg24 (SEQ ID NO:869) in Normal and Cancerous Breast Tissues

Expression of Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3 transcripts detectable by or according to seg24 HSSTROL3 seg24 (SEQ ID NO:869) amplicon(s) and HSSTROL3 seg24F (SEQ ID NO:867) and HSSTROL3 seg24R (SEQ ID NO:868) primers was measured by real time PCR. In parallel the expression of four housekeeping genes PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)) SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1, above, “Tissue samples in testing panel”), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 29A is a histogram showing over expression of the above-indicated Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) transcripts in cancerous breast samples relative to the normal samples. Values represent the average of duplicate experiments. Error bars indicate the minimal and maximal values obtained.

As is evident from FIG. 29A, the expression of Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos.56-60, 63-67 Table 1, “Tissue samples in testing panel”). Notably an over-expression of at least 5 fold was found in 20 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) transcripts detectable by the above amplicon(s) in Breast cancer samples versus the normal tissue samples was determined by T test as 6.46E-03.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 1.12E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results. Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: HSSTROL3 seg24F forward primer (SEQ ID NO:867); and HSSTROL3 seg24R reverse primer (SEQ ID NO:868).The present invention also preferably encompasses any amplicon obtained through the use of any suitable primer pair; for example, for the above experiment, the following amplicon was obtained as a non-limiting illustrative example only of a suitable amplicon: HSSTROL3 seg24 (SEQ ID NO:869).


HSSTROL3 seg24 Forward Primer (SEQ ID NO:867):
ATTTCCATCCTCAACTGGCAGA

HSSTROL3 seg24 Reverse Primer (SEQ ID NO:868):
TGCCCTGGAACCCACG

HSSTROL3 seg24 Amplicon: (SEQ ID NO:869):
ATTTCCATCCTCAACTGGCAGAGATGAGAGCCTGGAGCATTGCAGATGCC
AGGGACTTCACAAATGAAGGCACAGCATGGGAAACCTGCGTGGGTTCCAG
GGCA

Expression of Stromelysin-3 Precursor (EC 3.4.24.-) (Matrix Metalloproteinase-11) (MMP-11) (ST3) (SL-3)HSSTROL3 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name HSSTROL3 seg24 (SEQ ID NO:869) in Different Normal Tissues

Expression of Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) transcripts detectable by or according to HSSTROL3 seg24 (SEQ ID NO:869) amplicon(s) and HSSTROL3 seg24F (SEQ ID NO:867) and HSSTROL3 seg24R (SEQ ID NO:868) was measured by real time PCR. In parallel the expression of four housekeeping genes UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the lung samples (sample Nos. 15-17 Table 2,“Tissue samples on normal panel” above), to obtain a value of relative expression of each sample relative to median of the lung samples. Primers and amplicon are as above.

The results are presented in FIG. 29B, demonstrating the expression of Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3) HSSTROL3 transcripts, which are detectable by amplicon as depicted in sequence name HSSTROL3 seg24 (SEQ ID NO:869), in different normal tissues.

Expression of Stromelysin-3 Precursor (EC 3.4.24.-) (Matrix Metalloproteinase-11) (MMP-11) (ST3) (SL-3) HSSTROL3 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name HSSTROL3 junc20-21 (SEQ ID NO:872) in Normal and Cancerous Breast Tissues

Expression of Stromelysin-3 precursor transcripts detectable by or according to junc20-21, HSSTROL3junc20-21 (SEQ ID NO:872) amplicon(s) and primers HSSTROL3junc20-21F (SEQ ID NO:870) and HSSTROL3junc20-21R (SEQ ID NO:871) was measured by real time PCR. It should be noted that for this experiment, RNA was obtained from Clontech (Franklin Lakes, N.J. USA 07417, www.clontech.com), BioChain Inst. Inc. (Hayward, Calif. 94545 USA www.biochain.com), ABS (Wilmington, Del. 19801, USA, www.absbioreagents.com), GOG for ovary samples—Pediatic Cooperative Human Tissue Network, Gynecologic Oncology Group Tissue Bank, Children Hospital of Columbus (Columbus Ohio 43205 USA) or Ambion (Austin, Tex. 78744 USA, www.ambion.com). Alternatively, RNA was generated from tissue samples using TRI-Reagent (Molecular Research Center), according to Manufacturer's instructions. Tissue and RNA samples were obtained from patients or from postmortem. Total RNA samples were treated with DNaseI (Ambion).

In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 30A is a histogram showing over expression of the above-indicated Stromelysin-3 precursor transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 30A, the expression of Stromelysin-3 precursor transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above). Notably an over-expression of at least 5 fold was found in 13 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

The P value for the difference in the expression levels of Stromelysin-3 precursor transcripts detectable by the above amplicon(s) in breast cancer samples versus the normal tissue samples was determined by T test as 1.28E-02.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 4.26E-02 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: HSSTROL junc20-21F (SEQ ID NO:870) forward primer; and HSSTROL junc20-21R (SEQ ID NO:871) reverse primer.


Forward primer HSSTROL junc20-21F (SEQ ID NO:870):
TCTGCTGGCCACTGTGACTG

Reverse primer HSSTROL junc20-21R (SEQ ID NO:871):
GAAGAAAAAGAGCTCGCCTCG

Amplicon HSSTROL junc20-21 (SEQ ID NO:872):
TCTGCTGGCCACTGTGACTGCAGCATATGCCCTCAGCATGTGTCCCTCTC
TCCCACCCCAGCCAGACGCCCCGCCAGATGCCTGTGAGGCCTCCTTTGAC
GCGGTCTCCACCATCCGAGGCGAGCTCTTTTTCTTC

Expression of Stromelysin-3 Precursor (EC 3.4.24.-) (Matrix Metalloproteinase-11) (MMP-11) (ST3) (SL-3) HSSTROL3 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name HSSTROL3 junc21-27 (SEQ ID NO:875) in Normal and Cancerous Breast Tissues

Expression of Stromelysin-3 precursor transcripts detectable by or according to junc21-27, HSSTROL3 junc21-27 (SEQ ID NO:875) amplicon(s) and primers HSSTROL3junc21-27F (SEQ ID NO:873) and HSSTROL3junc21-27R (SEQ ID NO:874) was measured by real time PCR (RNA was as for the experiment above). In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 30B is a histogram showing over expression of the above-indicated Stromelysin-3 precursor transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 30B, the expression of Stromelysin-3 precursor transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67 Table 1: Tissue samples in testing panel, above). Notably an over-expression of at least 20 fold was found in 20 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

Threshold of 20 fold overexpression was found to differentiate between cancer and normal samples with P value of 3.66E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: HSSTROL junc21-27F forward primer (SEQ ID NO:873); and HSSTROL junc21-27R reverse primer (SEQ ID NO:874).


Forward primer HSSTROL junc21-27F (SEQ ID NO:873):
ACATTTGGTTCTTCCAAGGGACTAC

Reverse primer HSSTROL junc21-27R (SEQ ID NO:874):
TCGATCTCAGAGGGCACCC

Amplicon HSSTROL junc21-27 (SEQ ID NO:875):
ACATTTGGTTCTTCCAAGGGACTACTGGCGTTTCCACCCCAGCACCCGGC
GTGTAGACAGTCCCGTGCCCCGCAGGGCCACTGACTGGAGAGGGGTGCCC
TCTGAGATCGA

Expression of Stromelysin-3 Precursor (EC 3.4.24.-) (Matrix Metalloproteinase-11) (MMP-11) (ST3) (SL-3) HSSTROL3 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name HSSTROL3 seg25 (SEQ ID NO:878) in Normal and Cancerous Breast Tissues

Expression of Stromelysin-3 precursor transcripts detectable by or according to seg25, HSSTROL3 junc21-27 (SEQ ID NO:878) amplicon(s) and primers HSSTROL3junc21-27F (SEQ ID NO:876) and HSSTROL3junc21-27R (SEQ ID NO:877) was measured by real time PCR (RNA was as for the experiment above). In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 30C is a histogram showing over expression of the above-indicated Stromelysin-3 precursor transcripts in cancerous breast samples relative to the normal samples .

As is evident from FIG. 30C, the expression of Stromelysin-3 precursor transcripts detectable by the above amplicon(s) in cancer samples was significantly higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67 Table 1: Tissue samples in testing panel, above). Notably an over-expression of at least 5 fold was found in 20 out of 28 adenocarcinoma samples.

Statistical analysis was applied to verify the significance of these results, as described below.

Threshold of 5 fold overexpression was found to differentiate between cancer and normal samples with P value of 6.75E-03 as checked by exact fisher test. The above values demonstrate statistical significance of the results.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: HSSTROL seg25F forward primer (SEQ ID NO:876); and HSSTROL seg25R reverse primer (SEQ ID NO:877).


Forward primer HSSTROL seg25F (SEQ ID NO:876):
CACTGCCCCAGCTTATCCC

Reverse primer HSSTROL seg25R (SEQ ID NO:877):
CTCTCCCAGCCTCAGTTTCCT

Amplicon HSSTROL seg25 (SEQ ID NO:878):
CACTGCCCCAGCTTATCCCAGGCCTCCCGCTTCCCTCTGCGGGTGGGGTG
CTGAGCAGGCATTATTGGCCTGCATGTTTTACTGATGAGGAAACTGAGGC
TGGGAGAG

Description for Cluster AY180924

Cluster AY180924 features 1 transcript(s) and 3 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	AY180924_PEA_1_T1	276

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	AY180924_PEA_1_node_3	277
	AY180924_PEA_1_node_0	278
	AY180924_PEA_1_node_2	279

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	AY180924_PEA_1_P3	281

These sequences are variants of the known protein Latherin precursor (SEQ ID NO:280) (SwissProt accession identifier LATH_HUMAN; known also according to the synonyms Breast cancer and salivary gland expressed protein), SEQ ID NO: 280, referred to herein as the previously known protein.

Protein Latherin precursor (SEQ ID NO:280) is known or believed to have the following function(s): surfactant properties. The sequence for protein Latherin precursor (SEQ ID NO:280) is given at the end of the application, as “Latherin precursor (SEQ ID NO:280) amino acid sequence”. The protein Latherin localization is believed to be Secreted.

As noted above, cluster AY180924 features 1 transcript, which were listed in Table 1 above. This transcript encode for protein which is a variant of protein Latherin precursor (SEQ ID NO:280). A description of the variant protein according to the present invention is now provided.

Variant protein AY180924_PEA_—1_P3 (SEQ ID NO:281) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) AY180924_PEA_—1_T1 (SEQ ID NO:276). An alignment is given to the known protein (Latherin precursor (SEQ ID NO:280)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between AY180924_PEA_—1_P3 (SEQ ID NO:281) and LATH_HUMAN (SEQ ID NO:280):

1. An isolated chimeric polypeptide encoding for AY180924_PEA_—1_P3 (SEQ ID NO:281), comprising a first amino acid sequence being at least 90% homologous to MLNVSGLFVLLCGLLVSSSAQEVLAGVSSQLLN corresponding to amino acids 1-33 of LATH_HUMAN (SEQ ID NO:280), which also corresponds to amino acids 1-33 of AY180924_PEA_—1_P3 (SEQ ID NO:281) , and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GETVLLWVMQNPEPMPVKFSLAKYLGHNEHY (SEQ ID NO:971) corresponding to amino acids 34-64 of AY180924_PEA_—1_P3 (SEQ ID NO:281), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of AY180924_PEA_—1_P3 (SEQ ID NO:281) comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GETVLLWVMQNPEPMPVKFSLAKYLGHNEHY (SEQ ID NO:971) in AY180924_PEA_—1_P3(SEQ ID NO:281).

Variant protein AY180924_PEA_—1_P3 (SEQ ID NO:281) is encoded by the following transcript(s): AY180924_PEA_—1_T1 (SEQ ID NO:276), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript AY180924_PEA_—1_T1 (SEQ ID NO:276) is shown in bold; this coding portion starts at position 73 and ends at position 264. The transcript also has the following SNPs as listed in Table 4 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein AY180924_PEA_—1_P3 (SEQ ID NO:281) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 4


Nucleic acid SNPs

SNP position on nucleotide	Alternative	Previously known
sequence	nucleic acid	SNP?

361	C -> T	Yes
459	C -> A	Yes

As noted above, cluster AY180924 features 3 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster AY180924_PEA_—1_node_—3 (SEQ ID NO:277) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AY180924_PEA_—1_T1 (SEQ ID NO:276). Table 5 below describes the starting and ending position of this segment on each transcript.

TABLE 5


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

AY180924_PEA_1_T1	173	657
(SEQ ID NO: 276)

Segment cluster AY180924_PEA_—1_node_—0 (SEQ ID NO:278) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AY180924_PEA_—1_T1 (SEQ ID NO:276). Table 6 below describes the starting and ending position of this segment on each transcript.

TABLE 6


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

AY180924_PEA_1_T1	1	58
(SEQ ID NO: 276)

Segment cluster AY180924_PEA_—1_node_—2 (SEQ ID NO:279) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): AY180924_PEA_—1_T1 (SEQ ID NO:276). Table 7 below describes the starting and ending position of this segment on each transcript.

TABLE 7


Segment location on transcripts

	Segment
Transcript name	starting position	Segment ending position

AY180924_PEA_1_T1	59	172
(SEQ ID NO: 276)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/FepOCusBjG/YVh7Ev127H:LATH_HUMAN (SEQ ID NO:280)

Sequence documentation:

Alignment of: AY180924_PEA_—1_P3 (SEQ ID NO:281)×LATH_HUMAN (SEQ ID NO:280).

Alignment segment 1/1:



Quality:	300.00
Escore:	0
Matching length:	33	Total length:	33
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent	100.00	Total Percent Identity:	100.00
Similarity:
Gaps:	0

Alignment:


1	MLNVSGLFVLLCGLLVSSSAQEVLAGVSSQLLN	33
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MLNVSGLFVLLCGLLVSSSAQEVLAGVSSQLLN	33

Description for Cluster R75793

Cluster R75793 features 3 transcript(s) and 9 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	R75793_PEA_1_T1	282
	R75793_PEA_1_T3	283
	R75793_PEA_1_T5	284

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	R75793_PEA_1_node_0	285
	R75793_PEA_1_node_9	286
	R75793_PEA_1_node_11	287
	R75793_PEA_1_node_14	288
	R75793_PEA_1_node_4	289
	R75793_PEA_1_node_5	290
	R75793_PEA_1_node_6	291
	R75793_PEA_1_node_8	292
	R75793_PEA_1_node_13	293

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

R75793_PEA_1_P2	295	R75793_PEA_1_T1 (SEQ ID
		NO: 282)
R75793_PEA_1_P5	296	R75793_PEA_1_T5 (SEQ ID
		NO: 284)
R75793_PEA_1_P6	297	R75793_PEA_1_T3 (SEQ ID
		NO: 283)

Cluster R75793 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 31 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 31 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors and a mixture of malignant tumors from different tissues.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	epithelial	16
	general	5
	Breast	457

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

epithelial	3.3e−01	5.0e−01	9.2e−17	4.0	2.7e−07	2.0
general	1.3e−01	2.0e−01	3.4e−33	8.0	2.0e−17	3.9
Breast	5.9e−01	7.1e−01	1.2e−07	2.1	1.4e−02	1.0

As noted above, cluster R75793 features 3 transcript(s), which were listed in Table 1 above. A description of each variant protein according to the present invention is now provided.

Variant protein R75793_PEA_—1_P2 (SEQ ID NO:295) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R75793_PEA_—1_T1 (SEQ ID NO:282). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R75793_PEA_—1_P2 (SEQ ID NO:295) and Q96DR8 (SEQ ID NO: 294):

1. An isolated chimeric polypeptide encoding for R75793_PEA_—1_P2 (SEQ ID NO:295), comprising a first amino acid sequence being at least 90% homologous to MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAATTATTAAPT TATTAASTTARKDIP corresponding to amino acids 1-74 of Q96DR8 (SEQ ID NO:294), which also corresponds to amino acids 1-74 of R75793_PEA_—1_P2 (SEQ ID NO:295), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AP corresponding to amino acids 75-76 of R75793_PEA_—1_P2 (SEQ ID NO:295), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

Variant protein R75793_PEA_—1_P2 (SEQ ID NO:295) is encoded by the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R75793_PEA_—1_T1 (SEQ ID NO:282) is shown in bold; this coding portion starts at position 69 and ends at position 296. The transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R75793_PEA_—1_P2 (SEQ ID NO:295) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

15	C -> A	Yes
59	G -> T	Yes
179	T -> C	No
179	T -> G	No
227	G -> A	Yes
516	A -> T	No

Variant protein R75793_PEA_—1_P5 (SEQ ID NO:296) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R75793_PEA_—1_T5 (SEQ ID NO:284). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein R75793_PEA_—1_P5 (SEQ ID NO:296) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R75793_PEA_—1_P5 (SEQ ID NO:296) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

54	H -> R	Yes

Variant protein R75793_PEA_—1_P5 (SEQ ID NO:296) is encoded by the following transcript(s): R75793_PEA_—1_T5 (SEQ ID NO:284), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R75793_PEA_—1_T5 (SEQ ID NO:284) is shown in bold; this coding portion starts at position 69 and ends at position 383. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R75793_PEA_—1_P5 (SEQ ID NO:296) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

15	C -> A	Yes
59	G -> T	Yes
229	A -> G	Yes

Variant protein R75793_PEA_—1_P6 (SEQ ID NO:297) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R75793_PEA_—1_T3 (SEQ ID NO:283). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein R75793_PEA_—1_P6 (SEQ ID NO:297) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R75793_PEA_—1_P6 (SEQ ID NO:297) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

16	R -> Q	Yes

Variant protein R75793_PEA_—1_P6 (SEQ ID NO:297) is encoded by the following transcript(s): R75793_PEA_—1_T3 (SEQ ID NO:283), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R75793_PEA_—1_T3 (SEQ ID NO:283) is shown in bold; this coding portion starts at position 329 and ends at position 502. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R75793_PEA_—1_P6 (SEQ ID NO:297) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

327	T -> C	No
327	T -> G	No
375	G -> A	Yes
635	A -> T	No

As noted above, cluster R75793 features 9 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster R75793_PEA_—1_node_—0 (SEQ ID NO:285) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T3 (SEQ ID NO:283). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T3 (SEQ ID NO: 283)	1	274

Segment cluster R75793_PEA_—1_node_—9 (SEQ ID NO:286) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T5 (SEQ ID NO:284). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T5 (SEQ ID NO: 284)	169	491

Segment cluster R75793_PEA_—1_node_—11 (SEQ ID NO:287) according to the present invention is supported by 59 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282) and R75793_PEA_—1_T3 (SEQ ID NO:283). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	169	291
R75793_PEA_1_T3 (SEQ ID NO: 283)	317	439

Segment cluster R75793_PEA_—1_node_—14 (SEQ ID NO:288) according to the present invention is supported by 41 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282) and R75793_PEA_—1_T3 (SEQ ID NO:283). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	321	527
R75793_PEA_1_T3 (SEQ ID NO: 283)	440	646

Segment cluster R75793_PEA_—1_node_—4 (SEQ ID NO:289) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282) and R75793_PEA_—1_T5 (SEQ ID NO:284). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	1	41
R75793_PEA_1_T5 (SEQ ID NO: 284)	1	41

Segment cluster R75793_PEA_—1_node_—5 (SEQ ID NO:290) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282) and R75793_PEA_—1_T5 (SEQ ID NO:284). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	42	74
R75793_PEA_1_T5 (SEQ ID NO: 284)	42	74

Segment cluster R75793_PEA_—1_node_—6 (SEQ ID NO:291) according to the present invention is supported by 54 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282) and R75793_PEA_—1_T5 (SEQ ID NO:284). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	75	126
R75793_PEA_1_T5 (SEQ ID NO: 284)	75	126

Segment cluster R75793_PEA_—1_node_—8 (SEQ ID NO:292) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282), R75793_PEA_—1_T3 (SEQ ID NO:283) and R75793_PEA1_T5 (SEQ ID NO:284). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	127	168
R75793_PEA_1_T3 (SEQ ID NO: 283)	275	316
R75793_PEA_1_T5 (SEQ ID NO: 284)	127	168

Segment cluster R75793_PEA_—1_node_—13 (SEQ ID NO:293) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R75793_PEA_—1_T1 (SEQ ID NO:282). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

R75793_PEA_1_T1 (SEQ ID NO: 282)	292	320

Variant protein alignment to the previously known protein:

Sequence name: Q96DR8 (SEQ ID NO:294)

Sequence documentation:

Alignment of: R75793_PEA_—1_P2 (SEQ ID NO:295)×Q96DR8 (SEQ ID NO:294).

Alignment segment 1/1:



Quality:	681.00
Escore:	0
Matching length:	74	Total length:	74
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent	100.00	Total Percent Identity:	100.00
Similarity:
Gaps:	0

Alignment:


	. . . . .
1	MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKFLAVLVLLGVSIFLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAA	50
	. .
51	TTATTAAPTTATTAASTTARKDIP	74
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	TTATTAAPTTATTAASTTARKDIP	74

Expression of Homo Sapiens Small Breast Epithelial Mucin (LOC118430) R75793 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name R75793 junc11-13 (SEQ ID NO:881) in Normal and Cancerous Breast Tissues

Expression of Homo sapiens small breast epithelial mucin (LOC118430) transcripts detectable by or according to junc11-13, R75793 junc11-13 (SEQ ID NO:881) amplicon(s) and primers R75793 junc11-13F (SEQ ID NO:879) and R75793 junc11-13R (SEQ ID NO:880) was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) and G6PD. (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921 ), was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold differential expression for each sample relative to median of the normal PM samples.

In one experiment that was carried out no differential expression in the cancerous samples relative to the normal PM samples was observed. However, this may be due to a failure of this particular experiment.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: R75793 junc11-13F forward primer (SEQ ID NO:879); and R75793 junc11-13R reverse primer (SEQ ID NO:880).


Forward primer R75793 junc11-13F (SEQ ID NO:879):
TGATGATGAAGCCCCTGATG

Reverse primer R75793 junc11-13R (SEQ ID NO:880):
TATTGTCAAGGGGCTGGAATGT

Amplicon R75793 junc11-13 (SEQ ID NO:881):
TGATGATGAAGCCCCTGATGCTGAAACCACTGCTGCTGCAACCACTGCGA
CCACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACCACTGCTCGT
AAAGACATTCCAGCCCCTTGACAATA

Expression of Homo Sapiens Small Breast Epithelial Mucin (LOC118430) R75793 Transcripts Which Are Detectable by Amplicon as Depicted in Sequence Name R75793 seg9 (SEQ ID NO:884) in Normal and Cancerous Breast Tissues

Expression of Homo sapiens small breast epithelial mucin (LOC118430) transcripts detectable by or according to seg9, R75793seg9 (SEQ ID NO:884) amplicon(s) and primers R75793 seg9F (SEQ ID NO:882) and R75793seg9R (SEQ ID NO:883) was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold differential expression for each sample relative to median of the normal PM samples.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: R75793seg9F forward primer (SEQ ID NO:882); and R75793seg9R reverse primer (SEQ ID NO:883).


Forward primer R75793seg9F (SEQ ID NO:882):
TCCAGCAATAACCATTTTTCACTTC

Reverse primer R75793seg9R (SEQ ID NO:883):
GCTTTCACAGACTTTTGCTTAGGATT

Amplicon R75793seg9 (SEQ ID NO:884):
TCCAGCAATAACCATTTTTCACTTCCAGCCTCATGTCAAACAGCCAGTTT
CCATGTGGATAGTCTTTGTTATAAGGAATCCTAAGCAAAAGTCTGTGAAA
GC

Description for Cluster HUMCA1XIA

Cluster HUMCA1XIA features 4 transcript(s) and 46 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HUMCA1XIA_T16	298
	HUMCA1XIA_T17	299
	HUMCA1XIA_T19	300
	HUMCA1XIA_T20	301

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HUMCA1XIA_node_0	302
	HUMCA1XIA_node_2	303
	HUMCA1XIA_node_4	304
	HUMCA1XIA_node_6	305
	HUMCA1XIA_node_8	306
	HUMCA1XIA_node_9	307
	HUMCA1XIA_node_18	308
	HUMCA1XIA_node_54	309
	HUMCA1XIA_node_55	310
	HUMCA1XIA_node_92	311
	HUMCA1XIA_node_11	312
	HUMCA1XIA_node_15	313
	HUMCA1XIA_node_19	314
	HUMCA1XIA_node_21	315
	HUMCA1XIA_node_23	316
	HUMCA1XIA_node_25	317
	HUMCA1XIA_node_27	318
	HUMCA1XIA_node_29	319
	HUMCA1XIA_node_31	320
	HUMCA1XIA_node_33	321
	HUMCA1XIA_node_35	322
	HUMCA1XIA_node_37	323
	HUMCA1XIA_node_39	324
	HUMCA1XIA_node_41	325
	HUMCA1XIA_node_43	326
	HUMCA1XIA_node_45	327
	HUMCA1XIA_node_47	328
	HUMCA1XIA_node_49	329
	HUMCA1XIA_node_51	330
	HUMCA1XIA_node_57	331
	HUMCA1XIA_node_59	332
	HUMCA1XIA_node_62	333
	HUMCA1XIA_node_64	334
	HUMCA1XIA_node_66	335
	HUMCA1XIA_node_68	336
	HUMCA1XIA_node_70	337
	HUMCA1XIA_node_72	338
	HUMCA1XIA_node_74	339
	HUMCA1XIA_node_76	340
	HUMCA1XIA_node_78	341
	HUMCA1XIA_node_81	342
	HUMCA1XIA_node_83	343
	HUMCA1XIA_node_85	344
	HUMCA1XIA_node_87	345
	HUMCA1XIA_node_89	346
	HUMCA1XIA_node_91	347

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

HUMCA1XIA_P14	350	HUMCA1XIA_T16
		(SEQ ID NO:298)

HUMCA1XIA_P15	351	HUMCA1XIA_T17
		(SEQ ID NO:299)

HUMCA1XIA_P16	352	HUMCA1XIA_T19
		(SEQ ID NO:300)

HUMCA1XIA_P17	353	HUMCA1XIA_T20
		(SEQ ID NO:301)

These sequences are variants of the known protein Collagen alpha 1 (SEQ ID NO:348) (SwissProt accession identifier CA1B_HUMAN; known also according to the synonyms XI), SEQ ID NO:348, referred to herein as the previously known protein.

Protein Collagen alpha 1 (SEQ ID NO:348) is known or believed to have the following function(s): May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils. The sequence for protein Collagen alpha 1 (SEQ ID NO:348) is given at the end of the application, as “Collagen alpha 1 (SEQ ID NO:348) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

625	G -> V (in STL2). /FTId = VAR_013583.
676	G -> R (in STL2; overlapping phenotype with
	Marshall syndrome). /FTId = VAR_013584.
921-926	Missing (in STL2; overlapping phenotype with
	Marshall syndrome). /FTId = VAR_013585.
1313-1315	Missing (in STL2; overlapping phenotype with
	Marshall syndrome). /FTId = VAR_013586.
1516	G -> V (in STL2; overlapping phenotype with
	Marshall syndrome). /FTId = VAR_013587.
941-944	KDGL -> RMGC
986	Y -> H
1074	R -> P
1142	G -> D
1218	M -> W
1758	T -> A
1786	S -> N

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: cartilage condensation; vision; hearing; cell-cell adhesion; extracellular matrix organization and biogenesis, which are annotation(s) related to Biological Process; extracellular matrix structural protein; extracellular matrix protein, adhesive, which are annotation(s) related to Molecular Function; and extracellular matrix; collagen; collagen type XI, which are annotation(s) related to Cellular Component.

Cluster HUMCA1XIA can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 32 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 32 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: bone malignant tumors, epithelial malignant tumors, a mixture of malignant tumors from different tissues and lung malignant tumors.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Adrenal	0
	Bone	207
	Brain	13
	Colon	0
	epithelial	11
	general	11
	head and neck	0
	kidney	0
	Lung	0
	Breast	8
	pancreas	0
	stomach	73
	Uterus	9

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	4.2e−01	1.9e−01	9.6e−02	3.4	8.2e−02	3.6
Bone	2.4e−01	6.3e−01	7.7e−10	4.3	5.3e−03	1.6
Brain	5.0e−01	6.9e−01	1.8e−01	2.1	4.2e−01	1.3
Colon	1.3e−02	2.9e−02	2.4e−01	3.0	3.5e−01	2.4
epithelial	3.9e−04	3.2e−03	1.3e−03	2.3	1.8e−02	1.7
general	5.6e−05	1.6e−03	9.5e−17	4.5	1.1e−09	2.8
head and neck	1.2e−01	2.1e−01	1	1.3	1	1.1
kidney	6.5e−01	7.2e−01	3.4e−01	2.4	4.9e−01	1.9
Lung	5.3e−02	9.1e−02	5.5e−05	7.3	5.0e−03	4.0
Breast	4.3e−01	5.6e−01	6.9e−01	1.4	8.2e−01	1.1
pancreas	3.3e−01	1.8e−01	4.2e−01	2.4	1.5e−01	3.7
stomach	5.0e−01	6.1e−01	6.9e−01	1.0	6.7e−01	0.8
Uterus	7.1e−01	7.0e−01	6.6e−01	1.1	6.4e−01	1.1

As noted above, cluster HUMCA1XIA features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Collagen alpha 1 (SEQ ID NO:348). A description of each variant protein according to the present invention is now provided.

Variant protein HUMCA1XIA_P14 (SEQ ID NO:350) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMCA1XIA_T16 (SEQ ID NO:298). An alignment is given to the known protein (Collagen alpha 1 (SEQ ID NO:348)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMCA1XIA_P14 (SEQ ID NO:350) and CA1B_HUMAN_V5 (SEQ ID NO: 349):

1. An isolated chimeric polypeptide encoding for HUMCA1XIA_P14 (SEQ ID NO:350), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAG PRGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQG PIGPPGEKGPQGKPGLAGLPGADGPPGHPGKEGQSGEKGALGPPGPQGPIGYPGPRGVK GADGVRGLKGSKGEKGEDGFPGFKGDMGLKGDRGEVGQIGPRGEDGPEGPKGRAGPT GDPGPSGQAGEKGKLGVPGLPGYPGRQGPKGSTGFPGFPGANGEKGARGVAGKPGPR GQRGPTGPRGSRGARGPTGKPGPKGTSGGDGPPGPPGERGPQGPQGPVGFPGPKGPPGP PGKDGLPGHPGQRGETGFQGKTGPPGPGGVVGPQGPTGETGPIGERGHPGPPGPPGEQG LPGAAGKEGAKGDPGPQGISGKDGPAGLRGFPGERGLPGAQGAPGLKGGEGPQGPPGP V corresponding to amino acids 1-1056 of CA1B_HUMAN_V5 (SEQ ID NO:349), which also corresponds to amino acids 1-1056 of HUMCA1XIA_P14 (SEQ ID NO:350), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSMMIINSQTIMVVNYSSSFITLML (SEQ ID NO:972) corresponding to amino acids 1057-1081 of HUMCA1XIA_P14 (SEQ ID NO:350), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HUMCA1XIA_P14 (SEQ ID NO:350), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSMMIINSQTIMVVNYSSSFITLML (SEQ ID NO:972) in HUMCA1XIA_P14 (SEQ ID NO:350).

It should be noted that the known protein sequence (CA1B_HUMAN; SEQ ID NO:348) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for CA1B_HUMAN_V5 (SEQ ID NO:349) (SEQ ID NO:349). These changes were previously known to occur and are listed in the table below.

TABLE 7


Changes to CA1B_HUMAN_V5 (SEQ ID NO: 349)

SNP position(s) on
amino acid sequence	Type of change

987	conflict

Variant protein HUMCA1XIA_P14 (SEQ ID NO:350) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P14 (SEQ ID NO:350) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

8	W -> G	Yes
46	D -> E	Yes
559	G -> S	Yes
832	G -> *	Yes
986	H -> Y	Yes
1061	I -> M	Yes
1070	V -> A	Yes

Variant protein HUMCA1XIA_P14 (SEQ ID NO:350) is encoded by the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMCA1XIA_T16 (SEQ ID NO:298) is shown in bold; this coding portion starts at position 319 and ends at position 3561. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P14 (SEQ ID NO:350) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

157	A -> G	No
241	T -> A	Yes
340	T -> G	Yes
456	T -> G	Yes
1993	G -> A	Yes
2812	G -> T	Yes
3274	C -> T	Yes
3282	C -> T	Yes
3501	A -> G	Yes
3527	T -> C	Yes

Variant protein HUMCA1XIA_P15 (SEQ ID NO:351) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMCA1XIA_T17 (SEQ ID NO:299). An alignment is given to the known protein (Collagen alpha 1 (SEQ ID NO:348)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMCA1XIA_P15 (SEQ ID NO:351) and CA1B_HUMAN (SEQ ID NO:348):

1. An isolated chimeric polypeptide encoding for HUMCA1XIA_P15 (SEQ ID NO:351), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAG PRGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQG PIGPPGEK corresponding to amino acids 1-714 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-714 of HUMCA1XIA_P15 (SEQ ID NO:351 ), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MCCNLSFGILIPLQK (SEQ ID NO:973) corresponding to amino acids 715-729 of HUMCA1XIA_P15 (SEQ ID NO:351) , wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HUMCA1XIA_P15 (SEQ ID NO:351), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MCCNLSFGILIPLQK (SEQ ID NO:973) in HUMCA1XIA_P15 (SEQ ID NO:351).

Variant protein HUMCA1XIA_P15 (SEQ ID NO:351) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P15 (SEQ ID NO:351) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

8	W -> G	Yes
46	D -> E	Yes
559	G -> S	Yes

The glycosylation sites of variant protein HUMCA1XIA_P15 (SEQ ID NO:351), as compared to the known protein Collagen alpha 1 (SEQ ID NO:348), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 11


Glycosylation site(s)

	Position(s) on known	Present in
	amino acid sequence	variant protein?

	1640	no

Variant protein HUMCA1XIA_P15 (SEQ ID NO:351) is encoded by the following transcript(s): HUMCA1XIA_T17 (SEQ ID NO:299), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMCA1XIA_T17 (SEQ ID NO:299) is shown in bold; this coding portion starts at position 319 and ends at position 2505. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P15 (SEQ ID NO:351) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

157	A -> G	No
241	T -> A	Yes
340	T -> G	Yes
456	T -> G	Yes
1993	G -> A	Yes
2473	C -> T	Yes

Variant protein HUMCA1XIA_P16 (SEQ ID NO:352) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMCA1XIA_T19 (SEQ ID NO:300). An alignment is given to the known protein (Collagen alpha 1 (SEQ ID NO:348)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMCA1XIA_P16 (SEQ ID NO:352) and CA1B_HUMAN (SEQ ID NO:348):

1. An isolated chimeric polypeptide encoding for HUMCA1XIA_P16 (SEQ ID NO:352), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQT EANIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDSQRKNSED TLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEEFGPGVPAETDITETSIN GHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPAGIMGPPGLQGPTGPPGDPGDRGPPG RPGLPGADGLPGPPGTMLMLPFRYGGDGSKGPTISAQEAQAQAILQQARIALRGPPGPM GLTGRPGPVGGPGSSGAKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMP GEPGAKGDRGFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEA corresponding to amino acids 1-648 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-648 of HUMCA1XIA_P16 (SEQ ID NO:352), a second amino acid sequence being at least 90% homologous to GMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQGLPGPQGPIGPPGEK corresponding to amino acids 667-714 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 649-696 of HUMCA1XIA_P16 (SEQ ID NO:352), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSFSFSLFYKKVIKFACDKRFVGRHDERKVVKLSLPLYLIYE (SEQ ID NO:974) corresponding to amino acids 697-738 of HUMCA1XIA_P16 (SEQ ID NO:352), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.

2. An isolated chimeric polypeptide encoding for an edge portion of HUMCA1XIA_P16 (SEQ ID NO:352), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 648-x to 648; and ending at any of amino acid numbers 649+((n−2)−x), in which x varies from 0 to n−2.

3. An isolated polypeptide encoding for a tail of HUMCA1XIA_P16 (SEQ ID NO:352), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSFSFSLFYKKVIKFACDKRFVGRHDERKVVKLSLPLYLIYE (SEQ ID NO:974) in HUMCA1XIA_P16 (SEQ ID NO:352).

Variant protein HUMCA1XIA_P16 (SEQ ID NO:352) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P16 (SEQ ID NO:352) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

8	W -> G	Yes
46	D -> E	Yes
559	G -> S	Yes

The glycosylation sites of variant protein HUMCA1XIA_P16 (SEQ ID NO:352), as compared to the known protein Collagen alpha 1 (SEQ ID NO:348), are described in Table 14 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 14


Glycosylation site(s)

	Position(s) on known	Present in
	amino acid sequence	variant protein?

	1640	no

Variant protein HUMCA1XIA_P16 (SEQ ID NO:352) is encoded by the following transcript(s): HUMCA1XIA_T19 (SEQ ID NO:300), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMCA1XIA_T19 (SEQ ID NO:300) is shown in bold; this coding portion starts at position 319 and ends at position 2532. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P16 (SEQ ID NO:352) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

157	A -> G	No
241	T -> A	Yes
340	T -> G	Yes
456	T -> G	Yes
1993	G -> A	Yes
2606	C -> A	Yes
2677	T -> G	Yes
2849	C -> T	Yes

Variant protein HUMCA1XIA_P17 (SEQ ID NO:353) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMCA1XIA_T20 (SEQ ID NO:301). An alignment is given to the known protein (Collagen alpha 1 (SEQ ID NO:348)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMCA1XIA_P17 (SEQ ID NO:353) and CA1B_HUMAN (SEQ ID NO:348):

1. An isolated chimeric polypeptide encoding for HUMCA1XIA_P17 (SEQ ID NO:353), comprising a first amino acid sequence being at least 90% homologous to MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNSPEGISKTT GFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFSILFTVKPKKGIQSFLLSIY NEHGIQQIGVEVGRSPVFLFEDHTGKPAPEDYPLFRTVNIADGKWHRVAISVEKKTVTM IVDCKKKTTKPLDRSERAIVDTNGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEH YSPDCDSSAPKAAQAQEPQIDE corresponding to amino acids 1-260 of CA1B_HUMAN (SEQ ID NO:348), which also corresponds to amino acids 1-260 of HUMCA1XIA_P17 (SEQ ID NO:353), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRSTRPEKVFVFQ (SEQ ID NO:975) corresponding to amino acids 261-273 of HUMCA1XIA_P17 (SEQ ID NO:353), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HUMCA1XIA_P17 (SEQ ID NO:353), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRSTRPEKVFVFQ (SEQ ID NO:975) in HUMCA1XIA_P17 (SEQ ID NO:353).

Variant protein HUMCA1XIA_P17 (SEQ ID NO:353) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 16, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P17 (SEQ ID NO:353) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 16


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

8	W -> G	Yes
46	D -> E	Yes

The glycosylation sites of variant protein HUMCA1XIA_P17 (SEQ ID NO:353), as compared to the known protein Collagen alpha 1 (SEQ ID NO:348), are described in Table 17 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 17


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

1640	no

Variant protein HUMCA1XIA_P17 (SEQ ID NO:353) is encoded by the following transcript(s): HUMCA XIA_T20 (SEQ ID NO:301), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMCA1XIA_T20 (SEQ ID NO:301) is shown in bold; this coding portion starts at position 319 and ends at position 1137. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMCA1XIA_P17 (SEQ ID NO:353) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 18


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

157	A -> G	No
241	T -> A	Yes
340	T -> G	Yes
456	T -> G	Yes
1150	A -> C	Yes

As noted above, cluster HUMCA1XIA features 46 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HUMCA1XIA_node_—0 (SEQ ID NO:302) according to the present invention is supported by 13 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299), HUMCA1XIA_T19 (SEQ ID NO:300) and HUMCA1XIA_T20 (SEQ ID NO:301 ). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1	424

HUMCA1XIA_T17 (SEQ ID NO:299)	1	424

HUMCA1XIA_T19 (SEQ ID NO:300)	1	424

HUMCA1XIA_T20 (SEQ ID NO:301)	1	424

Segment cluster HUMCA1XIA_node_—2 (SEQ ID NO:303) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299), HUMCA1XIA_T19 (SEQ ID NO:300) and HUMCA1XIA_T20 (SEQ ID NO:301). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	425	592

HUMCA1XIA_T17 (SEQ ID NO:299)	425	592

HUMCA1XIA_T19 (SEQ ID NO:300)	425	592

HUMCA1XIA_T20 (SEQ ID NO:301)	425	592

Segment cluster HUMCA1XIA_node_—4 (SEQ ID NO:304) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299), HUMCA1XIA_T19 (SEQ ID NO:300) and HUMCA1XIA_T20 (SEQ ID NO:301). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	593	806

HUMCA1XIA_T17 (SEQ ID NO:299)	593	806

HUMCA1XIA_T19 (SEQ ID NO:300)	593	806

HUMCA1XIA_T20 (SEQ ID NO:301)	593	806

Microarray (chip) data is also available for this segment as follows. As described above with regard to the cluster itself, various oligonucleotides were tested for being differentially expressed in various disease conditions, particularly cancer. The following oligonucleotides were found to hit this segment (in relation to breast cancer), shown in Table 22.

TABLE 22


Oligonucleotides related to this segment

	Overexpressed	Chip
Oligonucleotide name	in cancers	reference

HUMCA1XIA_0_18_0	breast malignant	BRS
(SEQ ID NO:904)	tumors

Segment cluster HUMCA1XIA_node_—6 (SEQ ID NO:305) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299), HUMCA1XIA_T19 (SEQ ID NO:300) and HUMCA1XIA_T20 (SEQ ID NO:301). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	807	969

HUMCA1XIA_T17 (SEQ ID NO:299)	807	969

HUMCA1XIA_T19 (SEQ ID NO:300)	807	969

HUMCA1XIA_T20 (SEQ ID NO:301)	807	969

TABLE 24


Oligonucleotides related to this segment

	Overexpressed	Chip
Oligonucleotide name	in cancers	reference

HUMCA1XIA_0_18_0	breast malignant	BRS
(SEQ ID NO:904)	tumors

Segment cluster HUMCA1XIA_node_—8 (SEQ ID NO:306) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299), HUMCA1XIA_T19 (SEQ ID NO:300) and HUMCA1XIA_T20 (SEQ ID NO:301). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	970	1098

HUMCA1XIA_T17 (SEQ ID NO:299)	970	1098

HUMCA1XIA_T19 (SEQ ID NO:300)	970	1098

HUMCA1XIA_T20 (SEQ ID NO:301)	970	1098

Segment cluster HUMCA1XIA_node_—9 (SEQ ID NO:307) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T20 (SEQ ID NO:301). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T20 (SEQ ID NO:301)	1099	1271

Segment cluster HUMCA1XIA_node_—18 (SEQ ID NO:308) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1309	1522

HUMCA1XIA_T17 (SEQ ID NO:299)	1309	1522

HUMCA1XIA_T19 (SEQ ID NO:300)	1309	1522

Segment cluster HUMCA1XIA_node_—54 (SEQ ID NO:309) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T19 (SEQ ID NO:300). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T19 (SEQ ID NO:300)	2407	2836

Segment cluster HUMCA1XIA_node_—55 (SEQ ID NO:310) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T17 (SEQ ID NO 299)	2461	2648

HUMCA1XIA_T19 (SEQ ID NO 300)	2837	3475

TABLE 30


Oligonucleotides related to this segment

	Overexpressed	Chip
Oligonucleotide name	in cancers	reference

HUMCA1XIA_0_0_14909	breast malignant	BRS
(SEQ ID NO:903)	tumors

Segment cluster HUMCA1XIA_node_—92 (SEQ ID NO:311) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	3487	3615

Segment cluster HUMCA1XIA_node_—11 (SEQ ID NO:312) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1099	1215

HUMCA1XIA_T17 (SEQ ID NO:299)	1099	1215

HUMCA1XIA_T19 (SEQ ID NO:300)	1099	1215

Segment cluster HUMCA1XIA_node_—15 (SEQ ID NO:313) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1216	1308

HUMCA1XIA_T17 (SEQ ID NO:299)	1216	1308

HUMCA1XIA_T19 (SEQ ID NO:300)	1216	1308

Segment cluster HUMCA1XIA_node_—19 (SEQ ID NO:314) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1523	1563

HUMCA1XIA_T17 (SEQ ID NO:299)	1523	1563

HUMCA1XIA_T19 (SEQ ID NO:300)	1523	1563

Segment cluster HUMCA1XIA_node_—21 (SEQ ID NO:315) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1564	1626

HUMCA1XIA_T17 (SEQ ID NO:299)	1564	1626

HUMCA1XIA_T19 (SEQ ID NO:300)	1564	1626

Segment cluster HUMCA1XIA_node_—23 (SEQ ID NO:316) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1627	1668

HUMCA1XIA_T17 (SEQ ID NO:299)	1627	1668

HUMCA1XIA_T19 (SEQ ID NO:300)	1627	1668

Segment cluster HUMCA1XIA_node_—25 (SEQ ID NO:317) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1669	1731

HUMCA1XIA_T17 (SEQ ID NO:299)	1669	1731

HUMCA1XIA_T19 (SEQ ID NO:300)	1669	1731

Segment cluster HUMCA1XIA_node_—27 (SEQ ID NO:318) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1732	1806

HUMCA1XIA_T17 (SEQ ID NO:299)	1732	1806

HUMCA1XIA_T19 (SEQ ID NO:300)	1732	1806

Segment cluster HUMCA1XIA_node_—29 (SEQ ID NO:319) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1807	1890

HUMCA1XIA_T17 (SEQ ID NO:299)	1807	1890

HUMCA1XIA_T19 (SEQ ID NO:300)	1807	1890

Segment cluster HUMCA1XIA_node_—31 (SEQ ID NO:320) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1891	1947

HUMCA1XIA_T17 (SEQ ID NO:299)	1891	1947

HUMCA1XIA_T19 (SEQ ID NO:300)	1891	1947

Segment cluster HUMCA1XIA_node_—33 (SEQ ID NO:321) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	1948	2001

HUMCA1XIA_T17 (SEQ ID NO:299)	1948	2001

HUMCA1XIA_T19 (SEQ ID NO:300)	1948	2001

Segment cluster HUMCA1XIA_node_—35 (SEQ ID NO:322) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2002	2055

HUMCA1XIA_T17 (SEQ ID NO:299)	2002	2055

HUMCA1XIA_T19 (SEQ ID NO:300)	2002	2055

Segment cluster HUMCA1XIA_node_—37 (SEQ ID NO:323) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 43 below describes the starting and ending position of this segment on each transcript.

TABLE 43


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2056	2109

HUMCA1XIA_T17 (SEQ ID NO:299)	2056	2109

HUMCA1XIA_T19 (SEQ ID NO:300)	2056	2109

Segment cluster HUMCA1XIA_node_—39 (SEQ ID NO:324) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 44 below describes the starting and ending position of this segment on each transcript.

TABLE 44


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2110	2163

HUMCA1XIA_T17 (SEQ ID NO:299)	2110	2163

HUMCA1XIA_T19 (SEQ ID NO:300)	2110	2163

Segment cluster HUMCA1XIA_node_—41 (SEQ ID NO:325) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 45 below describes the starting and ending position of this segment on each transcript.

TABLE 45


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2164	2217

HUMCA1XIA_T17 (SEQ ID NO:299)	2164	2217

HUMCA1XIA_T19 (SEQ ID NO:300)	2164	2217

Segment cluster HUMCA1XIA_node_—43 (SEQ ID NO:326) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 46 below describes the starting and ending position of this segment on each transcript.

TABLE 46


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCAIXIA_T16 (SEQ ID NO:298)	2218	2262

HUMCA1XIA_T17 (SEQ ID NO:299)	2218	2262

HUMCA1XIA_T19 (SEQ ID NO:300)	2218	2262

Segment cluster HUMCA1XIA_node_—45 (SEQ ID NO:327) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298) and HUMCA1XIA_T17 (SEQ ID NO:299). Table 47 below describes the starting and ending position of this segment on each transcript.

TABLE 47


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2263	2316

HUMCA1XIA_T17 (SEQ ID NO:299)	2263	2316

Segment cluster HUMCA1XIA_node_—47 (SEQ ID NO:328) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298, HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 48 below describes the starting and ending position of this segment on each transcript.

TABLE 48


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2317	2361

HUMCA1XIA_T17 (SEQ ID NO:299)	2317	2361

HUMCA1XIA_T19 (SEQ ID NO:300)	2263	2307

Segment cluster HUMCA1XIA_node_—49 (SEQ ID NO:329) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 49 below describes the starting and ending position of this segment on each transcript.

TABLE 49


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2362	2415

HUMCA1XIA_T17 (SEQ ID NO:299)	2362	2415

HUMCA1XIA_T19 (SEQ ID NO:300)	2308	2361

Segment cluster HUMCA1XIA_node_—51 (SEQ ID NO:330) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298), HUMCA1XIA_T17 (SEQ ID NO:299) and HUMCA1XIA_T19 (SEQ ID NO:300). Table 50 below describes the starting and ending position of this segment on each transcript.

TABLE 50


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2416	2460

HUMCA1XIA_T17 (SEQ ID NO:299)	2416	2460

HUMCA1XIA_T19 (SEQ ID NO:300)	2362	2406

Segment cluster HUMCA1XIA_node_—57 (SEQ ID NO:331) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 51 below describes the starting and ending position of this segment on each transcript.

TABLE 51


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2461	2514

Segment cluster HUMCA1XIA_node_—59 (SEQ ID NO:332) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 52 below describes the starting and ending position of this segment on each transcript.

TABLE 52


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2515	2559

Segment cluster HUMCA1XIA_node_—62 (SEQ ID NO:333) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 53 below describes the starting and ending position of this segment on each transcript.

TABLE 53


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2560	2613

Segment cluster HUMCA1XIA_node_—64 (SEQ ID NO:334) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 54 below describes the starting and ending position of this segment on each transcript.

TABLE 54


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2614	2658

Segment cluster HUMCA1XIA_node_—66 (SEQ ID NO:335) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 55 below describes the starting and ending position of this segment on each transcript.

TABLE 55


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HUMCA1XIA_T16 (SEQ ID NO:298)	2659	2712

Segment cluster HUMCA1XIA_node_—68 (SEQ ID NO:336) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 56 below describes the starting and ending position of this segment on each transcript.

TABLE 56


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	2713	2820

Segment cluster HUMCA1XIA_node_—70 (SEQ ID NO:337) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 57 below describes the starting and ending position of this segment on each transcript.

TABLE 57


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	2821	2874

Segment cluster HUMCA1XIA_node_—72 (SEQ ID NO:338) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 58 below describes the starting and ending position of this segment on each transcript.

TABLE 58


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	2875	2928

Segment cluster HUMCA1XIA_node_—74 (SEQ ID NO:339) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 59 below describes the starting and ending position of this segment on each transcript.

TABLE 59


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	2929	2973

Segment cluster HUMCA1XIA_node_—76 (SEQ ID NO:340) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 60 below describes the starting and ending position of this segment on each transcript.

TABLE 60


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	2974	3027

Segment cluster HUMCA1XIA_node_—78 (SEQ ID NO:341) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 61 below describes the starting and ending position of this segment on each transcript.

TABLE 61


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3028	3072

Segment cluster HUMCA1XIA_node_—81 (SEQ ID NO:342) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 62 below describes the starting and ending position of this segment on each transcript.

TABLE 62


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3073	3126

Segment cluster HUMCA1XIA_node_—83 (SEQ ID NO:343) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 63 below describes the starting and ending position of this segment on each transcript.

TABLE 63


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3127	3180

Segment cluster HUMCA1XIA_node_—85 (SEQ ID NO:344) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 64 below describes the starting and ending position of this segment on each transcript.

TABLE 64


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3181	3234

Segment cluster HUMCA1XIA_node_—87 (SEQ ID NO:345) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 65 below describes the starting and ending position of this segment on each transcript.

TABLE 65


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3235	3342

Segment cluster HUMCA1XIA_node_—89 (SEQ ID NO:346) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 66 below describes the starting and ending position of this segment on each transcript.

TABLE 66


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3343	3432

Segment cluster HUMCA1XIA_node_—91 (SEQ ID NO:347) according to the present invention is supported by 11 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMCA1XIA_T16 (SEQ ID NO:298). Table 67 below describes the starting and ending position of this segment on each transcript.

TABLE 67


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMCA1XIA_T16 (SEQ ID NO:298)	3433	3486

Transcript nucleic acid sequences:

Variant protein alignment to the previously known protein:

Sequence name: CA1B_HUMAN_V5 (SEQ ID NO:349)

Sequence documentation:

Alignment of: HUMCA1XIA_P14 (SEQ ID NO:350)×CA1B_HUMAN_V5 (SEQ ID NO:349).

Alignment segment 1/1:



Quality:	10456.00
Escore:	0
Matching length:	1058	Total length:	1058
Matching Percent	99.91	Matching Percent	99.91
Similarity:		Identity:
Total Percent Similarity:	99.91	Total Percent Identity:	99.91
Gaps:	0

Alignment:


	. . . . .
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	. . . . .
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	. . . . .
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	. . . . .
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	. . . . .
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	. . . . .
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	. . . . .
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	. . . . .
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	. . . . .
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	. . . . .
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	. . . . .
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	. . . . .
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	. . . . .
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAGP	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAGP	650
	. . . . .
651	RGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	RGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	700
	. . . . .
701	LPGPQGPIGPPGEKGPQGKPGLAGLPGADGPPGHPGKEGQSGEKGALGPP	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	LPGPQGPIGPPGEKGPQGKPGLAGLPGADGPPGHPGKEGQSGEKGALGPP	750
	. . . . .
751	GPQGPIGYPGPRGVKGADGVRGLKGSKGEKGEDGFPGFKGDMGLKGDRGE	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	GPQGPIGYPGPRGVKGADGVRGLKGSKGEKGEDGFPGFKGDMGLKGDRGE	800
	. . . . .
801	VGQIGPRGEDGPEGPKGRAGPTGDPGPSGQAGEKGKLGVPGLPGYPGRQG	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	VGQIGPRGEDGPEGPKGRAGPTGDPGPSGQAGEKGKLGVPGLPGYPGRQG	850
	. . . . .
851	PKGSTGFPGFPGANGEKGARGVAGKPGPRGQRGPTGPRGSRGARGPTGKP	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	PKGSTGFPGFPGANGEKGARGVAGKPGPRGQRGPTGPRGSRGARGPTGKP	900
	. . . . .
901	GPKGTSGGDGPPGPPGERGPQGPQGPVGFPGPKGPPGPPGKDGLPGHPGQ	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	GPKGTSGGDGPPGPPGERGPQGPQGPVGFPGPKGPPGPPGKDGLPGHPGQ	950
	. . . . .
951	RGETGFQGKTGPPGPGGVVGPQGPTGETGPIGERGHPGPPGPPGEQGLPG	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	RGETGFQGKTGPPGPGGVVGPQGPTGETGPIGERGHPGPPGPPGEQGLPG	1000
	. . . . .
1001	AAGKEGAKGDPGPQGISGKDGPAGLRGFPGERGLPGAQGAPGLKGGEGPQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	AAGKEGAKGDPGPQGISGKDGPAGLRGFPGERGLPGAQGAPGLKGGEGPQ	1050

1051	GPPGPVVS	1058
	\|\|\|\|\|\| \|
1051	GPPGPVGS	1058

Sequence name: CA1B_HUMAN (SEQ ID NO:348)

Sequence documentation:

Alignment of: HUMCA1XIA_P15 (SEQ ID NO:351)×CA1B_HUMAN (SEQ ID NO:348).

Alignment segment 1/1:



Quality:	7073.00
Escore:	0
Matching length:	714	Total length:	714
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	. . . . .
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	. . . . .
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	. . . . .
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	. . . . .
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	. . . . .
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	. . . . .
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	. . . . .
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	. . . . .
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	. . . . .
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	. . . . .
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	. . . . .
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	. . . . .
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAGP	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAGP	650
	. . . . .
651	RGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	RGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	700
	.
701	LPGPQGPIGPPGEK	714
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	LPGPQGPIGPPGEK	714

Sequence name: CA1B_HUMAN (SEQ ID NO:348)

Sequence documentation:

Alignment of: HUMCA1XIA_P16 (SEQ ID NO:352)×CA1B_HUMAN (SEQ ID NO:348).

Alignment segment 1/1:



Quality:	6795.00
Escore:	0
Matching length:	696	Total length:	714
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	97.48	Total Percent Identity:	97.48
Gaps:	1

Alignment:


	. . . . .
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	. . . . .
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	. . . . .
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	. . . . .
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	. . . . .
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	. . . . .
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	AQAQEPQIDEYAPEDIIEYDYEYGEAEYKEAESVTEGPTVTEETIAQTEA	300
	. . . . .
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	NIVDDFQEYNYGTMESYQTEAPRHVSGTNEPNPVEEIFTEEYLTGEDYDS	350
	. . . . .
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	QRKNSEDTLYENKEIDGRDSDLLVDGDLGEYDFYEYKEYEDKPTSPPNEE	400
	. . . . .
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	FGPGVPAETDITETSINGHGAYGEKGQKGEPAVVEPGMLVEGPPGPAGPA	450
	. . . . .
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GIMGPPGLQGPTGPPGDPGDRGPPGRPGLPGADGLPGPPGTMLMLPFRYG	500
	. . . . .
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GDGSKGPTISAQEAQAQAILQQARIALRGPPGPMGLTGRPGPVGGPGSSG	550
	. . . . .
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	AKGESGDPGPQGPRGVQGPPGPTGKPGKRGRPGADGGRGMPGEPGAKGDR	600
	. . . . .
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEA..	648
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	GFDGLPGLPGDKGHRGERGPQGPPGPPGDDGMRGEDGEIGPRGLPGEAGP	650
	. . . . .
649	................GMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	682
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	RGLLGPRGTPGAPGQPGMAGVDGPPGPKGNMGPQGEPGPPGQQGNPGPQG	700
	.
683	LPGPQGPIGPPGEK	696
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	LPGPQGPIGPPGEK	714

Sequence name: CA1B_HUMAN (SEQ ID NO:348)

Sequence documentation:

Alignment of: HUMCA1XIA_P17 (SEQ ID NO:353)×CA1B HUMAN (SEQ ID NO:348).

Alignment segment 1/1:



Quality:	2561.00
Escore:	0
Matching length:	260	Total length:	260
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MEPWSSRWKTKRWLWDFTVTTLALTFLFQAREVRGAAPVDVLKALDFHNS	50
	. . . . .
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PEGISKTTGFCTNRKNSKGSDTAYRVSKQAQLSAPTKQLFPGGTFPEDFS	100
	. . . . .
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ILFTVKPKKGIQSFLLSIYNEHGIQQIGVEVGRSPVFLFEDHTGKPAPED	150
	. . . . .
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	YPLFRTVNIADGKWHRVAISVEKKTVTMIVDCKKKTTKPLDRSERAIVDT	200
	. . . . .
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	NGITVFGTRILDEEVFEGDIQQFLITGDPKAAYDYCEHYSPDCDSSAPKA	250
	.
251	AQAQEPQIDE	260
	\|\|\|\|\|\|\|\|\|\|
251	AQAQEPQIDE	260

Description for Cluster R20779

Cluster R20779 features 1 transcript(s) and 24 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	R20779_T7	354

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	R20779_node_0	355
	R20779_node_2	356
	R20779_node_7	357
	R20779_node_9	358
	R20779_node_18	359
	R20779_node_21	360
	R20779_node_24	361
	R20779_node_27	362
	R20779_node_28	363
	R20779_node_30	364
	R20779_node_31	365
	R20779_node_32	366
	R20779_node_1	367
	R20779_node_3	368
	R20779_node_10	369
	R20779_node_11	370
	R20779_node_14	371
	R20779_node_17	372
	R20779_node_19	373
	R20779_node_20	374
	R20779_node_22	375
	R20779_node_23	376
	R20779_node_25	377
	R20779_node_29	378

TABLE 3


Proteins of interest

Protein Name	Sequence ID No.	Corresponding Transcript(s)

R20779_P2	380	R20779_T7 (SEQ ID
		NO: 354)

These sequences are variants of the known protein Stanniocalcin 2 precursor (SEQ ID NO:379) (SwissProt accession identifier STC2_HUMAN; known also according to the synonyms STC-2; Stanniocalcin-related protein; STCRP; STC-related protein), SEQ ID NO: 379, referred to herein as the previously known protein.

Protein Stanniocalcin 2 precursor (SEQ ID NO:379) is known or believed to have the following function(s): Has an anti-hypocalcemic action on calcium and phosphate homeostasis. The sequence for protein Stanniocalcin 2 precursor (SEQ ID NO:379) is given at the end of the application, as “Stanniocalcin 2 precursor (SEQ ID NO:379) amino acid sequence”. Protein Stanniocalcin 2 precursor (SEQ ID NO:379) localization is believed to be Secreted (Potential).

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: cell surface receptor linked signal transduction; cell-cell signaling; nutritional response pathway, which are annotation(s) related to Biological Process; hormone, which are annotation(s) related to Molecular Function; and extracellular, which are annotation(s) related to Cellular Component.

Cluster R20779 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 33 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 33 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues and lung malignant tumors.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	Bone	825
	Brain	0
	Colon	0
	epithelial	32
	general	38
	kidney	22
	Liver	9
	Lung	11
	Lymph nodes	0
	Breast	215
	muscle	35
	Ovary	36
	pancreas	4
	prostate	80
	Skin	99
	stomach	0
	Uterus	4

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

Bone	5.9e−01	7.4e−01	1	0.2	1	0.1
Brain	2.5e−02	1.6e−02	2.2e−01	6.0	3.5e−02	8.0
Colon	1.7e−01	1.7e−01	1	1.3	7.7e−01	1.5
epithelial	1.7e−01	1.5e−03	5.9e−01	1.0	2.0e−04	2.0
general	2.4e−02	6.2e−07	7.6e−01	0.8	4.6e−05	1.6
kidney	4.3e−01	2.7e−01	6.2e−01	1.3	1.5e−01	2.0
Liver	8.3e−01	7.6e−01	1	0.8	3.3e−01	1.6
Lung	1.2e−01	1.4e−03	1.9e−01	2.9	1.6e−05	7.7
Lymph nodes	1	3.1e−01	1	1.0	1	1.4
Breast	6.8e−01	6.8e−01	6.9e−01	0.8	3.6e−01	0.8
muscle	9.2e−01	4.8e−01	1	0.3	1.4e−03	1.4
Ovary	8.4e−01	7.1e−01	9.0e−01	0.7	8.6e−01	0.8
pancreas	9.3e−01	6.8e−01	1	0.7	1.5e−01	2.0
prostate	9.1e−01	5.0e−01	9.8e−01	0.4	5.7e−01	0.7
Skin	6.3e−01	7.5e−01	7.1e−01	0.8	9.5e−01	0.3
stomach	1	4.5e−01	1	1.0	5.1e−01	1.8
Uterus	7.1e−01	2.6e−01	4.4e−01	1.7	4.1e−01	1.8

For this cluster, at least one oligonucleotide was found to demonstrate overexpression of the cluster, although not of at least one transcript/segment as listed below. Microarray (chip) data is also available for this cluster as follows. Various oligonucleotides were tested for being differentially expressed in various disease conditions, particularly cancer, as previously described. The following oligonucleotides were found to hit this cluster but not other segments/transcripts below, shown in Table 6.

TABLE 6


Oligonucleotides related to this cluster

Oligonucleotide name	Overexpressed in cancers	Chip reference

R20779_0_0_30670 (SEQ	breast malignant tumors	BRS
ID NO: 905)

As noted above, cluster R20779 features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Stanniocalcin 2 precursor (SEQ ID NO:379). A description of each variant protein according to the present invention is now provided.

Variant protein R20779_P2 (SEQ ID NO:380) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R20779_T7 (SEQ ID NO:354). An alignment is given to the known protein (Stanniocalcin 2 precursor (SEQ ID NO:379)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R20779_P2 (SEQ ID NO:380) and STC2_HUMAN (SEQ ID NO:379):

1. An isolated chimeric polypeptide encoding for R20779_P2 (SEQ ID NO:380), comprising a first amino acid sequence being at least 90% homologous to MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNTAEIQHCLV NAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGKSFIKDALKCKAHALRH RFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQENTRVIVEMIHFKDLLLHE corresponding to amino acids 1-169 of STC2_HUMAN (SEQ ID NO:379), which also corresponds to amino acids 1-169 of R20779_P2 (SEQ ID NO:380), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CYKIEITMPKRRKVKLRD (SEQ ID NO:976) corresponding to amino acids 170-187 of R20779_P2 (SEQ ID NO:380) , wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of R20779_P2 (SEQ ID NO:380), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CYKIEITMPKRRKVKLRD (SEQ ID NO:976) in R20779_P2 (SEQ ID NO:380).

Variant protein R20779_P2 (SEQ ID NO:380) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R20779_P2 (SEQ ID NO:380) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

16	L ->	No
98	Q ->	No
171	Y -> C	Yes
177	M -> V	Yes

The glycosylation sites of variant protein R20779_P2 (SEQ ID NO:380), as compared to the known protein Stanniocalcin 2 precursor (SEQ ID NO:379), are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 8


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

73	yes	73

Variant protein R20779_P2 (SEQ ID NO:380) is encoded by the following transcript(s): R20779_T7 (SEQ ID NO:354), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R20779_T7 (SEQ ID NO:354) is shown in bold; this coding portion starts at position 1397 and ends at position 1957. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R20779_P2 (SEQ ID NO:380) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

1442	T ->	No
1690	G ->	No
1732	C -> T	Yes
1867	G -> T	Yes
1908	A -> G	Yes
1925	A -> G	Yes
1968	G -> A	Yes
2087	C -> T	No
2138	C -> T	Yes
2270	C ->	No
2443	A ->	No
2478	G ->	No
2479	C -> A	No
2616	C -> A	No
2941	C ->	No
3196	-> A	No
3479	T -> G	Yes
4290	C -> T	Yes
4358	G -> A	Yes
5363	G -> A	No

As noted above, cluster R20779 features 24 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster R20779_node_—0 (SEQ ID NO:355) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1	1298

Segment cluster R20779_node_—2 (SEQ ID NO:356) according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1337	1506

Segment cluster R20779_node_—7 (SEQ ID NO:357) according to the present invention is supported by 63 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1548	1690

Segment cluster R20779_node_—9 (SEQ ID NO:358) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1691	1838

Segment cluster R20779_node_—18 (SEQ ID NO:359) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2009	2176

Segment cluster R20779_node_—21 (SEQ ID NO:360) according to the present invention is supported by 106 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2219	2796

Segment cluster R20779_node_—24 (SEQ ID NO:361) according to the present invention is supported by 100 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2977	3667

Segment cluster R20779_node_—27 (SEQ ID NO:362) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	3673	3803

Segment cluster R20779_node_—28 (SEQ ID NO:363) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	3804	4050

Segment cluster R20779_node_—30 (SEQ ID NO:364) according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	4068	4193

Segment cluster R20779_node_—31 (SEQ ID NO:365) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	4194	4424

Segment cluster R20779_node_—32 (SEQ ID NO:366) according to the present invention is supported by 88 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	4425	5503

Segment cluster R20779_node_—1 (SEQ ID NO:367) according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1299	1336

Segment cluster R20779_node_—3 (SEQ ID NO:368) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1507	1547

Segment cluster R20779_node_—10 (SEQ ID NO:369) according to the present invention can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1839	1849

Segment cluster R20779_node_—11 (SEQ ID NO:370) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1850	1902

Segment cluster R20779_node_—14 (SEQ ID NO:371) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1903	1975

Segment cluster R20779_node_—17 (SEQ ID NO:372) according to the present invention is supported by 54 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	1976	2008

Segment cluster R20779_node_—19 (SEQ ID NO:373) according to the present invention can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2177	2188

Segment cluster R20779_node_—20 (SEQ ID NO:374) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2189	2218

Segment cluster R20779_node_—22 (SEQ ID NO:375) according to the present invention is supported by 76 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2797	2899

Segment cluster R20779_node_—23 (SEQ ID NO:376) according to the present invention is supported by 81 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	2900	2976

Segment cluster R20779_node_—25 (SEQ ID NO:377) according to the present invention can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	3668	3672

Segment cluster R20779_node_—29 (SEQ ID NO:378) according to the present invention can be found in the following transcript(s): R20779_T7 (SEQ ID NO:354). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R20779_T7 (SEQ ID NO: 354)	4051	4067

Variant protein alignment to the previously known protein:

Sequence name: STC2_HUMAN (SEQ ID NO:379)

Sequence documentation:

Alignment of: R20779_P2 (SEQ ID NO:380)×STC2₁₃HUMAN (SEQ ID NO:379).

Alignment segment 1/1:



Quality:	1688.00
Escore:	0
Matching length:	171	Total length:	171
Matching Percent	99.42	Matching Percent	99.42
Similarity:		Identity:
Total Percent	99.42	Total Percent	99.42
Similarity:		Identity:
Gaps:	0

Alignment:


	. . . . .
1	MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNT	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MCAERLGQFMTLALVLATFDPARGTDATNPPEGPQDRSSQQKGRLSLQNT	50
	. . . . .
51	AEIQHCLVNAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGK	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AEIQHCLVNAGDVGCGVFECFENNSCEIRGLHGICMTFLHNAGKFDAQGK	100
	. . . . .
101	SFIKDALKCKAHALRHRFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQ	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	SFIKDALKCKAHALRHRFGCISRKCPAIREMVSQLQRECYLKHDLCAAAQ	150
	. .
151	ENTRVIVEMIHFKDLLLHECY	171
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	ENTRVIVEMIHFKDLLLHEPY	171

Description for Cluster HSS100PCB

Cluster HSS100PCB features 1 transcript(s) and 3 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSS100PCB_T1	381

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSS100PCB_node_3	382
	HSS100PCB_node_4	383
	HSS100PCB_node_5	384

TABLE 3


Proteins of interest

Protein Name	Sequence ID No.	Corresponding Transcript(s)

HSS100PCB_P3	386	HSS100PCB_T1 (SEQ ID
		NO: 381)

These sequences are variants of the known protein S-100P protein (SEQ ID NO:385) (SwissProt accession identifier S10P_HUMAN), SEQ ID NO: 385, referred to herein as the previously known protein.

The sequence for protein S-100P protein (SEQ ID NO:385) is given at the end of the application, as “S-100P protein (SEQ ID NO:385) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

32	E -> T
44	F -> E

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: calcium binding; protein binding, which are annotation(s) related to Molecular Function.

Cluster HSS100PCB can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 34 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 34 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: a mixture of malignant tumors from different tissues.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	Bladder	41
	Colon	37
	Epithelial	38
	General	22
	Kidney	0
	Liver	0
	Lung	18
	Breast	0
	bone marrow	0
	Ovary	0
	pancreas	0
	prostate	46
	stomach	553
	Uterus	13

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

bladder	3.3e−01	2.9e−01	2.9e−02	2.8	3.5e−02	2.8
Colon	3.0e−01	1.9e−01	5.2e−01	1.2	2.4e−01	1.7
epithelial	4.7e−02	1.6e−02	2.0e−01	1.2	6.1e−02	1.3
general	1.1e−03	6.8e−05	1.4e−02	1.5	4.9e−04	1.7
kidney	6.5e−01	7.2e−01	5.8e−01	1.7	7.0e−01	1.4
Liver	9.1e−01	4.9e−01	1	1.0	7.7e−02	2.1
Lung	6.8e−01	7.3e−01	2.2e−02	2.9	1.3e−01	1.7
Breast	2.8e−01	3.2e−01	4.7e−01	2.0	6.8e−01	1.5
bone marrow	1	6.7e−01	1	1.0	2.8e−01	2.8
Ovary	2.6e−01	3.0e−01	4.7e−01	2.0	5.9e−01	1.7
pancreas	3.3e−01	4.4e−01	7.6e−02	3.7	1.5e−01	2.8
prostate	9.1e−01	9.3e−01	5.8e−01	0.6	7.6e−01	0.5
stomach	3.7e−01	3.2e−01	1	0.1	1	0.3
Uterus	9.4e−01	7.0e−01	1	0.6	4.1e−01	1.1

As noted above, cluster HSS100PCB features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein S-100P protein (SEQ ID NO:385). A description of each variant protein according to the present invention is now provided.

Variant protein HSS100PCB_P3 (SEQ ID NO:386) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSS100PCB_T1 (SEQ ID NO:381). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSS100PCB_P3 (SEQ ID NO:386) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSS100PCB_P3 (SEQ ID NO:386) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

1	M -> R	Yes
11	M -> L	Yes
20	L -> F	Yes

Variant protein HSS100PCB_P3 (SEQ ID NO:386) is encoded by the following transcript(s): HSS100PCB_T1 (SEQ ID NO:381), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSS100PCB_T1 (SEQ ID NO:381) is shown in bold; this coding portion starts at position 1057 and ends at position 1533. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSS100PCB_P3 (SEQ ID NO:386) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

52	C -> T	Yes
107	A -> C	Yes
458	C -> T	Yes
468	A -> G	Yes
648	C -> T	Yes
846	C -> G	Yes
882	G -> A	Yes
960	C -> T	No
965	C -> T	Yes
1058	T -> G	Yes
1087	A -> C	Yes
1114	C -> T	Yes
1968	G -> A	Yes
1971	C -> T	Yes
2010	C -> A	Yes
2099	G ->	No

As noted above, cluster HSS100PCB features 3 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSS100PCB_node_—3 (SEQ ID NO:382) according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSS100PCB_T1 (SEQ ID NO:381). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSS100PCB_T1 (SEQ ID NO: 381)	1	1133

Segment cluster HSS100PCB_node_—4 (SEQ ID NO:383) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSS100PCB_T1 (SEQ ID NO:381). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSS100PCB_T1 (SEQ ID NO: 381)	1134	1923

TABLE 11


Oligonucleotides related to this segment

Oligonucleotide name	Overexpressed in cancers	Chip reference

HSS100PCB_0_0_12280	breast malignant tumors	BRS
(SEQ ID NO: 906)

Segment cluster HSS100PCB_node_—5 (SEQ ID NO:384) according to the present invention is supported by 141 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSS100PCB_T1 (SEQ ID NO:381). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSS100PCB_T1 (SEQ ID NO: 381)	1924	2201

Description for Cluster HSCOC4

Cluster HSCOC4 features 19 transcript(s) and 79 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSCOC4_PEA_1_T1	387
	HSCOC4_PEA_1_T2	388
	HSCOC4_PEA_1_T3	389
	HSCOC4_PEA_1_T4	390
	HSCOC4_PEA_1_T5	391
	HSCOC4_PEA_1_T7	392
	HSCOC4_PEA_1_T8	393
	HSCOC4_PEA_1_T11	394
	HSCOC4_PEA_1_T12	395
	HSCOC4_PEA_1_T14	396
	HSCOC4_PEA_1_T15	397
	HSCOC4_PEA_1_T20	398
	HSCOC4_PEA_1_T21	399
	HSCOC4_PEA_1_T25	400
	HSCOC4_PEA_1_T28	401
	HSCOC4_PEA_1_T30	402
	HSCOC4_PEA_1_T31	403
	HSCOC4_PEA_1_T32	404
	HSCOC4_PEA_1_T40	405

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSCOC4_PEA_1_node_1	406
	HSCOC4_PEA_1_node_5	407
	HSCOC4_PEA_1_node_7	408
	HSCOC4_PEA_1_node_30	409
	HSCOC4_PEA_1_node_33	410
	HSCOC4_PEA_1_node_35	411
	HSCOC4_PEA_1_node_37	412
	HSCOC4_PEA_1_node_39	413
	HSCOC4_PEA_1_node_43	414
	HSCOC4_PEA_1_node_48	415
	HSCOC4_PEA_1_node_49	416
	HSCOC4_PEA_1_node_51	417
	HSCOC4_PEA_1_node_58	418
	HSCOC4_PEA_1_node_59	419
	HSCOC4_PEA_1_node_62	420
	HSCOC4_PEA_1_node_66	421
	HSCOC4_PEA_1_node_72	422
	HSCOC4_PEA_1_node_77	423
	HSCOC4_PEA_1_node_79	424
	HSCOC4_PEA_1_node_93	425
	HSCOC4_PEA_1_node_100	426
	HSCOC4_PEA_1_node_105	427
	HSCOC4_PEA_1_node_107	428
	HSCOC4_PEA_1_node_108	429
	HSCOC4_PEA_1_node_109	430
	HSCOC4_PEA_1_node_110	431
	HSCOC4_PEA_1_node_112	432
	HSCOC4_PEA_1_node_113	433
	HSCOC4_PEA_1_node_2	434
	HSCOC4_PEA_1_node_8	435
	HSCOC4_PEA_1_node_10	436
	HSCOC4_PEA_1_node_12	437
	HSCOC4_PEA_1_node_14	438
	HSCOC4_PEA_1_node_17	439
	HSCOC4_PEA_1_node_19	440
	HSCOC4_PEA_1_node_21	441
	HSCOC4_PEA_1_node_22	442
	HSCOC4_PEA_1_node_28	443
	HSCOC4_PEA_1_node_29	444
	HSCOC4_PEA_1_node_41	445
	HSCOC4_PEA_1_node_45	446
	HSCOC4_PEA_1_node_47	447
	HSCOC4_PEA_1_node_50	448
	HSCOC4_PEA_1_node_53	449
	HSCOC4_PEA_1_node_55	450
	HSCOC4_PEA_1_node_57	451
	HSCOC4_PEA_1_node_60	452
	HSCOC4_PEA_1_node_64	453
	HSCOC4_PEA_1_node_69	454
	HSCOC4_PEA_1_node_70	455
	HSCOC4_PEA_1_node_71	456
	HSCOC4_PEA_1_node_73	457
	HSCOC4_PEA_1_node_74	458
	HSCOC4_PEA_1_node_75	459
	HSCOC4_PEA_1_node_76	460
	HSCOC4_PEA_1_node_78	461
	HSCOC4_PEA_1_node_80	462
	HSCOC4_PEA_1_node_82	463
	HSCOC4_PEA_1_node_83	464
	HSCOC4_PEA_1_node_84	465
	HSCOC4_PEA_1_node_85	466
	HSCOC4_PEA_1_node_86	467
	HSCOC4_PEA_1_node_87	468
	HSCOC4_PEA_1_node_88	469
	HSCOC4_PEA_1_node_89	470
	HSCOC4_PEA_1_node_90	471
	HSCOC4_PEA_1_node_91	472
	HSCOC4_PEA_1_node_92	473
	HSCOC4_PEA_1_node_94	474
	HSCOC4_PEA_1_node_96	475
	HSCOC4_PEA_1_node_97	476
	HSCOC4_PEA_1_node_98	477
	HSCOC4_PEA_1_node_99	478
	HSCOC4_PEA_1_node_101	479
	HSCOC4_PEA_1_node_102	480
	HSCOC4_PEA_1_node_103	481
	HSCOC4_PEA_1_node_104	482
	HSCOC4_PEA_1_node_106	483
	HSCOC4_PEA_1_node_111	484

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

HSCOC4_PEA_1_P3	488	HSCOC4_PEA_1_T1 (SEQ
		ID NO: 387)
HSCOC4_PEA_1_P5	489	HSCOC4_PEA_1_T3 (SEQ
		ID NO: 389)
HSCOC4_PEA_1_P6	490	HSCOC4_PEA_1_T4 (SEQ
		ID NO: 390)
HSCOC4_PEA_1_P12	491	HSCOC4_PEA_1_T11 (SEQ
		ID NO: 394)
HSCOC4_PEA_1_P15	492	HSCOC4_PEA_1_T14 (SEQ
		ID NO: 396)
HSCOC4_PEA_1_P16	493	HSCOC4_PEA_1_T15 (SEQ
		ID NO: 397)
HSCOC4_PEA_1_P20	494	HSCOC4_PEA_1_T20 (SEQ
		ID NO: 398)
HSCOC4_PEA_1_P9	495	HSCOC4_PEA_1_T21 (SEQ
		ID NO: 399)
HSCOC4_PEA_1_P22	496	HSCOC4_PEA_1_T25 (SEQ
		ID NO: 400)
HSCOC4_PEA_1_P23	497	HSCOC4_PEA_1_T28 (SEQ
		ID NO: 401)
HSCOC4_PEA_1_P24	498	HSCOC4_PEA_1_T30 (SEQ
		ID NO: 402)
HSCOC4_PEA_1_P25	499	HSCOC4_PEA_1_T31 (SEQ
		ID NO: 403)
HSCOC4_PEA_1_P26	500	HSCOC4_PEA_1_T32 (SEQ
		ID NO: 404)
HSCOC4_PEA_1_P30	501	HSCOC4_PEA_1_T40 (SEQ
		ID NO: 405)
HSCOC4_PEA_1_P38	502	HSCOC4_PEA_1_T2 (SEQ
		ID NO: 388)
HSCOC4_PEA_1_P39	503	HSCOC4_PEA_1_T5 (SEQ
		ID NO: 391)
HSCOC4_PEA_1_P40	504	HSCOC4_PEA_1_T7 (SEQ
		ID NO: 392)
HSCOC4_PEA_1_P41	505	HSCOC4_PEA_1_T8 (SEQ
		ID NO: 393)
HSCOC4_PEA_1_P42	506	HSCOC4_PEA_1_T12 (SEQ
		ID NO: 395)

These sequences are variants of the known protein Complement C4 precursor [Contains: C4a anaphylatoxin] (SwissProt accession identifier CO4_HUMAN) SEQ ID NO: 485), referred to herein as the previously known protein.

Protein Complement C4 precursor [Contains: C4a anaphylatoxin] (SEQ ID NO:485) is known or believed to have the following function(s): C4 plays a central role in the activation of the classical pathway of the complement system. It is processed by activated C1 which removes from the alpha chain the C4a anaphylatoxin. Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. The sequence for protein Complement C4 precursor [Contains: C4a anaphylatoxin] (SEQ ID NO:485) is given at the end of the application, as “Complement C4 precursor [Contains: C4a anaphylatoxin] (SEQ ID NO:485) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s)
onamino acid
sequence	Comment

477	R -> W (in allotype C4A6). /FTId = VAR_001987.
726	P -> L (in allotype C4A3). /FTId = VAR_001988.
1073	D -> G (in allotype C4A1, allotype C4B1 and allotype
	C4B3). /FTId = VAR_001989.
1120-1125	PCPVLD -> LSPVIH (in allotype C4B).
	/FTId = VAR_001990.
1176	N -> S (in allotype C4A1, allotype C4B1, allotype C4B3
	and allotype C4B5). /FTId = VAR_001991.
1201	S -> T (in allotype C4A6, allotype C4A3, allotype C4A1
	and allotype C4B). /FTId = VAR_001992.
1207	V -> A (in allotype C4A1, allotype C4B1, allotype C4B2
	and allotype C4B3). /FTId = VAR_001993.
1210	L -> R (in allotype C4A1, allotype C4B1, allotype C4B2
	and allotype C4B3). /FTId = VAR_001994.
1286	S -> A (in allotype C4A6, allotype C4A1, allotype
	C4A3A and allotype C4B). /FTId = VAR_001995.
1-12	MRLLWGLIWASS -> PREVRSVCLSAT
347	S -> Y
418	V -> A
727	D -> N
907	A -> T
980-981	VT -> LQ
1013	Q -> E
1317	I -> F
1418-1420	Missing
1654	T -> RA
1698	H -> Q

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: muscle contraction regulation; inflammatory response; complement activation; complement activation, classical pathway, which are annotation(s) related to Biological Process; complement component; proteinase inhibitor, which are annotation(s) related to Molecular Function; and extracellular; extracellular space, which are annotation(s) related to Cellular Component.

Cluster HSCOC4 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 35 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 35 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: brain malignant tumors, a mixture of malignant tumors from different tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	adrenal	853
	bladder	328
	bone	6
	brain	111
	colon	245
	epithelial	264
	general	163
	head and neck	0
	kidney	141
	liver	4109
	lung	64
	lymph nodes	120
	breast	96
	bone marrow	0
	ovary	116
	pancreas	20
	prostate	4
	stomach	36
	T cells	0
	Thyroid	12
	uterus	127

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	5.6e−01	5.9e−01	2.5e−06	0.3	4.3e−04	0.3
bladder	5.0e−01	6.6e−01	6.3e−01	0.9	9.1e−01	0.6
bone	5.5e−01	5.8e−01	1	1.1	7.0e−01	1.3
brain	4.6e−03	6.2e−02	7.7e−11	3.0	3.2e−05	1.7
colon	8.0e−01	8.3e−01	9.8e−01	0.4	9.9e−01	0.4
epithelial	1.7e−01	9.2e−01	9.3e−07	1.3	9.7e−01	0.7
general	3.2e−04	6.1e−01	1.5e−31	2.1	1.9e−03	1.1
head and neck	1.2e−01	2.1e−01	1	1.2	1	1.1
kidney	6.9e−01	8.1e−01	1.2e−04	2.4	1.5e−02	1.5
liver	7.1e−01	7.2e−01	5.0e−04	0.2	1	0.1
lung	2.9e−01	7.1e−01	4.2e−02	1.7	5.1e−01	0.8
lymph nodes	6.3e−01	8.2e−01	9.0e−01	0.5	1	0.3
breast	4.0e−02	1.8e−01	2.1e−06	6.0	3.9e−03	3.0
bone marrow	1	6.7e−01	1	1.0	2.8e−01	2.8
ovary	6.6e−01	7.3e−01	1.3e−01	1.5	3.6e−01	1.1
pancreas	1.7e−02	9.9e−02	4.8e−10	7.6	2.9e−07	5.1
prostate	5.8e−01	6.3e−01	4.1e−02	3.9	1.8e−03	3.8
stomach	2.7e−01	7.5e−01	1.1e−01	1.5	6.5e−01	0.8
T cells	1	6.7e−01	1	1.0	7.2e−01	1.4
Thyroid	3.4e−01	3.4e−01	3.0e−01	2.2	3.0e−01	2.2
uterus	1.2e−01	5.3e−01	6.6e−02	1.4	5.4e−01	0.8

As noted above, cluster HSCOC4 features 19 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Complement C4 precursor [Contains: C4a anaphylatoxin]. A description of each variant protein according to the present invention is now provided.

Variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T1 (SEQ ID NO:387). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P3 (SEQ ID NO:488) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P3 (SEQ ID NO:488), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTV corresponding to amino acids 1-865 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-865 of HSCOC4_PEA_—1_P3 (SEQ ID NO:488), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RPHRSLSIQELGEPGPSEGWGG (SEO ID NO:977) corresponding to amino acids 866-887 of HSCOC4_PEA_—1_P3 (SEO ID NO:488), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P3 (SEQ ID NO:488), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RPHRSLSIQELGEPGPSEGWGG (SEQ ID NO:977) in HSCOC4_PEA_—1_P3 (SEQ ID NO:488).

Variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
869	R -> G	Yes

The glycosylation sites of variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 8


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

1391	no
862	yes	862
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 9 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 9


Phosphorylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

1420	no
1422	no
1417	no

Variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488) is encoded by the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T1 (SEQ ID NO:387) is shown in bold; this coding portion starts at position 501 and ends at position 3161. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P3 (SEQ ID NO:488) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3105	A -> G	Yes
3167	G -> A	Yes
3228	T -> C	Yes
3259	G -> T	Yes
3332	G -> A	Yes
3490	A -> C	Yes
3569	T -> C	Yes
3724	G -> T	Yes
3831	A -> G	Yes
3898	C -> A	Yes
3972	C -> T	Yes
3975	G -> C	Yes
3983	T -> A	Yes
3986	G -> C	Yes
3988	C -> T	Yes
4140	G -> A	Yes
4147	T -> C	Yes
4228	C -> G	Yes
4233	C -> T	Yes
4242	G -> T	Yes
4243	G -> C	Yes
4339	G -> A	Yes
4345	C -> G	Yes
4348	G -> A	Yes
4469	G -> T	Yes
4562	A -> T	Yes
4781	A -> G	No
4873	T -> C	Yes
5007	G ->	No
5423	C -> G	Yes
5634	G -> C	No
5677	G -> A	Yes
5687	A -> C	Yes
5862	A -> C	Yes
5868	G -> A	Yes
5933	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T3 (SEQ ID NO:389). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P5 (SEQ ID NO:489) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P5 (SEQ ID NO:489), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKG corresponding to amino acids 1-818 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-818 of HSCOC4_PEA_—1_P5 (SEQ ID NO:489), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) corresponding to amino acids 819-843 of HSCOC4_PEA_—1_P5 (SEQ ID NO:489), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1P5 (SEQ ID NO:489), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) in HSCOC4_PEA_—1_P5 (SEQ ID NO:489).

Variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
829	L -> P	Yes
830	L -> I	Yes
840	S -> P	Yes

The glycosylation sites of variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 12 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 12


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

1391	no
862	no
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 13 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 13


Phosphorylation site(s)

	Position(s) on known
	amino acid sequence	Present in variant protein?

	1420	no
	1422	no
	1417	no

Variant protein HSCOC4_PEA_—1_P5 (SEQ ID NO:489) is encoded by the following transcript(s): HSCOC4_PEA_—1_T3 (SEQ ID NO:389), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T3 (SEQ ID NO:389) is shown in bold; this coding portion starts at position 501 and ends at position 3029. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_l_P5 (SEQ ID NO:489) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2986	T -> C	Yes
2988	C -> A	Yes
3018	T -> C	Yes
3070	C -> T	Yes
3081	C -> A	Yes
3093	A -> G	Yes
3101	G -> A	Yes
3106	G -> A	Yes
3174	G -> A	Yes
3193	A -> G	Yes
3201	T -> C	Yes
3233	C -> T	Yes
3363	A -> G	Yes
3425	G -> A	Yes
3486	T -> C	Yes
3517	G -> T	Yes
3590	G -> A	Yes
3748	A -> C	Yes
3827	T -> C	Yes
3982	G -> T	Yes
4089	A -> G	Yes
4156	C -> A	Yes
4230	C -> T	Yes
4233	G -> C	Yes
4241	T -> A	Yes
4244	G -> C	Yes
4246	C -> T	Yes
4398	G -> A	Yes
4405	T -> C	Yes
4486	C -> G	Yes
4491	C -> T	Yes
4500	G -> T	Yes
4501	G -> C	Yes
4597	G -> A	Yes
4603	C -> G	Yes
4606	G -> A	Yes
4727	G -> T	Yes
4820	A -> T	Yes
5039	A -> G	No
5131	T -> C	Yes
5265	G ->	No
5681	C -> G	Yes
5892	G -> C	No
5935	G -> A	Yes
5945	A -> C	Yes
6120	A -> C	Yes
6126	G -> A	Yes
6191	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T4 (SEQ ID NO:390). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P6 (SEQ ID NO:490) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P6 (SEQ ID NO:490), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKG corresponding to amino acids 1-1052 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-1052 of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGCKGKQEGGQERTVTGRWTAQEATEGKKGGP (SEQ ID NO:979) corresponding to amino acids 1053-1084 of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P6 (SEQ ID NO:490), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGCKGKQEGGQERTVTGRWTAQEATEGKKGGP (SEQ ID NO:979) in HSCOC4_PEA_—1_P6 (SEQ ID NO:490).

Variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1062	G -> V	Yes
1068	T ->	Yes

The glycosylation sites of variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 16 (given according to their position(s) on the amino acid sequence in the column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 16


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

1391	no
862	yes	862
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1P6 (SEQ ID NO:490), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 17 (given according to their position(s) on the amino acid sequence in the column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 17


Phosphorylation site(s)

	Position(s) on known amino
	acid sequence	Present in variant protein?

	1420	no
	1422	no
	1417	no

Variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490) is encoded by the following transcript(s): HSCOC4_PEA_—1_T4 (SEQ ID NO:390), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T4 (SEQ ID NO:390) is shown in bold; this coding portion starts at position 501 and ends at position 3752. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P6 (SEQ ID NO:490) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 18


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3685	G -> T	Yes
3702	A ->	Yes
3897	A -> G	Yes
3964	C -> A	Yes
4038	C -> T	Yes
4041	G -> C	Yes
4049	T -> A	Yes
4052	G -> C	Yes
4054	C -> T	Yes
4206	G -> A	Yes
4213	T -> C	Yes
4294	C -> G	Yes
4299	C -> T	Yes
4308	G -> T	Yes
4309	G -> C	Yes
4405	G -> A	Yes
4411	C -> G	Yes
4414	G -> A	Yes
4535	G -> T	Yes
4628	A -> T	Yes
4847	A -> G	No
4939	T -> C	Yes
5073	G ->	No
5489	C -> G	Yes
5700	G -> C	No
5743	G -> A	Yes
5753	A -> C	Yes
5928	A -> C	Yes
5934	G -> A	Yes
5999	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P12 (SEQ ID NO:491) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T11 (SEQ ID NO:394). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P12 (SEQ ID NO:491) and CO4_HUMAN_V1 (SEQ ID NO: 486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P12 (SEQ ID NO:491), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NRSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKV corresponding to amino acids 1-1380 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1380 of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RAREGVGPGTGGGEGVE (SEQ ID NO:980) corresponding to amino acids 1381-1397 of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P12 (SEQ ID NO:491), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RAREGVGPGTGGGEGVE (SEQ ID NO:980) in HSCOC4_PEA_—1_P12 (SEQ ID NO:491).

It should be noted that the known protein sequence (CO4_HUMAN (SEQ ID NO:485)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for CO4_HUMAN_V1 (SEQ ID NO:486). These changes were previously known to occur and are listed in the table below.

TABLE 19


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P12 (SEQ ID NO:491) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 20, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P12 (SEQ ID NO:491) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 20


Amino acid mutations

SNP position(s) on amino	Alternative amino
acid sequence	acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes

Variant protein HSCOC4_PEA_—1_P12 (SEQ ID NO:491) is encoded by the following transcript(s): HSCOC4_PEA_—1_T11 (SEQ ID NO:394), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T11 (SEQ ID NO:394) is shown in bold; this coding portion starts at position 501 and ends at position 4691. The transcript also has the following SNPs as listed in Table 21 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P12 (SEQ ID NO:491) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 21


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4859	C -> T	Yes
4876	C -> A	Yes
4882	C -> G	Yes
4924	G -> A	Yes
5205	C -> G	Yes
5596	C -> T	Yes
5717	A -> G	No
5809	T -> C	Yes
5943	G ->	No
6359	C -> G	Yes
6570	G -> C	No
6613	G -> A	Yes
6623	A -> C	Yes
6798	A -> C	Yes
6804	G -> A	Yes
6869	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P15 (SEQ ID NO:492) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T14 (SEQ ID NO:396). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P15 (SEQ ID NO:492) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P15 (SEQ ID NO:492), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQ corresponding to amino acids 1-1359 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1359 of HSCOC4_PEA_—1_P15 (SEQ ID NO:492), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VNHSLVNHSLAWVARTPGPRGQARSRPQPPTRGIPAALLPGVFGGRLTSWLRDLEL (SEQ ID NO:981) corresponding to amino acids 1360-1415 of HSCOC4_PEA_—1_P15 (SEQ ID NO:492, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P15 (SEQ ID NO:492), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VNHSLVNHSLAWVARTPGPRGQARSRPQPPTRGIPAALLPGVFGGRLTSWLRDLEL (SEQ ID NO:981) in HSCOC4_PEA_—1_P15 (SEQ ID NO:492).

TABLE 22


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P15 (SEQ ID NO:492) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 23, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P15 (SEQ ID NO:492) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 23


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A -> V	No
322	A ->	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1387	Q -> H	Yes
1411	R -> C	Yes

Variant protein HSCOC4_PEA_—1_P15 (SEQ ID NO:492) is encoded by the following transcript(s): HSCOC4_PEA_—1_T14 (SEQ ID NO:396), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T14 (SEQ ID NO:396) is shown in bold; this coding portion starts at position 501 and ends at position 4745. The transcript also has the following SNPs as listed in Table 24 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P15 (SEQ ID NO:492) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 24


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4661	A -> C	Yes
4731	C -> T	Yes
4872	A -> G	Yes
4905	C -> T	Yes
5061	A -> G	No
5153	T -> C	Yes
5287	G ->	No
5703	C -> G	Yes
5914	G -> C	No
5957	G -> A	Yes
5967	A -> C	Yes
6142	A -> C	Yes
6148	G -> A	Yes
6213	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P16 (SEQ ID NO:493) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T15 (SEQ ID NO:397). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P16 (SEQ ID NO:493) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P16 (SEQ ID NO:493), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPK corresponding to amino acids 1-1457 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1457 of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AERQGGAVWHGHRGRHPPEWIPRPAC (SEQ ID NO:982) corresponding to amino acids 1458-1483 of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P16 (SEQ ID NO:493), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AERQGGAVWHGHRGRHPPEWIPRPAC (SEQ ID NO:982) in HSCOC4_PEA_—1_P16 (SEQ ID NO:493).

TABLE 25


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P16 (SEQ ID NO:493) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 26, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P16 (SEQ ID NO:493) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 26


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No

Variant protein HSCOC4_PEA_—1_P16 (SEQ ID NO:493) is encoded by the following transcript(s): HSCOC4_PEA_—1_T15 (SEQ ID NO:397), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T15 (SEQ ID NO:397) is shown in bold; this coding portion starts at position 501 and ends at position 4949. The transcript also has the following SNPs as listed in Table 27 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_l_P16 (SEQ ID NO:493) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 27


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
5263	C -> G	Yes
5474	G -> C	No
5517	G -> A	Yes
5527	A -> C	Yes
5702	A -> C	Yes
5708	G -> A	Yes
5773	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P20 (SEQ ID NO:494) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T20 (SEQ ID NO:398). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P20 (SEQ ID NO:494) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P20 (SEQ ID NO:494), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQ corresponding to amino acids 1-1303 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1303 of HSCOC4_PEA_—1_P20 (SEQ ID NO:494), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGAVPGLWRGWVVLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH (SEO ID NO:983) corresponding to amino acids 1304-1349 of HSCOC4_PEA_—1_P20 (SEO ID NO:494), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P20 (SEQ ID NO:494), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:983)

	VGAVPGLWRGWVVLRPRACLSPGSTSLGHGDCPGCPVCLLDCLPHH

	in HSCOC4_PEA_1_P20 (SEQ ID NO:494).

TABLE 28


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P20 (SEQ ID NO:494) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 29, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P20 (SEQ ID NO:494) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 29


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1312	R -> G	Yes
1344	D -> V	Yes

Variant protein HSCOC4_PEA_—1_P20 (SEQ ID NO:494) is encoded by the following transcript(s): HSCOC4_PEA_—1_T20 (SEQ ID NO:398), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T20 (SEQ ID NO:398) is shown in bold; this coding portion starts at position 501 and ends at position 4547. The transcript also has the following SNPs as listed in Table 30 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P20 (SEQ ID NO:494) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 30


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4434	C -> G	Yes
4531	A -> T	Yes
4743	A -> C	Yes
4813	C -> T	Yes
4954	A -> G	Yes
4987	C -> T	Yes
5143	A -> G	No
5235	T -> C	Yes
5369	G ->	No
5785	C -> G	Yes
5996	G -> C	No
6039	G -> A	Yes
6049	A -> C	Yes
6224	A -> C	Yes
6230	G -> A	Yes
6295	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P9 (SEQ ID NO:495) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T21 (SEQ ID NO:399). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to, the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P9 (SEQ ID NO:495) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P9 (SEQ ID NO:495), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSV corresponding to amino acids 1-1529 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1529 of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGER (SEQ ID NO:984) corresponding to amino acids 1530-1533 of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P9 (SEQ ID NO:495), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGER (SEQ ID NO:984) in HSCOC4_PEA_—1_P9 (SEQ ID NO:495).

TABLE 31


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P9 (SEQ ID NO:495) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 32, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P9 (SEQ ID NO:495) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 32


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A -> V	No
322	A ->	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No

Variant protein HSCOC4_PEA_—1_P9 (SEQ ID NO:495) is encoded by the following transcript(s): HSCOC4_PEA1_T21 (SEQ ID NO:399), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T21 (SEQ ID NO:399) is shown in bold; this coding portion starts at position 501 and ends at position 5099. The transcript also has the following SNPs as listed in Table 33 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P9 (SEQ ID NO:495) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 33


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5561	G -> A	Yes
6026	T -> G	Yes
6348	G -> C	Yes
6966	C -> G	Yes
7177	G -> C	No
7220	G -> A	Yes
7230	A -> C	Yes
7405	A -> C	Yes
7411	G -> A	Yes
7476	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P22 (SEQ ID NO:496) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T25 (SEQ ID NO:400). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P22 (SEQ ID NO:496) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P22 (SEQ ID NO:496), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LASLVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAF RLFETKITQVLHF corresponding to amino acids 1-1653 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1653 of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SMKQTGEAGRAGGRQGG (SEQ ID NO:985) corresponding to amino acids 1654-1670 of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P22 (SEQ ID NO:496), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SMKQTGEAGRAGGRQGG (SEQ ID NO:985) in HSCOC4_PEA_—1_P22 (SEQ ID NO:496).

TABLE 34


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P22 (SEQ ID NO:496) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 35, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P22 (SEQ ID NO:496) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 35


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No
1604	R -> G	Yes

Variant protein HSCOC4_PEA_—1_P22 (SEQ ID NO:496) is encoded by the following transcript(s): HSCOC4_PEA_—1_T25 (SEQ ID NO:400), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T25 (SEQ ID NO:400) is shown in bold; this coding portion starts at position 501 and ends at position 5510. The transcript also has the following SNPs as listed in Table 36 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P22 (SEQ ID NO:496) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 36


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5310	C -> G	Yes
5783	G -> C	No
5826	G -> A	Yes
5836	A -> C	Yes
5974	C -> T	Yes
5981	C -> T	Yes
6154	A -> C	Yes
6160	G -> A	Yes
6225	A -> C	Yes
6283	C -> T	Yes
6548	C -> T	Yes
6567	C -> T	Yes
7300	C -> A	Yes
7520	C -> T	Yes
7685	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P23 (SEQ ID NO:497) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T28 (SEQ ID NO:401). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P23 (SEQ ID NO:497) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P23 (SEQ ID NO:497), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKANEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYG corresponding to amino acids 1-1626 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1626 of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence QSSHRGPGLTLPRGPAVLVSLGVACSSYRSCTQPVCSDTNFLPSQPQSNSPFPLLLTPS (SEQ ID NO:986) corresponding to amino acids 1627-1685 of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P23 (SEQ ID NO:497), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:986)

QSSHRGPGLTLPRGPAVLVSLGVACSSYRSCTQPVCSDTNFLPSQPQSNS

PFPLLLTPS in HSCOC4_PEA_1_P23 (SEQ ID NO:497).

TABLE 37


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P23 (SEQ ID NO:497) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 38, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P23 (SEQ ID NO:497) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 38


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A -> V	No
322	A ->	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No
1604	R -> G	Yes
1634	G ->	Yes

Variant protein HSCOC4_PEA_—1_P23 (SEQ ID NO:497) is encoded by the following transcript(s): HSCOC4_PEA_—1_T28 (SEQ ID NO:401), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T28 (SEQ ID NO:401) is shown in bold; this coding portion starts at position 501 and ends at position 5555. The transcript also has the following SNPs as listed in Table 39 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P23 (SEQ ID NO:497) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 39


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5310	C -> G	Yes
5402	C ->	Yes
5426	T -> C	Yes
5965	G -> C	No
6008	G -> A	Yes
6018	A -> C	Yes
6156	C -> T	Yes
6163	C -> T	Yes
6336	A -> C	Yes
6342	G -> A	Yes
6407	A -> C	Yes
6465	C -> T	Yes
6730	C -> T	Yes
6749	C -> T	Yes
7482	C -> A	Yes
7702	C -> T	Yes
7867	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P24 (SEQ ID NO:498) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T30 (SEQ ID NO:402). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P24 (SEQ ID NO:498) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P24 (SEQ ID NO:498), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDS corresponding to amino acids 1-1528 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1528 of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SADVLCFTGHQVRADSWPPCVLLKSASVLRGSALASVAPWSGVCRTRMATG (SEQ ID NO:987) corresponding to amino acids 1529-1579 of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P24 (SEQ ID NO:498), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:987)

	SADVLCFTGHQVRADSWPPCVLLKSASVLRGSALASVAPWSGVCRT

	RMATG in HSCOC4_PEA_1_P24 (SEQ ID NO:498).

TABLE 40


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

SNP position(s) on
amino acid sequence	Type of change

1177	variant
1202	variant
1208	variant
1211	variant
1287	variant

Variant protein HSCOC4_PEA_—1_P24 (SEQ ID NO:498) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 41, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P24 (SEQ ID NO:498) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 41


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No
1569	S -> R	Yes

Variant protein HSCOC4_PEA_—1_P24 (SEQ ID NO:498) is encoded by the following transcript(s): HSCOC4_PEA_—1_T30 (SEQ ID NO:402), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T30 (SEQ ID NO:402) is shown in bold; this coding portion starts at position 501 and ends at position 5237. The transcript also has the following SNPs as listed in Table 42 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P24 (SEQ ID NO:498) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 42


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5207	C -> G	Yes
5418	G -> C	No
5461	G -> A	Yes
5471	A -> C	Yes
5646	A -> C	Yes
5652	G -> A	Yes
5717	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P25 (SEQ ID NO:499) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T31 (SEQ ID NO:403). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P25 (SEQ ID NO:499) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P25 (SEQ ID NO:499), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEG corresponding to amino acids 1-1593 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1593 of HSCOC4_PEA_—1_P25 (SEQ ID NO:499), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDEVCLLLPPC GVRLPG (SEQ ID NO:988) corresponding to amino acids 1594-1657 of HSCOC4_PEA_—1_P25 (SEQ ID NO:499), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P25 (SEQ ID NO:499) comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:988)

ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDE

VCLLLPPCGVRLPG in HSCOC4_PEA_1_P25 (SEQ ID NO:

499).

TABLE 43


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

SNP position(s) on
amino acid sequence	Type of change

1177	variant
1202	variant
1208	variant
1211	variant
1287	variant

Variant protein HSCOC4_PEA_—1_P25 (SEQ ID NO:499) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 44, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P25 (SEQ ID NO:499) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 44


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No
1632	A -> G	Yes

Variant protein HSCOC4_PEA_—1_P25 (SEQ ID NO:499) is encoded by the following transcript(s): HSCOC4_PEA_—1_T31 (SEQ ID NO:403), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T31 (SEQ ID NO:403) is shown in bold; this coding portion starts at position 501 and ends at position 5471. The transcript also has the following SNPs as listed in Table 45 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P25 (SEQ ID NO:499) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 45


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5395	C -> G	Yes
5606	G -> C	No
5649	G -> A	Yes
5659	A -> C	Yes
5834	A -> C	Yes
5840	G -> A	Yes
5905	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P26 (SEQ ID NO:500) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T32 (SEQ ID NO:404). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P26 (SEQ ID NO:500) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P26 (SEQ ID NO:500), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLC SAEVCQCAEG corresponding to amino acids 1-1593 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1593 of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence


(SEQ ID NO:989)

ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDE

VCLLLPPCGVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL

corresponding to amino acids 1594-1691 of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P26 (SEQ ID NO:500), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


(SEQ ID NO:989)

ETEGLGRGSGGGMAGAPPTLSDGFPNFREVPSPASRPGAGSAGRGWLQDE

VCLLLPPCGVRSVFPPRPWPDPPSGTGCFGLSGCSLLLLQVMHAACLL

in HSCOC4_PEA_1_P26 (SEQ ID NO:500).

TABLE 46


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

SNP position(s) on
amino acid sequence	Type of change

1177	variant
1202	variant
1208	variant
1211	variant
1287	variant

Variant protein HSCOC4_PEA_—1_P26 (SEQ ID NO:500) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 47, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P26 (SEQ ID NO:500) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 47


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No
1632	A -> G	Yes
1663	P ->	Yes
1671	C -> R	Yes

Variant protein HSCOC4_PEA_—1_P26 (SEQ ID NO:500) is encoded by the following transcript(s): HSCOC4_PEA_—1_T32 (SEQ ID NO:404), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T32 (SEQ ID NO:404) is shown in bold; this coding portion starts at position 501 and ends at position 5573. The transcript also has the following SNPs as listed in Table 48 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P26 (SEQ ID NO:500) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 48


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5395	C -> G	Yes
5487	C ->	Yes
5511	T -> C	Yes
6050	G -> C	No
6093	G -> A	Yes
6103	A -> C	Yes
6278	A -> C	Yes
6284	G -> A	Yes
6349	A -> C	Yes
6407	C -> T	Yes
6672	C -> T	Yes
6691	C -> T	Yes
7424	C -> A	Yes
7644	C -> T	Yes
7809	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P30 (SEQ ID NO:501) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T40 (SEQ ID NO:405). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P30 (SEQ ID NO:501) and CO4_HUMAN_V3 (SEQ ID NO: 487):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P30 (SEQ ID NO:501), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGS corresponding to amino acids 1-1232 of CO4_HUMAN_V3 (SEQ ID NO:487), which also corresponds to amino acids 1-1232 of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RNPVRLLQPRAQMFCVLRGTK (SEQ ID NO:990) corresponding to amino acids 1233-1253 of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P30 (SEQ ID NO:501), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RNPVRLLQPRAQMFCVLRGTK (SEQ ID NO:990) in HSCOC4_PEA_—1_P30 (SEQ ID NO:501).

It should be noted that the known protein sequence (CO4_HUMAN (SEQ ID NO:485)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for CO4_HUMAN (SEQ ID NO:485)_V3 (SEQ ID NO:487). These changes were previously known to occur and are listed in the table below.

TABLE 49


Changes to CO4_HUMAN (SEQ ID NO: 485) _V3 (SEQ ID NO: 487)

SNP position(s) on
amino acid sequence	Type of change

1177	variant
1202	variant
1208	variant
1211	variant

Variant protein HSCOC4_PEA_—1_P30 (SEQ ID NO:501) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 50, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P30 (SEQ ID NO:501) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 50


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes

Variant protein HSCOC4_PEA_—1_P30 (SEQ ID NO:501) is encoded by the following transcript(s): HSCOC4_PEA_—1_T40 (SEQ ID NO:405), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T40 (SEQ ID NO:405) is shown in bold; this coding portion starts at position 501 and ends at position 4259. The transcript also has the following SNPs as listed in Table 51 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P30 (SEQ ID NO:501) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 51


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4348	C -> G	Yes
4559	G -> C	No
4602	G -> A	Yes
4612	A -> C	Yes
4787	A -> C	Yes
4793	G -> A	Yes
4858	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T2 (SEQ ID NO:388). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P38 (SEQ ID NO:502) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P38 (SEQ ID NO:502), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKG corresponding to amino acids 1-818 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-818 of HSCOC4_PEA_—1_P38 (SEQ ID NO:502), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) corresponding to amino acids 819-843 of HSCOC4_PEA_—1_P38 (SEQ ID NO:502), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P38 (SEQ ID NO:502) comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DVTLSGPQVTLLPFPCTPAPCSLCS (SEQ ID NO:978) in HSCOC4_PEA_—1_P38 (SEQ ID NO:502).

Variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 52, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 52


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
829	L -> P	Yes
830	L -> I	Yes
840	S -> P	Yes

The glycosylation sites of variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 53 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 53


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

1391	no
862	no
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 54 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 54


Phosphorylation site(s)

	Position(s) on known amino
	acid sequence	Present in variant protein?

	1420	no
	1422	no
	1417	no

Variant protein HSCOC4_PEA_—1_P38 (SEQ ID NO:502) is encoded by the following transcript(s): HSCOC4_PEA_—1_T2 (SEQ ID NO:388), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T2 (SEQ ID NO:388) is shown in bold; this coding portion starts at position 501 and ends at position 3029. The transcript also has the following SNPs as listed in Table 55 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA1_P38 (SEQ ID NO:502) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 55


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2986	T -> C	Yes
2988	C -> A	Yes
3018	T -> C	Yes
3070	C -> T	Yes
3081	C -> A	Yes
3093	A -> G	Yes
3101	G -> A	Yes
3106	G -> A	Yes
3174	G -> A	Yes
3193	A -> G	Yes
3201	T -> C	Yes
3233	C -> T	Yes
3373	T -> C	Yes
3404	G -> T	Yes
3477	G -> A	Yes
3635	A -> C	Yes
3714	T -> C	Yes
3869	G -> T	Yes
3976	A -> G	Yes
4043	C -> A	Yes
4117	C -> T	Yes
4120	G -> C	Yes
4128	T -> A	Yes
4131	G -> C	Yes
4133	C -> T	Yes
4285	G -> A	Yes
4292	T -> C	Yes
4373	C -> G	Yes
4378	C -> T	Yes
4387	G -> T	Yes
4388	G -> C	Yes
4484	G -> A	Yes
4490	C -> G	Yes
4493	G -> A	Yes
4614	G -> T	Yes
4707	A -> T	Yes
4926	A -> G	No
5018	T -> C	Yes
5152	G ->	No
5568	C -> G	Yes
5779	G -> C	No
5822	G -> A	Yes
5832	A -> C	Yes
6007	A -> C	Yes
6013	G -> A	Yes
6078	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T5 (SEQ ID NO:391). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P39 (SEQ ID NO:503) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P39 (SEQ ID NO:503), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQ corresponding to amino acids 1-387 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-387 of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSSRGEG (SEQ ID NO:992) corresponding to amino acids 388-394 of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P39 (SEQ ID NO:503), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSSRGEG (SEQ ID NO:992) in HSCOC4_PEA_—1_P39 (SEQ ID NO:503).

Variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 56, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 56


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A ->	No
322	A -> V	No
347	S -> Y	Yes

The glycosylation sites of variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 57 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 57


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

1391	no
862	no
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 58 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 58


Phosphorylation site(s)

	Position(s) on known amino
	acid sequence	Present in variant protein?

	1420	no
	1422	no
	1417	no

Variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503) is encoded by the following transcript(s): HSCOC4_PEA_—1_T5 (SEQ ID NO:391), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T5 (SEQ ID NO:391) is shown in bold; this coding portion starts at position 501 and ends at position 1682. The transcript also has the following SNPs as listed in Table 59 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P39 (SEQ ID NO:503) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 59


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1742	C -> A	Yes
1756	C -> A	Yes
1867	A ->	No
1877	C -> T	Yes
2032	C -> T	Yes
2084	C -> T	Yes
2245	A -> C	Yes
2261	G -> A	Yes
2421	C -> G	Yes
2448	A -> G	Yes
2534	G -> A	Yes
2639	C -> T	No
2776	C -> T	Yes
3074	C -> T	Yes
3214	T -> C	Yes
3245	G -> T	Yes
3318	G -> A	Yes
3476	A -> C	Yes
3555	T -> C	Yes
3710	G -> T	Yes
3817	A -> G	Yes
3884	C -> A	Yes
3958	C -> T	Yes
3961	G -> C	Yes
3969	T -> A	Yes
3972	G -> C	Yes
3974	C -> T	Yes
4126	G -> A	Yes
4133	T -> C	Yes
4214	C -> G	Yes
4219	C -> T	Yes
4228	G -> T	Yes
4229	G -> C	Yes
4325	G -> A	Yes
4331	C -> G	Yes
4334	G -> A	Yes
4455	G -> T	Yes
4548	A -> T	Yes
4767	A -> G	No
4859	T -> C	Yes
4993	G ->	No
5409	C -> G	Yes
5620	G -> C	No
5663	G -> A	Yes
5673	A -> C	Yes
5848	A -> C	Yes
5854	G -> A	Yes
5919	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T7 (SEQ ID NO:392). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P40 (SEQ ID NO:504) and CO4_HUMAN (SEQ ID NO:485):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P40 (SEQ ID NO:504), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKY corresponding to amino acids 1-236 of CO4_HUMAN (SEQ ID NO:485), which also corresponds to amino acids 1-236 of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AGEWTEPHFPLKGRVPGRPGEAEYGHY (SEQ ID NO:993) corresponding to amino acids 237-263 of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P40 (SEQ ID NO:504), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AGEWTEPHFPLKGRVPGRPGEAEYGHY (SEQ ID NO:993) in HSCOC4_PEA_—1_P40 (SEQ ID NO:504).

Variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 60, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 60


Amino acid mutations

SNP position(s) on
amino acid sequence	Alternative amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
254	R ->	No

The glycosylation sites of variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 61 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 61


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

1391	no
862	no
226	yes	226
1328	no

The phosphorylation sites of variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504), as compared to the known protein Complement C4 precursor [Contains: C4a anaphylatoxin], are described in Table 62 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 62


Phosphorylation site(s)

	Position(s) on known amino
	acid sequence	Present in variant protein?

	1420	no
	1422	no
	1417	no

Variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504) is encoded by the following transcript(s): HSCOC4_PEA_—1_T7 (SEQ ID NO:392), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T7 (SEQ ID NO:392) is shown in bold; this coding portion starts at position 501 and ends at position 1289. The transcript also has the following SNPs as listed in Table 63 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P40 (SEQ ID NO:504) sequence provides support for the deduced sequence variant protein according to the present invention).

TABLE 63


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1262	C ->	No
1262	C -> T	No
1314	C -> T	Yes
1337	C -> A	Yes
1565	A ->	No
1575	C -> T	Yes
1730	C -> T	Yes
1782	C -> T	Yes
1943	A -> C	Yes
1959	G -> A	Yes
2119	C -> G	Yes
2146	A -> G	Yes
2232	G -> A	Yes
2337	C -> T	No
2474	C -> T	Yes
2772	C -> T	Yes
2912	T -> C	Yes
2943	G -> T	Yes
3016	G -> A	Yes
3174	A -> C	Yes
3253	T -> C	Yes
3408	G -> T	Yes
3515	A -> G	Yes
3582	C -> A	Yes
3656	C -> T	Yes
3659	G -> C	Yes
3667	T -> A	Yes
3670	G -> C	Yes
3672	C -> T	Yes
3824	G -> A	Yes
3831	T -> C	Yes
3912	C -> G	Yes
3917	C -> T	Yes
3926	G -> T	Yes
3927	G -> C	Yes
4023	G -> A	Yes
4029	C -> G	Yes
4032	G -> A	Yes
4153	G -> T	Yes
4246	A -> T	Yes
4465	A -> G	No
4557	T -> C	Yes
4691	G ->	No
5107	C -> G	Yes
5318	G -> C	No
5361	G -> A	Yes
5371	A -> C	Yes
5546	A -> C	Yes
5552	G -> A	Yes
5617	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P41 (SEQ ID NO:505) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T8 (SEQ ID NO:393). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P41 (SEQ ID NO:505) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P41 (SEQ ID NO:505), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLL YFDSV corresponding to amino acids 1-1529 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1529 of HSCOC4_PEA_—1_P41 (SEQ ID NO:505), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SGER (SEQ ID NO:984) corresponding to amino acids 1530-1533 of HSCOC4_PEA_—1_P41 (SEQ ID NO:505), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P41 (SEQ ID NO:505), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SGER (SEQ ID NO:984) in HSCOC4_PEA_—1_P41 (SEQ ID NO:505).

It should be noted that the known protein sequence (CO4_HUMAN (SEQ ID NO:485) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for CO4_HUMAN_V1 (SEQ ID NO:486). These changes were previously known to occur and are listed in the table below.

TABLE 64


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P41 (SEQ ID NO:505) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 65, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P41 (SEQ ID NO:505) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 65


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A -> V	No
322	A ->	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No

Variant protein HSCOC4_PEA_—1_P41 (SEQ ID NO:505) is encoded by the following transcript(s): HSCOC4_PEA_—1_T8 (SEQ ID NO:393), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T8 (SEQ ID NO:393) is shown in bold; this coding portion starts at position 501 and ends at position 5099. The transcript also has the following SNPs as listed in Table 66 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P41 (SEQ ID NO:505) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 66


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5561	G -> A	Yes
6026	T -> G	Yes
6348	G -> C	Yes
6801	C -> G	Yes
7012	G -> C	No
7055	G -> A	Yes
7065	A -> C	Yes
7240	A -> C	Yes
7246	G -> A	Yes
7311	A -> C	Yes

Variant protein HSCOC4_PEA_—1_P42 (SEQ ID NO:506) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSCOC4_PEA_—1_T12 (SEQ ID NO:395). An alignment is given to the known protein (Complement C4 precursor [Contains: C4a anaphylatoxin]) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSCOC4_PEA_—1_P42 (SEQ ID NO:506) and CO4_HUMAN_V1 (SEQ ID NO:486):

1. An isolated chimeric polypeptide encoding for HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising a first amino acid sequence being at least 90% homologous to MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLR NPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLK DSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMV ENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVL PNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFR GLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAE LTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVP EVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPD SRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLA PSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDS LALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAG LAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTR LPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLID EDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQL RVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQ QVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREEL VYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRK ADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQ DPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASS FLGEKASAGLLGAHAAAITAYALTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSV TGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTR QGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVE YTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNRRRREAPKVVEEQESRV HYTVCIW corresponding to amino acids 1-1473 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1-1473 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence WAPGAALGQGREGRTQAGAGLLEPAQAEPGRQLTRLHR (SEQ ID NO:1021) corresponding to amino acids 1474-1511 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), a third amino acid sequence being at least 90% homologous to RNGKVGLSGMAIADVTLLSGFHALRADLEK corresponding to amino acids 1474-1503 of CO4_HUMAN_V1 (SEQ ID NO:486), which also corresponds to amino acids 1512-1541 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), and a fourth amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VWSATQGNPLCPRY (SEQ ID NO:995) corresponding to amino acids 1542-1555 of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), wherein said first amino acid sequence, second amino acid sequence, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for an edge portion of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for WAPGAALGQGREGRTQAGAGLLEPAQAEPGRQLTRLHR (SEQ ID NO: 1021), corresponding to HSCOC4_PEA_—1_P42 (SEQ ID NO:506).

3. An isolated polypeptide encoding for a tail of HSCOC4_PEA_—1_P42 (SEQ ID NO:506), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VWSATQGNPLCPRY (SEQ ID NO:995) in HSCOC4_PEA_—1_P42 (SEQ ID NO:506).

It should be noted that the known protein sequence (CO4_HUMAN (SEQ ID NO:485) ) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for CO4_HUMAN_V1 (SEQ ID NO:486). These changes were previously known to occur and are listed in the table below.

TABLE 67


Changes to CO4_HUMAN_V1 (SEQ ID NO: 486)

	SNP position(s) on
	amino acid sequence	Type of change

	1177	variant
	1202	variant
	1208	variant
	1211	variant
	1287	variant

Variant protein HSCOC4_PEA_—1_P42 (SEQ ID NO:506) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 68, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P42 (SEQ ID NO:506) sequence provides support for the deduced sequence s variant protein according to the present invention).

TABLE 68


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

128	Q ->	No
141	L -> V	Yes
183	G ->	No
211	G ->	No
322	A -> V	No
322	A ->	No
347	S -> Y	Yes
423	Q ->	No
478	P -> L	Yes
549	H -> P	Yes
608	L -> V	Yes
617	K -> E	Yes
726	P -> L	Yes
872	V -> A	Yes
907	A -> T	Yes
959	E -> D	Yes
1073	D -> G	Yes
1120	P -> L	Yes
1121	C -> S	Yes
1124	L -> I	Yes
1125	D -> H	Yes
1176	S -> N	Yes
1207	A -> V	Yes
1210	R -> L	Yes
1286	A -> S	Yes
1317	I -> F	Yes
1390	K -> E	No
1465	R ->	No

Variant protein HSCOC4_PEA_—1_P42 (SEQ ID NO:506) is encoded by the following transcript(s): HSCOC4_PEA_—1_T12 (SEQ ID NO:395), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSCOC4_PEA_—1_T12 (SEQ ID NO:395) is shown in bold; this coding portion starts at position 501 and ends at position 5165. The transcript also has the following SNPs as listed in Table 69 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSCOC4_PEA_—1_P42 (SEQ ID NO:506) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 69


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

304	A -> G	Yes
884	G ->	No
921	C -> G	Yes
1049	C ->	No
1131	G ->	No
1465	C ->	No
1465	C -> T	No
1517	C -> T	Yes
1540	C -> A	Yes
1768	A ->	No
1778	C -> T	Yes
1933	C -> T	Yes
1985	C -> T	Yes
2146	A -> C	Yes
2162	G -> A	Yes
2322	C -> G	Yes
2349	A -> G	Yes
2435	G -> A	Yes
2540	C -> T	No
2677	C -> T	Yes
2975	C -> T	Yes
3115	T -> C	Yes
3146	G -> T	Yes
3219	G -> A	Yes
3377	A -> C	Yes
3456	T -> C	Yes
3611	G -> T	Yes
3718	A -> G	Yes
3785	C -> A	Yes
3859	C -> T	Yes
3862	G -> C	Yes
3870	T -> A	Yes
3873	G -> C	Yes
3875	C -> T	Yes
4027	G -> A	Yes
4034	T -> C	Yes
4115	C -> G	Yes
4120	C -> T	Yes
4129	G -> T	Yes
4130	G -> C	Yes
4226	G -> A	Yes
4232	C -> G	Yes
4235	G -> A	Yes
4356	G -> T	Yes
4449	A -> T	Yes
4668	A -> G	No
4760	T -> C	Yes
4894	G ->	No
5765	G -> A	Yes
6230	T -> G	Yes
6552	G -> C	Yes
7005	C -> G	Yes
7216	G -> C	No
7259	G -> A	Yes
7269	A -> C	Yes
7444	A -> C	Yes
7450	G -> A	Yes
7515	A -> C	Yes

As noted above, cluster HSCOC4 features 79 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSCOC4_PEA_—1_node_—1 (SEQ ID NO:406) according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 70 below describes the starting and ending position of this segment on each transcript.

TABLE 70


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1	535
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1	535
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1	535
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1	535
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1	535
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1	535
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1	535
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1	535
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1	535
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1	535
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1	535
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1	535
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1	535
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1	535
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1	535
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1	535
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1	535
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1	535
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1	535
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—5 (SEQ ID NO:407) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 71 below describes the starting and ending position of this segment on each transcript.

TABLE 71


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	566	764
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	566	764
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	566	764
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	566	764
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	566	764
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	566	764
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	566	764
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	566	764
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	566	764
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	566	764
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	566	764
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	566	764
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	566	764
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	566	764
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	566	764
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	566	764
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	566	764
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	566	764
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	566	764
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—7 (SEQ ID NO:408) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 72 below describes the starting and ending position of this segment on each transcript.

TABLE 72


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	765	885
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	765	885
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	765	885
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	765	885
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	765	885
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	765	885
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	765	885
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	765	885
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	765	885
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	765	885
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	765	885
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	765	885
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	765	885
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	765	885
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	765	885
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	765	885
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	765	885
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	765	885
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	765	885
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—30 (SEQ ID NO:409) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11(SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 73 below describes the starting and ending position of this segment on each transcript.

TABLE 73


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1662	1841
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1662	1841
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1662	1841
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1662	1841
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1761	1940
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1459	1638
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1662	1841
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1662	1841
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1662	1841
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1662	1841
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1662	1841
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1662	1841
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1662	1841
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1662	1841
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1662	1841
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1662	1841
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1662	1841
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1662	1841
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1662	1841
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—33 (SEQ ID NO:410) according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 74 below describes the starting and ending position of this segment on each transcript.

TABLE 74


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1842	2024
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1842	2024
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1842	2024
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1842	2024
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1941	2123
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1639	1821
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1842	2024
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1842	2024
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1842	2024
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1842	2024
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1842	2024
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1842	2024
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1842	2024
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1842	2024
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1842	2024
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1842	2024
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1842	2024
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1842	2024
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1842	2024
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—35 (SEQ ID NO:411) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 75 below describes the starting and ending position of this segment on each transcript.

TABLE 75


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2025	2210
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2025	2210
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2025	2210
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2025	2210
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2124	2309
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1822	2007
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2025	2210
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2025	2210
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2025	2210
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2025	2210
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2025	2210
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2025	2210
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2025	2210
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2025	2210
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2025	2210
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2025	2210
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2025	2210
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2025	2210
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2025	2210
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—37 (SEQ ID NO:412) according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 76 below describes the starting and ending position of this segment on each transcript.

TABLE 76


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2211	2369
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2211	2369
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2211	2369
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2211	2369
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2310	2468
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2008	2166
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2211	2369
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2211	2369
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2211	2369
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2211	2369
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2211	2369
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2211	2369
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2211	2369
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2211	2369
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2211	2369
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2211	2369
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2211	2369
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2211	2369
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2211	2369
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—39 (SEQ ID NO:413) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 77 below describes the starting and ending position of this segment on each transcript.

TABLE 77


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2370	2496
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2370	2496
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2370	2496
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2370	2496
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2469	2595
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2167	2293
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2370	2496
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2370	2496
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2370	2496
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2370	2496
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2370	2496
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2370	2496
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2370	2496
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2370	2496
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2370	2496
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2370	2496
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2370	2496
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2370	2496
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2370	2496
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—43 (SEQ ID NO:414) according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_—T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1₋T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 78 below describes the starting and ending position of this segment on each transcript.

TABLE 78


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2572	2769
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2572	2769
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2572	2769
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2572	2769
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2671	2868
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2369	2566
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2572	2769
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2572	2769
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2572	2769
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2572	2769
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2572	2769
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2572	2769
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2572	2769
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2572	2769
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2572	2769
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2572	2769
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2572	2769
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2572	2769
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2572	2769
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—48 (SEQ ID NO:415) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T2 (SEQ ID NO:388) and HSCOC4_PEA_—1_T3 (SEQ ID NO:389). Table 79 below describes the starting and ending position of this segment on each transcript.

TABLE 79


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T2 (SEQ ID	2953	3210
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2953	3210
NO: 389)

Segment cluster HSCOC4_PEA_—1_node_—49 (SEQ ID NO:416) according to the present invention is supported by 37 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 80 below describes the starting and ending position of this segment on each transcript.

TABLE 80


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2953	3092
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3211	3350
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3211	3350
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2953	3092
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3052	3191
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2750	2889
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2953	3092
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2953	3092
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2953	3092
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2953	3092
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2953	3092
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2953	3092
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2953	3092
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2953	3092
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2953	3092
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2953	3092
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2953	3092
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2953	3092
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2953	3092
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—51 (SEQ ID NO:417) according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 81 below describes the starting and ending position of this segment on each transcript.

TABLE 81


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3206	3415
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3351	3560
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3464	3673
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3093	3302
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3192	3401
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2890	3099
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3093	3302
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3093	3302
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3093	3302
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3093	3302
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3093	3302
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3093	3302
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3093	3302
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3093	3302
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3093	3302
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3093	3302
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3093	3302
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3093	3302
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3093	3302
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—58 (SEQ ID NO:418) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ;ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 82 below describes the starting and ending position of this segment on each transcript.

TABLE 82


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3605	3767
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3750	3912
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3863	4025
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3492	3654
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3591	3753
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3289	3451
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3492	3654
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3492	3654
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3492	3654
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3492	3654
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3492	3654
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3492	3654
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3492	3654
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3492	3654
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3492	3654
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3492	3654
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3492	3654
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3492	3654
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3492	3654
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—59 (SEQ ID NO:419) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T4 (SEQ ID NO:390). Table 83 below describes the starting and ending position of this segment on each transcript.

TABLE 83


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T4 (SEQ ID	3655	3833
NO: 390)

Segment cluster HSCOC4_PEA_—1_node_—62 (SEQ ID NO:420) according to the present invention is supported by 61 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_—T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 84 below describes the starting and ending position of this segment on each transcript.

TABLE 84


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3844	4000
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3989	4145
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4102	4258
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3910	4066
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3830	3986
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3528	3684
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3731	3887
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3731	3887
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3731	3887
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3731	3887
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3731	3887
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3731	3887
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3731	3887
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3731	3887
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3731	3887
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3731	3887
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3731	3887
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3731	3887
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3731	3887
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—66 (SEQ ID NO:421) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 85 below describes the starting and ending position of this segment on each transcript.

TABLE 85


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4118	4289
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4263	4434
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4376	4547
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4184	4355
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4104	4275
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3802	3973
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4005	4176
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4005	4176
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4005	4176
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4005	4176
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4005	4176
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4005	4176
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4005	4176
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4005	4176
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4005	4176
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4005	4176
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4005	4176
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4005	4176
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4005	4176
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—72 (SEQ ID NO:422) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 86 below describes the starting and ending position of this segment on each transcript.

TABLE 86


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4392	4522
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4537	4667
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4650	4780
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4458	4588
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4378	4508
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4076	4206
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4279	4409
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4279	4409
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4279	4409
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4279	4409
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4279	4409
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4279	4409
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4279	4409
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4279	4409
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4279	4409
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4279	4409
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4279	4409
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4279	4409
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—77 (SEQ ID NO:423) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T14 (SEQ ID NO:396) and HSCOC4_PEA_—1_T20 (SEQ ID NO:398). Table 87 below describes the starting and ending position of this segment on each transcript.

TABLE 87


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T14 (SEQ ID	4578	4970
NO: 396)
HSCOC4_PEA_1_T20 (SEQ ID	4660	5052
NO: 398)

Segment cluster HSCOC4_PEA_—1_node_—79 (SEQ ID NO:424) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T11 (SEQ ID NO:394). Table 88 below describes the starting and ending position of this segment on each transcript.

TABLE 88


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T11 (SEQ ID	4638	5686
NO: 394)

Segment cluster HSCOC4_PEA_—1_node_—93 (SEQ ID NO:425) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T12 (SEQ ID NO:395) and HSCOC4_PEA_—1_T21 (SEQ ID NO:399). Table 89 below describes the starting and ending position of this segment on each transcript.

TABLE 89


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T8 (SEQ ID	5085	6566
NO: 393)
HSCOC4_PEA_1_T12 (SEQ ID	5289	6770
NO: 395)
HSCOC4_PEA_1_T21 (SEQ ID	5085	6566
NO: 399)

Segment cluster HSCOC4_PEA_—1_node_—100 (SEQ ID NO:426) according to the present invention is supported by 13 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T21 (SEQ ID NO:399). Table 90 below describes the starting and ending position of this segment on each transcript.

TABLE 90


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T21 (SEQ ID	6679	6843
NO: 399)

Segment cluster HSCOC4_PEA_—1_node_—105 (SEQ ID NO:427) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T28 (SEQ ID NO:401) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 91 below describes the starting and ending position of this segment on each transcript.

TABLE 91


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T28 (SEQ ID	5377	5558
NO: 401)
HSCOC4_PEA_1_T32 (SEQ ID	5462	5643
NO: 404)

TABLE 92


Oligonucleotides related to this segment

		Chip
Oligonucleotide name	Overexpressed in cancers	reference

HSCOC4_0_0_9883 (SEQ ID	breast malignant tumors	BRS
NO: 909)

Segment cluster HSCOC4_PEA_—1_node_—107 (SEQ ID NO:428) according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 93 below describes the starting and ending position of this segment on each transcript.

TABLE 93


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T25 (SEQ ID	5461	5722
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5643	5904
NO: 401)
HSCOC4_PEA_1_T32 (SEQ ID	5728	5989
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—108 (SEQ ID NO:429) according to the present invention is supported by 120 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 94 below describes the starting and ending position of this segment on each transcript.

TABLE 94


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5574	5706
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5719	5851
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5832	5964
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5640	5772
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5560	5692
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5258	5390
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6952	7084
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6510	6642
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7156	7288
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5854	5986
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5414	5546
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5936	6068
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7117	7249
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5723	5855
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5905	6037
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5358	5490
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5546	5678
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5990	6122
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4499	4631
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—109 (SEQ ID NO:430) according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T25 (SEQ ID NO:400) and HSCOC4_PEA_—1_T28 (SEQ ID NO:401). Table 95 below describes the starting and ending position of this segment on each transcript.

TABLE 95


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T25 (SEQ ID	5856	5998
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	6038	6180
NO: 401)

Segment cluster HSCOC4_PEA_—1_node_—110 (SEQ ID NO:431) according to the present invention is supported by 97 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 96 below describes the starting and ending position of this segment on each transcript.

TABLE 96


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5707	5856
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5852	6001
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5965	6114
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5773	5922
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5693	5842
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5391	5540
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	7085	7234
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6643	6792
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7289	7438
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5987	6136
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5547	5696
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	6069	6218
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7250	7399
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5999	6148
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	6181	6330
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5491	5640
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5679	5828
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	6123	6272
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4632	4781
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—112 (SEQ ID NO:432) according to the present invention is supported by 71 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 97 below describes the starting and ending position of this segment on each transcript.

TABLE 97


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5948	5989
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	6093	6134
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	6206	6247
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	6014	6055
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5934	5975
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5632	5673
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	7326	7367
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6884	6925
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7530	7571
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	6228	6269
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5788	5829
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	6310	6351
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7491	7532
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	6240	6619
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	6422	6801
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5732	5773
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5920	5961
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	6364	6743
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4873	4914
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—113 (SEQ ID NO:433) according to the present invention is supported by 19 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 98 below describes the starting and ending position of this segment on each transcript.

TABLE 98


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T25 (SEQ ID	6620	7765
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	6802	7947
NO: 401)
HSCOC4_PEA_1_T32 (SEQ ID	6744	7889
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—2 (SEQ ID NO:434) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 99 below describes the starting and ending position of this segment on each transcript.

TABLE 99


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	536	565
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	536	565
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	536	565
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	536	565
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	536	565
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	536	565
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	536	565
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	536	565
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	536	565
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	536	565
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	536	565
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	536	565
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	536	565
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	536	565
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	536	565
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	536	565
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	536	565
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	536	565
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	536	565
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—8 (SEQ ID NO:435) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 100 below describes the starting and ending position of this segment on each transcript.

TABLE 100


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	886	966
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	886	966
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	886	966
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	886	966
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	886	966
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	886	966
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	886	966
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	886	966
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	886	966
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	886	966
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	886	966
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	886	966
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	886	966
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	886	966
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	886	966
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	886	966
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	886	966
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	886	966
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	886	966
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—10 (SEQ ID NO:436) according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 101 below describes the starting and ending position of this segment on each transcript.

TABLE 101


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	967	1037
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	967	1037
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	967	1037
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	967	1037
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	967	1037
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	967	1037
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	967	1037
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	967	1037
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	967	1037
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	967	1037
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	967	1037
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	967	1037
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	967	1037
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	967	1037
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	967	1037
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	967	1037
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	967	1037
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	967	1037
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	967	1037
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—12 (SEQ ID NO:437) according to the present invention is supported by 33 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 102 below describes the starting and ending position of this segment on each transcript.

TABLE 102


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1038	1126
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1038	1126
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1038	1126
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1038	1126
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1038	1126
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1038	1126
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1038	1126
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1038	1126
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1038	1126
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1038	1126
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1038	1126
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1038	1126
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1038	1126
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1038	1126
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1038	1126
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1038	1126
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1038	1126
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1038	1126
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1038	1126
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—14 (SEQ ID NO:438) according to the present invention is supported by 30 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 103 below describes the starting and ending position of this segment on each transcript.

TABLE 103


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1127	1209
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1127	1209
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1127	1209
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1127	1209
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1127	1209
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1127	1209
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1127	1209
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1127	1209
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1127	1209
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1127	1209
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1127	1209
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1127	1209
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1127	1209
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1127	1209
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1127	1209
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1127	1209
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1127	1209
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1127	1209
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1127	1209
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—17 (SEQ ID NO:439) according to the present invention is supported by 28 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 104 below describes the starting and ending position of this segment on each transcript.

TABLE 104


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1210	1306
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1210	1306
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1210	1306
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1210	1306
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1210	1306
NO: 391)
HSCOC4_PEA_1_T8 (SEQ ID	1210	1306
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1210	1306
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1210	1306
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1210	1306
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1210	1306
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1210	1306
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1210	1306
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1210	1306
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1210	1306
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1210	1306
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1210	1306
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1210	1306
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1210	1306
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—19 (SEQ ID NO:440) according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_—T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 105 below describes the starting and ending position of this segment on each transcript.

TABLE 105


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1307	1412
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1307	1412
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1307	1412
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1307	1412
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1307	1412
NO: 391)
HSCOC4_PEA_1_T8 (SEQ ID	1307	1412
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1307	1412
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1307	1412
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1307	1412
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1307	1412
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1307	1412
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1307	1412
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1307	1412
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1307	1412
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1307	1412
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1307	1412
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1307	1412
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1307	1412
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—21 (SEQ ID NO:441) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 106 below describes the starting and ending position of this segment on each transcript.

TABLE 106


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1413	1439
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1413	1439
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1413	1439
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1413	1439
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1413	1439
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1210	1236
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1413	1439
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1413	1439
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1413	1439
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1413	1439
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1413	1439
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1413	1439
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1413	1439
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1413	1439
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1413	1439
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1413	1439
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1413	1439
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1413	1439
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1413	1439
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—22 (SEQ ID NO:442) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 107 below describes the starting and ending position of this segment on each transcript.

TABLE 107


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1440	1545
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1440	1545
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1440	1545
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1440	1545
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1440	1545
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1237	1342
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1440	1545
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1440	1545
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1440	1545
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1440	1545
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1440	1545
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1440	1545
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1440	1545
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1440	1545
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1440	1545
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1440	1545
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1440	1545
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1440	1545
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1440	1545
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—28 (SEQ ID NO:443) according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 108 below describes the starting and ending position of this segment on each transcript.

TABLE 108


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	1546	1661
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	1546	1661
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	1546	1661
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	1546	1661
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	1546	1661
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	1343	1458
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	1546	1661
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	1546	1661
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	1546	1661
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	1546	1661
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	1546	1661
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	1546	1661
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	1546	1661
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	1546	1661
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	1546	1661
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	1546	1661
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	1546	1661
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	1546	1661
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	1546	1661
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—29 (SEQ ID NO:444) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T5 (SEQ ID NO:391). Table 109 below describes the starting and ending position of this segment on each transcript.

TABLE 109


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T5 (SEQ ID	1662	1760
NO: 391)

Segment cluster HSCOC4_PEA_—1_node_—41 (SEQ ID NO:445) according to the present invention is supported by 32 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 110 below describes the starting and ending position of this segment on each transcript.

TABLE 110


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2497	2571
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2497	2571
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2497	2571
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2497	2571
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2596	2670
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2294	2368
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2497	2571
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2497	2571
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2497	2571
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2497	2571
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2497	2571
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2497	2571
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2497	2571
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2497	2571
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2497	2571
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2497	2571
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2497	2571
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2497	2571
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2497	2571
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—45 (SEQ ID NO:446) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 111 below describes the starting and ending position of this segment on each transcript.

TABLE 111


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2770	2881
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2770	2881
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2770	2881
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2770	2881
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2869	2980
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2567	2678
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2770	2881
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2770	2881
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2770	2881
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2770	2881
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2770	2881
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2770	2881
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2770	2881
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2770	2881
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2770	2881
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2770	2881
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2770	2881
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2770	2881
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2770	2881
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—47 (SEQ ID NO:447) according to the present invention is supported by 32 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 112 below describes the starting and ending position of this segment on each transcript.

TABLE 112


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	2882	2952
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	2882	2952
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	2882	2952
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	2882	2952
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	2981	3051
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	2679	2749
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	2882	2952
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	2882	2952
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	2882	2952
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	2882	2952
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	2882	2952
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	2882	2952
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	2882	2952
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	2882	2952
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	2882	2952
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	2882	2952
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	2882	2952
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	2882	2952
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	2882	2952
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—50 (SEQ ID NO:448) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387) and HSCOC4_PEA_—1_T3 (SEQ ID NO:389). Table 113 below describes the starting and ending position of this segment on each transcript.

TABLE 113


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3093	3205
NO: 387)
HSCOC4_PEA_1_T3 (SEQ ID	3351	3463
NO: 389)

Segment cluster HSCOC4_PEA_—1_node_—53 (SEQ ID NO:449) according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 114 below describes the starting and ending position of this segment on each transcript.

TABLE 114


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3416	3467
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3561	3612
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3674	3725
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3303	3354
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3402	3453
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3100	3151
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3303	3354
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3303	3354
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3303	3354
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3303	3354
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3303	3354
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3303	3354
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3303	3354
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3303	3354
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3303	3354
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3303	3354
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3303	3354
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3303	3354
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3303	3354
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—55 (SEQ ID NO:450) according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 115 below describes the starting and ending position of this segment on each transcript.

TABLE 115


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3468	3557
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3613	3702
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3726	3815
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3355	3444
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3454	3543
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3152	3241
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3355	3444
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3355	3444
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3355	3444
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3355	3444
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3355	3444
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3355	3444
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3355	3444
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3355	3444
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3355	3444
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3355	3444
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3355	3444
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3355	3444
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3355	3444
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—57 (SEQ ID NO:451) according to the present invention is supported by 42 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 116 below describes the starting and ending position of this segment on each transcript.

TABLE 116


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3558	3604
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3703	3749
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	3816	3862
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3445	3491
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3544	3590
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3242	3288
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3445	3491
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3445	3491
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3445	3491
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3445	3491
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3445	3491
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3445	3491
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3445	3491
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3445	3491
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3445	3491
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3445	3491
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3445	3491
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3445	3491
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3445	3491
NO: 405)

Segment cluster HSCOC4_PEA_—1—node_—60 (SEQ ID NO:452) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 117 below describes the starting and ending position of this segment on each transcript.

TABLE 117


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	3768	3843
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	3913	3988
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4026	4101
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	3834	3909
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3754	3829
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3452	3527
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3655	3730
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3655	3730
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3655	3730
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3655	3730
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3655	3730
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3655	3730
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3655	3730
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3655	3730
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3655	3730
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3655	3730
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3655	3730
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3655	3730
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3655	3730
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—64 (SEQ ID NO:453) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15(SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 118 below describes the starting and ending position of this segment on each transcript.

TABLE 118


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4001	4117
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4146	4262
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4259	4375
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4067	4183
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	3987	4103
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3685	3801
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	3888	4004
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	3888	4004
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	3888	4004
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	3888	4004
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	3888	4004
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	3888	4004
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	3888	4004
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	3888	4004
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	3888	4004
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	3888	4004
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	3888	4004
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	3888	4004
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	3888	4004
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—69 (SEQ ID NO:454) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 119 below describes the starting and ending position of this segment on each transcript.

TABLE 119


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4290	4309
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4435	4454
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4548	4567
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4356	4375
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4276	4295
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3974	3993
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4177	4196
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4177	4196
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4177	4196
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4177	4196
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4177	4196
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4177	4196
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4177	4196
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4177	4196
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4177	4196
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4177	4196
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4177	4196
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4177	4196
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4177	4196
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—70 (SEQ ID NO:455) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 120 below describes the starting and ending position of this segment on each transcript.

TABLE 120


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4310	4349
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4455	4494
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4568	4607
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4376	4415
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4296	4335
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	3994	4033
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4197	4236
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4197	4236
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4197	4236
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4197	4236
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4197	4236
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4197	4236
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4197	4236
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4197	4236
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4197	4236
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4197	4236
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4197	4236
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4197	4236
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—71 (SEQ ID NO:456) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1—T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 121 below describes the starting and ending position of this segment on each transcript.

TABLE 121


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4350	4391
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4495	4536
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4608	4649
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4416	4457
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4336	4377
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4034	4075
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4237	4278
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4237	4278
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4237	4278
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4237	4278
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4237	4278
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4237	4278
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4237	4278
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4237	4278
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4237	4278
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4237	4278
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4237	4278
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4237	4278
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—73 (SEQ ID NO:457) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T20 (SEQ ID NO:398). Table 122 below describes the starting and ending position of this segment on each transcript.

TABLE 122


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T20 (SEQ ID	4410	4491
NO: 398)

Segment cluster HSCOC4_PEA_—1_node_—74 (SEQ ID NO:458) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 123 below describes the starting and ending position of this segment on each transcript.

TABLE 123


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4523	4546
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4668	4691
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4781	4804
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4589	4612
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4509	4532
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4207	4230
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4410	4433
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4410	4433
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4410	4433
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4410	4433
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4410	4433
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4492	4515
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4410	4433
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4410	4433
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4410	4433
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4410	4433
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4410	4433
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4410	4433
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—75 (SEQ ID NO:459) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 124 below describes the starting and ending position of this segment on each transcript.

TABLE 124


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4547	4626
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4692	4771
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4805	4884
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4613	4692
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4533	4612
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4231	4310
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4434	4513
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4434	4513
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4434	4513
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4434	4513
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4434	4513
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4516	4595
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4434	4513
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4434	4513
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4434	4513
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4434	4513
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4434	4513
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4434	4513
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—76 (SEQ ID NO:460) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 125 below describes the starting and ending position of this segment on each transcript.

TABLE 125


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4627	4690
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4772	4835
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4885	4948
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4693	4756
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4613	4676
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4311	4374
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4514	4577
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4514	4577
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4514	4577
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4514	4577
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4514	4577
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	4596	4659
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4514	4577
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4514	4577
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4514	4577
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4514	4577
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4514	4577
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4514	4577
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—78 (SEQ ID NO:461) according to the present invention is supported by 71 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 126 below describes the starting and ending position of this segment on each transcript.

TABLE 126


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4691	4750
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4836	4895
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	4949	5008
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4757	4816
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4677	4736
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4375	4434
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4578	4637
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	4578	4637
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4578	4637
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	4971	5030
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4578	4637
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5053	5112
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4578	4637
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4578	4637
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4578	4637
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4578	4637
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4578	4637
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4578	4637
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—80 (SEQ ID NO:462) according to the present invention is supported by 75 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15(SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 127 below describes the starting and ending position of this segment on each transcript.

TABLE 127


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4751	4844
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4896	4989
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5009	5102
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4817	4910
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4737	4830
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4435	4528
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4638	4731
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5687	5780
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4638	4731
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5031	5124
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4638	4731
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5113	5206
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4638	4731
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4638	4731
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4638	4731
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4638	4731
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4638	4731
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4638	4731
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—82 (SEQ ID NO:463) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 128 below describes the starting and ending position of this segment on each transcript.

TABLE 128


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4845	4855
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	4990	5000
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5103	5113
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4911	4921
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4831	4841
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4529	4539
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4732	4742
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5781	5791
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4732	4742
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5125	5135
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4732	4742
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5207	5217
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4732	4742
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4732	4742
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4732	4742
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4732	4742
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4732	4742
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4732	4742
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—83 (SEQ ID NO:464) according to the present invention is supported by 77 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 129 below describes the starting and ending position of this segment on each transcript.

TABLE 129


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4856	4971
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5001	5116
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5114	5229
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	4922	5037
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4842	4957
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4540	4655
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4743	4858
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5792	5907
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4743	4858
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5136	5251
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4743	4858
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5218	5333
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4743	4858
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4743	4858
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4743	4858
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4743	4858
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4743	4858
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4743	4858
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—84 (SEQ ID NO:465) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 130 below describes the starting and ending position of this segment on each transcript.

TABLE 130


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4972	4984
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5117	5129
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5230	5242
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5038	5050
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4958	4970
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4656	4668
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4859	4871
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5908	5920
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4859	4871
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5252	5264
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4859	4871
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5334	5346
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4859	4871
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4859	4871
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4859	4871
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4859	4871
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4859	4871
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4859	4871
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—85 (SEQ ID NO:466) according to the present invention is supported by 68 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 131 below describes the starting and ending position of this segment on each transcript.

TABLE 131


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	4985	5031
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5130	5176
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5243	5289
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5051	5097
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	4971	5017
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4669	4715
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4872	4918
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5921	5967
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	4872	4918
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5265	5311
NO: 396)
HSCOC4_PEA_1_T20 (SEQ ID	5347	5393
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4872	4918
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4872	4918
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4872	4918
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4872	4918
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4872	4918
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4872	4918
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—86 (SEQ ID NO:467) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T12 (SEQ ID NO:395). Table 132 below describes the starting and ending position of this segment on each transcript.

TABLE 132


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T12 (SEQ ID	4919	5032
NO: 395)

Segment cluster HSCOC4_PEA_—1_node_—87 (SEQ ID NO:468) according to the present invention is supported by 74 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404) . Table 133 below describes the starting and ending position of this segment on each transcript.

TABLE 133


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5032	5122
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5177	5267
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5290	5380
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5098	5188
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5018	5108
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4716	4806
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	4919	5009
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	5968	6058
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	5033	5123
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5312	5402
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4872	4962
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5394	5484
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	4919	5009
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	4919	5009
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	4919	5009
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	4919	5009
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	4919	5009
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	4919	5009
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—88 (SEQ ID NO:469) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T12 (SEQ ID NO:395). Table 134 below describes the starting and ending position of this segment on each transcript.

TABLE 134


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T12 (SEQ ID	5124	5213
NO: 395)

Segment cluster HSCOC4_PEA_—1_node_—89 (SEQ ID NO:470) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 135 below describes the starting and ending position of this segment on each transcript.

TABLE 135


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5123	5131
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5268	5276
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5381	5389
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5189	5197
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5109	5117
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4807	4815
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	5010	5018
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6059	6067
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	5214	5222
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5403	5411
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4963	4971
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5485	5493
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	5010	5018
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5010	5018
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5010	5018
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5010	5018
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5010	5018
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5010	5018
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—90 (SEQ ID NO:471) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 136 below describes the starting and ending position of this segment on each transcript.

TABLE 136


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5132	5142
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5277	5287
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5390	5400
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5198	5208
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5118	5128
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4816	4826
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	5019	5029
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6068	6078
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	5223	5233
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5412	5422
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4972	4982
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5494	5504
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	5019	5029
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5019	5029
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5019	5029
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5019	5029
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5019	5029
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5019	5029
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—91 (SEQ ID NO:472) according to the present invention is supported by 78 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 137 below describes the starting and ending position of this segment on each transcript.

TABLE 137


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5143	5179
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5288	5324
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5401	5437
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5209	5245
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5129	5165
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4827	4863
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	5030	5066
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6079	6115
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	5234	5270
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5423	5459
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	4983	5019
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5505	5541
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	5030	5066
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5030	5066
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5030	5066
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5030	5066
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5030	5066
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5030	5066
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—92 (SEQ ID NO:473) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404) . Table 138 below describes the starting and ending position of this segment on each transcript.

TABLE 138


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5180	5197
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5325	5342
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5438	5455
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5246	5263
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5166	5183
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4864	4881
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	5067	5084
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6116	6133
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	5271	5288
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5460	5477
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5020	5037
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5542	5559
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	5067	5084
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5067	5084
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5067	5084
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5067	5084
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5067	5084
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5067	5084
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—94 (SEQ ID NO:474) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T12 (SEQ ID NO:395) and HSCOC4_PEA_—1_T21 (SEQ ID NO:399). Table 139 below describes the starting and ending position of this segment on each transcript.

TABLE 139


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T8 (SEQ ID	6567	6575
NO: 393)
HSCOC4_PEA_1_T12 (SEQ ID	6771	6779
NO: 395)
HSCOC4_PEA_1_T21 (SEQ ID	6567	6575
NO: 399)

Segment cluster HSCOC4_PEA_—1_node_—96 (SEQ ID NO:475) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 140 below describes the starting and ending position of this segment on each transcript.

TABLE 140


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5198	5205
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5343	5350
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5456	5463
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5264	5271
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5184	5191
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4882	4889
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6576	6583
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6134	6141
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6780	6787
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5478	5485
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5038	5045
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5560	5567
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6576	6583
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5085	5092
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5085	5092
NO: 401)
HSCOC4_PEA_1_T31 (SEQ ID	5085	5092
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5085	5092
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—97 (SEQ ID NO:476) according to the present invention can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 141 below describes the starting and ending position of this segment on each transcript.

TABLE 141


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5206	5222
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5351	5367
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5464	5480
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5272	5288
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5192	5208
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4890	4906
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6584	6600
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6142	6158
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6788	6804
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5486	5502
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5046	5062
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5568	5584
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6584	6600
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5093	5109
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5093	5109
NO: 401)
HSCOC4_PEA_1_T31 (SEQ ID	5093	5109
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5093	5109
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—98 (SEQ ID NO:477) according to the present invention is supported by 93 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 142 below describes the starting and ending position of this segment on each transcript.

TABLE 142


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5223	5271
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5368	5416
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5481	5529
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5289	5337
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5209	5257
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4907	4955
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6601	6649
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6159	6207
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6805	6853
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5503	5551
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5063	5111
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5585	5633
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6601	6649
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5110	5158
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5110	5158
NO: 401)
HSCOC4_PEA_1_T31 (SEQ ID	5110	5158
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5110	5158
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—99 (SEQ ID NO:478) according to the present invention is supported by 93 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 143 below describes the starting and ending position of this segment on each transcript.

TABLE 143


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5272	5300
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5417	5445
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5530	5558
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5338	5366
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5258	5286
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4956	4984
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6650	6678
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6208	6236
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6854	6882
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5552	5580
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5112	5140
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5634	5662
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6650	6678
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5159	5187
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5159	5187
NO: 401)
HSCOC4_PEA_1_T31 (SEQ ID	5159	5187
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5159	5187
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4197	4225
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—101 (SEQ ID NO:479) according to the present invention is supported by 116 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 144 below describes the starting and ending position of this segment on each transcript.

TABLE 144


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5301	5390
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5446	5535
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5559	5648
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5367	5456
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5287	5376
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	4985	5074
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6679	6768
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6237	6326
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6883	6972
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5581	5670
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5141	5230
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5663	5752
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6844	6933
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5188	5277
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5188	5277
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5085	5174
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5188	5277
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5188	5277
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4226	4315
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—102 (SEQ ID NO:480) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T31 (SEQ ID NO:403) and HSCOC4_PEA_—1_T32 (SEQ ID NO:404). Table 145 below describes the starting and ending position of this segment on each transcript.

TABLE 145


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T31 (SEQ ID	5278	5362
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5278	5362
NO: 404)

Segment cluster HSCOC4_PEA_—1_node_—103 (SEQ ID NO:481) according to the present invention is supported by 106 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 146 below describes the starting and ending position of this segment on each transcript.

TABLE 146


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5391	5463
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5536	5608
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5649	5721
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5457	5529
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5377	5449
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5075	5147
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6769	6841
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6327	6399
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	6973	7045
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5671	5743
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5231	5303
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5753	5825
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	6934	7006
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5278	5350
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5278	5350
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5175	5247
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5363	5435
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5363	5435
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4316	4388
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—104 (SEQ ID NO:482) according to the present invention is supported by 101 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 147 below describes the starting and ending position of this segment on each transcript.

TABLE 147


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5464	5489
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5609	5634
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5722	5747
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5530	5555
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5450	5475
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5148	5173
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6842	6867
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6400	6425
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7046	7071
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5744	5769
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5304	5329
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5826	5851
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7007	7032
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5351	5376
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5351	5376
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5248	5273
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5436	5461
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5436	5461
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4389	4414
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—106 (SEQ ID NO:483) according to the present invention is supported by 110 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 148 below describes the starting and ending position of this segment on each transcript.

TABLE 148


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5490	5573
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	5635	5718
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	5748	5831
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5556	5639
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5476	5559
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5174	5257
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	6868	6951
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6426	6509
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7072	7155
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	5770	5853
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5330	5413
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	5852	5935
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7033	7116
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	5377	5460
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	5559	5642
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5274	5357
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5462	5545
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	5644	5727
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4415	4498
NO: 405)

Segment cluster HSCOC4_PEA_—1_node_—111 (SEQ ID NO:484) according to the present invention is supported by 77 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSCOC4_PEA_—1_T1 (SEQ ID NO:387), HSCOC4_PEA_—1_T2 (SEQ ID NO:388), HSCOC4_PEA_—1_T3 (SEQ ID NO:389), HSCOC4_PEA_—1_T4 (SEQ ID NO:390), HSCOC4_PEA_—1_T5 (SEQ ID NO:391), HSCOC4_PEA_—1_T7 (SEQ ID NO:392), HSCOC4_PEA_—1_T8 (SEQ ID NO:393), HSCOC4_PEA_—1_T11 (SEQ ID NO:394), HSCOC4_PEA_—1_T12 (SEQ ID NO:395), HSCOC4_PEA_—1_T14 (SEQ ID NO:396), HSCOC4_PEA_—1_T15 (SEQ ID NO:397), HSCOC4_PEA_—1_T20 (SEQ ID NO:398), HSCOC4_PEA_—1_T21 (SEQ ID NO:399), HSCOC4_PEA_—1_T25 (SEQ ID NO:400), HSCOC4_PEA_—1_T28 (SEQ ID NO:401), HSCOC4_PEA_—1_T30 (SEQ ID NO:402), HSCOC4_PEA_—1_T31 (SEQ ID NO:403), HSCOC4_PEA_—1_T32 (SEQ ID NO:404) and HSCOC4_PEA_—1_T40 (SEQ ID NO:405). Table 149 below describes the starting and ending position of this segment on each transcript.

TABLE 149


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

HSCOC4_PEA_1_T1 (SEQ ID	5857	5947
NO: 387)
HSCOC4_PEA_1_T2 (SEQ ID	6002	6092
NO: 388)
HSCOC4_PEA_1_T3 (SEQ ID	6115	6205
NO: 389)
HSCOC4_PEA_1_T4 (SEQ ID	5923	6013
NO: 390)
HSCOC4_PEA_1_T5 (SEQ ID	5843	5933
NO: 391)
HSCOC4_PEA_1_T7 (SEQ ID	5541	5631
NO: 392)
HSCOC4_PEA_1_T8 (SEQ ID	7235	7325
NO: 393)
HSCOC4_PEA_1_T11 (SEQ ID	6793	6883
NO: 394)
HSCOC4_PEA_1_T12 (SEQ ID	7439	7529
NO: 395)
HSCOC4_PEA_1_T14 (SEQ ID	6137	6227
NO: 396)
HSCOC4_PEA_1_T15 (SEQ ID	5697	5787
NO: 397)
HSCOC4_PEA_1_T20 (SEQ ID	6219	6309
NO: 398)
HSCOC4_PEA_1_T21 (SEQ ID	7400	7490
NO: 399)
HSCOC4_PEA_1_T25 (SEQ ID	6149	6239
NO: 400)
HSCOC4_PEA_1_T28 (SEQ ID	6331	6421
NO: 401)
HSCOC4_PEA_1_T30 (SEQ ID	5641	5731
NO: 402)
HSCOC4_PEA_1_T31 (SEQ ID	5829	5919
NO: 403)
HSCOC4_PEA_1_T32 (SEQ ID	6273	6363
NO: 404)
HSCOC4_PEA_1_T40 (SEQ ID	4782	4872
NO: 405)

Variant protein alignment to the previously known protein:

Sequence name: CO4_HUMAN (SEQ ID NO:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P3 (SEQ ID NO:488)×CO4_HUMAN (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	8438.00
Escore:	0
Matching length:	870	Total length:	870
Matching Percent Similarity:	99.66	Matching Percent	99.66
		Identity:
Total Percent Similarity:	99.66	Total Percent Identity:	99.66
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	. .
851	LRPVLYNYLDKNLTVRPHRS	870
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \| \|
851	LRPVLYNYLDKNLTVSVHVS	870

Sequence name: CO4_HUMAN (SEQ ID NO:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P5 (SEQ ID NO:489)×CO4_HUMAN (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	7969.00
Escore:	0
Matching length:	818	Total length:	818
Matching Percent Similarity:	100.00	Matching Percent	100.00
		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DEVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNEEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLRLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	.
801	DSLTTWEIHGLSLSKTKG	818
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKG	818

Sequence name: CO4_HUMAN (SEQ ID NO:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P6 (SEQ ID NO:490)×CO4_HUMAN (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	10211.00
Escore:	0
Matching length:	1052	Total length:	1052
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFETLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVEREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

1051	KG	1052
	\|\|
1051	KG	1052

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P12 (SEQ ID NO:491)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	13367.00
Escore:	0
Matching length:	1380	Total length:	1380
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKV	1380
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKV	1380

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P15 (SEQ ID NO:492)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	13174.00
Escore:	0
Matching length:	1359	Total length:	1359
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGH0LFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLTQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

1351	IRGLEEELQ	1359
	\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQ	1359

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P16 (SEQ ID NO:493)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	14137.00
Escore:	0
Matching length:	1457	Total length:	1457
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

1451	RRREAPK	1457
	\|\|\|\|\|\|\|
1451	RRREAPK	1457

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P20 (SEQ ID NO:494)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	12641.00
Escore:	0
Matching length:	1303	Total length:	1303
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKCSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSEYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVEEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

1301	STQ	1303
	\|\|\|
1301	STQ	1303

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P9 (SEQ ID NO:495)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	14831.00
Escore:	0
Matching length:	1529	Total length:	1529
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLTWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGRLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DRPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSV	1529
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSV	1529

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P22 (SEQ ID NO:496)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	16066.00
Escore:	0
Matching length:	1654	Total length:	1654
Matching Percent	100.00	Matching Percent	99.94
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	99.94
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYTYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGTTDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWTASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. . . . .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550

	. . . . .
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR	1600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR	1600

	. . . . .
1601	ALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQV	1650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1601	ALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQV	1650

1651	LHFS	1654
	\|\|\|:
1651	LHFT	1654

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P23 (SEQ ID NO:497)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	15806.00
Escore:	0
Matching length:	1626	Total length:	1626
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSEFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPRPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDTPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. . . . .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550

	. . . . .
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR	1600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR	1600

	. .
1601	ALERGLQDEDGYRMKFACYYPRVEYG	1626
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1601	ALERGLQDEDGYRMKFACYYPRVEYG	1626

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P24 (SEQ ID NO:498)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	14823.00
Escore:	0
Matching length:	1528	Total length:	1528
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLESPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDS	1528
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDS	1528

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P25 (SEQ ID NO:499)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	15464.00
Escore:	0
Matching length:	1593	Total length:	1593
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGRLDEMQLDTQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. . . . .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550

	. . . .
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEG	1593
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEG	1593

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P26 (SEQ ID NO:500)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	15464.00
Escore:	0
Matching length:	1593	Total length:	1593
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDCDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. . . . .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQ	1550

	. . . .
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEG	1593
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1551	PASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEG	1593

Sequence name: CO4_HUMAN_V3 (SEQ ID NO:487)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P30 (SEQ ID NO:501)×CO4_HUMAN_V3 (SEQ ID NO:487).

Alignment segment 1/1:



Quality:	11940.00
Escore:	0
Matching length:	1232	Total length:	1232
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150


	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGS	1232
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGS	1232

Sequence name: CO4_HUMAN (SEQ ID NQ:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P38 (SEQ ID NO:502)×CO4_HUMAN (SEQ (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	7969.00
Escore:	0
Matching length:	818	Total length:	818
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	.
801	DSLTTWEIHGLSLSKTKG	818
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKG	818

Sequence name: CO4_HUMAN (SEQ ID NO:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P39 (SEQ ID NO:503)×CO4_HUMAN (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	3766.00
Escore:	0
Matching length:	387	Total length:	387
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alingment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQ	387
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQ	387

Sequence name: CO4_HUMAN (SEQ ID NO:485)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P40 (SEQ ID NO:504)×CO4_HUMAN (SEQ ID NO:485).

Alignment segment 1/1:



Quality:	2309.00
Escore:	0
Matching length:	236	Total length:	236
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKY	236
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKY	236

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P41 (SEQ ID NO:505)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	14831.00
Escore:	0
Matching length:	1529	Total length:	1529
Matching Percent	100.00	Matching Percent	100.00
Similarity:		Identity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPELLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPELLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYPVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVRVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQTEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQTEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD	1500

	. .
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSV	1529
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1501	LEKLTSLSDRYVSHFETEGPHVLLYFDSV	1529

Sequence name: CO4_HUMAN_V1 (SEQ ID NO:486)

Sequence documentation:

Alignment of: HSCOC4_PEA_—1_P42 (SEQ ID NO:506)×CO4_HUMAN_V1 (SEQ ID NO:486).

Alignment segment 1/1:



Quality:	14480.00
Escore:	0
Matching length:	1506	Total length:	1544
Matching Percent	99.93	Matching Percent	99.87
Similarity:		Identity:
Total Percent Similarity:	97.47	Total Percent Identity:	97.41
Gaps:	1

Alignment:


	. . . . .
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQ	50

	. . . . .
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	VVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLH	100

	. . . . .
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	QLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIY	150

	. . . . .
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	NPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQD	200

	. . . . .
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	DFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKP	250

	. . . . .
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	YILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE	300

	. . . . .
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGG	350

	. . . . .
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG	400

	. . . . .
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSA	450

	. . . . .
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	GSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGA	500

	. . . . .
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	TFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHG	550

	. . . . .
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	DHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA	600

	. . . . .
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAA	650

	. . . . .
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
651	GLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAK	700

	. . . . .
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQEAESLRKKSRDKG	750
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
701	RCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQEAESLRKKSRDKG	750

	. . . . .
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
751	QAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP	800

	. . . . .
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
801	DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLE	850

	. . . . .
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
851	LRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS	900

	. . . . .
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
901	VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNP	950

	. . . . .
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
951	LDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGV	1000

	. . . . .
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1001	ASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQ	1050

	. . . . .
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1051	KGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKL	1100

	. . . . .
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1101	QETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALH	1150

	. . . . .
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1151	HGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL	1200

	. . . . .
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1201	TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNP	1250

	. . . . .
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1251	SDPMPQAPALWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFR	1300

	. . . . .
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1301	STQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQ	1350

	. . . . .
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1351	IRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIE	1400

	. . . . .
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1401	VTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEGRRNR	1450

	. . . . .
1451	RRREAPKVVEEQESRVHYTVCIWWAPGAALGQGREGRTQAGAGLLEPAQA	1500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1451	RRREAPKVVEEQESRVHYTVCIW...........................	1473

	. . . .
1501	EPGRQLTRLHRRNGKVGLSGMAIADVTLLSGFHALRADLEKVWS	1544
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|: \|
1474	...........RNGKVGLSGMAIADVTLLSGFHALRADLEKLTS	1506

DESCRIPTION FOR CLUSTER HUMTREFAC

Cluster HUMTREFAC features 2 transcript(s) and 7 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HUMTREFAC_PEA_2_T4	507
	HUMTREFAC_PEA_2_T5	508

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HUMTREFAC_PEA_2_node_0	509
	HUMTREFAC_PEA_2_node_9	510
	HUMTREFAC_PEA_2_node_2	511
	HUMTREFAC_PEA_2_node_3	512
	HUMTREFAC_PEA_2_node_4	513
	HUMTREFAC_PEA_2_node_5	514
	HUMTREFAC_PEA_2_node_8	515

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

HUMTREFAC_PEA_2_P7	517	HUMTREFAC_PEA_2_T5
		(SEQ ID NO: 508)
HUMTREFAC_PEA_2_P8	518	HUMTREFAC_PEA_2_T4
		(SEQ ID NO: 507)

These sequences are variants of the known protein Trefoil factor 3 precursor (SwissProt accession identifier TFF3_HUMAN; known also according to the synonyms Intestinal trefoil factor; hP1.B), SEQ ID NO: 516, referred to herein as the previously known protein.

Protein Trefoil factor 3 precursor (SEQ ID NO:516) is known or believed to have the following function(s): May have a role in promoting cell migration (motogen). The sequence for protein Trefoil factor 3 precursor is given at the end of the application, as “Trefoil factor 3 precursor amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

74-76	QEA -> TRKT

Protein Trefoil factor 3 precursor (SEQ ID NO:516) localization is believed to be Secreted.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: defense response; digestion, which are annotation(s) related to Biological Process; and extracellular, which are annotation(s) related to Cellular Component.

Cluster HUMTREFAC can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 36 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 36 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: a mixture of malignant tumors from different tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	adrenal	40
	colon	797
	epithelial	95
	general	39
	liver	0
	lung	57
	lymph nodes	3
	breast	0
	muscle	3
	pancreas	2
	prostate	16
	stomach	0
	Thyroid	257
	uterus	54

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	6.4e−01	6.9e−01	7.1e−01	1.1	7.8e−01	0.9
colon	4.6e−01	5.7e−01	9.7e−01	0.5	1	0.4
epithelial	2.4e−02	3.4e−01	9.5e−10	2.0	5.3e−02	1.1
general	2.5e−04	3.9e−02	1.4e−28	3.6	1.9e−10	1.9
liver	1	6.8e−01	1	1.0	6.9e−01	1.4
lung	4.8e−01	7.6e−01	2.2e−03	1.0	1.6e−01	0.5
lymph nodes	5.1e−01	8.0e−01	2.3e−02	5.0	1.9e−01	2.1
breast	7.6e−02	1.2e−01	3.1e−06	12.0	1.1e−03	6.5
muscle	9.2e−01	4.8e−01	1	0.8	3.9e−01	2.1
pancreas	1.2e−01	2.4e−01	5.7e−03	6.5	2.1e−02	4.6
prostate	1.5e−01	2.7e−01	9.9e−10	8.1	3.1e−07	5.7
stomach	3.0e−01	1.3e−01	5.0e−01	2.0	6.7e−02	2.8
Thyroid	6.4e−01	6.4e−01	9.6e−01	0.5	9.6e−01	0.5
uterus	4.1e−01	7.3e−01	7.5e−02	1.3	4.0e−01	0.8

As noted above, cluster HUMTREFAC features 2 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Trefoil factor 3 precursor (SEQ ID NO:516). A description of each variant protein according to the present invention is now provided.

Variant protein HUMTREFAC_PEA_—2_P7 (SEQ ID NO:517) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HUMTREFAC_PEA_—2_P7 (SEQ ID NO:517) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMTREFAC_PEA_—2_P7 (SEQ ID NO:517) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

5	A -> S	No
5	A -> T	No
14	A -> V	Yes
43	L -> M	No
60	P -> S	Yes
123	S -> *	Yes

Variant protein HUMTREFAC_PEA_—2_P7 (SEQ ID NO:517) is encoded by the following transcript(s): HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508) is shown in bold; this coding portion starts at position 278 and ends at position 688. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMTREFAC_PEA_—2_P7 (SEQ ID NO:517) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

233	A -> G	Yes
290	G -> A	No
290	G -> T	No
318	C -> T	Yes
404	C -> A	No
404	C -> T	No
455	C -> T	Yes
645	C -> A	Yes
685	C -> T	No

Variant protein HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507). An alignment is given to the known protein (Trefoil factor 3 precursor (SEQ ID NO:516)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) and TFF3_HUMAN (SEQ ID NO:516):

1.An isolated chimeric polypeptide encoding for HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), comprising a first amino acid sequence being at least 90% homologous to MAARALCMLGLVLALLSSSSAEEYVGL corresponding to amino acids 1-27 of TFF3_HUMAN (SEQ ID NO:516), which also corresponds to amino acids 1-27 of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence WKVHLPKGEGFSSG (SEQ ID NO:996) corresponding to amino acids 28-41 of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence WKVHLPKGEGFSSG (SEQ ID NO:996) in HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518).

Variant protein HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

5	A -> S	No
5	A -> T	No
14	A -> V	Yes

Variant protein HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) is encoded by the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) is shown in bold; this coding portion starts at position 278 and ends at position 400. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

233	A -> G	Yes
290	G -> A	No
290	G -> T	No
318	C -> T	Yes
515	C -> A	No
515	C -> T	No
566	C -> T	Yes
756	C -> A	Yes
796	C -> T	No
1265	A -> C	No
1266	A -> T	No

As noted above, cluster HUMTREFAC features 7 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HUMTREFAC_PEA_—2_node_—0 (SEQ ID NO:509) according to the present invention is supported by 188 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	1	359
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	1	359
NO: 508)

Segment cluster HUMTREFAC_PEA_—2_node_—9 (SEQ ID NO:510) according to the present invention is supported by 150 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	681	1266
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	570	747
NO: 508)

Segment cluster HUMTREFAC_PEA_—2_node_—2 (SEQ ID NO:511) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507). Table 13 below describes the starting and ending position of this segment on each transcript.

TABLE 13


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	360	470
NO: 507)

Segment cluster HUMTREFAC_PEA_—2_node_—3 (SEQ ID NO:512) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 14 below describes the starting and ending position of this segment on each transcript.

TABLE 14


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	471	514
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	360	403
NO: 508)

Segment cluster HUMTREFAC_PEA_—2_node_—4 (SEQ ID NO:513) according to the present invention is supported by 197 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	515	611
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	404	500
NO: 508)

Segment cluster HUMTREFAC_PEA_—2_node_—5 (SEQ ID NO:514) according to the present invention is supported by 187 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	612	661
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	501	550
NO: 508)

Segment cluster HUMTREFAC_PEA_—2_node_—8 (SEQ ID NO:515) according to the present invention can be found in the following transcript(s): HUMTREFAC_PEA_—2_T4 (SEQ ID NO:507) and HUMTREFAC_PEA_—2_T5 (SEQ ID NO:508). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMTREFAC_PEA_2_T4 (SEQ ID	662	680
NO: 507)
HUMTREFAC_PEA_2_T5 (SEQ ID	551	569
NO: 508)

Variant protein alignment to the previously known protein:

Sequence name: TFF3_HUMAN (SEQ ID NO:516)

Sequence documentation:

Alignment of: HUMTREFAC_PEA_—2_P8 (SEQ ID NO:518)×TFF3_HUMAN (SEQ ID NO:516).

Alignment segment 1/1:



Quality:	246.00
Escore:	0
Matching length:	27	Total length:	27
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. .
1	MAARALCMLGLVLALLSSSSAEEYVGL	27
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAARALCMLGLVLALLSSSSAEEYVGL	27

DESCRIPTION FOR CLUSTER HUMOSTRO

Cluster HUMOSTRO features 3 transcript(s) and 30 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HUMOSTRO_PEA_1_PEA_1_T14	519
	HUMOSTRO_PEA_1_PEA_1_T16	520
	HUMOSTRO_PEA_1_PEA_1_T30	521

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HUMOSTRO_PEA_1_PEA_1_node_0	522
	HUMOSTRO_PEA_1_PEA_1_node_10	523
	HUMOSTRO_PEA_1_PEA_1_node_16	524
	HUMOSTRO_PEA_1_PEA_1_node_23	525
	HUMOSTRO_PEA_1_PEA_1_node_31	526
	HUMOSTRO_PEA_1_PEA_1_node_43	527
	HUMOSTRO_PEA_1_PEA_1_node_3	528
	HUMOSTRO_PEA_1_PEA_1_node_5	529
	HUMOSTRO_PEA_1_PEA_1_node_7	530
	HUMOSTRO_PEA_1_PEA_1_node_8	531
	HUMOSTRO_PEA_1_PEA_1_node_15	532
	HUMOSTRO_PEA_1_PEA_1_node_17	533
	HUMOSTRO_PEA_1_PEA_1_node_20	534
	HUMOSTRO_PEA_1_PEA_1_node_21	535
	HUMOSTRO_PEA_1_PEA_1_node_22	536
	HUMOSTRO_PEA_1_PEA_1_node_24	537
	HUMOSTRO_PEA_1_PEA_1_node_26	538
	HUMOSTRO_PEA_1_PEA_1_node_27	539
	HUMOSTRO_PEA_1_PEA_1_node_28	540
	HUMOSTRO_PEA_1_PEA_1_node_29	541
	HUMOSTRO_PEA_1_PEA_1_node_30	542
	HUMOSTRO_PEA_1_PEA_1_node_32	543
	HUMOSTRO_PEA_1_PEA_1_node_34	544
	HUMOSTRO_PEA_1_PEA_1_node_36	545
	HUMOSTRO_PEA_1_PEA_1_node_37	546
	HUMOSTRO_PEA_1_PEA_1_node_38	547
	HUMOSTRO_PEA_1_PEA_1_node_39	548
	HUMOSTRO_PEA_1_PEA_1_node_40	549
	HUMOSTRO_PEA_1_PEA_1_node_41	550
	HUMOSTRO_PEA_1_PEA_1_node_42	551

TABLE 3


Proteins of interest

	Sequence	Corresponding
Protein Name	ID No.	Transcript(s)

HUMOSTRO_PEA_1_PEA_1_P21	553	HUMOSTRO_PEA_1_PEA_1_T14
		(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_P25	554	HUMOSTRO_PEA_1_PEA_1_T16
		(SEQ ID NO:520)

HUMOSTRO_PEA_1_PEA_1_P30	555	HUMOSTRO_PEA_1_PEA_1_T30
		(SEQ ID NO:521)

These sequences are variants of the known protein Osteopontin precursor (SwissProt accession identifier OSTP_HUMAN; known also according to the synonyms Bone sialoprotein 1; Urinary stone protein; Secreted phosphoprotein 1; SPP-1; Nephropontin; Uropontin), SEQ ID NO: 552, referred to herein as the previously known protein.

Protein Osteopontin precursor (SEQ ID NO:552) is known or believed to have the following function(s): Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction;Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity (By similarity). The sequence for protein Osteopontin precursor (SEQ ID NO:552) is given at the end of the application, as “Osteopontin precursor (SEQ ID NO:552) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

301	R -> H (in dbSNP: 4660). /FTId = VAR_014717.
188	D -> H
237	T -> A
275-278	SHEF -> GNSL

Protein Osteopontin precursor (SEQ ID NO:552) localization is believed to be Secreted.

The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Regeneration, bone. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Bone formation stimulant. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Musculoskeletal.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: ossification; anti-apoptosis; inflammatory response; cell-matrix adhesion; cell-cell signaling, which are annotation(s) related to Biological Process; defense/immunity protein; cytokine; integrin ligand; protein binding; growth factor; apoptosis inhibitor, which are annotation(s) related to Molecular Function; and extracellular matrix, which are annotation(s) related to Cellular Component.

Cluster HUMOSTRO can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 37 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 37 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues, lung malignant tumors, breast malignant tumors, ovarian carcinoma and skin malignancies.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	adrenal	4
	bladder	0
	bone	897
	brain	506
	colon	69
	epithelial	548
	general	484
	head and neck	50
	kidney	5618
	liver	4
	lung	10
	lymph nodes	75
	breast	8
	bone marrow	62
	muscle	37
	ovary	40
	pancreas	845
	prostate	48
	skin	13
	stomach	73
	Thyroid	0
	uterus	168

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	1.5e−01	2.1e−01	2.0e−02	4.6	4.4e−02	3.6
bladder	1.2e−01	9.2e−02	5.7e−02	4.1	2.1e−02	4.3
bone	4.9e−01	7.4e−01	4.1e−06	0.6	5.4e−01	0.4
brain	6.6e−01	7.0e−01	3.2e−01	0.6	1	0.4
colon	2.7e−01	4.0e−01	3.1e−01	1.5	5.2e−01	1.1
epithelial	2.0e−07	1.6e−03	9.8e−01	0.7	1	0.5
general	1.2e−06	1.2e−02	7.9e−01	0.8	1	0.6
head and neck	3.4e−01	5.0e−01	1	0.7	1	0.7
kidney	6.8e−01	7.4e−01	1	0.2	1	0.1
liver	3.3e−01	2.5e−01	1	1.8	2.3e−01	2.6
lung	4.3e−04	4.6e−03	2.1e−30	15.0	2.8e−27	23.5
lymph nodes	6.7e−01	8.7e−01	8.1e−01	0.7	9.9e−01	0.3
breast	2.3e−01	3.0e−01	1.9e−04	6.2	4.1e−03	4.3
bone marrow	7.5e−01	7.8e−01	1	0.3	2.0e−02	1.2
muscle	4.0e−02	7.5e−02	1.1e−01	4.6	5.1e−01	1.5
ovary	4.7e−02	8.4e−02	1.9e−05	5.4	8.3e−04	3.7
pancreas	5.0e−02	3.3e−01	1	0.3	1	0.2
prostate	8.5e−01	9.0e−01	8.9e−01	0.7	9.5e−01	0.6
skin	1.6e−01	1.6e−01	1.2e−10	12.6	5.2e−04	4.1
stomach	1.5e−01	6.3e−01	5.0e−01	1.2	9.4e−01	0.6
Thyroid	2.9e−01	2.9e−01	5.9e−02	2.0	5.9e−02	2.0
uterus	6.1e−02	5.7e−01	1.1e−01	1.3	7.0e−01	0.7

As noted above, cluster HUMOSTRO features 3 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Osteopontin precursor (SEQ ID NO:552). A description of each variant protein according to the present invention is now provided.

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519). An alignment is given to the known protein (Osteopontin precursor (SEQ ID NO:552)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) and OSTP_HUMAN (SEQ ID NO:552):

1.An isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), comprising a first amino acid sequence being at least 90% homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQ corresponding to amino acids 1-58 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-58 of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VFLNFS (SEQ ID NO:997) corresponding to amino acids 59-64 of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VFLNFS (SEQ ID NO:997) in HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553).

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

7	C -> W	No
31	Q -> R	No
47	D -> V	Yes
49	S -> P	No

The glycosylation sites of variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553), as compared to the known protein Osteopontin precursor (SEQ ID NO:552), are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 8


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

79	no
106	no

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) is encoded by the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) is shown in bold; this coding portion starts at position 199 and ends at position 390. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

136	A -> G	Yes
154	T ->	No
159	G -> T	Yes
219	C -> G	No
274	-> G	No
290	A -> G	No
338	A -> T	Yes
343	T -> C	No
413	G -> C	Yes
707	C -> T	Yes
708	C -> A	Yes
715	A -> G	Yes
730	A -> C	No
730	A -> G	No
746	T -> C	Yes
767	C -> T	No
779	G -> A	Yes
866	-> G	No
869	T ->	No
889	-> A	No
891	A -> C	No
891	A -> G	No
905	T -> C	No
910	-> G	No
910	-> T	No
997	A -> G	No
1026	G -> C	No
1042	-> G	No
1042	-> T	No
1071	A ->	No
1071	A -> C	No
1098	A ->	No
1105	C -> T	No
1124	-> G	No
1135	G -> A	Yes
1136	T ->	No
1136	T -> G	No
1173	A -> C	No
1173	A -> G	No
1179	A -> G	No
1214	C -> T	Yes
1246	T ->	No
1246	T -> A	No
1359	A ->	No
1359	A -> G	No
1362	T ->	No
1365	C -> T	Yes
1366	G -> A	Yes
1408	A -> C	No
1418	A -> C	No
1433	A -> C	No
1456	A -> C	No
1524	T -> A	No
1524	T -> C	No
1547	A -> G	Yes
1553	T ->	No
1574	-> G	No
1654	A -> C	Yes
1691	A -> G	No
1703	A -> C	Yes
1755	A -> C	No
1764	T ->	No

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). An alignment is given to the known protein (Osteopontin precursor (SEQ ID NO:552) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) and OSTP_HUMAN (SEQ ID NO:552):

1.An isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), comprising a first amino acid sequence being at least 90% homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQ corresponding to amino acids 1-31 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-31 of HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence H corresponding to amino acids 32-32 of HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

7	C -> W	No
31	Q -> R	No

The glycosylation sites of variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554), as compared to the known protein Osteopontin precursor (SEQ ID NO:552), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 11


Glycosylation site(s)

Position(s) on known	Present in	Position
amino acid sequence	variant protein?	in variant protein?

79	no
106	no

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) is encoded by the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520) is shown in bold; this coding portion starts at position 199 and ends at position 294. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

136	A -> G	Yes
154	T ->	No
159	G -> T	Yes
219	C -> G	No
274	-> G	No
290	A -> G	No
419	C -> T	Yes
454	G -> C	Yes
527	A -> T	Yes
532	T -> C	No
630	C -> T	Yes
631	C -> A	Yes
638	A -> G	Yes
653	A -> C	No
653	A -> G	No
669	T -> C	Yes
690	C -> T	No
702	G -> A	Yes
789	-> G	No
792	T ->	No
812	-> A	No
814	A -> C	No
814	A -> G	No
828	T -> C	No
833	-> G	No
833	-> T	No
920	A -> G	No
949	G -> C	No
965	-> G	No
965	-> T	No
994	A ->	No
994	A -> C	No
1021	A ->	No
1028	C -> T	No
1047	-> G	No
1058	G -> A	Yes
1059	T ->	No
1059	T -> G	No
1096	A -> C	No
1096	A -> G	No
1102	A -> G	No
1137	C -> T	Yes
1169	T ->	No
1169	T -> A	No
1282	A ->	No
1282	A -> G	No
1285	T ->	No
1288	C -> T	Yes
1289	G -> A	Yes
1331	A -> C	No
1341	A -> C	No
1356	A -> C	No
1379	A -> C	No
1447	T -> A	No
1447	T -> C	No
1470	A -> G	Yes
1476	T ->	No
1497	-> G	No
1577	A -> C	Yes
1614	A -> G	No
1626	A -> C	Yes
1678	A -> C	No
1687	T ->	No

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). An alignment is given to the known protein (Osteopontin precursor (SEQ ID NO:552) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) and OSTP_HUMAN (SEQ ID NO:552):

1.An isolated chimeric polypeptide encoding for HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), comprising a first amino acid sequence being at least 90 % homologous to MRIAVICFCLLGITCAIPVKQADSGSSEEKQ corresponding to amino acids 1-31 of OSTP_HUMAN (SEQ ID NO:552), which also corresponds to amino acids 1-31 of HYMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSIFYVFI (SEQ ID NO:998) corresponding to amino acids 32-39 of HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSIFYVFI (SEQ ID NO:998) in HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555).

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

7	C -> W	No
31	Q -> R	No

The glycosylation sites of variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555), as compared to the known protein Osteopontin precursor (SEQ ID NO:552), are described in Table 14 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 14


Glycosylation site(s)

	Position(s) on known
	amino acid sequence	Present in variant protein?

	79	no
	106	no

Variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) is encoded by the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521) is shown in bold; this coding portion starts at position 199 and ends at position 315. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

136	A -> G	Yes
154	T ->	No
159	G -> T	Yes
219	C -> G	No
274	-> G	No
290	A -> G	No

As noted above, cluster HUMOSTRO features 30 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—0 (SEQ ID NO:522) according to the present invention is supported by 333 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519), HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520) and HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1	184
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1	184
(SEQ ID NO:520)

HUMOSTRO_PEA_1_PEA_1_T30	1	184
(SEQ ID NO:521)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—10 (SEQ ID NO:523) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T16	292	480
(SEQ ID NO: 520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—16 (SEQ ID NO:524) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	373	638
(SEQ ID NO:519)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—23 (SEQ ID NO:525) according to the present invention is supported by 334 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	804	967
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	727	890
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—31 (SEQ ID NO:526) according to the present invention is supported by 350 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 20 below describes the starting and ending position of this segment on each transcript.

TABLE 20


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1164	1393
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1087	1316
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—43 (SEQ ID NO:527) according to the present invention is supported by 192 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1810	1846
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1733	1769
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—3 (SEQ ID NO:528) according to the present invention is supported by 353 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14(SEQ ID NO:519), HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520) and HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	185	210
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	185	210
(SEQ ID NO:520)

HUMOSTRO_PEA_1_PEA_1_T30	185	210
(SEQ ID NO:521)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—5 (SEQ ID NO:529) according to the present invention is supported by 353 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519), HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520) and HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	211	252
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	211	252
(SEQ ID NO:520)

HUMOSTRO_PEA_1_PEA_1_T30	211	252
(SEQ ID NO:521)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—7 (SEQ ID NO:530) according to the present invention is supported by 357 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519), HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520) and HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	253	291
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	253	291
(SEQ ID NO:520)

HUMOSTRO_PEA_1_PEA_1_T30	253	291
(SEQ ID NO:521)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—8 (SEQ ID NO:531) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T30 (SEQ ID NO:521). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T30	292	378
(SEQ ID NO:521)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—15 (SEQ ID NO:532) according to the present invention is supported by 366 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	292	372
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	481	561
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—17 (SEQ ID NO:533) according to the present invention is supported by 261 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	639	680
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	562	603
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—20 (SEQ ID NO:534) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	681	688
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	604	611
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—21 (SEQ ID NO:535) according to the present invention is supported by 315 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	689	738
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	612	661
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—22 (SEQ ID NO:536) according to the present invention is supported by 322 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	739	803
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	662	726
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—24 (SEQ ID NO:537) according to the present invention is supported by 270 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	968	1004
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	891	927
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—26 (SEQ ID NO:538) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1005	1022
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	928	945
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—27 (SEQ ID NO:539) according to the present invention is supported by 260 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1023	1048
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	946	971
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—28 (SEQ ID NO:540) according to the present invention is supported by 273 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1049	1100
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	972	1023
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—29 (SEQ ID NO:541) according to the present invention is supported by 272 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1101	1151
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1024	1074
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—30 (SEQ ID NO:542) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1152	1163
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1075	1086
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—32 (SEQ ID NO:543) according to the present invention is supported by 293 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1394	1427
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1317	1350
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—34 (SEQ ID NO:544) according to the present invention is supported by 301 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1428	1468
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1351	1391
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—36 (SEQ ID NO:545) according to the present invention is supported by 292 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1469	1504
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1392	1427
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—37 (SEQ ID NO:546) according to the present invention is supported by 295 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1505	1623
(SEQ ID NO 519)

HUMOSTRO_PEA_1_PEA_1_T16	1428	1546
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—38 (SEQ ID NO:547) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1624	1634
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1547	1557
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—39 (SEQ ID NO:548) according to the present invention is supported by 268 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1635	1725
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1558	1648
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—40 (SEQ ID NO:549) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 43 below describes the starting and ending position of this segment on each transcript.

TABLE 43


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1726	1743
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1649	1666
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—41 (SEQ ID NO:550) according to the present invention can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 44 below describes the starting and ending position of this segment on each transcript.

TABLE 44


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1744	1749
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1667	1672
(SEQ ID NO:520)

Segment cluster HUMOSTRO_PEA_—1_PEA_—1_node_—42 (SEQ ID NO:551) according to the present invention is supported by 224 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMOSTRO_PEA_—1_PEA_—1_T14 (SEQ ID NO:519) and HUMOSTRO_PEA_—1_PEA_—1_T16 (SEQ ID NO:520). Table 45 below describes the starting and ending position of this segment on each transcript.

TABLE 45


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HUMOSTRO_PEA_1_PEA_1_T14	1750	1809
(SEQ ID NO:519)

HUMOSTRO_PEA_1_PEA_1_T16	1673	1732
(SEQ ID NO:520)

Variant protein alignment to the previously known protein:

Sequence name: OSTP_HUMAN (SEQ ID NO:552)

Sequence documentation:

Alignment of: HUMOSTRO_PEA_—1_PEA_—1_P21 (SEQ ID NO:553)×OSTP HUMAN (SEQ ID NO:552).

Alignment segment 1/1:



Quality:	578.00
Escore:	0
Matching length:	58	Total length:	58
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQ	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQ	50

51	KQNLLAPQ	58
	\|\|\|\|\|\|\|\|
51	KQNLLAPQ	58

Sequence name: OSTP_HUMAN (SEQ ID NO:552)

Sequence documentation:

Alignment of: HUMOSTRO_PEA_—1_PEA_—1_P25 (SEQ ID NO:554)×OSTP_HUMAN (SEQ ID NO:552).

Alignment segment 1/1:



Quality:	301.00
Escore:	0
Matching length:	31	Total length:	31
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · ·
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQ	31
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQ	31

Sequence name: OSTP_HUMAN (SEQ ID NO:552)

Sequence documentation:

Alignment of: HUMOSTRO_PEA_—1_PEA_—1_P30 (SEQ ID NO:555)×OSTP_HUMAN (SEQ ID NO:552).

Alignment segment 1/1:



Quality:	301.00
Escore:	0
Matching length:	31	Total length:	31
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · ·
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQ	31
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MRIAVICFCLLGITCAIPVKQADSGSSEEKQ	31

Description for Cluster R11723

Cluster R11723 features 6 transcript(s) and 26 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	R11723_PEA_1_T15	556
	R11723_PEA_1_T17	557
	R11723_PEA_1_T19	558
	R11723_PEA_1_T20	559
	R11723_PEA_1_T5	560
	R11723_PEA_1_T6	561

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	R11723_PEA_1_node_13	562
	R11723_PEA_1_node_16	563
	R11723_PEA_1_node_19	564
	R11723_PEA_1_node_2	565
	R11723_PEA_1_node_22	566
	R11723_PEA_1_node_31	567
	R11723_PEA_1_node_10	568
	R11723_PEA_1_node_11	569
	R11723_PEA_1_node_15	570
	R11723_PEA_1_node_18	571
	R11723_PEA_1_node_20	572
	R11723_PEA_1_node_21	573
	R11723_PEA_1_node_23	574
	R11723_PEA_1_node_24	575
	R11723_PEA_1_node_25	576
	R11723_PEA_1_node_26	577
	R11723_PEA_1_node_27	578
	R11723_PEA_1_node_28	579
	R11723_PEA_1_node_29	580
	R11723_PEA_1_node_3	581
	R11723_PEA_1_node_30	582
	R11723_PEA_1_node_4	583
	R11723_PEA_1_node_5	584
	R11723_PEA_1_node_6	585
	R11723_PEA_1_node_7	586
	R11723_PEA_1_node_8	587

TABLE 3


Proteins of interest

	Protein Name	Sequence ID No.

	R11723_PEA_1_P2	588
	R11723_PEA_1_P6	589
	R11723_PEA_1_P7	590
	R11723_PEA_1_P13	591
	R11723_PEA_1_P10	592

Cluster R11723 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the right hand column of the table and the numbers on the y-axis of FIG. 38 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 38 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues and kidney malignant tumors.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	adrenal	0
	brain	30
	epithelial	3
	general	17
	head and neck	0
	kidney	0
	lung	0
	breast	0
	ovary	0
	pancreas	10
	skin	0
	uterus	0

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	4.2e−01	4.6e−01	4.6e−01	2.2	5.3e−01	1.9
brain	2.2e−01	2.0e−01	1.2e−02	2.8	5.0e−02	2.0
epithelial	3.0e−05	6.3e−05	1.8e−05	6.3	3.4e−06	6.4
general	7.2e−03	4.0e−02	1.3e−04	2.1	1.1e−03	1.7
head and neck	1	5.0e−01	1	1.0	7.5e−01	1.3
kidney	1.5e−01	2.4e−01	4.4e−03	5.4	2.8e−02	3.6
lung	1.2e−01	1.6e−01	1	1.6	1	1.3
breast	5.9e−01	4.4e−01	1	1.1	6.8e−01	1.5
ovary	1.6e−02	1.3e−02	1.0e−01	3.8	7.0e−02	3.5
pancreas	5.5e−01	2.0e−01	3.9e−01	1.9	1.4e−01	2.7
skin	1	4.4e−01	1	1.0	1.9e−02	2.1
uterus	1.5e−02	5.4e−02	1.9e−01	3.1	1.4e−01	2.5

As noted above, cluster R11723 features 6 transcript(s), which were listed in Table 1 above. A description of each variant protein according to the present invention is now provided.

Variant protein R11723_PEA_—1_P2 (SEQ ID NO:588) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R11723_PEA_—1_T6 (SEQ ID NO:561). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein R11723_PEA_—1_P2 (SEQ ID NO:588) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P2 (SEQ ID NO:588) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

107	H -> P	Yes
70	G ->	No
70	G -> C	No

Variant protein R11723_PEA_—1_P2 (SEQ ID NO:588) is encoded by the following transcript(s): R11723_PEA_—1_T6 (SEQ ID NO:561), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R11723_PEA_—1_T6 (SEQ ID NO:561) is shown in bold; this coding portion starts at position 1716 and ends at position 2051. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P2 (SEQ ID NO:588) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

1231	C -> T	Yes
1278	G -> C	Yes
1923	G ->	No
1923	G -> T	No
2035	A -> C	Yes
2048	A -> C	No
2057	A -> G	Yes

Variant protein R11723_PEA_—1_P6 (SEQ ID NO:589) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R11723_PEA_—1_T15 (SEQ ID NO:556). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R11723_PEA_—1_P6 (SEQ ID NO:589) and Q8IXM0 (SEQ ID NO:885):

1 . An isolated chimeric polypeptide encoding for R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEJQSAGIMYRKSCASSAACLIASAGSPCRGLAPGREEQRALHKAGAVGGGVR (SEQ ID NO:1022) corresponding to amino acids 1-110 of R11723_PEA_—1_P6 (SEQ ID NO:589), and a second amino acid sequence being at least 90% homologous to MYAQALLVVGVLQRQAAAQHLHEHPPKLLRGHRVQERVDDRAEVEKRLREGEEDHV RPEVGPRPVVLGFGRSHDPPNLVGHPAYGQCHNNQPWADTSRRERQRKEKHSMRTQ corresponding to amino acids 1-112 of Q8IXM0, which also corresponds to amino acids 111-222 of R11723_PEA_—1_P6 (SEQ ID NO:589), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV	(SEQ ID NO:1022)
MEQSAGIMYRKSCASSAACLIASAGSPCRGLAPGREEQRALHKAGAVGGGVR

of R11723_PEA_1_P6.	(SEQ ID NO:589)

Comparison report between R11723_PEA_—1_P6 (SEQ ID NO:589) and Q96AC2 (SEQ ID NO:886):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAGIMYRKSCASSAACLIASAG corresponding to amino acids 1-83 of Q96AC2 (SEQ ID NO: 886), which also corresponds to amino acids 1-83 of R11723_PEA_—1_P6 (SEQ ID NO:589), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL RGHRVQERVDDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ CHNNQPWADTSRRERQRKEKHSMRTQ (SEQ ID NO: 1023) corresponding to amino acids 84-222 of R11723_PEA_—1_P6 (SEQ ID NO:589), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL	(SEQ ID NO:1023)
RGHRVQERVDDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ
CHNNQPWADTSRRERQRKEKHSMRTQ

in R11723_PEA_1_P6.	(SEQ ID NO:589)

Comparison report between R11723_PEA_—1_P6 (SEQ ID NO:589) and Q8N2G4 (SEQ ID NO:887):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAGIMYRKSCASSAACLIASAG corresponding to amino acids 1-83 of Q8N2G4, which also corresponds to amino acids 1-83 of R11723_PEA_—1_P6 (SEQ ID NO:589), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL RGHRVQERVDDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ CHNNQPWADTSRRERQRKEKHSMRTQ (SEQ ID NO:1023) corresponding to amino acids 84-222 of R11723_PEA_—1_P6 (SEQ ID NO:589), wherein said first and second amino acid sequences are contiguous and in a sequential order.


SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL	(SEQ ID NO:1023)
RGHRVQERVDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ
CHNNQPWADTSRRERQRKEKHSMRTQ

in R11723_PEA_1_P6.	(SEQ ID NO:589)

Comparison report between R11723_PEA_—1_P6 (SEQ ID NO:589) and BAC85518 (SEQ ID NO:888):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P6 (SEQ ID NO:589), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAGIMYRKSCASSAACLIASAG corresponding to amino acids 24-106 of BAC85518, which also corresponds to amino acids 1-83 of R11723_PEA_—1_P6 (SEQ ID NO:589), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL RGHRVQERVDDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ CHNNQPWADTSRRERQRKEKHSMRTQ (SEQ ID NO:1023) corresponding to amino acids 84-222 of R11723_PEA_—1_P6 (SEQ ID NO:589), wherein said first and second amino acid sequences are contiguous and in a sequential order.


SPCRGLAPGREEQRALHKAGAVGGGVRMYAQALLVVGVLQRQAAAQHLHEHPPKLL	(SEQ ID NO:1023)
RGHRVQERVDDRAEVEKRLREGEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQ
CHNNQPWADTSRRERQRKEKHSMRTQ

in R11723_PEA_1_P6.	(SEQ ID NO:589)

Variant protein R11723_PEA_—1_P6 (SEQ ID NO:589) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P6 (SEQ ID NO:589) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

180	G ->	No
180	G -> C	No
217	H -> P	Yes

Variant protein R11723_PEA_—1_P6 (SEQ ID NO:589) is encoded by the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R11723_PEA_—1_T15 (SEQ ID NO:556) is shown in bold; this coding portion starts at position 434 and ends at position 1099. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P6 (SEQ ID NO:589) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

971	G ->	No
971	G -> T	No
1083	A -> C	Yes
1096	A -> C	No
1105	A -> G	Yes

Variant protein R11723_PEA_—1_P7 (SEQ ID NO:590) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R11723_PEA_—1_T17 (SEQ ID NO:557). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R11723_PEA_—1_P7 (SEQ ID NO:590) and Q96AC2 (SEQ ID NO: 886):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAG corresponding to amino acids 1-64 of Q96AC2 (SEQ ID NO: 886), which also corresponds to amino acids 1-64 of R11723_PEA_—1_P7 (SEQ ID NO:590), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) corresponding to amino acids 65-93 of R11723_PEA_—1_P7 (SEQ ID NO:590), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) in R11723_PEA_—1_P7 (SEQ ID NO:590).

Comparison report between R11723_PEA_—1_P7 (SEQ ID NO:590) and Q8N2G4:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAG corresponding to amino acids 1-64 of Q8N2G4, which also corresponds to amino acids 1-64 of R11723_PEA_—1_P7 (SEQ ID NO:590), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) corresponding to amino acids 65-93 of R11723_PEA_—1_P7 (SEQ ID NO:590), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between R11723_PEA_—1_P7 (SEQ ID NO:590) and BAC85273:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MWVLG (SEQ ID NO:1025) corresponding to amino acids 1-5 of R11723_PEA_—1_P7 (SEQ ID NO:590), second amino acid sequence being at least 90% homologous to IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEVMEQSAG corresponding to amino acids 22-80 of BAC85273, which also corresponds to amino acids 6-64 of R11723_PEA_—1_P7 (SEQ ID NO:590), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) corresponding to amino acids 65-93 of R11723_PEA_—1_P7 (SEQ ID NO:590), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MWVLG (SEQ ID NO:1025) of R11723_PEA_—1_P7 (SEQ ID NO:590).

3. An isolated polypeptide encoding for a tail of R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) in R11723_PEA_—1_P7 (SEQ ID NO:590).

Comparison report between R11723_PEA_—1_P7 (SEQ ID NO:590) and BAC85518:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P7 (SEQ ID NO:590), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSAG corresponding to amino acids 24-87 of BAC85518, which also corresponds to amino acids 1-64 of R11723_PEA_—1_P7 (SEQ ID NO:590), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SHCVTRLECSGTISAHCNLCLPGSNDHPT (SEQ ID NO:1024) corresponding to amino acids 65-93 of R11723_PEA_—1_P7 (SEQ ID NO:590), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein R11723_PEA_—1_P7 (SEQ ID NO:590) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P7 (SEQ ID NO:590) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

67	C -> S	Yes

Variant protein R11723_PEA_—1_P7 (SEQ ID NO:590) is encoded by the following transcript(s): R11723_PEA_—1_T17 (SEQ ID NO:557), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R11723_PEA_—1_T17 (SEQ ID NO:557) is shown in bold; this coding portion starts at position 434 and ends at position 712. The transcript also has the following SNPs as listed in Table 11 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P7 (SEQ ID NO:590) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

625	G -> T	Yes
633	G -> C	Yes
1303	C -> T	Yes

Variant protein R11723_PEA_—1_P13 (SEQ ID NO:591) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R11723_PEA_—1_T19 (SEQ ID NO:558). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R11723_PEA_—1_P13 (SEQ ID NO:591) and Q96AC2 (SEQ ID NO: 886):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P13 (SEQ ID NO:591) comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 1-63 of Q96AC2 (SEQ ID NO: 886), which also corresponds to amino acids 1-63 of R11723_PEA_—1_P13 (SEQ ID NO:591), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO:1026) corresponding to amino acids 64-84 of R11723_PEA_—1_P13 (SEQ ID NO:591), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of R1723_PEA_—1_P13 (SEQ ID NO:591), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO:1026) in R11723_PEA_—1_P13 (SEQ ID NO:591).

Variant protein R11723_PEA_—1_P13 (SEQ ID NO:591) is encoded by the following transcript(s): R11723_PEA_—1_T19 (SEQ ID NO:558) and R11723_PEA_—1_T5 (SEQ ID NO:560), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R11723_PEA_—1_T19 (SEQ ID NO:558) is shown in bold; this coding portion starts at position 434 and ends at position 685. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R1172_PEA_—1_P13 (SEQ ID NO:591) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

778	G -> T	Yes
786	G -> C	Yes
1456	C -> T	Yes

Variant protein R11723_PEA_—1_P10 (SEQ ID NO:592) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) R11723_PEA_—1_T20 (SEQ ID NO:559). One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between R11723_PEA_—1_P10 (SEQ ID NO:592) and Q96AC2 (SEQ ID NO: 886):

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P10 (SEQ ID NO:592) comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 1-63 of Q96AC2 (SEQ ID NO: 886), which also corresponds to amino acids 1-63 of R11723_PEA_—1_P10 (SEQ ID NO:592), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) corresponding to amino acids 64-90 of R11723_PEA_—1_P10 (SEQ ID NO:592), wherein said first and second amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of R11723_PEA_—1_P10 (SEQ ID NO:592), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) in R11723_PEA_—1_P10 (SEQ ID NO:592).

Comparison report between R11723_PEA_—1_P10 (SEQ ID NO:592) and Q8N2G4:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P10 (SEQ ID NO:592), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 1-63 of Q8N2G4, which also corresponds to amino acids 1-63 of R11723_PEA_—1_P10 (SEQ ID NO:592), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) corresponding to amino acids 64-90 of R11723_PEA_—1_P10 (SEQ ID NO:592), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Comparison report between R11723_PEA_—1_P10 (SEQ ID NO:592) and BAC85273:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P10 (SEQ ID NO:592) comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MWVLG (SEQ ID NO:1025) corresponding to amino acids 1-5 of R11723_PEA_—1_P10 (SEQ ID NO:592), second amino acid sequence being at least 90% homologous to IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEVMEQSA corresponding to amino acids 22-79 of BAC85273, which also corresponds to amino acids 6-63 of R11723_PEA_—1_P10 (SEQ ID NO:592), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) corresponding to amino acids 64-90 of R11723_PEA_—1_P10 (SEQ ID NO:592), wherein said first, second and third amino acid sequences are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a head of R11723_PEA_—1_P10 (SEQ ID NO:592) comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MWVLG (SEQ ID NO:1025) of R11723_PEA_—1_P10 (SEQ ID NO:592)

3. An isolated polypeptide encoding for a tail of R11723_PEA_—1_P10 (SEQ ID NO:592), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) in R11723_PEA_—1_P10 (SEQ ID NO:592).

Comparison report between R11723_PEA_—1_P10 (SEQ ID NO:592) and BAC85518:

1. An isolated chimeric polypeptide encoding for R11723_PEA_—1_P10 (SEQ ID NO:592), comprising a first amino acid sequence being at least 90% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 24-86 of BAC85518, which also corresponds to amino acids 1-63 of R11723_PEA_—1_P10 (SEQ ID NO:592), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence DRVSLCHEAGVQWNNFSTLQPLPPRLK (SEQ ID NO:1027) corresponding to amino acids 64-90 of R11723_PEA_—1_P10 (SEQ ID NO:592), wherein said first and second amino acid sequences are contiguous and in a sequential order.

Variant protein R11723_PEA_—1_P10 (SEQ ID NO:592) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P10 (SEQ ID NO:592) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

66	V -> F	Yes

Variant protein R11723_PEA_—1_P10 (SEQ ID NO:592) is encoded by the following transcript(s): R11723_PEA_—1_T20 (SEQ ID NO:559), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript R11723_PEA_—1_T20 (SEQ ID NO:559) is shown in bold; this coding portion starts at position 434 and ends at position 703. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein R11723_PEA_—1_P10 (SEQ ID NO:592) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

629	G -> T	Yes
637	G -> C	Yes
1307	C -> T	Yes

As noted above, cluster R11723 features 26 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster R11723_PEA_—1_node_—13 (SEQ ID NO:562) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T19 (SEQ	624	776
ID NO: 558)
R11723_PEA_1_T5 (SEQ ID	624	776
NO: 560)
R11723_PEA_1_T6 (SEQ ID	658	810
NO: 561)

Segment cluster R11723_PEA_—1_node_—16 (SEQ ID NO:563) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558) and R11723_PEA_—1_T20 (SEQ ID NO:559). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment starting	Segment ending
Transcript name	position	position

R11723_PEA_1_T17 (SEQ	624	1367
ID NO: 557)
R11723_PEA_1_T19 (SEQ	777	1520
ID NO: 558)
R11723_PEA_1_T20 (SEQ	628	1371
ID NO: 559)

Segment cluster R11723_PEA_—1_node_—19 (SEQ ID NO:564) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T5 (SEQ ID	835	1008
NO: 560)
R11723_PEA_1_T6 (SEQ ID	869	1042
NO: 561)

Segment cluster R11723_PEA_—1_node_—2 (SEQ ID NO:565) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	1	309
ID NO: 556)
R11723_PEA_1_T17 (SEQ	1	309
ID NO: 557)
R11723_PEA_1_T19 (SEQ	1	309
ID NO: 558)
R11723_PEA_1_T20 (SEQ	1	309
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	1	309
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1	309
NO: 561)

Segment cluster R11723_PEA_—1_node_—22 (SEQ ID NO:566) according to the present invention is supported by 65 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T5 (SEQ ID	1083	1569
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1117	1603
NO: 561)

Segment cluster R11723_PEA_—1_node_—31 (SEQ ID NO:567) according to the present invention is supported by 70 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556, R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 20 below describes the starting and ending position of this segment on each transcript (it should be noted that these transcripts show alternative polyadenylation).

TABLE 20


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	1060	1295
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1978	2213
NO: 560)
R11723_PEA_1_T6 (SEQ ID	2012	2247
NO: 561)

Segment cluster R11723_PEA_—1_node_—10 (SEQ ID NO:568) according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556) R11723_PEA_—1_T17(SEQ ID NO:557), R11723_—1_PEA_—1_T19(SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	486	529
ID NO: 556)
R11723_PEA_1_T17 (SEQ	486	529
ID NO: 557)
R11723_PEA_1_T19 (SEQ	486	529
ID NO: 558)
R11723_PEA_1_T20 (SEQ	486	529
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	486	529
NO: 560)
R11723_PEA_1_T6 (SEQ ID	520	563
NO: 561)

Segment cluster R11723_PEA_—1_node_—11 (SEQ ID NO:569) according to the present invention is supported by 42 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556, R11723_PEA_—1_T17(SEQ ID NO:557), R11723_PEA_—1_T19(SEQ ID NO:558), R11723_PEA_—1_—T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	530	623
ID NO: 556)
R11723_PEA_1_T17 (SEQ	530	623
ID NO: 557)
R11723_PEA_1_T19 (SEQ	530	623
ID NO: 558)
R11723_PEA_1_T20 (SEQ	530	623
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	530	623
NO: 560)
R11723_PEA_1_T6 (SEQ ID	564	657
NO: 561)

Segment cluster R11723_PEA_—1_node_—15 (SEQ ID NO:570) according to the present invention can be found in the following transcript(s): R11723_PEA_—1_T20 (SEQ ID NO:559). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T20 (SEQ	624	627
ID NO: 559)

Segment cluster R11723_PEA_—1_node_—18 (SEQ ID NO:571) according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	624	681
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	777	834
NO: 560)
R11723_PEA_1_T6 (SEQ ID	811	868
NO: 561)

Segment cluster R11723_PEA_—1_node_—20 (SEQ ID NO:572) according to the present invention can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T5 (SEQ ID	1009	1019
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1043	1053
NO: 561)

Segment cluster R11723_PEA_—1_node_—21 (SEQ ID NO:573) according to the present invention is supported by 36 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T5 (SEQ ID	1020	1082
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1054	1116
NO: 561)

Segment cluster R11723_PEA_—1_node_—23 (SEQ ID NO:574) according to the present invention is supported by 39 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T5 (SEQ ID	1570	1599
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1604	1633
NO: 561)

Segment cluster R11723_PEA_—1_node_—24 (SEQ ID NO:575) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	682	765
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1600	1683
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1634	1717
NO: 561)

Segment cluster R11723_PEA_—1_node_—25 (SEQ ID NO:576) according to the present invention is supported by 54 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	766	791
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1684	1709
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1718	1743
NO: 561)

Segment cluster R11723_PEA_—1_node_—26 (SEQ ID NO:577) according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	792	904
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1710	1822
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1744	1856
NO: 561)

Segment cluster R11723_PEA_—1_node_—27 (SEQ ID NO:578) according to the present invention is supported by 67 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	905	986
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1823	1904
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1857	1938
NO: 561)

Segment cluster R11723_PEA_—1_node_—28 (SEQ ID NO:579) according to the present invention can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6(SEQ ID NO:561). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	987	1010
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1905	1928
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1939	1962
NO: 561)

Segment cluster R11723_PEA_—1_node_—29 (SEQ ID NO:580) according to the present invention is supported by 69 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	1011	1038
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1929	1956
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1963	1990
NO: 561)

Segment cluster R11723_PEA_—1_node_—3 (SEQ ID NO:581) according to the present invention can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	310	319
ID NO: 556)
R11723_PEA_1_T17 (SEQ	310	319
ID NO: 557)
R11723_PEA_1_T19 (SEQ	310	319
ID NO: 558)
R11723_PEA_1_T20 (SEQ	310	319
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	310	319
NO: 560)
R11723_PEA_1_T6 (SEQ ID	310	319
NO: 561)

Segment cluster R11723_PEA_—1_node_—30 (SEQ ID NO:582) according to the present invention can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	1039	1059
ID NO: 556)
R11723_PEA_1_T5 (SEQ ID	1957	1977
NO: 560)
R11723_PEA_1_T6 (SEQ ID	1991	2011
NO: 561)

Segment cluster R11723_PEA_—1_node_—4 (SEQ ID NO:583) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	320	371
ID NO: 556)
R11723_PEA_1_T17 (SEQ	320	371
ID NO: 557)
R11723_PEA_1_T19 (SEQ	320	371
ID NO: 558)
R11723_PEA_1_T20 (SEQ	320	371
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	320	371
NO: 560)
R11723_PEA_1_T6 (SEQ ID	320	371
NO: 561)

Segment cluster R11723_PEA_—1_node_—5 (SEQ ID NO:584) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	372	414
ID NO: 556)
R11723_PEA_1_T17 (SEQ	372	414
ID NO: 557)
R11723_PEA_1_T19 (SEQ	372	414
ID NO: 558)
R11723_PEA_1_T20 (SEQ	372	414
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	372	414
NO: 560)
R11723_PEA_1_T6 (SEQ ID	372	414
NO: 561)

Segment cluster R11723_PEA_—1_node_—6 (SEQ ID NO:585) according to the present invention is supported by 27 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	415	446
ID NO: 556)
R11723_PEA_1_T17 (SEQ	415	446
ID NO: 557)
R11723_PEA_1_T19 (SEQ	415	446
ID NO: 558)
R11723_PEA_1_T20 (SEQ	415	446
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	415	446
NO: 560)
R11723_PEA_1_T6 (SEQ ID	415	446
NO: 561)

Segment cluster R11723_PEA_—1_node_—7 (SEQ ID NO:586) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T15 (SEQ ID NO:556), R11723_PEA_—1_T17 (SEQ ID NO:557), R11723_PEA_—1_T19 (SEQ ID NO:558), R11723_PEA_—1_T20 (SEQ ID NO:559), R11723_PEA_—1_T5 (SEQ ID NO:560) and R11723_PEA_—1_T6 (SEQ ID NO:561). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T15 (SEQ	447	485
ID NO: 556)
R11723_PEA_1_T17 (SEQ	447	485
ID NO: 557)
R11723_PEA_1_T19 (SEQ	447	485
ID NO: 558)
R11723_PEA_1_T20 (SEQ	447	485
ID NO: 559)
R11723_PEA_1_T5 (SEQ ID	447	485
NO: 560)
R11723_PEA_1_T6 (SEQ ID	447	485
NO: 561)

Segment cluster R11723_PEA_—1_node_—8 (SEQ ID NO:587) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): R11723_PEA_—1_T6 (SEQ ID NO:561). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

R11723_PEA_1_T6 (SEQ ID	486	519
NO: 561)

Variant protein alignment to the previously known protein:

Sequence name: /tmp/gp6eQTLWqk/mFtjUpUzhb:Q8IXM0

Sequence documentation:

Alignment of: R11723_PEA_—1_P6 (SEQ ID NO:589)×Q8IXM0.

Alignment segment 1/1:



Quality:	1128.00
Escore:	0
Matching length:	112	Total length:	112
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
111	MYAQALLVVGVLQRQAAAQHLHEHPPKLLRGHRVQERVDDRAEVEKRLRE	160
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MYAQALLVVGVLQRQAAAQHLHEHPPKLLRGHRVQERVDDRAEVEKRLRE	50

	· · · · ·
161	GEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQCHNNQPWADTSRRE	210
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	GEEDHVRPEVGPRPVVLGFGRSHDPPNLVGHPAYGQCHNNQPWADTSRRE	100

·
211	RQRKEKHSMRTQ	222
	\|\|\|\|\|\|\|\|\|\|\|\|
101	RQRKEKHSMRTQ	112

Sequence name: /tmp/gp6eQTLWqk/mFtjUpUzhb:Q96AC2 (SEQ ID NO: 886)

Sequence documentation:

Alignment of: R11723_PEA_—1_P6 (SEQ ID NO:589)×Q96AC2 (SEQ ID NO: 886).

Alignment segment 1/1:



Quality:	835.00
Escore:	0
Matching length:	83	Total length:	83
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps: 0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	· · ·
51	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	83

Sequence name: /tmp/gp6eQTLWqk/mFtjUpUzhb:Q8N2G4

Sequence documentation:

Alignment of: R11723_PEA_—1_P6 (SEQ ID NO:589)×Q8N2G4.

Alignment segment 1/1:



Quality:	835.00
Escore:	0
Matching length:	83	Total length:	83
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGTAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	· · ·
51	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	83

Sequence name: /tmp/gp6eQTLWqk/mFtjUpUzhb:BAC85518

Sequence documentation:

Alignment of: R11723_PEA_—1_P6 (SEQ ID NO:589)×BAC85518.

Alignment segment 1/1:



Quality:	835.00
Escore:	0
Matching length:	83	Total length:	83
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
24	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	73

	· · ·
51	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	83
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
74	QDMCQKEVMEQSAGIMYRKSCASSAACLIASAG	106

Sequence name: /tmp/VXjdFlzdBX/bexTxTh0Th:Q96AC2 (SEQ ID NO: 886)

Sequence documentation:

Alignment of: R11723_PEA_—1_P7 (SEQ ID NO:590)×Q96AC2 (SEQ ID NO: 886).

Alignment segment 1/1:



Quality:	654.00
Escore:	0
Matching length:	64	Total length:	64
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	·
51	QDMCQKEVMEQSAG	64
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSAG	64

Sequence name: /tmp/VXjdFlzdBX/bexTxTh0Th:Q8N2G4

Sequence documentation:

Alignment of: R11723_PEA_—1_P7 (SEQ ID NO:590)×Q8N2G4.

Alignment segment 1/1:



Quality:	654.00
Escore:	0
Matching length:	64	Total length:	64
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	·
51	QDMCQKEVMEQSAG	64
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSAG	64

Sequence name: /tmp/VXjdFlzdBX/bexTxTh0Th:BAC85273

Sequence documentation:

Alignment of: R11723_PEA_—1_P7 (SEQ ID NO:590)×BAC85273.

Alignment segment 1/1:



Quality:	600.00
Escore:	0
Matching length:	59	Total length:	59
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
6	IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQ	55
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
22	IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQ	71

56	KEVMEQSAG	64
	\|\|\|\|\|\|\|\|\|
72	KEVMEQSAG	80

Sequence name: /tmp/VXjdFlzdBX/bexTxTh0Th:BAC85518

Sequence documentation:

Alignment of: R11723_PEA_—1_P7 (SEQ ID NO:590)×BAC85518.

Alignment segment 1/1:



Quality:	654.00
Escore:	0
Matching length:	64	Total length:	64
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
24	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	73

	·
51	QDMCQKEVMEQSAG	64
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|
74	QDMCQKEVMEQSAG	87

Sequence name: /tmp/OLMSexEmIh/pc7Z7Xm1YR:Q96AC2 (SEQ ID NO: 886)

Sequence documentation:

Alignment of: R11723_PEA_—1_P10 (SEQ ID NO:592)×Q96AC2 (SEQ ID NO: 886).

Alignment segment 1/1:



Quality:	645.00
Escore:	0
Matching length:	63	Total length:	63
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	·
51	QDMCQKEVMEQSA	63
	\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSA	63

Sequence name: /tmp/OLMSexEmIh/pc7Z7Xm1YR:Q8N2G4

Sequence documentation:

Alignment of: R11723_PEA_—1_P10 (SEQ ID NO:592)×Q8N2G4.

Alignment segment 1/1:



Quality:	645.00
Escore:	0
Matching length:	63	Total length:	63
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	·
51	QDMCQKEVMEQSA	63
	\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSA	63

Sequence name: /tmp/OLMSexEmIh/pc7Z7Xm1YR:BAC85273

Sequence documentation:

Alignment of: R11723_PEA_—1_P10 (SEQ ID NO:592)×BAC85273.

Alignment segment 1/1:



Quality:	591.00
Escore:	0
Matching length:	58	Total length:	58
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	. . . . .
6	IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQ	55
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
22	IAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQ	71

56	KEVMEQSA	63
	\|\|\|\|\|\|\|\|
72	KEVMEQSA	79

Sequence name: /tmp/OLMSexEmIh/pc7Z7Xm1YR:BAC85518.

Alignment documentation:

Alignment of: R11723_PEA_—1_P10 (SEQ ID NO:592)×BAC85518.

Alignment segment 1/1:



Quality:	645.00
Escore:	0
Matching length:	63	Total length:	63
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
24	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	73

	·
51	QDMCQKEVMEQSA	63
	\|\|\|\|\|\|\|\|\|\|\|\|\|
74	QDMCQKEVMEQSA	86

Alignment of: R11723_PEA_—1_—P13 (SEQ ID NO:591)×Q96AC2 (SEQ ID NO: 886).

Alignment segment 1/1:



Quality:	645.00
Escore:	0
Matching length:	63	Total length:	63
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNV	50

	·
51	QDMCQKEVMEQSA	63
	\|\|\|\|\|\|\|\|\|\|\|\|\|
51	QDMCQKEVMEQSA	63

Expression of R11723 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name R11723 Seg13 (SEQ ID NO:891) in Normal and Cancerous Breast Tissues

Expression of transcripts detectable by or according to seg13, R11723 seg13 amplicon(s) (SEQ ID NO:891) and R11723 seg13F (SEQ ID NO:889) and R11723 seg13R (SEQ ID NO:890) primers was measured by real time PCR. It should be noted that the variants of this cluster are variants of the hypothetical protein PSEC0181 (referred to herein as “PSEC”). In parallel the expression of four housekeeping genes PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1, “Tissue samples in testing panel” above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 39 is a histogram showing over expression of the above-indicated transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 39, the expression of transcripts detectable by the above amplicon(s) in cancer samples was higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67 Table 1, Tissue samples in testing panel). Notably an over-expression of at least 5 fold was found in 5 out of 28 adenocarcinoma samples.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: R11723 seg13F forward primer (SEQ ID NO:889); and R11723 seg13R reverse primer (SEQ ID NO:890).


R11723seg13F-
ACACTAAAAGAACAAACACCTTGCTC	(SEQ ID NO:889)

R11723seg13R-
TCCTCAGAAGGCACATGAAAGA	(SEQ ID NO:890)

R11723seg13 amplicon:
ACACTAAAAGAACAAACACCTTGCTCTTCGAGATGAGACATTTTGCCAAGCAGTTG	(SEQ ID NO:891)
ACCACTTAGTTCTCAAGAAGCAACTATCTCTTTCATGTGCCTTCTGAGGA

Expression of R11723 Transcripts Which are Detectable by Amplicon as Depicted in Sequence Name R11723Seg13 (SEQ ID NO:891) in Different Normal Tissues

Expression of R11723 transcripts detectable by or according to R11723seg13 amplicon (SEQ ID NO:891) and R11723seg13F (SEQ ID NO:889) R11723seg13R (SEQ ID NO:890) was measured by real time PCR. In parallel the expression of four housekeeping genes RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945 ) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the ovary samples (Sample Nos. 18-20 Table 2 “Tissue samples in normal panel” above), to obtain a value of relative expression of each sample relative to median of the ovary samples. Primers and amplicon are as above.

The results are presented in FIG. 40, demonstrating the expression of R11723 transcripts which are detectable by amplicon as depicted in sequence name R11723seg13 (SEQ ID NO:891) in different normal tissues.

Expression of R11723 Transcripts, Which are Detectable by Amplicon as Depicted in Sequence Name R11723 Junc11-18 (SEQ ID NO:894) in Normal and Cancerous Breast Tissues

Expression of transcripts detectable by or according to junc11-18, R11723 junc 11-18 amplicon(s) (SEQ ID NO:894) and R11723 junc11-18F (SEQ ID NO:892) and R11723 junc11-18R (SEQ ID NO:893) primers was measured by real time PCR (this junction and hence the amplicon are found in the previous known protein, also termed the “wild type” or WT protein, for which the sequence is given herein; the protein is also called “PSEC”). Use of the known protein (WT protein) for detection of breast cancer, alone or in combination with one or more variants of this cluster and/or of any other cluster and/or of any known marker, also comprises an embodiment of the present invention. In parallel the expression of four housekeeping genes PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933)), SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925 ), and G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)), was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the normal post-mortem (PM) samples (Sample Nos. 56-60, 63-67, Table 1: Tissue samples in testing panel, above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIG. 41A is a histogram showing over expression of the above-indicated transcripts in cancerous breast samples relative to the normal samples.

As is evident from FIG. 41A, the expression of transcripts detectable by the above amplicon in a few cancer samples was higher than in the non-cancerous samples (Sample Nos. 56-60, 63-67, Table 5: “Tissue samples in breast cancer testing panel”). Notably an over-expression of at least 5 fold was found in 5 out of 28 adenocarcinoma samples.

Primer pairs are also optionally and preferably encompassed within the present invention; for example, for the above experiment, the following primer pair was used as a non-limiting illustrative example only of a suitable primer pair: R11723 junc11-18F forward primer (SEQ ID NO:892); and R11723 junc11-18R reverse primer (SEQ ID NO:893).


R11723junc11-18F-
AGTGATGGAGCAAAGTGCCG	(SEQ ID NO:892)

R11723 junc11-18R-
CAGCAGCTGATGCAAACTGAG	(SEQ ID NO:893)

R11723 junc11-18-
AGTGATGGAGCAAAGTGCCGGGATCATGTACCGCAAGTCCTGTGCATCATCAGCGG	(SEQ ID NO:894)
CCTGTCTCATCGCCTCTGCCGGGTACCAGTCCTTCTGCTCCCCAGGGAAACTGAACT
CAGTTTGCATCAGCTGCTG

Expression of R11723 Transcripts, Which were Detected by Amplicon as Depicted in the Sequence Name R11723 junc11-18 (SEQ ID NO:894) in Different Normal Tissues

Expression of R11723 transcripts detectable by or according to R11723seg13 amplicon (SEQ ID NO:894) and R11723 junc11-18F (SEQ ID NO:892) R11723junc11-18R (SEQ ID NO:893) was measured by real time PCR (as described above, this junction and hence the amplicon are found in the previous known protein, also termed the “wild type” or WT protein, for which the sequence is given herein; the protein is also called “PSEC”). In parallel the expression of four housekeeping genes RPL19 (GenBank Accession No. NM_—000981 (SEQ ID NO:934); RPL19 amplicon (SEQ ID NO:937)), TATA box (GenBank Accession No. NM_—003194 (SEQ ID NO:938); TATA amplicon (SEQ ID NO:941)), UBC (GenBank Accession No. BC000449 (SEQ ID NO:942); amplicon—Ubiquitin-amplicon (SEQ ID NO:945)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicon was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample was then divided by the median of the quantities of the ovary samples (Sample Nos. 18-20, Table 2: Tissue samples in normal panel, above), to obtain a value of relative expression of each sample relative to median of the ovary samples. FIG. 41B shows the level of expression of this transcript. Primers and amplicon are as for the example above.

The variant transcript expression pattern for this cluster is similar to the wild type transcript expression. However, in some cases (e.g. ovary cancer) over expression of the variant seems to be higher (for example, with regard to R11723_PEA_—1_—T5 (SEQ ID NO:560)).

Description for Cluster T46984

Cluster T46984 features 21 transcript(s) and 49 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	T46984_PEA_1_T2	593
	T46984_PEA_1_T3	594
	T46984_PEA_1_T12	595
	T46984_PEA_1_T13	596
	T46984_PEA_1_T14	597
	T46984_PEA_1_T15	598
	T46984_PEA_1_T19	599
	T46984_PEA_1_T23	600
	T46984_PEA_1_T27	601
	T46984_PEA_1_T32	602
	T46984_PEA_1_T34	603
	T46984_PEA_1_T35	604
	T46984_PEA_1_T40	605
	T46984_PEA_1_T42	606
	T46984_PEA_1_T43	607
	T46984_PEA_1_T46	608
	T46984_PEA_1_T47	609
	T46984_PEA_1_T48	610
	T46984_PEA_1_T51	611
	T46984_PEA_1_T52	612
	T46984_PEA_1_T54	613

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	T46984_PEA_1_node_2	614
	T46984_PEA_1_node_4	615
	T46984_PEA_1_node_6	616
	T46984_PEA_1_node_12	617
	T46984_PEA_1_node_14	618
	T46984_PEA_1_node_25	619
	T46984_PEA_1_node_29	620
	T46984_PEA_1_node_34	621
	T46984_PEA_1_node_46	622
	T46984_PEA_1_node_47	623
	T46984_PEA_1_node_52	624
	T46984_PEA_1_node_65	625
	T46984_PEA_1_node_69	626
	T46984_PEA_1_node_75	627
	T46984_PEA_1_node_86	628
	T46984_PEA_1_node_9	629
	T46984_PEA_1_node_13	630
	T46984_PEA_1_node_19	631
	T46984_PEA_1_node_21	632
	T46984_PEA_1_node_22	633
	T46984_PEA_1_node_26	634
	T46984_PEA_1_node_28	635
	T46984_PEA_1_node_31	636
	T46984_PEA_1_node_32	637
	T46984_PEA_1_node_38	638
	T46984_PEA_1_node_39	639
	T46984_PEA_1_node_40	640
	T46984_PEA_1_node_42	641
	T46984_PEA_1_node_43	642
	T46984_PEA_1_node_48	643
	T46984_PEA_1_node_49	644
	T46984_PEA_1_node_50	645
	T46984_PEA_1_node_51	646
	T46984_PEA_1_node_53	647
	T46984_PEA_1_node_54	648
	T46984_PEA_1_node_55	649
	T46984_PEA_1_node_57	650
	T46984_PEA_1_node_60	651
	T46984_PEA_1_node_62	652
	T46984_PEA_1_node_66	653
	T46984_PEA_1_node_67	654
	T46984_PEA_1_node_70	655
	T46984_PEA_1_node_71	656
	T46984_PEA_1_node_72	657
	T46984_PEA_1_node_73	658
	T46984_PEA_1_node_74	659
	T46984_PEA_1_node_83	660
	T46984_PEA_1_node_84	661
	T46984_PEA_1_node_85	662

TABLE 3


Proteins of interest

	Sequence ID
Protein Name	No.	Corresponding Transcript(s)

T46984_PEA_1_P2	664	T46984_PEA_1_T2 (SEQ ID
		NO: 593);
		T46984_PEA_1_T12 (SEQ
		ID NO: 595);
		T46984_PEA_1_T23 (SEQ
		ID NO: 600)
T46984_PEA_1_P3	665	T46984_PEA_1_T3 (SEQ ID
		NO: 594);
		T46984_PEA_1_T19 (SEQ
		ID NO: 599)
T46984_PEA_1_P10	666	T46984_PEA_1_T13 (SEQ
		ID NO: 596)
T46984_PEA_1_P11	667	T46984_PEA_1_T14 (SEQ
		ID NO: 597)
T46984_PEA_1_P12	668	T46984_PEA_1_T15 (SEQ
		ID NO: 598)
T46984_PEA_1_P21	669	T46984_PEA_1_T27 (SEQ
		ID NO: 601)
T46984_PEA_1_P27	670	T46984_PEA_1_T34 (SEQ
		ID NO: 603)
T46984_PEA_1_P32	671	T46984_PEA_1_T40 (SEQ
		ID NO: 605)
T46984_PEA_1_P34	672	T46984_PEA_1_T42 (SEQ
		ID NO: 606)
T46984_PEA_1_P35	673	T46984_PEA_1_T43 (SEQ
		ID NO: 607)
T46984_PEA_1_P38	674	T46984_PEA_1_T47 (SEQ
		ID NO: 609)
T46984_PEA_1_P39	675	T46984_PEA_1_T48 (SEQ
		ID NO: 610)
T46984_PEA_1_P45	676	T46984_PEA_1_T32 (SEQ
		ID NO: 602)
T46984_PEA_1_P46	677	T46984_PEA_1_T35 (SEQ
		ID NO: 604)

These sequences are variants of the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SwissProt accession identifier RIB2_HUMAN; known also according to the synonyms EC 2.4.1.119; Ribophorin II; RPN-II; RIBIIR), SEQ ID NO: 663, referred to herein as the previously known protein.

Protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663) is known or believed to have the following function(s): Essential subunit of N-oligosaccharyl transferase enzyme which catalyzes the transfer of a high mannose oligosaccharide from a lipid-linked oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. The sequence for protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663) is given at the end of the application, as “Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

197	V -> L
201	F -> C
260	A -> S
423	V -> M

Protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663) localization is believed to be Type I membrane protein. Endoplasmic reticulum.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: protein modification, which are annotation(s) related to Biological Process; oligosaccharyl transferase; dolichyl-diphosphooligosaccharide-protein glycosyltransferase; transferase, which are annotation(s) related to Molecular Function; and oligosaccharyl transferase complex; integral membrane protein, which are annotation(s) related to Cellular Component.

Cluster T46984 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 42 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 42 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: epithelial malignant tumors, a mixture of malignant tumors from different tissues, breast malignant tumors, ovarian carcinoma and pancreas carcinoma.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	adrenal	240
	bladder	287
	bone	592
	brain	145
	colon	157
	epithelial	144
	general	163
	head and neck	50
	kidney	139
	liver	156
	lung	155
	lymph nodes	194
	breast	105
	bone marrow	62
	muscle	62
	ovary	0
	pancreas	72
	prostate	201
	skin	91
	stomach	219
	T cells	0
	Thyroid	0
	uterus	200

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

adrenal	6.3e−01	5.4e−01	6.2e−01	0.8	2.5e−01	1.0
bladder	5.4e−01	5.9e−01	3.0e−01	1.0	6.5e−01	0.7
bone	3.9e−01	3.7e−01	9.8e−01	0.4	9.9e−01	0.4
brain	3.3e−01	2.9e−01	1.4e−01	1.2	2.0e−01	1.0
colon	8.6e−02	5.9e−02	2.6e−01	1.3	2.1e−03	1.4
epithelial	5.3e−05	6.2e−07	2.8e−08	1.9	3.4e−21	2.4
general	1.0e−04	7.3e−08	9.3e−12	1.7	8.0e−33	2.0
head and neck	4.5e−01	5.4e−01	1	0.8	7.5e−01	0.9
kidney	6.6e−01	6.5e−01	3.2e−01	1.2	5.3e−02	1.5
liver	5.5e−01	5.6e−01	6.5e−01	1.0	1.2e−01	1.4
lung	3.0e−01	1.7e−01	1.5e−01	1.4	6.0e−02	1.4
lymph nodes	2.9e−01	5.5e−01	2.9e−01	0.8	4.3e−01	1.0
breast	2.4e−02	5.8e−03	3.7e−02	2.2	1.7e−04	2.7
bone marrow	7.1e−01	7.5e−01	1	0.3	1.2e−02	1.8
muscle	5.0e−01	3.7e−01	4.7e−01	1.5	2.1e−08	1.3
ovary	1.6e−02	7.0e−03	1.5e−02	6.1	4.8e−06	7.1
pancreas	1.4e−01	5.4e−02	2.2e−05	2.9	2.4e−07	3.9
prostate	3.4e−01	1.9e−01	2.2e−01	1.2	1.4e−01	1.3
skin	3.7e−01	1.5e−01	4.2e−02	2.4	1.1e−04	1.9
stomach	6.1e−01	1.4e−01	7.3e−01	0.4	6.1e−02	1.6
T cells	1	6.7e−01	1	1.0	5.2e−01	1.8
Thyroid	4.8e−02	4.8e−02	2.0e−01	3.4	2.0e−01	3.4
uterus	2.3e−01	1.3e−01	2.2e−02	1.5	5.0e−02	1.4

As noted above, cluster T46984 features 21 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663). A description of each variant protein according to the present invention is now provided.

Variant protein T46984_PEA_—1_P2 (SEQ ID NO:664) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T2 (SEQ ID NO:593). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P2 (SEQ ID NO:664) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P2 (SEQ ID NO:664), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNV corresponding to amino acids 1-498 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-498 of T46984_PEA_—1_P2 (SEQ ID NO:664), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VCA corresponding to amino acids 499-501 of T46984_PEA_—1_P2 (SEQ ID NO:664), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

The glycosylation sites of variant protein T46984_PEA_—1_P2 (SEQ ID NO:664), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 7 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 7


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P2 (SEQ ID NO:664) is encoded by the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T2 (SEQ ID NO:593) is shown in bold; this coding portion starts at position 316 and ends at position 1818. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P2 (SEQ ID NO:664) sequence provides support for the deduced sequence of the variant protein according to the present invention).

TABLE 8


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes
1588	A -> C	No
1618	T ->	No
1618	T -> C	No
1660	T ->	No
1693	A -> C	No
1693	A -> T	No
2099	G -> A	Yes
2124	C -> G	Yes
2124	C -> T	Yes
2133	A -> G	Yes
2501	C -> T	Yes
2617	G -> T	Yes
2683	C -> T	Yes
2741	G -> A	Yes
2940	T ->	No
3024	G -> A	Yes
3158	C ->	No
3158	C -> A	No
3165	C ->	No
3169	G ->	No
3354	C -> A	No
3374	T -> C	Yes
3468	C -> T	No
3501	A -> C	No
3513	A -> T	No
3528	G -> A	Yes
3534	-> A	No
3543	A -> G	No
3568	T -> G	No
3582	T -> A	No
3582	T -> G	No
3682	-> C	No
3691	T ->	No
3750	A -> C	No

Variant protein T46984_PEA_—1_P3 (SEQ ID NO:665) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T3 (SEQ ID NO:594). An alignment is given to the known protein (Dolichyl-diphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P3 (SEQ ID NO:665) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P3 (SEQ ID NO:665), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQ corresponding to amino acids 1-433 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-433 of T46984_PEA_—1_P3 (SEQ ID NO:665), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ICHIWKLIFLP (SEQ ID NO:947) corresponding to amino acids 434-444 of T46984_PEA_—1_P3 (SEQ ID NO:665), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P3 (SEQ ID NO:665), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ICHIWKLIFLP (SEQ ID NO:947) in T46984_PEA_—1_P3 (SEQ ID NO:665).

Variant protein T46984_PEA_—1_P3 (SEQ ID NO:665) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P3 (SEQ ID NO:665) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> R	No
302	Q -> L	No
326	T -> P	No
330	D -> N	No
354	G -> V	Yes
425	T -> P	No

The glycosylation sites of variant protein T46984_PEA_—1_P3 (SEQ ID NO:665), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 10 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 10


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P3 (SEQ ID NO:665) is encoded by the following transcript(s): T46984_PEA_—1_T3 (SEQ ID NO:594), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T3 (SEQ ID NO:594) is shown in bold; this coding portion starts at position 316 and ends at position 1647. The transcript also has the following SNPs as listed in Table 11 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P3 (SEQ ID NO:665) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes
1588	A -> C	No
1784	C -> T	Yes
1959	G -> A	Yes
2112	G -> A	Yes
2137	C -> G	Yes
2246	T ->	No
2246	T -> C	No
2288	T ->	No
2321	A -> C	No
2321	A -> T	No
2552	C ->	No
2552	C -> A	No
2559	C ->	No
2563	G ->	No
2748	C -> A	No
2768	T -> C	Yes
2862	C -> T	No
2895	A -> C	No
2907	A -> T	No
2922	G -> A	Yes
2928	-> A	No
2937	A -> G	No
2962	T -> G	No
2976	T -> A	No
2976	T -> G	No
3076	-> C	No
3085	T ->	No
3144	A -> C	No

Variant protein T46984_PEA_—1_P10 (SEQ ID NO:666) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T13 (SEQ ID NO:596). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P10 (SEQ ID NO:666) and RIB2_HUMAN SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P10 (SEQ ID NO:666), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNV corresponding to amino acids 1-498 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-498 of T46984_PEA_—1_P10 (SEQ ID NO:666), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LMDQK (SEQ ID NO:948) corresponding to amino acids 499-503 of T46984_PEA_—1_P10 (SEQ ID NO:666), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_—P10 (SEQ ID NO:666), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence LMDQK (SEQ ID NO:948) in T46984_PEA_—1_P10 (SEQ ID NO:666)

Variant protein T46984_PEA_—1_P10 (SEQ ID NO:666) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 12, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P10 (SEQ ID NO:666) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> R	No
302	Q -> L	No
326	T -> P	No
330	D -> N	No
354	G -> V	Yes
425	T -> P	No
435	F ->	No
435	F -> L	No
449	F ->	No
460	K -> *	No
460	K -> Q	No

The glycosylation sites of variant protein T46984_PEA_—1_P10 (SEQ ID NO:666), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 13 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 13


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P10 (SEQ ID NO:666) is encoded by the following transcript(s): T46984_PEA_—1_T13 (SEQ ID NO:596), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T13 (SEQ ID NO:596) is shown in bold; this coding portion starts at position 316 and ends at position 1824. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P10 (SEQ ID NO:666) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes
1588	A -> C	No
1618	T ->	No
1618	T -> C	No
1660	T ->	No
1693	A -> C	No
1693	A -> T	No
1845	T ->	No
1983	C ->	No
1983	C -> A	No
1990	C ->	No
1994	G ->	No
2179	C -> A	No
2199	T -> C	Yes
2293	C -> T	No
2326	A -> C	No
2338	A -> T	No
2353	G -> A	Yes
2359	-> A	No
2368	A -> G	No
2393	T -> G	No
2407	T -> A	No
2407	T -> G	No
2507	-> C	No
2516	T ->	No
2575	A -> C	No

Variant protein T46984_PEA_—1_P11 (SEQ ID NO:667) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T14 (SEQ ID NO:597). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P11 (SEQ ID NO:667) and RIB2_HUMAN SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P11 (SEQ ID NO:667), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFAL FFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDS ASGTYTLYLIIGDATLKNPILWNVADVVIKFPEEEAPSTVLSQNLFTPKQEIQHLFREPEK RPPTVVSNTFTALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGLMYVYWT QLNMFQTLKYLAILGSVTFLAGNRMLAQQAVKR corresponding to amino acids 1-628 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-628 of T46984_PEA_—1_P11 (SEQ ID NO:667).

Variant protein T46984_PEA_—1_P11 (SEQ ID NO:667) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P11 (SEQ ID NO:667) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q -> P	No
291	Q ->	No
302	Q -> L	No
302	Q -> R	No
326	T -> P	No
330	D -> N	No
354	G -> V	Yes
425	T -> P	No
435	F ->	No
435	F -> L	No
449	F ->	No
460	K -> Q	No
460	K -> *	No
537	P -> T	No
537	P ->	No
539	T ->	No
540	V ->	No
602	T -> N	No

The glycosylation sites of variant protein T46984_PEA_—1_P11 (SEQ ID NO:667), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 16 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 16


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P11 (SEQ ID NO:667) is encoded by the following transcript(s): T46984_PEA_—1_T14 (SEQ ID NO:597), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T14 (SEQ ID NO:597) is shown in bold; this coding portion starts at position 316 and ends at position 2199. The transcript also has the following SNPs as listed in Table 17 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P11 (SEQ ID NO:667) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 17


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes
1588	A -> C	No
1618	T ->	No
1618	T -> C	No
1660	T ->	No
1693	A -> C	No
1693	A -> T	No
1924	C ->	No
1924	C -> A	No
1931	C ->	No
1935	G ->	No
2120	C -> A	No
2140	T -> C	Yes
2449	A ->	Yes
2537	C -> T	Yes
2614	C -> T	Yes
2699	C -> T	Yes
2857	G -> A	Yes
2879	A -> G	Yes
3078	A -> G	Yes
3354	G -> A	Yes

Variant protein T46984_PEA_—1_P12 (SEQ ID NO:668) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T15 (SEQ ID NO:598). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P12 (SEQ ID NO:668) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P12 (SEQ ID NO:668), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMN corresponding to amino acids 1-338 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-338 of T46984_PEA_—1_P12 (SEQ ID NO:668), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SQDLH (SEQ ID NO:949) corresponding to amino acids 339-343 of T46984_PEA_—1_P12 (SEQ ID NO:668), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P12 (SEQ ID NO:668), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SQDLH (SEQ ID NO:949) in T46984_PEA_—1_P12 (SEQ ID NO:668).

Variant protein T46984_PEA_—1_P12 (SEQ ID NO:668) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 18, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P12 (SEQ ID NO:668) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 18


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> L	No
302	Q -> R	No
326	T -> P	No
330	D -> N	No

The glycosylation sites of variant protein T46984_PEA_—1_P12 (SEQ ID NO:668), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 19 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 19


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P12 (SEQ ID NO:668) is encoded by the following transcript(s): T46984_PEA_—1_T15 (SEQ ID NO:598), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T15 (SEQ ID NO:598) is shown in bold; this coding portion starts at position 316 and ends at position 1344. The transcript also has the following SNPs as listed in Table 20 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P12 (SEQ ID NO:668) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 20


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1505	A -> C	No
1535	T ->	No
1535	T -> C	No
1577	T ->	No
1610	A -> C	No
1610	A -> T	No
1841	C ->	No
1841	C -> A	No
1848	C ->	No
1852	G ->	No
2037	C -> A	No
2057	T -> C	Yes
2151	C -> T	No
2184	A -> C	No
2196	A -> T	No
2211	G -> A	Yes
2217	-> A	No
2226	A -> G	No
2251	T -> G	No
2265	T -> A	No
2265	T -> G	No
2365	-> C	No
2374	T ->	No
2433	A -> C	No

Variant protein T46984_PEA_—1_P21 (SEQ ID NO:669) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T27 (SEQ ID NO:601). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P21 (SEQ ID NO:669) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P21 (SEQ ID NO:669), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence M corresponding to amino acids 1-1 of T46984_PEA_—1_P21 (SEQ ID NO:669), and a second amino acid sequence being at least 90% homologous to KACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSSVTQIYHAV AALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVA RLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFES LSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKL EHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVEL RVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQLVDVNT GAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERKIEFDSASGTYTLYLII GDATLKNPILWNVADVVIKFPEEEAPSTVLSQNLFTPKQEIQHLFREPEKRPPTVVSNTF TALILSPLLLLFALWIRIGANVSNFTFAPSTIIFHLGHAAMLGLMYVYWTQLNMFQTLKY LAILGSVTFLAGNRMLAQQAVKRTAH corresponding to amino acids 70-631 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 2-563 of T46984_PEA_—1_P21 (SEQ ID NO:669), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

Variant protein T46984_PEA_—1_P21 (SEQ ID NO:669) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 21, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P21 (SEQ ID NO:669) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 21


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

31	G -> R	Yes
67	F ->	No
69	L ->	No
122	R ->	No
177	N ->	No
177	N -> D	No
183	E -> D	No
186	S -> N	Yes
223	Q -> P	No
223	Q ->	No
234	Q -> L	No
234	Q -> R	No
258	T -> P	No
262	D -> N	No
286	G -> V	Yes
357	T -> P	No
367	F -> L	No
367	F ->	No
381	F ->	No
392	K -> *	No
392	K -> Q	No
469	P ->	No
469	P -> T	No
471	T ->	No
472	V ->	No
534	T -> N	No

The glycosylation sites of variant protein T46984_PEA_—1_P21 (SEQ ID NO:669), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 22 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 22


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	38

Variant protein T46984_PEA_—1_P21 (SEQ ID NO:669) is encoded by the following transcript(s): T46984_PEA_—1_T27 (SEQ ID NO:601), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T27 (SEQ ID NO:601) is shown in bold; this coding portion starts at position 338 and ends at position 2026. The transcript also has the following SNPs as listed in Table 23 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P21 (SEQ ID NO:669) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 23


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

68	C -> T	Yes
194	A -> G	Yes
428	G -> A	Yes
536	T ->	No
542	C ->	No
662	C -> T	Yes
675	-> G	No
703	C ->	No
715	-> G	No
820	G -> A	No
866	A ->	No
866	A -> G	No
886	A -> C	No
894	G -> A	Yes
1005	A ->	No
1005	A -> C	No
1038	A -> G	No
1038	A -> T	No
1072	T -> G	No
1109	A -> C	No
1111	C -> G	No
1121	G -> A	No
1194	G -> T	Yes
1406	A -> C	No
1436	T ->	No
1436	T -> C	No
1478	T ->	No
1511	A -> C	No
1511	A -> T	No
1742	C ->	No
1742	C -> A	No
1749	C ->	No
1753	G ->	No
1938	C -> A	No
1958	T -> C	Yes
2052	C -> T	No
2085	A -> C	No
2097	A -> T	No
2112	G -> A	Yes
2118	-> A	No
2127	A -> G	No
2152	T -> G	No
2166	T -> A	No
2166	T -> G	No
2266	-> C	No
2275	T ->	No
2334	A -> C	No

Variant protein T46984_PEA_—1_P27 (SEQ ID NO:670) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T34 (SEQ ID NO:603). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P27 (SEQ ID NO:670) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P27 (SEQ ID NO:670) comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFA corresponding to amino acids 1-415 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-415 of T46984_PEA_—1_P27 (SEQ ID NO:670), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence FGSGLVPMSPTSLLLLARLYFTWDMLLCWDSCMSTGLSSTCSRP (SEQ ID NO:950) corresponding to amino acids 416-459 of T46984_PEA_—1_P27 (SEQ ID NO:670), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P27 (SEQ ID NO:670), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence FGSGLVPMSPTSLLLLARLYFTWDMLLCWDSCMSTGLSSTCSRP (SEQ ID NO:950) in T46984_PEA_—1_P27 (SEQ ID NO:670).

Variant protein T46984_PEA_—1_P27 (SEQ ID NO:670) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 24, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P27 (SEQ ID NO:670) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 24


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> R	No
302	Q -> L	No
326	T -> P	No
330	D -> N	No
354	G -> V	Yes
459	P -> T	No

The glycosylation sites of variant protein T46984_PEA_—1_P27 (SEQ ID NO:670), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 25 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 25


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P27 (SEQ ID NO:670) is encoded by the following transcript(s): T46984_PEA_—1_T34 (SEQ ID NO:603), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T34 (SEQ ID NO:603) is shown in bold; this coding portion starts at position 316 and ends at position 1692. The transcript also has the following SNPs as listed in Table 26 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P27 (SEQ ID NO:670) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 26


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes
1690	C -> A	No
1710	T -> C	Yes
1804	C -> T	No
1837	A -> C	No
1849	A -> T	No
1864	G -> A	Yes
1870	-> A	No
1879	A -> G	No
1904	T -> G	No
1918	T -> A	No
1918	T -> G	No
2018	-> C	No
2027	T ->	No
2086	A -> C	No

Variant protein T46984_PEA_—1_P32 (SEQ ID NO:671) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T40 (SEQ ID NO:605). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P32 (SEQ ID NO:671) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P32 (SEQ ID NO:671), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDN RYIANTVE corresponding to amino acids 1-364 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-364 of T46984_PEA_—1_P32 (SEQ ID NO:671), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GQVRWLTPVIPALWEAKAGGSPEVRSSILAWPT (SEQ ID NO:95 1) corresponding to amino acids 365-397 of T46984_PEA_—1_P32 (SEQ ID NO:671), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P32 (SEQ ID NO:671), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GQVRWLTPVIPALWEAKAGGSPEVRSSILAWPT (SEQ ID NO:951) in T46984_PEA_—1_P32 (SEQ ID NO:671).

Variant protein T46984_PEA_—1_P32 (SEQ ID NO:671) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 27, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P32 (SEQ ID NO:671) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 27


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> R	No
302	Q -> L	No
326	T -> P	No
330	D -> N	No
354	G -> V	Yes

The glycosylation sites of variant protein T46984_PEA_—1_P32 (SEQ ID NO:671), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 28 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 28


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P32 (SEQ ID NO:671) is encoded by the following transcript(s): T46984_PEA_—1_T40 (SEQ ID NO:605), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T40 (SEQ ID NO:605) is shown in bold; this coding portion starts at position 316 and ends at position 1506. The transcript also has the following SNPs as listed in Table 29 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P32 (SEQ ID NO:671) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 29


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1303	G -> A	No
1376	G -> T	Yes

Variant protein T46984_PEA_—1_P34 (SEQ ID NO:672) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T42 (SEQ ID NO:606). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P34 (SEQ ID NO:672) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P34 (SEQ ID NO:672), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQ PLTQATVKLEHAKSVASRATVLQKTSFTPVG corresponding to amino acids 1-329 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-329 of T46984_PEA_—1_P34 (SEQ ID NO:672).

Variant protein T46984_PEA_—1_P34 (SEQ ID NO:672) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 30, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P34 (SEQ ID NO:672) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 30


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
291	Q ->	No
291	Q -> P	No
302	Q -> L	No
302	Q -> R	No
326	T -> P	No

The glycosylation sites of variant protein T46984_PEA_—1_P34 (SEQ ID NO:672), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 31 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 31


Glycosylation site(s)

Position(s) on known	Present in	Position in
amino acid sequence	variant protein?	variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P34 (SEQ ID NO:672) is encoded by the following transcript(s): T46984_PEA_—1_T42 (SEQ ID NO:606), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T42 (SEQ ID NO:606) is shown in bold; this coding portion starts at position 316 and ends at position 1302. The transcript also has the following SNPs as listed in Table 32 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P34 (SEQ ID NO:672) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 32


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1187	A ->	No
1187	A -> C	No
1220	A -> G	No
1220	A -> T	No
1254	T -> G	No
1291	A -> C	No
1293	C -> G	No
1324	T -> C	Yes
1489	G -> A	Yes

Variant protein T46984_PEA_—1_P35 (SEQ ID NO:673) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T43 (SEQ ID NO:607). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P35 (SEQ ID NO:673) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P35 (SEQ ID NO:673), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLRSI VEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNA IFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAI corresponding to amino acids 1-287 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-287 of T46984_PEA_—1_P35 (SEQ ID NO:673), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GCWPSRQSREQHISSRRKMEILKTECQEKESRTIHSMRRKMEKKNFI (SEQ ID NO:952) corresponding to amino acids 288-334 of T46984_PEA_—1_P35 (SEQ ID NO:673), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P35 (SEQ ID NO:673), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


GCWPSRQSREQHISSRRKMEILKTECQEKESRTIHSMRRKMEKKNFI	(SEQ ID NO:952)

in T46984_PEA_1_P35.	(SEQ ID NO:673)

Variant protein T46984_PEA_—1_P35 (SEQ ID NO:673) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 33, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P35 (SEQ ID NO:673) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 33


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No
190	R ->	No
245	N ->	No
245	N -> D	No
251	E -> D	No
254	S -> N	Yes
320	T -> P	No
324	M -> L	No
329	E -> K	Yes
334	I -> V	No

The glycosylation sites of variant protein T46984_PEA_—1_P35 (SEQ ID NO:673), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 34 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 34


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P35 (SEQ ID NO:673) is encoded by the following transcript(s): T46984_PEA_—1_T43 (SEQ ID NO:607), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T43 (SEQ ID NO:607) is shown in bold; this coding portion starts at position 316 and ends at position 1317. The transcript also has the following SNPs as listed in Table 35 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P35 (SEQ ID NO:673) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 35


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
844	C -> T	Yes
857	-> G	No
885	C ->	No
897	-> G	No
1002	G -> A	No
1048	A ->	No
1048	A -> G	No
1068	A -> C	No
1076	G -> A	Yes
1240	C -> T	No
1273	A -> C	No
1285	A -> T	No
1300	G -> A	Yes
1306	-> A	No
1315	A -> G	No
1340	T -> G	No
1354	T -> A	No
1354	T -> G	No
1454	-> C	No
1463	T ->	No
1522	A -> C	No

Variant protein T46984_PEA_—1_P38 (SEQ ID NO:674) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T47 (SEQ ID NO:609). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P38 (SEQ ID NO:674) and RIB2_HUMAN (SEQ ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P38 (SEQ ID NO:674) comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEAL corresponding to amino acids 1-145 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-145 of T46984_PEA_—1_P38 (SEQ ID NO:674), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MDPDWCQCLQLHFCS (SEQ ID NO:953) corresponding to amino acids 146-160 of T46984_PEA_—1_P38 (SEQ ID NO:674), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of T46984_PEA_—1_P38 (SEQ ID NO:674), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MDPDWCQCLQLHFCS (SEQ ID NO:953) in T46984_PEA_—1_P38 (SEQ ID NO:674).

Variant protein T46984_PEA_—1_P38 (SEQ ID NO:674) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 36, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P38 (SEQ ID NO:674) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 36


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No

The glycosylation sites of variant protein T46984_PEA_—1_P38 (SEQ ID NO:674), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 37 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 37


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P38 (SEQ ID NO:674) is encoded by the following transcript(s): T46984_PEA_—1_T47 (SEQ ID NO:609), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T47 (SEQ ID NO:609) is shown in bold; this coding portion starts at position 316 and ends at position 795. The transcript also has the following SNPs as listed in Table 38 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_—PEA_—1_P38 (SEQ ID NO:674) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 38


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
879	C -> A	No
899	T -> C	Yes
993	C -> T	No
1026	A -> C	No
1038	A -> T	No
1053	G -> A	Yes
1059	-> A	No
1068	A -> G	No
1093	T -> G	No
1107	T -> A	No
1107	T -> G	No
1207	-> C	No
1216	T ->	No
1275	A -> C	No

Variant protein T46984_PEA_—1_P39 (SEQ ID NO:675) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T48 (SEQ ID NO:610). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P39 (SEQ ID NO:675) and RIB2_HUMAN (SEQ ID NO:663):

1.An isolated chimeric polypeptide encoding for T46984_PEA_—1_P39 (SEQ ID NO:675), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSS VTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLA corresponding to amino acids 1-160 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-160 of T46984_PEA_—1_P39 (SEQ ID NO:675).

Variant protein T46984_PEA_—1_P39 (SEQ ID NO:675) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 39, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P39 (SEQ ID NO:675) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 39


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes
135	F ->	No
137	L ->	No

The glycosylation sites of variant protein T46984_PEA_—1_P39 (SEQ ID NO:675), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 40 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 40


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

106	yes	106

Variant protein T46984_PEA_—1_P39 (SEQ ID NO:675) is encoded by the following transcript(s): T46984_PEA_—1_T48 (SEQ ID NO:610), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T48 (SEQ ID NO:610) is shown in bold; this coding portion starts at position 316 and ends at position 795. The transcript also has the following SNPs as listed in Table 41 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P39 (SEQ ID NO:675) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 41


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
718	T ->	No
724	C ->	No
848	G -> T	Yes
879	C -> G	Yes
1008	A -> G	Yes
1397	A -> G	Yes

Variant protein T46984_PEA_—1_P45 (SEQ ID NO:676) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T32 (SEQ ID NO:602). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P45 (SEQ ID NO:676) and RIB2_HUMAN (SEQ. ID NO:663):

1.An isolated chimeric polypeptide encoding for T46984_PEA_—1_P45 (SEQ ID NO:676), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCE corresponding to amino acids 1-101 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-101 of T46984_PEA_—1_P45 (SEQ ID NO:676), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) corresponding to amino acids 102-116 of T46984_PEA_—1_P45 (SEQ ID NO:676), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of T46984_PEA_—1_P45 (SEQ ID NO:676), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) in T46984_PEA_—1_P45 (SEQ ID NO:676).

Variant protein T46984_PEA_—1_P45 (SEQ ID NO:676) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 42, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P45 (SEQ ID NO:676) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 42


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	P ->	No
25	P -> R	Yes
99	G -> R	Yes

The glycosylation sites of variant protein T46984_PEA_—1_P45 (SEQ ID NO:676), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 43 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 43


Glycosylation site(s)

	Position(s) on known	Present in
	amino acid sequence	variant protein?

	106	no

Variant protein T46984_PEA_—1_P45 (SEQ ID NO:676) is encoded by the following transcript(s): T46984_PEA_—1_T32 (SEQ ID NO:602), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T32 (SEQ ID NO:602) is shown in bold; this coding portion starts at position 316 and ends at position 663. The transcript also has the following SNPs as listed in Table 44 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P45 (SEQ ID NO:676) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 44


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
610	G -> A	Yes
668	C -> T	Yes
681	-> G	No
709	C ->	No
721	-> G	No
826	G -> A	No
872	A ->	No
872	A -> G	No
892	A -> C	No
900	G -> A	Yes
1011	A ->	No
1011	A -> C	No
1044	A -> G	No
1044	A -> T	No
1078	T -> G	No
1115	A -> C	No
1117	C -> G	No
1127	G -> A	No
1200	G -> T	Yes
1412	A -> C	No
1442	T ->	No
1442	T -> C	No
1484	T ->	No
1517	A -> C	No
1517	A -> T	No
1748	C ->	No
1748	C -> A	No
1755	C ->	No
1759	G ->	No
1944	C -> A	No
1964	T -> C	Yes
2058	C -> T	No
2091	A -> C	No
2103	A -> T	No
2118	G -> A	Yes
2124	-> A	No
2133	A -> G	No
2158	T -> G	No
2172	T -> A	No
2172	T -> G	No
2272	-> C	No
2281	T ->	No
2340	A -> C	No

Variant protein T46984_PEA_—1_P46 (SEQ ID NO:677) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T46984_PEA_—1_T35 (SEQ ID NO:604). An alignment is given to the known protein (Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T46984_PEA_—1_P46 (SEQ ID NO:677) and RIB2_HUMAN (SEQ. ID NO:663):

1. An isolated chimeric polypeptide encoding for T46984_PEA_—1_P46 (SEQ ID NO:677), comprising a first amino acid sequence being at least 90% homologous to MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIVGLSSL GAQVPDAK corresponding to amino acids 1-69 of RIB2_HUMAN (SEQ ID NO:663), which also corresponds to amino acids 1-69 of T46984_PEA_—1_P46 (SEQ ID NO:677), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) corresponding to amino acids 70-84 of T46984_PEA_—1_P46 (SEQ ID NO:677), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of T46984_PEA_—1_P46 (SEQ ID NO:677), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NSPGSADSIPPVPAG (SEQ ID NO:954) in T46984_PEA_—1_P46 (SEQ ID NO:677).

Variant protein T46984_PEA_—1_P46 (SEQ ID NO:677) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 45, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P46 (SEQ ID NO:677) sequence provides support for the deduced sequence of this variant protein according to the present invention)

TABLE 45


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	P ->	No
25	P -> R	Yes

The glycosylation sites of variant protein T46984_PEA_—1_P46 (SEQ ID NO:677), as compared to the known protein Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 63 kDa subunit precursor (SEQ ID NO:663), are described in Table 46 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 46


Glycosylation site(s)

	Position(s) on known	Present in
	amino acid sequence	variant protein?

	106	no

Variant protein T46984_PEA_—1_P46 (SEQ ID NO:677) is encoded by the following transcript(s): T46984_PEA_—1_T35 (SEQ ID NO:604), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T46984_PEA_—1_T35 (SEQ ID NO:604) is shown in bold; this coding portion starts at position 316 and ends at position 567. The transcript also has the following SNPs as listed in Table 47 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T46984_PEA_—1_P46 (SEQ ID NO:677) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 47


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

28	G -> C	No
173	G -> C	Yes
256	C -> T	Yes
274	G -> C	Yes
325	C ->	No
389	C -> G	Yes
572	C -> T	Yes
585	-> G	No
613	C ->	No
625	-> G	No
730	G -> A	No
776	A ->	No
776	A -> G	No
796	A -> C	No
804	G -> A	Yes
915	A ->	No
915	A -> C	No
948	A -> G	No
948	A -> T	No
982	T -> G	No
1019	A -> C	No
1021	C -> G	No
1031	G -> A	No
1104	G -> T	Yes
1316	A -> C	No
1346	T ->	No
1346	T -> C	No
1388	T ->	No
1421	A -> C	No
1421	A -> T	No
1652	C ->	No
1652	C -> A	No
1659	C ->	No
1663	G ->	No
1848	C -> A	No
1868	T -> C	Yes
1962	C -> T	No
1995	A -> C	No
2007	A -> T	No
2022	G -> A	Yes
2028	-> A	No
2037	A -> G	No
2062	T -> G	No
2076	T -> A	No
2076	T -> G	No
2176	-> C	No
2185	T ->	No
2244	A -> C	No

As noted above, cluster T46984 features 49 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T46984_PEA_—1_node_—2 (SEQ ID NO:614) according to the present invention is supported by 240 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T48 (SEQ ID NO:610). Table 48 below describes the starting and ending position of this segment on each transcript.

TABLE 48


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1	328
T46984_PEA_1_T3 (SEQ ID NO: 594)	1	328
T46984_PEA_1_T12 (SEQ ID	1	328
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1	328
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1	328
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1	328
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1	328
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1	328
NO: 600)
T46984_PEA_1_T32 (SEQ ID	1	328
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1	328
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1	328
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1	328
NO: 605)
T46984_PEA_1_T42 (SEQ ID	1	328
NO: 606)
T46984_PEA_1_T43 (SEQ ID	1	328
NO: 607)
T46984_PEA_1_T47 (SEQ ID	1	328
NO: 609)
T46984_PEA_1_T48 (SEQ ID	1	328
NO: 610)

Segment cluster T46984_PEA_—1_node_—4 (SEQ ID NO:615) according to the present invention is supported by 321 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T48 (SEQ ID NO:610). Table 49 below describes the starting and ending position of this segment on each transcript.

TABLE 49


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	329	522
T46984_PEA_1_T3 (SEQ ID NO: 594)	329	522
T46984_PEA_1_T12 (SEQ ID	329	522
NO: 595)
T46984_PEA_1_T13 (SEQ ID	329	522
NO: 596)
T46984_PEA_1_T14 (SEQ ID	329	522
NO: 597)
T46984_PEA_1_T15 (SEQ ID	329	522
NO: 598)
T46984_PEA_1_T19 (SEQ ID	329	522
NO: 599)
T46984_PEA_1_T23 (SEQ ID	329	522
NO: 600)
T46984_PEA_1_T32 (SEQ ID	329	522
NO: 602)
T46984_PEA_1_T34 (SEQ ID	329	522
NO: 603)
T46984_PEA_1_T35 (SEQ ID	329	522
NO: 604)
T46984_PEA_1_T40 (SEQ ID	329	522
NO: 605)
T46984_PEA_1_T42 (SEQ ID	329	522
NO: 606)
T46984_PEA_1_T43 (SEQ ID	329	522
NO: 607)
T46984_PEA_1_T47 (SEQ ID	329	522
NO: 609)
T46984_PEA_1_T48 (SEQ ID	329	522
NO: 610)

Segment cluster T46984_PEA_—1_node_—6 (SEQ ID NO:616) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T27 (SEQ ID NO:601). Table 50 below describes the starting and ending position of this segment on each transcript.

TABLE 50


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T27 (SEQ ID	1	340
NO: 601)

Segment cluster T46984_PEA_—1_node_—12 (SEQ ID NO:617) according to the present invention is supported by 262 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T48 (SEQ ID NO:610). Table 51 below describes the starting and ending position of this segment on each transcript.

TABLE 51


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	619	751
T46984_PEA_1_T3 (SEQ ID NO: 594)	619	751
T46984_PEA_1_T12 (SEQ ID	619	751
NO: 595)
T46984_PEA_1_T13 (SEQ ID	619	751
NO: 596)
T46984_PEA_1_T14 (SEQ ID	619	751
NO: 597)
T46984_PEA_1_T15 (SEQ ID	619	751
NO: 598)
T46984_PEA_1_T19 (SEQ ID	619	751
NO: 599)
T46984_PEA_1_T23 (SEQ ID	619	751
NO: 600)
T46984_PEA_1_T27 (SEQ ID	437	569
NO: 601)
T46984_PEA_1_T34 (SEQ ID	619	751
NO: 603)
T46984_PEA_1_T40 (SEQ ID	619	751
NO: 605)
T46984_PEA_1_T42 (SEQ ID	619	751
NO: 606)
T46984_PEA_1_T43 (SEQ ID	619	751
NO: 607)
T46984_PEA_1_T47 (SEQ ID	619	751
NO: 609)
T46984_PEA_1_T48 (SEQ ID	619	751
NO: 610)

Segment cluster T46984_PEA_—1_node_—14 (SEQ ID NO:618) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T48 (SEQ ID NO:610). Table 52 below describes the starting and ending position of this segment on each transcript.

TABLE 52


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T48 (SEQ ID	795	1718
NO: 610)

Segment cluster T46984_PEA_—1_node_—25 (SEQ ID NO:619) according to the present invention is supported by 257 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606) and T46984_PEA_—1_T43 (SEQ ID NO:607). Table 53 below describes the starting and ending position of this segment on each transcript.

TABLE 53


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1006	1171
T46984_PEA_1_T3 (SEQ ID NO: 594)	1006	1171
T46984_PEA_1_T12 (SEQ ID	1006	1171
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1006	1171
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1006	1171
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1006	1171
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1006	1171
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1006	1171
NO: 600)
T46984_PEA_1_T27 (SEQ ID	824	989
NO: 601)
T46984_PEA_1_T32 (SEQ ID	830	995
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1006	1171
NO: 603)
T46984_PEA_1_T35 (SEQ ID	734	899
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1006	1171
NO: 605)
T46984_PEA_1_T42 (SEQ ID	1006	1171
NO: 606)
T46984_PEA_1_T43 (SEQ ID	1006	1171
NO: 607)

Segment cluster T46984_PEA_—1_node_—29 (SEQ ID NO:620) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T42 (SEQ ID NO:606). Table 54 below describes the starting and ending position of this segment on each transcript.

TABLE 54


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T42 (SEQ ID	1302	1501
NO: 606)

Segment cluster T46984_PEA_—1_node_—34 (SEQ ID NO:621) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T40 (SEQ ID NO:605). Table 55 below describes the starting and ending position of this segment on each transcript.

TABLE 55


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T40 (SEQ ID	1408	1717
NO: 605)

Segment cluster T46984_PEA_—1_node_—46 (SEQ ID NO:622) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T46 (SEQ ID NO:608). Table 56 below describes the starting and ending position of this segment on each transcript.

TABLE 56


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T46 (SEQ ID	1	306
NO: 608)

Segment cluster T46984_PEA_—1_node_—47 (SEQ ID NO:623) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T19 (SEQ ID NO:599) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 57 below describes the starting and ending position of this segment on each transcript.

TABLE 57


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T3 (SEQ ID NO: 594)	1615	2242
T46984_PEA_1_T19 (SEQ ID	1615	2242
NO: 599)
T46984_PEA_1_T46 (SEQ ID	307	934
NO: 608)

Segment cluster T46984_PEA_—1_node_—52 (SEQ ID NO:624) according to the present invention is supported by 29 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T19 (SEQ ID NO:599) and T46984_PEA_—1_T23 (SEQ ID NO:600). Table 58 below describes the starting and ending position of this segment on each transcript.

TABLE 58


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1838	2904
T46984_PEA_1_T19 (SEQ ID	2466	3532
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1838	2904
NO: 600)

Segment cluster T46984_PEA_—1_node_—65 (SEQ ID NO:625) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T51 (SEQ ID NO:611). Table 59 below describes the starting and ending position of this segment on each transcript.

TABLE 59


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T51 (SEQ ID	1	348
NO: 611)

Segment cluster T46984_PEA_—1_node_—69 (SEQ ID NO:626) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 60 below describes the starting and ending position of this segment on each transcript.

TABLE 60


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T52 (SEQ ID	1	927
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1	927
NO: 613)

Segment cluster T46984_PEA_—1_node_—75 (SEQ ID NO:627) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T14 (SEQ ID NO:597). Table 61 below describes the starting and ending position of this segment on each transcript.

TABLE 61


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T14 (SEQ ID	2199	3529
NO: 597)

Segment cluster T46984_PEA_—1_node_—86 (SEQ ID NO:628) according to the present invention is supported by 314 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 62 below describes the starting and ending position of this segment on each transcript.

TABLE 62


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3492	3750
T46984_PEA_1_T3 (SEQ ID NO: 594)	2886	3144
T46984_PEA_1_T12 (SEQ ID	2286	2544
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2317	2575
NO: 596)
T46984_PEA_1_T15 (SEQ ID	2175	2433
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4120	4378
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3396	3654
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2076	2334
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2082	2340
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1828	2086
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1986	2244
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1264	1522
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1578	1836
NO: 608)
T46984_PEA_1_T47 (SEQ ID	1017	1275
NO: 609)
T46984_PEA_1_T51 (SEQ ID	614	872
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1117	1375
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1117	1602
NO: 613)

Segment cluster T46984_PEA_—1_node_—9 (SEQ ID NO:629) according to the present invention is supported by 304 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T48 (SEQ ID NO:610). Table 63 below describes the starting and ending position of this segment on each transcript.

TABLE 63


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	523	618
T46984_PEA_1_T3 (SEQ ID NO: 594)	523	618
T46984_PEA_1_T12 (SEQ ID	523	618
NO: 595)
T46984_PEA_1_T13 (SEQ ID	523	618
NO: 596)
T46984_PEA_1_T14 (SEQ ID	523	618
NO: 597)
T46984_PEA_1_T15 (SEQ ID	523	618
NO: 598)
T46984_PEA_1_T19 (SEQ ID	523	618
NO: 599)
T46984_PEA_1_T23 (SEQ ID	523	618
NO: 600)
T46984_PEA_1_T27 (SEQ ID	341	436
NO: 601)
T46984_PEA_1_T32 (SEQ ID	523	618
NO: 602)
T46984_PEA_1_T34 (SEQ ID	523	618
NO: 603)
T46984_PEA_1_T40 (SEQ ID	523	618
NO: 605)
T46984_PEA_1_T42 (SEQ ID	523	618
NO: 606)
T46984_PEA_1_T43 (SEQ ID	523	618
NO: 607)
T46984_PEA_1_T47 (SEQ ID	523	618
NO: 609)
T46984_PEA_1_T48 (SEQ ID	523	618
NO: 610)

Segment cluster T46984_PEA_—1_node_—13 (SEQ ID NO:630) according to the present invention is supported by 232 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606), T46984_PEA_—1_T43 (SEQ ID NO:607) and T46984_PEA_—1_T48 (SEQ ID NO:610). Table 64 below describes the starting and ending position of this segment on each transcript.

TABLE 64


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	752	794
T46984_PEA_1_T3 (SEQ ID NO: 594)	752	794
T46984_PEA_1_T12 (SEQ ID	752	794
NO: 595)
T46984_PEA_1_T13 (SEQ ID	752	794
NO: 596)
T46984_PEA_1_T14 (SEQ ID	752	794
NO: 597)
T46984_PEA_1_T15 (SEQ ID	752	794
NO: 598)
T46984_PEA_1_T19 (SEQ ID	752	794
NO: 599)
T46984_PEA_1_T23 (SEQ ID	752	794
NO: 600)
T46984_PEA_1_T27 (SEQ ID	570	612
NO: 601)
T46984_PEA_1_T34 (SEQ ID	752	794
NO: 603)
T46984_PEA_1_T40 (SEQ ID	752	794
NO: 605)
T46984_PEA_1_T42 (SEQ ID	752	794
NO: 606)
T46984_PEA_1_T43 (SEQ ID	752	794
NO: 607)
T46984_PEA_1_T48 (SEQ ID	752	794
NO: 610)

Segment cluster T46984_PEA_—1_node_—19 (SEQ ID NO:631) according to the present invention is supported by 237 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606) and T46984_PEA_—1_T43 (SEQ ID NO:607). Table 65 below describes the starting and ending position of this segment on each transcript.

TABLE 65


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	795	870
T46984_PEA_1_T3 (SEQ ID NO: 594)	795	870
T46984_PEA_1_T12 (SEQ ID	795	870
NO: 595)
T46984_PEA_1_T13 (SEQ ID	795	870
NO: 596)
T46984_PEA_1_T14 (SEQ ID	795	870
NO: 597)
T46984_PEA_1_T15 (SEQ ID	795	870
NO: 598)
T46984_PEA_1_T19 (SEQ ID	795	870
NO: 599)
T46984_PEA_1_T23 (SEQ ID	795	870
NO: 600)
T46984_PEA_1_T27 (SEQ ID	613	688
NO: 601)
T46984_PEA_1_T32 (SEQ ID	619	694
NO: 602)
T46984_PEA_1_T34 (SEQ ID	795	870
NO: 603)
T46984_PEA_1_T35 (SEQ ID	523	598
NO: 604)
T46984_PEA_1_T40 (SEQ ID	795	870
NO: 605)
T46984_PEA_1_T42 (SEQ ID	795	870
NO: 606)
T46984_PEA_1_T43 (SEQ ID	795	870
NO: 607)

Segment cluster T46984_PEA_—1_node_—21 (SEQ ID NO:632) according to the present invention is supported by 242 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606) and T46984_PEA_—1_T43 (SEQ ID NO:607). Table 66 below describes the starting and ending position of this segment on each transcript.

TABLE 66


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	871	975
T46984_PEA_1_T3 (SEQ ID NO: 594)	871	975
T46984_PEA_1_T12 (SEQ ID	871	975
NO: 595)
T46984_PEA_1_T13 (SEQ ID	871	975
NO: 596)
T46984_PEA_1_T14 (SEQ ID	871	975
NO: 597)
T46984_PEA_1_T15 (SEQ ID	871	975
NO: 598)
T46984_PEA_1_T19 (SEQ ID	871	975
NO: 599)
T46984_PEA_1_T23 (SEQ ID	871	975
NO: 600)
T46984_PEA_1_T27 (SEQ ID	689	793
NO: 601)
T46984_PEA_1_T32 (SEQ ID	695	799
NO: 602)
T46984_PEA_1_T34 (SEQ ID	871	975
NO: 603)
T46984_PEA_1_T35 (SEQ ID	599	703
NO: 604)
T46984_PEA_1_T40 (SEQ ID	871	975
NO: 605)
T46984_PEA_1_T42 (SEQ ID	871	975
NO: 606)
T46984_PEA_1_T43 (SEQ ID	871	975
NO: 607)

Segment cluster T46984_PEA_—1_node_—22 (SEQ ID NO:633) according to the present invention is supported by 205 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605), T46984_PEA_—1_T42 (SEQ ID NO:606) and T46984_PEA_—1_T43 (SEQ ID NO:607). Table 67 below describes the starting and ending position of this segment on each transcript.

TABLE 67


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	976	1005
T46984_PEA_1_T3 (SEQ ID NO: 594)	976	1005
T46984_PEA_1_T12 (SEQ ID	976	1005
NO: 595)
T46984_PEA_1_T13 (SEQ ID	976	1005
NO: 596)
T46984_PEA_1_T14 (SEQ ID	976	1005
NO: 597)
T46984_PEA_1_T15 (SEQ ID	976	1005
NO: 598)
T46984_PEA_1_T19 (SEQ ID	976	1005
NO: 599)
T46984_PEA_1_T23 (SEQ ID	976	1005
NO: 600)
T46984_PEA_1_T27 (SEQ ID	794	823
NO: 601)
T46984_PEA_1_T32 (SEQ ID	800	829
NO: 602)
T46984_PEA_1_T34 (SEQ ID	976	1005
NO: 603)
T46984_PEA_1_T35 (SEQ ID	704	733
NO: 604)
T46984_PEA_1_T40 (SEQ ID	976	1005
NO: 605)
T46984_PEA_1_T42 (SEQ ID	976	1005
NO: 606)
T46984_PEA_1_T43 (SEQ ID	976	1005
NO: 607)

Segment cluster T46984_PEA_—1_node_—26 (SEQ ID NO:634) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605) and T46984_PEA_—1_T42 (SEQ ID NO:606). Table 68 below describes the starting and ending position of this segment on each transcript.

TABLE 68


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1172	1182
T46984_PEA_1_T3 (SEQ ID NO: 594)	1172	1182
T46984_PEA_1_T12 (SEQ ID	1172	1182
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1172	1182
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1172	1182
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1172	1182
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1172	1182
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1172	1182
NO: 600)
T46984_PEA_1_T27 (SEQ ID	990	1000
NO: 601)
T46984_PEA_1_T32 (SEQ ID	996	1006
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1172	1182
NO: 603)
T46984_PEA_1_T35 (SEQ ID	900	910
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1172	1182
NO: 605)
T46984_PEA_1_T42 (SEQ ID	1172	1182
NO: 606)

Segment cluster T46984_PEA_—1_node_—28 (SEQ ID NO:635) according to the present invention is supported by 242 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T40 (SEQ ID NO:605) and T46984_PEA_—1_T42 (SEQ ID NO:606). Table 69 below describes the starting and ending position of this segment on each transcript.

TABLE 69


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1183	1301
T46984_PEA_1_T3 (SEQ ID NO: 594)	1183	1301
T46984_PEA_1_T12 (SEQ ID	1183	1301
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1183	1301
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1183	1301
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1183	1301
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1183	1301
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1183	1301
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1001	1119
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1007	1125
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1183	1301
NO: 603)
T46984_PEA_1_T35 (SEQ ID	911	1029
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1183	1301
NO: 605)
T46984_PEA_1_T42 (SEQ ID	1183	1301
NO: 606)

Segment cluster T46984_PEA_—1_node_—31 (SEQ ID NO:636) according to the present invention is supported by 207 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T40 (SEQ ID NO:605). Table 70 below describes the starting and ending position of this segment on each transcript.

TABLE 70


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1302	1329
T46984_PEA_1_T3 (SEQ ID NO: 594)	1302	1329
T46984_PEA_1_T12 (SEQ ID	1302	1329
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1302	1329
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1302	1329
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1302	1329
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1302	1329
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1302	1329
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1120	1147
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1126	1153
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1302	1329
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1030	1057
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1302	1329
NO: 605)

Segment cluster T46984_PEA_—1_node_—32 (SEQ ID NO:637) according to the present invention is supported by 226 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T40 (SEQ ID NO:605). Table 71 below describes the starting and ending position of this segment on each transcript.

TABLE 71


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1330	1407
T46984_PEA_1_T3 (SEQ ID NO: 594)	1330	1407
T46984_PEA_1_T12 (SEQ ID	1330	1407
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1330	1407
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1330	1407
NO: 597)
T46984_PEA_1_T19 (SEQ ID	1330	1407
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1330	1407
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1148	1225
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1154	1231
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1330	1407
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1058	1135
NO: 604)
T46984_PEA_1_T40 (SEQ ID	1330	1407
NO: 605)

Segment cluster T46984_PEA_—1_node_—38 (SEQ ID NO:638) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603) and T46984_PEA_—1_T35 (SEQ ID NO:604). Table 72 below describes the starting and ending position of this segment on each transcript.

TABLE 72


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1408	1412
T46984_PEA_1_T3 (SEQ ID NO: 594)	1408	1412
T46984_PEA_1_T12 (SEQ ID	1408	1412
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1408	1412
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1408	1412
NO: 597)
T46984_PEA_1_T19 (SEQ ID	1408	1412
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1408	1412
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1226	1230
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1232	1236
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1408	1412
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1136	1140
NO: 604)

Segment cluster T46984_PEA_—1_node_—39 (SEQ ID NO:639) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603) and T46984_PEA_—1_T35 (SEQ ID NO:604). Table 73 below describes the starting and ending position of this segment on each transcript.

TABLE 73


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1413	1435
T46984_PEA_1_T3 (SEQ ID NO: 594)	1413	1435
T46984_PEA_1_T12 (SEQ ID	1413	1435
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1413	1435
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1413	1435
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1330	1352
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1413	1435
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1413	1435
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1231	1253
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1237	1259
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1413	1435
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1141	1163
NO: 604)

Segment cluster T46984_PEA_—1_node_—40 (SEQ ID NO:640) according to the present invention is supported by 227 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603) and T46984_PEA_—1_T35 (SEQ ID NO:604). Table 74 below describes the starting and ending position of this segment on each transcript.

TABLE 74


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1436	1499
T46984_PEA_1_T3 (SEQ ID NO: 594)	1436	1499
T46984_PEA_1_T12 (SEQ ID	1436	1499
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1436	1499
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1436	1499
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1353	1416
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1436	1499
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1436	1499
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1254	1317
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1260	1323
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1436	1499
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1164	1227
NO: 604)

Segment cluster T46984_PEA_—1_node_—42 (SEQ ID NO:641) according to the present invention is supported by 239 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603) and T46984_PEA_—1_T35 (SEQ ID NO:604). Table 75 below describes the starting and ending position of this segment on each transcript.

TABLE 75


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1500	1562
T46984_PEA_1_T3 (SEQ ID NO: 594)	1500	1562
T46984_PEA_1_T12 (SEQ ID	1500	1562
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1500	1562
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1500	1562
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1417	1479
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1500	1562
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1500	1562
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1318	1380
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1324	1386
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1500	1562
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1228	1290
NO: 604)

Segment cluster T46984_PEA_—1_node_—43 (SEQ ID NO:642) according to the present invention is supported by 235 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602) and T46984_PEA_—1_T35 (SEQ ID NO:604). Table 76 below describes the starting and ending position of this segment on each transcript.

TABLE 76


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1563	1614
T46984_PEA_1_T3 (SEQ ID NO: 594)	1563	1614
T46984_PEA_1_T12 (SEQ ID	1563	1614
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1563	1614
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1563	1614
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1480	1531
NO: 598)
T46984_PEA_1_T19 (SEQ ID	1563	1614
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1563	1614
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1381	1432
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1387	1438
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1291	1342
NO: 604)

Segment cluster T46984_PEA_—1_node_—48 (SEQ ID NO:643) according to the present invention is supported by 282 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 77 below describes the starting and ending position of this segment on each transcript.

TABLE 77


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1615	1715
T46984_PEA_1_T3 (SEQ ID NO: 594)	2243	2343
T46984_PEA_1_T12 (SEQ ID	1615	1715
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1615	1715
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1615	1715
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1532	1632
NO: 598)
T46984_PEA_1_T19 (SEQ ID	2243	2343
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1615	1715
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1433	1533
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1439	1539
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1343	1443
NO: 604)
T46984_PEA_1_T46 (SEQ ID	935	1035
NO: 608)

Segment cluster T46984_PEA_—1_node_—49 (SEQ ID NO:644) according to the present invention is supported by 262 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 78 below describes the starting and ending position of this segment on each transcript.

TABLE 78


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1716	1757
T46984_PEA_1_T3 (SEQ ID NO: 594)	2344	2385
T46984_PEA_1_T12 (SEQ ID	1716	1757
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1716	1757
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1716	1757
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1633	1674
NO: 598)
T46984_PEA_1_T19 (SEQ ID	2344	2385
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1716	1757
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1534	1575
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1540	1581
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1444	1485
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1036	1077
NO: 608)

Segment cluster T46984_PEA_—1_node_—50 (SEQ ID NO:645) according to the present invention is supported by 277 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 79 below describes the starting and ending position of this segment on each transcript.

TABLE 79


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1758	1809
T46984_PEA_1_T3 (SEQ ID NO: 594)	2386	2437
T46984_PEA_1_T12 (SEQ ID	1758	1809
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1758	1809
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1758	1809
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1675	1726
NO: 598)
T46984_PEA_1_T19 (SEQ ID	2386	2437
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1758	1809
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1576	1627
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1582	1633
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1486	1537
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1078	1129
NO: 608)

Segment cluster T46984_PEA_—1_node_—51 (SEQ ID NO:646) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T19 (SEQ ID NO:599) and T46984_PEA_—1_T23 (SEQ ID NO:600). Table 80 below describes the starting and ending position of this segment on each transcript.

TABLE 80


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	1810	1837
T46984_PEA_1_T12 (SEQ ID	1810	1837
NO: 595)
T46984_PEA_1_T19 (SEQ ID	2438	2465
NO: 599)
T46984_PEA_1_T23 (SEQ ID	1810	1837
NO: 600)

Segment cluster T46984_PEA_—1_node_—53 (SEQ ID NO:647) according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T19 (SEQ ID NO:599) and T46984_PEA_—1T23 (SEQ ID NO:600). Table 81 below describes the starting and ending position of this segment on each transcript.

TABLE 81


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	2905	2963
T46984_PEA_1_T13 (SEQ ID	1810	1868
NO: 596)
T46984_PEA_1_T19 (SEQ ID	3533	3591
NO: 599)
T46984_PEA_1_T23 (SEQ ID	2905	2963
NO: 600)

Segment cluster T46984_PEA_—1_node_—54 (SEQ ID NO:648) according to the present invention is supported by 18 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T19 (SEQ ID NO:599) and T46984_PEA_—1_T23 (SEQ ID NO:600). Table 82 below describes the starting and ending position of this segment on each transcript.

TABLE 82


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	2964	3043
T46984_PEA_1_T19 (SEQ ID	3592	3671
NO: 599)
T46984_PEA_1_T23 (SEQ ID	2964	3043
NO: 600)

Segment cluster T46984_PEA_—1_node_—55 (SEQ ID NO:649) according to the present invention is supported by 335 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_—T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 83 below describes the starting and ending position of this segment on each transcript.

TABLE 83


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3044	3110
T46984_PEA_1_T3 (SEQ ID NO: 594)	2438	2504
T46984_PEA_1_T12 (SEQ ID	1838	1904
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1869	1935
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1810	1876
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1727	1793
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3672	3738
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3044	3110
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1628	1694
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1634	1700
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1538	1604
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1130	1196
NO: 608)

Segment cluster T46984_PEA_—1_node_—57 (SEQ ID NO:650) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 84 below describes the starting and ending position of this segment on each transcript.

TABLE 84


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3111	3130
T46984_PEA_1_T3 (SEQ ID NO: 594)	2505	2524
T46984_PEA_1_T12 (SEQ ID	1905	1924
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1936	1955
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1877	1896
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1794	1813
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3739	3758
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3111	3130
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1695	1714
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1701	1720
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1605	1624
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1197	1216
NO: 608)

Segment cluster T46984_PEA_—1_node_—60 (SEQ ID NO:651) according to the present invention is supported by 326 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 85 below describes the starting and ending position of this segment on each transcript.

TABLE 85


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3131	3165
T46984_PEA_1_T3 (SEQ ID NO: 594)	2525	2559
T46984_PEA_1_T12 (SEQ ID	1925	1959
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1956	1990
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1897	1931
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1814	1848
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3759	3793
NO: 599)
T46984_PEA_1_T27 (SEQ ID	1715	1749
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1721	1755
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1625	1659
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1217	1251
NO: 608)

Segment cluster T46984_PEA_—1_node_—62 (SEQ ID NO:652) according to the present invention is supported by 335 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T35 (SEQ ID NO:604) and T46984_PEA_—1_T46 (SEQ ID NO:608). Table 86 below describes the starting and ending position of this segment on each transcript.

TABLE 86


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3166	3226
T46984_PEA_1_T3 (SEQ ID NO: 594)	2560	2620
T46984_PEA_1_T12 (SEQ ID	1960	2020
NO: 595)
T46984_PEA_1_T13 (SEQ ID	1991	2051
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1932	1992
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1849	1909
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3794	3854
NO: 599)
T46984_PEA_1_T27 (SEQ ID	1750	1810
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1756	1816
NO: 602)
T46984_PEA_1_T35 (SEQ ID	1660	1720
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1252	1312
NO: 608)

Segment cluster T46984_PEA_—1_node_—66 (SEQ ID NO:653) according to the present invention is supported by 336 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T51 (SEQ ID NO:611). Table 87 below describes the starting and ending position of this segment on each transcript.

TABLE 87


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3227	3261
T46984_PEA_1_T3 (SEQ ID NO: 594)	2621	2655
T46984_PEA_1_T12 (SEQ ID	2021	2055
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2052	2086
NO: 596)
T46984_PEA_1_T14 (SEQ ID	1993	2027
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1910	1944
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3855	3889
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3131	3165
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1811	1845
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1817	1851
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1563	1597
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1721	1755
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1313	1347
NO: 608)
T46984_PEA_1_T47 (SEQ ID	752	786
NO: 609)
T46984_PEA_1_T51 (SEQ ID	349	383
NO: 611)

Segment cluster T46984_PEA_—1_node_—67 (SEQ ID NO:654) according to the present invention is supported by 323 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609) and T46984_PEA_—1_T51 (SEQ ID NO:611). Table 88 below describes the starting and ending position of this segment on each transcript.

TABLE 88


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3262	3302
T46984_PEA_1_T3 (SEQ ID NO: 594)	2656	2696
T46984_PEA_1_T12 (SEQ ID	2056	2096
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2087	2127
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2028	2068
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1945	1985
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3890	3930
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3166	3206
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1846	1886
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1852	1892
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1598	1638
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1756	1796
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1348	1388
NO: 608)
T46984_PEA_1_T47 (SEQ ID	787	827
NO: 609)
T46984_PEA_1_T51 (SEQ ID	384	424
NO: 611)

Segment cluster T46984_PEA_—1_node_—70 (SEQ ID NO:655) according to the present invention is supported by 337 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 89 below describes the starting and ending position of this segment on each transcript.

TABLE 89


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3303	3377
T46984_PEA_1_T3 (SEQ ID NO: 594)	2697	2771
T46984_PEA_1_T12 (SEQ ID	2097	2171
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2128	2202
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2069	2143
NO: 597)
T46984_PEA_1_T15 (SEQ ID	1986	2060
NO: 598)
T46984_PEA_1_T19 (SEQ ID	3931	4005
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3207	3281
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1887	1961
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1893	1967
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1639	1713
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1797	1871
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1389	1463
NO: 608)
T46984_PEA_1_T47 (SEQ ID	828	902
NO: 609)
T46984_PEA_1_T51 (SEQ ID	425	499
NO: 611)
T46984_PEA_1_T52 (SEQ ID	928	1002
NO: 612)
T46984_PEA_1_T54 (SEQ ID	928	1002
NO: 613)

Segment cluster T46984_PEA_—1_node_—71 (SEQ ID NO:656) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 90 below describes the starting and ending position of this segment on each transcript.

TABLE 90


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3378	3399
T46984_PEA_1_T3 (SEQ ID NO: 594)	2772	2793
T46984_PEA_1_T12 (SEQ ID	2172	2193
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2203	2224
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2144	2165
NO: 597)
T46984_PEA_1_T15 (SEQ ID	2061	2082
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4006	4027
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3282	3303
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1962	1983
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1968	1989
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1714	1735
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1872	1893
NO: 604)
T46984_PEA_1_T46 (SEQ ID	1464	1485
NO: 608)
T46984_PEA_1_T47 (SEQ ID	903	924
NO: 609)
T46984_PEA_1_T51 (SEQ ID	500	521
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1003	1024
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1003	1024
NO: 613)

Segment cluster T46984_PEA_—1_node_—72 (SEQ ID NO:657) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 91 below describes the starting and ending position of this segment on each transcript.

TABLE 91


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T46984_PEA_1_T2 (SEQ ID NO: 593)	3400	3421
T46984_PEA_1_T3 (SEQ ID NO: 594)	2794	2815
T46984_PEA_1_T12 (SEQ ID	2194	2215
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2225	2246
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2166	2187
NO: 597)
T46984_PEA_1_T15 (SEQ ID	2083	2104
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4028	4049
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3304	3325
NO: 600)
T46984_PEA_1_T27 (SEQ ID	1984	2005
NO: 601)
T46984_PEA_1_T32 (SEQ ID	1990	2011
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1736	1757
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1894	1915
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1172	1193
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1486	1507
NO: 608)
T46984_PEA_1_T47 (SEQ ID	925	946
NO: 609)
T46984_PEA_1_T51 (SEQ ID	522	543
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1025	1046
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1025	1046
NO: 613)

Segment cluster T46984_PEA_—1_node_—73 (SEQ ID NO:658) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 92 below describes the starting and ending position of this segment on each transcript.

TABLE 92


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T2	3422	3428
(SEQ ID NO: 593)
T46984_PEA_1_T3	2816	2822
(SEQ ID NO: 594)
T46984_PEA_1_T12 (SEQ ID	2216	2222
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2247	2253
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2188	2194
NO: 597)
T46984_PEA_1_T15 (SEQ ID	2105	2111
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4050	4056
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3326	3332
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2006	2012
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2012	2018
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1758	1764
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1916	1922
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1194	1200
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1508	1514
NO: 608)
T46984_PEA_1_T47 (SEQ ID	947	953
NO: 609)
T46984_PEA_1_T51 (SEQ ID	544	550
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1047	1053
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1047	1053
NO: 613)

Segment cluster T46984_PEA_—1_node_—74 (SEQ ID NO:659) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T14 (SEQ ID NO:597), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 93 below describes the starting and ending position of this segment on each transcript.

TABLE 93


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T2	3429	3432
(SEQ ID NO: 593)
T46984_PEA_1_T3	2823	2826
(SEQ ID NO: 594)
T46984_PEA_1_T12 (SEQ ID	2223	2226
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2254	2257
NO: 596)
T46984_PEA_1_T14 (SEQ ID	2195	2198
NO: 597)
T46984_PEA_1_T15 (SEQ ID	2112	2115
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4057	4060
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3333	3336
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2013	2016
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2019	2022
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1765	1768
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1923	1926
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1201	1204
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1515	1518
NO: 608)
T46984_PEA_1_T47 (SEQ ID	954	957
NO: 609)
T46984_PEA_1_T51 (SEQ ID	551	554
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1054	1057
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1054	1057
NO: 613)

Segment cluster T46984_PEA_—1_node_—83 (SEQ ID NO:660) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 94 below describes the starting and ending position of this segment on each transcript.

TABLE 94


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T2 (SEQ ID NO:	3433	3437
593)
T46984_PEA_1_T3 (SEQ ID NO:	2827	2831
594)
T46984_PEA_1_T12 (SEQ ID	2227	2231
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2258	2262
NO: 596)
T46984_PEA_1_T15 (SEQ ID	2116	2120
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4061	4065
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3337	3341
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2017	2021
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2023	2027
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1769	1773
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1927	1931
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1205	1209
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1519	1523
NO: 608)
T46984_PEA_1_T47 (SEQ ID	958	962
NO: 609)
T46984_PEA_1_T51 (SEQ ID	555	559
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1058	1062
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1058	1062
NO: 613)

Segment cluster T46984_PEA_—1_node_—84 (SEQ ID NO:661) according to the present invention can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 95 below describes the starting and ending position of this segment on each transcript.

TABLE 95


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T2 (SEQ ID NO:	3438	3451
593)
T46984_PEA_1_T3 (SEQ ID NO:	2832	2845
594)
T46984_PEA_1_T12 (SEQ ID	2232	2245
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2263	2276
NO: 596)
T46984_PEA_1_T15 (SEQ ID	2121	2134
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4066	4079
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3342	3355
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2022	2035
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2028	2041
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1774	1787
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1932	1945
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1210	1223
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1524	1537
NO: 608)
T46984_PEA_1_T47 (SEQ ID	963	976
NO: 609)
T46984_PEA_1_T51 (SEQ ID	560	573
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1063	1076
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1063	1076
NO: 613)

Segment cluster T46984_PEA_—1_node_—85 (SEQ ID NO:662) according to the present invention is supported by 295 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T46984_PEA_—1_T2 (SEQ ID NO:593), T46984_PEA_—1_T3 (SEQ ID NO:594), T46984_PEA_—1_T12 (SEQ ID NO:595), T46984_PEA_—1_T13 (SEQ ID NO:596), T46984_PEA_—1_T15 (SEQ ID NO:598), T46984_PEA_—1_T19 (SEQ ID NO:599), T46984_PEA_—1_T23 (SEQ ID NO:600), T46984_PEA_—1_T27 (SEQ ID NO:601), T46984_PEA_—1_T32 (SEQ ID NO:602), T46984_PEA_—1_T34 (SEQ ID NO:603), T46984_PEA_—1_T35 (SEQ ID NO:604), T46984_PEA_—1_T43 (SEQ ID NO:607), T46984_PEA_—1_T46 (SEQ ID NO:608), T46984_PEA_—1_T47 (SEQ ID NO:609), T46984_PEA_—1_T51 (SEQ ID NO:611), T46984_PEA_—1_T52 (SEQ ID NO:612) and T46984_PEA_—1_T54 (SEQ ID NO:613). Table 96 below describes the starting and ending position of this segment on each transcript.

TABLE 96


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T46984_PEA_1_T2 (SEQ ID NO:	3452	3491
593)
T46984_PEA_1_T3 (SEQ ID NO:	2846	2885
594)
T46984_PEA_1_T12 (SEQ ID	2246	2285
NO: 595)
T46984_PEA_1_T13 (SEQ ID	2277	2316
NO: 596)
T46984_PEA_1_T15 (SEQ ID	2135	2174
NO: 598)
T46984_PEA_1_T19 (SEQ ID	4080	4119
NO: 599)
T46984_PEA_1_T23 (SEQ ID	3356	3395
NO: 600)
T46984_PEA_1_T27 (SEQ ID	2036	2075
NO: 601)
T46984_PEA_1_T32 (SEQ ID	2042	2081
NO: 602)
T46984_PEA_1_T34 (SEQ ID	1788	1827
NO: 603)
T46984_PEA_1_T35 (SEQ ID	1946	1985
NO: 604)
T46984_PEA_1_T43 (SEQ ID	1224	1263
NO: 607)
T46984_PEA_1_T46 (SEQ ID	1538	1577
NO: 608)
T46984_PEA_1_T47 (SEQ ID	977	1016
NO: 609)
T46984_PEA_1_T51 (SEQ ID	574	613
NO: 611)
T46984_PEA_1_T52 (SEQ ID	1077	1116
NO: 612)
T46984_PEA_1_T54 (SEQ ID	1077	1116
NO: 613)

Variant protein alignment to the previously known protein:

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P2 (SEQ ID NO:664)×RIB2_HUMAN (SEQ ID NO:663)

Alignment segment 1/1:



Quality:	4716.00
Escore:	0
Matching length:	498	Total length:	498
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · · · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300

	· · · · ·
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350

	· · · · ·
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400

	· · · · ·
401	KAKGTFIADSHQNFALFFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFV	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	KAKGTFIADSHQNFALFFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFV	450

	· · · ·
451	AEPDNKNVYKFELDTSERKIEFDSASGTYTLYLIIGDATLKNPILWNV	498
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	AEPDNKNVYKFELDTSERKIEFDSASGTYTLYLIIGDATLKNPILWNV	498

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P3 (SEQ ID NO:665)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	4085.00
Escore:	0
Matching length:	433	Total length:	433
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P10 (SEQ ID NO:666)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	4716.00
Escore:	0
Matching length:	498	Total length:	498
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · · · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300

	· · · · ·
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350

	· · · · ·
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400

	· · · · ·
401	KAKGTFIADSHQNFALFFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFV	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	KAKGTFIADSHQNFALFFQLVDVNTGAELTPHQTFVRLHNQKTGQEVVFV	450

	· · · ·
451	AEPDNKNVYKFELDTSERKIEFDSASGTYTLYLIIGDATLKNPILWNV	498
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	AEPDNKNVYKFELDTSERKIEFDSASGTYTLYLIIGDATLKNPILWNV	498

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P11 (SEQ ID NO:667)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	5974.00
Escore:	0
Matching length:	628	Total length:	628
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P12 (SEQ ID NO:668)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	3179.00
Escore:	0
Matching length:	338	Total length:	338
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P21 (SEQ ID NO:669)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	5348.00
Escore:	0
Matching length:	562	Total length:	562
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	· · · · ·
2	KACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSED	51
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
70	KACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSED	119

	· · · · ·
52	SSVTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTAS	101
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
120	SSVTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTAS	169

	· · · · ·
102	HLSQQADLRSIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLM	151
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
170	HLSQQADLRSIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLM	219

	· · · · ·
152	DHVGTEPSIKEDQVIQLMNAIFSKKNFESLSEAFSVASAAAVLSHNRYHV	201
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
220	DHVGTEPSIKEDQVIQLMNAIFSKKNFESLSEAFSVASAAAVLSHNRYHV	269

	· · · · ·
202	PVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATV	251
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
270	PVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATV	319

	· · · · ·
252	LQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVELRVKI	301
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
320	LQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVELRVKI	369

	· · · · ·
302	STEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQ	351
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
370	STEVGITNVDLSTVDKDQSIAPKTTRVTYPAKAKGTFIADSHQNFALFFQ	419

	· · · · ·
352	LVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERK	401
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
420	LVDVNTGAELTPHQTFVRLHNQKTGQEVVFVAEPDNKNVYKFELDTSERK	469

	· · · · ·
402	IEFDSASGTYTLYLIIGDATLKNPILWNVADVVIKFPEEEAPSTVLSQNL	451
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
470	IEFDSASGTYTLYLIIGDATLKNPILWNVADVVIKFPEEEAPSTVLSQNL	519

	· · · · ·
452	FTPKQEIQHLFREPEKRPPTVVSNTFTALILSPLLLLFALWIRIGANVSN	501
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
520	FTPKQEIQHLFREPEKRPPTVVSNTFTALILSPLLLLFALWIRIGANVSN	569

	· · · · ·
502	FTFAPSTIIFHLGHAAMLGLMYVYWTQLNMFQTLKYLAILGSVTFLAGNR	551
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
570	FTFAPSTIIFHLGHAAMLGLMYVYWTQLNMFQTLKYLAILGSVTFLAGNR	619

	·
552	MLAQQAVKRTAH	563
	\|\|\|\|\|\|\|\|\|\|\|\|
620	MLAQQAVKRTAH	631

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P27 (SEQ ID NO:670)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	3910.00
Escore:	0
Matching length:	415	Total length:	415
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · · · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300

	· · · · ·
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350

	· · · · ·
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	EVEGDNRYIANTVELRVKISTEVGITNVDLSTVDKDQSIAPKTTRVTYPA	400

	·
401	KAKGTFIADSHQNFA	415
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	KAKGTFIADSHQNFA	415

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P32 (SEQ ID NO:671)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	3434.00
Escore:	0
Matching length:	373	Total length:	373
Matching Percent	98.93	Matching Percent Identity:	98.39
Similarity:
Total Percent Similarity:	98.93	Total Percent Identity:	98.39
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · · · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300

	· · · · ·
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLV	350

	· ·
351	EVEGDNRYIANTVEGQVRWLTPV	373
	\|\|\|\|\|\|\|\|\|\|\|\|\|\| :\|: \| \|
351	EVEGDNRYIANTVELRVKISTEV	373

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P34 (SEQ ID NO:672)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	3087.00
Escore:	0
Matching length:	329	Total length:	329
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQTYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQTYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · · · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPL	300

	· ·
301	TQATVKLEHAKSVASRATVLQKTSFTPVG	329
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	TQATVKLEHAKSVASRATVLQKTSFTPVG	329

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P35 (SEQ ID NO:673)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	2697.00
Escore:	0
Matching length:	287	Total length:	287
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	· · · · ·
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQ	200

	· · · · ·
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	FEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLS	250

	· · ·
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAI	287
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	EAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAI	287

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P38 (SEQ ID NO:674)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	1368.00
Escore:	0
Matching length:	145	Total length:	145
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	· · · · ·

51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	· · · ·

101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEAL	145
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEAL	145

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P39 (SEQ ID NO:675)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	1500.00
Escore:	0
Matching length:	160	Total length:	160
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

	· · · · ·
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	EISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTA	150

	·
151	RLSKEETVLA	160
	\|\|\|\|\|\|\|\|\|\|
151	RLSKEETVLA	160

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P45 (SEQ ID NO:676)×RIB2_HUMAN (SEQ ID NO:663)

Alignment segment 1/1:



Quality:	970.00
Escore:	0
Matching length:	103	Total length:	103
Matching Percent	99.03	Matching Percent Identity:	99.03
Similarity:
Total Percent Similarity:	99.03	Total Percent Identity:	99.03
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	· · · · ·
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGC	100

101	ENS	103
	\| \|
101	EIS	103

Sequence name: RIB2_HUMAN (SEQ ID NO:663)

Sequence documentation:

Alignment of: T46984_PEA_—1_P46 (SEQ ID NO:677)×RIB2_HUMAN (SEQ ID NO:663).

Alignment segment 1/1:



Quality:	656.00
Escore:	0
Matching length:	69	Total length:	69
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment


	· · · · ·
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLES	50

	·
51	AFYSIVGLSSLGAQVPDAK	69
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	AFYSIVGLSSLGAQVPDAK	69

Description for Cluster T11628

Cluster T11628 features 6 transcript(s) and 25 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	T11628_PEA_1_T3	678
	T11628_PEA_1_T4	679
	T11628_PEA_1_T5	680
	T11628_PEA_1_T7	681
	T11628_PEA_1_T9	682
	T11628_PEA_1_T11	683

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	T11628_PEA_1_node_7	684
	T11628_PEA_1_node_11	685
	T11628_PEA_1_node_16	686
	T11628_PEA_1_node_22	687
	T11628_PEA_1_node_25	688
	T11628_PEA_1_node_31	689
	T11628_PEA_1_node_37	690
	T11628_PEA_1_node_0	691
	T11628_PEA_1_node_4	692
	T11628_PEA_1_node_9	693
	T11628_PEA_1_node_13	694
	T11628_PEA_1_node_14	695
	T11628_PEA_1_node_17	696
	T11628_PEA_1_node_18	697
	T11628_PEA_1_node_19	698
	T11628_PEA_1_node_24	699
	T11628_PEA_1_node_27	700
	T11628_PEA_1_node_28	701
	T11628_PEA_1_node_29	702
	T11628_PEA_1_node_30	703
	T11628_PEA_1_node_32	704
	T11628_PEA_1_node_33	705
	T11628_PEA_1_node_34	706
	T11628_PEA_1_node_35	707
	T11628_PEA_1_node_36	708

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

T11628_PEA_1_P2	712	T11628_PEA_1_T3 (SEQ ID
		NO: 678);
		T11628_PEA_1_T5 (SEQ ID
		NO: 680);
		T11628_PEA_1_T7 (SEQ ID
		NO: 681)
T11628_PEA_1_P5	713	T11628_PEA_1_T9 (SEQ ID
		NO: 682)
T11628_PEA_1_P7	714	T11628_PEA_1_T11 (SEQ
		ID NO: 683)
T11628_PEA_1_P10	715	T11628_PEA_1_T4 (SEQ ID
		NO: 679)

These sequences are variants of the known protein Myoglobin (SwissProt accession identifier MYG_HUMAN), SEQ ID NO: 709, referred to herein as the previously known protein.

Protein Myoglobin (SEQ ID NO:709) is known or believed to have the following function(s): Serves as a reserve supply of oxygen and facilitates the movement of oxygen within muscles. The sequence for protein Myoglobin (SEQ ID NO:709) is given at the end of the application, as “Myoglobin (SEQ ID NO:709) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

54	E -> K. /FTId = VAR_003180.
133	K -> N. /FTId = VAR_003181.
139	R -> Q. /FTId = VAR_003182.
139	R -> W. /FTId = VAR_003183.
128	Q -> E

As noted above, cluster T11628 features 6 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Myoglobin (SEQ ID NO:709). A description of each variant protein according to the present invention is now provided.

Variant protein T11628_PEA_—1_P2 (SEQ ID NO:712) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T11628_PEA_—1_T3 (SEQ ID NO:678). An alignment is given to the known protein (Myoglobin (SEQ ID NO:709)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T11628_PEA_—1_P2 (SEQ ID NO:712) and Q8WVH6 (SEQ ID NO:711) (SEQ ID NO:711):

1.An isolated chimeric polypeptide encoding for T11628_PEA_—1_—P2 (SEQ ID NO:712), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE (SEQ ID NO:956) corresponding to amino acids 1-55 of T11628_PEA_—1_P2 (SEQ ID NO:712), and a second amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 1-99 of Q8WVH6 (SEQ ID NO:711), which also corresponds to amino acids 56-154 of T11628_PEA_—1_P2 (SEQ ID NO:712), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a head of T11628_PEA_—1_P2 (SEQ ID NO:712), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE	(SEQ ID NO:956)

of T11628_PEA_1_P2.	(SEQ ID NO:712)

Variant protein T11628_PEA_—1_P2 (SEQ ID NO:712) also has the following non-silent SNPs(Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P2 (SEQ ID NO:712) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 5


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

26	G ->	No
44	F ->	No
92	Q -> R	No
135	A ->	No
141	K ->	No
153	Q ->	No

Variant protein T11628_PEA_—1_P2 (SEQ ID NO:712) is encoded by the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T11628_PEA_—1_T3 (SEQ ID NO:678) is shown in bold; this coding portion starts at position 220 and ends at position 681. The transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P2 (SEQ ID NO:712) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 6


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

83	G -> A	Yes
93	G -> A	Yes
95	G -> A	Yes
146	G -> A	Yes
295	G ->	No
349	T ->	No
393	G -> A	Yes
423	C -> T	Yes
494	A -> G	No
498	G -> A	No
623	C ->	No
642	G ->	No
678	G ->	No
686	C ->	No
686	C -> A	No
717	C ->	No
787	T -> G	No
820	G -> T	No
826	G -> T	No
850	C ->	No
934	T -> G	No
975	A -> G	Yes
1117	G ->	No
1218	A -> G	No

Variant protein T11628_PEA_—1_P5 (SEQ ID NO:713) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T11628_PEA_—1_T9 (SEQ ID NO:682). An alignment is given to the known protein (Myoglobin (SEQ ID NO:709) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T11628_PEA_—1_P5 (SEQ ID NO:713) and MYG_HUMAN_—V1 (SEQ ID NO:710):

1.An isolated chimeric polypeptide encoding for T11628_PEA_—1_P5 (SEQ ID NO:713), comprising a first amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 56-154 of MYG_HUMAN_V1 (SEQ ID NO:710), which also corresponds to amino acids 1-99 of T11628_PEA_—1_P5 (SEQ ID NO:713).

It should be noted that the known protein sequence (MYG_HUMAN (SEQ ID NO:709)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for MYG_HUMAN_V1 (SEQ ID NO: 710). These changes were previously known to occur and are listed in the table below.

TABLE 7


Changes to MYG_HUMAN_V1 (SEQ ID NO: 710)

SNP position(s) on
amino acid sequence	Type of change

1	init_met

Variant protein T11628_PEA_—1_P5 (SEQ ID NO:713) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P5 (SEQ ID NO:713) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

37	Q -> R	No
80	A ->	No
86	K ->	No
98	Q ->	No

Variant protein T11628_PEA_—1_P5 (SEQ ID NO:713) is encoded by the following Transcript(s): T11628_PEA_—1_T9 (SEQ ID NO:682), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T11628_PEA_—1_T9 (SEQ ID NO:682) is shown in bold; this coding portion starts at position 211 and ends at position 507. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P5 (SEQ ID NO:713) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

2	C -> T	Yes
175	T ->	No
219	G -> A	Yes
249	C -> T	Yes
320	A -> G	No
324	G -> A	No
449	C ->	No
468	G ->	No
504	G ->	No
512	C ->	No
512	C -> A	No
543	C ->	No
613	T -> G	No
646	G -> T	No
652	G -> T	No
676	C ->	No
760	T -> G	No
801	A -> G	Yes
943	G ->	No
1044	A -> G	No

Variant protein T11628_PEA_—1_P7 (SEQ ID NO:714) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T11628_PEA_—1_T11 (SEQ ID NO:683). An alignment is given to the known protein (Myoglobin (SEQ ID NO:709)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T11628_PEA_—1_P7 (SEQ ID NO:714) and MYG _HUMAN_V1 (SEQ ID NO:710):

1. An isolated chimeric polypeptide encoding for T11628_PEA_—1_P7 (SEQ ID NO:714), comprising a first amino acid sequence being at least 90% homologous to MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDEMK ASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQVLQ SKHPGDFGADAQGAMNK corresponding to amino acids 1-134 of MYG_HUMAN_V1, which also corresponds to amino acids 1-134 of T11628_PEA_—1_P7 (SEQ ID NO:714), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence G corresponding to amino acids 135-135 of T11628_PEA_—1_P7 (SEQ ID NO:714), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

It should be noted that the known protein sequence (MYG_HUMAN (SEQ ID NO:709)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for MYG_HUMAN_V1 (SEQ ID NO:710). These changes were previously known to occur and are listed in the table below.

TABLE 10


Changes to MYG_HUMAN_V1 (SEQ ID NO: 710)

SNP position(s) on
amino acid sequence	Type of change

1	init_met

Variant protein T11628_PEA_—1_P7 (SEQ ID NO:714) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P7 (SEQ ID NO:714) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

26	G ->	No
44	F ->	No
92	Q -> R	No

Variant protein T11628_PEA_—1_P7 (SEQ ID NO:714) is encoded by the following transcript(s): T11628_PEA_—1_T11 (SEQ ID NO:683), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T11628_PEA_—1_T11 (SEQ ID NO:683) is shown in bold; this coding portion starts at position 319 and ends at position 723. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P7 (SEQ ID NO:714) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

394	G ->	No
448	T ->	No
492	G -> A	Yes
522	C -> T	Yes
593	A -> G	No
597	G -> A	No
728	C ->	No
728	C -> A	No
759	C ->	No
829	T -> G	No
862	G -> T	No
868	G -> T	No
892	C ->	No
976	T -> G	No
1017	A -> G	Yes
1159	G ->	No
1260	A -> G	No

Variant protein T11628_PEA_—1_P10 (SEQ ID NO:715) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) T11628_PEA_—1_T4 (SEQ ID NO:679). An alignment is given to the known protein (Myoglobin (SEQ ID NO:709)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between T11628_PEA_—1_P10 (SEQ ID NO:715) and Q8WVH6 (SEQ ID NO:711):

1.An isolated chimeric polypeptide encoding for T11628_PEA_—1_P10 (SEQ ID NO:715), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE (SEQ ID NO:956) corresponding to amino acids 1-55 of T11628_PEA_—1_P10 (SEQ ID NO:715), and a second amino acid sequence being at least 90% homologous to MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYLEFISECIIQV LQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG corresponding to amino acids 1-99 of Q8WVH6 (SEQ ID NO:711), which also corresponds to amino acids 56-154 of T11628_PEA_—1_P10 (SEQ ID NO:715), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a head of T11628_PEA_—1_P10 (SEQ ID NO:715), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHLKSEDE	(SEQ ID NO:956)

of T11628_PEA_1_P10.	(SEQ ID NO:715)

Variant protein T11628_PEA_—1_P10 (SEQ ID NO:715) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P10 (SEQ ID NO:715) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

26	G ->	No
44	F ->	No
92	Q -> R	No
135	A ->	No
141	K ->	No
153	Q ->	No

Variant protein T11628_PEA_—1_P10 (SEQ ID NO:715) is encoded by the following transcript(s): T11628_PEA_—1_T4 (SEQ ID NO:679), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript T11628_PEA_—1_T4 (SEQ ID NO:679) is shown in bold; this coding portion starts at position 205 and ends at position 666. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein T11628_PEA_—1_P10 (SEQ ID NO:715) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on
nucleotide sequence	Alternative nucleic acid	Previously known SNP?

280	G ->	No
334	T ->	No
378	G -> A	Yes
408	C -> T	Yes
479	A -> G	No
483	G -> A	No
608	C ->	No
627	G ->	No
663	G ->	No
671	C ->	No
671	C -> A	No
702	C ->	No
772	T -> G	No
805	G -> T	No
811	G -> T	No
835	C ->	No
919	T -> G	No
960	A -> G	Yes
1102	G ->	No
1203	A -> G	No

As noted above, cluster T11628 features 25 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster T11628_PEA_—1_node_—7 (SEQ ID NO:684) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678). Table 15 below describes the starting and ending position of this segment on each transcript.

TABLE 15


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T11628_PEA_1_T3 (SEQ ID NO:	1	211
678)

Segment cluster T11628_PEA_—1_node_—11 (SEQ ID NO:685) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T5 (SEQ ID NO:680). Table 16 below describes the starting and ending position of this segment on each transcript.

TABLE 16


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T11628_PEA_1_T5 (SEQ ID NO:	48	178
680)

Segment cluster T11628_PEA_—1_node_—16 (SEQ ID NO:686) according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T11 (SEQ ID NO:683). Table 17 below describes the starting and ending position of this segment on each transcript.

TABLE 17


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T11628_PEA_1_T11 (SEQ ID	1	214
NO: 683)

Segment cluster T11628_PEA_—1_node_—22 (SEQ ID NO:687) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T9 (SEQ ID NO:682). Table 18 below describes the starting and ending position of this segment on each transcript.

TABLE 18


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T11628_PEA_1_T9 (SEQ ID NO:	1	140
682)

Segment cluster T11628_PEA_—1_node_—25 (SEQ ID NO:688) according to the present invention is supported by 129 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 19 below describes the starting and ending position of this segment on each transcript.

TABLE 19


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	395	537
T11628_PEA_1_T4 (SEQ ID NO: 679)	380	522
T11628_PEA_1_T5 (SEQ ID NO: 680)	362	504
T11628_PEA_1_T7 (SEQ ID NO: 681)	347	489
T11628_PEA_1_T9 (SEQ ID NO: 682)	221	363
T11628_PEA_1_T11 (SEQ ID	494	636
NO: 683)

TABLE 20


Oligonucleotides related to this segment

Oligonucleotide name	Overexpressed in cancers	Chip reference

T11628_0_9_0 (SEQ ID	breast malignant tumors	BRS
NO: 911)

Segment cluster T11628_PEA_—1_node_—31 (SEQ ID NO:689) according to the present invention is supported by 137 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 21 below describes the starting and ending position of this segment on each transcript.

TABLE 21


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	702	831
T11628_PEA_1_T4 (SEQ ID NO: 679)	687	816
T11628_PEA_1_T5 (SEQ ID NO: 680)	669	798
T11628_PEA_1_T7 (SEQ ID NO: 681)	654	783
T11628_PEA_1_T9 (SEQ ID NO: 682)	528	657
T11628_PEA_1_T11 (SEQ ID	744	873
NO: 683)

Segment cluster T11628_PEA_—1_node_—37 (SEQ ID NO:690) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 22 below describes the starting and ending position of this segment on each transcript.

TABLE 22


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	1086	1225
T11628_PEA_1_T4 (SEQ ID NO: 679)	1071	1210
T11628_PEA_1_T5 (SEQ ID NO: 680)	1053	1192
T11628_PEA_1_T7 (SEQ ID NO: 681)	1038	1177
T11628_PEA_1_T9 (SEQ ID NO: 682)	912	1051
T11628_PEA_1_T11 (SEQ ID	1128	1267
NO: 683)

Segment cluster T11628_PEA_—1_node_—0 (SEQ ID NO:691) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T4 (SEQ ID NO:679). Table 23 below describes the starting and ending position of this segment on each transcript.

TABLE 23


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T4 (SEQ ID NO: 679)	1	93

Segment cluster T11628_PEA_—1_node_—4 (SEQ ID NO:692) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T4 (SEQ ID NO:679). Table 24 below describes the starting and ending position of this segment on each transcript.

TABLE 24


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T4 (SEQ ID NO: 679)	94	196

Segment cluster T11628_PEA_—1_node_—9 (SEQ ID NO:693) according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T5 (SEQ ID NO:680) and T11628_PEA_—1_T7 (SEQ ID NO:681). Table 25 below describes the starting and ending position of this segment on each transcript.

TABLE 25


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T5 (SEQ ID NO: 680)	1	47
T11628_PEA_1_T7 (SEQ ID NO: 681)	1	47

Segment cluster T11628_PEA_—1_node_—13 (SEQ ID NO:694) according to the present invention can be found in the following transcript(s): T11628_PEA_—1_T7 (SEQ ID NO:681). Table 26 below describes the starting and ending position of this segment on each transcript.

TABLE 26


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T7 (SEQ ID NO: 681)	48	65

Segment cluster T11628_PEA_—1_node_—14 (SEQ ID NO:695) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T7 (SEQ ID NO:681). Table 27 below describes the starting and ending position of this segment on each transcript.

TABLE 27


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T7 (SEQ ID NO: 681)	66	163

Segment cluster T11628_PEA_—1_node_—17 (SEQ ID NO:696) according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T11 (SEQ ID NO:683). Table 28 below describes the starting and ending position of this segment on each transcript.

TABLE 28


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

T11628_PEA_1_T11 (SEQ ID	215	310
NO: 683)

Segment cluster T11628_PEA_—1_node_—18 (SEQ ID NO:697) according to the present invention is supported by 98 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	212	289
T11628_PEA_1_T4 (SEQ ID NO: 679)	197	274
T11628_PEA_1_T5 (SEQ ID NO: 680)	179	256
T11628_PEA_1_T7 (SEQ ID NO: 681)	164	241
T11628_PEA_1_T11 (SEQ ID NO: 683)	311	388

Segment cluster T11628_PEA_—1_node_—19 (SEQ ID NO:698) according to the present invention can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681) and T11628_PEA_—1_T11(SEQ ID NO:683). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	290	314
T11628_PEA_1_T4 (SEQ ID NO: 679)	275	299
T11628_PEA_1_T5 (SEQ ID NO: 680)	257	281
T11628_PEA_1_T7 (SEQ ID NO: 681)	242	266
T11628_PEA_1_T11 (SEQ ID NO: 683)	389	413

Segment cluster T11628_PEA_—1_node_—24 (SEQ ID NO:699) according to the present invention is supported by 112 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	315	394
T11628_PEA_1_T4 (SEQ ID NO: 679)	300	379
T11628_PEA_1_T5 (SEQ ID NO: 680)	282	361
T11628_PEA_1_T7 (SEQ ID NO: 681)	267	346
T11628_PEA_1_T9 (SEQ ID NO: 682)	141	220
T11628_PEA_1_T11 (SEQ ID	414	493
NO: 683)

Segment cluster T11628_PEA_—1_node_—27 (SEQ ID NO:700) according to the present invention is supported by 119 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	538	621
T11628_PEA_1_T4 (SEQ ID NO: 679)	523	606
T11628_PEA_1_T5 (SEQ ID NO: 680)	505	588
T11628_PEA_1_T7 (SEQ ID NO: 681)	490	573
T11628_PEA_1_T9 (SEQ ID NO: 682)	364	447
T11628_PEA_1_T11 (SEQ ID	637	720
NO: 683)

TABLE 33


Oligonucleotides related to this segment

Oligonucleotide name	Overexpressed in cancers	Chip reference

T11628_0_9_0 (SEQ ID	breast malignant tumors	BRS
NO: 911)

Segment cluster T11628_PEA_—1_node_—28 (SEQ ID NO:701) according to the present invention is supported by 115 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681) and T11628_PEA_—1_T9 (SEQ ID NO:682). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	622	650
T11628_PEA_1_T4 (SEQ ID NO: 679)	607	635
T11628_PEA_1_T5 (SEQ ID NO: 680)	589	617
T11628_PEA_1_T7 (SEQ ID NO: 681)	574	602
T11628_PEA_1_T9 (SEQ ID NO: 682)	448	476

Segment cluster T11628_PEA_—1_node_—29 (SEQ ID NO:702) according to the present invention is supported by 113 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681) and T11628_PEA_—1_T9 (SEQ ID NO:682). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	651	678
T11628_PEA_1_T4 (SEQ ID NO: 679)	636	663
T11628_PEA_1_T5 (SEQ ID NO: 680)	618	645
T11628_PEA_1_T7 (SEQ ID NO: 681)	603	630
T11628_PEA_1_T9 (SEQ ID NO: 682)	477	504

Segment cluster T11628_PEA_—1_node_—30 (SEQ ID NO:703) according to the present invention can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	679	701
T11628_PEA_1_T4 (SEQ ID NO: 679)	664	686
T11628_PEA_1_T5 (SEQ ID NO: 680)	646	668
T11628_PEA_1_T7 (SEQ ID NO: 681)	631	653
T11628_PEA_1_T9 (SEQ ID NO: 682)	505	527
T11628_PEA_1_T11 (SEQ ID	721	743
NO: 683)

Segment cluster T11628_PEA_—1_node_—32 (SEQ ID NO:704) according to the present invention can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	832	844
T11628_PEA_1_T4 (SEQ ID NO: 679)	817	829
T11628_PEA_1_T5 (SEQ ID NO: 680)	799	811
T11628_PEA_1_T7 (SEQ ID NO: 681)	784	796
T11628_PEA_1_T9 (SEQ ID NO: 682)	658	670
T11628_PEA_1_T11 (SEQ ID	874	886
NO: 683)

Segment cluster T11628_PEA_—1_node_—33 (SEQ ID NO:705) according to the present invention can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	845	866
T11628_PEA_1_T4 (SEQ ID NO: 679)	830	851
T11628_PEA_1_T5 (SEQ ID NO: 680)	812	833
T11628_PEA_1_T7 (SEQ ID NO: 681)	797	818
T11628_PEA_1_T9 (SEQ ID NO: 682)	671	692
T11628_PEA_1_T11 (SEQ ID	887	908
NO: 683)

Segment cluster T11628_PEA_—1_node_—34 (SEQ ID NO:706) according to the present invention is supported by 122 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	867	911
T11628_PEA_1_T4 (SEQ ID NO: 679)	852	896
T11628_PEA_1_T5 (SEQ ID NO: 680)	834	878
T11628_PEA_1_T7 (SEQ ID NO: 681)	819	863
T11628_PEA_1_T9 (SEQ ID NO: 682)	693	737
T11628_PEA_1_T11 (SEQ ID	909	953
NO: 683)

Segment cluster T11628_PEA_—1_node_—35 (SEQ ID NO:707) according to the present invention is supported by 126 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682 and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	912	967
T11628_PEA_1_T4 (SEQ ID NO: 679)	897	952
T11628_PEA_1_T5 (SEQ ID NO: 680)	879	934
T11628_PEA_1_T7 (SEQ ID NO: 681)	864	919
T11628_PEA_1_T9 (SEQ ID NO: 682)	738	793
T11628_PEA_1_T11 (SEQ ID	954	1009
NO: 683)

Segment cluster T11628_PEA_—1_node_—36 (SEQ ID NO:708) according to the present invention is supported by 122 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): T11628_PEA_—1_T3 (SEQ ID NO:678), T11628_PEA_—1_T4 (SEQ ID NO:679), T11628_PEA_—1_T5 (SEQ ID NO:680), T11628_PEA_—1_T7 (SEQ ID NO:681), T11628_PEA_—1_T9 (SEQ ID NO:682) and T11628_PEA_—1_T11 (SEQ ID NO:683). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

		Segment
	Segment	ending
Transcript name	starting position	position

T11628_PEA_1_T3 (SEQ ID NO: 678)	968	1085
T11628_PEA_1_T4 (SEQ ID NO: 679)	953	1070
T11628_PEA_1_T5 (SEQ ID NO: 680)	935	1052
T11628_PEA_1_T7 (SEQ ID NO: 681)	920	1037
T11628_PEA_1_T9 (SEQ ID NO: 682)	794	911
T11628_PEA_1_T11 (SEQ ID	1010	1127
NO: 683)

Variant protein alignment to the previously known protein:

Sequence name: Q8WVH6 (SEQ ID NO:711)

Sequence documentation:

Alignment of: T11628_PEA_—1_P2 (SEQ ID NO:712)×Q8WVH6 (SEQ ID NO:711).

Alignment segment 1/1:



Quality:	962.00
Escore:	0
Matching length:	99	Total length:	99
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
56	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	105
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	50

	· · · ·
106	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	154
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	99

Sequence name: MYG_HUMAN_V1 (SEQ ID NO:710)

Sequence documentation:

Alignment of: T11628_PEA_—1_P5 (SEQ ID NO:713)×MYG_HUMAN_V1 (SEQ ID NO:710).

Alignment segment 1/1:



Quality:	962.00
Escore:	0
Matching length:	99	Total length:	99
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
56	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	105

	· · · ·
51	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	99
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
106	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	154

Sequence name: MYG_HUMAN_V1 (SEQ ID NO:710)

Sequence documentation:

Sequence of: T11628_PEA_—1_P7 (SEQ ID NO:714)×MYG_HUMAN_V1 (SEQ ID NO:710).

Alignment segment 1/1:



Quality:	1315.00
Escore:	0
Matching length:	134	Total length:	134
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHL	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETLEKFDKFKHL	50

	· · · · ·
51	KSEDEMKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKI	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	KSEDEMKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKI	100

	· · ·
101	PVKYLEFISECIIQVLQSKHPGDFGADAQGAMNK	134
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	PVKYLEFISECIIQVLQSKHPGDFGADAQGAMNK	134

Sequence name: Q8WVH6 (SEQ ID NO:711)

Sequence documentation:

Alignment of: T11628_PEA_—1_P10 (SEQ ID NO:715)×Q8WVH6 (SEQ ID NO:711).

Alignment segment 1/1:



Quality:	962.00
Escore:	0
Matching length:	99	Total length:	99
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
56	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	105
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKASEDLKKHGATVLTALGGILKKKGHHEAEIKPLAQSHATKHKIPVKYL	50

	· · · ·
106	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	154
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	EFISECIIQVLQSKHPGDFGADAQGAMNKALELFRKDMASNYKELGFQG	99

Description for Cluster M78076

Cluster M78076 features 9 transcript(s) and 35 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	M78076_PEA_1_T2	716
	M78076_PEA_1_T3	717
	M78076_PEA_1_T5	718
	M78076_PEA_1_T13	719
	M78076_PEA_1_T15	720
	M78076_PEA_1_T23	721
	M78076_PEA_1_T26	722
	M78076_PEA_1_T27	723
	M78076_PEA_1_T28	724

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	M78076_PEA_1_node_0	725
	M78076_PEA_1_node_10	726
	M78076_PEA_1_node_15	727
	M78076_PEA_1_node_18	728
	M78076_PEA_1_node_20	729
	M78076_PEA_1_node_24	730
	M78076_PEA_1_node_26	731
	M78076_PEA_1_node_29	732
	M78076_PEA_1_node_32	733
	M78076_PEA_1_node_35	734
	M78076_PEA_1_node_37	735
	M78076_PEA_1_node_46	736
	M78076_PEA_1_node_47	737
	M78076_PEA_1_node_54	738
	M78076_PEA_1_node_1	739
	M78076_PEA_1_node_2	740
	M78076_PEA_1_node_3	741
	M78076_PEA_1_node_6	742
	M78076_PEA_1_node_7	743
	M78076_PEA_1_node_12	744
	M78076_PEA_1_node_22	745
	M78076_PEA_1_node_27	746
	M78076_PEA_1_node_30	747
	M78076_PEA_1_node_31	748
	M78076_PEA_1_node_34	749
	M78076_PEA_1_node_36	750
	M78076_PEA_1_node_41	751
	M78076_PEA_1_node_42	752
	M78076_PEA_1_node_43	753
	M78076_PEA_1_node_45	754
	M78076_PEA_1_node_49	755
	M78076_PEA_1_node_50	756
	M78076_PEA_1_node_51	757
	M78076_PEA_1_node_52	758
	M78076_PEA_1_node_53	759

TABLE 3


Proteins of interest

	Sequence
Protein Name	ID No.	Corresponding Transcript(s)

M78076_PEA_1_P3	761	M78076_PEA_1_T2 (SEQ ID
		NO: 716);
		M78076_PEA_1_T5 (SEQ ID
		NO: 718)
M78076_PEA_1_P4	762	M78076_PEA_1_T3 (SEQ ID
		NO: 717)
M78076_PEA_1_P12	763	M78076_PEA_1_T13 (SEQ
		ID NO: 719)
M78076_PEA_1_P14	764	M78076_PEA_1_T15 (SEQ
		ID NO: 720)
M78076_PEA_1_P21	765	M78076_PEA_1_T23 (SEQ
		ID NO: 721)
M78076_PEA_1_P24	766	M78076_PEA_1_T26 (SEQ
		ID NO: 722)
M78076_PEA_1_P2	767	M78076_PEA_1_T27 (SEQ
		ID NO: 723)
M78076_PEA_1_P25	768	M78076_PEA_1_T28 (SEQ
		ID NO: 724)

These sequences are variants of the known protein Amyloid-like protein 1 precursor (SwissProt accession identifier APP1_HUMAN; known also according to the synonyms APLP; APLP-1), SEQ ID NO: 760, referred to herein as the previously known protein.

Protein Amyloid-like protein 1 precursor (SEQ ID NO:760) is known or believed to have the following function(s): May play a role in postsynaptic function. The C-terminal gamma-secretase processed fragment, ALID1, activates transcription activation through APBB1 (Fe65) binding (By similarity). Couples to JIP signal transduction through C-terminal binding. May interact with cellular G-protein signaling pathways. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I. The gamma-CTF peptide, C30, is a potent enhancer of neuronal apoptosis (By similarity). The sequence for protein Amyloid-like protein 1 precursor (SEQ ID NO:760) is given at the end of the application, as “Amyloid-like protein 1 precursor (SEQ ID NO:760) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

48	A -> P

Protein Amyloid-like protein 1 precursor (SEQ ID NO:760) localization is believed to be Type I membrane protein. C-terminally processed in the Golgi complex.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: endocytosis; apoptosis; cell adhesion; neurogenesis; cell death, which are annotation(s) related to Biological Process; protein binding; heparin binding, which are annotation(s) related to Molecular Function; and basement membrane; coated pit; integral membrane protein, which are annotation(s) related to Cellular Component.

The GO assignment relies on information from one or more of the SwissProt/TremB1 Protein knowledgebase, available from <http://www.expasy.ch/sprot/>; or Locuslink, available from <http://www.ncbi.nlm.nih.gov/projects/LocusLink/>.

As noted above, cluster M78076 features 9 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Amyloid-like protein 1 precursor (SEQ ID NO:760). A description of each variant protein according to the present invention is now provided.

Variant protein M78076_PEA_—1_P3 (SEQ ID NO:761) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T2 (SEQ ID NO:716). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P3 (SEQ ID NO:761) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P3 (SEQ ID NO:761), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKD corresponding to amino acids 1-517 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-517 of M78076_PEA_—1_P3 (SEQ ID NO:761), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GE corresponding to amino acids 518-519 of M78076_PEA_—1_P3 (SEQ ID NO:761), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

Variant protein M78076_PEA_—1_P3 (SEQ ID NO:761) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P3 (SEQ ID NO:761) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 5


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P3 (SEQ ID NO:761), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 6


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	461
551	no

Variant protein M78076_PEA_—1_P3 (SEQ ID NO:761) is encoded by the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T2 (SEQ ID NO:716) is shown in bold; this coding portion starts at position 142 and ends at position 1698. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P3 (SEQ ID NO:761) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
2146	G -> A	Yes
2224	C -> T	No
2362	C -> T	Yes
2513	A -> G	No
2656	C -> T	Yes

Variant protein M78076_PEA_—1_P4 (SEQ ID NO:762) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T3 (SEQ ID NO:717). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P4 (SEQ ID NO:762) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P4 (SEQ ID NO:762), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKG corresponding to amino acids 1-526 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-526 of M78076_PEA_—1_P4 (SEQ ID NO:762), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ECLTVNPSLQIPLNP (SEQ ID NO:958) corresponding to amino acids 527-541 of M78076_PEA_—1_P4 (SEQ ID NO:762), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P4 (SEQ ID NO:762), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECLTVNPSLQIPLNP (SEQ ID NO:958) in M78076_PEA_—1_P4 (SEQ ID NO:762).

Variant protein M78076_PEA_—1_P4 (SEQ ID NO:762) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P4 (SEQ ID NO:762) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P4 (SEQ ID NO:762), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 9 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 9


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	461
551	no

Variant protein M78076_PEA_—1_P4 (SEQ ID NO:762) is encoded by the following transcript(s): M78076_PEA_—1_T3 (SEQ ID NO:717), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T3 (SEQ ID NO:717) is shown in bold; this coding portion starts at position 142 and ends at position 1764. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P4 (SEQ ID NO:762) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
1817	G -> A	Yes
2362	G -> A	Yes
2440	C -> T	No
2578	C -> T	Yes
2729	A -> G	No
2872	C -> T	Yes

Variant protein M78076_PEA_—1_P12 (SEQ ID NO:763) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T13 (SEQ ID NO:719). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P12 (SEQ ID NO:763) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P12 (SEQ ID NO:763), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKG corresponding to amino acids 1-526 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-526 of M78076_PEA_—1_P12 (SEQ ID NO:763), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ECVCSKGFPFPLIGDSEG (SEQ ID NO:959) corresponding to amino acids 527-544 of M78076_PEA_—1_P12 (SEQ ID NO:763), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P12 (SEQ ID NO:763), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ECVCSKGFPFPLIGDSEG (SEQ ID NO:959) in M78076_PEA_—1_P12 (SEQ ID NO:763).

Variant protein M78076_PEA_—1_P12 (SEQ ID NO:763) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P12 (SEQ ID NO:763) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P12 (SEQ ID NO:763), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 12 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 12


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	461
551	no

Variant protein M78076_PEA_—1_P12 (SEQ ID NO:763) is encoded by the following transcript(s): M78076_PEA_—1_T13 (SEQ ID NO:719), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T13 (SEQ ID NO:719) is shown in bold; this coding portion starts at position 142 and ends at position 1773. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P12 (SEQ ID NO:763) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
1816	G -> A	Yes
1894	C -> T	No
2032	C -> T	Yes
2183	A -> G	No
2326	C -> T	Yes

Variant protein M78076_PEA_—1_P14 (SEQ ID NO:764) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T15 (SEQ ID NO:720). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P14 (SEQ ID NO:764) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P14 (SEQ ID NO:764), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMTLPKGST EQDAASPEKEKMNPLEQYERKVNASVPRGFPFHSSEIQRDEL corresponding to amino acids 1-570 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-570 of M78076_PEA_—1_P14 (SEQ ID NO:764), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRGGTAGYLGEETRGQRPGCDSQSHTGPSKKPSAPSPLPAGTSWDRGVP (SEQ ID NO:960) corresponding to amino acids 571-619 of M78076_PEA_—1_P14 (SEQ ID NO:764), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P14 (SEQ ID NO:764), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


VRGGTAGYLGEETRGQRPGCDSQSHTGPSKKPSAPSPLPAGTSWDRGVP	(SEQ ID NO:960)

in M78076_PEA_1_P14.	(SEQ ID NO:764)

Variant protein M78076_PEA_—1_P14 (SEQ ID NO:764) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P14 (SEQ ID NO:764) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P14 (SEQ ID NO:764), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 15 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 15


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	461
551	yes	551

Variant protein M78076_PEA_—1_P14 (SEQ ID NO:764) is encoded by the following transcript(s): M78076_PEA_—1_T15 (SEQ ID NO:720), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T15 (SEQ ID NO:720) is shown in bold; this coding portion starts at position 142 and ends at position 1998. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P14 (SEQ ID NO:764) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 16


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
2008	G -> A	Yes
2086	C -> T	No
2224	C -> T	Yes
2375	A -> G	No
2518	C -> T	Yes

Variant protein M78076_PEA_—1_P21 (SEQ ID NO:765) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T23 (SEQ ID NO:721). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P21 (SEQ ID NO:765) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P21 (SEQ ID NO:765), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN E corresponding to amino acids 1-352 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-352 of M78076_PEA_—1_P21 (SEQ ID NO:765), and a second amino acid sequence being at least 90% homologous to AERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQ SLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDKGGLQPPDSKDDTPMT LPKGSTEQDAASPEKEKMNPLEQYERKVNASVPRGFPFHSSEIQRDELAPAGTGVSREA VSGLLIMGAGGGSLIVLSMLLLRRKKPYGAISHGVVEVDPMLTLEEQQLRELQRHGYE NPTYRFLEERP corresponding to amino acids 406-650 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 353-597 of M78076_PEA_—1_P21 (SEQ ID NO:765), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated chimeric polypeptide encoding for an edge portion of M78076_PEA_—1_P21 (SEQ ID NO:765), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EA, having a structure as follows: a sequence starting from any of amino acid numbers 352-x to 352; and ending at any of amino acid numbers 353+((n-2)−x), in which x varies from 0 to n-2.

Variant protein M78076_PEA_—1_P21 (SEQ ID NO:765) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 17, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P21 (SEQ ID NO:765) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 17


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes

The glycosylation sites of variant protein M78076_PEA_—1_P21 (SEQ ID NO:765), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 18 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 18


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	408
551	yes	498

Variant protein M78076_PEA_—1_P21 (SEQ ID NO:765) is encoded by the following transcript(s): M78076_PEA_—1_T23 (SEQ ID NO:721), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T23 (SEQ ID NO:721) is shown in bold; this coding portion starts at position 142 and ends at position 1932. The transcript also has the following SNPs as listed in Table 19 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P21 (SEQ ID NO:765) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 19


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1239	G -> T	Yes
1264	C -> T	Yes
1728	G -> A	Yes
1806	C -> T	No
1944	C -> T	Yes
2095	A -> G	No
2238	C -> T	Yes

Variant protein M78076_PEA_—1_P24 (SEQ ID NO:766) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T26 (SEQ ID NO:722). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P24 (SEQ ID NO:766) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P24 (SEQ ID NO:766), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLD QNPHLAQELRPQI corresponding to amino acids 1-481 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-481 of M78076_PEA_—1_P24 (SEQ ID NO:766), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence RECLLPWLPLQISEGRS (SEQ ID NO:961) corresponding to amino acids 482-498 of M78076_PEA_—1_P24 (SEQ ID NO:766), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P24 (SEQ ID NO:766), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence RECLLPWLPLQISEGRS (SEQ ID NO:961) in M78076_PEA_—1_P24 (SEQ ID NO:766).

Variant protein M78076_PEA_—1_P24 (SEQ ID NO:766) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 20, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P24 (SEQ ID NO:766) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 20


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P24 (SEQ ID NO:766), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 21 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 21


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	yes	461
551	no

Variant protein M78076_PEA_—1_P24 (SEQ ID NO:766) is encoded by the following transcript(s): M78076_PEA_—1_T26 (SEQ ID NO:722), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T26 (SEQ ID NO:722) is shown in bold; this coding portion starts at position 142 and ends at position 1635. The transcript also has the following SNPs as listed in Table 22 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P24 (SEQ ID NO:766) sequence provides support for the deduced sequence variant protein according to the present invention).

TABLE 22


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
2184	G -> A	Yes

Variant protein M78076_PEA_—1_P2 (SEQ ID NO:767) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T27 (SEQ ID NO:723). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P2 (SEQ ID NO:767) and APP1_HUMAN (SEQ ID NO:760):

1. An isolated chimeric polypeptide encoding for M78076_PEA_—1_P2 (SEQ ID NO:767), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQV corresponding to amino acids 1-449 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-449 of M78076_PEA_—1_P2 (SEQ ID NO:767), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence LTSFQLPNAPLFLRRPRLRLFSCPLDPLSVSWTPSYPLNTASLPLPSLSAQLPDPETWTLT CCVFDPCFLALGFLLPPPSILCSVPWIFTAFPRIVFFFFFFLRQVLALSPRQESSVRSWLIAT STSWVQAILLPQPLE (SEQ ID NO:962) corresponding to amino acids 450-588 of M78076_PEA_—1_P2 (SEQ ID NO:767), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P2 (SEQ ID NO:767), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


LTSFQLPNAPLFLRRPRLRLFSCPLDPLSVSWTPSYPLNTASLPLPSLSAQLPDPETWTLT	(SEQ ID NO:962)
CCVFDPCFLALGFLLPPPSILCSVPWIFTAFPRIVFFFFFFLRQVLALSPRQESSVRSWLIAT
STSWVQAILLPQPLE

in M78076_PEA_1_P2.	(SEQ ID NO:767)

Variant protein M78076_PEA_—1_P2 (SEQ ID NO:767) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 23, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P2 (SEQ ID NO:767) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 23


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No
520	A -> S	Yes
546	F ->	Yes
564	S -> C	Yes

The glycosylation sites of variant protein M78076_PEA_—1_P2 (SEQ ID NO:767), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 24 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 24


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	no
551	no

Variant protein M78076_PEA_—1_P2 (SEQ ID NO:767) is encoded by the following transcript(s): M78076_PEA_—1_T27 (SEQ ID NO:723), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T27 (SEQ ID NO:723) is shown in bold; this coding portion starts at position 142 and ends at position 1905. The transcript also has the following SNPs as listed in Table 25 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P2 (SEQ ID NO:767) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 25


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
1500	C -> T	Yes
1699	G -> T	Yes
1725	G -> A	Yes
1777	T ->	Yes
1831	A -> T	Yes
2274	A -> G	Yes
2525	A -> G	Yes
2681	G -> A	Yes
3831	G -> A	Yes

Variant protein M78076_PEA_—1_P25 (SEQ ID NO:768) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) M78076_PEA_—1_T28 (SEQ ID NO:724). An alignment is given to the known protein (Amyloid-like protein 1 precursor (SEQ ID NO:760)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between M78076_PEA_—1_P25 (SEQ ID NO:768) and APP1_HUMAN (SEQ ID NO:760):

1.An isolated chimeric polypeptide encoding for M78076_PEA_—1_P25 (SEQ ID NO:768), comprising a first amino acid sequence being at least 90% homologous to MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEAPGSAQVAGL CGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYPELQIARVEQATQAIPME RWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQ EAQEACSSQGLILHGSGMLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPG SRVEGAEDEEEEESFPQPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGV DIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALN EHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQADPPQAERVLL ALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQ corresponding to amino acids 1-448 of APP1_HUMAN (SEQ ID NO:760), which also corresponds to amino acids 1-448 of M78076_PEA_—1_P25 (SEQ ID NO:768), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence PQNPNSQPRAAGSLEVIISHPFVRRLEILISPFQFQNSIPKNSQIVPAASPRGTSSP (SEQ ID NO:963) corresponding to amino acids 449-505 of M78076_PEA_—1_P25 (SEQ ID NO:768), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated polypeptide encoding for a tail of M78076_PEA_—1_P25 (SEQ ID NO:768), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


PQNPNSQPRAAGSLEVIISHPFVRRLEILISPFQFQNSIPKNSQIVPAASPRGTSSP	(SEQ ID NO:963)

in M78076_PEA_1_P25.	(SEQ ID NO:768)

Variant protein M78076_PEA_—1_P25 (SEQ ID NO:768) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 26, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P25 (SEQ ID NO:768) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 26


Amino acid mutations

SNP position(s) on amino acid	Alternative
sequence	amino acid(s)	Previously known SNP?

4	A -> P	Yes
6	P -> H	Yes
13	R -> H	Yes
34	Q ->	No
38	G -> R	Yes
88	P -> R	Yes
124	R -> Q	Yes
127	S ->	No
145	F -> S	No
214	G -> R	No
214	G ->	No
262	Q ->	No
270	V ->	No
309	G -> E	Yes
370	Q ->	No

The glycosylation sites of variant protein M78076_PEA_—1_P25 (SEQ ID NO:768), as compared to the known protein Amyloid-like protein 1 precursor (SEQ ID NO:760), are described in Table 27 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 27


Glycosylation site(s)

Position(s) on known amino	Present in	Position
acid sequence	variant protein?	in variant protein?

337	yes	337
461	no
551	no

Variant protein M78076_PEA_—1_P25 (SEQ ID NO:768) is encoded by the following transcript(s): M78076_PEA_—1_T28 (SEQ ID NO:724), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript M78076_PEA_—1_T28 (SEQ ID NO:724) is shown in bold; this coding portion starts at position 142 and ends at position 1656. The transcript also has the following SNPs as listed in Table 28 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein M78076_PEA_—1_P25 (SEQ ID NO:768) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 28


Nucleic acid SNPs

SNP position on nucleotide	Alternative
sequence	nucleic acid	Previously known SNP?

114	G ->	No
151	G -> C	Yes
158	C -> A	Yes
179	G -> A	Yes
219	A -> G	Yes
243	G ->	No
253	G -> A	Yes
315	A -> G	Yes
366	A -> G	Yes
404	C -> G	Yes
512	G -> A	Yes
522	C ->	No
522	C -> T	No
575	T -> C	No
781	G ->	No
781	G -> A	No
927	G ->	No
951	C ->	No
1067	G -> A	Yes
1077	G -> A	Yes
1251	G ->	No
1398	G -> T	Yes
1423	C -> T	Yes
1593	A -> G	No
1736	C -> T	Yes

As noted above, cluster M78076 features 35 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster M78076_PEA_—1_node_—0 (SEQ ID NO:725) according to the present invention is supported by 47 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 29 below describes the starting and ending position of this segment on each transcript.

TABLE 29


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1	160
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1	160
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1	160
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1	160
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1	160
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1	160
NO: 721)
M78076_PEA_1_T26 (SEQ ID	1	160
NO: 722)
M78076_PEA_1_T27 (SEQ ID	1	160
NO: 723)
M78076_PEA_1_T28 (SEQ ID	1	160
NO: 724)

Segment cluster M78076_PEA_—1_node_—10 (SEQ ID NO:726) according to the present invention is supported by 70 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	433	565
NO: 716)
M78076_PEA_1_T3 (SEQ ID	433	565
NO: 717)
M78076_PEA_1_T5 (SEQ ID	433	565
NO: 718)
M78076_PEA_1_T13 (SEQ ID	433	565
NO: 719)
M78076_PEA_1_T15 (SEQ ID	433	565
NO: 720)
M78076_PEA_1_T23 (SEQ ID	433	565
NO: 721)
M78076_PEA_1_T26 (SEQ ID	433	565
NO: 722)
M78076_PEA_1_T27 (SEQ ID	433	565
NO: 723)
M78076_PEA_1_T28 (SEQ ID	433	565
NO: 724)

Segment cluster M78076_PEA_—1_node_—15 (SEQ ID NO:727) according to the present invention is supported by 74 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	679	812
NO: 716)
M78076_PEA_1_T3 (SEQ ID	679	812
NO: 717)
M78076_PEA_1_T5 (SEQ ID	679	812
NO: 718)
M78076_PEA_1_T13 (SEQ ID	679	812
NO: 719)
M78076_PEA_1_T15 (SEQ ID	679	812
NO: 720)
M78076_PEA_1_T23 (SEQ ID	679	812
NO: 721)
M78076_PEA_1_T26 (SEQ ID	679	812
NO: 722)
M78076_PEA_1_T27 (SEQ ID	679	812
NO: 723)
M78076_PEA_1_T28 (SEQ ID	679	812
NO: 724)

Segment cluster M78076_PEA_—1_node_—18 (SEQ ID NO:728) according to the present invention is supported by 95 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	813	991
NO: 716)
M78076_PEA_1_T3 (SEQ ID	813	991
NO: 717)
M78076_PEA_1_T5 (SEQ ID	813	991
NO: 718)
M78076_PEA_1_T13 (SEQ ID	813	991
NO: 719)
M78076_PEA_1_T15 (SEQ ID	813	991
NO: 720)
M78076_PEA_1_T23 (SEQ ID	813	991
NO: 721)
M78076_PEA_1_T26 (SEQ ID	813	991
NO: 722)
M78076_PEA_1_T27 (SEQ ID	813	991
NO: 723)
M78076_PEA_1_T28 (SEQ ID	813	991
NO: 724)

Segment cluster M78076_PEA_—1_node_—20 (SEQ ID NO:729) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	992	1122
NO: 716)
M78076_PEA_1_T3 (SEQ ID	992	1122
NO: 717)
M78076_PEA_1_T5 (SEQ ID	992	1122
NO: 718)
M78076_PEA_1_T13 (SEQ ID	992	1122
NO: 719)
M78076_PEA_1_T15 (SEQ ID	992	1122
NO: 720)
M78076_PEA_1_T23 (SEQ ID	992	1122
NO: 721)
M78076_PEA_1_T26 (SEQ ID	992	1122
NO: 722)
M78076_PEA_1_T27 (SEQ ID	992	1122
NO: 723)
M78076_PEA_1_T28 (SEQ ID	992	1122
NO: 724)

Segment cluster M78076_PEA_—1_node_—24 (SEQ ID NO:730) according to the present invention is supported by 105 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1198	1356
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1198	1356
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1198	1356
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1198	1356
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1198	1356
NO: 720)
M78076_PEA_1_T26 (SEQ ID	1198	1356
NO: 722)
M78076_PEA_1_T27 (SEQ ID	1198	1356
NO: 723)
M78076_PEA_1_T28 (SEQ ID	1198	1356
NO: 724)

Segment cluster M78076_PEA_—1_node_—26 (SEQ ID NO:731) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 35 below describes the starting and ending position of this segment on each transcript.

TABLE 35


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1357	1485
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1357	1485
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1357	1485
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1357	1485
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1357	1485
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1198	1326
NO: 721)
M78076_PEA_1_T26 (SEQ ID	1357	1485
NO: 722)
M78076_PEA_1_T27 (SEQ ID	1357	1485
NO: 723)
M78076_PEA_1_T28 (SEQ ID	1357	1485
NO: 724)

Segment cluster M78076_PEA_—1_node_—29 (SEQ ID NO:732) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T27 (SEQ ID NO:723). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T27 (SEQ ID	1490	3132
NO: 723)

Segment cluster M78076_PEA_—1_node_—32 (SEQ ID NO:733) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T26 (SEQ ID NO:722) and M78076_PEA_—1_T27 (SEQ ID NO:723). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T26 (SEQ ID	1586	2457
NO: 722)
M78076_PEA_1_T27 (SEQ ID	3233	4104
NO: 723)

Segment cluster M78076 PEA_—1_node_—35 (SEQ ID NO:734) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716) and M78076_PEA_—1_T5 (SEQ ID NO:718). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1694	1952
NO: 716)
M78076_PEA_1_T5 (SEQ ID	1694	1952
NO: 718)

Segment cluster M78076_PEA_—1_node_—37 (SEQ ID NO:735) according to the present invention is supported by 11 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T3 (SEQ ID NO:717) and M78076_PEA_—1_T5 (SEQ ID NO:718). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T3 (SEQ ID	1718	2180
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1977	2439
NO: 718)

Segment cluster M78076_PEA_—1_node_—46 (SEQ ID NO:736) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T15 (SEQ ID NO:720). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T15 (SEQ ID	1852	1972
NO: 720)

Segment cluster M78076_PEA_—1_node_—47 (SEQ ID NO:737) according to the present invention is supported by 155 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718) M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 41 below describes the starting and ending position of this segment on each transcript.

TABLE 41


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2111	2254
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2327	2470
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2586	2729
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1781	1924
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1973	2116
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1693	1836
NO: 721)

Segment cluster M78076_PEA_—1_node_—54 (SEQ ID NO:738) according to the present invention is supported by 133 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2412	2715
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2628	2931
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2887	3190
NO: 718)
M78076_PEA_1_T13 (SEQ ID	2082	2385
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2274	2577
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1994	2297
NO: 721)
M78076_PEA_1_T28 (SEQ ID	1492	1795
NO: 724)

Segment cluster M78076_PEA_—1_node_—1 (SEQ ID NO:739) according to the present invention is supported by 47 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 43 below describes the starting and ending position of this segment on each transcript.

TABLE 43


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	161	204
NO: 716)
M78076_PEA_1_T3 (SEQ ID	161	204
NO: 717)
M78076_PEA_1_T5 (SEQ ID	161	204
NO: 718)
M78076_PEA_1_T13 (SEQ ID	161	204
NO: 719)
M78076_PEA_1_T15 (SEQ ID	161	204
NO: 720)
M78076_PEA_1_T23 (SEQ ID	161	204
NO: 721)
M78076_PEA_1_T26 (SEQ ID	161	204
NO: 722)
M78076_PEA_1_T27 (SEQ ID	161	204
NO: 723)
M78076_PEA_1_T28 (SEQ ID	161	204
NO: 724)

Segment cluster M78076_PEA_—1_node_—2 (SEQ ID NO:740) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 44 below describes the starting and ending position of this segment on each transcript.

TABLE 44


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	205	224
NO: 716)
M78076_PEA_1_T3 (SEQ ID	205	224
NO: 717)
M78076_PEA_1_T5 (SEQ ID	205	224
NO: 718)
M78076_PEA_1_T13 (SEQ ID	205	224
NO: 719)
M78076_PEA_1_T15 (SEQ ID	205	224
NO: 720)
M78076_PEA_1_T23 (SEQ ID	205	224
NO: 721)
M78076_PEA_1_T26 (SEQ ID	205	224
NO: 722)
M78076_PEA_1_T27 (SEQ ID	205	224
NO: 723)
M78076_PEA_1_T28 (SEQ ID	205	224
NO: 724)

Segment cluster M78076_PEA_—1node_—3 (SEQ ID NO:741) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718) M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 45 below describes the starting and ending position of this segment on each transcript.

TABLE 45


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	225	288
NO: 716)
M78076_PEA_1_T3 (SEQ ID	225	288
NO: 717)
M78076_PEA_1_T5 (SEQ ID	225	288
NO: 718)
M78076_PEA_1_T13 (SEQ ID	225	288
NO: 719)
M78076_PEA_1_T15 (SEQ ID	225	288
NO: 720)
M78076_PEA_1_T23 (SEQ ID	225	288
NO: 721)
M78076_PEA_1_T26 (SEQ ID	225	288
NO: 722)
M78076_PEA_1_T27 (SEQ ID	225	288
NO: 723)
M78076_PEA_1_T28 (SEQ ID	225	288
NO: 724)

Segment cluster M78076_PEA_—1_node_—6 (SEQ ID NO:742) according to the present invention is supported by 59 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 46 below describes the starting and ending position of this segment on each transcript.

TABLE 46


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	289	370
NO: 716)
M78076_PEA_1_T3 (SEQ ID	289	370
NO: 717)
M78076_PEA_1_T5 (SEQ ID	289	370
NO: 718)
M78076_PEA_1_T13 (SEQ ID	289	370
NO: 719)
M78076_PEA_1_T15 (SEQ ID	289	370
NO: 720)
M78076_PEA_1_T23 (SEQ ID	289	370
NO: 721)
M78076_PEA_1_T26 (SEQ ID	289	370
NO: 722)
M78076_PEA_1_T27 (SEQ ID	289	370
NO: 723)
M78076_PEA_1_T28 (SEQ ID	289	370
NO: 724)

Segment cluster M78076_PEA_—1_node_—7 (SEQ ID NO:743) according to the present invention is supported by 64 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 47 below describes the starting and ending position of this segment on each transcript.

TABLE 47


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	371	432
NO: 716)
M78076_PEA_1_T3 (SEQ ID	371	432
NO: 717)
M78076_PEA_1_T5 (SEQ ID	371	432
NO: 718)
M78076_PEA_1_T13 (SEQ ID	371	432
NO: 719)
M78076_PEA_1_T15 (SEQ ID	371	432
NO: 720)
M78076_PEA_1_T23 (SEQ ID	371	432
NO: 721)
M78076_PEA_1_T26 (SEQ ID	371	432
NO: 722)
M78076_PEA_1_T27 (SEQ ID	371	432
NO: 723)
M78076_PEA_1_T28 (SEQ ID	371	432
NO: 724)

Segment cluster M78076_PEA_—1_node_—12 (SEQ ID NO:744) according to the present invention is supported by 71 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 48 below describes the starting and ending position of this segment on each transcript.

TABLE 48


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	566	678
NO: 716)
M78076_PEA_1_T3 (SEQ ID	566	678
NO: 717)
M78076_PEA_1_T5 (SEQ ID	566	678
NO: 718)
M78076_PEA_1_T13 (SEQ ID	566	678
NO: 719)
M78076_PEA_1_T15 (SEQ ID	566	678
NO: 720)
M78076_PEA_1_T23 (SEQ ID	566	678
NO: 721)
M78076_PEA_1_T26 (SEQ ID	566	678
NO: 722)
M78076_PEA_1_T27 (SEQ ID	566	678
NO: 723)
M78076_PEA_1_T28 (SEQ ID	566	678
NO: 724)

Segment cluster M78076_PEA_—1_node_—22 (SEQ ID NO:745) according to the present invention is supported by 92 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722), M78076_PEA_—1_T27 (SEQ ID NO:723) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 49 below describes the starting and ending position of this segment on each transcript.

TABLE 49


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1123	1197
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1123	1197
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1123	1197
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1123	1197
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1123	1197
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1123	1197
NO: 721)
M78076_PEA_1_T26 (SEQ ID	1123	1197
NO: 722)
M78076_PEA_1_T27 (SEQ ID	1123	1197
NO: 723)
M78076_PEA_1_T28 (SEQ ID	1123	1197
NO: 724)

Segment cluster M78076_PEA_—1_node_—27 (SEQ ID NO:746) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T27 (SEQ ID NO:723). Table 50 below describes the starting and ending position of this segment on each transcript.

TABLE 50


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T27 (SEQ ID	1486	1489
NO: 723)

Segment cluster M78076_PEA_—1_node_—30 (SEQ ID NO:747) according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722) and M78076_PEA_—1_T27 (SEQ ID NO:723). Table 51 below describes the starting and ending position of this segment on each transcript.

TABLE 51


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1486	1557
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1486	1557
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1486	1557
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1486	1557
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1486	1557
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1327	1398
NO: 721)
M78076_PEA_1_T26 (SEQ ID	1486	1557
NO: 722)
M78076_PEA_1_T27 (SEQ ID	3133	3204
NO: 723)

Segment cluster M78076_PEA_—1_node_—31 (SEQ ID NO:748) according to the present invention is supported by 89 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721), M78076_PEA_—1_T26 (SEQ ID NO:722) and M78076_PEA_—1_T27 (SEQ ID NO:723). Table 52 below describes the starting and ending position of this segment on each transcript.

TABLE 52


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1558	1585
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1558	1585
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1558	1585
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1558	1585
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1558	1585
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1399	1426
NO: 721)
M78076_PEA_1_T26 (SEQ ID	1558	1585
NO: 722)
M78076_PEA_1_T27 (SEQ ID	3205	3232
NO: 723)

Segment cluster M78076_PEA_—1_node_—34 (SEQ ID NO:749) according to the present invention is supported by 103 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 53 below describes the starting and ending position of this segment on each transcript.

TABLE 53


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1586	1693
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1586	1693
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1586	1693
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1586	1693
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1586	1693
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1427	1534
NO: 721)

Segment cluster M78076_PEA_—1_node_—36 (SEQ ID NO:750) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 54 below describes the starting and ending position of this segment on each transcript.

TABLE 54


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1953	1976
NO: 716)
M78076_PEA_1_T3 (SEQ ID	1694	1717
NO: 717)
M78076_PEA_1_T5 (SEQ ID	1953	1976
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1694	1717
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1694	1717
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1535	1558
NO: 721)

Segment cluster M78076_PEA_—1_node_—41 (SEQ ID NO:751) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T3 (SEQ ID NO:717) and M78076_PEA_—1_T5 (SEQ ID NO:718). Table 55 below describes the starting and ending position of this segment on each transcript.

TABLE 55


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T3 (SEQ ID	2181	2192
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2440	2451
NO: 718)

Segment cluster M78076_PEA_—1_node_—42 (SEQ ID NO:752) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 56 below describes the starting and ending position of this segment on each transcript.

TABLE 56


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1977	1985
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2193	2201
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2452	2460
NO: 718)
M78076_PEA_1_T15 (SEQ ID	1718	1726
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1559	1567
NO: 721)

Segment cluster M78076_PEA_—1_node_—43 (SEQ ID NO:753) according to the present invention is supported by 110 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 57 below describes the starting and ending position of this segment on each transcript.

TABLE 57


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	1986	2047
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2202	2263
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2461	2522
NO: 718)
M78076_PEA_1_T15 (SEQ ID	1727	1788
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1568	1629
NO: 721)

TABLE 58


Oligonucleotides related to this segment

Oligonucleotide name	Overexpressed in cancers	Chip reference

M78076_0_7_0 (SEQ ID	breast malignant tumors	BRS
NO: 914)

Segment cluster M78076_PEA_—1_node_—45 (SEQ ID NO:754) according to the present invention is supported by 132 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 59 below describes the starting and ending position of this segment on each transcript.

TABLE 59


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2048	2110
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2264	2326
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2523	2585
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1718	1780
NO: 719)
M78076_PEA_1_T15 (SEQ ID	1789	1851
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1630	1692
NO: 721)

TABLE 60


Oligonucleotides related to this segment

Oligonucleotide name	Overexpressed in cancers	Chip reference

M78076_0_7_0 (SEQ ID	breast malignant tumors	BRS
NO: 914)

Segment cluster M78076_PEA_—1_node_—49 (SEQ ID NO:755) according to the present invention is supported by 129 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 61 below describes the starting and ending position of this segment on each transcript.

TABLE 61


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2255	2290
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2471	2506
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2730	2765
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1925	1960
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2117	2152
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1837	1872
NO: 721)

Segment cluster M78076_PEA_—1_node_—50 (SEQ ID NO:756) according to the present invention is supported by 125 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 62 below describes the starting and ending position of this segment on each transcript.

TABLE 62


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2291	2329
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2507	2545
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2766	2804
NO: 718)
M78076_PEA_1_T13 (SEQ ID	1961	1999
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2153	2191
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1873	1911
NO: 721)

Segment cluster M78076_PEA_—1_node_—51 (SEQ ID NO:757) according to the present invention is supported by 123 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 63 below describes the starting and ending position of this segment on each transcript.

TABLE 63


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2330	2388
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2546	2604
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2805	2863
NO: 718)
M78076_PEA_1_T13 (SEQ ID	2000	2058
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2192	2250
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1912	1970
NO: 721)

Segment cluster M78076_PEA_—1_node_—52 (SEQ ID NO:758) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720) and M78076_PEA_—1_T23 (SEQ ID NO:721). Table 64 below describes the starting and ending position of this segment on each transcript.

TABLE 64


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2389	2405
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2605	2621
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2864	2880
NO: 718)
M78076_PEA_1_T13 (SEQ ID	2059	2075
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2251	2267
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1971	1987
NO: 721)

Segment cluster M78076_PEA_—1_node_—53 (SEQ ID NO:759) according to the present invention can be found in the following transcript(s): M78076_PEA_—1_T2 (SEQ ID NO:716), M78076_PEA_—1_T3 (SEQ ID NO:717), M78076_PEA_—1_T5 (SEQ ID NO:718), M78076_PEA_—1_T13 (SEQ ID NO:719), M78076_PEA_—1_T15 (SEQ ID NO:720), M78076_PEA_—1_T23 (SEQ ID NO:721) and M78076_PEA_—1_T28 (SEQ ID NO:724). Table 65 below describes the starting and ending position of this segment on each transcript.

TABLE 65


Segment location on transcripts

	Segment	Segment
Transcript name	starting position	ending position

M78076_PEA_1_T2 (SEQ ID	2406	2411
NO: 716)
M78076_PEA_1_T3 (SEQ ID	2622	2627
NO: 717)
M78076_PEA_1_T5 (SEQ ID	2881	2886
NO: 718)
M78076_PEA_1_T13 (SEQ ID	2076	2081
NO: 719)
M78076_PEA_1_T15 (SEQ ID	2268	2273
NO: 720)
M78076_PEA_1_T23 (SEQ ID	1988	1993
NO: 721)
M78076_PEA_1_T28 (SEQ ID	1486	1491
NO: 724)

Variant protein alignment to the previously known protein:

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P3 (SEQ ID NO:761)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:

Quality: 5132.00



Quality:	5132.00
Escore:	0
Matching length:	517	Total length:	517
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · · · ·
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500

	·
501	GGSSEDKGGLQPPDSKD	517
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GGSSEDKGGLQPPDSKD	517

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P4 (SEQ ID NO:762)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	5223.00
Escore:	0
Matching length:	526	Total length:	526
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRRTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · · · ·
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500

	· ·
501	GGSSEDKGGLQPPDSKDDTPMTLPKG	526
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GGSSEDKGGLQPPDSKDDTPMTLPKG	526

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1P12 (SEQ ID NO:763)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	5223.00
Escore:	0
Matching length:	526	Total length:	526
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · · · ·
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500

	· ·
501	GGSSEDKGGLQPPDSKDDTPMTLPKG	526
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GGSSEDKGGLQPPDSKDDTPMTLPKG	526

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1P14 (SEQ ID NO:764)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	5672.00
Escore:	0
Matching length:	575	Total length:	575
Matching Percent	99.48	Matching Percent Identity:	99.48
Similarity:
Total Percent Similarity:	99.48	Total Percent Identity:	99.48
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · · · ·
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500

	· · · · ·
501	GGSSEDKGGLQPPDSKDDTPMTLPKGSTEQDAASPEKEKMNPLEQYERKV	550
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GGSSEDKGGLQPPDSKDDTPMTLPKGSTEQDAASPEKEKMNPLEQYERKV	550

	· ·
551	NASVPRGFPFHSSEIQRDELVRGGT	575
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|
551	NASVPRGFPFHSSEIQRDELAPAGT	575

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P21 (SEQ ID NO:765)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	5822.00
Escore:	0
Matching length:	597	Total length:	650
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	91.85	Total Percent Identity:	91.85
Gaps:	1

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NE................................................	352
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
353	.....AERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	397
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · · · ·
398	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	447
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAP	500

	· · · · ·
448	GGSSEDKGGLQPPDSKDDTPMTLPKGSTEQDAASPEKEKMNPLEQYEPKV	497
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
501	GGSSEDKGGLQPPDSKDDTPMTLPKGSTEQDAASPEKEKMNPLEQYERKV	550

	· · · · ·
498	NASVPRGFPFHSSEIQRDELAPAGTGVSREAVSGLLIMGAGGGSLIVLSM	547
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
551	NASVPRGFPFHSSEIQRDELAPAGTGVSREAVSGLLIMGAGGGSLIVLSM	600

	· · · · ·
548	LLLRRKKPYGAISHGVVEVDPMLTLEEQQLRELQRHGYENPTYRFLEERP	597
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
601	LLLRRKKPYGAISHGVVEVDPMLTLEEQQLRELQRHGYENPTYRFLEERP	650

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P24 (SEQ ID NO:766)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	4791.00
Escore:	0
Matching length:	485	Total length:	485
Matching Percent	99.79	Matching Percent Identity:	99.59
Similarity:
Total Percent Similarity:	99.79	Total Percent Identity:	99.59
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGETSEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGETSEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

	· · ·
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIRECL	485
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|:\| \|
451	THLQVIEERVNQSLGLLDQNPHLAQELRPQIQELL	485

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P2 (SEQ ID NO:767)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	4474.00
Escore:	0
Matching length:	454	Total length:	454
Matching Percent	99.56	Matching Percent Identity:	99.34
Similarity:
Total Percent Similarity:	99.56	Total Percent Identity:	99.34
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDIYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVL	450
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVH	450

451	TSFQ	454
	\| :\|
451	THLQ	454

Sequence name: APP1_HUMAN (SEQ ID NO:760)

Sequence documentation:

Alignment of: M78076_PEA_—1_P25 (SEQ ID NO:768)×APP1_HUMAN (SEQ ID NO:760).

Alignment segment 1/1:



Quality:	4455.00
Escore:	0
Matching length:	448	Total length:	448
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	100.00	Total Percent Identity:	100.00
Gaps:	0

Alignment:


	· · · · ·
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGGSPGAAEA	50

	· · · · ·
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
51	PGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLEYCRQMYP	100

	· · · · ·
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
101	ELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEAL	150

	· · · · ·
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
151	LVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGMLLPCGSD	200

	· · · · ·
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
201	RFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWPPGSRVEGAEDEEEEESFP	250

	· · · · ·
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDTYFGM	300
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
251	QPVDDYFVEPPQAEEEEETVPPPSSHTLAVVGKVTPTPRPTDGVDTYFGM	300

	· · · · ·
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
301	PGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQAL	350

	· · · · ·
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
351	NEHFQSILQTLEEQVSGERQRLVETHATRVIALINDQRRAALEGFLAALQ	400

	· · · ·
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQ	448
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
401	ADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQ	448

Description for Cluster HSMUC1A

Cluster HSMUC1A features 14 transcript(s) and 22 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSMUC1A_PEA_1_T12	769
	HSMUC1A_PEA_1_T26	770
	HSMUC1A_PEA_1_T28	771
	HSMUC1A_PEA_1_T29	772
	HSMUC1A_PEA_1_T30	773
	HSMUC1A_PEA_1_T31	774
	HSMUC1A_PEA_1_T33	775
	HSMUC1A_PEA_1_T34	776
	HSMUC1A_PEA_1_T35	777
	HSMUC1A_PEA_1_T36	778
	HSMUC1A_PEA_1_T40	779
	HSMUC1A_PEA_1_T42	780
	HSMUC1A_PEA_1_T43	781
	HSMUC1A_PEA_1_T47	782

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSMUC1A_PEA_1_node_0	783
	HSMUC1A_PEA_1_node_14	784
	HSMUC1A_PEA_1_node_24	785
	HSMUC1A_PEA_1_node_29	786
	HSMUC1A_PEA_1_node_35	787
	HSMUC1A_PEA_1_node_38	788
	HSMUC1A_PEA_1_node_3	789
	HSMUC1A_PEA_1_node_4	790
	HSMUC1A_PEA_1_node_5	791
	HSMUC1A_PEA_1_node_6	792
	HSMUC1A_PEA_1_node_7	793
	HSMUC1A_PEA_1_node_17	794
	HSMUC1A_PEA_1_node_18	795
	HSMUC1A_PEA_1_node_20	796
	HSMUC1A_PEA_1_node_21	797
	HSMUC1A_PEA_1_node_23	798
	HSMUC1A_PEA_1_node_26	799
	HSMUC1A_PEA_1_node_27	800
	HSMUC1A_PEA_1_node_31	801
	HSMUC1A_PEA_1_node_34	802
	HSMUC1A_PEA_1_node_36	803
	HSMUC1A_PEA_1_node_37	804

TABLE 3


Proteins of interest

Sequence ID

Corresponding

Protein Name	No.	Transcript(s)

HSMUC1A_PEA_1_P25	806	HSMUC1A_PEA_1_T26
		(SEQ ID NO:770)

HSMUC1A_PEA_1_P29	807	HSMUC1A_PEA_1_T33
		(SEQ ID NO:775)

HSMUC1A_PEA_1_P30	808	HSMUC1A_PEA_1_T34
		(SEQ ID NO:776)

HSMUC1A_PEA_1_P32	809	HSMUC1A_PEA_1_T36
		(SEQ ID NO:778)

HSMUC1A_PEA_1_P36	810	HSMUC1A_PEA_1_T40
		(SEQ ID NO:779)

HSMUC1A_PEA_1_P39	811	HSMUC1A_PEA_1_T43
		(SEQ ID NO:781)

HSMUC1A_PEA_1_P45	812	HSMUC1A_PEA_1_T29
		(SEQ ID NO:772)

HSMUC1A_PEA_1_P49	813	HSMUC1A_PEA_1_T12
(SEQ ID NO:813)		(SEQ ID NO:769)

HSMUC1A_PEA_1_P52	814	HSMUC1A_PEA_1_T30
		(SEQ ID NO:773)

HSMUC1A_PEA_1_P53	815	HSMUC1A_PEA_1_T31
		(SEQ ID NO:774)

HSMUC1A_PEA_1_P56	816	HSMUC1A_PEA_1_T42
		(SEQ ID NO:780)

HSMUC1A_PEA_1_P58	817	HSMUC1A_PEA_1_T35
		(SEQ ID NO:777)

HSMUC1A_PEA_1_P59	818	HSMUC1A_PEA_1_T28
		(SEQ ID NO:771)

HSMUC1A_PEA_1_P63	819	HSMUC1A_PEA_1_T47
		(SEQ ID NO:782)

These sequences are variants of the known protein Mucin 1 precursor (SwissProt accession identifier MUC1_HUMAN; known also according to the synonyms MUC-1; Polymorphic epithelial mucin; PEM; PEMT; Episialin; Tumor-associated mucin; Carcinoma-associated mucin; Tumor-associated epithelial membrane antigen; EMA; H23AG; Peanut-reactive urinary mucin; PUM; Breast carcinoma-associated antigen DF3; CD227 antigen), SEQ ID NO: 805, referred to herein as the previously known protein.

Protein Mucin 1 precursor (SEQ ID NO:805) is known or believed to have the following function(s): May play a role in adhesive functions and in cell-cell interactions, metastasis and signaling. May provide a protective layer on epithelial surfaces. Direct or indirect interaction with actin cytoskeleton. Isoform 7 behaves as a receptor and binds the secreted isoform 5. The binding induces the phosphorylation of the isoform 7, alters cellular morphology and initiates cell signaling. Can bind to GRB2 adapter protein. The sequence for protein Mucin 1 precursor (SEQ ID NO:805) is given at the end of the application, as “Mucin 1 precursor (SEQ ID NO:805) amino acid sequence”. Known polymorphisms for this sequence are as shown in Table 4.

TABLE 4


Amino acid mutations for Known Protein

SNP position(s) on
amino acid sequence	Comment

1116	D->E: NO EFFECT ON BINDING OF
	ISOFORM 7.
1116	D->A: DRASTICALLY REDUCED BINDING OF
	ISOFORM 7.
2	T -> A
134	P -> Q
154	P -> Q
1021	S -> T
1117	V -> M
1193	Q -> L
1231	K -> T
1251	A -> T

Protein Mucin 1 precursor (SEQ ID NO:805) localization is believed to be Type I membrane protein. Two secreted forms (5 and 9) are also produced.

The previously known protein also has the following indication(s) and/or potential thereaputic use(s): Cancer, breast; Cancer, lung, non-small cell; Cancer, ovarian; Cancer, prostate. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: CD8 agonist; DNA antagonist; Immunostimulant; Interferon gamma agonist; MUC-1 inhibitor. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anticancer; Monoclonal antibody, murine; Immunotoxin; Immunostimulant; Immunoconjugate.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: actin binding, which are annotation(s) related to Molecular Function; and cytoskeleton; integral plasma membrane protein, which are annotation(s) related to Cellular Component.

Cluster HSMUC1A can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 43 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 43 and Table 5. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: a mixture of malignant tumors from different tissues, breast malignant tumors, pancreas carcinoma and prostate cancer.

TABLE 5


Normal tissue distribution

	Name of Tissue	Number

	bladder	41
	brain	2
	colon	66
	epithelial	96
	general	36
	head and neck	314
	kidney	282
	lung	200
	breast	61
	ovary	0
	pancreas	12
	prostate	24
	stomach	296
	Thyroid	0
	uterus	122

TABLE 6


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

bladder	3.3e−01	4.5e−01	1.8e−02	2.4	8.9e−02	1.7
brain	3.0e−02	2.6e−02	1.2e−01	4.6	1.1e−01	3.9
colon	1.2e−01	2.4e−01	3.8e−01	1.6	5.9e−01	1.2
epithelial	5.4e−02	6.0e−01	7.3e−06	1.8	6.2e−02	1.1
general	6.5e−07	2.6e−03	4.0e−23	3.6	1.7e−12	2.3
head and neck	6.4e−01	7.2e−01	1	0.3	1	0.3
kidney	7.8e−01	8.1e−01	1	0.3	1	0.2
lung	7.6e−01	7.9e−01	6.7e−01	0.8	1	0.4
breast	8.2e−02	1.3e−01	4.1e−03	3.6	7.7e−02	2.0
ovary	3.0e−02	4.3e−02	6.9e−02	4.4	1.6e−01	3.2
pancreas	7.2e−02	1.4e−01	9.6e−07	5.4	1.5e−05	4.5
prostate	7.0e−01	6.0e−01	1.5e−02	1.4	6.9e−04	3.2
stomach	3.1e−01	7.1e−01	1.5e−01	0.4	4.6e−01	0.8
Thyroid	2.9e−01	2.9e−01	4.4e−01	2.0	4.4e−01	2.0
uterus	2.4e−01	6.5e−01	1.6e−01	1.0	7.0e−01	0.6

TABLE 7


Oligonucleotides related to this cluster

Oligonucleotide

Overexpressed in

Chip

	name	cancers	reference

HSMUC1A_0_0_11364	breast malignant	BRS
(SEQ ID NO:916)	tumors

As noted above, cluster HSMUC1A features 14 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Mucin 1 precursor (SEQ ID NO:805). A description of each variant protein according to the present invention is now provided.

Variant protein HSMUC1A_PEA_—1_P25 (SEQ ID NO:806) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T26 (SEQ ID NO:770). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide.

Variant protein HSMUC1A_PEA_—1_P25 (SEQ ID NO:806) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P25 (SEQ ID NO:806) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 8


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

90	S -> N	Yes
91	D -> N	No
157	Y ->	No
187	S -> G	No

Variant protein HSMUC1A_PEA_—1_P25 (SEQ ID NO:806) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T26 (SEQ ID NO:770) is shown in bold; this coding portion starts at position 507 and ends at position 1115. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P25 (SEQ ID NO:806) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 9


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
775	G -> A	Yes
777	G -> A	No
977	C ->	No
1065	A -> G	No
1073	C -> T	No
1079	C -> T	Yes
1124	C -> T	Yes
1177	C -> T	No
1197	C -> T	Yes
1303	G ->	No
1315	G -> A	Yes
1316	C ->	No
1316	C -> T	No
1405	A -> T	No

Variant protein HSMUC1A_PEA_—1_P29 (SEQ ID NO:807) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T33 (SEQ ID NO:775). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P29 (SEQ ID NO:807) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T33 (SEQ ID NO:775) is shown in bold; this coding portion starts at position 507 and ends at position 953. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P29 (SEQ ID NO:807) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 10


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
964	C ->	No
1052	A -> G	No
1060	C -> T	No
1066	C -> T	Yes
1111	C -> T	Yes
1164	C -> T	No
1184	C -> T	Yes
1290	G ->	No
1302	G -> A	Yes
1303	C ->	No
1303	C -> T	No
1392	A -> T	No

Variant protein HSMUC1A_PEA_—1_P30 (SEQ ID NO:808) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T34 (SEQ ID NO:776). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide.

Variant protein HSMUC1A_PEA_—1_P30 (SEQ ID NO:808) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P30 (SEQ ID NO:808) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 11


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

120	Y ->	No
150	S -> G	No

Variant protein HSMUC1A_PEA_—1_P30 (SEQ ID NO:808) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T34 (SEQ ID NO:776) is shown in bold; this coding portion starts at position 507 and ends at position 1004. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P30 (SEQ ID NO:808) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 12


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

599	A -> G	No
866	C ->	No
954	A -> G	No
962	C -> T	No
968	C -> T	Yes
1013	C -> T	Yes
1066	C -> T	No
1086	C -> T	Yes
1192	G ->	No
1204	G -> A	Yes
1205	C ->	No
1205	C -> T	No
1294	A -> T	No

Variant protein HSMUC1A_PEA_—1_P32 (SEQ ID NO:809) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T36 (SEQ ID NO:778). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide.

Variant protein HSMUC1A_PEA_—1_P32 (SEQ ID NO:809) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P32 (SEQ ID NO:809) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 13


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

111	Y ->	No
141	S -> G	No

Variant protein HSMUC1A_PEA_—1_P32 (SEQ ID NO:809) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T36 (SEQ ID NO:778) is shown in bold; this coding portion starts at position 507 and ends at position 977. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P32 (SEQ ID NO:809) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 14


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
839	C ->	No
927	A -> G	No
935	C -> T	No
941	C -> T	Yes
986	C -> T	Yes
1039	C -> T	No
1059	C -> T	Yes
1165	G ->	No
1177	G -> A	Yes
1178	C ->	No
1178	C -> T	No
1267	A -> T	No

Variant protein HSMUC1A_PEA_—1_P36 (SEQ ID NO:810) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T40 (SEQ ID NO:779). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P36 (SEQ ID NO:810) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P36 (SEQ ID NO:810) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 15


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

113	Y ->	No
143	S -> G	No

Variant protein HSMUC1A_PEA_—1_P36 (SEQ ID NO:810) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T40 (SEQ ID NO:779) is shown in bold; this coding portion starts at position 507 and ends at position 983. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P36 (SEQ ID NO:810) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 16


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

599	A -> G	No
845	C ->	No
933	A -> G	No
941	C -> T	No
947	C -> T	Yes
992	C -> T	Yes
1045	C -> T	No
1065	C -> T	Yes
1171	G ->	No
1183	G -> A	Yes
1184	C ->	No
1184	C -> T	No
1273	A -> T	No

Variant protein HSMUC1A_PEA_—1_P39 (SEQ ID NO:811) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T43 (SEQ ID NO:781). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P39 (SEQ ID NO:811) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 17, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P39 (SEQ ID NO:811) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 17


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

90	Y ->	No
120	S -> G	No

Variant protein HSMUC1A_PEA_—1_P39 (SEQ ID NO:811) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T43 (SEQ ID NO:781), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) is shown in bold; this coding portion starts at position 507 and ends at position 914. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P39 (SEQ ID NO:811) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 18


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

599	A -> G	No
776	C ->	No
864	A -> G	No
872	C -> T	No
878	C -> T	Yes
923	C -> T	Yes
976	C -> T	No
996	C -> T	Yes
1102	G ->	No
1114	G -> A	Yes
1115	C ->	No
1115	C -> T	No
1204	A -> T	No

Variant protein HSMUC1A_PEA_—1_P45 (SEQ ID NO:812) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T29 (SEQ ID NO:772). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P45 (SEQ ID NO:812) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T29 (SEQ ID NO:772) is shown in bold; this coding portion starts at position 507 and ends at position 746. The transcript also has the following SNPs as listed in Table 19 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P45 (SEQ ID NO:812) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 19


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

599	A -> G	No
746	G -> A	Yes
748	G -> A	No
948	C ->	No
1036	A -> G	No
1044	C -> T	No
1050	C -> T	Yes
1095	C -> T	Yes
1148	C -> T	No
1168	C -> T	Yes
1274	G ->	No
1286	G -> A	Yes
1287	C ->	No
1287	C -> T	No
1376	A -> T	No

Variant protein HSMUC1A_PEA_—1_P49 (SEQ ID NO:813) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T12 (SEQ ID NO:769). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P49 (SEQ ID NO:813) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T12 (SEQ ID NO:769) is shown in bold; this coding portion starts at position 507 and ends at position 884. The transcript also has the following SNPs as listed in Table 20 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P49 (SEQ ID NO:813) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 20


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
704	G -> A	Yes
1012	G -> A	Yes
1088	G -> A	Yes
1090	G -> A	No
1290	C ->	No
1378	A -> G	No
1386	C -> T	No
1392	C -> T	Yes
1437	C -> T	Yes
1490	C -> T	No
1510	C -> T	Yes
1616	G ->	No
1628	G -> A	Yes
1629	C ->	No
1629	C -> T	No
1718	A -> T	No

Variant protein HSMUC1A_PEA_—1_P52 (SEQ ID NO:814) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T30 (SEQ ID NO:773). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to was secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P52 (SEQ ID NO:814) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T30 (SEQ ID NO:773) is shown in bold; this coding portion starts at position 507 and ends at position 719. The transcript also has the following SNPs as listed in Table 21 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P52 (SEQ ID NO:814) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 21


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
719	G -> A	Yes
721	G -> A	No
921	C ->	No
1009	A -> G	No
1017	C -> T	No
1023	C -> T	Yes
1068	C -> T	Yes
1121	C -> T	No
1141	C -> T	Yes
1247	G ->	No
1259	G -> A	Yes
1260	C ->	No
1260	C -> T	No
1349	A -> T	No

Variant protein HSMUC1A_PEA_—1_P53 (SEQ ID NO:815) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T31 (SEQ ID NO:774). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P53 (SEQ ID NO:815) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T31 (SEQ ID NO:774) is shown in bold; this coding portion starts at position 507 and ends at position 665. The transcript also has the following SNPs as listed in Table 22 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P53 (SEQ ID NO:815) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 22


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
669	G -> A	Yes
671	G -> A	No
871	C ->	No
959	A -> G	No
967	C -> T	No
973	C -> T	Yes
1018	C -> T	Yes
1071	C -> T	No
1091	C -> T	Yes
1197	G ->	No
1209	G -> A	Yes
1210	C ->	No
1210	C -> T	No
1299	A -> T	No

Variant protein HSMUC1A_PEA_—1_P56 (SEQ ID NO:816) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T42 (SEQ ID NO:780). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P56 (SEQ ID NO:816) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 23, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P56 (SEQ ID NO:816) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 23


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

117	P ->	No

Variant protein HSMUC1A_PEA_—1_P56 (SEQ ID NO:816) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T42 (SEQ ID NO:780) is shown in bold; this coding portion starts at position 507 and ends at position 890. The transcript also has the following SNPs as listed in Table 24 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P56 (SEQ ID NO:816) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 24


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
855	C ->	No
943	A -> G	No
951	C -> T	No
957	C -> T	Yes
1002	C -> T	Yes
1055	C -> T	No
1075	C -> T	Yes
1181	G ->	No
1193	G -> A	Yes
1194	C ->	No
1194	C -> T	No
1283	A -> T	No

Variant protein HSMUC1A_PEA_—1_P58 (SEQ ID NO:817) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T35 (SEQ ID NO:777). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P58 (SEQ ID NO:817) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 25, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P58 (SEQ ID NO:817) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 25


Amino acid mutations

SNP position(s) on	Alternative	Previously
amino acid sequence	amino acid(s)	known SNP?

147	P ->	No

Variant protein HSMUC1A_PEA_—1_P58 (SEQ ID NO:817) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T35 (SEQ ID NO:777) is shown in bold; this coding portion starts at position 507 and ends at position 980. The transcript also has the following SNPs as listed in Table 26 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P58 (SEQ ID NO:817) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 26


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
945	C ->	No
1033	A -> G	No
1041	C -> T	No
1047	C -> T	Yes
1092	C -> T	Yes
1145	C -> T	No
1165	C -> T	Yes
1271	G ->	No
1283	G -> A	Yes
1284	C ->	No
1284	C -> T	No
1373	A -> T	No

Variant protein HSMUC1A_PEA_—1_P59 (SEQ ID NO:818) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T28 (SEQ ID NO:771). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.

Variant protein HSMUC1A_PEA_—1_P59 (SEQ ID NO:818) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T28 (SEQ ID NO:771) is shown in bold; this coding portion starts at position 507 and ends at position 794. The transcript also has the following SNPs as listed in Table 27 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P59 (SEQ ID NO:818) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 27


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
794	G -> A	Yes
796	G -> A	No
996	C ->	No
1084	A -> G	No
1092	C -> T	No
1098	C -> T	Yes
1143	C -> T	Yes
1196	C -> T	No
1216	C -> T	Yes
1322	G ->	No
1334	G -> A	Yes
1335	C ->	No
1335	C -> T	No
1424	A -> T	No

Variant protein HSMUC1A_PEA_—1_P63 (SEQ ID NO:819) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). An alignment is given to the known protein (Mucin 1 precursor (SEQ ID NO:805) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSMUC1A_PEA_—1_P63 (SEQ ID NO:819) and MUC1_HUMAN (SEQ ID NO:805):

1.An isolated chimeric polypeptide encoding for HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), comprising a first amino acid sequence being at least 90% homologous to MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSV corresponding to amino acids 1-45 of MUC1_HUMAN (SEQ ID NO:805), which also corresponds to amino acids 1-45 of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK (SEQ ID NO:946) corresponding to amino acids 46-85 of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2. An isolated polypeptide encoding for a tail of HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence


EEEVSADQVSVGASGVLGSFKEARNAPSFLSWSFSMGPSK	(SEQ ID NO:946)

in HSMUC1A_PEA_1_P63.	(SEQ ID NO:819)

The glycosylation sites of variant protein HSMUC1A_PEA_—1_P63 (SEQ ID NO:819), as compared to the known protein Mucin 1 precursor (SEQ ID NO:805), are described in Table 28 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 28


Glycosylation site(s)

	Position(s) on known	Present in
	amino acid sequence	variant protein?

	1055	no
	957	no
	975	no
	1133	no
	1029	no

Variant protein HSMUC1A_PEA_—1_P63 (SEQ ID NO:819) is encoded by the following transcript(s): HSMUC1A_PEA_—1_T47 (SEQ ID NO:782), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSMUC1A_PEA_—1_T47 (SEQ ID NO:782) is shown in bold; this coding portion starts at position 507 and ends at position 761. The transcript also has the following SNPs as listed in Table 29 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSMUC1A_PEA_—1_P63 (SEQ ID NO:819) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 29


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

572	A -> G	No
900	A ->	No
904	C ->	No
963	A -> C	Yes
1211	A -> G	No
1219	C -> T	No
1225	C -> T	Yes
1270	C -> T	Yes
1323	C -> T	No
1343	C -> T	Yes
1449	G ->	No
1461	G -> A	Yes
1462	C ->	No
1462	C -> T	No
1551	A -> T	No

As noted above, cluster HSMUC1A features 22 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSMUC1A_PEA_—1_node_—0 (SEQ ID NO:783) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 30 below describes the starting and ending position of this segment on each transcript.

TABLE 30


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	1	564
(SEQ ID NO:769)

HSMUC1A_PEA_1_T26	1	564
(SEQ ID NO:770)

HSMUC1A_PEA_1_T28	1	564
(SEQ ID NO:771)

HSMUC1A_PEA_1_T29	1	564
(SEQ ID NO:772)

HSMUC1A_PEA_1_T30	1	564
(SEQ ID NO:773)

HSMUC1A_PEA_1_T31	1	564
(SEQ ID NO:774)

HSMUC1A_PEA_1_T33	1	564
(SEQ ID NO:775)

HSMUC1A_PEA_1_T34	1	564
(SEQ ID NO:776)

HSMUC1A_PEA_1_T35	1	564
(SEQ ID NO:777)

HSMUC1A_PEA_1_T36	1	564
(SEQ ID NO:778)

HSMUC1A_PEA_1_T40	1	564
(SEQ ID NO:779)

HSMUC1A_PEA_1_T42	1	564
(SEQ ID NO:780)

HSMUC1A_PEA_1_T43	1	564
(SEQ ID NO:781)

HSMUC1A_PEA_1_T47	1	564
(SEQ ID NO:782)

Segment cluster HSMUC1A_PEA_—1_node_—14 (SEQ ID NO:784) according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769). Table 31 below describes the starting and ending position of this segment on each transcript.

TABLE 31


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	666	841
(SEQ ID NO:769)

Segment cluster HSMUC1A_PEA_—1_node_—24 (SEQ ID NO:785) according to the present invention is supported by 135 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769). Table 32 below describes the starting and ending position of this segment on each transcript.

TABLE 32


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	953	1084
(SEQ ID NO:769)

Segment cluster HSMUC1A_PEA_—1_node_—29 (SEQ ID NO:786) according to the present invention is supported by 156 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780) and HSMUC1A_PEA_—1_T43 (SEQ ID NO:781). Table 33 below describes the starting and ending position of this segment on each transcript.

TABLE 33


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	1207	1346
(SEQ ID NO:769)

HSMUC1A_PEA_1_T26	894	1033
(SEQ ID NO:770)

HSMUC1A_PEA_1_T28	913	1052
(SEQ ID NO:771)

HSMUC1A_PEA_1_T29	865	1004
(SEQ ID NO:772)

HSMUC1A_PEA_1_T30	838	977
(SEQ ID NO:773)

HSMUC1A_PEA_1_T31	788	927
(SEQ ID NO:774)

HSMUC1A_PEA_1_T33	881	1020
(SEQ ID NO:775)

HSMUC1A_PEA_1_T34	783	922
(SEQ ID NO:776)

HSMUC1A_PEA_1_T35	862	1001
(SEQ ID NO:777)

HSMUC1A_PEA_1_T36	756	895
(SEQ ID NO:778)

HSMUC1A_PEA_1_T40	762	901
(SEQ ID NO:779)

HSMUC1A_PEA_1_T42	772	911
(SEQ ID NO:780)

HSMUC1A_PEA_1_T43	693	832
(SEQ ID NO:781)

Segment cluster HSMUC1A_PEA_—1_node_—35 (SEQ ID NO:787) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 34 below describes the starting and ending position of this segment on each transcript.

TABLE 34


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T47	666	1189
(SEQ ID NO:782)

TABLE 35


Oligonucleotides related to this segment

Oligonucleotide

Overexpressed in

Chip

	name	cancers	reference

HSMUC1A_0_0_11365	breast malignant	BRS
(SEQ ID NO:917)	tumors

Segment cluster HSMUC1A_PEA_—1_node_—38 (SEQ ID NO:788) according to the present invention is supported by 140 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 36 below describes the starting and ending position of this segment on each transcript.

TABLE 36


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	1488	1749
(SEQ ID NO:769)

HSMUC1A_PEA_1_T26	1175	1436
(SEQ ID NO:770)

HSMUC1A_PEA_1_T28	1194	1455
(SEQ ID NO:771)

HSMUC1A_PEA_1_T29	1146	1407
(SEQ ID NO:772)

HSMUC1A_PEA_1_T30	1119	1380
(SEQ ID NO:773)

HSMUC1A_PEA_1_T31	1069	1330
(SEQ ID NO:774)

HSMUC1A_PEA_1_T33	1162	1423
(SEQ ID NO:775)

HSMUC1A_PEA_1_T34	1064	1325
(SEQ ID NO:776)

HSMUC1A_PEA_1_T35	1143	1404
(SEQ ID NO:777)

HSMUC1A_PEA_1_T36	1037	1298
(SEQ ID NO:778)

HSMUC1A_PEA_1_T40	1043	1304
(SEQ ID NO:779)

HSMUC1A_PEA_1_T42	1053	1314
(SEQ ID NO:780)

HSMUC1A_PEA_1_T43	974	1235
(SEQ ID NO:781)

HSMUC1A_PEA_1_T47	1321	1582
(SEQ ID NO:782)

Segment cluster HSMUC1A_PEA_—1_node_—3 (SEQ ID NO:789) according to the present invention is supported by 17 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779) and HSMUC1A_PEA_—1_T43 (SEQ ID NO:781). Table 37 below describes the starting and ending position of this segment on each transcript.

TABLE 37


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T29	565	591
(SEQ ID NO:772)

HSMUC1A_PEA_1_T34	565	591
(SEQ ID NO:776)

HSMUC1A_PEA_1_T40	565	591
(SEQ ID NO:779)

HSMUC1A_PEA_1_T43	565	591
(SEQ ID NO:781)

Segment cluster HSMUC1A_PEA_—1_node_—4 (SEQ ID NO:790) according to the present invention can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 38 below describes the starting and ending position of this segment on each transcript.

TABLE 38


Segment location on transcripts

	Segment	Segment
	starting	ending

	Transcript name	position	position

HSMUC1A_PEA_1_T12	565	573
(SEQ ID NO:769)

HSMUC1A_PEA_1_T26	565	573
(SEQ ID NO:770)

HSMUC1A_PEA_1_T28	565	573
(SEQ ID NO:771)

HSMUC1A_PEA_1_T29	592	600
(SEQ ID NO:772)

HSMUC1A_PEA_1_T30	565	573
(SEQ ID NO:773)

HSMUC1A_PEA_1_T31	565	573
(SEQ ID NO:774)

HSMUC1A_PEA_1_T33	565	573
(SEQ ID NO:775)

HSMUC1A_PEA_1_T34	592	600
(SEQ ID NO:776)

HSMUC1A_PEA_1_T35	565	573
(SEQ ID NO:777)

HSMUC1A_PEA_1_T36	565	573
(SEQ ID NO:778)

HSMUC1A_PEA_1_T40	592	600
(SEQ ID NO:779)

HSMUC1A_PEA_1_T42	565	573
(SEQ ID NO:780)

HSMUC1A_PEA_1_T43	592	600
(SEQ ID NO:781)

HSMUC1A_PEA_1_T47	565	573
(SEQ ID NO:782)

Segment cluster HSMUC1A_PEA_—1_node_—5 (SEQ ID NO:791) according to the present invention is supported by 34 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 39 below describes the starting and ending position of this segment on each transcript.

TABLE 39


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	574	600
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	574	600
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	574	600
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	601	627
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	574	600
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	574	600
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	574	600
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	601	627
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	574	600
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	574	600
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	601	627
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	574	600
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	601	627
(SEQ ID NO: 781)

HSMUC1A_PEA_1_T47	574	600
(SEQ ID NO: 782)

Segment cluster HSMUC1A_PEA_—1_node_—6 (SEQ ID NO:792) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 40 below describes the starting and ending position of this segment on each transcript.

TABLE 40


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	601	638
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	601	638
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	601	638
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	628	665
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	601	638
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	601	638
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	601	638
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	628	665
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	601	638
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	601	638
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	628	665
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	601	638
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	628	665
(SEQ ID NO: 781)

HSMUC1A_PEA_1_T47	601	638
(SEQ ID NO: 782)

Segment cluster HSMUC1A_PEA_—1_node_—7 (SEQ ID NO:793) according to the present invention is supported by 32 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780) and HSMUC1A_PEA_—1_T43 (SEQ ID NO:781). Table 42 below describes the starting and ending position of this segment on each transcript.

TABLE 42


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	639	665
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	639	665
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	639	665
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	666	692
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	639	665
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	639	665
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	639	665
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	666	692
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	639	665
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	639	665
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	666	692
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	639	665
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	666	692
(SEQ ID NO: 781)

Segment cluster HSMUC1A_PEA_—1_node_—17 (SEQ ID NO:794) according to the present invention can be found in the following transcript(s): HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775) and HSMUC1A_PEA_—1_T40 (SEQ ID NO:779). Table 44 below describes the starting and ending position of this segment on each transcript.

TABLE 44


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T28	666	684
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T33	666	684
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T40	693	711
(SEQ ID NO: 779)

Segment cluster HSMUC1A_PEA_—1_node_—18 (SEQ ID NO:795) according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779) and HSMUC1A_PEA_—1_T42 (SEQ ID NO:780). Table 45 below describes the starting and ending position of this segment on each transcript.

TABLE 45


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	842	891
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	666	715
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	685	734
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	693	742
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	666	715
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T33	685	734
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T35	666	715
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T40	712	761
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	666	715
(SEQ ID NO: 780)

Segment cluster HSMUC1A_PEA_—1_node_—20 (SEQ ID NO:796) according to the present invention can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777) and HSMUC1A_PEA_—1_T42 (SEQ ID NO:780). Table 46 below describes the starting and ending position of this segment on each transcript.

TABLE 46


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	892	900
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	716	724
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	735	743
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T33	735	743
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T35	716	724
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T42	716	724
(SEQ ID NO: 780)

Segment cluster HSMUC1A_PEA_—1_node_—21 (SEQ ID NO:797) according to the present invention is supported by 97 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777) and HSMUC1A_PEA_—1_T42 (SEQ ID NO:780). Table 47 below describes the starting and ending position of this segment on each transcript.

TABLE 47


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	901	947
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	725	771
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	744	790
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T33	744	790
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T35	725	771
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T42	725	771
(SEQ ID NO: 780)

Segment cluster HSMUC1A_PEA_—1_node_—23 (SEQ ID NO:798) according to the present invention can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769). Table 48 below describes the starting and ending position of this segment on each transcript.

TABLE 48


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	948	952
(SEQ ID NO: 769)

Segment cluster HSMUC1A_PEA_—1_node_—26 (SEQ ID NO:799) according to the present invention is supported by 129 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773) and HSMUC1A_PEA_—1_T31 (SEQ ID NO:774). Table 49 below describes the starting and ending position of this segment on each transcript.

TABLE 49


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	1085	1116
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	772	803
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	791	822
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	743	774
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	716	747
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	666	697
(SEQ ID NO: 774)

Segment cluster HSMUC1A_PEA_—1_node_—27 (SEQ ID NO:800) according to the present invention is supported by 140 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777) and HSMUC1A_PEA_—1_T36 (SEQ ID NO:778). Table 50 below describes the starting and ending position of this segment on each transcript.

TABLE 50


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	1117	1206
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	804	893
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	823	912
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	775	864
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	748	837
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	698	787
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	791	880
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	693	782
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	772	861
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	666	755
(SEQ ID NO: 778)

Segment cluster HSMUC1A_PEA_—1_node_—31 (SEQ ID NO:801) according to the present invention can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780) and HSMUC1A_PEA_—1_T43 (SEQ ID NO:781). Table 51 below describes the starting and ending position of this segment on each transcript.

TABLE 51


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	1347	1356
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	1034	1043
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	1053	1062
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	1005	1014
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	978	987
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	928	937
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	1021	1030
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	923	932
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	1002	1011
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	896	905
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	902	911
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	912	921
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	833	842
(SEQ ID NO: 781)

Segment cluster HSMUC1A_PEA_—1_node_—34 (SEQ ID NO:802) according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 52 below describes the starting and ending position of this segment on each transcript.

TABLE 52


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T47	639	665
(SEQ ID NO: 782)

Segment cluster HSMUC1A_PEA_—1_node_—36 (SEQ ID NO:803) according to the present invention is supported by 135 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 53 below describes the starting and ending position of this segment on each transcript.

TABLE 53


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	1357	1388
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	1044	1075
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	1063	1094
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	1015	1046
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	988	1019
(SEQ ID NO: 773)

HSMUC1A_PEA_1_T31	938	969
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	1031	1062
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	933	964
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	1012	1043
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	906	937
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	912	943
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	922	953
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	843	874
(SEQ ID NO: 781)

HSMUC1A_PEA_1_T47	1190	1221
(SEQ ID NO: 782)

Segment cluster HSMUC1A_PEA_—1_node_—37 (SEQ ID NO:804) according to the present invention is supported by 146 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSMUC1A_PEA_—1_T12 (SEQ ID NO:769), HSMUC1A_PEA_—1_T26 (SEQ ID NO:770), HSMUC1A_PEA_—1_T28 (SEQ ID NO:771), HSMUC1A_PEA_—1_T29 (SEQ ID NO:772), HSMUC1A_PEA_—1_T30 (SEQ ID NO:773), HSMUC1A_PEA_—1_T31 (SEQ ID NO:774), HSMUC1A_PEA_—1_T33 (SEQ ID NO:775), HSMUC1A_PEA_—1_T34 (SEQ ID NO:776), HSMUC1A_PEA_—1_T35 (SEQ ID NO:777), HSMUC1A_PEA_—1_T36 (SEQ ID NO:778), HSMUC1A_PEA_—1_T40 (SEQ ID NO:779), HSMUC1A_PEA_—1_T42 (SEQ ID NO:780), HSMUC1A_PEA_—1_T43 (SEQ ID NO:781) and HSMUC1A_PEA_—1_T47 (SEQ ID NO:782). Table 54 below describes the starting and ending position of this segment on each transcript.

TABLE 54


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSMUC1A_PEA_1_T12	1389	1487
(SEQ ID NO: 769)

HSMUC1A_PEA_1_T26	1076	1174
(SEQ ID NO: 770)

HSMUC1A_PEA_1_T28	1095	1193
(SEQ ID NO: 771)

HSMUC1A_PEA_1_T29	1047	1145
(SEQ ID NO: 772)

HSMUC1A_PEA_1_T30	1020	1118
(SEQ ID NO: 773)

HSMUCIA_PEA_1_T31	970	1068
(SEQ ID NO: 774)

HSMUC1A_PEA_1_T33	1063	1161
(SEQ ID NO: 775)

HSMUC1A_PEA_1_T34	965	1063
(SEQ ID NO: 776)

HSMUC1A_PEA_1_T35	1044	1142
(SEQ ID NO: 777)

HSMUC1A_PEA_1_T36	938	1036
(SEQ ID NO: 778)

HSMUC1A_PEA_1_T40	944	1042
(SEQ ID NO: 779)

HSMUC1A_PEA_1_T42	954	1052
(SEQ ID NO: 780)

HSMUC1A_PEA_1_T43	875	973
(SEQ ID NO: 781)

HSMUC1A_PEA_1_T47	1222	1320
(SEQ ID NO: 782)

Variant protein alignment to the previously known protein:

Sequence name: MUC1_HUMAN (SEQ ID NO:805)

Sequence documentation:

Alignment of: HSMUC1A_PEA_—1_P63 (SEQ ID NO:819)×MUC1_HUMAN (SEQ ID NO:805).

Alignment segment 1/1:



Quality:	429.00
Escore:	0
Matching length:	59	Total length:	59
Matching Percent	86.44	Matching Percent Identity:	81.36
Similarity:
Total Percent Similarity:	86.44	Total Percent Identity:	81.36
Gaps:	0

Alignment:


	. . . . .
1	MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSVEEEVS	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MTPGTQSPFFLLLLLTVLTVVTGSGHASSTPGGEKETSATQRSSVPSSTE	50

51	ADQVSVGAS	59
	: \|\|: :\|
51	KNAVSMTSS	59

Combined Expression of 8 Sequences (T10888seg11-17 (SEQ ID NO: 832), HUMGR5E junc3-7 (SEQ ID NO: 857), HSSTROL3seg24 (SEQ ID NO: 869), T94936 Seg 14 (SEQ ID NO: 861), Z21368 seg39 (SEQ ID NO: 844), Z21368 junc17-21 (SEQ ID NO: 847), T59832 jun6-25-26 (SEQ ID NO: 854) and M85491seg24 (SEQ ID NO: 866)) in Normal and Cancerous Breast Tissues

Expression of CEA6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6, GRP_HUMAN—gastrin-releasing peptide, Stromelysin-3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11) (ST3) (SL-3), Homo sapiens breast cancer membran protein 11 (BCMP11), SUL1_HUMAN, Ephrin type-B receptor 2 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor EPH-3 and gamma-interferon inducible lysosomal thiol recductase (GILT) transcripts detectable by or according to T10888seg11-17 (SEQ ID NO: 832), HUMGR5E junc3-7 (SEQ ID NO: 857), HSSTROL3seg24 (SEQ ID NO: 869), T94936 Seq 14 (SEQ ID NO: 861), Z21368 seg39 (SEQ ID NO: 844), Z21368 junc17-21 (SEQ ID NO: 874), T58832 jun6-25-26 (SEQ ID NO: 854) and M85491seg24 (SEQ ID NO: 866) amplicons and T10888seg11-17F (SEQ ID NO: 830), T10888seg11-17R (SEQ ID NO: 831), HUMGR5E junc3-7F(SEQ ID NO: 855), HUMGR5E junc3-7F (SEQ ID NO: 856), HSSTROL3seg24F (SEQ ID NO:867), HSSTROL3seg24R (SEQ ID NO: 868), T94936seg14F (SEQ ID NO: 859), T94936seg14R (SEQ ID NO: 860), Z21368 seg39F (SEQ ID NO: 842), Z21368 seg39R (SEQ ID NO: 843), Z21368junc17-21F (SEQ ID NO: 845), Z21368junc17-21R (SEQ ID NO: 846), T59832 jun6-25-26F (SEQ ID NO: 852), T59832 jun6-25-26F (SEQ ID NO: 853), M85491seg24F (SEQ ID NO: 864) and M85491seg24R (SEQ ID NO: 865) primers was measured by real time PCR. In parallel the expression of four housekeeping genes—PBGD (GenBank Accession No. BC019323 (SEQ ID NO:926); amplicon—PBGD-amplicon (SEQ ID NO:929)), HPRT1 (GenBank Accession No. NM_—000194 (SEQ ID NO:930); amplicon—HPRT1-amplicon (SEQ ID NO:933 ), G6PD (GenBank Accession No. NM_—000402 (SEQ ID NO:918); G6PD-amplicon (SEQ ID NO:921)) and SDHA (GenBank Accession No. NM_—004168 (SEQ ID NO:922); amplicon—SDHA-amplicon (SEQ ID NO:925)) was measured similarly. For each RT sample, the expression of the above amplicons was normalized to the geometric mean of the quantities of the housekeeping genes. The normalized quantity of each RT sample of each amplicon was then divided by the median of the quantities of the normal post-mortem (PM) samples detected for the same amplicon (Sample Nos. 56-60, 63-67 Table 1, “Tissue samples in testing panel” above), to obtain a value of fold up-regulation for each sample relative to median of the normal PM samples.

FIGS. 44-47 are histograms showing differential expression of the above-indicated transcripts in cancerous breast samples relative to the normal samples, in different combinations. The number and percentage of samples that exhibit at least 5 fold differential of at least one of the sequences, out of the total number of samples tested is indicated in the bottom.

As is evident from FIGS. 44-47, differential expression of at least 5 fold in at least one of the sequences was found in 25 out of 28 adenocarcinoma samples in all different combinations.

Statistical analysis was applied to verify the significance of these results, as described below. Threshold of 5 fold differential expression of at least one of the amplicons was found to differentiate between cancer and normal samples.

The above values demonstrate statistical significance of the results.

Description for Cluster HSU33147

Cluster HSU33147 features 2 transcript(s) and 5 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.

TABLE 1


Transcripts of interest

	Transcript Name	Sequence ID No.

	HSU33147_PEA_1_T1	820
	HSU33147_PEA_1_T2	821

TABLE 2


Segments of interest

	Segment Name	Sequence ID No.

	HSU33147_PEA_1_node_0	822
	HSU33147_PEA_1_node_2	823
	HSU33147_PEA_1_node_4	824
	HSU33147_PEA_1_node_7	825
	HSU33147_PEA_1_node_3	826

TABLE 3


Proteins of interest

	Sequence ID	Corresponding
Protein Name	No.	Transcript(s)

HSU33147_PEA_1_P5	828	HSU33147_PEA_1_T1;
		(SEQ ID NO: 820)

		HSU33147_PEA_1_T2
		(SEQ ID NO: 821)

These sequences are variants of the known protein Mammaglobin A precursor (SwissProt accession identifier MGBA_HUMAN; known also according to the synonyms Mammaglobin 1; Secretoglobin family 2A member 2), SEQ ID NO: 827, referred to herein as the previously known protein.

The sequence for protein Mammaglobin A precursor (SEQ ID NO:827) is given at the end of the application, as “Mammaglobin A precursor (SEQ ID NO:827) amino acid sequence”.

It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Immunostimulant. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anticancer.

The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: steroid binding, which are annotation(s) related to Molecular Function.

Cluster HSU33147 can be used as a diagnostic marker according to overexpression of transcripts of this cluster in cancer. Expression of such transcripts in normal tissues is also given according to the previously described methods. The term “number” in the left hand column of the table and the numbers on the y-axis of FIG. 48 refer to weighted expression of ESTs in each category, as “parts per million” (ratio of the expression of ESTs for a particular cluster to the expression of all ESTs in that category, according to parts per million).

Overall, the following results were obtained as shown with regard to the histograms in FIG. 48 and Table 4. This cluster is overexpressed (at least at a minimum level) in the following pathological conditions: a mixture of malignant tumors from different tissues.

TABLE 4


Normal tissue distribution

	Name of Tissue	Number

	epithelial	6
	general	2
	lung	0
	breast	131

TABLE 5


P values and ratios for expression in cancerous tissue

Name of Tissue	P1	P2	SP1	R3	SP2	R4

epithelial	4.1e−02	6.4e−02	1.5e−12	2.6	2.2e−06	1.5
general	1.6e−02	1.1e−02	1.2e−22	4.4	7.2e−13	2.4
lung	1	6.3e−01	1	1.0	6.2e−01	1.6
breast	8.6e−02	1.1e−01	3.4e−07	1.7	2.6e−03	1.0

As noted above, cluster HSU33147 features 2 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Mammaglobin A precursor (SEQ ID NO:827). A description of each variant protein according to the present invention is now provided.

Variant protein HSU33147_PEA_—1_P5 (SEQ ID NO:828) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSU33147_PEA_—1_T1 (SEQ ID NO:820). An alignment is given to the known protein (Mammaglobin A precursor (SEQ ID NO:827) ) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:

Comparison report between HSU33147_PEA_—1_P5 (SEQ ID NO:828) and MGBA_HUMAN (SEQ ID NO:827):

1.An isolated chimeric polypeptide encoding for HSU33147_PEA_—1_P5 (SEQ ID NO:828), comprising a first amino acid sequence being at least 90% homologous to MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQVSKTEYKELLQEFIDDNATTNAI DELKECFLNQTDETLSNVE corresponding to amino acids 1-78 of MGBA_HUMAN (SEQ ID NO:827), which also corresponds to amino acids 1-78 of HSU33147_PEA_—1_P5 (SEQ ID NO:828), and a second amino acid sequence being at least 90% homologous to QLIYDSSLCDLF corresponding to amino acids 82-93 of MGBA_HUMAN (SEQ ID NO:827) which also corresponds to amino acids 79-90 of HSU33147_PEA_—1_P5 (SEQ ID NO:828), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.

2.An isolated chimeric polypeptide encoding for an edge portion of HSU33147_PEA_—1_P5 (SEQ ID NO:828), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EQ, having a structure as follows: a sequence starting from any of amino acid numbers 78−x to 78; and ending at any of amino acid numbers 79+((n−2)−x), in which x varies from 0 to n−2.

The glycosylation sites of variant protein HSU33147_PEA_—1_P5 (SEQ ID NO:828), as compared to the known protein Mammaglobin A precursor (SEQ ID NO:827), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).

TABLE 6


Glycosylation site(s)

Position(s) on known amino	Present in
acid sequence	variant protein?	Position in variant protein?

68	yes	68
53	yes	53

Variant protein HSU33147_PEA_—1_P5 (SEQ ID NO:828) is encoded by the following transcript(s): HSU33147_PEA_—1_T1 (SEQ ID NO:820), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSU33147_PEA_—1_T1 (SEQ ID NO:820) is shown in bold; this coding portion starts at position 72 and ends at position 341. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSU33147_PEA_—1_P5 (SEQ ID NO:828) sequence provides support for the deduced sequence of this variant protein according to the present invention).

TABLE 7


Nucleic acid SNPs

SNP position on	Alternative	Previously
nucleotide sequence	nucleic acid	known SNP?

84	A -> C	No
124	C ->	No
396	A -> G	No

As noted above, cluster HSU33147 features 5 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.

Segment cluster HSU33147_PEA_—1_node_—0 (SEQ ID NO:822) according to the present invention is supported by 38 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSU33147_PEA_—1_T1 (SEQ ID NO:820) and HSU33147_PEA_—1_T2 (SEQ ID NO:821). Table 8 below describes the starting and ending position of this segment on each transcript.

TABLE 8


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSU33147_PEA_1_T1	1	126
(SEQ ID NO: 820)

HSU33147_PEA_1_T2	1	126
(SEQ ID NO: 821)

Segment cluster HSU33147_PEA_—1_node_—2 (SEQ ID NO:823) according to the present invention is supported by 44 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSU33147_PEA_—1_T1 (SEQ ID NO:820) and HSU33147_PEA_—1_T2 (SEQ ID NO:821). Table 9 below describes the starting and ending position of this segment on each transcript.

TABLE 9


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSU33147_PEA_1_T1	127	305
(SEQ ID NO: 820)

HSU33147_PEA_1_T2	127	305
(SEQ ID NO: 821)

Segment cluster HSU33147_PEA_—1_node_—4 (SEQ ID NO:824) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSU33147_PEA_—1_T2 (SEQ ID NO:821). Table 10 below describes the starting and ending position of this segment on each transcript.

TABLE 10


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSU33147_PEA_1_T2	315	907
(SEQ ID NO: 821)

Segment cluster HSU33147_PEA_—1_node_—7 (SEQ ID NO:825) according to the present invention is supported by 35 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSU33147_PEA_—1_T1 (SEQ ID NO:820). Table 11 below describes the starting and ending position of this segment on each transcript.

TABLE 11


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSU33147_PEA_1_T1	306	516
(SEQ ID NO: 820)

Segment cluster HSU33147_PEA_—1_node_—3 (SEQ ID NO:826) according to the present invention can be found in the following transcript(s): HSU33147_PEA_—1_T2 (SEQ ID NO:821) Table 12 below describes the starting and ending position of this segment on each transcript.

TABLE 12


Segment location on transcripts

	Segment	Segment
	starting	ending
Transcript name	position	position

HSU33147_PEA_1_T2	306	314
(SEQ ID NO: 821)

Sequence name: MGBA_HUMAN (SEQ ID NO:827)

Sequence documentation:

Alignment of: HSU33147_PEA_—1_P5 (SEQ ID NO:828)×MGBA_HUMAN (SEQ ID NO:827).

Alignment segment 1/1:



Quality:	776.00
Escore:	0
Matching length:	90	Total length:	93
Matching Percent	100.00	Matching Percent Identity:	100.00
Similarity:
Total Percent Similarity:	96.77	Total Percent Identity:	96.77
Gaps:	1

Alignment:


	. . . . .
1	MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQVSKTEYKELLQEFI	50
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
1	MKLLMVLMLAALSQHCYAGSGCPLLENVISKTINPQVSKTEYKELLQEFI	50

	. . . .
51	DDNATTNAIDELKECFLNQTDETLSNVE...QLIYDSSLCDLF	90
	\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\| \|\|\|\|\|\|\|\|\|\|\|\|
51	DDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF	93

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

Claims

1. An isolated polynucleotide comprising a polynucleotide having a sequence of R11723_PEA_—1_T5 (SEQ ID NO:560).

2. The isolated polynucleotide of claim 1, comprising a node having a sequence of: R11723_PEA_—1_node_—13(SEQ ID NO:562).

3. An isolated polypeptide comprising a polypeptide having a sequence of: R11723_PEA_—1_P13 (SEQ ID NO:591).

4. The isolated polypeptide of claim 3, comprising a chimeric polypeptide encoding for R11723_PEA_—1_P13 (SEQ ID NO:591), comprising a first amino acid sequence being at least 95% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 1-63 of Q96AC2 (SEQ ID NO:886), which also corresponds to amino acids 1-63 of R11723_PEA_—1_P13 (SEQ ID NO:591), and a second amino acid sequence being at least about 95% homologous to a polypeptide having the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO:1026) corresponding to amino acids 64-84 of R11723_PEA_—1_P13 (SEQ ID NO:591), wherein said first and second amino acid sequences are contiguous and in a sequential order.

4. (canceled)

5. The isolated polynucleotide of claim 1, comprising an amplicon according to SEQ ID NO: 975.

6. A primer pair, comprising a pair of isolated oligonucleotides capable of amplifying said amplicon of claim 5.

7. The primer pair of claim 6, comprising a pair of isolated oligonucleotides: SEQ NOs 973 and 974.

8. An antibody capable of specifically binding to an epitope of an amino acid sequence (SEQ ID NO:591) of claim 3.

9. The antibody of claim 8, wherein said amino acid sequence comprises said tail (SEQ ID NO:1026) of claim 4.

10. The antibody of claim 8, wherein said antibody is capable of differentiating between a splice variant having said epitope and a corresponding known protein PSEC (SEQ ID NO:886).

11. A kit for detecting breast cancer, comprising a kit detecting overexpression of a splice variant according to claim 1.

12. The kit of claim 11, wherein said kit comprises a NAT-based technology.

13. The kit of claim 11, wherein said kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence according to claim 1.

14. The kit of claim 11, wherein said kit further comprises at least one oligonucleotide capable of selectively hybridizing to a nucleic acid sequence according to claim 1.

12. (canceled)

13. (canceled)

14. (canceled)

15. The method of claim 26, wherein said detecting overexpression is performed with a NAT-based technology.

16. A method for detecting breast cancer, comprising detecting overexpression of a splice variant according to claim 3, wherein said detecting overexpression is performed with an immunoassay.

17. The method of claim 16, wherein said immunoassay comprises an antibody according to claim 8.

18. A biomarker capable of detecting breast cancer, comprising a nucleic acid sequence according to claim 1 or a fragment thereof, or an amino acid sequence according to claim 3 or a fragment thereof.

19. A method for screening for breast cancer, comprising detecting breast cancer cells with a biomarker according to claim 18.

20. A method for diagnosing breast cancer, comprising detecting breast cancer cells with a biomarker according to claim 18.

21. A method for monitoring disease progression and/or treatment efficacy and/or relapse of breast cancer, comprising detecting breast cancer cells with a biomarker according to claim 18.

22. A method of selecting a therapy for breast cancer, comprising detecting breast cancer cells with a biomarker according to claim 18 and selecting a therapy according to said detection.

23. The isolated polypeptide of claim 4, comprising a tail of R11723_PEA_—1_P13 (SEQ ID NO:591), comprising a polypeptide being at least about 95% homologous to the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO:1026) in R11723_PEA_—1_P13 (SEQ ID NO:591).

24. A kit for detecting breast cancer, comprising a kit detecting overexpression of a splice variant according to claim 3, said kit comprising an antibody according to claim 8.

25. The kit of claim 24, wherein said kit further comprises at least one reagent for performing an ELISA or a Western blot.

26. A method for detecting breast cancer, comprising detecting overexpression of a splice variant according to claim 1.

Resources